


















Histology	The	 liver	 plays	 very	 important	 roles	 in	 mammals,	 as	 center	 of	 many	 metabolic	reactions,	 as	 a	 gland,	 as	 a	 blood	 reservoir,	 and	 takes	 part	 in	 the	 modulation	 of	immune	reactions.	From	 the	 histological	 point	 of	 view,	 the	 liver	 parenchyma	 has	 a	 significant	complexity,	even	though	it	comprises	a	limited	number	of	cell	types.	Hepatocytes,	which	 represent	 the	majority	 of	 cells	 (60%	by	 number	 and	 80%	by	volume)	are	spatially	organized	in	the	parenchyma	in	rows	(one	or	two	composing	the	 hepatocytes	 plate),	 and	 are	 surrounded	 by	 4	 types	 of	 non-parenchymal	 cells	(35%	by	number	and	17%	by	volume):	endothelial	 cells	 lined	along	 the	sinusoids	and	 forming	 the	 vascular	walls;	 resident	macrophages	 (also	 called	 Kupffer	 cells);	perisinusoidal	 cells	 (also	 known	 as	 stellate	 cells	 or	 ito	 cells)	 and	 large	 granular	lymphocytes	[1].		Hepatocytes	are	 large	polygonal	 cells.	 In	adult	 rats,	 up	 to	40%	of	hepatocytes	are	tetraploid	but	only	20%	out	of	them	are	binucleated	[2].	In	human	the	frequency	of	binucleated	cells	is	approximately	10%	[3].	Each	nucleus	has	two	or	more	nucleoli.	The	average	 life	span	of	hepatocytes	 is	 five	months.	They	contain	abundant	rough	endoplasmic	reticulum	and	mitochondria,	large	stores	of	glycogen,	lipid	droplets	of	various	sizes,	and	several	small	elaborate	Golgi	complexes.	They	also	contain	many	peroxisomes,	a	variable	amount	of	smooth	endoplasmic	reticulum	and	lysosomes.		Hepatocytes	are	organized	in	trabeculae	separates	by	a	vascular	space:	the	sinusoid.	In	the	sinusoids,	the	blood	flows	towards	the	central	vein	which	drains	into	the	sub-hepatic	veins,	then	further	in	the	vena	cava.	At	the	distal	end	of	the	sinusoid,	there	is	the	portal	space	or	triad.	The	“portal	triad”	is	a	key	element	of	liver	architecture:	it	contains	the	intra-hepatic	bile	ducts,	and	the	terminal	branch	of	hepatic	arteries	and	portal	 veins,	 delimited	 by	 connective	 tissue.	 It	 represents	 the	 major	 element	 of	discontinuity	 in	 the	 liver	 parenchyma.	 Vessels	 and	 bile	 ducts	 are	 responsible	 for	transportation	and	distribution	of	fluids	(blood	and	bile)	through	the	organ.		The	 liver	 receives	 blood	 from	 the	 hepatic	 artery	 and	 from	 the	 portal	 vein,	which	represents	 about	 60%	 of	 the	 incoming	 blood.	 The	 blood	 from	 the	 hepatic	 artery	supplies	the	liver	with	oxygen.	The	blood	from	the	portal	vein	has	already	supplied	
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the	 small	 intestine,	 pancreas	 and	 spleen,	 and	 is	 largely	 deoxygenated	 when	 it	reaches	 the	 liver.	 It	 contains	 nutrients	 and	 noxious	 substances	 absorbed	 in	 the	intestine,	blood	cells	and	their	breakdown	products	from	the	spleen,	and	endocrine	secretions	 from	the	pancreas.	Because	blood	 from	these	 two	sources	 intermingles	as	 it	perfuse	 the	hepatocytes,	 it	 is	 less	 saturated	 in	O2	 compared	 to	arterial	blood	found	 elsewhere	 in	 the	 body.	 This	 means	 that	 hepatocytes	 carry	 out	 their	 many	activities	under	low	oxygen	conditions	that	most	other	cells	could	not	tolerate	[4].	The	 oxygen	 deficit	 of	 portal	 blood	 in	 the	 liver	 is	 compensated	 by	 an	 higher	 O2	extraction	capacity	compared	to	other	organs	(e.g.	intestine)	[5].	Bile	ducts	are	tubular	structures	arranged	in	a	branching	tree	carrying	the	bile	from	the	hepatocytes	down	to	the	intestine.	They	are	covered	by	a	monolayer	of	cubical	or	columnar	epithelial	tissue.	The	bile	is	produced	by	the	hepatocytes	and	flows	in	between	hepatocytes,	 through	bile	 canaliculi	delimited	by	a	 specialized	portion	of	the	plasma	membrane	of	adjacent	hepatocytes.	At	the	end	of	this	canaliculi,	the	bile	is	 collected	 by	 intrahepatic	 bile	 ducts	 sitting	 in	 the	 portal	 spaces	 and;	 and	 flows	towards	the	larger	–	extrahepatic	–	bile	ducts.	The	bile	is	then	drained	into	the	gall	bladder	 where	 it	 is	 concentrated.	 The	 bile	 function	 is	 to	 help	 the	 elimination	 of	unsuitable	 metabolites	 and	 to	 solubilize	 fats	 present	 in	 food	 to	 facilitate	 their	absorption	[4].	Hepatocytes	have	a	remarkable	metabolic	diversity.	Many	functional	models	for	this	organ	 have	 been	 proposed	 based	 on	 metabolic	 differences	 between	 hepatocytes	spatially	 distributed	 along	 the	 periportal-pericentral	 axis	 [6]	 (Fig.	 1).	 The	 first	model	 was	 proposed	 by	 Kiernan	 in	 1833,	 and	 was	 based	 on	 “Lobule”	 structure,	which	 is	 the	polygonal	 structure,	 composed	of	parenchymal	 cells	 surrounding	 the	central	 vein.	 This	 structure	 is	 delimited	 by	 connective	 tissue	 and	 the	 corners	 are	represented	by	 the	portal	 spaces,	 containing	 the	 terminal	branches	of	portal	vein,	hepatic	artery	and	bile	duct.	A	second	model	was	proposed	by	Matsumoto	in	1979,	and	was	based	on	the	“portal	unit”	 or	 “sickle	 zone”:	 it	 differs	 from	 the	 previous	 anatomical	 model	 on	 that	 it	represents	 a	 functional	 model	 based	 on	 microcirculation.	 In	 this	 latter	 case,	 the	functional	unit	is	composed	by	the	polygonal	structure	between	three	central	veins	surrounding	one	portal	space.		
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Earlier	in	the	1960,	Rappaport	described	the	“liver	acinus”:	in	this	structure,	three	different	 regions	 can	 be	 delimited	 on	 the	 base	 of	 their	 spatial	 distribution	 and	 of	their	specific	metabolisms.	The	zone	I	or	periportal,	composed	by	the	hepatocytes	surrounding	 the	 portal	 space,	 the	 zone	 III	 or	 perivenous,	 composed	 by	 the	hepatocytes	 surrounding	 the	 central	 vein	 and,	 ultimately,	 the	 zone	 II,	 a	 transition	zone	 between	 the	 zone	 I	 and	 III.	 Rappaport’s	 model	 is,	 currently,	 the	 most	accredited	liver	functional	model.		
	http://fblt.cz/wp-content/uploads/2013/12/jaterni-acinus-a-portalni-lalucek-ENG-01.jpg	Schematic	representation	of	liver	functional	models		Models	 based	 on	 microcirculation,	 as	 the	 latter	 two	 cases,	 take	 into	 account	 the	distribution	 and	 availability	 of	 substrates	 and	 products,	 which	 can	 influence	 the	enzymatic	distribution	and	the	consequent	metabolic	activity.	Many	 liver	specific	enzymes	have	been	studied	 in	 the	years	and	 their	activity	and	localization	within	the	liver	parenchyma	have	been	described	[7,	8].		The	gene	expression	of	these	enzymes	and	their	metabolic	functions	in	the	liver	are	strictly	 and	 precisely	 regulated.	 A	 key	 regulator	 of	 the	metabolic	 zonation	 of	 the	liver	seems	to	be	the	interplay	between	the	WNT/β	Catenin	pathway	and	Hedgehog	(Hh)	signaling.	The	two	pathways	create	opposite	gradients	and	play	their	roles	by	mutual	inhibition,	depending	on	the	strength	of	their	activity	gradients.	Hh	signaling	appears	 to	be	an	 important	regulator	of	 lipid	metabolism	(lipogenesis,	cholesterol	synthesis,	 VLDL	 formation)	 in	 the	 Zone	 I	 -	 periportal	 area.	 Contrarily,	 WNT/β	Catenin	appears	to	control	ammonia	production,	bile	acid	synthesis	and	xenobiotic	
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metabolism	 in	 the	 Zone	 III	 -	 centro-lobular	 area	 [9-12].	 Unfortunately,	 this	mechanism	was	not	 totally	proven	and	 it	was,	 in	part,	 built	 on	 indirect	 evidences	and	speculations.		




Introduction	Drug-induced	liver	injury	(DILI)	is	a	broad	term	applied	to	any	injury	to	the	liver	by	a	prescribed	medication,	over-the-counter	medication,	herb,	or	dietary	supplement,	manifesting	 as	 a	 spectrum	 from	 asymptomatic	 liver	 test	 elevations,	 to	 acute	 liver	failure	(ALF).	DILI	can	lead	to	clinically	significant	acute	and	chronic	liver	disease	in	both	 children	 and	 adults.	 Drug-induced	 liver	 injury	 remains	 the	 leading	 cause	 of	ALF	in	western	countries	and	the	most	common	reason	for	withdrawal	of	approved	medications	from	the	marketplace	[14].	Limited	data	exist	on	the	incidence	of	DILI	in	 the	 population,	 and	 some	 recent	 epidemiologic	 data	 indicate	 an	 annual	 crude	incidence	rate	of	approximately	20	new	cases	of	DILI	per	100,000	 inhabitants	per	year	[15].	However,	these	numbers	may	be	much	higher,	because	of	underreporting,	difficulties	 in	 detection	 or	 diagnosis,	 and	 incomplete	 observation	 of	 persons	exposed.	The	lack	of	objective	diagnostic	tests,	the	lack	of	specificity	of	clinical	presentations	and	 idiosyncratic	 nature	 of	most	 cases	makes	 DILI	 a	 significant	 challenge	 for	 the	gastroenterologist.	 As	 reported	 by	 the	 U.S.	 Drug	 Induced	 Liver	 Injury	 Network	(DILIN),	 the	 initial	 symptoms	and	signs	of	DILI	are	often	non-specific	and	 include	fatigue,	 nausea	 and	 abdominal	 pain.	 The	 onset	 of	 clinical	 symptoms	 can	 be	important	 in	 determining	 the	 latency	 of	 a	 possible	 DILI	 episode.	 Liver	 specific	symptoms	 as	 pruritus,	 jaundice,	 ascites	 and	 encephalopathy	 are	 usually	 reported	only	 in	 patients	 with	 more	 severe	 DILI;	 jaundice	 in	 the	 setting	 of	 an	 acute	 one.	Drugs	 and	herbal	 dietary	 supplements	 often	 cause	 subclinical	 liver	 injury	 as	mild	serum	 alanine	 aminotransferase	 (ALT)	 elevations	 or	 slight	 unconjugated	hyperbilirubinemia.	Getting	accurate	timing	of	medication	start	and	stop	dates,	onset	of	symptoms,	liver	biochemistry	abnormalities	and	liver	recovery	are	of	importance	in	order	to	reach	a	proper	 diagnosis	 of	 DILI.	 The	 pattern	 of	 liver	 biochemistry	 elevations	 at	presentation	is	second	only	to	a	good	anamnesis	in	diagnostic	importance.	The	type	of	 liver	 injury	 can	 be	 inferred	 by	 elevations	 of	 liver	 enzymes,	 and	 they	 are	categorized	by	the	R	value	(R	=	[ALT	value	/ALT	upper	limit	of	normal]	÷	[alkaline	
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phosphatase	(AP)	value	/AP	upper	limit	normal]).	R	values	of	>5	are	considered	as	hepatocellular,	 <2	 cholestatic	 and	 2-5	 as	mixed	 [17].	 Although	many	medications	responsible	 for	 DILI	 produce	 stereotypical	 biochemical	 signatures,	 it	 should	 be	noted	that	different	biochemical	patterns	could	be	caused	by	the	same	medication.	Serious	 DILI	 is	 usually	 characterized	 by	 the	 ‘Hy’s	 law’,	 a	 combination	 of	hepatocellular	 injury	 (AST	 elevation)	 and	 jaundice,	 and	 is	 associated	 with	 a	mortality	of	10%	[16].	The	diagnosis	of	DILI	usually	does	not	always	require	a	 liver	biopsy,	however	 the	collection	 of	 a	 biopsy	 sample	 might	 be	 necessary	 in	 case	 of	 clinical	 situation	complicated	 by	 concurrent	 medical	 conditions	 (e.g.	 autoimmune	 hepatitis)	 or	multiple	potential	drug	candidates.	The	liver	biopsy	serves	multiple	purposes	in	the	evaluation	of	DILI,	as	 the	 identification	of	morphological	pattern	of	 liver	 injury,	 to	include	or	exclude	DILI	in	the	differential	diagnosis,	by	matching	reported	patterns	of	injury,	to	unravel	the	mechanisms	of	injury,	and	to	assess	the	degree	of	injury	as	evaluation	of	liver	fibrosis	in	chronic	methotrexate	therapy.	The	evaluation	of	liver	biopsy	in	a	case	of	suspected	DILI	is	challenging	because	of	several	reasons,	including:	1)	Drug-related	injury	can	mimic	any	pattern	of	primary	liver	disease,	2)	an	unequivocal	histological	diagnosis	is	not	possible	in	many	cases	3)	 inadequate	 clinical	 history	 and/or	 multiple	 drugs	 being	 taken	 simultaneously	often	confound	the	problem,	4)	it	can	be	difficult	to	obtain	information	about	herbal	agents,	 over-the-counter	 medications	 and	 exposure	 to	 household	 or	 industrial	toxins.	Occasionally	 a	 liver	 biopsy	may	 be	 necessary	 for	 continued	 use	 or	 contemplated	rechallenge	 with	 medication	 such	 as	 a	 chemotherapeutic	 drug	 for	 advanced	malignancy.			
Patterns	of	injury	of	DILI	Although	the	pathological	changes	in	DILI	can	mimic	essentially	every	nontoxic	liver	disease,	the	patterns	associated	with	one	agent	are	limited,	and	sometimes	drugs	in	the	same	class	will	cause	similar	patterns	of	injury.	The	observed	injury	pattern	also	narrows	 the	 pathological	 differential	 diagnosis.	 Injury	 patterns	 may	 be	 broadly	categorized	 as	 hepatitic	 (necroinflammatory),	 cholestatic,	 steatotic,	 vascular	 and	neoplastic,	whereas	necroinflammatory	and	cholestatic	injuries	account	for	around	
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• Unpredictable	Injuries	 belonging	 to	 the	 latter	 category	 can	 be	 classified	 as	 host-dependent	(genetic,	metabolic)	or	host-independent	(immunologic),	although	this	distinction	is	somehow	not	precise	[20],	as	 for	 instance	 immunologic	responses	can	have	also	a	genetic	 or	 a	 metabolic	 basis,	 or	 metabolic	 mechanisms	 can	 elicit	 inflammatory	responses.		The	role	of	the	liver	in	the	coordination	of	the	metabolism	of	the	whole	body	cannot	be	 underestimated.	 In	 particular,	 the	 liver	 is	 essential	 for	 xenobiotic	 metabolism	and	detoxification,	is	a	mediator	of	innate	immune	response	and	it	is	involved	in	the	regulation	 of	 the	 immune	 system	 [21].	 It	 is	 therefore	 also	 morphologically,	biochemically	 and	 functionally	 heterogeneous	 [22,	 23].	 That	 means	 that	 the	capacity	 of	 the	 liver	 to	 react	 to	 drugs	 is	 different	 in	 the	 different	 zones	 of	 the	parenchyma.	In	 general,	 the	 aim	 of	 drug	 metabolism	 is	 the	 biotransformation	 of	 a	 nonpolar	compound	in	a	polar	one	(Phase	I)	and	subsequent	conjugation	with	a	hydrophilic	component	(Phase	II)	to	facilitate	the	excretion	[24].	These	reactions	take	place	in	several	 subcellular	 compartments	 (smooth	 endoplasmic	 reticulum	 -	 SER,	mitochondria,	lysosomes,	etc.).	The	Phase	I	can	be	achieved	by	[25,	26]:	1. Oxidation:	loss	of	electrons.	Generally	involves	cytochromes	(CYP).	2. Reduction:	 gain	 of	 electrons.	 Generally	 involves	 GSH,	 FADH,	 FMNH	 and	NAD[P]H.		
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3. Hydrolysis:	 production	 of	 two	 molecules	 or	 opening	 a	 ring	 in	 a	 molecule.	Involves	different	enzymes.	Phase	 II	 can	 be	 glucuronidation,	 sulfation,	 amino	 acid	 conjugation,	 acetylation,	methylation	or	GSH	conjugation	and	takes	generally	place	in	the	cytosol	[20,	27].	The	 final	 step	 of	 the	 biotransformation	 in	 the	 liver	 (so-called	 phase	 III)	 is	 the	transmembrane	 transport	 to	 the	 blood	 or	 to	 the	 bile.	 Molecular	 transporters	 are	generally	found	on	the	canalicular	or	sinusoidal	membranes	of	the	hepatocytes	and	are	important	for	the	clearance	of	xenobiotic.	The	most	important	transporters	are	the	ABCC	(ATP-binding	cassette	transporter	family,	subfamily	C)	efflux	proteins	and	the	 multidrug	 resistance	 proteins	 (MDRs).	 They	 can	 be	 found	 on	 the	 sinusoidal	and/or	the	canalicular	membrane	of	hepatocytes	[28].		During	biotransformation	short-lived	intermediates	are	produced,	and	they	may	be	very	reactive	and	therefore	harmful.	They	include	[29-32]:		1. Electrophiles	 (the	 vast	 majority):	 produced	 by	 redox	 reactions.	 The	compound	 loses	 electrons	 and	 is	 charged	 positively.	 Examples:	 aromatic	compounds,	like	epoxides,	quinone	imines	(paracetamol,	diclofenac)	2. Nucleophiles	(a	small	number):	produced	by	redox	reactions.	The	compound	is	charged	negatively.	Example:	hydrazines	(isoniazide,	rifampicin)	3. Free	radicals:	molecule	containing	one	or	more	unpaired	electrons.	They	are	formed	 when	 a	 compound	 loses	 or	 acquires	 an	 electron.	 Examples:	metabolism	of	aromatic	substances,	quinones,	etc.	They	can	extract	electrons	from	other	substances,	forming	new	free	radicals	(cisplatin)		4. Reactive	 Oxygen	 Species	 (ROS):	 Produced	 during	 the	 metabolism	 of	xenobiotics	 and	 drugs,	 in	 particular	when	 the	 CYP450	 system	 is	 impaired.	Examples:	 Superoxide	 (O2-•),	 Hydroxyl	 (OH•),	 Peroxyl	 (RO2•).	 When	produced	in	excessive	amounts,	ROS	are	harmful	because	they	saturate	GSH,	inducing	 then	 oxidative	 modifications	 of	 macromolecules	 (azathioprine,	cyclosporine	A).		On	the	other	hand,	drugs	or	their	reactive	metabolites	can	exert	their	effect	on	the	hepatocyte	by	three	different	mechanisms	[33-39]:	1. Direct	injury	to	the	hepatocyte	impairing	critical	cellular	functions.		a. Paracetamol,	 Diclofenac:	 the	 reactive	 intermediate	 (quinone	 imine)	binds	 covalently	 to	 glutathione	 (GSH).	 The	 antioxidative	 capacity	 of	
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the	liver	is	thus	impaired,	with	the	consequence	of	a	diffuse	oxidative	damage	(stress)	of	the	cell	and	subsequent	necrosis.	b. Azathioprine:	 the	 free	 radicals	 saturate	 the	 GSH	with	mitochondrial	damage	and	necrosis	c. Cisplatin:	 the	 formation	 of	 ROS	 induces	 mainly	 a	 mitochondrial	damage	that	leads	to	apoptosis	2. Sensitization	to	cytokine-induced	effect.	a. Diclofenac,	 Chlorpromazine,	 Amiodarone:	 a	 single	 dose	 of	 drug	 can	induce	 hepatocellular	 necrosis	 through	 a	 mechanism	 similar	 to	bacterial	lipopolysaccharide	3. Covalent	modification	of	proteins	(so-called	haptenization)	with	triggering	of	immune	response	similar	to	autoimmune	reaction	a. Halothane,	dicloxacillin,	nitrofurantoin,	methyldopa.	In	summary,	when	endogenous	biomolecules	are	permanently	damaged	or	the	cell	cannot	 react	 adequately	 to	 the	 damage	 induced	 by	 reactive	 species,	 subcellular	structures	 and/or	 essential	 metabolic	 pathways	 can	 be	 affected,	 leading	 to	 cell	death	and	eventually	to	clinical	manifestations	[24].		Possible	mechanisms	at	subcellular/cellular	level	are:	
Mitochondrial	 dysfunction:	 the	 enhanced	 membrane	 permeability	 induced	 by	drugs	can	activate	the	intrinsic	pathway	of	apoptosis	by	release	of	cytochromes	in	the	 cytosol.	More	 serious	 damage	 can	 lead	 to	 rupture	 of	 the	mitochondrion,	with	subsequent	hepatocyte	necrosis.	These	mechanisms	are	well	known	in	 the	case	of	paracetamol,	 where	 the	 formation	 of	 a	 highly	 reactive	 intermediate,	 N-acetyl-p-benzoquinone	 imine	 (NAPQI)	 leads	 to	 saturation	 of	 GSH	 and	 subsequent	accumulation	 of	 toxic	 compounds	 [40-43].	 Moreover,	 the	 overwhelming	 redox	changes	 induced	 by	 NAPQI	 may	 activate	 of	 the	 janus-kinase	 (JNK)	 pathway	 thus	leading	 to	 proapoptotic	 signaling	 and	 inhibition	 of	 the	 respiratory	 chain	 with	subsequent	cell	death	[44].	Some	drugs	 (e.g.	 valproate,	 alcohol,	 tetracycline,	 amiodarone,	 antiviral	 drugs)	 can	directly	 or	 indirectly	 inhibit	 beta-oxydation	 of	 fat	 acids,	 leading	 to	 micro-	 or	macrovesicular	steatosis	that	can	progress	to	steatohepatitis	and	cirrhosis	[45-47].	Mutations	 and	 or	 inactivation	 of	 genes	 such	 as	 mitochondrial	 DNA	 polymerase	gamma	 (POLG)	 or	 superoxide	 dismutase	 2	 (SOD2)	 are	 involved	 in	 this	metabolic	
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effect	[46,	48].	Valproate	can	also	impair	the	respiratory	chain	leading	to	depletion	of	ATP	and	finally	to	activation	of	programmed	cell	death	[49].		
Activation	 of	 the	 liver	 immune	 system:	 it	 is	clear	 that	several	 instances	of	DILI	involve	 immune	 mechanisms,	 including	 innate	 and	 adaptive	 processes	 [50].	Haptenization,	i.e.	covalent	binding	of	the	drug	or	its	metabolite(s)	to	proteins	can	create	 neoantigens,	 that	 trigger	 an	 autoimmune-like	 response	 (halothane,	diclofenac)	 [20,	 39].	 An	 alternative	 mechanism	 is	 the	 possibility	 of	 an	 immune	reaction	 against	 the	 drug	 itself	 by	 direct	 stimulation	 of	 the	 T-Cell	 receptor	(sulfomethoxazol,	carbamazepine)	[51,	52].		Release	 of	 apoptotic	 bodies	 or	 cellular	 fragments	 from	 necrotic	 hepatocytes	 can	elicit	the	immune	response	with	release	of	proinflammatory	molecules,	such	as	high	mobility	 group	 box	 1,	 heat	 shock	 proteins,	 hyaluronate,	 beta-defensin	 (so-called	damage-associated	molecular	pattern,	DAMP)	[50].	Additionally,	cytokines	released	during	the	inflammatory	response	may	enhance	the	toxic	effect	of	drugs.	Examples	are	Interferon-gamma,	MIF,	IL-1	and	TNF-alpha	in	paracetamol	toxicity	[50].	
Intrahepatic	 cholestasis:	 it	 is	 characterized	 by	 impaired	 bile	 flow,	 with	subsequent	cytotoxic	damage	of	hepatocytes	and	cholangiocytes.	The	final	effect	can	be	liver	fibrosis	and/or	cirrhosis	[53].	As	recalled	above,	 functional	 impairment	of	the	membrane	transporters	(ABC	superfamily,	MDR2	and	MDR3	and	bile	salt	pump,	BSEP)	can	lead	to	accumulation	of	bile	compounds	and	xenobiotics	in	the	liver,	with	cholestatic	liver	damage	(ciclosporin,	rifampicin,	estradiol)	[54,	55].	Variation	in	the	expression	of	the	corresponding	genes	may	explain	the	different	sensitivity	to	drugs	in	different	individuals	as	well	as	the	susceptibility	to	progressive	liver	disease	[55,	56].	 Another	 possibility	 is	 triggering	 of	 immune-mediated	 damage	 to	 biliary	epithelium	[28,	57,	58].	
Vascular	 abnormalities:	 chemicals	 and	 their	 metabolites	 can	 damage	 hepatic	sinusoids,	 portal	 venules,	 arterioles	 and	 hepatic	 veins.	 The	 resultant	 lesions	produce	 a	 range	 of	 liver	 diseases,	 including	 non-cirrhotic	 portal	 hypertension,	sinusoidal	 dilatation,	 peliosis	 hepatis,	 nodular	 regenerative	 hyperplasia,	 occlusion	of	 portal	 veins	 and	 sinusoidal	 obstruction	 syndrome	 (veno-occlusive	 syndrome)	including	large	vein	obstruction	and	thrombosis,	obstruction	of	small	hepatic	veins	and	 sinusoids.	 In	 addition,	 vascular	 tumors,	 especially	 angiosarcoma,	 have	 been	associated	 with	 agents	 as	 arsenic	 and	monovinyl	 chloride	 that	 more	 often	 cause	
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non-cirrhotic	portal	hypertension.	Individual	drugs	have	been	associated	with	more	than	 one	 type	 of	 hepatic	 vascular	 injury.	 It	 seems	 likely,	 therefore	 that	 these	disorders	are	 inter-related	and	represent	varying	manifestations	of	damage	to	the	vascular	endothelium	Many	 vascular	 alterations	 are	 associated	 with	 drug	 intake,	 with	 distinctive	morphological	features.	
Sinusoidal	obstruction	syndrome	(SOS):	Sinusoidal	endothelial	cells	(SECs),	may	be	 more	 susceptible	 to	 toxic	 injury	 than	 hepatocytes	 themselves	 [59].	 As	 for	hepatocytes,	 the	CYP450	system	plays	a	crucial	role,	probably	together	with	nitric	oxide	 (NO)	 depletion,	metalloproteinases	 (MMPs)	 and	 clotting	 factors	 [60].	Drugs	associated	with	 SOS	are	metabolized	by	 the	CYP450	 system.	Metabolites	 are	 than	detoxified	by	GSH	as	in	the	hepatocytes.	Severe	depletion	of	GSH	due	to	overload	of	metabolites	 leads	 to	mitochondrial	 damage,	 apoptosis	 and	 necrosis,	 as	 described	above	 [61,	62].	Experimentally,	 it	 has	been	 shown	 that	 inhibition	of	NO	 synthesis	and	administration	of	MMP	can	exacerbate	SOS	[63,	64].	SOS	is	associated	to:	1. Conditioning	 before	 bone	 marrow	 transplantation:	 cyclophosphamide	together	with	busulfan	 and	 total	 body	 irradiation.	 In	 this	 case	probably	 an	additional	 effect	 is	 due	 to	 the	 irradiation	 effect	 on	 bone	marrow	 stem	 cell	repair	of	SECs	[65].	2. Cytoreductive	therapy	of	metastatic	colorectal	cancer:	oxaliplatin	may	cause	SOS	[66].	3. Chemotherapy	 for	AML:	gemtuzumab	ozogamicin	 (GO).	SOS	 is	described	 in	ca.	9%	of	cases	[67].	
Peliosis	hepatis:	This	phenomen	is	related,	like	SOS,	to	an	intrinsic	toxicity	effect	of	drugs	 against	 SECs,	 through	 the	 CYP450	 system.	 Drugs	 causing	 peliosis	 are	androgens,	contraceptive,	thiopurine-derivatives.	Major	morphological	patterns	of	vascular	injury	are	summarized	in	Supplementary	Table	2		
Cholestatic	DILI	Cholestatic	damage	to	the	liver,	characterized	by	elevation	of	alkaline	phosphatase	(AP)	 levels	 in	 serum,	 represents	 the	 second	most	 frequent	 type	of	DILI	 (30%).	 In	general,	symptoms	resolve	with	withdrawal	of	the	drug,	but	in	some	cases,	if	there	
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is	significant	loss	of	bile	duct,	damage	can	become	chronic.		Drugs	can	impair	bile	excretion	by	directly	or	indirectly	interfering	with	membrane	transporter	 such	 as	BSEP,	ABC	 superfamily,	MDRs	 [54,	 55,	 68].	 Interestingly,	 also	nuclear	 receptors	such	as	FXR,	RXR,	LRH-1,	LXR,	are	 involved	 in	 the	regulation	of	bile	 acid	 homeostasis.	 Therefore	 drugs	 or	metabolites	 that	 act	 on	 such	 receptors	(rifampicin,	 dexamathasone	 phenobarbital),	 can	 influence	 cholestasis	 [68-70].	Another	mechanism	is	the	obstruction	to	bile	flow	after	secretion,	following	damage	to	cholangiocytes/bile	ducts	[68,	71].	
Histology	of	cholestatic	DILI	In	summary,	cholestatic	damage	to	the	liver	can	be	classified	as	follows	[68]:	1. Acute	Drug-Induced	Cholestasis	without	Hepatitis	(bland	cholestasis).		2. Acute	 Drug-Induced	 Cholestasis	 with	 Hepatitis	 (Cholestatic	 Hepatitis).	Canalicular	 and	 hepatocellular	 cholestasis	 with	 lobular	 and	 portal	inflammation	and	hepatocellular	necrosis.		3. Chronic	Drug-Induced	Cholangiopathies.		A	variable	pattern,	from	mild	duct	injury	to	vanishing	bile	duct	syndrome	and/or	sclerosing	cholangitis.	
Acute	drug-induced	cholestasis	without	hepatitis	(bland	cholestasis).		Bile	 plugs	 are	 seen	 in	 hepatocytes	 and/or	 canaliculi,	 without	 inflammation,	prevalently	 in	zone	3	of	 the	hepatic	 lobule.	This	 is	 the	 typical	reaction	 to	anabolic	steroids	 or	 contraceptives.	 Other	 possible	 causes	 are	 prochlorperazine,	thiabendazole	 and	warfarin	 [72,	 73].	 The	 differential	 diagnosis	 is	 essentially	with	sepsis,	 shock,	 cardiac	 failure,	 acute	 large	 duct	 obstruction	 and	 benign	 recurrent	intrahepatic	cholestasis	(BRIC)	[72].		
Acute	Drug-Induced	Cholestasis	with	Hepatitis	(Cholestatic	Hepatitis).		Characterized	by	neutrophilic	and	eosinophilic	 inflammation,	canalicular	and	 liver	cell	cholestasis	and/or	cholatostasis.	Many	antibiotics	can	be	associated	with	such	damage:	 erythromicin,	 tetracyclines,	 ciprofloxacin,	 cephalosporines.	 Other	 drugs	associated	with	cholestatic	hepatitis	are	chlorpromazine,	risperidone,	amitryptiline,	azathioprine	 [71,	 73,	 74].	 The	 differential	 diagnosis	 is	 with	 acute	 viral	 hepatitis,	autoimmune	hepatitis,	 and	 acute	 large	duct	 obstruction.	 In	 general,	 it	 can	be	 said	that	 localization	of	the	damage	in	zone	3	of	the	hepatic	 lobule	 is	more	 likely	to	be	due	to	drug	injury	[73-75].	
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Chronic	drug-induced	Cholangiopathies.		Chronic	drug-induced	cholestasis	is	defined	as	a	cholestasis	lasting	more	than	three	months	 [73].	 The	 cholestasis	 induces	 a	 necroinflammatory	 portal	 and	 lobular	necrosis,	 leading	 to	 duct	 sclerosis	 and	 loss,	 periportal	 cholestasis,	 portal	 fibrosis,	and	copper	accumulation	 in	periportal	hepatocytes	 (orcein	or	rodhamin	staining).	Hepatocytes	often	show	a	clear	aspect,	due	to	accumulation	of	bile	salts.	Bile	duct	hyperplasia	('neoductulation’)	may	also	be	observed.	If	the	damage	is	very	severe,	it	can	 progress	 to	 liver	 fibrosis	 and,	 very	 rarely,	 to	 cirrhosis.	 The	 continuous	inflammation	 eventually	 leads	 to	 vanishing	 bile	 duct	 syndrome	 (VBDS,	 >	 50%	 of	portal	 fields	 lacking	 bile	 ducts).	 Drugs	 involved	 in	 chronic	 cholestasis	 are	 the	association	 amoxicillin-clavulanic	 acid,	 flucloxacillin,	 terbinafine	 (an	 antifungine)	amiodarone.	 VBDS	 can	 be	 associated	 with	 carbamazepine	 and	 zonisamide,	antipsychotics	such	as	chlorpromazine	and	sulpiride,	NSAIDs	such	as	ibuprofen	and	tenoxicam,	 and	 antibiotics	 such	 as	 amoxicillin,	 flucloxacillin,	 clindamycin	 and	trimethoprim-sulfamethoxazole	[71,	73,	74].	The	differential	diagnosis	is	with	PBC	or	 obstructive	 biliary	 diseases	 rely	 also	 on	 clinical	 and	 imaging	 data	 (AMA	determination,	biliary	tree	imaging).	Major	morphological	patterns	of	cholestatic	DILI	are	summarized	in	supplementary	table	3	
Prognosis.		As	 mentioned	 above,	 most	 cholestatic	 DILIs	 resolve	 after	 withdrawal	 of	 the	causative	 drug.	 However,	 in	 recent	 series,	 cases	 with	 severe/chronic	 cholestatic	injuries	are	associated	with	a	mortality	rate	from	5%	to	14%	[74,	76,	77].	A	chronic	evolution,	 defined	 as	 above,	 was	 observed	 in	 roughly	 5%	 of	 cases,	 whereas	 the	development	of	cirrhosis	is	very	rare	[78].	
Hepatotoxicity	induced	by	Herbal	and	Dietary	Supplements	Herbal	 and	 dietary	 supplements	 (HDS)	 are	 emerging	 as	 a	 major	 cause	 of	 DILI	worldwide.	The	 incidence	 of	 DILI	 from	 HDS	 varies	 by	 geography	 and	 patterns	 HDS	 use.	 It	accounts	for	approximately	9%	of	the	cases	of	DILI	in	United	States	and	up	to	19%	to	63%	of	the	cases	of	DILI	in	Asian	Countries	[79-81].	These	numbers	however	are	probably	underestimated	because	 the	widespread	availability	of	HDS	and	 the	 low	frequency,	with	which	patients	 report	 their	use,	means	 that	 the	 true	 frequency	of	
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attributable	 hepatotoxicity	 is	 unknown.	 The	 clinical	 as	well	 as	 the	morphological	presentation	of	HDS-associated	hepatotoxicity	is	similar	to	that	of	DILI.	The	general	patterns	of	presentation	are	either	predominantly	hepatocellular	or	predominantly	cholestatic.	However,	vascular	lesions	are	also	rather	frequently	observed.	Major	herbals	 and	dietary	 supplements	 causing	hepatotoxicity	 are	 summarized	 in	supplementary	table	4	
Toxicology	study:	state	of	the	art	of	in	vitro	systems,	regulations	for	in	vivo	
studies	and	limitations	of	the	experimental	models		Toxicology	studies	are	performed	in	order	to	predict	adverse	reaction	in	response	to	a	specific	compound.	These	studies	can	be	performed	in	vitro	or	in	vivo,	although	the	current	regulation	imposes	the	safety	assessment	in	animal,	to	support	the	first	clinical	trial	in	human,	and	registration	of	new	medicines.		In	 vitro	 studies	 are	 performed	 on	 live	 material	 out	 of	 its	 biological	 context.	 In	fundamental	 research,	 cell	 culture	 is	 one	 of	 the	 most	 common	 and	 widely	 used	experimental	 approaches.	 It	 allows	 the	 reduction	 of	 the	 biological	 complexity	(organism/organ/tissue/cells)	in	order	to	better	understand	basic	mechanisms.	The	 need	 of	 an	 unlimited	 source	 of	 biological	 material,	 led	 to	 the	 established	 of	many	 organ-specific	 cell	 lines.	 These	 cell	 lines	 derived	 from	 neoplastic	 tissues	through	 a	 clonal	 expansion,	 resulting	 in	 a	 monoclonal	 cell	 lineage	 with	 specific	genotypic	 and	 phenotypic	 features.	 Unfortunately	 being	 derived	 from	 neoplastic	material,	 the	 cell	 lines	 also	 carry	 many	 specific	 aberrations	 (e.g.	 in	 the	 liver	 cell	lines,	 alteration	 in	 the	 innate	 immunity	 attitudes	 [82],	 lack	 of	 gene/proteins	expression	 [83],	 several	 biologically	 relevant	 SNPs,	 lack	 of	 the	 metabolic	 genes’	expression).	 Despite	 the	 large	 use	 of	 cell	 lines	 in	 the	 basic	 research,	 the	translatability	 of	many	 findings	 and,	 consequently,	 their	 usefulness	 for	 toxicology	assessment,	are	limited.			Primary	 human	 hepatocytes	 (PHH)	 are	 still	 the	 state	 of	 art	 in	 the	 study	 of	phenomena	related	with	 liver	 toxicity	 in	vitro.	 In	optimized	conditions	 those	cells	preserve	 the	 liver	 metabolic	 enzymes	 (CYPs)	 and	 most	 of	 the	 liver	 specific	functions.	 Unfortunately,	 PHH	 availability	 is	 limited	 from	 the	 liver	 explants	 and	organ	donation	shortage.	The	cells	have	a	high	batch-to-batch	variability	and	even	if	
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cultured	 in	 optimized	 conditions,	 they	 tend	 to	 de-differentiate	 towards	 a	mesenchymal	 phenotype	 within	 few	 days/weeks,	 loosing	 liver	 specific	 functions.	Specific	culturing	system,	such	as	co-culture	with	non-parenchymal	cells[84],	use	of	specific	substrates	and	specific	media,	3D	printing/culturing,	microfluidic	perfusion	systems	[84]	and	bioreactor-assisted	culturing	[85],	helped	 in	preserving	the	 liver	specific	 phenotype,	 but	 the	 improvements	 are	 limited	 and	 these	 modifications	increased	the	handling	costs	of	several	folds.	Given	 the	 limitations	 of	 in	 vitro	models,	 one	 can	 understand	 the	 need	 of	 a	more	reliable	system	for	drug	safety	assessment.	Thus,	experiments	preformed	on	animal	models	are,	not	only	a	legal	requirement	for	the	submission	of	new	drugs,	but	they	are	also	justified	scientifically.	The	Declaration	of	Helsinki	imposes	the	need	for	a	preclinical	safety	testing	before	the	introduction	of	new	drugs	into	human	beings.	Regulatory	approval	 is	required	prior	to	the	first	clinical	trial	and	this	 is	contingent	on	the	assessment	of	potential	risks	through	preclinical	safety	studies.	Currently,	these	studies	must	be	performed	on	 animal	models	 in	 order	 to	 identify	 the	 safe	 dose	 for	 human,	 and	 the	 potential	target	organs	of	toxicity.	This	has	a	huge	economic	and	emotional	impact	on	society,	raising	also	significant	ethical	questions.		A	toxicological	study	should	be	designed	to	obtain	the	following	 information,	with	the	minimal	use	of	model	animals:	target	organ(s)	of	toxicity,	relationship	between	dose/exposure	 (Pharmacokinetics-PK)	 and	 response	 (Pharmacodinamics-PD),	potential	 reversibility	 of	 any	 adverse	 effect,	 relevance	 to	 human	 and	 potential	parameters	for	identification	and	monitoring	of	adverse	event	in	clinical	studies.	Another	 crucial	 parameter	 to	 be	 determined	 in	 toxicological	 studies	 is	 the	relationship	between	dose,	exposure	and	effectiveness.	The	legislation	requires	that	a	drug	must	be	safe	after	repeated	dosing	to	a	specific	exposure	[86].	This	needs	the	assessment,	 during	 the	 animal	 studies,	 of	 a	 maximum	 exposure	 dosage	 and	minimum	exposure	dosage.		The	 maximum	 exposure	 determines	 toxicity	 and	 target	 organ	 damage.	 The	induction	and	the	identification	of	tissue	damage	are,	therefore,	critical,	although	it	should	be	minimized	to	reduce	the	animal	suffering.		The	minimum	exposure,	vice	versa,	represents	the	condition	that	causes	no	tangible	effect	and	no	toxicity.	
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Regulatory	 authorities	 suggest	 designing	 toxicological	 studies	 including	 repeated	exposure	at	high,	medium	and	low	dosages.	The	highest	dose	at	which	no	overt	toxicity	occurs	in	a	90-day	study	(the	maximum	
tolerated	dose),	is	generally	used	to	establish	animal	dosing	levels	for	chronic	assays	that	provide	insight	into	potential	latent	effects	[86].	Reversibility	of	damage	can	be	assessed	by	 introducing	 recovering	 time,	 aimed	at	providing	 to	 the	animals	 the	 time	 to	 excrete	 the	 toxins	 and	 recover	 from	adverse	event.	Relevance	for	human	safety	is,	indeed,	one	of	goals	of	the	toxicological	studies	and	it	is	the	most	difficult	result	to	achieve.	This	implies	a	deep	knowledge	of	the	species	specificities,	leading	to	the	selection	of	the	correct	animal	model.		Toxicology	 tests	 are	 fairly	 standardized	 and	 outlined	 in	 the	 ICH	 guidance	documents	 (S1-5,	 S7-8).	 In	 general,	 two	 animal	 species	 are	 used	 to	maximize	 the	chance	of	detecting	toxicity,	a	rodent	and	non-rodent	species	[87].		It	is	currently	well	known	that	animal	models	differ	from	human	for	the	genes	and	the	 proteins	 involved	 in	 drug	 metabolism,	 and	 ultimately	 in	 the	 production	 of	catabolites.	 Rodents	 have	 a	 peculiar	 hepatic	 xenobiotic	 metabolism	 regulation,	operated	 through	 the	 Growth	 Hormone	 (GH),	 which	 generates	 strong	 sexual	dimorphism	and	differences	in	the	circadian	cycle.	Contrarily,	other	animal	models	are	less	affected	by	this	dimorphism.		Considerations	 for	 species	 selection	 also	 include:	 pharmacokinetics,	 metabolites,	activity/affinity	 of	 the	 molecule	 at	 the	 target	 and	 at	 related	 targets,	 and	 non-sensitive	vs	too-sensitive	species	[87].	Nowadays	 many	 databases	 reporting	 the	 species-specificities	 toxicity	 of	 some	compound	have	been	published	online	and	represent	a	useful	source	of	information	for	researcher	and	regulatory	authorities	[88].		However,	for	new	compounds	the	identification	of	the	most	appropriate	species	for	toxicological	studies	is	still	crucial.	Economical	and	ethical	reasons	do	not	allow	to	run	 systematically	 those	 studies	on	non-human	primates	 (NHP),	 closer	 to	human,	however,	 a	 deep	 knowledge	 of	 species	 (and	 tissue)	 specificities	might	 drastically	reduce,	in	the	future,	the	risk	of	drug	induced	adverse	events,	and	drastically	reduce	the	use	of	irrelevant	animal	models,	thus	reducing	the	economic	impact	of	the	safety	assessment	for	new	drugs.	
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In	 common	practice,	 animal	 studies	 start	with	 rodents,	 but	 genetic	 and	metabolic	differences	 with	 human,	 or	 susceptibility	 to	 specific	 pathologies,	 may	 reduce	drastically	the	relevance	of	those	experiments.	The	dog	is	generally	the	non-rodent	species	of	choice.	Toxins	 do	 not	 target	 in	 same	 way	 all	 the	 tissues/organs	 in	 the	 body.	 The	 target	organ	is	determined	by	the	capacity	of	the	tissue	to	absorb	the	xenobiotic	itself	or,	produce	or	absorb	metabolites	thereof.	The	route	of	administration	also	determines	the	 target	organ.	Oral	administration	 is	adsorbed	by	 the	 intestine	and	reaches	 the	liver	 through	 the	 portal	 vein,	 where	 most	 of	 drugs	 are	 metabolized.	 Drug	administered	intravenously	reaches	rapidly	the	heart	and	the	lung.		Liver	is	the	organ	exposed	to	the	highest	risk	of	drug	toxicity.	However,	due	to	the	differential	metabolic	functions	and	capacity	to	break	down	drugs	and	metabolites	between	the	hepatocytes	spatially	distributed	along	the	periportal-pericentral	area,	the	concept	of	target	organ	should	be	further	extended	to	a	cell	specific	resolution	in	this	organ.	
Toxicogenomics	and	transcriptomic	Toxicology	 aims	 at	 understanding	 the	 effects	 of	 acute,	 prolonged	 or	 repeated	exposure	 to	 a	 compound.	 It	 makes	 use	 of	 all	 the	 basic	 research	 tools	 for	understanding	when,	where	and	how	a	compound	may	injury	a	tissue.	Transcriptomics	 is	 the	 study	 of	 gene	 transcripts	 (mRNA),	 made	 by	 different	technologies	(i.e.	oligonucleotide	chips	or	RNAseq).	Toxicogenomics	is	transcriptomics	applied	to	toxicology.	The	basic	assumption	is	that	the	transcriptome	reflects	the	metabolic	state	of	a	cell	and	 the	 changes	 from	 a	 baseline	 can	 be	 used	 for	 the	 study	 of	 the	 drug-induced	alterations.		The	obvious	advantage	is	to	be	able	to	observe	changes	in	wide	spectrum	and	not	only	 in	 pathways	 conceivably	 involved	 in	 the	 metabolism	 of	 a	 compound.	 This	allows	the	identification	of	previously	unknown	mechanisms	of	toxicity.		
Aim	of	the	project	and	methodological	approach	to	resolve	the	tissue	
heterogeneity.	Several	 factors,	 related	 to	 the	 individual	 genetic	 background	 and	 the	 intrinsic	characteristics	of	the	organs	involved	in	drug	metabolism,	contribute	to	the	toxicity	
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of	compounds.	This	makes	the	prediction	of	adverse	events	induced	by	drugs	in	the	patients	(the	ultimate	goal	of	toxicology),	a	challenging	task.	The	 technological	 advances	 have	 improved	 predictive	 capabilities	 by	 providing	more	 sensitive	 methodologies,	 able	 to	 perceive	 minor	 molecular	 changes	 in	 the	target	organ.		However,	more	efforts	are	required	in	order	to	achieve	the	ambitious	goal	of	early	prediction	of	drug	induced	adverse	event.	For	these,	two	points	are	crucial:		
• Sensitivity:	methods	must	be	capable	of	identifying	phenomena	that	occur	at	the	single	cell	level.		
• Reference	data	for	qualification:	reference	values	must	be	in	order	to	provide	the	 necessary	 basis	 for	 interpretation	 of	 subsequent	 experiments	 (e.g.	baseline,	or	typical	changes).	Nowadays,	 the	 technologies	 are	 so	 sensitive	 that	 in	 most	 of	 cases	 they	 have	 a	resolving	power	sufficient	to	detect	small	phenomena.	However,	the	most	sensitive	technique	 still	 requires	 some	 criteria	 for	 the	 discrimination	 between	 relevant	variations,	 though	 minor,	 and	 random	 variations	 (noise).	 This	 is	 particularly	problematic	 in	 the	 field	 of	 the	 transcriptomic	 analysis,	 for	 genes	 with	 low	expression	values	[89].	The	new	–omics	technologies	are	 in	general	very	sensitive	to	minor	phenomena,	but	the	interpretation	and	the	discrimination	of	(non)relevant	noise,	is	sometimes	the	major	issue	limiting	the	understanding	of	such	phenomena.	This	 limitation	 is	 amplified	 when	 transcriptomics	 are	 applied	 to	 the	 study	 of	heterogeneous	 tissues,	 where	 all	 the	 cells	 concur	 to	 the	 transcriptomic	 profile.	Variation	 of	 gene	 expression	 values	 between	 experimental	 conditions	 are	proportional,	not	only	to	the	magnitude	of	a	molecular	phenomenon	in	cells	(up-	or	down-regulation),	but	also,	and	in	big	extent,	to	the	change	of	this	cell	population	in	the	 whole	 tissue.	 In	 other	 words,	 the	 transcriptomic	 profile	 of	 a	 single	 cell	population	is	averaged	by	those	of	the	other	cells	composing	the	tissue,	and	a	gene	highly	 expressed	 in	 a	 small	 subset	of	 cells	 can	have	 a	 low	expression	value	when	estimated	from	the	expression	profile	of	the	entire	tissue.	In	 this	 respect,	 it	 is	often	difficult	 to	deconvolve	whole	 tissue	 transcriptomic	data	and	 identify	 changes	 in	 a	 rare	 cell	 population	 with	 optimal	 specificity	 and	sensitivity,	 mostly	 because	 the	 apparent	 expression	 value	 of	 specific	 genes	 is	difficult	 to	distinguish	 from	 the	background	noise.	 To	help	 overcome	 this	 issue,	 a	
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detailed	 transcriptomic	 profile	 of	 the	 cell	 types	 that	 compose	 the	 tissue	 in	 a	homeostatic	state	could	be	useful,	but	is	in	most	of	cases	missing.	The	 untreated	 controls	 included	 in	 all	 the	 studies,	 while	 providing	 global	information	 on	 the	 tissue	 in	 analysis,	 fail	 to	 provide	 information	 at	 single	 cell	resolution,	because	of	their	own	heterogeneous	composition.	Moreover,	traditional	analysis	 of	 large	 sets	 of	 gene	 expression	 data	 make	 extensive	 use	 of	 statistical	filtering	in	order	to	reduce	the	likelihood	of	false	discovery.	In	this	scenario,	minor	events,	as	well	as	big	events	occurring	at	a	minor	cell	population,	are	systematically	underestimated	due	to	the	precedence	given	to	statistical	significance.	As	previously	discussed,	 the	 liver	 is	one	of	 the	organs	mainly	affected	by	the	drug	induced	 injury.	 The	 understanding	 of	 the	 molecular	 mechanisms	 leading	 to	 the	injury	in	this	organ	is	challenging	due	to	its	histological	and	functional	complexity.		For	 this	 reason,	we	 undertook	 the	 creation	 of	 a	 transcriptomic	map	 of	 the	major	histological	 components	 of	 the	 normal	 liver	 from	 the	 species	 usually	 used	 for	preclinical	safety	assessment	of	drug	candidates.	We	 decided	 to	 approach	 the	 creation	 of	 this	 detailed	 gene	 expression	 map	 by	 a	technique,	the	Laser	Capture	Microdissection	(LCM),	able	to	isolate	cell	populations	from	heterogeneous	tissues,	based	on	a	morphological	anchor.	Specifically,	we	aim	at	profiling	the	functional	areas	of	the	liver	parenchyma	(liver	zone	I	and	zone	III),	the	 bile	 ducts	 and	 the	 blood	 vessels,	 all	 potential	 target	 organs	 for	 several	compounds.	We	 have	 chosen	 to	 combine	 the	 LCM	 and	 the	 immuno-LCM,	 the	 laser	 capture	microdissection	guided	by	immunolabeling	of	target	cells,	with	the	oligonucleotide	technology	for	profiling	the	transcriptome	of	those	tissues.	The	resulting	data	will	serve	as	a	comparative	tool	in	prospective	and	retrospective	studies	in	drug	safety	investigations.		Here	we	will	also	use	this	data,	as	tool	for	the	early	detection	of	the	morphological	and	molecular	 changes	 occurring	 in	 rats,	 upon	 the	 administration	 of	 a	 reference	compound:	 Methapyrilene.	 We	 explored	 how	 minimal	 molecular	 changes,	 which	would	have	not	been	taken	into	account	using	traditional	filtering	because	of	their	limited	 statistical	 value	 in	 the	 pool	 of	 a	 transcriptomic	 analysis,	might	 indeed	 be	indicative	of	morphological	changes	in	the	liver,	which	would	have	been	diagnosed	only	at	a	later	time-point	by	a	standard	approach.			
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Laser	capture	microdissection	Many	 groups	 attempted,	 over	 the	 years,	 to	 profile	 the	 liver	 gene	 expression:	 in	preclinical	 studies,	 where	 transcriptomics	 has	 become	 a	 fundamental	 tool	 for	screening	 early	 toxicity	 [90-95],	 and	 in	 clinical	 study	 for	 identification	 of	mechanisms	in	 liver	diseases	[96-99].	 In	most	of	cases,	 the	studies	relied	on	usual	statistical	 filtering	 of	 expression	 data	 generated	 from	whole	 liver	 tissue	 or	 small	tissue	biopsies,	underestimating	the	importance	of	the	tissue	heterogeneity	and	its	impact	on	the	gene	expression	profiling.	Beside	 specific	 methods	 based	 on	 tissue	 digestion	 and	 cell	 sorting	 (e.g.	 the	fluorescence-activated	 cell	 sorting	 or	 the	 immuno-magnetic	 separation),	 the	possibility	to	analyze	the	gene	expression	in	situ,	in	ex-vivo	liver	tissues,	is	limited	to	few	options.	While	in	situ	PCR	based	methods	(i.e.	target	amplification)	are	very	sensitive,	 they	 are	 targeting	 a	 single	 transcript	 per	 assay	 and	 are	 prone	 to	 false	positive	signals	due	to	contamination	and/or	insufficient	primer	specificity	[100].		Modern	 multiplex	 in	 situ	 hybridization	 systems	 allows	 the	 localization	 in	 situ	 of	only	some	transcripts.	Both	 these	 approaches	 are	 not	 any	 close	 to	 the	 power	 of	 transcriptome-wide	profiling	to	help	generate	hypotheses.	Laser	capture	microdissection	(LCM)	is	a	technique	to	isolate	microscopic	samples,	using	pulsed	 lasers	 technology,	which	makes	possible	dissection	 and	 collection	of	small	portion	of	 tissue,	under	 the	direct	operator	control,	 from	frozen	or	 formalin	fixed	paraffin	embedded	(FFPE)	tissue	sections.	The	technique,	introduced	in	1976	[101],	 has	 had	 extensive	 development	 and	 improvement	 by	 the	 late	 years	 90s	onwards	to	date,	and	can	be	considered	a	well-established	methodology,	commonly	used	in	the	molecular	pathology	field	[102-105].	In	general,	 a	 laser	 capture	microdissector	 consists	of	 a	microscope	 (working	with	transmitted	 and	 reflected	 light),	 a	 computer	 controlled	 stage,	 a	 laser	 unit,	 and	 a	tissue	collector.	Current	technology	allows	isolating	samples	as	small	as	single	cell,	or	even	smaller	sub-cellular	structures	(e.g.	metaphasic	chromosomes)	[106].	LCM	derived	 samples	 can	be	used	 for	protein	 [107]	 and	nucleic	 acid	purification	 [108,	109],	and	also	for	single	live	cell	collection	[110-112].	
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Currently,	 two	 technologies	 are	 available,	 which	 differ	 for	 the	 method	 of	 tissue	collection	 and	 for	 the	 physical	 features	 of	 the	 laser	 used	 to	 cut	 and	 collect	 the	tissues.		All	 the	equipment	 so	 far	 available	makes	use	of	UV-A	 (349	nm)	 laser,	 and,	 in	one	case,	of	an	additional	infrared	(IR)	laser.		The	 UV	 light	 is	 the	 only	 one	 fulfilling	 the	 requirement	 of	 a	 sufficient	 energy	 for	vaporizing	and	cutting	the	tissues.	However,	the	energy	transferred	to	tissue	during	the	laser	capture	microdissection	may	easily	lead	to	the	degradation	of	the	nucleic	acid,	due	to	the	transformation	of	the	energy	in	heat.		
	http://marktechopto.com/img/uv-color-spectrum.png		There	 is	an	 inverse	 relationship	between	 the	wave	 length	and	 the	energy	of	 light.		Therefore,	within	the	UV	spectrum,	the	UV-A,	located	at	the	top	of	the	wave	length	range,	is	the	one,	among	the	UV	classes,	with	the	lowest	energy,	and	represents	the	best	 compromise	 between	 the	 need	 of	 energy	 for	 cutting	 and	 the	 preservation	 of	biological	molecules.	Differently,	the	use	of	the	IR	laser	does	not	impact	the	organic	molecules,	due	to	its	high	frequency	and	low	energy.		Beyond	the	physical	properties	of	laser	beams,	additional	precautions	are	necessary	for	avoiding	the	excessive	irradiation	of	the	tissues	during	the	laser	capturing.	For	instance,	 pulse-width	 modulation	 (PWM)	 is	 mechanism	 commonly	 used	 in	 LCM	applications	to	modulated	the	laser	energy.	The	use	of	different	lasers	influences	the	precision	of	the	systems:	the	UV-A	(only)	based	systems	resulted	generally	more	precise	than	the	one	using	a	combination	of	UV-A	and	IR.	This	is	due	to	intrinsic	characteristic	of	the	light	frequency	and	also	to	the	collection	method	associated	with	the	different	lasers.	That	is,	if	the	UV-A	based	systems	are	able	to	reach	a	minimal	laser	spot	diameter	as	small	as	0.5µm,	and	they	
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have	an	estimated	precision	of	1µm	[113],	the	system	using	a	combination	of	UV-A	and	IR	laser	can	reach	only	a	precision	of	7.5µm	(spot	diameter)	[114].	The	collection	of	dissected	tissue	samples	is	operated	in	different	ways.	The	systems	based	on	UV-A	use	 two	different	approaches:	 the	 laser	pressure	 catapult	 (LPC)	 in	which,	after	the	cutting	phase,	the	laser	is	refocused	at	a	lower	plane	than	that	of	the	tissue.	A	single	laser	shot	is	then	used	for	generating	pressure	wave,	able	to	catapult	the	cut	tissue	up	in	the	tissue	collector.	This	system	is	effective,	but	it	is	affected	by	the	size	and	the	weight	of	the	microdissected	area	(representative	picture	below).			
	https://lookfordiagnosis.com/mesh_info.php?term=laser%20capture%20microdissection&lang=1		The	second	approach	to	the	tissue	collection	is	a	gravity	assisted	system,	in	which	the	 tissue	 collector	 has	 been	 moved	 below	 the	 tissue	 and	 the	 dissected	 area	 is	catapulted	down	with	the	help	of	the	gravity	force.	The	last	approach	to	the	tissue	collection	is	typical	of	the	hybrid	systems	(UV-A/IR).	It	makes	use	of	a	plastic	device	covered	by	a	plastic	microfilm.	The	IR	light	is	then	used	 to	melt	 and	 fuse	 together	 the	microdissected	area	 and	 the	plastic	device.	As	this	 system	 is	 the	 less	 affected	 by	 the	 size	 of	 the	microdissected	 tissue	 are,	 it	 is	intuitively	the	best	one	for	applications	that	are	aiming	at	large	lesions	and	do	not	require	very	high	topographical	precision	(representative	picture	below).		
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	https://lookfordiagnosis.com/mesh_info.php?term=laser%20capture%20microdissection&lang=1		In	terms	of	sample	purity,	the	first	approach	allows	better	results,	since	there	is	no	physical	interaction	with	the	tissue,	which	is,	instead,	necessary	by	using	the	plastic	devices	for	the	collection.	In	this	project	we	had	the	possibility	to	use	two	different	systems,	taking	advantage	from	 their	 collecting	 system,	 in	 order	 to	 achieve	 the	 best	 results	 with	 samples	differing	by	sizes.	The	combination	of	laser	microdissection	techniques	with	those	of	oligonucleotide	array	 technology	 has	 revolutionized	 the	 molecular	 analysis	 of	 heterogeneous	tissues.	 Nevertheless,	 many	 drawbacks	 have	 limited	 the	 use	 of	 LCM	 to	 specific	fields.		As	general	observation,	the	generation	of	the	transcriptomic	profile	and	the	analysis	of	LCM	derived	samples	is	time	consuming	and	extremely	expensive.	The	LCM	 involves	 complex	 and	 lengthy	procedures	 that	may	negatively	 affect	 the	RNA	integrity.		The	choice	of	 the	right	starting	material	 is	crucial	 for	the	final	results.	Despite	the	plethora	of	protocols	for	extracting	RNA	from	FFPE	tissues	[108,	109,	115,	116],	the	resulting	 RNA	 quality	 is	 generally	 poor,	 due	 to	 degradation	 by	 endogenous	ribonucleases	 (RNAses),	 or	 cross-links	 between	 nucleic	 acids	 and	 proteins,	which	results	 in	 a	 massive	 RNA	 fragmentation	 and	 a	 lower	 yield	 of	 the	 purification	procedure.	
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Tissue	 collection,	 embedding	 and	 freezing,	 sectioning,	 fixation,	 staining,	 and	microdissection	are	the	common	preparation	phases	of	LCM	samples:	each	of	them	may	hide	potential	risks	for	the	RNA	integrity.		The	tissue	should	be	quickly	resected,	embedded	and	kept	at	low	temperature	until	the	sectioning	and	fixation.	The	 fixatives	 can	 be	 divided	 into	 two	major	 categories:	 the	 precipitating	 fixatives	(alcohol)	and	the	cross	linking	fixatives	(aldehydes).	Several	 authors	 have	 investigated	 the	 capacity	 of	 different	 fixatives	 to	 preserve	nucleic	 acids,	 concluding	 that	 the	 precipitating	 fixatives	 were	 more	 effective	 to	preserve	RNA	than	the	cross	linking	ones	[117,	118].		The	 aldehydes	 form	 covalent	 crosslinks	 between	 nucleic	 acids	 and	 proteins,	 and	their	 penetration	 in	 the	 tissues	 is	 slower	 than	 alcoholic	 fixatives.	 Both	 factors	contribute	to	the	poor	yield	and	quality	of	the	RNA	purified	out	of	FFPE	samples.		The	 denaturation	 operated	 by	 the	 alcohol	 is	 based	 on	 removal	 of	 water	 from	specimen	and	is	far	less	effective	as	fixation	method	compare	to	cross-linking.	The	RNases	 can	 return	 to	 their	 native	 conformation	 and	 activity	 during	 sample	processing,	where	water	or	water-based	buffers	are	necessary.	Therefore,	the	use	of	alcohol	 fixatives	 imposes	 a	 fast	 processing	 in	 order	 to	 limit	 the	 re-activation	 of	endogenous	RNases.	The	 isolation	 of	 specific	 tissue	 structures	 from	 the	 surrounding	 using	 LCM	 is	possible	 from	 unstained	 sections	 or	 from	 sections	 stained	 by	 chemical	 dyes	 (e.g.	hematoxylin-eosin,	 cresyl	 violet,	 etc)	 [113,	 119,	 120].	 Such	 staining	 is	 fast,	 and	therefore	 does	 not	 strongly	 affect	 the	 RNA	 quality.	 However,	 they	 are	 often	inadequate	 for	 the	 isolation	 of	 specific	 structures	 or	 single	 cells,	 due	 to	 the	 low	specificity	of	the	stains.		The	 use	 of	 specific	 immuno-staining	 is	 strongly	 recommended	 in	 order	 to	selectively	 highlight	 structures	 of	 interest	 and,	 thus,	 limit	 the	 possible	 cross	contamination	from	surrounding	cells	or	tissues	[121-127].	The	 introduction	 of	 immunohistochemical	 technique	 in	 the	 LCM	 workflow,	however,	greatly	complicates	the	entire	procedure,	because	it	generally	requires	a	longer	processing	time	than	the	chemical	dye.	Tissue	exposure	to	water-based	solution	is	detrimental	for	the	RNA	quality	because	chemical	RNA	hydrolysis	may	occur	in	certain	conditions,	and,	most	importantly,	it	
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allows	 the	 reactivation	 of	 endogenous	 RNases.	 Fend	 et	 al.	 have	 shown	 that	 it	 is	possible	 to	minimize	 the	 immunohistochemistry	 processing	 time,	 thus	 preserving	the	 RNA	 quality,	 however,	 the	 interaction	 antigen-antibody	 requires	 time	 and	during	this	time	the	endogenous	RNase,	reactivated,	can	freely	operate	[122].	The	use	of	enzymatic	RNase	inhibitors,	to	limit	the	RNase	activity,	is	controversial:	some	authors,	such	as	Kube	et	al.	believe	that	the	RNase	inhibitors	may	improve	the	RNA	quality	 [105],	 some	 other	 authors,	 such	 as	 Zhou	 et	al.,	 argue	 that	 the	 use	 of	inhibitors	does	not	result	in	any	improvement	[102].	Tissue	dehydration	and	the	lack	of	coverslip,	due	to	the	need	to	have	free	access	to	tissues	 for	 microdissection,	 represent	 further	 difficulties,	 because	 they	 reduce	drastically	the	morphology	and	make	difficult	to	discern	different	cell	types.	A	fluid	cover	medium,	 specifically	 designed	 for	 this	 purpose	 seems	 to	 improve	 both	 the	morphology	and	the	capturing,	but	may	reduce	the	catapulting	efficiency	in	the	LPC	system	[128].		Over	 all,	 the	 processing	 optimization	 and	 the	 time	 reduction	 are	 of	 primary	importance.	Laser	 microdissection	 has	 been	 used	 by	 several	 groups	 for	 the	 study	 of	 liver	malignancies	and	bile	ducts	diseases	[104,	129-135].	While	the	use	of	chemical	dyes	in	 these	 studies	 has	 allowed	 the	 identification	 and	 isolation	 of	 regions	 of	 interest	with	 sufficient	 precision,	 the	 dissection	 of	 bile	 ducts	 might	 have	 been	 greatly	improved	by	immunofluorescence	due	to	the	direct	and	the	unambiguous	 labeling	of	these	tissues.	The	use	of	immunostaining	to	guide	LCM	have	greatly	increased	the	accuracy	of	the	identification	of	specific	structures,	and	has	to	some	extend	allowed	operators	less	trained	in	histology	or	pathology	to	perform	adequate	LCM.	The	resulting	increase	in	 dissection	 accuracy	 improves	 the	 precision	 of	 the	 resulting	 gene	 expression	profile	by	reducing	the	likelihood	and	the	amount	of	contamination	of	the	sample	by	surrounding	tissues.		Finally,	RNA	purification	from	LCM	samples	is	a	challenging	activity	because	of	the	limited	abundance	and	the	inherent	fragility	of	this	type	of	nuclei	acids.		The	amount	of	RNA	obtained	from	LCM	derived	samples	 is	usually	 insufficient	 for	array-based	 methods	 of	 gene	 expression	 analysis.	 Sample	 pooling	 from	 serial	sections	appears	to	be	the	only	solution	to	solve	this	issue	[127].	
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The	classical	approach	for	nucleic	acid	purification	is	not	able	to	provide	a	sufficient	yield	and	the	use	of	specific	kits	is	most	recommended.	RNAs	 quality	 should	 be	 preserved	 as	 much	 as	 possible,	 due	 to	 the	 necessity	 of	preserving	full-length	RNAs	for	an	effective	hybridization	with	the	oligonucleotides	spotted	on	the	chips.	RNAseq	 methodologies	 may	 greatly	 overcome	 the	 current	 challenges	 associated	with	 LCM	and	 gene	 expression	profiling,	 as	 they	 are	 less	 sensitive	 to	 partial	 RNA	degradation	 and	 could	 allow	 molecular	 profiling	 from	 FFPE	 samples.	 This	 may	represent	in	the	future,	an	important	step	forward	in	the	field,	allowing	the	use	of	the	huge	amount	of	samples	stored	in	the	tissue	bio	banks	of	pathology	institutes	all	around	the	world.		
Gene	expression	profile		
Affymetrix	Gene	Chip	platform	The	study	of	gene	expression	by	oligonucleotide	array	(Affymetrix	GeneChip	3’IVT)	has	become	a	very	common	practice	 in	 last	years,	 thanks	 to	 the	 lowering	of	 costs	and	 the	 standardization	 of	 some	 processes	 of	 analysis,	 which	 have	 made	 this	approach	accessible	to	a	wide	audience	of	researchers.	This	approach	will	be,	likely,	eclipsed	 in	 the	 next	 years,	 by	 the	 RNAseq	 technology,	 more	 powerful	 and	 less	sensitive	 to	 partial	 RNA	 degradation,	 but	 oligonucleotide	 arrays	 still	 represent	 a	good	and	reliable	option	for	high-throughput	gene	expression	profiling.	The	success	of	these	platforms,	was	based	on	the	multi-probes	system,	which	make	them	very	reliable	and	reproducible.	The	 technology	 is	 based	 on	 synthetic	 supports	 spotted,	 through	 lithography	process,	 with	 many	 hundred	 thousand	 of	 short	 oligonucleotide	 (21	 bases	 each),	complementary	 to	 species-specific	 gene	 sequences.	 In	 brief,	 the	 entire	transcriptome	 contained	 in	 a	 sample	 is	 retrotranscribed	 and	 the	 resulting	 cDNAs	are	hybridized	onto	 the	 spotted	probe	set	arrays.	The	hybridization	 results	 into	a	fluorescence	signal	 the	 intensity	of	which	 is	 thought	to	be	 linearly	proportional	 to	the	abundance	each	single	transcript	[136].	Additionally,	each	probe	set	includes	a	mismatched	nucleotide	probe.	Those	probes	are	intended	to	provide	an	estimation	of	the	fluorescence	background,	versus	the	actual	signal	determined	by	the	perfect	matched	probes	[137].		
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Data	pre-processing	Fluorescence	raw	data	require	pre-processing	 in	order	 to	make	 them	reliable	and	comparable	with	 data	 from	other	 sources	 (data	 from	 the	 same	 array	 type	 can	 be	compared	upon	pre-processing	and	normalization).	Pre-processing	includes	several	steps:	 raw	 data	 quality	 control,	 background	 reduction,	 summarization	 and	normalization,	transformation	in	logarithmic	scale.	The	raw	data	quality	control	addresses	 the	quality	of	 the	samples	and	 the	correct	hybridization	on	the	array	surface	[138].		Nowadays	 the	 summarization	 algorithms	 more	 widely	 used	 for	 the	 Affymetrix	platform	3'IVT	are	the	Robust	Multi-array	Average	(RMA)	[139]	and	the	Affymetrix	Micro	 Array	 Suite	 rel.	 5.0	 (MAS5)	 [140].	 Additional	 algorithms	 are	 modified	 and	optimized	variants	of	these	basic	algorithms	(GC-RMA,	PLIER,	etc.).		An	alternative	and	uncommon	approach	to	the	analysis	of	the	Affymetrix	GeneChip	was	the	one	proposed	by	Li	and	Wong,	based	on	the	 identification	of	single-probe	outliers	within	the	probe	sets	targeting	a	single	transcript	[141].		The	choice	of	the	right	algorithm	may	influence	in	some	extent	the	data	distribution,	thus	 it	 is	 important	 to	 know	 the	 peculiar	 characteristics	 of	 each	 approach	 and	choose	the	algorithm	which	best	fit	to	the	experimental	design.		Algorithms	 differ	 in	 the	 approach	 to	 data	 summarization	 and	 the	 background	correction:	MAS5	fully	utilizes	the	characteristics	of	the	Affymetrix	chips,	using	the	perfect	 match	 probes	 (PM)	 and	 the	 mismatch	 ones	 (MM)	 for	 the	 reduction	 of	background	 (PM-MM	 =	 raw	 signal).	 MAS5	 has	 been	 further	 improved	 to	 avoid	attributing	 negative	 values,	 if	 the	 intensity	 of	 a	 MM	 probe	 exceeds	 that	 of	 the	corresponding	PM,	generating	a	negative	value.		A	further	peculiarity	of	the	algorithm	MAS5	is	represented	by	the	call	flag	(Present,	Marginal	or	Absent,	P,	M,	A)	attributed	to	each	probe	set	by	the	analysis	software.	This	flag	represents	an	indication	of	how	reliable	the	expression	measurement	is.	In	other	 words,	 the	 MAS5	 algorithm	 not	 only	 provides	 a	 measure	 of	 the	 gene	expression,	 but	 also	 an	 additional	 parameter	 on	 the	 reliability	 of	 such	 a	measurement.		The	use	of	call	flag	as	pre-filtering	tool	allows	a	high	correspondence	between	data	pre-processed	by	MAS5	or	RMA	algorithm.	However,	 this	 strategy	may	 results,	 in	
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specific	cases,	in	a	too	stringent	filtering	[140,	142].	In	our	study	we	will	show	how	the	 application	 of	 this	 filter	 may	 result	 in	 the	 exclusion	 of	 relevant	 biological	information.	The	RMA	and	GCRMA	have	a	completely	different	approach	to	data	summarization	and	 background	 correction:	 they	 do	 not	 take	 advantage	 of	 the	 MM	 probes,	 but	perform	a	normalization	of	the	data	across	chips:	in	brief	data	are	sorted	in	a	table;	values	 are	 then	distributed	 in	descending	order	 in	 the	 columns,	 according	 to	 raw	intensity	 values.	 Then,	 the	 expression	 values	 in	 each	 row	 are	 replaced	 by	 the	median	value	of	 that	 row.	Finally,	 the	data	are	 re-sorted	according	 to	 the	original	order.	By	 this,	 the	data	 frequency	distribution	 is	 identical	 in	 all	 the	 chips	 and	 the	data	will	 be	 perfectly	 comparable.	 This	 system,	 although	 theoretically	more	 solid	and	 less	 prone	 to	 give	 false	 positives,	 showed	 a	 major	 issue,	 introducing	 a	nonexistent	correlation	between	samples,	in	specific	experimental	conditions,	such	as	low	expressed	genes	and	few	replicates	[143].	The	algorithm	developed	by	Li	and	Wong	takes	into	account	the	variation	of	signal	within	the	single	probe	set,	assuming	that	variability	between	probes,	belonging	to	the	 same	 probe	 set	 and	 targeting	 the	 same	 transcript,	 should	 be	 minimal.	 This	algorithm,	tries	to	overcome	an	off-target	bias	(probe	targeting	random	transcripts,	different	from	the	probe	set	target)	common	in	the	Affymetrix	platform	[141]	The	discussion	on	which	algorithm	returns	the	best	results	is	still	ongoing.	All	these	methods	have	weaknesses.	It	is	common	opinion	that	the	increased	accuracy	of	the	algorithms,	which	do	not	take	into	account	the	MM	probes,	 is	obtained,	 in	most	of	cases,	at	the	expense	of	sensitivity.	The	MAS5	has	been	much	criticized	over	the	years	for	 its	tendency	to	return	false	positives,	but	it	remains	a	valid	algorithm.	Here	 we	 will	 also	 explore	 the	 possible	 differences	 between	 the	 two	 major	algorithms	applied	at	our	data	set.		
The	statistical	approach	to	the	tissue	deconvolution	In	 the	 past	 decade,	 gene	 expression	 profiling	 has	 demonstrated	 an	 amazing	potential	 for	 identifying	 disease	 biomarkers	 and	 improving	 our	 understanding	 of	cellular	processes.	Several	groups	have	attempted	to	resolve	the	issue	derived	from	the	 tissue	heterogeneity	and	 the	derived	variability	 in	 the	 transcriptomic	analysis	
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by	 statistical	 methods	 [144-147].	 Although	 those	 studies	 look	 promising	 and	 the	possibility	 to	 deconvolve	 the	 histological	 complexity	 of	 tissues,	 by	 just	 applying	statistical	 methods	 sounds	 very	 appealing,	 the	 reality	 is	 that	 these	 approaches	require	 at	 least	 a	 validation	 phase,	 based	 on	 experimental	 data,	 derived	 by	 pure	tissues	or	cells.		The	most	significant	current	limitation	of	these	statistical	methods,	and	indeed	of	all	signature	gene–based	methods,	is	the	robustness	of	reference	profiles.	In	 our	 study,	 therefore,	 instead	 of	 approaching	 this	 issue	 from	 the	 computational	and	 analytical	 point	 of	 view,	 we	 decided	 to	 first	 generate	 tissue	 and	 cell-type	specific	profiles,	necessary	for	the	deconvolution	of	whole	tissue	profiles,	and	then	apply	that	knowledge	to	analyses	focusing	on	biologically	relevant	questions.			
Tool	compound:	Methapyrilene		
N,N-dimethyl-N'-pyridin-2-yl-N'-(2-thienylmethyl)ethane-1,2-diamine		
Background	Methapyrilene	 (MP)	 is	 an	 antihistaminic	 compound	 once	 used	 as	 sleep-aid	component	 and	also	used	 in	 cold	 and	allergy	medications.	 It	was	 found	 to	 induce	hepatocellular	carcinomas	and	cholangiocellular	carcinomas	in	rats	[148-150],	and	was	 subsequently	 withdrawn	 from	 the	 market.	 However,	 its	 carcinogenicity	appears	to	be	species-specific	because	no	evidence	has	been	found	of	MP-associated	carcinogenesis	 in	 mice	 [150,	 151]	 guinea	 pigs,	 hamsters	 [152]	 or	 human	 [153].	Methapyrilene	was	negative	in	a	series	of	assays,	performed	by	independent	groups	all	around	the	world,	aimed	at	understanding	if	the	drug	was	mutagenic,	an	inducer	of	 DNA	 synthesis,	 or	 a	 cause	 of	 sister-chromatin	 exchange	 [154-158].	 However,	despite	the	number	of	studies	performed,	there	is	not	so	far	a	clear	explanation	on	how	this	compound	induces	the	liver	cancers.	The	most	accredited	theory	is	that	the	carcinogenicity	 of	 this	 drug	 is	 played	 during	 the	 phase	 I	 of	 the	 drug	metabolism;	theory	 endorsed	 also	 by	 the	 evidence	 that	 CYP450	 inhibitors	 protect	 from	 the	toxicity	 [159].	 It	 is	 therefore	possible	 that,	 in	rat,	 the	catabolites	derived	 from	the	metabolism	phase	I	cause	oxidative	stress	and	cell	proliferation,	both	contributing	to	 the	 development	 of	 the	 hepatocellular	 carcinoma	 and	 cholangiocellular	carcinoma	 [160,	 161].	 Despite	 these	 extensive	 studies,	 there	 has	 been	 limited	
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characterization	 of	 the	 relationship	 between	 molecular	 changes	 and	 microscopic	observations	resulting	from	MP	exposure.	Hamadeh	 et	 al.,	 have	 tried	 to	 correlate	 the	 molecular	 changes	 and	 the	histopathological	 alteration	 observed	 in	 the	 liver	 of	 SD	 rats	 treated	 with	 MP	 at	different	doses	[162],	showing	a	high	correlation	between	gene	expression	patterns	and	histopathological	findings.			 	
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Material	and	Methods			
Animals	and	necropsy	Wistar	Han	(WH)	and	Sprague	Dawley	(SD)	adult	healthy	rats	(3+3	males	and	3+3	females)	were	provided	from	Harlan	Laboratories.	Canis	 lupus	 familiaris	 liver	 samples	 (3	 males	 and	 3	 females),	 as	 well	 as	 Macaca	fascicularis	 liver	 (3	 males	 and	 3	 females)	 were	 collected	 from	 healthy	 control	animals	 enrolled	 in	 other	 Novartis	 studies,	 performed	 according	 with	 the	 local	Country	animal	protection	laws.	Specifically	rat	and	dog	samples	were	collected	in	Switzerland	(Basel)	and	monkey	tissues	were	collected	in	USA	and	then	transferred	to	Switzerland	in	line	with	the	current	regulations.	For	the	rodent	experiments,	the	study	was	performed	in	conformity	with	the	Swiss	Animal	Welfare	Law	(Tierschutzgesetz,	1978,	1981).	Specifically,	rats	were	euthanized	by	CO2	during	necropsy	under	the	Animal	License	No.	 5109	 by	 'Kantonales	 Veterinäramt	 Basel	 Land'	 (Cantonal	 Veterinary	 Office,	Basel	Land).		Liver	 tissues	 were	 rapidly	 dissected,	 embedded	 in	 OCT	 and	 then	 frozen	 by	 the	immersion	in	liquid	nitrogen	chilled	methylbutane.	The	tissues	were	stored	at	-80°C	until	the	use.	Liver	 portions	 from	 additional	 male	 Wistar	 Han	 rats	 were	 snap	 frozen	 in	 liquid	nitrogen	and	stored	at	-80°C	until	the	use	for	RNA	purification.		
Fixation	methods	for	immuno-LCM		The	fixation	methods	could	strongly	impact	the	RNAs	quality	and	yield,	and	this	is	especially	 true	 in	case	of	LCM	samples.	Several	 fixation	conditions	were	 tested,	 in	order	to	identify	the	one	associated	with	the	best	preservation	of	RNAs	during	the	immuno-LCM	procedures.	Sections	 (8	 µm	 thick)	 from	 Wistar	 Han	 control	 rat	 livers	 were	 mounted	 onto	polyethylene	naphthalate	(PEN)	membrane	glass	slides	(Arcturus,	Mountain	View,	CA	USA).		To	assess	 the	ability	of	 fixative	 to	preserve	 the	RNA,	 two	groups	of	 sections	were	fixed	by	 five	different	protocols	 as	 following:	30	 seconds	 in	 ethanol	75%	at	 room	temperature	 (RT)	 as	described	by	 the	HistoGene	LCM	Frozen	Section	Staining	Kit	protocol	 (Arcturus,	 Mountain	 View,	 CA	 USA);	 5	 minutes	 in	 ethanol	 75%	 RT;	 5	
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minutes	in	ethanol	100%	RT;	5	minutes	in	methanol	100%	at	-20°C;	and	10	minutes	in	10	%	buffered	formalin	RT.	The	sections	were,	then,	immersed	in	water	to	allow	the	reactivation	of	endogenous	RNase	and	check	 the	 fixation	protection.	Exposure	to	 an	 aqueous	 environment	 is	what	 normally	 occurs	during	 the	 immuno-staining.	For	this	reason,	upon	fixation,	the	tissue	slices	were	exposed	to	water	for	a	period	of	5	 or	 15	minutes,	 corresponding	 to	 immuno-LCM	 staining	 times.	 The	 slides	were,	then,	 dehydrated	 in	 RNase	 free	 ethanol	 ascending	 scale	 and	 clarified	 by	 Xylene	(Arcturus,	Mountain	View,	CA	USA).	After	additional	10	minutes	of	exposure	to	air,	the	PEN	membrane	was	cut	and	sections	were	removed	from	the	slides,	collected	in	microcentrifuge	tubes	containing	50	μL	of	extraction	buffer	(PicoPure	RNA	Isolation	Kit,	Arcturus,	Mountain	View,	CA	USA),	and	placed	at	42°C	for	30	minutes	according	with	the	manufacturer's	protocol.	The	samples	were	then	stored	at	-80°C	until	the	RNA	purification.	To	assess	the	initial	RNA	quality,	one	additional	section	of	tissue	was	collected	in	a	microcentrifuge	tube	during	the	sectioning	session,	50	μL	of	extraction	buffer	were	added,	and	subsequently	it	was	incubated	at	42°C.	The	 RNA	was	 purified	 using	 the	 PicoPure	 RNA	 Isolation	 Kit	 (Arcturus,	 Mountain	View,	 CA	 USA),	 according	 with	 the	manufacturer's	 protocol,	 including	 on-column	DNase	 treatment	 (Qiagen,	 Valencia,	 CA	 USA)	 and	 eluted	 in	 (20µL)	 elution	 buffer	(Arcturus,	Mountain	View,	CA).	The	sections	 fixed	by	10%	buffered	 formalin	were	additionally	treated	with	proteinase	K	(Qiagen	19131,	Valencia,	CA	USA)	as	follow:	after	 the	 DNase	 digestion	 and	 following	 rinse	 in	 wash	 buffer	 1	 (W1,	 Arcturus,	Mountain	 View,	 CA	USA),	 75	 µL	 of	 proteinase	 K	 (Qiagen,	 Valencia,	 CA	USA)	were	applied	 to	 the	 RNA	 purification	 columns,	 in	 order	 to	 break	 the	 fixative	 induced	cross-links.	The	columns	were	 incubated	at	55°C	 for	15	minutes	and	 then	at	80°C	for	15	minutes.	The	RNA	purification	columns	were	 then	 rinsed	by	100	µL	of	W1	buffer	(Arcturus,	Mountain	View,	CA	USA).	The	RNA	purification	was,	then,	carried	out	according	with	the	kit	manufacturer's	protocol.	RNA	quality	was	assessed	using	an	Agilent	2100	bioanalyzer,	RNA	6000	Pico	Chips	and	Agilent	2100	Expert	software	(Agilent	Technologies,	Palo	Alto,	CA	USA).	All	the	conditions	were	tested	in	triplicate	(Figure	1,	A).		
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RNase	inhibitors	efficacy	To	evaluate	 the	usefulness	of	RNase	 inhibitors	 in	 the	 context	of	 the	 immuno-LCM	experiment,	Wistar	 Han	 rat	 liver	 sections	were	 fixed	 in	methanol	 at	 -20	 °	 C,	 and	then,	 treated	 using	 the	 HistoGene	 LCM	 Frozen	 Section	 Staining	 Kit	 (Arcturus,	Mountain	 View,	 CA	 USA)	 according	 to	 the	 manufacturer's	 protocol,	 with	 the	following	modifications.		Protector	 RNase	 Inhibitor	 (0	 U/µL,	 4	 U/µL,	 8	 U/µL	 final	 concentrations;	03335402001,	 Roche	 Applied	 Science,	Mannheim,	 DE)	was	 added	 to	 the	 staining	solutions	(composed	by	Antibody	Diluent,	S3022,	Dako,	Baar	CH	and	normal	rabbit	policlonal	 IgG	 2µg/mL,	 ab27478,	 Abcam,	 Cambridge	 UK).	 50	 μL	 of	 solution	were	added	to	each	section.	Tissue	sections	were	incubated	for	5	and	15	minutes	at	room	temperature	(RT)	to	emulate	the	experimental	condition	of	the	immuno-LCM.	According	to	the	manufacturer's	protocol	the	slides	were,	then,	rinsed	in	RNase	free	water,	dehydrated	in	RNase	free	ethanol	ascending	scale	and	clarified	by	Xylene.	The	microdissection	was	 performed	 by	 the	 Arcturus	 Veritas	 (Arcturus,	 Mountain	View,	 CA	 USA)	 system,	 using	 the	 CapSure	 Macro	 LCM	 caps	 (Arcturus,	 Mountain	View,	 CA	USA),	within	 a	 time	 of	 15	 (±10)	minutes	 (power	 90mW,	 pulse	 3000µs).	One	 square	 millimeter	 (±0.1mm2)	 of	 liver	 parenchyma	 was	 captured	 from	 each	slide.		After	the	dissection,	the	plastic	membrane	caps	with	the	microdissected	tissue	were	transferred	 to	 microcentrifuge	 tubes	 containing	 50	 μL	 of	 extraction	 buffer	(PicoPure	RNA	Isolation	Kit,	Arcturus,	Mountain	View,	CA)	and	put	up	side	down	at	42°C	for	30	minutes	according	with	the	manufacturer's	protocol.	The	samples	were	then	stored	at	-80°C	until	the	RNA	purification.	To	assess	the	starting	RNA	quality,	one	section	of	untreated	tissue	was	collected	in	a	microcentrifuge	tube	during	the	sectioning	session.	The	RNA	was	purified	according	with	the	manufacturer’s	instruction.	The	 RNA	was	 purified	 using	 the	 PicoPure	 RNA	 Isolation	 Kit	 (Arcturus,	 Mountain	View,	 CA),	 according	 to	 the	 manufacturer's	 protocol,	 including	 on-column	 DNase	treatment	(Qiagen,	Valencia,	CA)	and	eluted	in	(11µL)	elution	buffer	(20	µL	for	the	control	section	[Arcturus,	Mountain	View,	CA	USA]).	RNA	quality	was	assessed	using	an	Agilent	2100	bioanalyzer,	RNA	6000	Pico	Chips	and	Agilent	2100	Expert	software	(Agilent	Technologies,	Palo	Alto,	CA	USA).	
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All	the	conditions	were	tested	in	triplicate.	For	each	single	group	of	samples,	the	average	RIN	score	was	recorded	and	the	RNA	degradation	 percentage	 was	 expressed	 in	 absolute	 terms	 (absolute	 degradation,	AD:	 tested	 condition	 RIN/10*100),	 assuming	 the	 highest	 RIN	 score	 (10)	 and	 the	relative	RNA	degradation	(relative	degradation,	RD:	tested	condition	RIN/untreated	tissue	 RIN*100),	 assuming	 the	 unfixed	 section	 RIN	 as	 highest	 value.	 T-tests	 was	used	to	assess	significant	differences	between	treated	and	untreated	samples	pairs	(Figure	1,	B-C).		
Immunofluorescence	for	laser	capture	microdissection	(immuno-LCM)	Frozen	 liver	 was	 sectioned	 by	 cryostat	 (Hyrax	 C50,	 Carl	 Zeiss,	 Oberkochen,	 DE).	Sections	 (8	 µm	 thick)	 were	 mounted	 onto	 polyethylene	 naphthalate	 (PEN)	membrane	glass	slides	(Arcturus,	Mountain	View,	CA	USA),	and	kept	at	-20°C	until	the	tissue	fixation	to	prevent	RNA	degradation.		Tissue	 sections	 were	 fixed	 in	 absolute	 methanol	 (-20°C	 for	 5	 minutes)	 and	 then	rapidly	rinsed	in	RNase	free	water.	The	 excess	 of	 water	 was	 drained	 from	 the	 slide.	 Tissues	 were	 stained	 by	immunofluorescence	 (IF),	 using	 a	 mix	 of	 mouse	 monoclonal	 antibodies	 against	Cytokeratin	19	and	Cytokeratin	7	 for	bile	ducts	 labeling,	and	a	mouse	monoclonal	antibody	against	Alpha	2	Actin	(Alpha	2	Smooth	Muscle	Actin,	αSMA)	conjugated	to	Cy3	 for	 the	vessels	 labelling	(antibodies	details	 in	Table	1).	The	antibody	solution	(50	µL,	composed	of	antibody	at	experimental	established	titer,	diluted	in	Antibody	Diluent,	 S3022,	 Dako,	 Baar	 CH	 +	 Protector	 RNase	 Inhibitor,	 8	 U/µL	 final	concentration,	 03335402001,	Roche	Applied	 Science,	Mannheim,	DE)	was	 applied	on	the	tissue.		For	detection	of	 antibodies	 targeting	 the	 cytokeratins,	 after	 8	minutes	 of	 primary	antibody	 incubation,	 a	 secondary	 antibody	 solution	 (10ul,	 goat	 anti	 mouse	 Alexa	Fluor	546)	was	added	on	the	slide	and	incubated	for	additional	7	minutes.	This	step	was	not	necessary	for	vessel	labeling.	The	sections,	then,	were	rinsed	in	RNase	free	water,	dehydrated	in	ascending	scale	RNase	free	ethanol	and	clarified	in	RNase	free	xylen,	 according	 with	 HistoGene	 LCM	 Frozen	 Section	 Staining	 Kit	 protocol	(Arcturus,	Mountain	View,	CA	USA).	The	 tissues	 then	were	used	 for	 laser	 capture	microdissection.	
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Laser	capture	microdissection	The	Palm	MicroBeam	(Carl	Zeiss,	Oberkochen,	DE)	was	used	 for	 the	 laser	capture	microdissection	 of	 intrahepatic	 bile	 ducts,	 liver	 parenchyma	 zone	 I	 and	 zone	 III	(according	with	Rappaport	 liver	model	 description)	 and	 the	 isolation	 of	 vein	 and	artery	 from	the	portal	space.	All	 the	slides	were	processed	within	30±15	minutes.	The	 Carl	 Zeiss	 LD	 Planar	 Neofluorar	 20X	 objective	 was	 used	 for	 the	 in	 situ	observation	 and	 selection	 of	 the	 tissues.	 The	 laser	 energy	 power	 and	 focus	parameters	were	set	at	46±2	and	72±2	respectively.	Two	consecutive	cutting	cycles	were	used	 to	 avoid	high	 laser	power	 and,	 consequently,	 an	 extensive	UV-A	 tissue	irradiation.		The	RNase	free	AdhesiveCap	tubes	(415101-4400-250,	Carl	Zeiss,	Oberkochen,	DE)	were	used	as	microdissected	tissue	collector.		Total	microdissected	surface	area	was	used	as	quantitative	parameter,	at	least	0.5-0.7	mm2	were	collected	to	obtain	sufficient	RNA	for	the	further	analysis.	An	average	of	25	bile	ducts	was	isolated	from	each	liver	section.	Pooling	of	bile	ducts	from	5	to	8	serial	sections	was	necessary	(figure	2,	A-C).		Similarly,	 0.7-1	 mm2	 of	 microdissected	 tissue	 from	 liver	 parenchyma	 zone	 I	 and	zone	 III	 were	 isolated	 from	 liver	 sections,	 previously	 stained	 by	 Mayer’s	hematoxylin	and	water	based	eosin.	The	RNAs	from	each	single	area	were	isolated	and	 subsequently	 analyzed	 for	 gene	 expression	 in	 biological	 triplicates	 and	technical	duplicates	(zone	I	and	III)	per	each	single	animal	(Figure	2,	D-I).	In	a	similar	way,	portal	vein	and	hepatic	artery	were	isolated	and	collected	using	a	multi	 collector	 tube	 holder,	 by	 immune-LCM	 using	 the	 anti-αSMA	 antibody	conjugated	with	Cy3	(Sigma	Aldrich)	(Figure	2,	J-N).			
RNA	purification	and	quality	assessment	RNA	from	laser-captured	tissues	was	purified	using	the	PicoPure	RNA	Isolation	Kit	(Arcturus,	 Mountain	 View,	 CA	 USA),	 according	 to	 the	 manufacturer's	 protocol,	including	 on-column	 DNase	 treatment	 (Qiagen,	 Valencia,	 CA	 USA)	 and	 eluted	 in	(11µL)	elution	buffer.		
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RNA	 from	 snap	 frozen	 liver	 (200-400	 micrograms	 of	 tissue)	 was	 purified	 using	Trizol	solution	(Invitrogen,	Carlsbad,	CA,	USA)	in	combination	with	RNeasy	(Qiagen,	Valencia,	CA	USA)	kit,	according	with	manufacturer’s	protocols.	RNA	quality	was	 assessed	 using	 an	Agilent	 2100	 bioanalyzer	 and	RNA	6000	Pico	Chips	according	to	the	manufacturer's	protocol	(Agilent	Technologies,	Palo	Alto,	CA	USA).	 RNA	 Integrity	 Number	 (RIN)	 score	 and	 electropherogram	 were	 used	 as	reference	qualitative	parameters	(figure	2,	O).			
Total	RNA	amplification	and	Affymetrix	array	hybridization	Total	 RNA,	 from	 LCM	 derived	 samples,	 as	 well	 as,	 from	 liver	 section	 scraped	 off	from	 glass	 slides,	 were	 amplified	 by	 a	 RNA-dependent	 DNA	 polymerase	 reaction	(Ovation	Pico	WTA	System,	NuGEN,	AC	Bemmel,	Netherlands).	Total	RNA	was	pre-amplified	 according	 to	 the	 manufacturer's	 protocol	 and	 4.55	 μg	 of	 SPIA	 cDNA	targets	from	previous	step	were	used	for	the	hybridization	on	GeneChip	platform.	RNA	from	snap	frozen	tissues	was	not	pre-amplified.	Hybridization	 mixtures	 were	 prepared	 according	 to	 Affymetrix	 procedures.	 The	Affymetrix	Rat	Genome	230	2.0,	Canine	Genome	2.0	and	Human	Genome	U133	Plus	2.0	3’	IVT	chips	were	used	respectively	for	rat,	dog	and	monkey	tissues	(Macaca	f.	chip	was	not	available).	Affymetrix	 arrays	 were	 hybridized,	 washed	 and	 revealed	 according	 to	 the	manufacturer’s	protocol.	GeneChips	were	scanned	using	a	7	G	scanner	(Affymetrix)	and	 images	 (DAT	 files)	were	converted	 to	 .CEL	 files.	Data	analysis	was	performed	using	Agilent	Gene	Spring	GX	11.5.1,	Tibco	Spotfire	and	GraphPad	Prism	software.	Using	Gene	Spring	GX,	raw	data	were	pre-processed	by	Robust	Multi-array	Analysis	(RMA)	 algorithm	 (including	 quantile	 normalization).	 Alternatively,	 raw	data	were	pre-processed	 by	 Microarray	 Suite	 5.0	 (MAS5)	 algorithm.	 Where	 not	 differently	specified,	 data	 were,	 then,	 Log	 transformed	 and	 pre	 filtered	 within	 the	 20-100	percentile	assuming	the	median	as	baseline	(RAW	data).	Spearman	rank	correlation	factor	and	Bland-Altman	plot	were	used	to	explore	the	agreement	between	the	two	Pre-processing	algorithms	(Figure	3).	Quality	controls,	 including	correlation	analysis	across	arrays	and	Affymetrix	chips	internal	 quality	 control	 showed	 any	 abnormalities	 in	 the	 hybridization	 processes	(data	not	shown).	
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Principal	component	analysis	(PCA)	was	used	as	unsupervised	approach	to	explore	sample	variance	(PCA	on	sample	groups,	number	of	principal	components=2).	Linear	regression	analysis	on	 fold	change	(FC)	 frequency	distribution	was	used	to	identify	best	fitting	FC	value	for	gene	signature	definition.	Differential	gene	expression	was	assessed	by	volcano	plot	and	asymptotic	unpaired	T-test	with	Benjamini-Hochberg	false	discovery	rate	(FDR;	p	value	≤0.05	where	not	differently	specified).		Impact	of	Affymetrix	expression	call	flag	pre-filtering	(agreement	in	at	least	80%	of	samples	in	analysis)	on	low	or	specifically	expressed	genes	was	evaluated	by	Venn	diagram	based	on	the	expression	call	flags	assigned	by	MAS5	algorithm	(Figure	11).		
Methapyrilene	study	A	 total	 of	 96	 Sprague	 Dawley	 rats	 have	 been	 enrolled	 in	 a	 past	 study	 aiming	 at	qualifying	 biomarkers	 of	 renal	 damage.	 Methapyrilene	 was	 used	 as	 control	compound	devoid	of	 renal	effects,	but	causing	clear	hepatic	effects	 [163].	Animals	have	been	treated	with	the	drug	at	different	concentrations	and	for	different	time,	according	 with	 the	 following	 table.	 Animals	 were	 sacrificed	 at	 the	 specific	 time-point	unless	clear	evidences	of	sufferance	emerged	earlier	during	the	treatment,	in	which	case	the	subject	have	been	excluded	from	the	following	analysis.			 Day	1	 Day	3	 Day	7	 Day	14	Controls*	 Controls*	 Controls*	 Controls*	15mg/kg/day*	 15mg/kg/day*	 15mg/kg/day*	 15mg/kg/day*	30mg/kg/day*	 30mg/kg/day*	 30mg/kg/day*	 30mg/kg/day*	60mg/kg/day*	 60mg/kg/day*	 60mg/kg/day*	 60mg/kg/day*	Scheme	of	the	Methapyrilene	study	(*	daily	oral	administration,	controls	treated	with	vehicle,	H2O).		At	 time-points	 the	 animals	 have	 been	 euthanized	 by	 CO2	 and	 all	 the	 organs	 have	been	collected	during	the	necropsy.	In	the	specific	liver	was	divided	and	collected	in	order	 to	have	 snap	 frozen	 samples	 for	molecular	 biology	 applications	 (lateral	 left	lobe	allocated	for	gene	expression	profiling)	and	samples	for	the	histopathological	analysis	 (caudate	 lobes	and	papillary	process,	allocated	 for	histology),	 these	 latter	were	 fixed	 in	 10%	 buffered	 formalin	 for	 48	 hours	 and	 then	 dehydrated	 and	embedded	in	paraffin.	
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Total	RNA	from	whole	liver	tissue	was	purified	and	processed	for	the	hybridization	on	 Affymetrix	 Rat	 Genome	 230	 2.0,	 as	 previously	 described,	 without	 pre-amplification	 step.	 Raw	data	were	 pre-processed	 by	Microarray	 Suite	 5.0	 (MAS5)	algorithm,	 including	 Log	 transformation	 and	 pre-filtering	 on	 20-100	 percentile	assuming	the	median	as	baseline	(RAW	data).	The	standard	internal	controls	have	been	verified.	






















n	time	anti-Krt7	(Abcam	ab9021)	 IF-LCM	 None	 1/50	Eq.	20µg/mL	 8	min	
Goat	anti-mouse	Alexa	Fluor	546	(Invitrogen,	A11030)	 1/25	Eq.	80µg/mL	 7	min	Anti-Actin,	α-Smooth	Muscle	-	Cy3		 IF-LCM	 None	 1/50		 8	min	 None	 NA	 NA	anti-Krt7	(Dako	M7018)	 IHC	 Protease	 1/50	Eq.	5µg/mL	 6	h	
Donkey	anti-mouse	biotin-conjugated	(Jackson	Immunoreasearch)	 1/500	Eq.	~	3µg/mL	 16	min	anti-Krt19	(Biodesign	M08029M)	 IF-LCM	 None	 1/50	Eq.	1µg/mL	 8	min	
Goat	anti-mouse	Alexa	Fluor	546	(Invitrogen,	A11030)	 1/25	Eq.	80µg/mL	 7	min	anti-Krt19	(Novocastra	NCL-CK19)	 IHC	 Protease	 1/200	 6	h	
Donkey	anti-mouse	biotin-conjugated	(Jackson	Immunoreasearch)	 1/500	Eq.	~	3µg/mL	 16	min	anti-Krt20	(Dako	M7019)	 IHC	 Protease	 1/100	Eq.	0.5µg/mL	 6	h	
Donkey	anti-mouse	biotin-conjugated	(Jackson	Immunoreasearch)	 1/500	Eq.	~	3µg/mL	 16	min	anti-Claudin6	(Abcam	ab107059)	 IHC	 Heat	 1/200	 6	h	
UltraMap®	anti-rabbit	HRP-conjugated	(Ventana)	 Ready	to	use	 16	min	anti-Claudin7	(Abcam	ab27487)	 IHC	 Heat	 1/200	Eq.	1µg/mL	 6	h	
UltraMap®	anti-rabbit	HRP-conjugated	(Ventana)	 Ready	to	use	 16	min	Anti-LOX	(Novus	Bio	NB100-2530)	 IHC	 None	(frozen	sections)	 1/100	 ON	4°C	
Donkey	anti-rabbit	biotin	conjugated	(Jackson	Immunoreasearch)	 1/500	Eq.	~	3µg/mL	 1hr	RT	Anti-Col1A1	(ABonline	ABIN97475)	 IHC	 Heat	 1/200	Eq.	1µg/mL	 3	h	
Donkey	anti-rabbit	biotin	conjugated	(Jackson	Immunoreasearch)	 1/500	Eq.	~	3µg/mL	 16	min	Muc1	(Abcam	ab15481)	 IHC	 Heat	 1/200	Eq.	1µg/mL	 3	h	
Donkey	anti-rabbit	biotin	conjugated	(Jackson	Immunoreasearch)	 1/500	Eq.	~	3µg/mL	 16	min	Antibodies	and	experimental	conditions	for	protein	localization	
Isotype	controls	Al	 the	 histological	 assays	 have	been	 run	on	paired	 sections	with	mouse	 or	 rabbit	anti-target	 antibodies	 and	 normal	 mouse	 or	 rabbit	 isotype	 controls	 to	 prove	 the	specificity	 of	 the	 primary	 antibody.	 All	 the	 antibodies,	 used	 in	 the	 conditions	previously	described,	did	not	show	any	non-specific	binding	 in	 the	 liver	 tissues	of	the	 3	 species	 analyzed	 (representative	 picture	 in	 the	 Supplementary	 Data,	Supplementary	Picture	1)	
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Image	analysis		Immunohistochemistry	stained	slides	(controls	vs.	60mg/Kg/day	at	time-point	day	3,	day	7	and	day	14)	were	scanned	by	Hamamatsu	Nanozoomer	2.0	HT.	RAW	data	(.ndpi	files)	were	converted	in	Tiff	RGB	files.	RGB	 tiff	 files	 were	 deconvolved	 for	 the	 isolation	 of	 the	 signal	 revealed	 by	 3,3'-Diaminobenzidine	 (DAB).	 The	 pictures	 were	 then	 converted	 in	 binary	 and	 the	positive	area	has	been	quantified	in	pixels	by	ImageJ	software.	Numerical	data	have	been	exported	to	GraphPad	Prism	software	for	the	statistical	analysis.		 	
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Results	
Effect	of	tissue	fixation	on	RNA	quality	RIN	 score	 has	 been	 used	 as	 a	 qualitative	 parameter	 for	 the	 evaluation	 of	 RNA	integrity.	 The	 RIN	 is	 a	 numeric	 score	 in	 the	 range	 from	 1	 to	 10,	 provided	 by	 the	Agilent	 2100	 expert	 software,	 and	 it	 is	 calculated	 based	 on	 a	 complex	 algorithm	taking	into	account	many	characteristics	recorded	during	a	gel	filled	capillaries	RNA	electrophoresis.	 The	 RIN	 has	 proved	 to	 be	 a	 valid	 indicator	 of	 RNA	 quality	 (62).	Nevertheless,	the	Agilent	2100	expert	software	has	failed	several	times	in	the	LCM	derived	 samples	 RIN	 allocation.	 This	 issue	 could	 be	 due	 to	 the	 low	 RNA	concentration,	which	was	at	limit	of	the	detection	threshold.		Five	different	fixation	procedures	were	tested	to	identify	the	one	that	provides	the	best	 results	 in	 experiments	 of	 immuno-LCM.	 The	 fixation	 in	 75%	 ethanol	 for	 30	seconds,	 suggested	 by	 HistoGene	 LCM	 Frozen	 Section	 Staining	 Kit	 protocol,	 has	been	compared	with	other	methods.		The	 tissue	 sections	 were,	 then,	 exposed	 to	 an	 aqueous	 environment	 in	 order	 to	reproduce	 the	 conditions	 occurring	 during	 the	 immuno-staining.	 The	 qualitative	assessment	 was	 performed	 for	 two	 time-points	 (5	 minutes	 and	 15	 minutes)	 to	verify	to	which	extent	the	fixative	protective	effect	can	be	considered.		The	 graph	 in	 Fig	 1A	 shows	 the	 RIN	 scores	 found	 after	 RNA	 purification	 from	samples	exposed	to	water	for	5	and	15	minutes.	After	5	minutes,	the	embedding	and	cryo-sectioning	processes	lead	to	RNA	deterioration	estimable	by	around	20%	(AD	17%)	as	detectable	 in	untreated	section.	As	expected,	exposure	 to	water	 for	short	time	does	not	lead	to	massive	RNA	degradation:	all	sections	fixed	with	precipitating	fixatives	reached	a	detectable	RIN	scores	as	shown,	the	software	was	not	repeatedly	able	to	assign	a	correct	RIN	score	to	formalin	fixed	sample,	probably	due	to	the	low	RNA	concentration.		The	 data	 analysis	 did	 not	 show	 significant	 differences	 between	 the	 precipitating	fixation	methods	at	this	time-point.		Data	previously	observed	were	confirmed	by	exposing	the	tissue	sections	to	water	for	 15	 minutes.	 No	 significant	 difference	 between	 precipitating	 fixation	 methods	was	 found.	 The	 RNA	 quality	 and	 quantity	 from	 formalin	 fixed	 sections	 was	 not	sufficient	for	the	RIN	allocation.	As	in	the	previous	test,	the	highest	RIN	score	was	
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obtained	 with	 5	 minutes	 ethanol	 75%	 fixation,	 followed	 by	 cold	 methanol,	 30	seconds	ethanol	75%,	and	ultimately,	5	minutes	absolute	ethanol.		We	 therefore	 conclude	 that	 the	 exposure	 to	water	 based	 solution,	 like	 during	 an	immune-staining,	 is	 detrimental	 for	 the	RNA.	The	 contribution	of	 fixatives	 for	 the	RNA	 preservation	 is	 minimal.	 For	 the	 specific	 application,	 the	 use	 of	 alcoholic	fixative	is	recommended,	although	we	could	not	appreciate	differences	between	the	alcoholic	 fixatives	 in	 analysis.	 Contrarily,	 the	 use	 of	 aldehydes,	 should	 be	discouraged	due	to	the	low	yield	obtained	in	the	RNA	purification.			
Effect	of	RNase	inhibitors	use	on	RNA	quality	In	order	 to	ascertain	 the	 real	usefulness	of	 the	RNase	 inhibitors	 in	LCM	protocols	development,	we	used	a	similar	experimental	approach	to	the	fixatives	test,	based	on	 the	 exposure	of	 tissue	 to	different	 conditions	 and	 evaluating	 the	RIN	 after	 the	RNA	extraction.	Methanol	 fixed	 sections	were	 rinsed	 and	 exposed	 to	water	based	solution	 in	 presence	 and	 absence	 of	 RNase	 inhibitors	 for	 different	 time	 (5	 or	 15	minutes).	The	RNA	purified	 from	RNase	 inhibitors	 treated	and	untreated	sections,	as	well	 as	RNA	 from	a	 single	 unfixed	 section	 collected	 during	 the	 cryo-sectioning	session,	were	compared	by	the	RIN	scores	(average	±	SD).	Absolute	 RNA	 degradation	 and	 relative	 RNA	 degradation	 were	 calculated,	 as	described	in	material	and	methods	and	shown	in	Fig1	B	and	C.	Similarly,	to	what	we	described	in	the	previous	paragraph,	freezing,	embedding,	and	cryo-sectioning	 processes	 lead	 to	 an	 absolute	 RNA	 degradation	 estimable,	 in	 this	case,	by	around	40%	in	the	untreated	section.	The	entire	staining	procedure	leads	to	a	further	degradation	in	the	section	exposed	to	water	solution	not	containing	RNase	inhibitors	(0U/µl).	RNase	 inhibitors	 concentrations	 up	 to	 4	 U/µL	 have	 limited	 protection	 effect	 on	section	 exposed	 to	 water	 for	 5	 minutes.	 Contrarily,	 the	 use	 of	 8	 U/µL	 is	 able	 to	completely	inhibit	the	endogenous	RNases	effect.	In	fact,	there	were	not	significant	differences	between	the	starting	 tissues	(RIN	score)	and	sections	 treated	with	 the	highest	RNase	inhibitor	dose	Fig	1B.	RIN	 scores	 recorded	 from	 sections	 exposed	 for	 15	 minutes	 to	 water	 confirmed	previous	data,	emphasizing	the	usefulness	of	RNA	protectors	in	these	experimental	
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conditions.	 The	 RNA	 quality	 of	 the	 unprotected	 sections	 (0	 U/µL)	 was	 very	 low	(average	RIN	=	2.73),	 the	use	of	 inhibitors	at	 concentrations	of	4	U/µL	blocks	 the	endogenous	RNase	only	partially.	A	significant	improvement	is	achieved	by	raising	the	inhibitors	concentration	up	to	8	U/µL	Fig1C.	
	Figure	1:	The	use	of	different	fixatives	does	not	significantly	improve	the	RNA	quality	for	immuno-LCM	 applications:	 alcohol	 fixed	 tissues	 yielded	 comparable	 RNA	 quality	 compared	 to	 an	 unfixed	section	(in	A)	collected	in	RNA	extraction	buffer	during	cryosectioning.	Formaldehyde	did	not	allow	recovering	a	sufficient	amount	of	RNA	for	the	analysis.		Contrarily,	 the	 use	 of	 RNase	 inhibitors	 at	 certain	 concentrations	 showed	 to	 be	 very	 effective	 in	preserving	the	RNA	quality.	Indeed,	while	the	absence	or	the	use	of	insufficient	RNase	inhibitors	(up	
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to	 4U/µl)	 lead	 to	 RNA	 degradation	 already	 after	 5	minutes	 (B)	 and	more	 after	 15	minutes	 (C)	 of	exposure	 to	 a	 water	 based	 solution,	 tissues	 treated	 with	 8U/µl	 of	 RNase	 inhibitors	 showed	 no	difference	 compared	 with	 a	 reference	 tissue	 collected	 in	 RNA	 extraction	 buffer	 during	 the	cryosectioning,	neither	after	5	minutes,	nor	after	15	minutes	(C).		In	summary	the	use	of	the	RNase	inhibitors	is	strongly	recommended	for	immuno-LCM	experiments,	due	to	their	beneficial	effects.	However,	we	should	note	that	the	amount	of	 enzymes	used	 for	 this	kind	of	 experiment	 is	 extremely	high	and	above	the	 doses	 suggested	 for	 other	 kind	 of	 experiments	 (i.e.	 RT-PCR).	 In	 this	 concern,	beside	 the	 economical	 factor	 resulting	 from	 the	 huge	 use	 of	 reagent,	 it	 should	 be	taken	into	account	also	the	composition	of	the	RNAses	inhibitor	buffer.	Specifically,	it	 contains	 glycerol,	 which	 at	 high	 concentration	 might	 inhibit	 the	 interaction	antigen-antibody	during	the	immunolabeling	reaction.	We	then	discourage	the	use	of	 concentration	above	 the	ones	used	 in	 this	 test,	 because	 the	buffer	 composition	might	impact	the	sensitivity	and	specificity	of	the	antibody.			
Laser	capture	microdissection	(LCM)	and	Immuno-LCM		The	laser	microdissection	is	a	complex	and	time	consuming	activity.		The	isolation	of	liver	parenchyma’s	regions	(zone	I	and	zone	III)	was	possible	using	a	 chemical	 dye	 (eosin),	 which	 allowed	 enough	 resolution	 for	 the	 correct	identification	of	 the	periportal-pericentral	axis	and,	 therefore,	 the	 identification	of	the	 3	 liver	 zones.	 Hepatocytes	 lying	 between	 adjacent	 portal	 fields	were	 selected	and	 isolated	 as	 zone	 I	 (Fig	2	D,	 E,	 F).	A	 round	area	 composed	of	 few	hepatocytes	layers	surrounding	the	central	veins	was	identified	and	isolated	as	zone	III	(Fig	2	G,	H,	 I).	 Tissues	 isolated	 from	 a	 single	 liver	 section	were	 normally	 enough	 (roughly	1mm2)	for	providing	sufficient	total	RNA	upon	purification.	Despite	that	the	recognition	of	the	parenchymal	areas	was	possible	using	the	eosin	staining,	this	approach	was	not	as	good	enough	for	the	identification	and	isolation	of	bile	ducts	and	vessels	from	the	portal	area.	Additionally,	due	to	the	small	size	of	these	structures,	a	possible	contamination	derived	from	an	approximate	histological	identification,	 with	 surrounding	 stromal	 cells,	 would	 have	 resulted	 in	 a	contaminated	RNA	samples	and	a	transcriptome	not	representative	of	 the	original	tissues.	
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Thus	we	decided	to	implement	the	method	with	an	immune-detection	of	the	tissue	of	interest	(Immuno-LCM).	The	immuno-LCM,	however	is	very	demanding	due	to	the	fast	RNA	degradation	and	the	 need	 for	 very	 specific	 and	 reactive	 antibodies,	 targeting	 the	markers	 for	 cell	discrimination.	The	labeling	of	the	bile	ducts	(Fig	2	A,	B,	C)	and	vessels	(Fig	2	J,	K,	M)	by	immunofluorescence,	substantially	 improved	the	detection	quality	and	strongly	increases	the	laser	microdissection	precision.	Due	to	 the	small	size	of	bile	ducts	and	vessels,	 the	pooling	of	samples	obtained	 in	many	 experiments	was	necessary	 in	 order	 to	 reach	 a	 tissue	 amount	 sufficient	 for	RNA	purification.	Consistency	of	selection,	dissection	and	collection	processes	was	visually	 inspected	 after	 each	 experiment,	 double-checking	 the	 collector	 tube.	 The	number	of	bile	ducts	and	vessels	collected	was	compared	with	the	collected	area	by	the	software.	The	entire	process	of	staining	and	microdissection	was	performed	in	an	average	time	of	45	minutes.		Bile	ducts	were	stained	with	a	monoclonal	antibody	against	cytokeratins	(7	and	19),	allowing	the	selection	and	isolation.	For	the	 isolation	of	vessels,	we	used	an	antibody	against	 the	smooth	muscle	actin.	This	 antibody	marks	 the	 smooth	muscle	 cells	 resident	 in	 the	vessels	wall	 (Tunica	Media).	We	did	not	observe	other	cells	labeled	by	this	antibody	in	the	liver.		However,	as	we	used	smooth	muscle	actin	staining	for	immuno-LCM	approach,	the	discrimination	between	hepatic	arteries	and	portal	veins	was	based	mainly	on	the	experience	 and	 knowledge	 of	 the	 operator	 and	 on	 the	 histological	 features	 of	 the	tissues	(thickness	of	tunica	media	and	elastic	lamina).	Overall,	 the	 optimization	 of	 tissue	 fixation,	 the	 use	 of	 RNase	 inhibitors	 and	 the	processing	time	reduction	allowed	the	collection	of	samples	with	good	RNA	quality	and	quantity	for	this	kind	of	samples	(Fig	2	O,	RIN	ranging	between	5	and	7).		
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	Figure	2:	representative	isolation	of	liver	tissue	by	laser	capture	microdissection	(LCM).	Picture	are	representative	 of	 the	whole	 tissue	before	 and	 after	 the	dissection	 and	of	 the	 isolated	 tissue,	 upon	collection.	Immuno-LCM	has	been	used	for	the	isolation	of	intrahepatic	bile	ducts	and	blood	vessels	from	 the	 portal	 area	 (A-C	 and	 J-N).	 Liver	 zone	 I	 and	 liver	 zone	 III	 have	 been	 recognized	 by	 eosin	staining,	 based	 on	 the	 tissue	morphological	 features	 (D-I).	 RNA	was	 purified	 and	 its	 integrity	 has	been	 verified	 by	 micro-capillary	 electrophoresis	 (Agilent	 Bioanalyser).	 The	 presence	 of	 both	 the	ribosomal	RNA	bands	is	indicative	of	good	quality	and	low	degradation	(L,	ladders;	1,	liver	zone	I;	2,	liver	zone	III;	3,	hepatic	artery;	4,	portal	vein;	5,	liver	bile	duct;	6,	whole	liver	scrape).	
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	Transcriptomic	analysis		Total	 RNA	 were	 amplified	 and	 hybridized	 on	 the	 species-specific	 Affymetrix	GeneChip	platforms	 (GeneChip®Rat	Genome	230	2.0,	GeneChip®	Canine	Genome	2.0),	except	for	the	samples	from	Macaca	fascicularis,	which	was	hybridized	on	the	Human	Genome	U133	Plus	2.0	Array.		
Pre-processing	algorithms	Rat	 samples	 were	 used	 as	 pilot	 study	 with	 the	 aim	 to	 identify	 the	 best	 pre-processing	procedure.	RMA	and	MAS5	pre-processing	 algorithms	were	 compared.	Transcriptomic	 raw	 data	 have	 been	 pre-processed	 by	 the	 software	 Agilent	GeneSpring	(ver.11.5.1),	as	described	in	materials	and	methods,	using	the	RMA	and	the	MAS5	algorithms.	To	assess	the	agreement	between	the	data	pre-processed	by	the	 two	 algorithms,	 the	 average	 expression	 values	 from	 whole	 rat	 liver	 were	compared	by	Spearman	rank	correlation	and,	visualized	by	Bland-Altman	plot.	The	analysis	revealed	a	high	correlation,	with	a	value	of	rank	R	squared	of	0.90	(rank	R	0.95,	p	value	<0.001)	(Fig	3	A).	Rank	R	squared	reached	0.95	(rank	R	0.97,	p	value	<0.001)	if	the	analysis	was	limited	to	the	probe	set	receiving	Affymetrix	expression	flag	“present”	in	80%	of	samples	in	analysis	(Fig	3	B).	Recently,	some	groups	have	proposed	 such	 a	 method	 for	 increasing	 the	 correlation	 between	 pre-processing	algorithms	and	to	 increase	the	statistical	power	of	 the	results.	 In	our	data	set,	 the	improvement	determined	by	the	pre-filtering	on	present	calls	was	limited.	We	have	analyzed	 the	 effects	 of	 this	 pre-filtering	 procedure	 on	 transcriptomic	 analysis	 of	heterogeneous	tissue	samples	and	our	findings	will	be	further	described	in	the	next	chapter.	According	with	previous	data,	the	Bland-Altman	graph	also	showed	that	there	is	an	agreement	of	94.7%	between	the	two	algorithms	(number	of	probe	sets	comprised	within	the	interval	of	Average	±1.96*SD	[Fig	3	C]).	
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	Figure	3:	The	correlation	between	different	pre-processing	(MAS5	and	RMA)	approaches	has	been	tested	 comparing	 the	 gene	 expression	profiles	 of	 rat	whole	 liver.	We	performed	 a	 Spearman	 rank	correlation	of	the	whole	data	set	and	of	the	data	set	pre	filtered	by	the	presence	call	flag	parameter	(respectively	A	and	B)	and,	alternatively,	a	Bland-Altman	distribution	graph	(whole	data	set;	C).	In	all	the	 tests,	 the	data	sets	showed	a	good	correlations	degree.	MAS	5	algorithm	has	been	used	 for	 the	following	analysis.	
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	As	 previously	 described,	 some	 groups	 have	 demonstrated	 an	 algorithm	 driven	artifact	 in	 the	RMA,	 inducing	an	artificial	 correlation	between	 samples,	 in	 specific	experimental	 conditions,	 including	 a	 limited	 sample	 number	 and	 low	 expressed	genes.	 Our	 experimental	 system	 was	 characterized	 by	 a	 restricted	 number	 of	samples,	due	to	the	difficulties	of	obtaining	LCM	enriched	tissues,	and	many	genes	showed	a	low	expression.	Although	the	high	correlation	between	data	preprocessed	with	 the	 two	algorithms	suggests	comparable	results,	our	dataset	 is	characterized	by	 those	 peculiarities	 by	 which	 the	 RMA	 algorithm	 may	 incur	 in	 the	 artifact	described	previously.	Therefore,	we	decided	to	use	only	the	MAS5	preprocessing	for	the	following	analysis.		
Quality	controls	and	PCA	Common	quality	controls	like	3’/5’	ratio,	internal	Affymetrix	hybridization	controls,	inter-assays	 correlation	 plot	 (Pearson’s	 correlation)	 showed	 no	 abnormalities	 in	any	of	the	species-specific	platform,	upon	data	pre-processing	and	normalization.		In	 order	 to	 visualize,	 in	 an	 unbiased	 way,	 the	 inherent	 characteristics	 of	 LCM	samples,	 a	 Principal	 Component	 Analysis	 was	 run	 (PCA	 on	 sample	 groups,	 2	principal	components).	In	all	the	species	(Figure	4.	A,	Rat;	B,	Dog;	C,	Monkey),	liver	scrape,	 liver	 zone	 I	 and	 liver	 zone	 III,	 always	 clustered	 together,	 likely	due	 to	 the	sample	compositions,	mostly	hepatocytes.	Similarly,	portal	vein	and	hepatic	arteries	clustered	 together,	 far	 from	the	previous	group.	Finally,	bile	ducts	represented	an	independent	 group	 in	 all	 the	 species.	 The	 analysis	 showed	 a	 good	 separation	between	samples,	indicating	good	cell	phenotype	enrichment	obtained	by	LCM.		
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	Figure	4:	The	principal	component	analysis	(PCA)	performed	on	all	the	data	sets	from	the	3	animal	species.	 In	 all	 the	 graphs,	 the	 tissues	 clustered	 according	 with	 their	 characteristic:	 whole	 liver	scrapes	clustered	with	 liver	zone	 I	 and	 liver	zone	 III	 samples,	based	on	 their	 cellular	 composition.	Arteries	and	veins	also	clustered	close	to	each	other.	Finally,	intrahepatic	bile	ducts	were	separated	from	all	the	other	samples.	This	unbiased	analysis	revealed	the	good	tissue	enrichment	obtained	by	LCM.		
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Comparative	gene	expression	analysis	
Unbiased	approach	for	designing	structure	specific	gene	signatures	Potentially	pure	samples,	isolated	by	LCM,	provided	the	possibility	to	identify	genes	selectively	 expressed	 in	 some	 cells	 among	 a	 heterogeneous	 tissue.	 Of	 particular	interest,	 the	 possibility	 to	 analyze	 the	 transcriptome	 from	 the	 bile	 ducts,	 isolated	from	 the	whole	 liver,	 offered	 the	 unique	 possibility	 to	 delineate	 a	 gene	 signature	specific	 for	 those	 structures	 and	 a	 physiological	 baseline	 for	 comparative	 studies.	Nevertheless,	 the	definition	of	 a	 specific	 signature	 is	 a	 challenging	exercise.	Given	the	peculiarities	of	samples	isolated	by	LCM	and	the	experimental	approach	chosen,	we	 attempted	 to	 identify	 a	methodology,	 based	on	 comparative	 approach,	 able	 to	discriminate	 with	 maximum	 sensitivity	 and	 specificity,	 genes	 strongly	 enriched	and/or	 selectively	 expressed	 in	 bile	 duct.	We	 have	 therefore	 generated	 a	 binned	fold	change	frequency	histogram,	in	an	interval	between	0	and	50	fold	changes	(FC;	Figure	5	A).	An	exponential	shape	characterizes	the	histogram;	however,	two	linear	stages	(Figure	5B	and	5C),	defined	by	 linear	regression	analysis,	can	be	 identified.	Interestingly	these	two	linear	phases	intersected	at	value	of	9.2	FC	(in	rat	data	set).		In	 fact,	 this	cutoff	value	determines	 the	best	compromise	 in	 the	R	square	value	of	the	 two	 linear	 phases	 (FC≤9.2	 r2	 =	 0.974;	 9.2<FC≤50	 r2	 =	 0.928).	 Under	 the	biological	 point	 of	 view,	 this	 intersection	 represents	 the	 joint	 point	 between	 two	different	trends:	below	9.2	FC,	small	variation	determines	a	significant	 increase	 in	the	number	of	probe	sets	selected,	 likely	associated	with	a	decrease	 in	specificity.	Above	this	FC	value,	vice	versa,	small	variation	does	not	determine	massive	changes	in	the	number	of	probe	sets	selected.	We	therefore	decided	to	use	this	value	of	9.2	as	 a	 cutoff	 value	 (p	 ≤	 0.05,	 Student’s	 t-test	 unpaired,	 multiple	 testing	 correction	Benjamini-Hochberg	[164])	for	the	selection	of	genes	enriched	in	bile	ducts	(Figure	6).	According	with	this	parameter,	767	probe	sets,	out	of	31099	probe	sets	present	on	Rat	Genome	230	2.0	 chips,	were	 selected	 as	 significantly	 increased	 in	 the	 bile	duct,	in	comparison	with	whole	liver	(liver	scrape).		
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	Figure	5:	The	approach	used	for	the	selection	of	genes	enriched	and/or	selectively	expressed	in	rat	bile	 ducts.	 The	 whole	 data	 set	 has	 been	 ranked	 according	 with	 the	 fold	 change	 (FC)	 in	 gene	expression,	 in	 bile	 ducts	 vs.	 whole	 liver	 scrape.	 The	 FC	 values	 were	 then	 classified	 in	 categories	between	 1	 and	 50	 (binned	 FC,	 Fig	 5A,	 X	 axis).	 Those	 values	 have	 been	 plotted	 together	with	 the	number	of	genes	selected	as	enriched	in	bile	duct,	by	the	corresponding	FC	value	(Fig	5A,	Y	axis).	The	resulting	 distribution	 describes	 an	 exponential	 curve,	 characterized	 by	 two	 major	 linear	 phases,	identified	by	linear	regression	analysis	(Fig	5B	and	5C).	The	intersection	point	of	the	two	best	fitting	linear	phases	 (FC≤9.2	 r2	 =	0.974;	 9.2<FC≤50	 r2	 =	0.928),	 determines	 the	best	 cut-off	 value	 for	 the	selection	of	genes	enriched	in	the	bile	ducts.			
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In	a	similar	manner,	based	on	the	same	selection	criterion,	we	have	chosen	the	FC	cutoff	 for	 selection	 of	 bile	 ducts	 specific	 signatures	 also	 in	 the	 other	 2	 species,	obtaining	values	close	to	that	obtained	in	rats	(dog	FC	cutoff	8.17,	765	probe	sets;	monkey	FC	cutoff	9.14,	709	probe	sets).	Based	on	the	success	of	the	empirical	definition	of	criteria,	it	might	be	interesting	to	pursue	 the	 development	 of	 an	 algorithmic	 method,	 able	 to	 adjust	 the	 cutoff	according	with	our	experimental	observations.		
	Figure	6:	a	volcano	plot	showing	genes	selected	by	using	a	FC	cut-off	of	9.2	(bile	duct	vs.	whole	liver	scrape.	p	≤	0.05,	Mann-Whitney	unpaired	test,	multiple	testing	correction	Benjamini-Hochberg).	The	genes	up	regulated	in	right	hand	side	of	the	graph	represent	our	gene	signature	for	bile	ducts.		
Liver	zonation	For	the	selection	of	liver	parenchymal	zone	I	and	zone	III	gene	signatures,	we	used	a	different	 comparative	 approach.	 Specifically,	 assuming	 that	 the	 comparison	 was	made	 between	 two	 similar	 cell	 populations	 (mostly	 composed	 by	 hepatocytes),	 a	very	high	FC	cutoff	would	have	not	been	biologically	meaningful,	unless	to	highlight	genes	selectively	expressed	in	one	rather	than	in	the	other	zone.	We	have,	therefore,	used	 as	 an	 arbitrary	 FC	 cutoff	 of	 2	 in	 a	 volcano	 plot	 (p	 ≤	 0.05)	 to	 identify	 genes	enriched,	as	well	as	selectively	expressed,	either	in	zone	I	or	zone	III	(Figure	7).	
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	Figure	7:	a	volcano	plot	showing	the	selection	of	genes	enriched	either	in	liver	zone	I	or	in	liver	zone	III	 in	 rat	 (rat	 liver	 zone	 I	 vs.	 zone	 III,	 p	 ≤	 0.05,	 Mann-Whitney	 unpaired	 test,	 multiple	 testing	correction	 Benjamini-Hochberg).	 The	 same	 approach	 has	 been	 used	 for	 the	 selection	 of	 enriched	genes	in	dog	and	in	monkey.		The	comparison	showed	631	probe	sets	differentially	expressed	in	rat	 liver	zone	I	vs.	liver	zone	III	(p	≤	0.05,	Mann-Whitney	unpaired	test,	multiple	testing	correction	Benjamini-Hochberg).	 Out	 of	 this	 number,	 130	 probe	 sets	 were	 differentially	expressed	in	zone	I	and	501	in	zone	III.	Similarly,	709	probe	sets	were	differentially	expressed	in	dog	 liver	zone	I	vs.	 liver	zone	 III.	Out	of	 this	number,	305	probe	sets	were	up	 regulated	 in	 zone	 I	 and	404	were	up	regulated	in	zone	III.	Ultimately,	 the	 comparison	 in	monkey	 liver	 revealed	242	probe	 sets	differentially	expressed	in	liver	zone	I	vs.	liver	zone	III:	91	probe	sets	were	up	regulated	in	zone	I	and	151	were	up	regulated	in	zone	III.	We	 then	 investigated	 selectively	 the	 expression	 of	Wnt	 genes	 (19	members	 from	Wnt1	 to	Wnt16),	 the	 major	 driver	 of	 liver	 zonation.	 Interestingly,	 most	 of	 those	genes	 resulted	 not	 significantly	 regulated.	 A	 focused	 analysis,	 however,	 revealed	that	 in	 rat	 and	 monkey	 liver	 zone	 III,	 Wnt2	 was	 significantly	 up	 regulated,	 in	
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comparison	to	liver	zone	I	(Figure	8A	and	8C).	In	dog,	none	of	the	annotated	genes	belonging	to	the	WNT	family	reached	the	statistical	significance	in	the	comparative	analysis.	However,	WNT5B	was	the	only	one	member	of	the	family	enriched	in	liver	zone	 III	 (p=0.03,	 corrected	 p=0.2,	 Figure	 8B)	 although	 its	 profile	 was	 rather	 flat,	showing	limited	differences	between	the	tissues	in	analysis.	In	 order	 to	 verify	 the	 effect	 of	 the	Wnt	 expression,	we	 have	 selected	 as	 reporter	gene	 of	 the	Wnt	 pathway,	 Axin2	 and	Glul.	 The	 2	 genes	were	 also	 enriched	 in	 the	liver	zone	III	of	rats	and	monkey	(Figure	8A	and	8C).	In	dog,	according	with	the	lack	of	a	significant	driver	gene,	Axin2	was	equally	expressed	in	most	of	the	liver	tissues.	GLUL	 gene,	 however,	 conserved	 its	 pericentral	 expression	 (Figure	 8B).	We	might	speculate	on	a	different	mechanisms	regulating	the	liver	zonation,	which	might	not	be	unique	across	species.	Additionally,	 the	preservation	of	 the	GLUL	expression	in	the	pericentral	area	in	dog	(together	with	many	other	zone	III	specific	genes),	might	be	indicative	of	a	different	mechanism	driving	the	liver	zonation,	independent	from	the	 postulated	 WNT	 gradient.	 An	 alternative	 explanation	 might	 also	 be	 that,	additional	WNT	genes,	not	annotated	in	dog	platform,	may	play	a	role	in	driving	the	liver	 zonation	 in	 this	 species,	 although	 this	 would	 not	 explain	 the	 lack	 of	 the	 up	regulation	of	AXIN2	in	the	same	area.		
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	Figure	8:	The	gene	expression	profile	of	the	liver	zonation	driver	genes	WNT2(rat	and	monkey)	and	WNT5B	(dog),	and	genes	down-stream	in	the	WNT	pathway	(AXIN	2	and	GLUL).	Interestingly,	while	in	 rat	 and	 monkey	 we	 were	 able	 to	 identify	 WNT2	 as	 the	 only	 member	 of	 the	 WNT	 family	significantly	up	regulated	in	the	liver	zone	III	vs.	all	the	other	liver	samples,	in	dog,	none	of	the	WNT	genes	was	up	regulated	 in	the	same	area.	Accordingly,	AXIN2	and	GLUL	were	up	regulated	 in	 liver	zone	 III	 in	 rat	 and	 monkey.	 In	 dog,	 only	 the	 GLUL	 preserved	 its	 enrichment	 in	 liver	 zone	 III	(Normalized	expression	data	in	log	scale).		
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Gender	differences	and	Liver	zonation		In	order	 to	assess	 the	presence	a	sexual	dimorphism	 in	 the	 liver	gene	expression,	we	compared,	in	first	instance,	the	gene	expression	profile	of	the	whole	liver	tissues	derived	from	male	and	female	animals.	We	then	used	the	LCM	derived	tissues	(liver	zone	I	and	liver	zone	III)	and	we	compared	the	expression	profiles	of	male	animals	to	those	of	the	female	animals	in	those	specific	areas,	in	order	to	highlight	a	gender	specific	mechanism	orchestrating	the	gene	expression,	in	the	liver	zones.	Interestingly,	 the	 direct	 comparison	 of	 whole	 liver	 tissues	 from	male	 and	 female	animals	yielded	only	a	 limited	number	of	gender	 specific	genes.	 In	 the	 specific,	 in	rats	 we	 obtained	 a	 total	 of	 76	 probe	 set	 significantly	 differentially	 regulated	between	males	and	females	(Volcano	plot,	Mann-Whitney	unpaired	test,	p	≤	0.05,	FC	cutoff	2,	multiple	testing	correction	Benjamini-Hochberg;	34	probe	sets	enriched	in	females,	 and	 42	 enriched	 in	 the	 males).	 In	 dog	 and	 monkey	 only	 one	 probe	 set	reached	the	statistical	significance	(Volcano	plot,	Mann-Whitney	unpaired	test,	p	≤	0.05,	FC	cutoff	2,	multiple	testing	correction	Benjamini-Hochberg;	MYNN	transcript	up	regulated	in	female	dogs,	TSIX	transcript	up	regulated	in	female	monkeys).	We	 then	 compared	 the	 LCM	 liver	 zone	 I	 and	 liver	 zone	 III,	 in	 male	 vs.	 female	(Volcano	plot,	Mann-Whitney	unpaired	 test,	p	≤	0.05,	FC	 cutoff	2,	multiple	 testing	correction	Benjamini-Hochberg)	in	all	the	species.		In	 rat	 liver	 zone	 I	 the	 comparison	 revealed	 130	 probe	 sets	 with	 an	 absolute	 FC	greater	than	2	in	male	vs.	female,	but	only	27	were	statistically	significant	(14	probe	sets	enriched	in	male	animals	and	13	enriched	in	female	animals).	Similarly,	 in	 rat	 liver	 zone	 III,	 we	 found	 501	 regulated	 probe	 sets,	 218	 with	statistical	 significance	 (male	 vs.	 female,	 194	 enriched	 in	 male	 animals	 and	 24	enriched	in	female	animals)	(Figure	9).	Any	probe	set	reached	the	statistical	relevance	in	neither	liver	zone	I	nor	zone	III	in	dog	and	monkey	samples	(Figure	9B	&	9C).	The	results	are	consistent	with	the	literature	describing	a	strong	sexual	dimorphism	in	rodents,	which	resulted	much	less	evident	in	other	mammals	[165,	166].		
	 63	
	Figure	 9:	 The	 genes	 enriched	 in	 liver	 zone	 I	 and	 liver	 zone	 III	 have	 been	 screened	 to	 verify	 the	existence	of	a	gender	specific	gene	expression	regulation.	 In	rats,	many	genes	 involved	 in	 the	 liver	zonation,	 were	 also	 regulated	 in	 different	 way,	 in	 male	 animals	 than	 in	 female	 ones.	 This	phenomenon	 was	 however	 not	 detectable	 in	 the	 other	 two	 species	 (Volcano	 plot,	 Mann-Whitney	unpaired	test,	p	≤	0.05,	FC	cutoff	2,	multiple	testing	correction	Benjamini-Hochberg).		
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Cross	species	comparison	A	reliable	comparison	of	genes	enriched	in	specific	cell	phenotypes	across	different	species	is	challenging.	There	are	some	limitations	linked	to	the	technology	used	in	this	project	and	in	general	to	our	knowledge	of	the	gene	ontology.	The	annotation	of	Affymetrix	probe	sets	is	regularly	updated.	Nevertheless,	a	relative	high	number	of	probe	 sets	 are	not	 annotated	or	 generically	 annotated	 as	 putative	 transcript.	 In	 a	similar	 manner,	 the	 species-specific	 platforms	 have	 different	 transcript	 libraries,	therefore,	 genes	 present	 on	 one	 platform	 may	 be	 absent	 on	 another	 platform.	Furthermore,	the	gene	nomenclature	is	sometime	not	consistent	across	the	species:	orthologous	 transcripts	 do	 not	 necessarily	 have	 the	 same	 name	 in	 the	 different	species.	 All	 this	 factors	 are	 strongly	 affecting	 the	 possibility	 to	 compare	 gene	signatures	for	different	species,	especially	using	the	GeneChip	technology.	We	 limited	 our	 analysis	 to	 the	 transcripts	 correctly	 annotated	 by	 Affymetrix	 and	which	were	 recognized	 as	 orthologous	 genes	 by	 the	Agilent	 software.	 In	 order	 to	achieve	 this	result,	 the	software	used	the	human	annotation	as	reference.	Rat	and	dog	 genes,	 included	 in	 the	 tissue	 signatures,	 were	 translated	 to	 the	 orthologous	human	genes	and,	finally,	the	resulting	lists	were	compared	by	a	Venn	diagram.		Venn	diagram	in	Figure	10	showed	the	number	of	genes	shared	between	the	species	based	on	their	localization.		The	 analysis	 revealed	 only	 a	 limited	 number	 of	 shared	 transcripts	 enriched	 or	selectively	expressed	in	the	bile	ducts	of	all	the	species	(Fig	10A).	In	some	cases	this	was	 clearly	 due	 to	 the	 absence	 of	 some	 transcript	 in	 one	 or	 some	 of	 the	 gene	libraries	of	the	chips	(e.g.	Krt19	in	dog	platform)	in	some	other	it	might	be	due	to	an	annotation	 discrepancy,	 which	 the	 software	 was	 not	 able	 to	 resolve.	 We	 further	tried	to	investigate	more	in	detail	this	issue	of	species-specificities	providing	some	examples	 of	 genes	 identified	 in	 the	 bile	 ducts	 of	 some	 species	 and	 absent	 in	 the	others,	validating	the	transcriptomic	data	by	protein	localization.	Similarly,	we	investigated	the	similarities	in	the	gene	signature	for	liver	zone	I	(Fig	10B)	and	liver	zone	III	(Fig	10C).		In	 all	 the	 cases,	 the	 number	 of	 common	 genes	 between	 species	was	 very	 limited.	Based	on	this	result,	it	is	not	clear	so	far	if	the	data	we	were	able	to	obtain	by	this	approach	 and	 software	 reflects	 the	 reality.	 Indeed,	 a	 so	 small	 overlap	 in	 the	 gene	expression	of	the	same	organ,	in	mammals,	is	quite	surprising,	but	the	explanation	
	 65	
may	be	linked	to	technical	limitations	more	than	in	a	so	striking	biological	diversity	between	species.		
	Figure	10:	A	cross-species	comparison	of	the	gene	signature	identified	(A,	bile	duct	signature;	B,	liver	zone	I;	C,	liver	zone	III)	has	been	performed.	Surprisingly,	the	number	of	common	probe	sets	across	the	 species	 resulted	 very	 limited.	 Intrinsic	 limitations	 (e.g.	 gene	 annotation	 or	 orthologous	nomenclature)	 of	 the	 technology	 used	 in	 this	 study	 might	 be	 responsible	 for	 the	 low	 amount	 of	common	genes	in	same	tissues	of	different	species.		
Affymetrix	expression	flag	pre-filtering	Affymetrix	gene	 chips	are	on	 the	market	 since	 long	 time	and	can	be	 considered	a	reliable	method	 for	 the	 gene	 expression	 profiling.	 One	 commonly	 used	 feature	 of	this	platform	is	the	Affymetrix	expression	flag,	introduced	with	the	MAS5	algorithm.	This	parameter	provides	an	estimation	of	reliability	of	the	expression	data.	The	use	of	 this	 parameter	 improves	 the	 specificity	 of	 the	 assay	 at	 the	 expense	 of	 the	sensitivity,	reducing	the	false	positive	near	or	just	above	the	background	threshold.		However,	the	use	of	this	pre-filtering	methodology,	without	any	consideration	of	the	tissue	 composition,	 may	 result	 in	 a	 loss	 of	 precious	 information.	 Indeed,	 low	abundant	cell	phenotypes	and	their	biological	processes	can	be	mostly	filtered	out	by	this	approach.	Taking	 advantage	 from	 the	 LCM	 samples,	 we	 tried	 to	 evaluate	 the	 impact	 of	 the	expression	 flag	 pre-filtering	 on	 the	 expression	 analysis	 of	 the	whole	 liver.	 In	 the	specific,	 we	 screened	 the	 assignment	 of	 the	 “present”	 flag	within	 the	whole	 liver	transcriptome.	We	have	then	evaluated	the	presence	of	genes,	belonging	to	the	bile	duct	 signature	 obtained	 by	 LCM,	 in	 those	 that	 received	 the	 “present”	 flag	 in	 the	whole	liver	data	set.	Cholangiocytes	represent	less	than	10%	of	the	total	amount	of	
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cells	 in	 the	 liver.	Their	 specific	 transcriptome	 is	weakly	 represented	 in	 the	whole	liver	transcriptome,	due	to	their	low	abundance.		The	analysis	revealed	that	the	application	of	expression	flag	pre-filtering	on	whole	liver,	resulted	in	the	inclusion	of	only	a	limited	number	of	genes,	ranging	between	2%	and	60%	(between	species),	of	those	genes	enriched	or	selectively	expressed	in	bile	ducts	(Figure	11;	38	probe	sets	included,	out	of	815	probe	sets	included	in	bile	duct	signature	for	rat;	similarly,	in	dog	412/731	and	in	monkey	487/800).		
	Figure	11:	the	impact	of	a	pre-filtering	based	on	Affymetrix	call	flag	on	the	analysis	of	heterogeneous	tissues,	 and	 specifically	 on	 the	 expression	 profile	 of	 low	 represented	 cell	 populations.	 In	 this	example,	 we	 analyzed	 the	 whole	 liver	 scrape	 data	 set,	 excluding	 from	 the	 analysis	 the	 probe	 set	which	 received	 in	 80%	 of	 whole	 liver	 samples	 the	 call	 flags	 “marginal	 and	 absents”.	 We	 then	compared	 the	 resulting	 data	 set	 with	 the	 gene	 signature	 of	 bile	 ducts.	 Not	 surprisingly,	 the	 pre-filtering	 strategy	 excluded	 from	 the	 analysis	 a	 relevant	 number	 of	 those	 genes.	 The	 use	 of	 this	strategy	 irrespectively	 of	 the	 tissue	 composition,	may,	 therefore,	 lead	 to	 the	 exclusion	 of	 relevant	
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data	and	consequently	to	the	miss	interpretation	of	biological	phenomena	affecting	low	represented	cell	populations.		These	 results	 showed	 that	 the	 application	 of	 this	 pre-filtering	 excludes	 data	representative	 of	 a	 liver	 cell	 sub-population,	 thus	 excluding	 a	 priori	 biologically	relevant	data.		By	 this	way,	we	 showed	 the	massive	 impact	 that	 this	 approach	might	have	 in	 the	study	 of	 tissue	 specificities	 and	 the	 importance	 to	 evaluate	 correctly	 the	 sample	composition	for	a	correct	pre-processing	and	interpretation	of	transcriptomic	data.			
Validation	of	bile	duct	gene	signatures	by	immunohistochemistry	Amongst	the	genes	included	in	the	bile	duct	signatures,	according	with	the	criteria	described,	we	 identified	 some	 genes,	 expressed	 in	 all	 the	 species,	 to	 validate	 our	gene	 expression	 profiles.	 Considering	 the	 low	 RNA	 yield	 obtained	 by	 LCM,	 we	decided	 to	validate	 the	 signature	 specificity	by	 immunohistochemistry	and	not	by	real	time	PCR.	However,	 the	 number	 of	 antibodies	 commercially	 available,	 with	 a	 cross-species	reactivity,	drastically	limited	the	number	of	candidate	target	proteins.	We	have	 identified	some	candidates	 (keratin	7,	19	and	20,	mucin	1	and	claudin	6	and	7),	we	have	exported	the	expression	values	 from	the	 transcriptomic	data	sets	and	 verified	 their	 statistical	 significance	 (BD	 vs	 whole	 liver).	 Finally,	 we	 have	localized	the	corresponding	proteins	in	situ.	We	 have	 localized	 keratin	 7,	 keratin	 19	 and	 keratin	 20	 in	 FFPE	 liver	 sections	 of	control	 animals	 by	 immunohistochemistry	 (Figure	12,	 gene	 expression	profile	 for	each	 single	marker,	 gene	 enrichment	 in	 bile	 ducts	 vs.	 whole	 liver,	multiple	 t-test	analysis	corrected	for	multiple	comparisons	with	Bonferroni-Dunn	method).		Keratin	7	 is	 a	well-known	marker	of	 epithelial	 tissues.	 Indeed,	our	 IHC	confirmed	the	localization	of	this	protein	in	the	bile	ducts	of	all	the	species,	in	agreement	with	the	expression	data.	Similarly,	also	keratin	19	is	a	marker	of	epithelium	and	this	protein	was	expressed	in	 intrahepatic	 cholangiocytes	 in	 all	 the	 3	 species.	 Interestingly,	 the	 Canine	 chip	from	 Affymetrix	 lacks	 the	 probe	 set	 for	 this	 specific	 transcript,	 so	 we	 were	 not	aware	of	the	gene	expression	profile	relative	to	the	keratin	19	in	dog	livers.	
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Keratin	20,	as	 the	previous	ones,	 is	a	marker	of	epithelium,	but	 the	 localization	of	this	protein	revealed	some	differences	across	the	species	in	analysis.	Indeed,	while	the	gene	and	protein	were	expressed	in	the	cholangiocytes	in	rat,	the	transcriptomic	data	revealed	no	significant	differences	between	bile	ducts	and	whole	liver	in	dog.	Accordingly,	the	protein	was	not	detectable	in	dog	liver.			
	Figure	12:	Validation	of	 the	bile	duct	 signature	 specificity.	Three	genes	 (Keratin	7,	Keratin	19	and	Keratin	 20)	 have	 been	 selected	 among	 the	 genes	 included	 in	 the	 bile	 duct	 signature.	 A	 significant	enrichment	 has	 been	 shown	 in	 LCM	 samples	 vs	 whole	 liver	 (t-test,	 corrected	 for	 multiple	comparisons	 with	 Bonferroni-Dunn	 method;	 ****	 p<0.001).	 To	 validate	 the	 signature,	 the	corresponding	 proteins	 have	 been	 localized	 in	 the	 livers	 of	 the	 3	 species.	 Accordingly,	 with	 the	expression	data,	proteins	have	been	found	only	in	the	bile	ducts	in	all	the	species.		Ultimately,	transcriptomic	data	showed	a	significant	enrichment	of	keratin	20	in	the	bile	 ducts	 of	Macaca	 f.,	 however,	 in	 our	 first	 analysis	we	 observed	 only	 a	 limited	number	 of	 bile	 ducts	 positive	 for	 this	 protein.	 A	more	 accurate	 analysis	 revealed	that	 terminal	 branches	 of	 bile	 ducts	 (Figure	 13A),	 in	 Cyno	monkey	 liver,	 resulted	
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negative	 for	 the	Keratin	20,	but	 the	 frequency	of	positive	 cells	 increased	 together	with	the	size	of	bile	ducts	(Figure	13B).	This	gradient	of	expression	reached	the	gall	bladder,	which	was	completely	positive	 for	keratin	20	(Figure	13C)	and	represent	one	of	the	species	specificities	we	wanted	to	explore	by	this	project.		
	Figure	13:	the	peculiar	Keratin	20	gene/protein	expression	in	the	monkey	liver	(labeled	as	L)	and	in	the	gall	bladder	(labeled	as	GB).	In	these	pictures	we	have	shown	the	absence	of	the	protein	in	the	small	terminal	branches	of	bile	duct	(A),	 the	expression	in	few	cells	 in	the	bigger	 intra	hepatic	bile	ducts	(B)	and	finally,	the	expression	in	all	the	cells	in	the	gall	bladder	(C).	This	peculiarity	has	been	never	described	so	far	and	was	observed	only	in	monkey	in	this	study.		Similarly,	we	localized	also	protein	poorly	described	in	the	liver:	Mucin	1,	Claudin	6	and	Claudin	7	(Figure	14).	
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	Figure	14:	Additional	three	genes	(Mucin	1,	Claudin	6	and	Claudin	7)	have	also	been	selected	among	the	 genes	 included	 in	 the	 bile	 duct	 signature.	 A	 significant	 enrichment	 has	 been	 shown	 in	 LCM	samples	 vs	whole	 liver	 (t-test,	 corrected	 for	multiple	 comparisons	with	Bonferroni-Dunn	method;	****	p<0.001).	Mucin	1	and	Claudin	7	were	expressed	in	the	bile	ducts	in	all	the	species,	confirming	the	 expression	 data.	 Claudin	 6	 was	 significantly	 enriched	 only	 in	 rat	 bile	 ducts.	 The	 protein	localization	confirmed	also	this	data,	showing	a	strong	specificity	of	the	expression	profiling	in	LCM	samples.		Mucin	1	gene	was	strongly	enriched	in	all	the	species	in	the	cholangiocytes	derived	by	 LCM.	 The	 protein	 localization	 confirmed	 the	 transcriptomic	 data.	 The	 protein	showed	also	a	peculiar	apical	expression	in	the	bile	ducts.	Claudins	 are	 a	 family	 of	 proteins	 present	 in	 the	 tight	 junction	 of	 epithelia.	 In	 the	liver	Claudin	1	has	been	extensively	studied,	due	to	its	function	as	HCV	receptor	and	entry	factor,	but	the	function	and	the	specific	localization	of	other	members	of	this	family	is	rather	unknown.	
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LCM	 data	 showed	 an	 enrichment	 of	 Claudin	 6	 in	 rat	 bile	 ducts,	while	 in	 dog	 and	monkey	we	did	not	observe	significant	differences.	The	protein	localization	indeed	revealed	that	Claudin	6	is	expressed	only	in	rat	bile	ducts.	 A	 minimal	 expression	 however	 was	 also	 observed	 in	 small	 artery	endothelium	 and	 this	 faint	 positivity	 was	 common	 in	 all	 the	 species.	 A	 deeper	investigation	 revealed	 that	 this	 species	 specificity	 was	 not	 limited	 to	 rat	cholangiocytes,	while	 also	other	 rat	 cubic	 epitheliums	 (i.e.	 thyroid	 epithelium,	 Fig	15)	showed	Claudin	6	expression.	Claudin	 7	 belongs	 to	 the	 same	 protein	 family	 of	 Claudin	 6,	 however,	 this	 gene	showed	a	different	profile.	The	gene	was	enriched	in	bile	ducts	of	all	the	species	and	the	protein	was	localized	according	with	the	gene	expression	profile.		
	Figure	 15:	 The	Claudin	6	 has	 been	 identified	 as	 a	 gene	 enriched	 in	 bile	 ducts	 (BD)	 in	 rats.	 In	 this	species	its	expression	is	common	in	all	the	cubic	epithelia	(CE),	like	the	thyroid	epithelium,	as	shown	in	these	pictures.	Surprisingly,	in	the	other	two	species,	both	the	bile	duct	and	the	thyroid	epithelia	
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resulted	negative	for	this	protein,	which	is	indeed	expressed	from	smooth	muscle	cells	in	the	tunica	media	of	the	small	arteries	(A).	
Genes	and	protein	selectively	expressed	in	liver	zone	I	or	zone	III	The	liver	zonation	is	a	phenomenon	well	known	for	many	years,	therefore	it	is	not	surprising	 that	 many	 genes	 and	 proteins	 have	 been	 described	 as	 expressed	 in	 a	specific	 location	 in	 the	 liver	 parenchyma.	We	have	mentioned	 in	 the	 introduction	some	of	the	pathway	involved	in	the	establishment	of	the	liver	zonation.	One	gene	downstream	 in	 the	 WNT	 pathway	 is	 the	 glutamine	 synthetase	 (GLUL).	 The	localization	of	 the	 corresponding	protein	 is	used	as	diagnostic	 tool	 for	 some	 liver	malignancies.	 Indeed	in	most	of	the	hepatocellular	carcinomas,	the	WNT/βCatenin	pathway	is	strongly	altered,	which	results	in	the	perturbation	of	the	liver	zonation.	In	those	cases,	the	Glutamine	synthetase,	which	is	normally	expressed	in	a	tiny	layer	of	hepatocytes	around	the	central	vein,	will	then	be	expressed	from	most	of	cells	in	the	 parenchyma.	 Here	 we	 have	 localized	 the	 Glutamine	 synthetase	 in	 all	 the	 3	species	in	normal	livers,	and	the	localization,	as	expected,	was	in	a	limited	number	of	pericentral	hepatocytes	(Figure	16A,	rat	liver;	B,	dog	liver;	C,	monkey	liver).		
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	Figure	 16:	 Glutamine	 synthetase	 localization	 in	 normal	 livers	 of	 the	 3	 species	 (A,	 rat;	 B,	 dog;	 C,	monkey)		It	 is	 not	 in	 the	 aim	 of	 this	 study	 to	 describe	 all	 the	 genes/protein	 expressed	selectively	 in	 only	 one	 area	 of	 liver	 parenchyma,	 but	 we	 found	 one	 gene	 in	 the	analysis	of	gender	and	zone	specific	expression,	which	showed	a	very	characteristic	profiles.	The	Lysyl	oxidase	(LOX),	also	known	as	protein-lysine	6-oxidase	resulted	selectively	expressed	in	liver	zone	III	of	only	male	rats.		
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We	therefore	wanted	to	localize	the	corresponding	protein,	in	order	to	validate	its	peculiar	profile.	In	Figure	17	A	we	can	observe	the	localization	of	this	protein	in	a	male	 rat	 liver.	 In	 agreement	 with	 the	 trascriptomic	 data	 (data	 not	 shown),	 the	protein	 was	 expressed	 only	 in	 pericentral	 area.	 In	 female	 rat	 liver,	 indeed,	 the	protein	was	almost	not	expressed.	Lysyl	oxidase	is	an	extracellular	copper	enzyme	that	 catalyzes	 formation	of	 aldehydes	 from	 lysine	 residues	 in	 collagen	and	elastin	precursors.	The	protein	localization	was	mainly	extracellular,	which	match	perfectly	with	the	biological	function	of	this	enzyme.		
	Figure	17:	The	Lysyl	oxidase	localization	in	male	(A)	and	female	(B)	rat	livers.	Signal	was	detectable	only	around	the	central	veins	(CV)	in	male	rats	and,	sometimes,	within	the	portal	fields	(PF).			Based	on	the	peculiar	localization	of	the	Lox	protein,	we	investigated	the	presence	of	a	substrate	for	this	enzyme,	which	might	have	had	the	same	peculiar	localization	in	rat	liver.	Indeed,	we	found	that	the	Collagen	1A1	also	showed	a	zone	and	gender	
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specific	profile,	thus	we	decided	to	validate	the	transcriptomic	data	by	localizing	the	corresponding	protein.	In	Figure	18	we	showed	the	localization	of	the	Collagen	1A1	protein	in	male	(A)	rat	liver	 and	 in	 female	 (B)	 rat	 liver.	 Similarly	 to	 the	 Lox	 protein,	 also	 in	 this	 case,	accordingly	 with	 the	 biological	 function	 of	 this	 protein,	 its	 localization	 was	exclusively	extracellular.		
	Figure	 17:	 The	 Collagen	 1A1	 localization	 in	male	 (A)	 and	 female	 (B)	 rat	 livers.	 Collagen	 1A1	was	more	abundant	in	male	rats	than	in	female	rats,	and	in	both	the	cases,	the	protein	was	localized	in	the	pericentral	area	(CV,	central	vein;	PF,	portal	field).		
Methapyrilene	study:	transcriptomic	analysis	based	on	data	generated	
by	independent	LCM	experiment		As	a	case	study	for	the	application	of	the	knowledge	generated	from	the	analysis	of	the	 LCM	 samples,	 we	 retrospectively	 analyzed	 a	 study	 performed	 on	 a	 reference	compound	 withdrawn	 from	 the	 marked	 due	 to	 its	 carcinogenicity	 in	 rodents:	
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Methapyrilene.	We	performed	an	analysis	of	the	whole	liver	transcriptomic	profiles	using	 the	 various	 structure-specific	 gene	 signatures	 established	 previously.	 We	wanted	 to	 prove	 that	 making	 use	 of	 the	 knowledge	 generated	 by	 LCM,	 we	 may	identify	the	cell	type	affected	by	the	toxicity,	based	on	whole	tissue	transcriptomic	profiles.	 Conceptually,	 the	 use	 of	 LCM	 profiles,	 allows	 a	 “conscious”	 analysis	 of	whole	tissue	transcriptomes,	allowing	the	identification	of	phenomena	occurring	at	the	level	of	different	cell	populations.	Thus,	the	(comparative)	analysis	is	not	strictly	dependent	 on	 the	 statistical	 significance	 anymore.	 In	 this	 respect,	 changes	 in	 the	expression	of	groups	of	genes	belonging	to	a	specific	gene	signature,	although	not	statistically	 significant,	 can	 give	 indications	 on	 the	 target	 site	 of	 toxicity.	 The	validation	 of	 these	 findings,	 then,	 is	 no	 longer	 delegated	 (only)	 to	 statistical	significance	of	the	transcriptomic	profile,	but	to	further	in	situ	investigations.	The	study	 included	96	SD	rats,	 treated	daily	by	oral	administration	of	 the	drug	or	vehicle	(H2O).	The	drug	administration	lead	to	no	unscheduled	death	and	only	thin	appearance	of	sufferance	were	detectable	in	2	of	the	6	animals	treated	with	60mg/kg/day	for	14	days.	The	 histopathological	 analysis	 revealed	 minimal	 histological	 changes	 in	 all	 the	treated	 groups,	 including	 increase	 of	mitotic	 figures,	minimal	 single	 cell	 necrosis,	and	a	dose	and	time	dependent	bile	duct	hyperplasia	(ductal	reaction),	detectable	in	all	 the	 conditions,	 but	 graded	 as	minimal	 by	 the	 pathologist.	None	 of	 the	 animals	developed	neoplasia.		The	initial	study	design	included	4	time-points,	as	described	in	material	&	methods:	day	 1,	 day	 3,	 day	 7	 and	 day	 14.	 However,	 during	 the	 quality	 control	 of	 the	transcriptomic	 data,	 the	 principal	 component	 analysis	 revealed	 that	 the	 samples	collected	 at	 the	 first	 time-point	 clustered	 all	 together,	 but	 they	 showed	 massive	differences	in	comparison	with	the	other	groups	(Figure	18).			
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	Figure	 18:	 Principal	 Component	 Analysis	 of	 all	 samples	 included	 in	 the	Methapyrilene	 study.	 The	sample	 collected	 at	 first	 time-point	 showed	 clear	 dissimilarities	 compared	 to	 the	 rest	 of	 samples	(PCA	performed	by	Dr..	Eleine	Tritto).			A	deeper	analysis	revealed,	 indeed,	big	differences	within	 the	controls	 (266	genes	differentially	expressed	between	the	controls	at	day	1	and	the	controls	at	the	other	time-points,	data	not	shown).	Thus,	due	to	the	high	variations	within	the	controls,	we	considered	the	samples	of	 the	 first	 time-point	as	not	reliable	and	we	excluded	them	from	the	following	analysis.	The	transcriptomic	data	were	pre-processed	as	described	in	material	and	methods	and	analyzed	by	Agilent	Gene	Spring	software.	In	 order	 to	 understand	 if	 the	 drug	 treatment	 induced	 a	 specific	 pattern	 of	expression,	with	one	or	more	pathways	involved,	we	performed	a	gene	and	sample	clustering	analysis	(Hierarchical	clustering,	Euclidean	distance	metric	and	complete	linkage).	The	analysis	revealed	the	absence	of	specific	pattern	of	gene	expression,	highlighted	by	a	random	and	non-patterned	distribution	of	genes	and	sample	 in	the	heat	map	(Figure	19A).	
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	Figure	19:	Clustering	analysis	of	the	transcriptomic	data	set	from	controls	and	Methapyrilene	treated	samples	(A).	Gene	differentially	expressed	(controls	vs.	 treated)	were	 identified	by	an	ANOVA	test.	However,	 also	 restricting	 the	 clustering	 analysis	 to	 the	 differentially	 expressed	 genes,	 it	 did	 not	emerge	 any	 specific	 pattern	 of	 expression	 (as	 demonstrated	 by	 the	 short	metrical	 distance	 in	 the	hierarchical	tree)	(B).	This	is	indicative	that	the	drug	induced	only	subtle	molecular	changes	and	did	not	massively	impact	the	gene	expression	profile.		To	 reveal	 changes	with	 a	 statistical	 relevance	we	 performed	 an	 ANOVA	 analysis,	comparing	all	 the	 treated	samples	with	 the	corresponding	control	 (per	each	time-point,	controls	vs.	60	mg	treated;	one	way	ANOVA,	p≤0.05,	Tukey	honest	significant	difference	[HSD]	post-hoc	test,	Benjamini-Hochberg	multiple	test	correction),	which	identified	 8608	 probe	 sets	 with	 a	 significant	 differential	 expression.	 We	 then	repeated	 the	 clustering	 analysis	 on	 this	 significant	 sub	 set	 of	probes	 (Figure19B).	Despite	the	reduction	of	the	probe	set	number	and	their	significant	regulation,	the	clustering	revealed	again	the	lack	of	a	driving	pathway.	A	very	general	 increase	in	the	gene	expression	value	was	observable	 in	 the	samples	 treated	with	the	highest	dose	at	day	7	and	day	14	(Figure	19B).	
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The	 principal	 component	 analysis	 confirmed	 the	 absence	 of	 a	 driving	 force	regulating	 the	gene	expression.	 Indeed,	 samples	did	not	cluster	 together,	but	 they	were	rather	randomly	distributed	in	the	plane	(Figure	20).		
	Figure	20:	The	principal	component	analysis	revealed	a	dose-dependent	distribution	of	samples	 in	the	plane.	However,	the	lack	of	clusters	containing	samples	with	similar	features	is,	again,	indicative	of	 small	 molecular	 changes	 and	 the	 lack	 of	 any	 driving	 pathway	 induced	 by	 the	 drug	 (index	structure:	[time-point-dose	(mg/kg/day)]).		In	our	analysis,	we	were	interested	in	understanding	if	the	knowledge	generated	by	the	 laser	 capture	 microdissection	 on	 normal	 liver	 might	 have	 been	 useful	 for	addressing	 a	 specific	 tissue,	 impacted	 by	 the	 drug	 treatment.	 We	 therefore	identified	the	genes	induced	by	the	drug	and	verified	their	link	with	a	specific	liver	tissue,	by	using	the	gene	signature	generated	by	our	LCM	sample	analysis.	We	therefore	selected	the	genes	up	regulated	(>2FC,	from	those	resulted	significant	in	the	previous	ANOVA	test)	at	all	 the	time-points,	 in	the	animals	treated	with	the	highest	 drug	 dose,	 in	 comparison	 with	 their	 corresponding	 controls	 (Figure	 21),	generating	gene	lists	specific	per	each	time-point.		
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	Figure	 21:	 bar	 plot	 showing	 all	 the	 genes	 up	 regulated	 upon	 the	 drug	 administration	 (FC>2	 in	controls	vs.	treated	with	60mg/kg/day,	at	all	time-points).		We	then	compared	together	those	gene	 lists	by	a	Venn	diagram.	Beside	few	genes	expressed	 selectively	 in	 one	 or	 few	 conditions,	 most	 of	 them	 (1561	 transcripts)	were	 common	 in	 all	 the	 3	 time-points.	 They	 represented	 the	 transcripts	 up	regulated	by	the	treatment	with	Methapyrilene	(Figure	22).		
	Figure	22:	using	a	Venn	diagram	we	compared	the	list	of	genes	up	regulated	at	different	time-points.	1561	transcripts	were	up	regulated	in	all	the	time-points.			
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We	 then	 compared	 those	 1561	 genes	 with	 the	 genes	 included	 in	 the	 bile	 duct	signature,	generated	from	the	LCM	samples.	This	comparison	revealed	an	abundant	number	of	common	genes	(Figure	23	A).	More	in	detail,	we	analyzed	the	number	of	genes	present	in	the	bile	duct	signature	and	up	regulated	at	the	different	time-points	of	the	treatment.	Indeed	the	number	of	those	genes	was	almost	 constant	 in	all	 the	 time-points	 (120	at	day	3,	Figure	23B;	131	 at	 day	 7,	 Figure	 23C;	 and	 132	 at	 day	 14,	 Fig	 23D).	 Despite	 the	 need	 for	 a	validation	of	these	findings,	this	approach	provided	a	specific	indication	of	the	cell	type	 interested	 by	 the	 drug	 induced	 molecular	 changes,	 supporting	 the	histopathological	analysis	and	predicting	this	finding	at	an	earlier	time-point.		





Validation	of	gene	regulation	in	bile	ducts	In	 order	 to	 validate	 the	 involvement	 of	 bile	 ducts,	 predicted	 from	 the	 metadata	analysis,	 in	 the	 phenomena	 induced	 by	 the	 drug	 treatment,	 we	 performed	 the	immunolocalization	(IHC)	of	some	validated	marker	of	bile	ducts.	Specifically,	 we	 used	 antibodies	 against	 Keratin	 19	 and	 Claudin	 7.	 As	 previously	described,	both	the	genes,	and	the	derived	proteins,	are	selectively	expressed	in	the	liver	 bile	 ducts.	 Indeed,	 also	 in	 the	 animals	 included	 in	 this	 study	 those	markers	showed	their	specificity	as	shown	in	the	Figure	24	and	25.	
	Figure	24:	Keratin	19	localization	in	control	(A)	and	treated	animals	(60mg/kg/day)	at	day	3	(B),	day	7	(C)	and	day	14	(D)		
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	Figure	25:	Claudin	7	localization	in	control	(A)	and	treated	animals	(60mg/kg/day)	at	day	3	(B),	day	7	(C)	and	day	14	(D)			To	 quantitatively	 evaluate	 the	 increase	 of	 the	 proteins	 in	 the	 treated	 animals,	we	performed	 an	 image	 analysis	 on	 the	 IHC	 pictures	 acquired	 in	 bright	 field	microscopy.	 In	 order	 to	 isolate	 the	 signal	 from	 the	 RGB	 images,	 we	 applied	 an	algorithm	for	color	deconvolution	(Figure	26).	This	step	allowed	the	isolation	of	the	signal	derived	for	the	chromogenic	staining.	The	signal	has	been	then	converted	in	binary	pictures	and	therefore	we	quantified	the	area	covered	from	the	cells	labeled	with	the	specific	marker.		
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	Figure	26:	the	image	analysis	steps,	leading	from	an	RGB	picture	acquired	at	brightfield	microscope,	through	 the	 color	deconvolution,	 for	 the	 isolation	of	 the	 region	of	 interest	 (ROI)	 and	 finally	 to	 the	binary	 conversion.	 This	 process	 allowed	 the	 quantification	 of	 the	 area	 covered	 by	 bile	 ducts	 in	controls	and	in	treated	animals.		The	image	analysis	revealed	an	increase	of	both	the	proteins	at	all	the	time-points.	This	increase	was	statistically	not	significant	at	day	3,	neither	for	Keratin19,	nor	for	Claudin7,	however,	it	was	significant	at	day	7	and	day	14	(Fig	27,	average	of	3	fields	per	 each	 time-point,	 ±	 SD;	 multiple	 t-test,	 significance	 corrected	 for	 multiple	comparison	by	Holm-Sidak	method,	p≤0.05).		
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	Figure	27:	the	graphs	represented	the	area	(average	of	3	fields	per	each	time-point,	±	SD)	covered	by	the	 cells	 labeled	 with	 the	 respective	 antibodies	 against	 the	 Krt19	 and	 Cldn7	 (multiple	 t-test,	significance	corrected	for	multiple	comparison	by	Holm-Sidak	method,	p≤0.05).		This	data	confirmed	the	involvement	of	the	bile	duct	in	the	phenomena	induced	by	the	 drug.	 Indeed,	 the	 drug	 is	 inducing	 a	 ductal	 reaction,	 a	 proliferation	 of	 biliary	epithelial	 tissues	outside	 the	portal	 tract.	This	hyperplasia	was	 correctly	detected	by	the	increase	of	the	area	corresponding	to	the	cells	labeled	by	both	the	antibodies	at	all	the	time-points.	Despite	this	data	validated	the	histopathological	analysis	and,	most	important,	our	findings	from	the	transcriptomic	metadata	analysis,	due	to	the	lack	 of	 significance	 at	 day	 3,	 we	 can	 conclude	 that	 the	 predictive	 power	 derived	from	the	IHC	investigation	was	limited	to	conditions	in	which	the	phenomena	were	likely	 detectable	 by	 a	 trained	 veterinary	 pathologist,	 thus	 resulting	 less	 sensitive	than	 the	 metadata	 analysis,	 which,	 using	 the	 bile	 duct	 signature,	 identified	comparable	molecular	changes	in	all	the	time-points.	
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Discussion	Nowadays,	 the	 pharmaceutical	 companies	 invest	 conspicuous	 capitals	 in	 the	development	 of	 new	 compounds.	 This	 is	 a	 long	 process	 (one	 decade	 in	 average),	which	rarely	(less	than	10%	of	the	compounds)	leads	to	the	commercialization	of	a	new	drug	[167].	As	 largely	 discussed,	 preclinical	 toxicological	 studies	 are	 routinely	 performed	 in	order	 to	 explore	 all	 the	 possible	 risks	 associated	 with	 new	 compounds.	 In	 this	respect,	all	the	drugs	on	the	market	have	a	well-defined	safety	profile,	considered	as	acceptable	for	a	given	indication.	The	general	improvement	of	the	investigative	methodologies	has	led	to	an	increase	of	 the	 drug	 safety	 (and	 also	 a	 corresponding	 decrease	 of	 the	 drugs	 reaching	advanced	preclinical	phases	and/or	on	the	market)	[168].	The	 introduction	of	high-throughput	screening	methods	allowed	the	simultaneous	detection	of	thousand	parameters	in	one	single	assay.	The	use	of	those	technologies	for	exploring	the	genomic,	transcriptomic,	proteomic	and	phosphoproteomic	aspects	of	biological	samples,	in	the	context	of	a	toxicology	study,	is	frequent	(reviewed	in	[169-171]	and	in	[172-174]).	Intuitively,	the	reason	is	that	the	possibility	to	explore	the	state	of	a	tissue	from	multiple	angles	increases	the	likelihood	of	understanding	the	effects	of	a	compound.		However,	 the	 interpretation	 of	 such	 a	 multi-modal	 picture	 might	 not	 be	 so	immediate	if	the	sample	in	analysis	is	not	pure.	Indeed,	while	 those	methods	provide	 insight	 about	 the	 transcriptomic	 and/or	 the	proteomic	 of	 the	 sample	 in	 analysis,	 the	data	 they	produce	 is	 not	 usually	 used	 to	infer	information	about	cellular	composition	of	the	sample	and	the	contribution	of	each	single	cell	type	in	the	global	picture.	In	 the	 context	 of	 the	 –omic	 data	 analysis,	 the	 tissue	 deconvolution,	 meant	 as	 an	analytical	process	able	to	decompose	a	tissue	in	its	components,	attributing	to	each	of	them	a	fraction	of	the	total,	in	a	proportional	manner	to	the	relative	abundance	of	the	 components	 and/or	 to	 the	magnitude	of	 a	 phenomenon,	 is	 a	 very	 challenging	activity	that	researchers	are	called	to	sort	out.	Despite	that	many	groups	have	attempted	to	approach	this	issue	a	posteriori,	using	statistical	 and	 mathematical	 methods	 [144-147],	 the	 reality	 is	 that	 those	
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approaches	require	at	least	a	validation	phase,	based	on	experimental	data	derived	by	pure	tissues	or	cells.		On	 the	 other	 hand,	 the	 use	 of	 in	 vitro	 systems	 or	 the	 collection	 of	 pure	 cell	populations	from	tissue,	with	some	available	methods,	is	controversial,	if	the	aim	is	to	reproduce	the	features	of	the	original	organ.	The	use	of	in	vitro	system,	based	on	primary	cells	or	on	immortalized	cell	lines,	has	shown	significant	limitations	in	resembling	normal	tissues.	Essentially,	primary	cell	lines	 are	 low	 representative	 of	 the	 derivative	 tissues	 due	 to	 the	 batch-to-batch	variations,	 and	 their	 availability	 is	 determined	 by	 the	 organ	 donations.	Immortalized	cell	lines	derive,	in	most	of	the	cases,	by	tumor	tissue,	and,	in	the	time	(decades),	they	became	monoclonal,	 losing	in	fact	the	cell	heterogeneity,	typical	of	the	heterogeneous	tissues.	Additionally,	the	culturing	conditions	strongly	influence	the	cell	phenotype.	The	 isolation	 of	 cells	 from	 tissue	 by	 enzymatic	 methods	 may	 by	 itself	 induce	changes	 in	 the	 gene	 expression	 profile	 and	 in	 the	 phosphorylation	 state	 of	many	proteins,	 resulting	 therefore	 low	 representative	 of	 the	 tissue	 physiological	 steady	state.	This	 aim	 of	 this	 study	 was	 to	 generate	 the	 knowledge	 necessary	 to	 operate	 the	tissue	deconvolution	of	the	liver.	To	achieve	this	objective,	we	created	a	map	of	gene	expression	of	the	liver.	This	 map	 can	 be	 considered	 as	 a	 primordial	 and	 essential	 step	 to	 further	understand	mechanisms	of	drug	injury.		Other	 authors	have	described	 the	 gene	 expression	 in	 the	 liver,	 but	 in	most	of	 the	cases	they	have	made	use	of	whole	liver	tissues	[98,	175-177].	We	 decided	 to	 isolate	 metabolic	 relevant	 area	 of	 liver	 (zone	 I	 and	 zone	 III),	representative	of	those	areas	where	the	drug	metabolism	happens;	and	the	bile	duct	and	the	blood	vessels,	also	as	possible	target	tissues	of	some	drugs.		We	 took	advantage	of	 the	 laser	 capture	microdissection,	 for	 the	 isolation	of	 those	areas,	directly	from	frozen	tissue.	The	laser	capture	microdissection,	however,	is	a	demanding	activity.	It	is	expensive,	time	 consuming	 and	 requires	 a	 long	 process	 optimization,	 in	 order	 to	 provide	reliable	results.	
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One	of	 first	 issue	we	were	called	 to	solve	was	 the	 intrinsic	RNA	 instability	and	 its	degradation	during	the	sample	processing	and	the	microdissection.	RNA	degradation	in	tissue	sections	is	primarily	due	to	endogeneous	RNases,	which	are	activated	in	an	aqueous	medium.	The	 addition	 of	 RNase	 inhibitors	 is	 generally	 accepted	 as	 necessary	 to	 prevent	endogeneous	 RNases	 reactivation	 during	 the	 staining	 process,	 and	 reduce	 RNA	degradation	 [105,	 122].	 In	 only	 one	 study,	 it	 was	 mentioned	 that	 their	 role	 was	uncertain,	reporting	no	improvement	in	RNA	quantity	and	even	a	decreased	in	RNA	quality	[102].	In	previous	LCM	protocols	discussion,	authors	also	recommended	to	cool	 all	 reagents	 for	 fixation,	 staining	 and	dehydration	 at	4°C	 and	 to	 carry	on	 the	staining	 on	 ice.	 This	 could	 preserve	 the	 RNA	 integrity,	 but,	 on	 the	 other	 hand,	 is	generally	 not	 applicable	 when	 an	 immunohistochemical	 staining	 is	 required,	because	the	low	temperature	slows	down	the	enzymatic	activity	of	RNAses,	but	also	the	kinetic	of	the	antibody	binding	to	the	epitopes.	The	 fixatives	used	and	 the	 staining	 time	are	 also	 crucial	 factors	determining	RNA	quality.	 The	 ethanol	 fixation	 was	 shown	 to	 improve	 RNA	 quality	 and	 quantity	compared	 to	 unfixed	 sections	 [102].	 Moreover,	 cross-linking	 reagents	 such	 as	paraformaldehyde	was	reported	to	decline	the	amplifiable	RNA	on	the	contrary	to	precipitating	 agents	 (acetone,	 methanol	 or	 ethanol)	 which	 gave	 superior	performance	in	downstream	RNA	analysis	[122].	An	essential	property	of	fixatives	is	to	preserve	tissue	and	an	optimal	compromise	should	 be	 found	 to	 maximize	 the	 balance	 between	 RNA	 integrity	 and	 tissue	morphology.	In	our	study,	we	adopt	an	iced-cooled	methanol	fixation	step,	although	we	 did	 not	 observe	 significant	 differences	 between	 the	 precipitating	 fixatives.	Additionally,	in	agreement	with	literature,	we	were	not	able	to	collect	RNA	of	good	quality	upon	the	fixation	with	formaldehyde.	To	determine	the	RNA	quality,	we	used	the	Agilent	2100	Bioanalyzer	able	to	assign	integrity	 score	 from	 a	 software	 algorithm.	 This	 method	 is	 considered	 by	 some	authors	as	a	reliable,	reproducible	and	standardized	approach	to	classify	the	quality	of	 RNA	 samples	 [102].	 According	 to	 some	 other	 authors,	 determination	 of	 RNA	quality	using	 the	Agilent	Bioanalyzer	 lacks	 reproducibility	 [105].	 In	our	 study,	we	encountered	 some	 technical	 difficulties	 with	 the	 Bioanalyzer	 because	 of	 the	 very	
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small	 amounts	 of	RNA,	 often	 a	 second	 run	 of	 analysis	 has	 been	necessary,	 in	 few	instances	the	software	failed	in	assigning	the	RIN	score.		The	precision	of	microdissection	is	generally	limited	by	the	difficulty	to	identify	cell	types	 by	morphology	 alone,	mainly	 because	 of	 staining	 and	 dehydration	 process,	which	deeply	alter	tissue	quality	[122].	The	use	of	frozen	sections	and	the	absence	of	 the	 final	mounting	with	 a	 coverslip	 are	 also	 necessary	 for	microdissection	 but	reduce	 cellular	 details,	 further	 diminishing	 the	 ability	 to	 isolate	 a	 specific	 cell	population.	 In	 our	 study	 the	main	 challenge	 remained	 the	 identification	 of	 small	portal	structures	since	HE	staining	did	not	allow	to	distinguish	small	biliary	ducts	from	 portal	 vessels	 with	 a	 sufficient	 confidence.	 To	 solve	 this	 problem,	 we	developed	 a	 rapid	 immunostaining	 procedure,	 similar	 to	 those	 described	 in	 the	literature	 [122,	 127,	 178].	 The	 immuno-LCM	 technique	 allows	 the	 isolation	 of	specific	 cell	 populations	 according	 to	 their	 immunophenotype,	 even	 if	 they	 are	 of	similar	 morphology.	 The	 specificity	 and	 precision	 of	 microdissection	 is	 greatly	increased	by	the	ease	of	identification	of	labeled	cells.	As	 regarding	 RNA	 quality	 with	 immuno-LCM,	 the	 RNA	 extracted	 from	immunostained	 tissue	 was	 of	 equal	 quality	 compared	 to	 unstained	 (control	 -	scrape)	or	quick	HE	stained	sections.	For	the	gene	expression	profiling	we	used	the	GeneChip	platform	from	Affymetrix.	They	are	oligonucleotide	chips	able	to	quantitatively	evaluate	the	gene	expression	transcriptome-wide.	The	GeneChip	are	species-specific	platform,	however	at	time	of	this	 study,	 there	 was	 not	 a	 specific	 assay	 designed	 for	 Macaca	 fascicularis.	 To	overcome	 this	 limitation,	we	 used	 the	Human	 Genome	U133	 plus	 2.0.	 One	 group	have	shown	the	feasibility	of	this	approach,	demonstrating	an	average	consistency	of	85.78%	between	human	and	rhesus	monkey,	indicating	that	a	human	microarray	might	provide	a	part	of	the	information	for	monkey	sample	testing	(Illumina	Chips)	[179].	 We	 did	 not	 perform	 specific	 investigations	 for	 assessing	 the	 level	 of	sensitivity	 and	 specificity	 achievable	 in	 this	 hybrid	 experimental	 condition;	however,	we	were	able	to	validate	the	presence	of	genes	detected	as	low	expressed.	The	 use	 of	 different	 algorithm	 for	 pre-processing	 the	 raw	 expression	 data	 is	 still	controversial.	
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Affymetrix	 provided	 its	 own	 solution	with	 the	MAS5	 algorithm,	which	 use	 all	 the	technical	 specifications	 of	 the	 GeneChip	 platform	 (PM	 and	 MM	 probe	 set).	 This	results	in	reliable	results,	but	at	the	expense	of	a	reduced	sensitivity.	Many	independent	groups	have	provided	their	alternative	solution	to	 improve	the	data	pre-processing.	In	 our	 project	 we	 have	 compared	 data	 pre-processed	 with	 the	 MAS5	 and	 RMA	algorithms.		Our	 correlation	 analysis	 revealed	 a	 high	 agreement	 between	 the	 two	data	 sets	 in	our	 LCM	 experimental	 conditions.	 From	 the	 practical	 point	 of	 view,	 we	 did	 not	observe	 differences	 between	 the	 two	 algorithms.	 However	 one	 group	 have	described	 an	 algorithm	 driven	 artifact	 affecting	 the	 RMA	 algorithm,	which	would	overestimate	the	similarities	between	samples	in	specific	conditions	[180].	Assuming	the	absence	of	a	real	advantage	in	using	the	RMA	algorithm	vs.	the	MAS5	in	our	data	set,	and	the	possibility	to	incur	in	this	artificial	correlation,	we	decided	to	proceed	with	only	the	MAS5	algorithm.	Upon	 the	 pre-processing	 and	 normalization	 of	 the	 data,	 we	 proceeded	 with	 the	analysis.	We	approached	the	analysis	in	a	first	instance	in	an	unsupervised	manner.	We	 analyzed	 all	 the	 data	 sets	 from	 the	 3	 species	 using	 a	 Principal	 Component	Analysis,	to	highlight	the	intrinsic	characteristic	of	our	samples.	In	all	the	species	we	obtained	an	optimal	distribution	of	the	samples,	according	with	their	cellular	composition.	Indeed,	the	clustering	together	of	the	liver	zone	I,	zone	III	and	whole	liver	tissue	can	be	easily	explained	by	the	major	cell	composition	of	those	samples.	The	hepatocytes	represent	 the	 majority	 of	 cells	 in	 those	 samples,	 and	 their	 expression	 profile	influenced	 in	 large	extent	 the	variance	and	 the	distribution	of	 samples	 in	 the	PCA	analysis.	Similarly,	the	clustering	of	arteries	and	veins	can	be	explained	by	the	similar	cellular	composition,	although	the	greater	distance	between	these	samples,	compared	with	the	samples	 in	the	previous	group,	 is	 likely	determined	by	the	difference	between	the	artery	and	vein	tissues	(e.g.	the	more	abundant	presence	of	smooth	muscle	cells	in	the	tunica	media	of	arteries).	
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The	 isolation	of	 the	bile	duct	 sample	 is,	 as	well,	 a	 sign	of	 a	 successful	 enrichment	process.		The	graph	 in	Figure	4	 represents	alone	 the	proof	 that	 it	 is	possible	 to	 isolate	and	profile	histological	elements	from	a	heterogeneous	tissue	like	the	liver.	For	the	selection	of	genes	enriched	in	the	bile	ducts,	we	tried	to	identify	a	method	with	the	highest	sensitivity	and	specificity.	The	 selection	 of	 gene	 signature	 is	 based	 on	 a	 comparative	 process.	 Here	 we	compared	 the	whole	 liver	 samples	with	 the	LCM	bile	ducts,	using	 the	 fold	 change	value	as	selection	and	cut	off	parameter.	Generally,	 the	selection	of	a	cut	off	parameter	is	arbitrary,	but	we	tried	to	identify	universal	criteria	applicable	in	all	the	species	in	analysis.	Our	 analysis	 revealed	 that	 a	 unique	 cut	 off	 value	 could	 be	 identified	 in	 order	 to	achieve	the	best	compromise	between	sensitivity	and	specificity.	Indeed,	 in	 our	 explorative	 analysis	 on	 rat	 tissue,	 the	 intersection	 of	 the	 two	 best	fitting	linear	phases,	 identified	in	the	global	exponential	curve	of	the	FC	frequency	distribution,	corresponded	to	the	best	compromise	in	sensitivity	and	specificity	for	the	selection	of	genes	specific	for	bile	ducts.	An	 increase	of	 the	FC	value	 from	0	 to	9.2	 leads	 to	 an	 exclusion	of	 roughly	20000	probe	 sets.	 This	 of	 course	 increases	 the	 specificity	 of	 our	 signature.	 Above	 this	value,	a	further	increase	of	the	FC	cut	off,	would	result	in	a	minimal	increase	of	the	specificity.	 Indeed,	 a	 further	 increase	 from	 a	 FC	 9	 to	 FC	 18,	 would	 result	 in	 the	exclusion	 of	 only	 80	 probe	 sets,	 a	 very	minimal	 increase	 of	 the	 specificity	 at	 the	expense	of	sensitivity.	Although	 this	 approach	 is	 empirical	 in	 some	 extent	 and	 arbitrary,	 it	 allowed	 the	selection	of	bile	duct	gene	signatures	in	all	the	species.	Interestingly	enough,	the	cut	off	values	resulted	quite	similar	in	all	the	species,	possibly	due	to	a	common	tissue	specific	expression	pattern.	As	 expected,	 the	 signatures	 included	 well-known	 epithelial	 markers,	 functional	markers	(e.g.	bile	carriers)	and	metabolic	elements.	Our	 gene	 expression	 analysis	 has	 been	 followed	 by	 a	 validation	 step.	 Due	 to	 the	limited	amount	of	RNA	we	obtained	from	the	LCM	samples,	it	has	not	been	possible	to	validate	directly	the	expression	profiles	by	real-time	PCR.		
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On	the	other	hand,	the	validation	of	oligonucleotide	array	data	by	real	time	PCR	is	controversial.	Several	authors	have	shown	a	good	agreement	between	real	time	PCR	data	 and	 oligonucleotide	 array	 data	 in	 many	 different	 applications	 [181-183],	others	 have	 shown	 significant	 differences	 [184],	which	 can	be	 corrected	by	using	specific	algorithms	for	the	pre-processing	of	the	chip	data	.	We	decided	then	to	validate	some	of	our	markers	by	protein	localization.	The	 validation	 has	 been	 performed	 cross-species	 and	 this	 limited	 the	 number	 of	targets	 we	 could	 localize.	 Indeed,	 the	 number	 of	 antibodies	 recognizing	 epitopes	from	different	species	with	comparable	efficiency	is	very	restricted.	We	could	localize	6	markers	of	bile	ducts:	keratin7,	keratin19	and	keratin20,	mucin	1,	claudin	6,	and	claudin	7.	We	 found	 those	 proteins	 expressed	 in	 the	 bile	 ducts,	 according	 with	 the	 gene	expression	profiles,	 in	which	we	observed	a	 strong	enrichment	of	 the	gene	 in	 the	LCM	bile	duct	versus	the	whole	liver.		Interestingly	we	were	able	to	find	the	keratin	19	also	in	dog,	an	unpredicted	data,	due	to	the	lack	of	the	specific	probe	set	in	the	dog	Chip.		We	 were	 also	 capable	 to	 show,	 for	 the	 first	 time,	 in	 best	 of	 our	 knowledge,	 a	gradient	of	expression	of	keratin	20	in	the	biliary	tree,	inside	the	liver	and	in	the	gall	bladder	of	monkey.	Furthermore,	we	discovered	an	additional	specie-specificity	relative	to	the	claudin	6,	expressed	in	the	bile	duct	only	in	rat.	Although	the	number	of	protein	localized	was	not	very	high,	based	on	these	results,	we	were	very	optimistic	about	the	specificity	of	our	gene	signature.	For	the	gene	signature	relative	to	the	liver	zone	I	and	zone	III,	we	did	not	perform	specific	analysis,	for	the	selection	of	a	specific	FC	value.	The	cellular	composition	of	those	samples	was	very	similar,	therefore	we	used	a	FC	2	in	order	to	identify	most	of	 the	 metabolic	 specificities	 of	 each	 zone,	 without	 the	 need	 to	 highlight	 genes	selectively	expressed	in	one	area.	We	validated	transcriptomic	data	for	some	gene	expressed	in	the	liver	zone	III.	We	localized	the	Glutamine	synthetase	as	a	marker	of	the	liver	zone	III.	This	marker	is	well	known	 to	be	expressed	 in	a	 tiny	 layer	of	hepatocytes	 in	 the	pericentral	area,	and	 it	 has	 a	 biological	 and	 diagnostic	 relevance	 [185,	 186].	 According	 to	
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transcriptomic	 data,	 the	 Glutamine	 synthetase	 was	 localized	 in	 all	 the	 species	around	the	central	vein.	Recently,	we	have	 contributed	 to	 show	 that	RSPO-LGR4/5-ZNRF3/RNF43	module	controls	 metabolic	 liver	 zonation	 and	 is	 a	 hepatic	 growth/size	 rheostat	 during	development,	 homeostasis	 and	regeneration	 [187],	 providing	 evidences	 that	 both,	Wnt	 ligand	and	the	entire	system	of	receptors	and	enhancer	are	necessary	for	the	activation	of	β	Catenin	and	the	establishment	of	the	liver	zonation	in	mice.	Based	 on	 these	 evidences,	 the	 Rappaport’s	model	 could	 be	 revised:	 if	 the	 driving	forces	of	 liver	zonation	are	actually	two	(the	Wnt	pathway	as	we	have	shown	and	Hedgehog	 as	 shown	 by	 other	 authors	 [10]),	 and	 the	 mechanism	 is	 based	 on	gradients’	opposition,	the	intermediate	area,	defined	by	Rappaport	as	zone	II,	could	be,	 not	 only	 topographically,	 but	 also	 from	 the	 metabolic	 point	 of	 view,	 just	 a	transition	area,	where	none	of	the	two	pathways	is	strong	enough	to	overwhelm	the	other.	In	this	respect	the	zone	II	assumes	less	importance	because	it	actually	suffers	the	influence	of	both	the	driving	forces	without,	apparently,	having	an	active	role	in	the	liver	zonation.	Despite	all	 the	species	 showed	a	number	of	genes	 regulated	either	 in	zone	 I	or	 in	zone	III,	we	managed	to	 identify	only	 in	rat	and	in	monkey	the	putative	drivers	of	the	liver	zonation.	The	gene	WNT2	indeed,	was	differentially	expressed	in	liver	zone	III,	 in	these	two	species.	Other	two	genes	downstream	in	β	Catenin	pathway	were	up	regulated	as	well	(AXIN2	and	GLUG).	Moreover,	the	absence	of	a	significantly	regulated	WNT	gene	in	the	zone	III	in	dog	is	very	surprising.	Despite	this	absence,	we	were	able	to	distinguish	a	liver	zonation	in	this	 species,	 highlighted	 also	 by	 the	 GLUL	 expression	 profile	 and	 protein	localization.	 The	 explanation	 of	 this	 might	 be	 either	 technical	 or	 biological.	 The	GeneChip	technology	relies	on	the	gene	annotation,	therefore	some	genes	might	not	be	 annotated	 or	 not	 present	 at	 all	 on	 the	 hybridization	 platform.	 Indeed,	 we	observed	 a	 similar	 issue	with	 the	KRT19	 transcript,	 not	 present	 at	 all	 on	 the	dog	chip.	 A	 second	 explanation	 could	 be	 that	 the	 mechanism	 leading	 to	 the	establishment	of	 liver	zonation	 in	dog	differs	substantially	 from	the	other	species.	This	might	 be	 corroborated	 also	 by	 the	 lack	 of	 induction	 of	 the	AXIN	 2,	 although	requires	additional	investigation.	
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Next,	 we	 wanted	 to	 verify	 the	 influence	 of	 the	 sexual	 dimorphism	 on	 the	 liver	zonation.	Not	 surprisingly,	 this	phenomenon	 interested	only	 the	 rodent.	 In	 rat	we	were	able	to	detect	a	conspicuous	number	of	genes	regulated	in	different	manner	in	male	or	female	animals,	both	in	the	zone	I	and	in	the	zone	III.	This	finding	is	in	agreement	with	a	recent	publication,	in	which	the	authors,	using	a	similar	approach,	isolated	by	LCM	the	zone	I	and	zone	III	from	mouse	livers	[188].		Within	 the	 genes	 with	 a	 gender	 and	 zone	 specific	 profile,	 we	 localized	 the	 lysyl	oxidase	 (Lox).	 Lysyl	 Oxidase,	 also	 known	 as	 protein-lysine	 6-oxidase,	 is	 an	extracellular	 copper	 enzyme	 that	 catalyzes	 formation	 of	 aldehydes	 from	 lysine	residues	in	collagen	and	elastin	precursors.	The	Lox	transcript	has	been	found,	in	rats	only,	in	the	liver	zone	III	of	male	subjects.	The	protein	 localization	 confirmed	 this	 specific	 pattern	of	 expression.	 Indeed,	 the	protein	was	 localized	 in	 the	extracellular	space	 in	 the	pericentral	area	 in	male	rat	livers.	 It	 remains	 unclear	 why	 an	 enzyme	 playing	 an	 important	 role	 in	 the	stabilization	of	the	extracellular	matrix	 is	expressed	only	 in	male	animals	and	in	a	limited	region	of	the	organ.	Moreover,	we	were	also	capable	to	confirm	the	same	pattern	of	expression	in	one	of	the	substrate	of	this	enzyme:	the	collagen	1A1,	at	transcriptional	and	protein	level.	One	of	the	most	critical	analysis	performed	in	this	study,	is	the	one	comparing	the	tissue	specific	gene	signatures	previously	identified,	across	the	3	species	in	analysis.	We	 approached	 this	 comparison,	 using	 the	 same	 software	 we	 used	 for	 the	expression	analysis,	GeneSpring	from	Agilent.	This	 software	 can	 compare	 cross-species	 platform,	 operating	 a	 series	 of	translations,	to	convert	gene	signatures	from	one	species	to	another.	Intuitively,	the	software	makes	use	of	 the	orthologous	databases,	and	operates	 in	order	 to	 finally	obtain	lists	with	comparable	names/data.	Unfortunately,	 in	 this	multistep	 process	 there	 are	 some	 limitations,	which	 indeed	reduced	 the	 efficacy	 of	 the	 entire	 analysis.	 The	 first	 issue	 is	 the	 detail	 of	 the	GeneChip	annotation:	although	Affymetrix	tried	in	the	years	to	keep	up	to	date	the	gene	annotation	on	its	platforms,	all	of	them	have	a	conspicuous	number	of	probes	annotated	as	putative	genes,	genes	of	uncertain	function	(LOC	sites),	and	probes	not	annotated	at	all.	Intuitively	those	probes	cannot	be	translated	and	will	be	lost	in	the	cross-species	comparison.	Additionally,	we	have	found	several	transcripts	for	which	
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there	was	not	a	corresponding	probe	set	on	the	Chip	for	one	species	(e.g.	KRT19	in	dog).	Second	 limitation	 is	 not	 related	 to	 the	 technology,	 but	 might	 be	 related	 to	 the	annotation	 of	 the	 genes	 in	 the	 global	 databases.	 Gene	 orthologues	 might	 have	different	names	and	the	recognition	by	the	software	might	not	be	perfect.	In	this	context,	we	tried	to	run	our	cross-species	analysis,	but	the	results	were	not	very	convincing.	The	number	of	genes	common	between	species	in	zone	I,	zone	III	or	bile	ducts	 results	very	 limited.	 In	our	opinion	 it	 is	unlikely	 that	 tissues	with	so	close	biological	functions	can	share	so	few	genes.	We	are	rather	convinced	that	this	analysis	was	strongly	 impacted	by	 the	approach	and	by	 the	 limitation	dictated	by	the	technical	characteristics	of	Chips	and	databases.	In	the	future	a	more	accurate	analysis	might	be	performed	based	on	the	sequence	homology,	making	use	of	the	modern	algorithm	optimized	for	the	alignment	of	the	RNAseq	 data,	 and	 remapping	 the	 oligonucleotide	 sequences	 and	 therefore	 the	target	transcripts.	A	sequence	based	comparison	across	species	might	provide	more	reliable	results.	This	approach,	anyhow	would	require	a	bigger	computational	effort	in	 order	 to	 remap	 the	 600000-1	 mio	 of	 probes	 spotted	 on	 the	 chip	 of	 different	species.	Our	 final	analysis	on	 the	gene	expression	data	 set	was	 focalized	 in	understanding	the	 impact	 of	 the	 call	 flag	 pre-filtering	 strategy,	 in	 order	 to	 increase	 the	 global	statistical	power	of	the	analysis.	As	described,	Affymetrix	introduced	this	parameter	in	its	MAS5	algorithm,	in	order	to	provide	estimation	about	reliability	of	the	gene	expression	data.	However,	the	use	of	this	pre-filtering	strategy	might	result	too	stringent	and	lead	to	the	loss	of	biologically	relevant	data.	We	analyzed	the	gene	expression	profile	 from	the	whole	 liver	scrape,	pre-filtering	all	the	genes	labeled	as	present	in	at	least	80%	of	the	samples	in	analysis.	We	then	evaluated	the	impact	of	this	filtering	on	genes	representing	a	small	cell	population	in	the	liver,	as	the	bile	duct.	To	do	this	we	calculated	how	many	genes	present	in	the	bile	duct	signature	were	excluded	by	the	pre-filtering.		Whole	 liver	data	 set,	 pre-filtered	by	 the	 “present”	 flag	 included	only	between	2%	and	60%	of	the	bile	duct	genes	in	the	different	species.	In	other	words,	an	analysis	performed	on	a	data	set	pre-filtered	on	“present”	flag,	may	strongly	underestimate	
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biological	 phenomena	 happening	 in	 the	 bile	 ducts,	 masked	 by	 the	 dilution	 effect	operated	by	the	sample	composition	on	the	transcriptomic	data.	With	the	validation	of	the	specificity	of	our	signatures,	we	concluded	the	first	phase	of	our	project,	consisting	of	generating	the	tissue	specific	knowledge	relative	to	liver	sub-units.		We	selected	a	restricted	number	of	proteins	belonging	to	the	gene	signature	of	bile	ducts	 and	 liver	 zones.	 In	 this	we	 focused	more	 on	 the	 validation	 of	 the	 bile	 duct	signature	than	on	the	others.	The	reason	was	that	for	bile	duct	genes	we	used	a	very	high	FC	cut	off	and	we	wanted	to	be	sure	that	also	genes	with	a	very	low	expression,	selected	 by	 our	 empirical	 approach,	 were	 actually	 expressed	 in	 this	 tissue.	 The	selection	 of	 the	 candidate	 proteins	was	 in	 large	 extent	 dictated	 by	 the	 antibodies	availability,	therefore	the	selection	of	Keratin	7	and	19	is,	overall	not	surprising.	For	those	two	markers	very	good	antibodies	are	commercially	available	 for	diagnostic	purpose.	Nevertheless,	we	also	included	proteins	poorly	described	like	the	Claudins.	In	 this	 we	 wanted	 to	 include	 markers	 with	 a	 low	 gene	 expression	 and	 not	homogeneously	distributed	across	the	species,	like	the	Claudin	6.	The	 immunohistochemistry	 analysis	 validated	 all	 the	 transcriptomic	 findings,	reflecting	perfectly	the	gene	expression	profiles	in	all	the	species,	and	leading	to	the	description	 of	 species	 specificities	 (e.g.	 the	 peculiar	 gene	 expression	 profile	 and	protein	 localization	of	KRT20	 in	monkey,	 the	Claudin6,	expressed	only	only	 in	 rat	bile	ducts,	the	Lox	and	the	Col1A1).	All	this,	made	us	very	confident	of	the	profiles	derived	by	the	LCM	experiments,	but	we	wanted	to	challenge	these	 findings	 in	 the	context	of	a	real	 toxicology	study,	 to	assess	the	value	of	the	data	set	for	drug	safety.	We	wanted	 to	 assess	 if,	 based	 on	 our	molecular	 profiling	 (LCM),	 we	would	 have	been	able	to	address	the	drug	toxicity	to	a	specific	tissue	structure	within	the	liver.	We	decided	to	retrospectively	analyze	a	study	on	the	effect	of	Methapyrilene	on	SD	rat.	We	 approached	 the	 study	 in	 an	 unsupervised	 way,	 although	 the	 molecular	 and	morphological	 alterations	 induced	 by	 this	 drug	 have	 been	 largely	 explored	 in	 the	past	from	other	groups	(e.g.	in	[162]).	The	 evaluation	of	 drug	 safety	has	been	based	on	whole	 liver	 transcriptomic	data,	the	histopathological	report	of	the	study	and	the	IHC	analysis.	
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As	our	standard	we	performed	first	an	unsupervised	analysis	of	the	whole	data	set	of	transcriptomic	data	relative	to	this	study.	The	Principle	Component	Analysis	revealed	an	unusual	sample	segregation.	Indeed,	the	 animal	 (controls	 and	 treated)	 belonging	 to	 the	 first	 time-point,	 showed	 a	significant	 divergence	 versus	 all	 the	 other	 groups.	 From	 a	 deeper	 analysis	 we	discovered	 that	 there	was	 a	 difference	 in	 terms	 of	 global	 gene	 expression	 in	 this	sample	 group,	which	 interested	many	 genes	 involved	 in	 the	 circadian	 cycle	 (data	not	shown).	Not	being	able	to	assess	if	this	phenomenon	was	relevant	or	not	for	the	following	analysis,	we	decided	to	exclude	this	sample	group.	We	then	clustered	genes	and	samples	in	an	unsupervised	gene	clustering	analysis.	In	 line	with	 previous	 report	 [162],	 this	 analysis	 revealed	 just	minimal	 variations,	dose	and	time	dependently,	and	highlighted	the	lack	of	driving	pathways.	The	gene	expression	variations	were	mainly	subtle	and	isolated.	Other	authors	also	found	 the	absence	of	driving	mechanisms.	This	might	explain	why,	 so	 far,	nobody	could	identify	a	unique	drug	induced	mechanism	driving	the	liver	cancer	in	rats.	In	summary,	the	unsupervised	analysis	showed	a	minimal	impact	of	the	drug	in	all	tested	conditions.	The	 lack	of	gene	expression	pattern	 in	 this	study	represents,	however,	 the	perfect	condition	for	testing	our	approach,	making	use	of	the	knowledge	generated	by	LCM	samples.	The	 histopathological	 analysis,	 in	 agreement	with	 the	 literature,	 and	 consistently	with	the	lack	of	a	gene	expression	pattern	observed,	described	single	cell	necrosis	and	 a	 general	 increase	 of	 mitotic	 figures,	 associated	 with	 a	 minimal	 bile	 duct	hyperplasia.	All	this	morphological	changes,	were	however,	reported	as	mild.	In	 this	 context,	 if	 bile	 ducts	were	 affected	by	 the	drug	 toxicity,	 there	 should	have	been	molecular	 alterations,	 even	 though	minimal.	 Now,	 if	 these	 signals	 were	 not	perceptible	due	to	the	dilution	effect	in	the	pool	of	the	whole	tissue	transcriptome,	then,	 we	 should	 be	 able	 to	 observe	 them	 by	 applying	 the	 bile	 duct-specific	 gene	signature	generated	by	LCM.	Indeed,	 upon	 a	 statistical	 analysis	 aimed	 at	 identifying	 the	 significant	 gene	variations,	we	evaluated	the	overlap	between	the	regulated	genes	and	our	bile	duct	signature.	
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A	conspicuous	amount	of	genes	(120	transcripts	at	day	3,	131	at	day	7	and	132	at	day	14)	from	the	bile	duct	signature	were	indeed	induced	by	the	drug,	providing	a	strong	evidence	that	the	drug	impacted	bile	ducts.	Interestingly,	the	number	of	genes	interested	was	almost	constant	at	all	time-point,	showing	a	precise	pattern	of	toxicology,	onset	from	the	earliest	time-point	on.	To	validate	this	observation,	we	performed	the	localization	of	the	bile	duct	markers	(keratin	19	and	claudin7)	and	we	quantified	the	bile	duct	area	by	image	analysis.	This	 analysis	 confirmed	 the	 bile	 duct	 area	 enlargement,	 in	 agreement	 with	 the	increase	in	expression	of	bile	duct	markers	and	in	agreement	with	the	observed	and	reported	bile	duct	hyperplasia.	The	image	analysis,	however,	did	not	produce	statistically	significant	results	at	first	time-point,	 showing	 in	 this,	 a	 lower	predictive	and	diagnostic	power	compared	 to	the	molecular	profiling	of	tissues.	Similarly,	 and	more	striking,	 the	morphological	alterations	were	classified	only	as	mild	in	the	literature	and	in	the	histopathological	report.	Therefore,	 this	 analysis	 revealed	 that	 it	 was	 possible	 to	 identify	 the	 specific	structures	 targeted	 by	 toxicity	 in	 a	 complex	 tissue,	 by	 analyzing	 the	whole	 tissue	transcriptomic	 data,	with	 the	 help	 of	 a	molecular	 signature	 generated	by	 LCM	on	independent	 ‘reference’	 samples.	 It	 also	 shows	 that	 the	 deconvolution	 of	 the	transcriptomic	data	from	a	heterogeneous	tissue,	like	the	liver,	is	possible,	provided	that	the	adequate	reference	data	are	available.	The	transcriptomic	data	were	more	sensitive	and	reliable	than	the	histopathological	analysis,	 based	 on	 the	 critical	 observation	 of	 the	 hematoxylin	 and	 eosin	 staining,	and	 also	 of	 the	 IHC	 data,	 not	 enough	 sensitive	 at	 an	 early	 time-point,	 to	 reach	 a	significant	evaluation	of	the	phenomena.	This	 study	 was	 not	 aimed	 at	 identifying	 the	 molecular	 mechanism	 of	 the	Methapyrilene	 toxicity,	which	were	 so	 far	 still	 unclear	 and	 subject	 of	 speculation	from	 several	 groups.	 Our	 aim	was	 to	 show	 that,	 in	 the	 analysis	 of	 new	 drug,	 the	transcriptomic	 data	 could	 provide	 precious	 insight	 in	 the	 molecular	 alteration,	responsible	for	morphological	alterations.	Moreover,	the	use	of	molecular	signature,	like	 the	one	 generated	by	LCM,	 could	 increase	 the	predictive	 value	 and	 analytical	power	of	the	transcriptomic	data,	by	several	folds.	
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Indeed,	 the	 general	 level	 of	 expression	 of	 the	 genes	 used	 for	 the	 retrospective	diagnosis	 of	 the	 bile	 duct	 hyperplasia,	 was	 very	 low	 in	 the	 data	 set	 from	 the	Methapyrilene	 treated	 animals.	 However,	 with	 the	 support	 of	 our	 LCM	 data,	 we	were	able	to	approach	to	this	analysis,	without	the	strict	necessity	of	the	statistical	power,	corroborated	by	the	certainty	of	the	specificity	of	our	markers.	Our	study	is	in	 full	 agreement	 with	 another	 report	 about	 the	 Methapyrilene	 treatment	 [162].	This	 study	 introduces	 the	 concept	 of	 functional	 toxicogenomic.	 Functional	toxicogenomic	 is	 the	 study	 of	 the	 biological	 activities	 of	 genes	 in	 the	 context	 of	effects	 of	 a	 compound	 on	 an	 organism	 and	 or	 on	 a	 specific	 target	 organ.	 Gene	expression	changes	can	be	analyzed	for	information	that	might	provide	insight	into	specific	mechanistic	pathways	driving	morphological	changes.	These	observations	are	of	importance	because	they	suggest	that	molecular	changes	in	 genes	 associated	 with	 specific	 histological	 structure	 are	 predictive	 of	morphological	 alteration	 and	 can	 be	 measured	 with	 more	 sensitivity	 than	microscopic	observation.		Here	we	showed	that	our	approach,	although	time	consuming	and	expensive,	may	provide	 the	 knowledge	 to	 improve	 and	 increase	 the	 predictive	 power	 of	toxicogenomic	studies,	both,	retrospectively	and	prospectively.	However,	 our	 methods	 resulted	 still	 arbitrary	 and	 basic	 in	 the	 gene	 selection	criteria	and	in	the	application	of	the	knowledge	generated,	to	new	studies.	In	 both	 these	 contexts,	 we	 performed	 a	 simple	 comparative	 analysis,	 which	provided	solid	evidences,	but	not	supported	by	any	statistical	validation.	They	then	required	an	additional	experimental	validation.	In	the	future	 it	would	be	valuable	to	explore	mathematical	models	 for	selection	of	tissue	specific	genes,	able	to	describe	what	we	were	only	able	to	assess	empirically	and	based	on	our	experience.		
Intellectual	and	practical	contribution	This	work	was	 developed	 under	 the	 supervision	 of	MD	PhD	Pierre	Moulin	 at	 the	Preclinical	 Safety	 unit	 of	 the	Novartis	 Institute	 for	 BioMedical	 Research,	 and	was	completely	founded	by	Novartis	Pharma	AG.	
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Diego	Calabrese	performed	all	the	experiments	and	the	analysis	for	this	project,	as	described	in	the	manuscript,	with	the	following	exceptions.		Fannie	 Baudimont	 performed	 the	 LCM	 from	 dog	 livers.	 She	 performed	 the	experiments	 and	 a	 basic	 analysis,	 writing	 a	 short	 descriptive	 report	 on	 the	contribution	of	Laser	Capture	Microdissection	in	the	modern	molecular	pathology,	the	 report	has	been	 submitted	 for	her	board	 certification	 in	Veterinary	Pathology	(Fr).	 She	 was	 tutored	 during	 her	 fellowship	 at	 NIBR	 from	 Diego	 Calabrese	 and	Pierre	Moulin.	Andrè	 Cordier,	 Elaine	 Tritto	 and	 Carlo	 Ravagli	 introduced	 me	 to	 the	 molecular	profiling	and	transcriptomic	data	analysis.	Katy	 Darribat	 and	 Serafino	 Pantano	 provided	 technical	 advices	 for	 the	 LCM	execution	and	troubleshooting.	Valerie	 Dubost,	 Geraldine	 Wacker,	 Brigrite	 Greiner	 and	 Magali	 Jivkov	 provided	technical	advices	for	the	immunohistochemistry	and	in	situ	hybridization	assays.	Methapyrilene	 study	 was	 performed	 at	 Norvartis	 Pharma.	 Tissue	 sampling	 and	transcriptomic	analysis	(GeneChip	hybridization	only)	were	previously	performed.	Metadata	analysis,	histopathological	assays	and	image	analysis	were	performed	by	Diego	Calabrese.	Diego	Calabrese	wrote	this	manuscript.	Pierre	Moulin	and	Luigi	Terracciano	revised	it,	providing	critical	suggestions	for	the	manuscript	improving.	The	data	in	this	manuscript	are	in	large	extent	still	unpublished;	therefore	a	delayed	publication	will	be	requested	at	time	of	the	submission	to	the	University	office.		
Summary	Animal	models	are	widely	used	 in	toxicology	studies	of	new	chemical	compounds.	The	metabolism	of	drugs	occurs	largely	in	the	liver,	but	interspecies	differences	in	the	 molecular	 mechanisms	 at	 the	 basis	 of	 drug	 metabolism	 have	 been	 widely	demonstrated.	 These	 differences	 may	 limit	 the	 translatability	 of	 the	 results	 to	human,	and	compromise	the	safety	assessment	for	new	compounds.	Urge	therefore	a	 more	 in-depth	 understanding	 of	 the	 molecular	 mechanisms	 of	 liver	 for	 the	selection	 of	 suitable	 animal	 models,	 which	 are	 the	 most	 representative	 for	 the	
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human.	 In	addition	an	 in-depth	knowledge	of	 the	cells	specific	 transcriptome	may	drastically	improve	the	identification	of	the	target	organ	of	toxicity.	Accordingly,	 in	 this	 experimental	 work	 we	 focused	 our	 attention	 in	 generating	 a	molecular	 map	 of	 liver	 gene	 expression	 for	 different	 animal	 models,	 taking	advantage	 from	the	use	of	 laser	capture	microdissection	 for	obtaining	cell-specific	transcriptomes,	from	rat,	dog	and	monkey	liver	slices.	We	developed	LCM	and	 immuno-LCM	protocols	 for	 liver	zone	I,	 liver	zone	III,	bile	ducts,	 hepatic	 arteries	 and	 portal	 veins	 specimen	 collection	 and	 we	 profiled	 the	transcriptomes	of	these	samples	by	oligonucleotide	arrays.	The	 analysis	 confirmed	 the	 enrichment	 of	 specific	 cells/tissues	 and	 allowed	 the	identification	of	known	and	unknown	tissue-specific	genes.	We	have	 then	 investigated	 the	 impact	 of	 sexual	 dimorphism	on	 the	 expression	of	zone	 specific	 genes.	 We	 showed	 that	 sexual	 dimorphism	 in	 liver	 zonation	 is	 a	phenomenon	 interesting	 only	 rats	 and	 we	 couldn’t	 observe	 any	 significant	differentially	expressed	gene	in	other	species.	The	cross	species	comparison	of	gene	signature	 for	 liver	zone	I,	 III	and	bile	ducts,	revealed	 a	 surprising	 low	number	 of	 common	genes.	However	 this	 data	might	 be	dependent	from	technical	 limitations	more	than	from	actual	biological	diversity	of	similar	tissues	in	different	species.	The	 specificity	 of	 our	 gene	 signatures	 has	 been	 proved,	 at	 protein	 level,	 by	 IHC,	resulting	 in	 all	 the	 cases	 valid	 and	 revealing	 additional	 species	 specificities	unknown	so	far.	We	 have	 applied	 the	 knowledge	 generated	 in	 the	 first	 phase	 of	 this	 project	 to	 a	retrospective	case	study	on	toxic	effects	of	Methapyrilene	in	rat	liver.	The	 histopathology	 report	 described	 minimal	 histological	 changes	 in	 treated	animals,	 including	 single	 cell	 necrosis,	 increase	 of	 mitotic	 figures	 and	 bile	 duct	hyperplasia.	At	transcriptomic	level,	the	exposure	to	Methapyrilene	induced	a	mild	impact	on	the	global	liver	gene	expression,	and	a	specific	gene	expression	pattern	of	toxicity	was	not	detectable.	The	analysis	of	differentially	expressed	genes,	revealed	1500	up	regulated	genes	in	treated	animals	vs.	 controls	and	 the	comparison	of	 those	genes	with	 the	bile	duct	
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Supplementary	  table	  2:	  Main	  types	  of	  drug-­‐induced	  vascular	  injury	  
	  
Condition	   Clinical	  features	   Diagnosis	   Causative	  Agents	  Nodular	  regenerative	  hyperplasia	   Portal	  hypertension;	  rarely	  hepatic	  encepha-­‐lopathy,	  especially	  after	  variceal	  bleed	  
Liver	  histology	   Azathioprin;	  oxaliplatin;	  busulfan;	  doxorubicin,	  cyclophosphamide,	  bleomycin,	  carmustine,	  6-­‐thioguanine	  Non-­‐cirrhotic	  portal	  hypertension	  (perisinusoidal	  fibrosis)	  
Portal	  hypertension,	  splenomegaly,	  hypersplenism	  
Doppler	  ultrasonography;	  liver	  biopsy	   Vitamin	  A;	  cytotoxic	  agents;	  methotrexate;	  azathioprine;	  vinyl	  chloride;	  arsenic	  Sinusoidal	  dilatation	   Hepatomegaly,	  abdominal	  pain	   Imaging;	  incidental	  histology	   Oral	  contraceptives	  (sex	  steroids)	  Peliosis	  hepatis	   Hepatomegaly;	  portal	  hypertension	   Imaging;	  appearence	  at	  surgery;	  avoid	  liver	  biopsy	  
Anabolic	  steroids;	  azathioprine;	  oestrogens;	  6-­‐thioguanine	  Budd-­‐Chiari	  syndrome	   Abdominal	  pain,	  tender	  hepatomegaly,	  ascites;liver	  failure;	  portal	  hypertension	  
Doppler	  ultrasonography;	  MRI;	  hepatic	  venography;	  liver	  biopsy	  
Oestrogens;	  dacarbazine	  
Sinusoidal	  obstruction	  syndrome	  (veno-­‐occlusive	  syndrome)	  
Abdominal	  pain,	  tender	  hepatomegaly,	  ascites;liver	  failure;	  
Imaging	  similar	  to	  Budd-­‐Chiari	  syndrome,	  execpt	  large	  hepatic	  veins	  patent	  
Pyrrolizydine	  and	  other	  plant	  alkaloids;	  azathioprine;	  oxyliplatin,	  carmustine,	  busulfan;	  cyclophosphamide;	  	  Cytosine	  arabinoside	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Supplementary	  table	  3:	  Drugs	  involved	  in	  cholestatic	  DILI	  	  
Drug	   Histology	   Remarks	  Amoxicillin/clavulanic	  acid	   Bland	  cholestasis,	  cholestatic	  hepatitis	  or	  (rarely)	  VBDS	  
Age	  >	  65,	  sex	  (F),	  repeated	  courses	  higher	  risk	  
Flucloxacillin	   Cholestatic	  hepatitis,	  VBDS,	  biliary	  cirrhosis	  
Age	  >	  65,	  sex	  (F),	  high	  doses	  higher	  risk	  Cloxacillin	   Cholestatic	  hepatitis	   	  Dicloxacillin	   Cholestatic	  hepatitis	   	  Oxacillin	   Cholestatic	  hepatitis	   	  Amoxicillin	   Severe	  cholestatic	  hepatis,	  VBDS	   	  Ciprofloxacin	   Cholestatic	  hepatitis	   	  Benzylpenicillin	   Severe	  cholestasis	   	  Cephalosporin	   Cholestatic	  hepatitis	   Relatively	  rare;	  1	  case	  with	  liver	  failure	  Erithromycin	   Cholestasis,	  cholestatic	  hepatitis	   	  Clarithromycin	   Cholestatic	  hepatitis	   	  Azithromycin	   Cholestatic	  hepatitis	   	  Clindamycin	   Cholestatic	  hepatitis,	  VBDS	   	  Trimethoprim/sulfamethoxazole	   Cholestasis,	  cholestatic	  hepatitis	  with	  cholangiolitis,	  VBDS	  
Cholestasis	  due	  to	  sulfamethoxazole	  
Tetracyclines	   Cholestatic	  hepatitis	   	  Thiabendazole	   Cholestasic	  hepatitis	   May	  progess	  to	  cirrhosis	  Terbinafine	   Severe	  cholestatic	  hepatitis,	  acute	  liver	  failure	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Chlorpromazine	   Cholestatic	  hepatitis,	  VBDS	   May	  progress	  to	  biliary	  cirrhosis	  Risperidone	   Cholestatic	  hepatitis	   	  Sulpiride	   VBDS	   	  Imipramine	   Cholestatic	  hepatitis	   	  Amitryptiline	   Cholestatic	  hepatitis	   	  Duloxetine	   Cholestatic	  hepatitis	   Dose-­‐dependent?	  Carbamazepine	   VBDS	   	  Zonisamide	   VBDS	   Complete	  restitutio	  after	  drug	  withdrawal	  Amiodarone	   Cholestatic	  hepatitis	   May	  become	  chronic	  5-­‐FU	   PSC-­‐like	   	  Azathioprine	   Severe	  cholestatic	  hepatitis	   Sometimes	  associated	  with	  NRH	  [189]	  Diclofenac	   Cholestasis,	  cholestatic	  hepatitis	   	  Ibuprofen	   Cholestatic	  hepatitis	   VBDS	  in	  pediatric	  age	  [74]	  Nimesulide	   Cholestatic	  hepatitis	   	  Tenoxicam	   VBDS	   	  Sulindac	   Cholestasis,	  cholestatic	  hepatitis	   	  Nevirapine	   Cholestatic	  Hepatitis	   May	  develop	  portal	  hypertension	  Didanosine	   Cholestatic	  hepatitis	   May	  develop	  portal	  hypertension	  Oral	  contraceptives	   Canalicular	  cholestasis	   	  Anabolic	  steroids	   Canalicular	  cholestasis	   	  Warfarin	   Canalicular	  cholestasis	   	  Rivaroxaban	   Canalicular	  cholestasis,	  severe	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Supplementary	  table	  4:	  Selected	  Herbals	  and	  Dietary	  Supplements	  Causing	  Hepatotoxicity	  	  
Herbals	  &	  Dietary	  
Supplements	  
Common	  use	   Phenotype	  /	  Liver	  histology	  Aloe	  vera	   Gastrointestinal	  aliments	  /	  topical	  emollient	   Acute	  hepatocellular	  injury;	  portal/	  lobular	  inflammation	  with	  eosinophilic	  infiltrates	  and	  acidophilic	  bodies	  Atractylis	  	  gummifera	  (Disthaff	  thistle,	  African	  remedy)	   Multiple	  uses:	  Antipyretic,	  antiemetic,	  abortifacient	   Acute	  liver	  failure;	  diffuse	  hepatic	  necrsosis	  Ayurvedic	  herbs	  :	  Psoralea	  corylifolia,	  Acacia	  catechu,	  Eclipta	  alba,	  Bacopa	  monnieri	   Miscellaneous	  purposes	   Acute	  and	  chronic	  hepatitis;	  granulomatous	  hepatitis,	  cirrhosis	  Black	  cohosh	  (Cimicifuga	  racemosa)	   Ameliorating	  menopausal	  vasomotor	  symptoms	   Autoimmune	  features	  Callilepsis	  laureola	  (Impila,	  Zulu	  remedy)	   Gastric	  problems,	  tapeworm	  infestations,	  cough	   Acute	  liver	  and	  renal	  failure,	  diffuse	  hepatic	  necrsosis	  Cascara	  sagrada	  (Rhamnus	  purshiana	   Constipation	   Cholestatic	  hepatitis,	  bile	  drug	  injury,	  portal	  inflammation,	  intracanalicular	  bile	  stasis	  Champhor	  oil	  (Cinnamomum	  camphora)	   Rubefacient,	  mucolytic	   Acute	  hepatitis,	  mimics	  Reye	  syndrome	  Centella	  asiatica	   Would	  healing,	  psycophysical	  regenerator	  and	  blood	  purifier	   Autoimmune	  features,	  cellular	  necrosis,	  	  apoptosis	  and	  lymphoplasmacytic	  infiltrate	  Chaparral	  (Larrea	  tridentate,	  Larrea	  divariatica)	   Bronchitis,	  rheumatic	  pain,	  weight	  loss,	  stomach	  pain	   Cholestatic	  hepatitis,	  biliary	  changes,	  cirrhosis,	  massive	  necrosis	  Jin	  Bu	  Huan	  (Lycopodium	  serratum)	   Sedation	   Chronic	  hepatitis,	  portal	  fibrosis,	  steatosis,	  cholesttaic	  hepatitis	  Ma-­‐Huang	  (Ephedra	  sinnica)	   Weight	  loss	   Hepatocellular	  damage	  with	  autoimmune	  features;	  massive	  necrosis	  
	   110	  
Dai-­‐saiko-­‐to	   Hypertension;	  shoulder	  stiffness;	  	  insomnia;	  anxiety;	  	   Autoimmune	  features	  Germander	  (Teucrium	  chamaedrys)	   Weight	  loss;	  tonic	   Acute	  and	  chronic	  hepatitis,	  massive	  necrosis.	  cirrhosis,	  	  Green	  tea	  (Camellia	  sinensis)	   Weight	  loss	   Acute	  hepatocellular	  injury,	  cholestasis,	  steatosis	  Herbalife;	  nutritional	  supplements	   Weight	  loss,	  nutritional	  supplementation	   Acute	  and	  chronic	  lobular	  and	  portal	  hepatitis,with	  eosinophilic	  infiltrates	  Kava	  Kava	  (piper	  methysticum)	   Anxiety;	  depressive	  symptoms	   Acute	  cholestatic	  hepatitis;	  bile	  duct	  injury,	  hepatic	  necrosis	  Pennyroyal	  (Mentha	  pulegium	  Hedeoma	  pulegoides)	   Abortifacient;	  menses	  induction	   Acute	  liver	  failure;	  centrilobular	  degeneration	  and	  massive	  necrosis	  
	 111	
Bibliography	
1. Vidal-Vanaclocha F: Functional heterogeneity of liver tissue: from cell lineage 
diversity to sublobular compartment-specific pathogenesis. Austin, New 
York: Landes; Distributed by Chapman & Hall; 1997. 
2. Guidotti JE, Bregerie O, Robert A, Debey P, Brechot C, Desdouets C: Liver cell 
polyploidization: a pivotal role for binuclear hepatocytes. The Journal of 
biological chemistry 2003, 278(21):19095-19101. 
3. Kudriavtsev BN, Kudriavtseva MV, Zavadskaia EE, Smirnova SA, Skorina AD: 
[Polyploidy in the human liver normally and in hepatitis]. Tsitologiia 1982, 
24(4):436-444. 
4. Histology course for medicine school [http://www.courseweb.uottawa.ca/medicine-histology/English/Gastrointestinal/Liver.htm] 
5. Lutz J, Henrich H, Bauereisen E: Oxygen supply and uptake in the liver and 
the intestine. Pflugers Arch 1975, 360(1):7-15. 
6. Torre C, Perret C, Colnot S: Molecular determinants of liver zonation. Prog 
Mol Biol Transl Sci 2010, 97:127-150. 
7. Wang J, Olin M, Rozell B, Bjorkhem I, Einarsson C, Eggertsen G, Gafvels M: 
Differential hepatocellular zonation pattern of cholesterol 7alpha-
hydroxylase (Cyp7a1) and sterol 12alpha-hydroxylase (Cyp8b1) in the 
mouse. Histochem Cell Biol 2007, 127(3):253-261. 
8. Gebhardt R, Gaunitz F: Cell-cell interactions in the regulation of the 
expression of hepatic enzymes. Cell Biol Toxicol 1997, 13(4-5):263-273. 
9. Gebhardt R, Matz-Soja M: Liver zonation: Novel aspects of its regulation and 
its impact on homeostasis. World J Gastroenterol 2014, 20(26):8491-8504. 
10. Matz-Soja M, Hovhannisyan A, Gebhardt R: Hedgehog signalling pathway in 
adult liver: a major new player in hepatocyte metabolism and zonation? Med 
Hypotheses 2013, 80(5):589-594. 
11. Benhamouche S, Decaens T, Godard C, Chambrey R, Rickman DS, Moinard C, 
Vasseur-Cognet M, Kuo CJ, Kahn A, Perret C et al: Apc tumor suppressor gene 
is the "zonation-keeper" of mouse liver. Dev Cell 2006, 10(6):759-770. 
12. Loeppen S, Schneider D, Gaunitz F, Gebhardt R, Kurek R, Buchmann A, 
Schwarz M: Overexpression of glutamine synthetase is associated with beta-
catenin-mutations in mouse liver tumors during promotion of 
hepatocarcinogenesis by phenobarbital. Cancer research 2002, 62(20):5685-
5688. 
13. Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS: Robbins and Cotran 
pathologic basis of disease, 7th edn. Philadelphia: Elsevier Saunders; 2005. 
14. Hayashi PH, Fontana RJ: Clinical features, diagnosis, and natural history of 
drug-induced liver injury. Seminars in liver disease 2014, 34(2):134-144. 
15. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, 
Lemoine A, Hillon P: Incidence of drug-induced hepatic injuries: a French 
population-based study. Hepatology (Baltimore, Md) 2002, 36(2):451-455. 
16. Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Caliz I, 
Gonzalez-Jimenez A, Ulzurrun E, Gonzalez AF, Fernandez MC, Romero-Gomez 
M et al: Use of Hy's law and a new composite algorithm to predict acute liver 
failure in patients with drug-induced liver injury. Gastroenterology 2014, 
147(1):109-118.e105. 
	112	
17. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ: 
ACG Clinical Guideline: the diagnosis and management of idiosyncratic 
drug-induced liver injury. The American journal of gastroenterology 2014, 
109(7):950-966; quiz 967. 
18. Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, 
Hayashi PH, Davern TJ, Navarro V, Reddy R et al: Hepatic histological 
findings in suspected drug-induced liver injury: systematic evaluation and 
clinical associations. Hepatology (Baltimore, Md) 2014, 59(2):661-670. 
19. Tujios S, Fontana RJ: Mechanisms of drug-induced liver injury: from bedside 
to bench. Nature reviews Gastroenterology & hepatology 2011, 8(4):202-211. 
20. Njoku DB: Drug-induced hepatotoxicity: metabolic, genetic and 
immunological basis. International journal of molecular sciences 2014, 
15(4):6990-7003. 
21. Nemeth E, Baird AW, O'Farrelly C: Microanatomy of the liver immune 
system. Seminars in immunopathology 2009, 31(3):333-343. 
22. Gebhardt R: Metabolic zonation of the liver: regulation and implications for 
liver function. Pharmacology & therapeutics 1992, 53(3):275-354. 
23. Jungermann K, Kietzmann T: Zonation of parenchymal and nonparenchymal 
metabolism in liver. Annual review of nutrition 1996, 16:179-203. 
24. Gu X, Manautou JE: Molecular mechanisms underlying chemical liver injury. 
Expert reviews in molecular medicine 2012, 14:e4. 
25. Testa B, Kramer SD: The biochemistry of drug metabolism--an introduction: 
part 3. Reactions of hydrolysis and their enzymes. Chemistry & biodiversity 
2007, 4(9):2031-2122. 
26. Testa B, Kramer SD: The biochemistry of drug metabolism--an introduction: 
Part 2. Redox reactions and their enzymes. Chemistry & biodiversity 2007, 
4(3):257-405. 
27. Testa B, Kramer SD: The biochemistry of drug metabolism--an introduction: 
part 4. reactions of conjugation and their enzymes. Chemistry & biodiversity 
2008, 5(11):2171-2336. 
28. Kosters A, Karpen SJ: The role of inflammation in cholestasis: clinical and 
basic aspects. Seminars in liver disease 2010, 30(2):186-194. 
29. Brabec V, Kasparkova J: Modifications of DNA by platinum complexes. 
Relation to resistance of tumors to platinum antitumor drugs. Drug 
resistance updates : reviews and commentaries in antimicrobial and anticancer 
chemotherapy 2005, 8(3):131-146. 
30. Mason RP, Chignell CF: Free radicals in pharmacology and toxicology--
selected topics. Pharmacological reviews 1981, 33(4):189-211. 
31. Saad EI, El-Gowilly SM, Sherhaa MO, Bistawroos AE: Role of oxidative stress 
and nitric oxide in the protective effects of alpha-lipoic acid and 
aminoguanidine against isoniazid-rifampicin-induced hepatotoxicity in rats. 
Food and chemical toxicology : an international journal published for the British 
Industrial Biological Research Association 2010, 48(7):1869-1875. 
32. Testa B, Kramer SD: The biochemistry of drug metabolism--an introduction: 
part 5. Metabolism and bioactivity. Chemistry & biodiversity 2009, 6(5):591-
684. 
33. Buchweitz JP, Ganey PE, Bursian SJ, Roth RA: Underlying endotoxemia 
augments toxic responses to chlorpromazine: is there a relationship to drug 
idiosyncrasy? The Journal of pharmacology and experimental therapeutics 
2002, 300(2):460-467. 
	 113	
34. Deng X, Stachlewitz RF, Liguori MJ, Blomme EA, Waring JF, Luyendyk JP, 
Maddox JF, Ganey PE, Roth RA: Modest inflammation enhances diclofenac 
hepatotoxicity in rats: role of neutrophils and bacterial translocation. The 
Journal of pharmacology and experimental therapeutics 2006, 319(3):1191-1199. 
35. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, 
Day CP, Aithal GP: Human leucocyte antigen class II genotype in 
susceptibility and resistance to co-amoxiclav-induced liver injury. Journal of 
hepatology 2010, 53(6):1049-1053. 
36. Dugan CM, MacDonald AE, Roth RA, Ganey PE: A mouse model of severe 
halothane hepatitis based on human risk factors. The Journal of 
pharmacology and experimental therapeutics 2010, 333(2):364-372. 
37. Jaeschke H, Knight TR, Bajt ML: The role of oxidant stress and reactive 
nitrogen species in acetaminophen hepatotoxicity. Toxicology letters 2003, 
144(3):279-288. 
38. Lu J, Jones AD, Harkema JR, Roth RA, Ganey PE: Amiodarone exposure 
during modest inflammation induces idiosyncrasy-like liver injury in rats: 
role of tumor necrosis factor-alpha. Toxicological sciences : an official journal 
of the Society of Toxicology 2012, 125(1):126-133. 
39. Pohl LR, Satoh H, Christ DD, Kenna JG: The immunologic and metabolic basis 
of drug hypersensitivities. Annual review of pharmacology and toxicology 1988, 
28:367-387. 
40. Nelson SD: Molecular mechanisms of the hepatotoxicity caused by 
acetaminophen. Seminars in liver disease 1990, 10(4):267-278. 
41. Fromenty B, Pessayre D: Inhibition of mitochondrial beta-oxidation as a 
mechanism of hepatotoxicity. Pharmacology & therapeutics 1995, 67(1):101-
154. 
42. Jones BE, Lo CR, Liu H, Srinivasan A, Streetz K, Valentino KL, Czaja MJ: 
Hepatocytes sensitized to tumor necrosis factor-alpha cytotoxicity undergo 
apoptosis through caspase-dependent and caspase-independent pathways. 
The Journal of biological chemistry 2000, 275(1):705-712. 
43. Joza N, Susin SA, Daugas E, Stanford WL, Cho SK, Li CY, Sasaki T, Elia AJ, 
Cheng HY, Ravagnan L et al: Essential role of the mitochondrial apoptosis-
inducing factor in programmed cell death. Nature 2001, 410(6828):549-554. 
44. Han D, Shinohara M, Ybanez MD, Saberi B, Kaplowitz N: Signal transduction 
pathways involved in drug-induced liver injury. Handbook of experimental 
pharmacology 2010(196):267-310. 
45. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH: Drug-induced liver injury: 
mechanisms and test systems. Hepatology (Baltimore, Md) 2001, 33(4):1009-
1013. 
46. Kakuda TN: Pharmacology of nucleoside and nucleotide reverse transcriptase 
inhibitor-induced mitochondrial toxicity. Clinical therapeutics 2000, 
22(6):685-708. 
47. Silva MF, Ruiter JP, Illst L, Jakobs C, Duran M, de Almeida IT, Wanders RJ: 
Valproate inhibits the mitochondrial pyruvate-driven oxidative 
phosphorylation in vitro. Journal of inherited metabolic disease 1997, 
20(3):397-400. 
48. Lucena MI, Andrade RJ, Fernandez MC, Pachkoria K, Pelaez G, Duran JA, Villar 
M, Rodrigo L, Romero-Gomez M, Planas R et al: Determinants of the clinical 
expression of amoxicillin-clavulanate hepatotoxicity: a prospective series 
from Spain. Hepatology (Baltimore, Md) 2006, 44(4):850-856. 
	114	
49. Kass GE, Price SC: Role of mitochondria in drug-induced cholestatic injury. 
Clinics in liver disease 2008, 12(1):27-51, vii. 
50. Holt M, Ju C: Drug-induced liver injury. Handbook of experimental 
pharmacology 2010(196):3-27. 
51. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler 
WJ, Pirmohamed M, Park BK: Hypersensitivity reactions to carbamazepine: 
characterization of the specificity, phenotype, and cytokine profile of drug-
specific T cell clones. Molecular pharmacology 2003, 63(3):732-741. 
52. Pichler WJ: Direct T-cell stimulations by drugs--bypassing the innate 
immune system. Toxicology 2005, 209(2):95-100. 
53. Li MK, Crawford JM: The pathology of cholestasis. Seminars in liver disease 
2004, 24(1):21-42. 
54. Pauli-Magnus C, Meier PJ: Hepatobiliary transporters and drug-induced 
cholestasis. Hepatology (Baltimore, Md) 2006, 44(4):778-787. 
55. Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH: Liver disease 
associated with canalicular transport defects: current and future therapies. 
Journal of hepatology 2010, 52(2):258-271. 
56. Colombo C, Vajro P, Degiorgio D, Coviello DA, Costantino L, Tornillo L, Motta 
V, Consonni D, Maggiore G: Clinical features and genotype-phenotype 
correlations in children with progressive familial intrahepatic cholestasis 
type 3 related to ABCB4 mutations. Journal of pediatric gastroenterology and 
nutrition 2011, 52(1):73-83. 
57. Adams DH, Ju C, Ramaiah SK, Uetrecht J, Jaeschke H: Mechanisms of 
immune-mediated liver injury. Toxicological sciences : an official journal of 
the Society of Toxicology 2010, 115(2):307-321. 
58. Degott C, Feldmann G, Larrey D, Durand-Schneider AM, Grange D, Machayekhi 
JP, Moreau A, Potet F, Benhamou JP: Drug-induced prolonged cholestasis in 
adults: a histological semiquantitative study demonstrating progressive 
ductopenia. Hepatology (Baltimore, Md) 1992, 15(2):244-251. 
59. Fan CQ, Crawford JM: Sinusoidal obstruction syndrome (hepatic veno-
occlusive disease). Journal of clinical and experimental hepatology 2014, 
4(4):332-346. 
60. Helmy A: Review article: updates in the pathogenesis and therapy of hepatic 
sinusoidal obstruction syndrome. Alimentary pharmacology & therapeutics 
2006, 23(1):11-25. 
61. Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, 
Krishnamoorthy R: Glutathione S-transferase M1 polymorphism: a risk 
factor for hepatic venoocclusive disease in bone marrow transplantation. 
Blood 2004, 104(5):1574-1577. 
62. Vreuls CP, Olde Damink SW, Koek GH, Winstanley A, Wisse E, Cloots RH, van 
den Broek MA, Dejong CH, Bosman FT, Driessen A: Glutathione S-transferase 
M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with 
metastatic colorectal cancer. British journal of cancer 2013, 108(3):676-680. 
63. DeLeve LD, Ito Y, Bethea NW, McCuskey MK, Wang X, McCuskey RS: 
Embolization by sinusoidal lining cells obstructs the microcirculation in rat 
sinusoidal obstruction syndrome. American journal of physiology 
Gastrointestinal and liver physiology 2003, 284(6):G1045-1052. 
64. DeLeve LD, Wang X, Kanel GC, Ito Y, Bethea NW, McCuskey MK, Tokes ZA, 
Tsai J, McCuskey RS: Decreased hepatic nitric oxide production contributes 
	 115	
to the development of rat sinusoidal obstruction syndrome. Hepatology 
(Baltimore, Md) 2003, 38(4):900-908. 
65. Harb R, Xie G, Lutzko C, Guo Y, Wang X, Hill CK, Kanel GC, DeLeve LD: 
Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells 
after liver injury. Gastroenterology 2009, 137(2):704-712. 
66. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier 
M, Dousset B, Morel P, Soubrane O, Chaussade S et al: Severe hepatic 
sinusoidal obstruction associated with oxaliplatin-based chemotherapy in 
patients with metastatic colorectal cancer. Annals of oncology : official journal 
of the European Society for Medical Oncology / ESMO 2004, 15(3):460-466. 
67. Tallman MS, McDonald GB, DeLeve LD, Baer MR, Cook MN, Graepel GJ, 
Kollmer C: Incidence of sinusoidal obstruction syndrome following Mylotarg 
(gemtuzumab ozogamicin): a prospective observational study of 482 patients 
in routine clinical practice. International journal of hematology 2013, 
97(4):456-464. 
68. Yang K, Kock K, Sedykh A, Tropsha A, Brouwer KL: An updated review on 
drug-induced cholestasis: mechanisms and investigation of physicochemical 
properties and pharmacokinetic parameters. Journal of pharmaceutical 
sciences 2013, 102(9):3037-3057. 
69. Geier A, Wagner M, Dietrich CG, Trauner M: Principles of hepatic organic 
anion transporter regulation during cholestasis, inflammation and liver 
regeneration. Biochimica et biophysica acta 2007, 1773(3):283-308. 
70. Zollner G, Marschall HU, Wagner M, Trauner M: Role of nuclear receptors in 
the adaptive response to bile acids and cholestasis: pathogenetic and 
therapeutic considerations. Molecular pharmaceutics 2006, 3(3):231-251. 
71. Nakanishi Y, Saxena R: Pathophysiology and Diseases of the Proximal 
Pathways of the Biliary System. Archives of pathology & laboratory medicine 
2015, 139(7):858-866. 
72. Kleiner DE: The pathology of drug-induced liver injury. Seminars in liver 
disease 2009, 29(4):364-372. 
73. Ramachandran R, Kakar S: Histological patterns in drug-induced liver disease. 
Journal of clinical pathology 2009, 62(6):481-492. 
74. Bjornsson ES, Jonasson JG: Drug-induced cholestasis. Clinics in liver disease 
2013, 17(2):191-209. 
75. Trauner M, Boyer JL: Bile salt transporters: molecular characterization, 
function, and regulation. Physiological reviews 2003, 83(2):633-671. 
76. Bjornsson E, Olsson R: Outcome and prognostic markers in severe drug-
induced liver disease. Hepatology (Baltimore, Md) 2005, 42(2):481-489. 
77. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, 
Yang H, Rochon J: Causes, clinical features, and outcomes from a prospective 
study of drug-induced liver injury in the United States. Gastroenterology 
2008, 135(6):1924-1934, 1934.e1921-1924. 
78. Bjornsson E, Davidsdottir L: The long-term follow-up after idiosyncratic 
drug-induced liver injury with jaundice. Journal of hepatology 2009, 
50(3):511-517. 
79. Navarro VJ, Lucena MI: Hepatotoxicity induced by herbal and dietary 
supplements. Seminars in liver disease 2014, 34(2):172-193. 
80. Suk KT, Kim DJ, Kim CH, Park SH, Yoon JH, Kim YS, Baik GH, Kim JB, 
Kweon YO, Kim BI et al: A prospective nationwide study of drug-induced 
	116	
liver injury in Korea. The American journal of gastroenterology 2012, 
107(9):1380-1387. 
81. Zhou Y, Yang L, Liao Z, He X, Zhou Y, Guo H: Epidemiology of drug-induced 
liver injury in China: a systematic analysis of the Chinese literature 
including 21,789 patients. European journal of gastroenterology & hepatology 
2013, 25(7):825-829. 
82. Feigelstock DA, Mihalik KB, Kaplan G, Feinstone SM: Increased susceptibility 
of Huh7 cells to HCV replication does not require mutations in RIG-I. Virol 
J 2010, 7:44. 
83. Humphrey-Johnson A, Abukalam R, Eltom SE: Stability of the aryl 
hydrocarbon receptor and its regulated genes in the low activity variant of 
Hepa-1 cell line. Toxicology letters 2015, 233(2):59-67. 
84. Kang YB, Sodunke TR, Lamontagne J, Cirillo J, Rajiv C, Bouchard MJ, Noh M: 
Liver sinusoid on a chip: Long-term layered co-culture of primary rat 
hepatocytes and endothelial cells in microfluidic platforms. Biotechnol Bioeng 
2015. 
85. Bricks T, Hamon J, Fleury MJ, Jellali R, Merlier F, Herpe YE, Seyer A, 
Regimbeau JM, Bois F, Leclerc E: Investigation of omeprazole and phenacetin 
first-pass metabolism in humans using a microscale bioreactor and 
pharmacokinetic models. Biopharm Drug Dispos 2015, 36(5):275-293. 
86. National Research Council (U.S.). Committee on Applications of Toxicogenomic 
Technologies to Predictive Toxicology.: Applications of toxicogenomic 
technologies to predictive toxicology and risk assessment. Washington, D.C.: 
National Academies Press; 2007. 
87. Bussiere JL: Species selection considerations for preclinical toxicology studies 
for biotherapeutics. Expert opinion on drug metabolism & toxicology 2008, 
4(7):871-877. 
88. Interspecies [http://www.interspeciesinfo.com/ ] 
89. Richard AC, Lyons PA, Peters JE, Biasci D, Flint SM, Lee JC, McKinney EF, 
Siegel RM, Smith KG: Comparison of gene expression microarray data with 
count-based RNA measurements informs microarray interpretation. BMC 
genomics 2014, 15:649. 
90. Kulkarni K, Larsen P, Linninger AA: Assessing chronic liver toxicity based on 
relative gene expression data. J Theor Biol 2008, 254(2):308-318. 
91. Heinloth AN, Boorman GA, Foley JF, Flagler ND, Paules RS: Gene expression 
analysis offers unique advantages to histopathology in liver biopsy 
evaluations. Toxicologic pathology 2007, 35(2):276-283. 
92. Fielden MR, Brennan R, Gollub J: A gene expression biomarker provides early 
prediction and mechanistic assessment of hepatic tumor induction by 
nongenotoxic chemicals. Toxicological sciences : an official journal of the 
Society of Toxicology 2007, 99(1):90-100. 
93. Heinloth AN, Irwin RD, Boorman GA, Nettesheim P, Fannin RD, Sieber SO, 
Snell ML, Tucker CJ, Li L, Travlos GS et al: Gene expression profiling of rat 
livers reveals indicators of potential adverse effects. Toxicological sciences : 
an official journal of the Society of Toxicology 2004, 80(1):193-202. 
94. Nie AY, McMillian M, Parker JB, Leone A, Bryant S, Yieh L, Bittner A, Nelson 
J, Carmen A, Wan J et al: Predictive toxicogenomics approaches reveal 
underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol 
Carcinog 2006, 45(12):914-933. 
	 117	
95. Van Hummelen P, Sasaki J: State-of-the-art genomics approaches in 
toxicology. Mutation research 2010, 705(3):165-171. 
96. Shackel NA, Gorrell MD, McCaughan GW: Gene array analysis and the liver. 
Hepatology (Baltimore, Md) 2002, 36(6):1313-1325. 
97. Morgan KT, Jayyosi Z, Hower MA, Pino MV, Connolly TM, Kotlenga K, Lin J, 
Wang M, Schmidts HL, Bonnefoi MS et al: The hepatic transcriptome as a 
window on whole-body physiology and pathophysiology. Toxicologic 
pathology 2005, 33(1):136-145. 
98. Shackel NA, Seth D, Haber PS, Gorrell MD, McCaughan GW: The hepatic 
transcriptome in human liver disease. Comparative hepatology 2006, 5:6. 
99. Yano N, Habib NA, Fadden KJ, Yamashita H, Mitry R, Jauregui H, Kane A, 
Endoh M, Rifai A: Profiling the adult human liver transcriptome: analysis by 
cDNA array hybridization. Journal of hepatology 2001, 35(2):178-186. 
100. Shin YJ, Cho SW, Hahm KB, Kim YS, Kim JH, Park KH, Lee SI: Localization 
of hepatitis B virus DNA in hepatocellular carcinoma by polymerase chain 
reaction in situ hybridization. J Korean Med Sci 1998, 13(4):377-382. 
101. Meier-Ruge W, Bielser W, Remy E, Hillenkamp F, Nitsche R, Unsold R: The 
laser in the Lowry technique for microdissection of freeze-dried tissue slices. 
Histochem J 1976, 8(4):387-401. 
102. Wang S, Wang L, Zhu T, Gao X, Li J, Wu Y, Zhu H: Improvement of tissue 
preparation for laser capture microdissection: application for cell type-
specific miRNA expression profiling in colorectal tumors. BMC genomics 
2010, 11:163. 
103. Cerroni L, Minkus G, Putz B, Hofler H, Kerl H: Laser beam microdissection in 
the diagnosis of cutaneous B-cell lymphoma. Br J Dermatol 1997, 136(5):743-
746. 
104. Yim SH, Ward JM, Dragan Y, Yamada A, Scacheri PC, Kimura S, Gonzalez FJ: 
Microarray analysis using amplified mRNA from laser capture 
microdissection of microscopic hepatocellular precancerous lesions and 
frozen hepatocellular carcinomas reveals unique and consistent gene 
expression profiles. Toxicologic pathology 2003, 31(3):295-303. 
105. Kube DM, Savci-Heijink CD, Lamblin AF, Kosari F, Vasmatzis G, Cheville JC, 
Connelly DP, Klee GG: Optimization of laser capture microdissection and 
RNA amplification for gene expression profiling of prostate cancer. BMC 
molecular biology 2007, 8:25. 
106. Stark RW, Rubio-Sierra FJ, Thalhammer S, Heckl WM: Combined 
nanomanipulation by atomic force microscopy and UV-laser ablation for 
chromosomal dissection. Eur Biophys J 2003, 32(1):33-39. 
107. Mouledous L, Hunt S, Harcourt R, Harry J, Williams KL, Gutstein HB: 
Navigated laser capture microdissection as an alternative to direct 
histological staining for proteomic analysis of brain samples. Proteomics 
2003, 3(5):610-615. 
108. Burgemeister R: Laser capture microdissection of FFPE tissue sections 
bridging the gap between microscopy and molecular analysis. Methods Mol 
Biol 2011, 724:105-115. 
109. Burgemeister R: Nucleic acids extraction from laser microdissected FFPE 
tissue sections. Methods Mol Biol 2011, 724:117-129. 
110. Stich M, Thalhammer S, Burgemeister R, Friedemann G, Ehnle S, Luthy C, 
Schutze K: Live cell catapulting and recultivation. Pathol Res Pract 2003, 
199(6):405-409. 
	118	
111. Langer S, Geigl JB, Ehnle S, Gangnus R, Speicher MR: Live cell catapulting 
and recultivation does not change the karyotype of HCT116 tumor cells. 
Cancer Genet Cytogenet 2005, 161(2):174-177. 
112. Podgorny OV: Live cell isolation by laser microdissection with gravity 
transfer. J Biomed Opt 2013, 18(5):55002. 
113. Lu JX, Szeto CC: Gene expression using the PALM system. Methods Mol Biol 
2011, 755:47-56. 
114. Ladanyi A, Sipos F, Szoke D, Galamb O, Molnar B, Tulassay Z: Laser 
microdissection in translational and clinical research. Cytometry A 2006, 
69(9):947-960. 
115. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H: Quantitative 
gene expression analysis in microdissected archival formalin-fixed and 
paraffin-embedded tumor tissue. The American journal of pathology 2001, 
158(2):419-429. 
116. Lehmann U, Kreipe H: Real-time PCR analysis of DNA and RNA extracted 
from formalin-fixed and paraffin-embedded biopsies. Methods (San Diego, 
Calif) 2001, 25(4):409-418. 
117. Su JM, Perlaky L, Li XN, Leung HC, Antalffy B, Armstrong D, Lau CC: 
Comparison of ethanol versus formalin fixation on preservation of histology 
and RNA in laser capture microdissected brain tissues. Brain Pathol 2004, 
14(2):175-182. 
118. Liu A: Laser capture microdissection in the tissue biorepository. J Biomol 
Tech 2010, 21(3):120-125. 
119. Gallagher RI, Blakely SR, Liotta LA, Espina V: Laser capture microdissection: 
Arcturus(XT) infrared capture and UV cutting methods. Methods Mol Biol 
2012, 823:157-178. 
120. Bevilacqua C, Makhzami S, Helbling JC, Defrenaix P, Martin P: Maintaining 
RNA integrity in a homogeneous population of mammary epithelial cells 
isolated by Laser Capture Microdissection. BMC Cell Biol 2010, 11:95. 
121. Baskin DG, Bastian LS: Immuno-laser capture microdissection of rat brain 
neurons for real time quantitative PCR. Methods Mol Biol 2010, 588:219-230. 
122. Fend F, Emmert-Buck MR, Chuaqui R, Cole K, Lee J, Liotta LA, Raffeld M: 
Immuno-LCM: laser capture microdissection of immunostained frozen 
sections for mRNA analysis. The American journal of pathology 1999, 
154(1):61-66. 
123. Brown AL, Smith DW: Improved RNA preservation for immunolabeling and 
laser microdissection. RNA 2009, 15(12):2364-2374. 
124. Fend F, Kremer M, Quintanilla-Martinez L: Laser capture microdissection: 
methodical aspects and applications with emphasis on immuno-laser capture 
microdissection. Pathobiology 2000, 68(4-5):209-214. 
125. Kaneko T, Okiji T, Kaneko R, Suda H, Nor JE: Laser-capture microdissection 
for Factor VIII-expressing endothelial cells in cancer tissues. Methods Mol 
Biol 2011, 755:395-403. 
126. Gallup JM, Kawashima K, Lucero G, Ackermann MR: New quick method for 
isolating RNA from laser captured cells stained by immunofluorescent 
immunohistochemistry; RNA suitable for direct use in fluorogenic TaqMan 
one-step real-time RT-PCR. Biol Proced Online 2005, 7:70-92. 
127. Macdonald JA, Murugesan N, Pachter JS: Validation of immuno-laser capture 
microdissection coupled with quantitative RT-PCR to probe blood-brain 
barrier gene expression in situ. J Neurosci Methods 2008, 174(2):219-226. 
	 119	
128. Micke P, Bjornsen T, Scheidl S, Stromberg S, Demoulin JB, Ponten F, Ostman 
A, Lindahl P, Busch C: A fluid cover medium provides superior morphology 
and preserves RNA integrity in tissue sections for laser microdissection and 
pressure catapulting. J Pathol 2004, 202(1):130-138. 
129. Blatt R, Srinivasan S: Defining disease with laser precision: laser capture 
microdissection in gastroenterology. Gastroenterology 2008, 135(2):364-369. 
130. Honda M, Kawai H, Shirota Y, Yamashita T, Kaneko S: Differential gene 
expression profiles in stage I primary biliary cirrhosis. The American journal 
of gastroenterology 2005, 100(9):2019-2030. 
131. Schulze F, Schardt K, Wedemeyer I, Konze E, Wendland K, Dirsch O, Tox U, 
Dienes HP, Odenthal M: [Epithelial-mesenchymal transition of biliary 
epithelial cells in advanced liver fibrosis]. Verh Dtsch Ges Pathol 2007, 
91:250-256. 
132. Baba N, Kobashi H, Yamamoto K, Terada R, Suzuki T, Hakoda T, Okano N, 
Shimada N, Fujioka S, Iwasaki Y et al: Gene expression profiling in biliary 
epithelial cells of primary biliary cirrhosis using laser capture 
microdissection and cDNA microarray. Transl Res 2006, 148(3):103-113. 
133. Dos Santos A, Court M, Thiers V, Sar S, Guettier C, Samuel D, Brechot C, Garin 
J, Demaugre F, Masselon CD: Identification of cellular targets in human 
intrahepatic cholangiocarcinoma using laser microdissection and accurate 
mass and time tag proteomics. Mol Cell Proteomics 2010, 9(9):1991-2004. 
134. Tretiakova M, Hart J: Laser microdissection for gene expression study of 
hepatocellular carcinomas arising in cirrhotic and non-cirrhotic livers. 
Methods Mol Biol 2011, 755:233-244. 
135. Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, Venesio 
T, Capussotti L, Risio M, Aglietta M: Somatic mutations of epidermal growth 
factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 2006, 
12(6):1680-1685. 
136. Fidanza JA, McGall GH: High-density nucleoside analog probe arrays for 
enhanced hybridization. Nucleosides Nucleotides 1999, 18(6-7):1293-1295. 
137. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ: High density synthetic 
oligonucleotide arrays. Nat Genet 1999, 21(1 Suppl):20-24. 
138. Eijssen LM, Jaillard M, Adriaens ME, Gaj S, de Groot PJ, Muller M, Evelo CT: 
User-friendly solutions for microarray quality control and pre-processing on 
ArrayAnalysis.org. Nucleic acids research 2013, 41(Web Server issue):W71-76. 
139. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, 
Speed TP: Exploration, normalization, and summaries of high density 
oligonucleotide array probe level data. Biostatistics (Oxford, England) 2003, 
4(2):249-264. 
140. Pepper SD, Saunders EK, Edwards LE, Wilson CL, Miller CJ: The utility of 
MAS5 expression summary and detection call algorithms. BMC 
bioinformatics 2007, 8:273. 
141. Li C, Wong WH: Model-based analysis of oligonucleotide arrays: expression 
index computation and outlier detection. Proceedings of the National Academy 
of Sciences of the United States of America 2001, 98(1):31-36. 
142. McClintick JN, Edenberg HJ: Effects of filtering by Present call on analysis of 
microarray experiments. BMC bioinformatics 2006, 7:49. 
143. Lim WK, Wang K, Lefebvre C, Califano A: Comparative analysis of 
microarray normalization procedures: effects on reverse engineering gene 
networks. Bioinformatics (Oxford, England) 2007, 23(13):i282-288. 
	120	
144. Clarke J, Seo P, Clarke B: Statistical expression deconvolution from mixed 
tissue samples. Bioinformatics (Oxford, England) 2010, 26(8):1043-1049. 
145. Li Y, Xie X: A mixture model for expression deconvolution from RNA-seq in 
heterogeneous tissues. BMC bioinformatics 2013, 14 Suppl 5:S11. 
146. Gong T, Szustakowski JD: DeconRNASeq: a statistical framework for 
deconvolution of heterogeneous tissue samples based on mRNA-Seq data. 
Bioinformatics (Oxford, England) 2013, 29(8):1083-1085. 
147. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn 
M, Alizadeh AA: Robust enumeration of cell subsets from tissue expression 
profiles. Nature methods 2015, 12(5):453-457. 
148. Habs M, Shubik P, Eisenbrand G: Carcinogenicity of methapyrilene 
hydrochloride, mepyramine hydrochloride, thenyldiamine hydrochloride, 
and pyribenzamine hydrochloride in Sprague-Dawley rats. Journal of cancer 
research and clinical oncology 1986, 111(1):71-74. 
149. Lijinsky W, Reuber MD, Blackwell BN: Liver tumors induced in rats by oral 
administration of the antihistaminic methapyrilene hydrochloride. Science 
(New York, NY) 1980, 209(4458):817-819. 
150. Lijinsky W: Chronic toxicity tests of pyrilamine maleate and methapyrilene 
hydrochloride in F344 rats. Food and chemical toxicology : an international 
journal published for the British Industrial Biological Research Association 
1984, 22(1):27-30. 
151. Brennan LM, Creasia DA: The effects of methapyrilene hydrochloride on 
hepatocarcinogenicity and pentobarbital-induced sleeping time in rats and 
mice. Toxicology and applied pharmacology 1982, 66(2):252-258. 
152. Lijinsky W, Knutsen G, Reuber MD: Failure of methapyrilene to induce 
tumors in hamsters or guinea pigs. Journal of toxicology and environmental 
health 1983, 12(4-6):653-657. 
153. Mirsalis JC: Genotoxicity, toxicity, and carcinogenicity of the antihistamine 
methapyrilene. Mutation research 1987, 185(3):309-317. 
154. Casciano DA, Schol HM: Methapyrilene is inactive in the hepatocyte-
mediated Chinese hamster ovary/hypoxanthine-guanine phosphoribosyl 
transferase mutational assay. Cancer letters 1984, 21(3):337-341. 
155. Casciano DA, Shaddock JG, Talaska G: The potent hepatocarcinogen 
methapyrilene does not form DNA adducts in livers of Fischer 344 rats. 
Mutation research 1988, 208(3-4):129-135. 
156. Casciano DA, Talaska G, Clive D: The potent hepatocarcinogen 
methapyrilene induces mutations in L5178Y mouse lymphoma cells in the 
apparent absence of DNA adduct formation. Mutation research 1991, 
263(2):127-132. 
157. Lijinsky W, Yamashita K: Lack of binding of methapyrilene and similar 
antihistamines to rat liver DNA examined by 32P postlabeling. Cancer 
research 1988, 48(22):6475-6477. 
158. Oberly TJ, Scheuring JC, Richardson KA, Richardson FC, Garriott ML: The 
evaluation of methapyrilene for bacterial mutation with metabolic activation 
by Aroclor-induced, methapyrilene-induced and noninduced rat-liver S9. 
Mutation research 1993, 299(2):77-84. 
159. Ratra GS, Cottrell S, Powell CJ: Effects of induction and inhibition of 
cytochromes P450 on the hepatotoxicity of methapyrilene. Toxicological 
sciences : an official journal of the Society of Toxicology 1998, 46(1):185-196. 
	 121	
160. Ratra GS, Powell CJ, Park BK, Maggs JL, Cottrell S: Methapyrilene 
hepatotoxicity is associated with increased hepatic glutathione, the formation 
of glucuronide conjugates, and enterohepatic recirculation. Chemico-
biological interactions 2000, 129(3):279-295. 
161. Richardson FC, Copple DM, Eacho PI: Effects of methapyrilene on DNA 
synthesis in mice and rats following continuous dietary exposure. 
Carcinogenesis 1992, 13(12):2453-2457. 
162. Hamadeh HK, Knight BL, Haugen AC, Sieber S, Amin RP, Bushel PR, Stoll R, 
Blanchard K, Jayadev S, Tennant RW et al: Methapyrilene toxicity: anchorage 
of pathologic observations to gene expression alterations. Toxicologic 
pathology 2002, 30(4):470-482. 
163. Dieterle F, Perentes E, Cordier A, Roth DR, Verdes P, Grenet O, Pantano S, 
Moulin P, Wahl D, Mahl A et al: Urinary clusterin, cystatin C, beta2-
microglobulin and total protein as markers to detect drug-induced kidney 
injury. Nature biotechnology 2010, 28(5):463-469. 
164. Ferreira JA: The Benjamini-Hochberg method in the case of discrete test 
statistics. The international journal of biostatistics 2007, 3(1):Article 11. 
165. Waxman DJ: Growth hormone pulse-activated STAT5 signalling: a unique 
regulatory mechanism governing sexual dimorphism of liver gene 
expression. Novartis Foundation symposium 2000, 227:61-74; discussion 75-81. 
166. Roy AK, Chatterjee B: Sexual dimorphism in the liver. Annual review of 
physiology 1983, 45:37-50. 
167. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: new 
estimates of drug development costs. Journal of health economics 2003, 
22(2):151-185. 
168. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J: Clinical 
development success rates for investigational drugs. Nature biotechnology 
2014, 32(1):40-51. 
169. Kennedy S: The role of proteomics in toxicology: identification of biomarkers 
of toxicity by protein expression analysis. Biomarkers : biochemical indicators 
of exposure, response, and susceptibility to chemicals 2002, 7(4):269-290. 
170. Miller I, Serchi T, Murk AJ, Gutleb AC: The added value of proteomics for 
toxicological studies. Journal of toxicology and environmental health Part B, 
Critical reviews 2014, 17(4):225-246. 
171. Cui Y, Paules RS: Use of transcriptomics in understanding mechanisms of 
drug-induced toxicity. Pharmacogenomics 2010, 11(4):573-585. 
172. Ren X, Li J, Xia B, Liu W, Yang X, Hong WX, Huang P, Wang Y, Li S, Zou F et 
al: Phosphoproteomic analyses of L-02 liver cells exposed to 
trichloroethylene. Toxicology mechanisms and methods 2015, 25(6):459-466. 
173. Pan X, Whitten DA, Wu M, Chan C, Wilkerson CG, Pestka JJ: Early 
phosphoproteomic changes in the mouse spleen during deoxynivalenol-
induced ribotoxic stress. Toxicological sciences : an official journal of the 
Society of Toxicology 2013, 135(1):129-143. 
174. Williams TD, Mirbahai L, Chipman JK: The toxicological application of 
transcriptomics and epigenomics in zebrafish and other teleosts. Briefings in 
functional genomics 2014, 13(2):157-171. 
175. Boorman GA, Irwin RD, Vallant MK, Gerken DK, Lobenhofer EK, Hejtmancik 
MR, Hurban P, Brys AM, Travlos GS, Parker JS et al: Variation in the hepatic 
gene expression in individual male Fischer rats. Toxicologic pathology 2005, 
33(1):102-110. 
	122	
176. Minami K, Saito T, Narahara M, Tomita H, Kato H, Sugiyama H, Katoh M, 
Nakajima M, Yokoi T: Relationship between hepatic gene expression profiles 
and hepatotoxicity in five typical hepatotoxicant-administered rats. 
Toxicological sciences : an official journal of the Society of Toxicology 2005, 
87(1):296-305. 
177. Seth D, Leo MA, McGuinness PH, Lieber CS, Brennan Y, Williams R, Wang 
XM, McCaughan GW, Gorrell MD, Haber PS: Gene expression profiling of 
alcoholic liver disease in the baboon (Papio hamadryas) and human liver. 
The American journal of pathology 2003, 163(6):2303-2317. 
178. Murakami H, Liotta L, Star RA: IF-LCM: laser capture microdissection of 
immunofluorescently defined cells for mRNA analysis rapid communication. 
Kidney international 2000, 58(3):1346-1353. 
179. Lu YR, Wang LN, Jin X, Chen YN, Cong C, Yuan Y, Li YC, Tang WD, Li HX, 
Wu XT et al: A preliminary study on the feasibility of gene expression profile 
of rhesus monkey detected with human microarray. Transplantation 
proceedings 2008, 40(2):598-602. 
180. Giorgi FM, Bolger AM, Lohse M, Usadel B: Algorithm-driven artifacts in 
median polish summarization of microarray data. BMC bioinformatics 2010, 
11:553. 
181. Etienne W, Meyer MH, Peppers J, Meyer RA, Jr.: Comparison of mRNA gene 
expression by RT-PCR and DNA microarray. BioTechniques 2004, 36(4):618-
620, 622, 624-616. 
182. Rajeevan MS, Vernon SD, Taysavang N, Unger ER: Validation of array-based 
gene expression profiles by real-time (kinetic) RT-PCR. The Journal of 
molecular diagnostics : JMD 2001, 3(1):26-31. 
183. Rajeevan MS, Ranamukhaarachchi DG, Vernon SD, Unger ER: Use of real-time 
quantitative PCR to validate the results of cDNA array and differential 
display PCR technologies. Methods (San Diego, Calif) 2001, 25(4):443-451. 
184. Yuen T, Wurmbach E, Pfeffer RL, Ebersole BJ, Sealfon SC: Accuracy and 
calibration of commercial oligonucleotide and custom cDNA microarrays. 
Nucleic acids research 2002, 30(10):e48. 
185. Osada T, Nagashima I, Tsuno NH, Kitayama J, Nagawa H: Prognostic 
significance of glutamine synthetase expression in unifocal advanced 
hepatocellular carcinoma. Journal of hepatology 2000, 33(2):247-253. 
186. Cadoret A, Ovejero C, Terris B, Souil E, Levy L, Lamers WH, Kitajewski J, 
Kahn A, Perret C: New targets of beta-catenin signaling in the liver are 
involved in the glutamine metabolism. Oncogene 2002, 21(54):8293-8301. 
187. Planas-Paz L, Orsini V, Boulter L, Calabrese D, Pikiolek M, Nigsch F, Xie Y, 
Roma G, Donovan A, Marti P et al: The RSPO-LGR4/5-ZNRF3/RNF43 
module controls liver zonation and size. Nature cell biology 2016. 
188. Saito K, Negishi M, James Squires E: Sexual dimorphisms in zonal gene 
expression in mouse liver. Biochemical and biophysical research 
communications 2013, 436(4):730-735. 
189. Bastida G, Nos P, Aguas M, Beltran B, Rubin A, Dasi F, Ponce J: Incidence, 
risk factors and clinical course of thiopurine-induced liver injury in patients 
with inflammatory bowel disease. Alimentary pharmacology & therapeutics 




Probe	Set	ID	 Corrected	p---value	p---value	 FCAbsolute	 Gene	Symbol	 Gene	Title	AFFX_Rat_Hexokinase_5_at	 2.02E---05	 9.09E---06	 13.693078	 Hk1	 hexokinase	1	1367571_a_at	 4.66E---04	 4.10E---04	 12.500559	 Igf2	 insulin---like	growth	factor	2	1367581_a_at	 1.27E---08	 2.97E---10	 36.448788	 Spp1	 secreted	phosphoprotein	1	1367584_at	 2.63E---07	 2.46E---08	 13.694988	 Anxa2	 annexin	A2	1367592_at	 3.42E---06	 9.05E---07	 49.07222	 Tnnt2	 troponin	T	type	2	(cardiac)	1367614_at	 3.85E---08	 1.70E---09	 23.178629	 Anxa1	 annexin	A1	1367655_at	 1.45E---05	 6.03E---06	 14.330635	 Tmsb10	 thymosin	beta---10---like///thymosin,	beta	10	1367661_at	 7.10E---08	 4.01E---09	 37.7763	 S100a6	 S100	calcium	binding	protein	A6	1367823_at	 1.83E---07	 1.57E---08	 13.835695	 Timp2	 TIMP	metallopeptidase	inhibitor	2	1367851_at	 3.09E---07	 3.07E---08	 27.330727	 Ptgds	 prostaglandin	D2	synthase	(brain)	1367858_at	 4.05E---04	 3.52E---04	 10.284656	 Mmp11	 matrix	metallopeptidase	11	1367880_at	 1.43E---05	 5.88E---06	 12.941892	 Lamb2	 laminin,	beta	2	1368003_at	 8.10E---07	 1.09E---07	 95.26397	 Aldh1a2	 aldehyde	dehydrogenase	1	family,	member	A2	1368005_at	 8.57E---05	 5.53E---05	 9.883257	 Itpr3	 inositol	1,4,5---trisphosphate	receptor,	type	3	1368007_at	 1.59E---10	 1.95E---13	 50.854095	 Dmbt1///LOC100	913031	 deleted	in	malignant	brain	tumors	1///deleted	in	malignant	brain	tumors	1		protein---like	1368008_at	 1.88E---04	 1.42E---04	 12.854971	 Prom1	 prominin	1	1368013_at	 4.55E---06	 1.31E---06	 9.4272995	 Ddit4l///LOC1003	63484	 DNA---damage---inducible	transcript	4---like///DNA---damage---inducible	transcript	4---	like	protein---like	1368052_at	 1.76E---06	 3.91E---07	 86.02309	 Tspan8	 tetraspanin	8	1368097_a_at	 1.05E---04	 7.05E---05	 10.079666	 Rtn1	 reticulon	1	1368123_at	 3.57E---04	 3.04E---04	 21.487787	 Igf1r	 insulin---like	growth	factor	1	receptor	1368131_at	 1.59E---06	 3.25E---07	 37.547344	 Capn6	 calpain	6	1368200_at	 4.39E---06	 1.25E---06	 18.500254	 Cx3cl1	 chemokine	(C---X3---C	motif)	ligand	1	1368250_at	 5.78E---05	 3.39E---05	 13.464029	 Tekt1	 tektin	1	1368254_a_at	 2.01E---07	 1.80E---08	 21.959936	 Sphk1	 sphingosine	kinase	1	1368278_at	 2.15E---07	 1.98E---08	 54.886753	 Lgals2	 lectin,	galactoside---binding,	soluble,	2	1368281_at	 3.83E---04	 3.30E---04	 10.997819	 Dpep1	 dipeptidase	1	(renal)	1368350_at	 1.25E---04	 8.67E---05	 34.15715	 Ptprz1	 protein	tyrosine	phosphatase,	receptor---type,	Z	polypeptide	1	1368363_at	 1.24E---05	 4.85E---06	 32.857944	 Klf5	 Kruppel---like	factor	5	1368374_a_at	 1.14E---08	 2.29E---10	 56.173866	 Ggt1	 gamma---glutamyltransferase	1	1368391_at	 3.10E---05	 1.53E---05	 11.326229	 Slc7a1	 solute	carrier	family	7	(cationic	amino	acid	transporter,	y+	system),	member	1	1368392_at	 0.002102866	 0.002051262	 9.339462	 Slc7a1	 solute	carrier	family	7	(cationic	amino	acid	transporter,	y+	system),	member	1	1368395_at	 1.78E---06	 4.06E---07	 14.945976	 Gpc3	 glypican	3	1368398_at	 1.70E---04	 1.25E---04	 11.446347	 Cacna1h	 calcium	channel,	voltage---dependent,	T	type,	alpha	1H	subunit	1368404_at	 8.03E---06	 2.81E---06	 13.423091	 Dbn1	 drebrin	1	1368411_a_at	 4.04E---09	 3.10E---11	 62.83263	 Map2	 microtubule---associated	protein	2	1368413_at	 2.76E---05	 1.32E---05	 11.373006	 Abp1	 amiloride	binding	protein	1	(amine	oxidase,	copper---containing)	1368441_at	 5.19E---07	 6.11E---08	 106.69083	 Msln	 mesothelin	1368469_at	 8.73E---09	 1.07E---10	 157.86432	 Aqp5	 aquaporin	5	1368515_at	 1.45E---04	 1.05E---04	 10.89343	 Epb41l3	 erythrocyte	membrane	protein	band	4.1---like	3	1368521_at	 3.25E---06	 8.43E---07	 10.534752	 Napsa	 napsin	A	aspartic	peptidase	1368527_at	 6.51E---07	 8.39E---08	 48.73094	 Ptgs2	 prostaglandin---endoperoxide	synthase	2	1368555_at	 4.72E---04	 4.18E---04	 9.211765	 Cd37	 CD37	molecule	1368612_at	 8.15E---06	 2.89E---06	 10.481842	 Itgb4	 integrin,	beta	4	1368887_at	 1.46E---05	 6.09E---06	 40.16622	 Cdh22	 cadherin	22	1368920_at	 7.83E---07	 1.02E---07	 45.95985	 Slit3	 slit	homolog	3	(Drosophila)	1368921_a_at	 5.61E---06	 1.71E---06	 30.379755	 Cd44	 Cd44	molecule	1368949_at	 5.07E---05	 2.86E---05	 10.462679	 Ebf1	 early	B---cell	factor	1	1368983_at	 8.12E---05	 5.16E---05	 9.253278	 Hbegf	 heparin---binding	EGF---like	growth	factor	1369105_a_at	 1.32E---04	 9.35E---05	 22.487028	 Pkib	 protein	kinase	(cAMP---dependent,	catalytic)	inhibitor	beta	1369128_at	 1.27E---04	 8.82E---05	 9.439171	 Grik5	 glutamate	receptor,	ionotropic,	kainate	5	1369135_at	 1.56E---04	 1.14E---04	 16.748272	 Syt11	 synaptotagmin	XI	1369167_at	 2.73E---04	 2.22E---04	 25.706429	 Gfra2	 GDNF	family	receptor	alpha	2	1369185_a_at	 2.40E---05	 1.10E---05	 16.476957	 Syt7	 synaptotagmin	VII	1369213_at	 8.19E---06	 2.91E---06	 11.828588	 L1cam	 L1	cell	adhesion	molecule	1369263_at	 3.99E---04	 3.46E---04	 10.105852	 Wnt5a	 wingless---type	MMTV	integration	site	family,	member	5A	1369301_at	 2.00E---05	 8.96E---06	 25.398272	 Aplnr	 apelin	receptor	1369336_at	 1.47E---05	 6.13E---06	 16.566042	 Hr	 hair	growth	associated	1369353_at	 1.11E---04	 7.52E---05	 21.358007	 Erbb4	 v---erb---a	erythroblastic	leukemia	viral	oncogene	homolog	4	(avian)	1369358_a_at	 1.86E---06	 4.31E---07	 12.13524	 Hap1	 huntingtin---associated	protein	1	1369373_at	 1.76E---04	 1.30E---04	 10.354804	 Fgfr3	 fibroblast	growth	factor	receptor	3	1369381_a_at	 4.73E---06	 1.38E---06	 30.748932	 Slc15a1	 solute	carrier	family	15	(oligopeptide	transporter),	member	1	1369385_at	 1.74E---04	 1.28E---04	 10.134165	 Afap1	 actin	filament	associated	protein	1	1369441_at	 4.22E---05	 2.27E---05	 9.354585	 Capn5	 calpain	5	1369458_at	 2.65E---05	 1.26E---05	 12.489753	 Gab2	 GRB2---associated	binding	protein	2	1369484_at	 6.23E---07	 7.95E---08	 112.22871	 Wisp2	 WNT1	inducible	signaling	pathway	protein	2	1369500_at	 5.61E---05	 3.23E---05	 12.561653	 Kcnk1	 potassium	channel,	subfamily	K,	member	1	1369513_at	 6.28E---04	 5.71E---04	 10.85835	 Ccl28	 chemokine	(C---C	motif)	ligand	28	1369516_at	 7.22E---05	 4.46E---05	 22.151363	 Pdx1	 pancreatic	and	duodenal	homeobox	1	1369640_at	 3.85E---08	 1.65E---09	 19.856825	 Gja1	 gap	junction	protein,	alpha	1	1369670_at	 6.63E---06	 2.13E---06	 27.442968	 Cd200	 Cd200	molecule	1369686_at	 3.35E---08	 1.27E---09	 22.78919	 Dclk1	 doublecortin---like	kinase	1	1369698_at	 2.01E---04	 1.53E---04	 11.581351	 Abcc3	 ATP---binding	cassette,	subfamily	C	(CFTR/MRP),	member	3	1369735_at	 5.48E---08	 2.89E---09	 18.456982	 Gas6	 growth	arrest	specific	6	1369759_at	 2.15E---04	 1.66E---04	 16.507908	 Slc5a1	 solute	carrier	family	5	(sodium/glucose	cotransporter),	member	1	1369798_at	 3.78E---04	 3.24E---04	 9.236135	 Atp1b2	 ATPase,	Na+/K+	transporting,	beta	2	polypeptide	1369949_at	 1.27E---07	 8.70E---09	 24.296352	 Bcam	 basal	cell	adhesion	molecule	(Lutheran	blood	group)	1369953_a_at	 4.05E---10	 9.95E---13	 27.058285	 Cd24	 CD24	molecule	1369963_at	 3.15E---04	 2.64E---04	 9.25386	 Pafah1b3	 platelet---activating	factor	acetylhydrolase	1b,	catalytic	subunit	3	1370011_at	 1.50E---04	 1.09E---04	 20.099453	 Ak1	 adenylate	kinase	1	1370026_at	 2.43E---08	 8.06E---10	 22.020063	 Cryab	 crystallin,	alpha	B	1370072_at	 3.42E---05	 1.75E---05	 17.481222	 Mme	 membrane	metallo---endopeptidase	1370122_at	 5.80E---06	 1.80E---06	 33.097958	 Rab27b	 RAB27B,	member	RAS	oncogene	family	1370143_at	 1.78E---06	 4.06E---07	 10.144477	 Smo	 smoothened,	frizzled	family	receptor	1370217_at	 1.53E---06	 3.10E---07	 15.142731		 	1370218_at	 5.31E---06	 1.60E---06	 20.30291	 Ldhb	 lactate	dehydrogenase	B	1370233_at	 4.94E---04	 4.40E---04	 10.535631	 Fgf12	 fibroblast	growth	factor	12	1370269_at	 6.13E---05	 3.62E---05	 35.851364	 Cyp1a1	 cytochrome	P450,	family	1,	subfamily	a,	polypeptide	1	1370367_at	 1.21E---04	 8.32E---05	 10.029843	 Slc1a1	 solute	carrier	family	1	(neuronal/epithelial	high	affinity	glutamate	transporter,		system	Xag),	member	1	1370379_at	 1.71E---06	 3.70E---07	 15.166229	 Prss8	 protease,	serine,	8	1370406_a_at	 0.002605047	 0.002560298	 9.537443	 Cd55	 Cd55	molecule	1370410_at	 7.35E---04	 6.75E---04	 14.036026	 Igsf1	 immunoglobulin	superfamily,	member	1	1370418_s_at	 5.09E---05	 2.88E---05	 18.103872	 Syt17	 synaptotagmin	XVII	1370448_at	 2.52E---05	 1.18E---05	 13.860155	 Gpc2	 glypican	2	1370514_a_at	 5.25E---07	 6.44E---08	 33.56122	 Syt7	 synaptotagmin	VII	1370515_x_at	 5.55E---05	 3.19E---05	 11.055471	 Syt7	 synaptotagmin	VII	1370561_at	 1.17E---05	 4.50E---06	 15.606807	 A3galt2	 alpha	1,3---galactosyltransferase	2	1370594_at	 1.24E---05	 4.82E---06	 41.762447	 Igsf1	 immunoglobulin	superfamily,	member	1	1370657_at	 5.72E---05	 3.32E---05	 25.157446	 Cdh6	 cadherin	6	1370692_at	 0.001035933	 9.80E---04	 9.792784	 Il1rl1	 interleukin	1	receptor---like	1	1370727_at	 2.54E---06	 6.38E---07	 24.19306	 Pdgfd	 platelet	derived	growth	factor	D	1370864_at	 5.35E---07	 6.64E---08	 11.312916	 Col1a1	 collagen,	type	I,	alpha	1	1370894_at	 1.37E---06	 2.41E---07	 56.5471	 Cldn7	 claudin	7	1370902_at	 1.52E---06	 3.04E---07	 21.273922	 Akr1b8	 aldo---keto	reductase	family	1,	member	B8	1370912_at	 1.36E---04	 9.65E---05	 12.633699	 Hspa1a	 heat	shock	70kD	protein	1A	1370956_at	 3.72E---06	 1.02E---06	 14.101621	 Dcn	 decorin	1370963_at	 7.37E---05	 4.59E---05	 16.265783	 Gas7	 growth	arrest	specific	7	1370973_at	 3.13E---04	 2.62E---04	 18.037725	 Scn7a	 sodium	channel,	voltage---gated,	type	VII,	alpha	
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	 1371130_at	 1.62E---05	 6.89E---06	 9.662579	 Slc1a3	 solute	carrier	family	1	(glial	high	affinity	glutamate	transporter),	member	3	1371133_a_at	 1.56E---05	 6.62E---06	 13.122443	 Prkar2b	 protein	kinase,	cAMP	dependent	regulatory,	type	II	beta	1371164_at	 3.70E---05	 1.93E---05	 15.912628	Mcpt10///RGD15	65970	 mast	cell	protease	10///similar	to	mast	cell	protease	8	1371256_at	 5.91E---05	 3.47E---05	 12.501319	 Ptpn18	 protein	tyrosine	phosphatase,	non---receptor	type	18	1371260_at	 4.45E---04	 3.92E---04	 15.473067	Mcpt2	 mast	cell	protease	2	1371360_at	 8.57E---05	 5.53E---05	 17.334116	 Ndrg1	 N---myc	downstream	regulated	1	1371393_at	 1.14E---08	 2.39E---10	 12.367773	 Clstn1	 calsyntenin	1	1371472_at	 4.07E---07	 4.30E---08	 12.167263		 	1371499_at	 2.52E---06	 6.23E---07	 11.708584	 Cd9	 CD9	molecule	1371527_at	 1.16E---06	 1.87E---07	 12.16712	 Emp1	 epithelial	membrane	protein	1	1371671_at	 0.001260288	 0.001206166	 11.366027		 	1371696_at	 1.36E---06	 2.35E---07	 19.252666	 Gpr56	 G	protein---coupled	receptor	56	1371700_at	 1.38E---07	 1.02E---08	 14.689907	 LOC100911714///	Mfap4	 microfibril---associated	glycoprotein	4---like///microfibrillar---associated	protein	4	1371861_at	 1.44E---04	 1.04E---04	 10.911258	 Sfrp1	 secreted	frizzled---related	protein	1	1371883_at	 5.16E---06	 1.55E---06	 14.574821	Mmd	 monocyte	to	macrophage	differentiation---associated	1372002_at	 5.41E---10	 1.99E---12	 10.582753	 Gja1	 gap	junction	protein,	alpha	1	1372063_at	 1.09E---05	 4.10E---06	 12.944598		 	1372064_at	 1.64E---07	 1.29E---08	 14.624378	 Cxcl16	 chemokine	(C---X---C	motif)	ligand	16	1372111_at	 1.52E---06	 2.98E---07	 12.275206	 Cav1	 caveolin	1,	caveolae	protein	1372162_at	 5.03E---07	 5.78E---08	 11.715216	 Acss1	 acyl---CoA	synthetase	short---chain	family	member	1	1372179_at	 3.02E---07	 2.93E---08	 9.3302765	 Hpcal1	 hippocalcin---like	1	1372208_at	 7.24E---06	 2.42E---06	 26.82274	 Ppp1r1b	 protein	phosphatase	1,	regulatory	(inhibitor)	subunit	1B	1372256_at	 1.40E---06	 2.57E---07	 13.957351	 Crip1	 cysteine---rich	protein	1	(intestinal)	1372481_at	 1.24E---05	 4.79E---06	 18.029274		 	1372615_at	 2.59E---06	 6.59E---07	 15.894693	 Aoc3	 amine	oxidase,	copper	containing	3	1372641_at	 1.79E---04	 1.33E---04	 12.194944	 Alpk3	 alpha---kinase	3	1372658_at	 1.90E---06	 4.50E---07	 14.413948	 Synm	 synemin,	intermediate	filament	protein	1372708_at	 1.93E---05	 8.58E---06	 23.943815		 	1372725_at	 4.22E---05	 2.27E---05	 23.333735	 Plscr2	 phospholipid	scramblase	2	1372805_at	 9.60E---06	 3.51E---06	 20.450375	 Endod1	 endonuclease	domain	containing	1	1372818_at	 7.71E---04	 7.11E---04	 10.684435	 Colec12	 collectin	sub---family	member	12	1372820_at	 6.65E---06	 2.15E---06	 23.599646	 LOC691984	 similar	to	Glypican---6	precursor	1372967_at	 1.78E---04	 1.32E---04	 9.255879	 Arhgef25	 Rho	guanine	nucleotide	exchange	factor	(GEF)	25	1373000_at	 7.39E---05	 4.62E---05	 18.801155	 Srpx2	 sushi---repeat---containing	protein,	X---linked	2	1373006_at	 3.76E---05	 1.97E---05	 12.144326	 Tmem171	 transmembrane	protein	171	1373008_x_at	 4.27E---04	 3.74E---04	 13.407098	 Rtn4r	 reticulon	4	receptor	1373035_at	 6.62E---05	 4.01E---05	 12.2618		 	1373089_at	 1.86E---06	 4.33E---07	 23.736456	 Cdh3	 cadherin	3	1373148_at	 1.02E---04	 6.76E---05	 10.292156	 Cpxm2	 carboxypeptidase	X	(M14	family),	member	2	1373210_at	 2.86E---05	 1.40E---05	 12.738761	 Lamb1	 laminin,	beta	1	1373224_at	 1.81E---08	 4.88E---10	 11.811304	 St3gal4	 ST3	beta---galactoside	alpha---2,3---sialyltransferase	4	1373232_at	 1.70E---06	 3.65E---07	 23.180397	 LOC302022	 similar	to	nidogen	2	protein	1373330_at	 2.80E---05	 1.36E---05	 14.919093	 LOC690323	 similar	to	Myosin---15	(Myosin	XV)	(Unconventional	myosin---15)	1373458_at	 4.04E---09	 3.07E---11	 22.041267	 Bex4	 brain	expressed,	X---linked	4	1373485_at	 4.38E---05	 2.38E---05	 20.451302		 	1373521_at	 4.72E---04	 4.18E---04	 9.50532	 Sh3tc2	 SH3	domain	and	tetratricopeptide	repeats	2	1373631_at	 5.03E---07	 5.77E---08	 61.254997	 Rap1gap	 Rap1	GTPase---activating	protein	1373651_at	 4.53E---05	 2.48E---05	 22.103037		 	1373696_at	 4.75E---05	 2.64E---05	 12.527222	 LOC100910558	 uncharacterized	LOC100910558	1373725_at	 2.40E---05	 1.10E---05	 22.412664		 	1373839_at	 8.54E---04	 7.96E---04	 12.593703		 	1373860_at	 1.36E---06	 2.39E---07	 9.241785	 Sox4	 SRY	(sex	determining	region	Y)---box	4	1373900_at	 6.38E---05	 3.83E---05	 61.61385	 Krt7	 keratin	7	1373902_at	 5.97E---04	 5.41E---04	 11.736959	 Rimklb	 ribosomal	modification	protein	rimK---like	family	member	B	1373908_at	 6.59E---06	 2.11E---06	 13.293645		 	1373914_at	 3.37E---04	 2.84E---04	 18.194729		 	1373928_at	 1.24E---05	 4.83E---06	 28.494877	 Il17re	 interleukin	17	receptor	E	1373977_at	 3.29E---06	 8.61E---07	 9.845295		 	1373985_at	 1.24E---05	 4.88E---06	 12.060419		 	1374022_at	 5.03E---07	 5.78E---08	 36.05377		 	1374056_at	 1.72E---04	 1.27E---04	 11.899961	 Rbm24	 RNA	binding	motif	protein	24	1374070_at	 8.25E---06	 2.95E---06	 74.624214	 Gpx2	 glutathione	peroxidase	2	1374089_at	 6.38E---05	 3.83E---05	 13.56553		 	1374106_at	 7.43E---05	 4.65E---05	 26.521767		 	1374119_at	 1.06E---05	 3.93E---06	 10.975694	 Elf3	 E74---like	factor	3	1374122_at	 2.86E---05	 1.40E---05	 38.222332	Myo5c	 myosin	VC	1374151_at	 5.35E---05	 3.05E---05	 11.93909		 	1374193_at	 5.25E---04	 4.70E---04	 11.04623		 	1374195_at	 1.35E---04	 9.60E---05	 14.124624	 Lad1	 ladinin	1	1374342_at	 5.51E---04	 4.96E---04	 9.492553	 Ly6g6c	 lymphocyte	antigen	6	complex,	locus	G6C	1374376_at	 3.65E---07	 3.67E---08	 15.596862	 Arhgef28	 Rho	guanine	nucleotide	exchange	factor	(GEF)	28	1374427_at	 1.21E---04	 8.27E---05	 22.748371		 	1374434_at	 7.41E---06	 2.51E---06	 23.213726	 LOC498222	 similar	to	specifically	androgen---regulated	protein	1374488_at	 1.81E---06	 4.17E---07	 22.39445	 Gramd1b	 GRAM	domain	containing	1B	1374496_at	 8.04E---04	 7.46E---04	 9.200513	 Tril	 TLR4	interactor	with	leucine---rich	repeats	1374557_at	 1.38E---04	 9.89E---05	 13.465133	Wls	 wntless	homolog	(Drosophila)	1374573_at	 4.54E---05	 2.49E---05	 12.199232	 Dync2li1	 dynein	cytoplasmic	2	light	intermediate	chain	1	1374594_at	 1.39E---05	 5.63E---06	 61.74779	 LOC363060	 similar	to	RIKEN	cDNA	1600029D21	1374630_at	 3.23E---08	 1.19E---09	 56.059574	 Clic3	 chloride	intracellular	channel	3	1374691_at	 1.76E---06	 3.96E---07	 22.866798	 Sult5a1	 sulfotransferase	family	5A,	member	1	1374699_at	 3.15E---05	 1.57E---05	 39.059124	 Fam84a	 family	with	sequence	similarity	84,	member	A	1374705_at	 3.16E---05	 1.59E---05	 13.600379	 Col4a5	 collagen,	type	IV,	alpha	5	1374708_at	 2.51E---04	 2.02E---04	 10.279355	 RGD1565043	 similar	to	Rho	guanine	nucleotide	exchange	factor	(GEF)	10	1374726_at	 3.79E---05	 2.00E---05	 10.783984	 Fndc1	 fibronectin	type	III	domain	containing	1	1374728_at	 3.05E---04	 2.53E---04	 11.212997		 	1374768_at	 5.40E---05	 3.09E---05	 15.707371	 Ccdc65	 coiled---coil	domain	containing	65	1374774_at	 1.76E---06	 3.95E---07	 15.635612		 	1374812_at	 3.76E---08	 1.57E---09	 13.4769745	 Ptpn13	 protein	tyrosine	phosphatase,	non---receptor	type	13	1374817_at	 8.29E---07	 1.14E---07	 37.459064		 	1374870_at	 3.42E---04	 2.89E---04	 10.816524		 	1374910_at	 2.31E---06	 5.58E---07	 25.026775	 Celsr2	 cadherin,	EGF	LAG	seven---pass	G---type	receptor	2	1374963_s_at	 6.34E---05	 3.77E---05	 18.970654		 	1374976_a_at	 3.56E---05	 1.85E---05	 18.247913	 Soat1	 sterol	O---acyltransferase	1	1375030_at	 1.42E---06	 2.65E---07	 50.26162	 B3galt5	 UDP---Gal:betaGlcNAc	beta	1,3---galactosyltransferase,	polypeptide	5	1375032_at	 1.82E---07	 1.54E---08	 82.186005	 Kndc1	 kinase	non---catalytic	C---lobe	domain	(KIND)	containing	1	1375039_x_at	 2.45E---04	 1.96E---04	 9.804144	 Fcgbpl1	 Fc	fragment	of	IgG	binding	protein---like	1	1375051_at	 0.001628648	 0.001572695	 9.648176		 	1375062_at	 1.09E---05	 4.10E---06	 19.397228	 Ap1m2	 adaptor---related	protein	complex	1,	mu	2	subunit	1375083_at	 4.00E---05	 2.11E---05	 36.525898		 	1375084_at	 1.78E---06	 4.01E---07	 26.43655	 Serinc2	 serine	incorporator	2	1375136_at	 4.90E---06	 1.44E---06	 9.371695		 	1375170_at	 1.14E---08	 1.80E---10	 32.225735	 S100a11	 S100	calcium	binding	protein	A11	1375267_at	 3.54E---08	 1.43E---09	 20.533499	 Ppic	 peptidylprolyl	isomerase	C	1375320_at	 3.57E---04	 3.03E---04	 15.71609		 	1375358_at	 1.07E---06	 1.69E---07	 21.041254		 	1375359_at	 1.76E---04	 1.30E---04	 17.94388	 Gfra2	 GDNF	family	receptor	alpha	2	1375377_at	 3.27E---05	 1.67E---05	 21.766483	 Igsf3	 immunoglobulin	superfamily,	member	3	1375485_at	 2.76E---05	 1.33E---05	 10.310503	 Prrx1	 paired	related	homeobox	1	1375708_at	 3.20E---04	 2.68E---04	 13.255325	 Col27a1	 collagen,	type	XXVII,	alpha	1	1375719_s_at	 2.38E---04	 1.87E---04	 10.560182	 Cdh13	 cadherin	13	1375849_at	 1.84E---04	 1.39E---04	 11.833174	 Rgma	 RGM	domain	family,	member	A	1375908_at	 5.76E---07	 7.28E---08	 13.846147	Mpzl2	 myelin	protein	zero---like	2	1375958_at	 2.43E---04	 1.93E---04	 10.672437	 Tsc22d4	 TSC22	domain	family,	member	4	
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	 1376025_at	 2.03E---04	 1.56E---04	 10.097886	 Prmt2	 protein	arginine	methyltransferase	2	1376102_at	 1.52E---06	 3.06E---07	 11.710049	 Tmbim1	 transmembrane	BAX	inhibitor	motif	containing	1	1376104_at	 1.24E---05	 4.90E---06	 10.3597975	 Soga2	 SOGA	family	member	2	1376109_at	 5.61E---05	 3.23E---05	 15.3869		 	1376198_at	 1.09E---04	 7.32E---05	 13.470737	 Clmp	 CXADR---like	membrane	protein	1376292_at	 9.17E---07	 1.32E---07	 94.05401		 	1376297_at	 1.64E---05	 7.00E---06	 11.935768	 Arrdc1	 arrestin	domain	containing	1	1376362_at	 1.29E---05	 5.16E---06	 13.867951	 Nptxr	 neuronal	pentraxin	receptor	1376457_at	 7.81E---06	 2.68E---06	 32.761745	 Crispld2	 cysteine---rich	secretory	protein	LCCL	domain	containing	2	1376465_at	 1.65E---05	 7.07E---06	 13.777263		 	1376564_at	 6.62E---05	 4.01E---05	 10.780192	 Sptbn4	 spectrin,	beta,	non---erythrocytic	4	1376632_at	 7.83E---07	 1.03E---07	 14.634426	 Lmcd1	 LIM	and	cysteine---rich	domains	1	1376640_at	 1.63E---06	 3.39E---07	 13.753034	 Fam171a1	 family	with	sequence	similarity	171,	member	A1	1376661_at	 1.60E---04	 1.17E---04	 9.63517	 Kazn	 kazrin,	periplakin	interacting	protein	1376770_at	 3.02E---07	 2.92E---08	 15.225313	 Efhd1	 EF---hand	domain	family,	member	D1	1376877_at	 1.16E---06	 1.90E---07	 30.346548	 Cdcp1	 CUB	domain	containing	protein	1	1376937_at	 0.001056015	 0.001000299	 9.217573	 Filip1l	 filamin	A	interacting	protein	1---like	1376953_at	 7.66E---04	 7.05E---04	 9.947374	 Unc5cl	 unc---5	homolog	C	(C.	elegans)---like	1377008_at	 8.36E---04	 7.77E---04	 12.75111	 RGD1566401	 similar	to	GTL2,	imprinted	maternally	expressed	untranslated	1377018_at	 2.24E---08	 6.87E---10	 21.025244		 	1377034_at	 1.95E---08	 5.50E---10	 30.448162	 Serpinb1a	 serine	(or	cysteine)	proteinase	inhibitor,	clade	B,	member	1a	1377046_at	 1.35E---05	 5.48E---06	 14.686747	 Ankrd6	 ankyrin	repeat	domain	6	1377088_at	 1.90E---06	 4.53E---07	 33.31594	 Slc52a3	 solute	carrier	family	52,	riboflavin	transporter,	member	3	1377180_at	 3.15E---05	 1.58E---05	 23.011261		 	1377249_at	 6.77E---04	 6.19E---04	 11.117941	 Gspt2	 G1	to	S	phase	transition	2	1377308_a_at	 3.06E---04	 2.54E---04	 12.293895		 	1377336_at	 1.16E---04	 7.88E---05	 17.960976	 Sema3b	 sema	domain,	immunoglobulin	domain	(Ig),	short	basic	domain,	secreted,	(semaphorin)	3B	1377363_at	 5.03E---07	 5.80E---08	 12.715094	 Rab25	 RAB25,	member	RAS	oncogene	family	1377365_at	 3.50E---06	 9.32E---07	 15.139032	 Plekhn1	 pleckstrin	homology	domain	containing,	family	N	member	1	1377366_at	 5.19E---07	 6.10E---08	 59.286716		 	1377383_at	 2.00E---05	 8.93E---06	 40.24625	 Efs	 embryonal	Fyn---associated	substrate	1377428_at	 4.16E---05	 2.22E---05	 12.263563	 Lama5	 laminin,	alpha	5	1377449_at	 1.08E---06	 1.73E---07	 22.9782	 Pvrl4	 poliovirus	receptor---related	4	1377450_s_at	 9.89E---07	 1.44E---07	 38.76371	 Pvrl4	 poliovirus	receptor---related	4	1377522_a_at	 5.25E---05	 2.99E---05	 19.815933	 Zfr2	 zinc	finger	RNA	binding	protein	2	1377606_at	 6.96E---06	 2.30E---06	 13.590374	 Cdk14	 cyclin---dependent	kinase	14	1377867_at	 2.52E---06	 6.24E---07	 9.537132	 RGD1562284	 similar	to	Glutaminyl---peptide	cyclotransferase	precursor	(QC)	1378421_at	 2.43E---04	 1.93E---04	 9.418797	 LOC100910996	 uncharacterized	LOC100910996	1379031_at	 1.04E---05	 3.84E---06	 24.523722	 Gca	 grancalcin	1379451_at	 4.20E---04	 3.66E---04	 13.12676		 	1379936_at	 1.25E---06	 2.08E---07	 49.771782		 	1381341_at	 5.61E---06	 1.72E---06	 38.729553	 LOC688459	 hypothetical	protein	LOC688459	1382320_at	 5.61E---06	 1.72E---06	 17.960115	 RGD1307315	 LOC362793	1382375_at	 8.63E---09	 9.53E---11	 94.69858		 	1382581_at	 1.28E---06	 2.17E---07	 26.30913	 Ehf	 ets	homologous	factor	1382849_at	 1.29E---05	 5.14E---06	 35.12849		 	1383058_at	 9.02E---06	 3.24E---06	 26.19916		 	1383322_at	 5.61E---05	 3.24E---05	 25.40111	 Rasl11b	 RAS---like	family	11	member	B	1383460_at	 1.37E---06	 2.45E---07	 33.874184		 	1383649_a_at	 0.001743348	 0.001687732	 15.475113	 Ddx26b	 DEAD/H	(Asp---Glu---Ala---Asp/His)	box	polypeptide	26B	1383855_at	 1.14E---08	 2.21E---10	 47.80753	 Degs2	 delta(4)---desaturase,	sphingolipid	2	1383935_at	 6.43E---08	 3.47E---09	 13.840781		 	1384027_a_at	 5.68E---07	 7.11E---08	 85.607506		 	1384028_at	 2.62E---06	 6.70E---07	 26.478008		 	1384329_at	 5.07E---05	 2.86E---05	 19.057688	 Prss22	 protease,	serine,	22	1384473_at	 4.74E---05	 2.63E---05	 9.581018		 	1385088_at	 4.91E---04	 4.36E---04	 11.561647	 RGD1310262	 hypothetical	LOC304650	1385805_at	 1.25E---06	 2.09E---07	 17.987728		 	1386466_at	 2.30E---04	 1.80E---04	 16.720318		 	1386862_at	 1.27E---08	 2.88E---10	 16.405445	 Anxa5	 annexin	A5	1386903_at	 2.72E---05	 1.30E---05	 20.4798	 S100b	 S100	calcium	binding	protein	B	1386911_at	 8.03E---06	 2.81E---06	 13.242101	 Atp1a2	 ATPase,	Na+/K+	transporting,	alpha	2	polypeptide	1386921_at	 2.29E---04	 1.79E---04	 17.455502	 Cpe	 carboxypeptidase	E	1386943_at	 8.47E---05	 5.42E---05	 29.594782	 Pllp	 plasmolipin	1386974_at	 3.02E---04	 2.50E---04	 11.743908	 Phldb1	 pleckstrin	homology---like	domain,	family	B,	member	1	1387004_at	 0.001479186	 0.001424738	 11.30693	 Nbl1	 neuroblastoma	1,	DAN	family	BMP	antagonist	1387011_at	 8.65E---07	 1.20E---07	 89.603325	 Lcn2	 lipocalin	2	1387040_at	 1.28E---04	 9.03E---05	 25.030117	Mal	 mal,	T---cell	differentiation	protein	1387043_at	 0.004582734	 0.004560242	 9.821113	 Lypd3	 Ly6/Plaur	domain	containing	3	1387059_at	 0.001210771	 0.001157289	 10.051012	 Stk39	 serine	threonine	kinase	39	1387122_at	 2.93E---05	 1.44E---05	 81.27568	 Plagl1	 pleiomorphic	adenoma	gene---like	1	1387153_at	 4.75E---07	 5.18E---08	 24.505636	 Ril	 reversion	induced	LIM	gene	1387195_at	 1.07E---06	 1.64E---07	 16.865726	 St14	 suppression	of	tumorigenicity	14	(colon	carcinoma)	1387276_at	 1.21E---07	 8.01E---09	 15.8604145	 Dclk1	 doublecortin---like	kinase	1	1387315_at	 1.00E---06	 1.48E---07	 17.810762	 Sftpd	 surfactant	protein	D	1387348_at	 1.17E---05	 4.46E---06	 14.967701	 Igfbp5	 insulin---like	growth	factor	binding	protein	5	1387439_at	 1.82E---07	 1.52E---08	 41.994915	Megf6	 multiple	EGF---like---domains	6	1387454_at	 1.43E---05	 5.88E---06	 10.222892	 Fam129a	 family	with	sequence	similarity	129,	member	A	1387459_at	 4.15E---05	 2.21E---05	 21.004295	 Pkib	 protein	kinase	(cAMP---dependent,	catalytic)	inhibitor	beta	1387483_at	 1.80E---04	 1.36E---04	 9.235196	 Plcg2	 phospholipase	C,	gamma	2	1387581_at	 0.002578954	 0.002531489	 10.670871	 Rassf9	 Ras	association	(RalGDS/AF---6)	domain	family	(N---terminal)	member	9	1387600_at	 5.21E---07	 6.27E---08	 41.38266	 Gabrp	 gamma---aminobutyric	acid	(GABA---A)	receptor,	pi	1387611_at	 2.69E---04	 2.17E---04	 20.667196	 Bcl2	 B---cell	CLL/lymphoma	2	1387671_at	 1.75E---06	 3.86E---07	 28.843006	 Sctr	 secretin	receptor	1387713_a_at	 5.85E---04	 5.30E---04	 9.704559	 Fcer1a	 Fc	fragment	of	IgE,	high	affinity	I,	receptor	for;	alpha	polypeptide	1387791_at	 7.83E---07	 1.04E---07	 15.13041	 Ace	 angiotensin	I	converting	enzyme	(peptidyl---dipeptidase	A)	1	1387813_at	 1.21E---07	 7.87E---09	 54.650253	 Erbb2	 v---erb---b2	erythroblastic	leukemia	viral	oncogene	homolog	2,	neuro/glioblastoma	derived	oncogene	homolog	(avian)	1387922_at	 4.82E---06	 1.41E---06	 23.322363	 Crispld2	 cysteine---rich	secretory	protein	LCCL	domain	containing	2	1387932_at	 1.21E---04	 8.34E---05	 15.162415	 Slc1a1	 solute	carrier	family	1	(neuronal/epithelial	high	affinity	glutamate	transporter,	system	Xag),	member	1	1387952_a_at	 1.57E---06	 3.20E---07	 11.562165	 Cd44	 Cd44	molecule	1388011_a_at	 7.44E---05	 4.68E---05	 14.010181	 Tgfb2	 transforming	growth	factor,	beta	2	1388015_at	 1.53E---04	 1.12E---04	 10.227247	 Ptprz1	 protein	tyrosine	phosphatase,	receptor---type,	Z	polypeptide	1	1388074_at	 1.49E---07	 1.14E---08	 108.330734	 Krt20	 keratin	20	1388111_at	 3.66E---04	 3.13E---04	 9.707632	 Eln	 elastin	1388152_at	 2.32E---05	 1.06E---05	 27.87469	Map2	 microtubule---associated	protein	2	1388176_at	 1.05E---04	 7.01E---05	 21.007301	 Cml5	 camello---like	5	1388199_at	 1.14E---08	 1.73E---10	 14.865608	 Epcam	 epithelial	cell	adhesion	molecule	1388227_at	 2.86E---04	 2.34E---04	 9.290555	Mr1	 major	histocompatibility	complex,	class	I---related	1388274_at	 3.61E---05	 1.88E---05	 10.518496	 Bmyc	 brain	expressed	myelocytomatosis	oncogene	1388335_at	 2.38E---08	 7.60E---10	 12.113955	 Tagln2	 transgelin	2	1388433_at	 1.81E---08	 4.77E---10	 46.840206	 Krt19	 keratin	19	1388439_at	 1.00E---04	 6.62E---05	 10.94992	 Fkbp10	 FK506	binding	protein	10	1388547_at	 4.72E---08	 2.29E---09	 88.98381	 Cldn4	 claudin	4	1388557_at	 1.44E---07	 1.08E---08	 16.91733	 C7///Tubb4b	 complement	component	7///tubulin,	beta	4B	class	IVb	1388618_at	 2.37E---06	 5.77E---07	 9.747248	 Nid2	 nidogen	2	(osteonidogen)	1388670_at	 2.25E---04	 1.75E---04	 13.572557		 	1388802_at	 3.12E---08	 1.07E---09	 114.31808	 Bex1///LOC10091	2195	 brain	expressed,	X---linked	1///protein	BEX1---like	1388856_at	 8.57E---05	 5.52E---05	 11.81065	 Kitlg	 KIT	ligand	1388902_at	 2.19E---04	 1.69E---04	 9.232997	 Loxl1	 lysyl	oxidase---like	1	1388932_at	 1.52E---06	 3.02E---07	 91.28662	 Lama5	 laminin,	alpha	5	1388939_at	 5.98E---06	 1.88E---06	 25.853521	 Col15a1///LOC10	0909752	 collagen,	type	XV,	alpha	1///collagen	alpha---1(XV)	chain---like	
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	 1388955_at	 1.07E---06	 1.70E---07	 9.5735445		 	1388963_at	 1.91E---05	 8.47E---06	 16.460987	 Astn1	 astrotactin	1	1388972_at	 3.10E---04	 2.58E---04	 10.575199	 Rtn4r	 reticulon	4	receptor	1388991_at	 2.89E---04	 2.37E---04	 11.765579	 Sestd1	 SEC14	and	spectrin	domains	1	1389067_at	 8.61E---05	 5.57E---05	 16.197939	 Slco4a1	 solute	carrier	organic	anion	transporter	family,	member	4a1	1389085_at	 1.17E---07	 7.48E---09	 39.918575		 	1389095_at	 5.57E---06	 1.69E---06	 24.668417	 Boc	 BOC	cell	adhesion	associated,	oncogene	regulated	1389186_at	 1.66E---06	 3.53E---07	 29.645475		 	1389193_at	 3.72E---06	 1.02E---06	 10.920559	 Sorcs2	 sortilin---related	VPS10	domain	containing	receptor	2	1389282_at	 9.32E---07	 1.35E---07	 80.933334	 Itga3	 integrin,	alpha	3	1389349_s_at	 1.64E---07	 1.28E---08	 46.179253	 Il17re	 interleukin	17	receptor	E	1389360_at	 5.03E---07	 5.66E---08	 31.939844	 Fxyd3	 FXYD	domain---containing	ion	transport	regulator	3	1389367_at	 2.02E---06	 4.82E---07	 9.508542	 Schip1	 schwannomin	interacting	protein	1	1389409_at	 7.84E---06	 2.70E---06	 13.454418	 Tes	 testis	derived	transcript	1389424_at	 7.59E---05	 4.80E---05	 21.686674	 LOC688452	 hypothetical	protein	LOC688452	1389502_at	 4.61E---05	 2.54E---05	 14.437923		 	1389532_at	 2.14E---04	 1.65E---04	 14.472314		 	1389584_at	 1.12E---04	 7.55E---05	 11.608463		 	1389697_at	 1.09E---05	 4.05E---06	 13.927736		 	1389706_at	 2.91E---05	 1.43E---05	 106.52444	 Dclk1	 doublecortin---like	kinase	1	1389745_at	 1.36E---06	 2.37E---07	 35.10711		 	1389755_at	 3.99E---04	 3.46E---04	 9.220638	 Cdca7l	 cell	division	cycle	associated	7	like	1389759_at	 4.62E---05	 2.55E---05	 24.639694		 	1389762_at	 4.36E---04	 3.83E---04	 9.670752	 Fcgbp	 Fc	fragment	of	IgG	binding	protein	1389763_at	 2.98E---04	 2.45E---04	 16.61675		 	1389783_s_at	 9.59E---06	 3.49E---06	 14.673447	 Fcgbp///Fcgbpl1	 Fc	fragment	of	IgG	binding	protein///Fc	fragment	of	IgG	binding	protein---like	1	1389787_at	 1.00E---04	 6.58E---05	 16.722956	 Ptk7	 protein	tyrosine	kinase	7	1389788_at	 4.20E---04	 3.67E---04	 12.701558	Morn4	 MORN	repeat	containing	4	1389795_at	 8.92E---08	 5.47E---09	 58.41622		 	1389800_at	 2.57E---05	 1.21E---05	 14.25204	 Pwwp2b	 PWWP	domain	containing	2B	1389803_at	 5.72E---05	 3.33E---05	 12.763009		 	1389921_at	 5.88E---06	 1.84E---06	 32.802216	 Evl	 Enah/Vasp---like	1390070_at	 1.45E---05	 6.03E---06	 25.619055	 LOC100911253	 uncharacterized	LOC100911253	1390121_at	 1.63E---06	 3.39E---07	 12.06244	 Glis2	 GLIS	family	zinc	finger	2	1390123_at	 4.72E---05	 2.61E---05	 18.948364	 Tmem45b	 transmembrane	protein	45b	1390191_at	 6.38E---05	 3.82E---05	 22.399778	 Hunk	 hormonally	upregulated	Neu---associated	kinase	1390192_at	 4.74E---05	 2.63E---05	 17.250414	 Slc27a3	 solute	carrier	family	27	(fatty	acid	transporter),	member	3		1390312_at	 	 3.11E---04		 2.59E---04		 9.210211	 LOC500013///LO	C684193///Samd	9l	 similar	to	sterile	alpha	motif	domain	containing	9---like///similar	to	sterile	alpha	motif	domain	containing	9---like///sterile	alpha	motif	domain	containing	9---like	1390379_at	 7.31E---05	 4.54E---05	 12.390947	 Lmo4	 LIM	domain	only	4	1390437_at	 1.52E---06	 3.06E---07	 13.947505	 Sema5a	 sema	domain,	seven	thrombospondin	repeats	(type	1	and	type	1---like),	transmembrane	domain	(TM)	and	short	cytoplasmic	domain,	(semaphorin)	5A	1390459_at	 1.28E---04	 9.01E---05	 9.414595		 	1390471_at	 3.93E---07	 4.05E---08	 12.389903		 	1390495_at	 7.43E---05	 4.67E---05	 11.388913		 	1390547_at	 2.46E---04	 1.97E---04	 21.699644		 	1390557_at	 5.20E---07	 6.19E---08	 16.90128	 Gca	 grancalcin	1390566_a_at	 3.15E---05	 1.58E---05	 52.090405	 Ckmt1b	 creatine	kinase,	mitochondrial	1B	1390656_at	 3.52E---06	 9.47E---07	 21.913763		 	1390659_at	 1.01E---06	 1.50E---07	 59.544975		 	1390724_at	 1.51E---04	 1.10E---04	 19.69446		 	1390741_at	 1.45E---06	 2.76E---07	 15.502336	 Zfr2	 zinc	finger	RNA	binding	protein	2	1391012_at	 2.25E---04	 1.74E---04	 18.681198	 Fam83f	 family	with	sequence	similarity	83,	member	F	1391228_at	 2.36E---05	 1.08E---05	 36.517487	 Rsph1	 radial	spoke	head	1	homolog	(Chlamydomonas)	1391509_at	 1.80E---05	 7.87E---06	 26.101778	 Tacstd2	 tumor---associated	calcium	signal	transducer	2	1391611_at	 3.39E---08	 1.33E---09	 26.07404	 Kif12	 kinesin	family	member	12	1392053_at	 1.08E---04	 7.28E---05	 13.31703	Mmrn1	 multimerin	1	1392209_at	 1.50E---06	 2.88E---07	 57.176632	 Gcnt3	 glucosaminyl	(N---acetyl)	transferase	3,	mucin	type	1392778_at	 4.38E---05	 2.38E---05	 13.038555	 LOC100910594	 uncharacterized	LOC100910594	1393018_at	 5.30E---04	 4.74E---04	 14.234815	 LOC100912649	 uncharacterized	LOC100912649	1393031_at	 1.16E---04	 7.93E---05	 14.9234085	 Abo	 ABO	blood	group	(transferase	A,	alpha	1---3---N---acetylgalactosaminyltransferase;	transferase	B,	alpha	1---3---galactosyltransferase)	1398245_at	 4.74E---09	 4.65E---11	 64.41337	 Sncg	 synuclein,	gamma	(breast	cancer---specific	protein	1)	1398287_at	 8.45E---04	 7.87E---04	 20.763414	 Plau	 plasminogen	activator,	urokinase	1398305_at	 9.12E---05	 5.95E---05	 12.640652	 Syt17	 synaptotagmin	XVII	1398318_at	 5.63E---06	 1.73E---06	 28.047886	Muc1	 mucin	1,	cell	surface	associated	1398365_at	 1.14E---06	 1.84E---07	 16.268112	 Tppp3	 tubulin	polymerization---promoting	protein	family	member	3	1398373_at	 1.40E---06	 2.57E---07	 53.34996	 B3galnt1	 beta---1,3---N---acetylgalactosaminyltransferase	1	(globoside	blood	group)	1398445_at	 6.77E---06	 2.22E---06	 11.381075		 	1398458_at	 1.40E---05	 5.71E---06	 14.8164625	Wnk2	 WNK	lysine	deficient	protein	kinase	2	1377546_at	 7.54E---05	 4.76E---05	 25.361177		 	1377631_at	 5.69E---06	 1.76E---06	 34.336933	 Col9a3	 collagen,	type	IX,	alpha	3	1377635_at	 1.30E---05	 5.22E---06	 12.111018	 Fmo2	 flavin	containing	monooxygenase	2	1377636_at	 2.29E---05	 1.04E---05	 17.117167		 	1377646_at	 0.001415647	 0.001358326	 10.158515		 	1377655_at	 0.002031373	 0.00197903	 10.747581	 Fgf12	 fibroblast	growth	factor	12	1377778_at	 2.04E---04	 1.57E---04	 10.138667	 Vof16	 ischemia	related	factor	vof---16	1377877_at	 6.77E---06	 2.21E---06	 10.907633		 	1377928_at	 4.92E---04	 4.37E---04	 15.835536	 Tm4sf20	 transmembrane	4	L	six	family	member	20	1377940_at	 3.86E---06	 1.07E---06	 33.672817	 Fam101b	 family	with	sequence	similarity	101,	member	B	1377954_at	 1.39E---06	 2.52E---07	 29.20925		 	1377974_at	 1.89E---06	 4.44E---07	 99.063255		 	1377993_at	 4.04E---09	 2.67E---11	 248.86186	 Gng13	 guanine	nucleotide	binding	protein	(G	protein),	gamma	13	1378015_at	 7.22E---05	 4.46E---05	 21.18032	 Ccl21	 chemokine	(C---C	motif)	ligand	21	1378063_at	 8.98E---04	 8.42E---04	 10.80965		 	1378107_at	 1.21E---06	 1.98E---07	 63.552532		 	1378156_at	 1.89E---05	 8.32E---06	 19.586706	 Cys1	 cystin	1	1378168_at	 7.24E---06	 2.43E---06	 35.013176	 Fam101b	 family	with	sequence	similarity	101,	member	B	1378241_at	 1.48E---05	 6.21E---06	 24.329958		 	1378262_at	 3.72E---06	 1.02E---06	 20.842182		 	1378302_at	 2.52E---05	 1.18E---05	 11.067706		 	1378305_at	 1.81E---05	 7.91E---06	 24.204073	 Tm4sf1	 transmembrane	4	L	six	family	member	1	1378348_at	 2.66E---05	 1.26E---05	 25.817154	 Tmem200c	 transmembrane	protein	200C	1378420_at	 4.73E---06	 1.37E---06	 10.117996		 	1378424_at	 1.85E---04	 1.40E---04	 14.051369	 Trim46	 tripartite	motif---containing	46	1378470_at	 1.37E---06	 2.45E---07	 9.292493	 Paqr5	 progestin	and	adipoQ	receptor	family	member	V	1378480_at	 3.65E---04	 3.11E---04	 10.355568		 	1378484_at	 2.26E---05	 1.02E---05	 16.442146	 Rasl12	 RAS---like,	family	12	1378523_at	 1.24E---05	 4.85E---06	 10.30297	 Ttc12	 tetratricopeptide	repeat	domain	12	1378645_at	 0.001072231	 0.001018291	 20.197554		 	1378665_at	 2.50E---04	 2.00E---04	 14.548567		 	1378667_at	 0.001959899	 0.001904589	 10.632616		 	1378801_at	 3.06E---06	 7.89E---07	 23.907564		 	1378857_at	 0.002828256	 0.002786613	 10.563026	 Tceal5	 transcription	elongation	factor	A	(SII)---like	5	1378867_at	 7.15E---05	 4.41E---05	 19.091784	 LOC100912465	 uncharacterized	LOC100912465	1378915_x_at	 2.54E---06	 6.39E---07	 9.386923	 LOC308990	 hypothetical	protein	LOC308990	1378930_a_at	 1.16E---04	 7.85E---05	 13.783088	 LOC100912518	 uncharacterized	LOC100912518	1378947_at	 4.89E---05	 2.74E---05	 11.009889	 Tns4	 tensin	4	1379008_at	 7.10E---06	 2.36E---06	 15.744608		 	1379081_at	 7.24E---06	 2.43E---06	 14.721452	 Noxo1	 NADPH	oxidase	organizer	1	1379106_at	 4.33E---04	 3.79E---04	 11.804127		 	1379142_at	 0.00262327	 0.002581426	 9.275517		 	1379143_at	 1.17E---05	 4.52E---06	 12.527533		 	1379324_at	 1.64E---07	 1.31E---08	 40.9145		 	1379340_at	 2.01E---07	 1.82E---08	 49.34641	 Lamc2	 laminin,	gamma	2	
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	 1379345_at	 7.95E---06	 2.76E---06	 32.291435	 Col15a1///LOC10	0909752	 collagen,	type	XV,	alpha	1///collagen	alpha---1(XV)	chain---like	1379390_at	 3.90E---08	 1.82E---09	 11.250758	 St6galnac2	 ST6	(alpha---N---acetyl---neuraminyl---2,3---beta---galactosyl---1,3)---N---acetylgalactosaminide	alpha---2,6---sialyltransferase	2	1379393_at	 3.18E---05	 1.60E---05	 16.51206	 Vil1	 villin	1	1379416_at	 7.92E---06	 2.74E---06	 19.688921		 	1379440_at	 1.09E---05	 4.04E---06	 31.337374	 Fstl3	 follistatin---like	3	(secreted	glycoprotein)	1379474_at	 1.42E---05	 5.81E---06	 31.00735		 	1379614_at	 3.16E---08	 1.12E---09	 95.25962		 	1379681_at	 7.81E---06	 2.68E---06	 14.549558	 Ttc22	 tetratricopeptide	repeat	domain	22	1379705_at	 5.14E---05	 2.91E---05	 10.950823		 	1379741_at	 5.70E---04	 5.14E---04	 15.271897	 Atp6v0a4	 ATPase,	H+	transporting,	lysosomal	V0	subunit	A4	1379761_at	 1.48E---04	 1.07E---04	 25.399488	 LOC100911253	 uncharacterized	LOC100911253	1379772_at	 2.90E---06	 7.45E---07	 13.162013	 Aplnr	 apelin	receptor	1379791_at	 3.43E---05	 1.77E---05	 9.822134	 Cd3e	 CD3	molecule,	epsilon	1379889_at	 2.53E---05	 1.19E---05	 15.327981	 Lamc2	 laminin,	gamma	2	1379903_at	 0.007573801	 0.007573801	 10.516568		 	1379906_at	 1.52E---06	 2.96E---07	 11.270258	 Atp1b2	 ATPase,	Na+/K+	transporting,	beta	2	polypeptide	1380052_at	 2.76E---05	 1.33E---05	 9.668791		 	1380084_at	 1.17E---05	 4.45E---06	 9.200554		 	1380086_at	 2.01E---04	 1.54E---04	 10.422925		 	1380105_at	 1.07E---06	 1.70E---07	 52.491142		 	1380172_at	 5.80E---06	 1.81E---06	 15.780717	 Kif5c	 kinesin	family	member	5C	1380222_at	 3.15E---05	 1.57E---05	 26.722694		 	1380249_at	 9.47E---04	 8.89E---04	 11.8609085		 	1380261_at	 1.79E---04	 1.34E---04	 18.656294	 Erich2	 glutamate---rich	2	1380346_at	 1.17E---05	 4.46E---06	 21.334492	 Serpinb1a	 serine	(or	cysteine)	proteinase	inhibitor,	clade	B,	member	1a	1380424_at	 2.42E---04	 1.91E---04	 9.457797	 Ubxn11	 UBX	domain	protein	11	1380460_at	 1.94E---04	 1.47E---04	 10.418154	 RGD1311267	 similar	to	RIKEN	cDNA	4931426K16	gene	1380477_at	 6.77E---06	 2.22E---06	 12.485085		 	1380574_at	 6.77E---06	 2.22E---06	 32.03558		 	1380642_at	 0.001066378	 0.001011423	 9.213547		 	1380684_at	 1.45E---05	 6.01E---06	 20.023506		 	1380725_at	 8.67E---05	 5.64E---05	 11.219623	 Tspan5	 tetraspanin	5	1380766_a_at	 9.61E---04	 9.04E---04	 9.5978775	 RGD1563510	 similar	to	RIKEN	cDNA	8430427H17	gene	1380804_at	 1.30E---04	 9.13E---05	 17.943388		 	1380806_at	 2.32E---04	 1.82E---04	 10.125011		 	1380851_at	 1.16E---04	 7.83E---05	 11.250254	 Sema3f	 sema	domain,	immunoglobulin	domain	(Ig),	short	basic	domain,	secreted,	(semaphorin)	3	F	1380908_at	 4.96E---06	 1.48E---06	 19.787077		 	1380909_at	 2.27E---06	 5.45E---07	 10.905282	 Slc25a24	 solute	carrier	family	25	(mitochondrial	carrier,	phosphate	carrier),	member	24	1380934_at	 3.77E---04	 3.23E---04	 10.443719		 	1380971_at	 4.21E---06	 1.20E---06	 24.60701		 	1381003_at	 1.41E---04	 1.01E---04	 10.853533	 Ikzf2	 IKAROS	family	zinc	finger	2	1381125_at	 1.98E---04	 1.51E---04	 16.06805		 	1381135_at	 6.77E---06	 2.20E---06	 15.361736		 	1381160_at	 3.23E---05	 1.63E---05	 18.422583	 Tmem200c	 transmembrane	protein	200C	1381218_at	 5.25E---07	 6.42E---08	 26.854576		 	1381388_at	 1.42E---04	 1.02E---04	 13.101712	 Ccdc19	 coiled---coil	domain	containing	19	1381418_at	 0.001084984	 0.001031733	 9.614085		 	1381434_s_at	 5.69E---05	 3.29E---05	 28.040277	 LOC100912349///	LOC302022	 nidogen---2---like///similar	to	nidogen	2	protein	1381517_at	 7.85E---04	 7.27E---04	 10.490591		 	1381537_at	 9.61E---06	 3.53E---06	 12.13241	 Klc3	 kinesin	light	chain	3	1381591_at	 5.77E---05	 3.38E---05	 11.650048		 	1381643_at	 0.001283033	 0.001229507	 14.59521		 	1381668_at	 6.92E---05	 4.24E---05	 23.602009		 	1381696_at	 0.001030117	 9.73E---04	 9.756935		 	1381747_at	 3.09E---05	 1.53E---05	 9.807296		 	1381775_at	 1.07E---04	 7.17E---05	 13.237714	 RGD1566102	 RGD1566102	1381795_at	 1.79E---04	 1.33E---04	 22.178213		 	1381848_at	 4.88E---05	 2.73E---05	 12.823439		 	1381956_at	 3.23E---04	 2.71E---04	 9.997453		 	1381960_at	 2.98E---04	 2.46E---04	 16.100039	 Ropn1l	 rhophilin	associated	tail	protein	1---like	1381963_at	 2.40E---05	 1.11E---05	 12.348793	 Thsd4	 thrombospondin,	type	I,	domain	containing	4	1382021_at	 8.15E---06	 2.89E---06	 45.828182	 Pkd2	 polycystic	kidney	disease	2	(autosomal	dominant)	1382050_at	 1.63E---04	 1.19E---04	 12.237961		 	1382072_at	 4.14E---06	 1.17E---06	 43.883057	 Olfml2a	 olfactomedin---like	2A	1382089_at	 1.75E---06	 3.80E---07	 19.382765		 	1382185_at	 0.001628353	 0.001570412	 11.275856	 C1qtnf2	 C1q	and	tumor	necrosis	factor	related	protein	2	1382211_at	 4.18E---04	 3.63E---04	 18.626793		 	1382217_at	 2.55E---06	 6.45E---07	 36.176918		 	1382258_at	 1.90E---06	 4.50E---07	 19.497894	 Arhgef28	 Rho	guanine	nucleotide	exchange	factor	(GEF)	28	1382291_at	 8.66E---08	 5.20E---09	 38.22118		 	1382356_at	 8.12E---04	 7.54E---04	 10.947568	 Efhc2	 EF---hand	domain	(C---terminal)	containing	2	1382387_at	 1.63E---06	 3.44E---07	 28.228888	 Ano1	 anoctamin	1,	calcium	activated	chloride	channel	1382403_at	 1.27E---04	 8.84E---05	 13.611981	 LOC498662	 similar	to	RIKEN	cDNA	2610019F03	1382439_at	 3.29E---06	 8.55E---07	 78.806404	 Itgb6	 integrin,	beta	6	1382444_at	 7.89E---07	 1.06E---07	 135.32335	 Pitpnm3	 PITPNM	family	member	3	1382591_at	 2.41E---04	 1.91E---04	 10.728073		 	1382638_at	 1.56E---05	 6.59E---06	 28.890053		 	1382647_at	 8.90E---04	 8.33E---04	 10.391697		 	1382686_at	 4.20E---04	 3.66E---04	 10.386313		 	1382710_at	 7.01E---06	 2.32E---06	 9.8385725	 Enc1	 ectodermal---neural	cortex	1	1382745_at	 1.58E---05	 6.73E---06	 9.429281		 	1382776_at	 1.52E---05	 6.40E---06	 14.513216	Mboat1	 membrane	bound	O---acyltransferase	domain	containing	1	1382781_at	 1.66E---07	 1.36E---08	 40.278545		 	1382814_at	 1.35E---07	 9.60E---09	 31.124146	 Tenm3	 teneurin	transmembrane	protein	3	1382835_at	 1.50E---04	 1.09E---04	 12.133341		 	1382878_at	 2.03E---04	 1.55E---04	 16.248476	 Sfrp1	 secreted	frizzled---related	protein	1	1382882_x_at	 3.68E---04	 3.15E---04	 17.847145		 	1382913_at	 3.50E---06	 9.36E---07	 12.027652	 Cttnbp2	 cortactin	binding	protein	2	1382937_at	 1.68E---06	 3.60E---07	 19.786959	 Spdef	 SAM	pointed	domain	containing	ets	transcription	factor	1382964_at	 5.26E---05	 3.00E---05	 37.7751		 	1382983_at	 2.37E---04	 1.86E---04	 10.201146		 	1383129_at	 9.11E---06	 3.29E---06	 22.485722	Wls	 wntless	homolog	(Drosophila)	1383137_at	 9.46E---06	 3.44E---06	 16.480057	 Sox4	 SRY	(sex	determining	region	Y)---box	4	1383143_at	 1.36E---06	 2.33E---07	 18.049498		 	1383173_at	 1.75E---06	 3.82E---07	 13.478271	Mapre3	 microtubule---associated	protein,	RP/EB	family,	member	3	1383266_at	 3.77E---06	 1.04E---06	 32.500725	 Sfrp1	 secreted	frizzled---related	protein	1	1383290_at	 1.07E---06	 1.64E---07	 20.492765	 Spint1	 serine	peptidase	inhibitor,	Kunitz	type	1	1383291_at	 6.21E---06	 1.96E---06	 20.244171	 C7///Tubb4b	 complement	component	7///tubulin,	beta	4B	class	IVb	1383311_at	 1.78E---04	 1.33E---04	 9.873728	Mtmr11	 myotubularin	related	protein	11	1383353_at	 3.23E---05	 1.63E---05	 10.53137		 	1383401_at	 1.39E---06	 2.53E---07	 13.854533	 Tes	 testis	derived	transcript	1383419_at	 2.65E---04	 2.14E---04	 14.738533	 Lhfpl3	 lipoma	HMGIC	fusion	partner---like	3	1383422_at	 3.12E---04	 2.61E---04	 16.964212	 Bend5	 BEN	domain	containing	5	1383433_at	 8.67E---05	 5.64E---05	 10.448679	 Klhl23	 kelch---like	family	member	23	1383496_at	 1.32E---05	 5.32E---06	 29.213024	 Esrp1	 epithelial	splicing	regulatory	protein	1	1383571_at	 0.003919413	 0.003895367	 9.929289	 Rapgefl1	 Rap	guanine	nucleotide	exchange	factor	(GEF)---like	1	1383645_at	 1.07E---06	 1.67E---07	 92.38302		 	1383668_at	 4.13E---06	 1.16E---06	 9.270344	Mmp15	 matrix	metallopeptidase	15	1383673_at	 0.003245082	 0.00321721	 9.817131	 Nap1l2	 nucleosome	assembly	protein	1---like	2	1383694_at	 2.54E---06	 6.39E---07	 22.098726	 Rnf208	 ring	finger	protein	208	1383750_at	 4.43E---05	 2.41E---05	 19.041412		 	1383766_at	 0.001862203	 0.001807365	 10.586014	 Sgcb	 sarcoglycan,	beta	(dystrophin---associated	glycoprotein)	
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	 1383879_at	 3.62E---06	 9.78E---07	 43.24303	 LOC688163	 hypothetical	protein	LOC688163	1383900_at	 1.79E---05	 7.79E---06	 19.862154	 Qrich2	 glutamine	rich	2	1383989_at	 6.66E---05	 4.04E---05	 12.946113	 Sox4	 SRY	(sex	determining	region	Y)---box	4	1383991_at	 2.76E---05	 1.33E---05	 13.519815	 Lrrc8e	 leucine	rich	repeat	containing	8	family,	member	E	1384000_at	 3.77E---07	 3.84E---08	 17.173275	 Sox4	 SRY	(sex	determining	region	Y)---box	4	1384036_s_at	 0.005385248	 0.005372032	 11.021998		 	1384079_at	 4.75E---07	 5.18E---08	 38.321655	 Eps8l1	 EPS8---like	1	1384206_at	 6.32E---04	 5.76E---04	 10.994225	 Sdr16c5	 short	chain	dehydrogenase/reductase	family	16C,	member	5	1384208_at	 0.001693521	 0.001637416	 12.672404	 Igj	 immunoglobulin	joining	chain	1384264_at	 4.07E---07	 4.29E---08	 10.861856	Myh14	 myosin,	heavy	chain	14,	non---muscle	1384276_at	 0.002336342	 0.002284742	 9.522519	 LOC363458	 similar	to	procollagen,	type	IV,	alpha	6	1384322_at	 3.27E---05	 1.66E---05	 16.498205		 	1384438_at	 1.28E---07	 8.95E---09	 19.626469		 	1384442_at	 1.52E---08	 3.73E---10	 39.02556	 Cldn6	 claudin	6	1384468_at	 1.41E---06	 2.62E---07	 56.083447		 	1384479_at	 1.33E---05	 5.37E---06	 9.249574	 Galnt3	 UDP---N---acetyl---alpha---D---galactosamine:polypeptide	N---	acetylgalactosaminyltransferase	3	(GalNAc---T3)	1384485_at	 9.02E---06	 3.24E---06	 9.605184	 Ptpru	 protein	tyrosine	phosphatase,	receptor	type,	U	1384500_at	 9.97E---04	 9.40E---04	 12.656652	 Ccdc30	 coiled---coil	domain	containing	30	1384509_s_at	 1.77E---05	 7.68E---06	 10.327072	 Pcdh17	 protocadherin	17	1384536_at	 6.91E---04	 6.33E---04	 10.522925		 	1384554_at	 1.65E---05	 7.05E---06	 10.295791		 	1384701_at	 1.77E---04	 1.31E---04	 10.398885		 	1384707_at	 3.30E---06	 8.70E---07	 18.677006	 Scara5	 scavenger	receptor	class	A,	member	5	(putative)	1384925_at	 5.37E---04	 4.82E---04	 16.145845	 LOC100912219	 uncharacterized	LOC100912219	1384927_at	 7.54E---06	 2.56E---06	 22.836277	 Tubb4a	 tubulin,	beta	4A	class	IVa	1384939_at	 1.43E---04	 1.03E---04	 9.523808		 	1384944_at	 1.21E---04	 8.28E---05	 13.680715	 Bcl11b	 B---cell	CLL/lymphoma	11B	(zinc	finger	protein)	1384960_at	 1.05E---05	 3.86E---06	 36.319767	 Cftr	 cystic	fibrosis	transmembrane	conductance	regulator		1384993_at	 	 1.77E---05		 7.67E---06		 17.365559		RGD1309847	 similar	to	peptidylglycine	alpha---amidating	monooxygenase	COOH---terminal	interactor;	peptidylglycine	alpha---amidating	monooxygenase	COOH---terminal	interactor	protein---1	1385014_at	 0.006355397	 0.006347599	 12.621086	 Nudt10	 nudix	(nucleoside	diphosphate	linked	moiety	X)---type	motif	10	1385033_at	 4.10E---05	 2.18E---05	 15.07228		 	1385058_at	 6.68E---05	 4.06E---05	 15.346487	 Cldn8	 claudin	8	1385120_at	 7.62E---06	 2.60E---06	 26.392225	 Pof1b	 premature	ovarian	failure	1B	1385166_at	 5.00E---05	 2.81E---05	 15.898907		 	1385190_at	 4.58E---07	 4.89E---08	 107.99972	 Gabrp	 gamma---aminobutyric	acid	(GABA---A)	receptor,	pi	1385274_at	 0.002134164	 0.00208441	 10.1672535	 Pcdhb19	 protocadherin	beta	19	1385357_at	 3.97E---04	 3.44E---04	 11.726316		 	1385369_at	 8.39E---08	 4.84E---09	 28.409658	 Dzip1l	 DAZ	interacting	zinc	finger	protein	1---like	1385436_at	 1.37E---07	 9.90E---09	 25.186365	 LOC100909619///	Tmc4	 transmembrane	channel---like	protein	4---like///transmembrane	channel---like	4	1385464_at	 2.26E---05	 1.02E---05	 24.762989	 Foxq1	 forkhead	box	Q1	1385472_at	 2.43E---05	 1.13E---05	 9.898441	 Zbtb8a	 zinc	finger	and	BTB	domain	containing	8a	1385534_at	 6.46E---05	 3.88E---05	 10.483006	 Ngfrap1	 nerve	growth	factor	receptor	(TNFRSF16)	associated	protein	1	1385591_at	 1.00E---04	 6.60E---05	 14.531951		 	1385614_at	 1.23E---06	 2.03E---07	 28.44431	Mlph	 melanophilin	1385701_at	 7.38E---06	 2.49E---06	 10.461933		 	1385706_at	 1.07E---06	 1.61E---07	 12.168478		 	1385714_at	 6.76E---04	 6.17E---04	 15.618451	 LOC100909619///	Tmc4	 transmembrane	channel---like	protein	4---like///transmembrane	channel---like	4	1385716_at	 8.53E---08	 5.03E---09	 50.09981		 	1385778_at	 1.94E---04	 1.47E---04	 13.708647	 Siat7E	 sialyltransferase	7E	1385830_at	 8.71E---04	 8.13E---04	 9.619808	 RGD1561507	 similar	to	hypothetical	protein	FLJ31606	1385875_at	 1.76E---05	 7.60E---06	 11.691571		 	1385876_at	 0.003422362	 0.003397167	 15.576265	 LOC691984	 similar	to	Glypican---6	precursor	1385899_at	 2.50E---04	 2.01E---04	 10.790482	 Trim16	 tripartite	motif---containing	16	1385961_at	 7.10E---08	 4.00E---09	 121.492676		 	1385969_at	 3.12E---05	 1.55E---05	 18.991758		 	1385978_at	 2.08E---08	 6.11E---10	 56.918144		 	1386628_at	 3.89E---04	 3.36E---04	 11.787127		 	1386695_at	 5.06E---04	 4.51E---04	 22.925386		 	1386724_at	 4.89E---06	 1.43E---06	 18.214127		 	1390931_at	 8.11E---06	 2.85E---06	 37.49837	 Adamts15	 ADAM	metallopeptidase	with	thrombospondin	type	1	motif,	15	1390936_at	 3.90E---08	 1.79E---09	 423.01794		 	1391022_at	 1.29E---05	 5.12E---06	 27.028555	 Lamb3	 laminin,	beta	3	1391026_at	 8.47E---05	 5.44E---05	 14.031144		 	1391051_at	 2.73E---05	 1.30E---05	 16.925434		 	1391060_at	 4.22E---05	 2.28E---05	 10.908334		 	1391063_at	 1.25E---04	 8.65E---05	 14.135125	 Kif23	 kinesin	family	member	23	1391067_at	 4.19E---05	 2.25E---05	 22.093008		 	1391162_at	 8.99E---07	 1.27E---07	 41.68468	 Dcdc2	 doublecortin	domain	containing	2	1391187_at	 4.39E---06	 1.26E---06	 11.846029	 Ppl	 periplakin	1391209_at	 8.13E---05	 5.20E---05	 23.890455		 	1391251_at	 1.09E---05	 4.07E---06	 16.626629		 	1391331_at	 3.05E---07	 2.99E---08	 28.908821		 	1391337_at	 1.27E---04	 8.86E---05	 10.707527		 	1391341_at	 2.76E---04	 2.24E---04	 9.696374	 Plxdc1	 plexin	domain	containing	1	1391375_at	 9.20E---05	 6.01E---05	 38.64931		 	1391459_at	 6.91E---04	 6.34E---04	 13.236974	 Nudt11	 nudix	(nucleoside	diphosphate	linked	moiety	X)---type	motif	11	1391520_at	 4.96E---06	 1.48E---06	 34.60108		 	1391542_at	 6.88E---05	 4.21E---05	 14.079774		 	1391582_at	 1.19E---04	 8.10E---05	 13.178047		 	1391673_at	 4.35E---04	 3.82E---04	 9.3122	 Arhgap20	 Rho	GTPase	activating	protein	20	1391684_at	 1.04E---04	 6.92E---05	 13.806882	 Tmem14a	 transmembrane	protein	14A	1391810_at	 2.99E---04	 2.47E---04	 9.800334	 Rbm20	 RNA	binding	motif	protein	20	1391856_at	 1.05E---04	 7.01E---05	 17.232664	 Sema3g	 sema	domain,	immunoglobulin	domain	(Ig),	short	basic	domain,	secreted,	(semaphorin)	3G	1391887_at	 3.30E---05	 1.69E---05	 10.699146	 Igsf9	 immunoglobulin	superfamily,	member	9	1392003_at	 0.003160681	 0.003125778	 9.29454		 	1392068_at	 1.97E---05	 8.80E---06	 10.408668		 	1392117_at	 1.45E---06	 2.73E---07	 25.85493		 	1392155_at	 5.82E---04	 5.27E---04	 9.520539		 	1392364_at	 9.76E---04	 9.19E---04	 9.315585		 	1392409_at	 5.48E---08	 2.89E---09	 115.09578		 	1392489_at	 2.09E---04	 1.61E---04	 21.208672		 	1392556_at	 1.27E---07	 8.61E---09	 9.900584	 Shroom3	 shroom	family	member	3	1392557_at	 8.27E---07	 1.13E---07	 29.435995		 	1392619_at	 2.19E---04	 1.70E---04	 12.045918	 Ebf1	 early	B---cell	factor	1	1392754_at	 3.70E---06	 1.00E---06	 19.764801	 Adam8	 ADAM	metallopeptidase	domain	8	1392782_at	 0.003125279	 0.003086932	 9.574871		 	1392813_at	 4.04E---09	 3.47E---11	 43.626003		 	1392863_at	 1.71E---05	 7.34E---06	 26.725548		 	1392865_at	 1.19E---04	 8.12E---05	 16.520456	 Fgf9	 fibroblast	growth	factor	9	1392901_at	 4.90E---06	 1.45E---06	 15.06059	 Lrrc1	 leucine	rich	repeat	containing	1	1392971_at	 4.69E---04	 4.14E---04	 12.917377		 	1393003_at	 3.50E---04	 2.97E---04	 9.618179		 	1393167_at	 2.80E---05	 1.36E---05	 12.436018		 	1393206_at	 3.91E---06	 1.09E---06	 44.442936		 	1393210_at	 2.33E---04	 1.83E---04	 11.69808	 LOC100361383	 extracellular	matrix	protein	2---like	1393234_at	 2.80E---04	 2.29E---04	 16.806387	 LOC687105	 hypothetical	protein	LOC687105	1393240_at	 2.45E---05	 1.14E---05	 10.977029	 Efemp2	 EGF---containing	fibulin---like	extracellular	matrix	protein	2	1393252_at	 2.82E---07	 2.66E---08	 25.24019		 	1393263_at	 2.29E---05	 1.04E---05	 24.213043	 Snhg11	 small	nucleolar	RNA	host	gene	11	(non---protein	coding)	1393281_at	 4.72E---08	 2.32E---09	 13.156326	 Cav1	 caveolin	1,	caveolae	protein	
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	 1393282_at	 1.21E---04	 8.30E---05	 9.359753	 Spns2	 spinster	homolog	2	1393297_at	 0.001125008	 0.001071173	 9.930364	 Pou2af1	 POU	class	2	associating	factor	1	1393337_at	 4.72E---08	 2.37E---09	 16.095142	 Tfcp2l1	 transcription	factor	CP2---like	1	1393338_at	 9.36E---06	 3.39E---06	 26.963902	 Scx	 scleraxis	1393368_at	 1.08E---07	 6.79E---09	 11.883907	 Osbpl5	 oxysterol	binding	protein---like	5	1393401_at	 0.002448426	 0.002400359	 11.284812		 	1393452_at	 1.14E---08	 1.85E---10	 62.1806	 Car9	 carbonic	anhydrase	9	1393454_at	 5.37E---04	 4.81E---04	 16.05036	 Pcdh17	 protocadherin	17	1393469_at	 3.78E---04	 3.26E---04	 18.688608		 	1393510_at	 5.97E---04	 5.42E---04	 21.60685	 Sybu	 syntabulin	(syntaxin---interacting)	1393559_at	 0.001030117	 9.73E---04	 14.926427		 	1393570_at	 1.04E---06	 1.55E---07	 51.18359		 	1393571_at	 6.40E---06	 2.03E---06	 38.40082	 Sox4	 SRY	(sex	determining	region	Y)---box	4	1393584_at	 3.91E---04	 3.38E---04	 10.094089	 Tnfrsf21	 tumor	necrosis	factor	receptor	superfamily,	member	21	1393613_at	 6.05E---05	 3.57E---05	 14.495151	 Zfp462	 zinc	finger	protein	462	1393617_at	 4.96E---06	 1.49E---06	 28.052345		 	1393633_at	 3.91E---06	 1.09E---06	 20.307856	 Ano9	 anoctamin	9	1393635_x_at	 2.74E---05	 1.31E---05	 26.936386	 Tubb4a	 tubulin,	beta	4A	class	IVa	1393638_at	 1.63E---06	 3.42E---07	 20.29371		 	1393641_at	 3.45E---04	 2.93E---04	 9.567698	 Blnk	 B---cell	linker	1393719_at	 7.84E---04	 7.25E---04	 22.392132		 	1393732_at	 7.23E---05	 4.48E---05	 17.726828		 	1393740_at	 2.42E---04	 1.91E---04	 14.751152	 Cnksr1	 connector	enhancer	of	kinase	suppressor	of	Ras	1	1393806_at	 1.14E---08	 1.99E---10	 12.273276		 	1393845_a_at	 1.86E---07	 1.64E---08	 67.98524	 LOC100909619///	Tmc4	 transmembrane	channel---like	protein	4---like///transmembrane	channel---like	4	1393850_at	 2.83E---05	 1.38E---05	 10.056748	 Cfc1	 cripto,	FRL---1,	cryptic	family	1	1393896_at	 1.00E---04	 6.57E---05	 19.596245	 Lamc3	 laminin	gamma	3	1393911_at	 6.80E---05	 4.15E---05	 11.494704	 Sh3bp4	 SH3---domain	binding	protein	4	1393935_at	 2.52E---05	 1.18E---05	 19.589827	 Tmem139	 transmembrane	protein	139	1393953_at	 7.37E---05	 4.60E---05	 23.837893	 Eps8l3///LOC100	912384	 EPS8---like	3///epidermal	growth	factor	receptor	kinase	substrate	8---like	protein	3---	like	1394039_at	 1.75E---06	 3.84E---07	 146.67313	 Klf5	 Kruppel---like	factor	5	1394047_at	 7.71E---04	 7.11E---04	 9.937352		 	1394156_at	 3.72E---05	 1.94E---05	 11.434554	 Igsf3	 immunoglobulin	superfamily,	member	3	1394408_at	 8.03E---06	 2.82E---06	 16.391623	 RGD1563692	 similar	to	hypothetical	protein	FLJ22671	1394451_at	 1.89E---05	 8.33E---06	 12.705467	 Anxa1	 annexin	A1	1394571_at	 6.62E---05	 4.01E---05	 26.889793	 Fam227a	 family	with	sequence	similarity	227,	member	A	1394594_at	 2.45E---04	 1.95E---04	 13.778246		 	1394709_at	 1.27E---05	 5.04E---06	 54.665806		 	1394754_at	 4.52E---05	 2.47E---05	 13.783065	 LOC100911253	 uncharacterized	LOC100911253	1394786_at	 3.54E---05	 1.83E---05	 14.265297	 Sorl1	 sortilin---related	receptor,	LDLR	class	A	repeats---containing	1394802_at	 5.77E---05	 3.38E---05	 12.996676		 	1394831_at	 1.66E---07	 1.36E---08	 10.494431		 	1394847_at	 2.52E---04	 2.03E---04	 11.581087	 Syde1	 synapse	defective	1,	Rho	GTPase,	homolog	1	(C.	elegans)	1394896_at	 1.33E---04	 9.42E---05	 18.243921		 	1395176_at	 1.78E---04	 1.32E---04	 10.286077		 	1395249_at	 0.001159925	 0.001105842	 14.614697	 Snhg11	 small	nucleolar	RNA	host	gene	11	(non---protein	coding)	1395357_at	 8.73E---05	 5.69E---05	 17.422134	Map1b	 microtubule---associated	protein	1B	1395365_at	 2.43E---04	 1.94E---04	 9.629207		 	1395372_at	 3.51E---05	 1.81E---05	 10.761291		 	1395390_at	 3.30E---06	 8.68E---07	 44.01907		 	1395437_at	 6.40E---06	 2.03E---06	 13.206172		 	1395663_at	 3.09E---04	 2.57E---04	 14.873993	Mall	 mal,	T---cell	differentiation	protein---like	1395673_at	 4.43E---05	 2.41E---05	 20.342983		 	1395754_at	 8.13E---05	 5.18E---05	 18.488964	 Frem2	 Fras1	related	extracellular	matrix	protein	2	1395761_at	 1.52E---06	 2.96E---07	 13.3368025		 	1395887_at	 1.45E---06	 2.72E---07	 21.867783	 LOC363060	 similar	to	RIKEN	cDNA	1600029D21	1395966_at	 2.43E---04	 1.93E---04	 10.776749	 Kctd14	 potassium	channel	tetramerisation	domain	containing	14	1395968_at	 6.34E---05	 3.77E---05	 15.791612	 LOC690323	 similar	to	Myosin---15	(Myosin	XV)	(Unconventional	myosin---15)	1395986_at	 4.03E---05	 2.14E---05	 18.938015	 Slit2	 slit	homolog	2	(Drosophila)	1396009_at	 6.57E---06	 2.09E---06	 35.93999		 	1396073_at	 3.93E---05	 2.07E---05	 9.316064		 	1396087_at	 3.39E---04	 2.87E---04	 9.554482	 Arhgef28	 Rho	guanine	nucleotide	exchange	factor	(GEF)	28	1396180_at	 8.76E---04	 8.19E---04	 10.354705	 Lrrc16a	 leucine	rich	repeat	containing	16A	1396214_at	 4.62E---05	 2.55E---05	 12.421315	 Kitlg	 KIT	ligand	1396289_at	 6.97E---05	 4.28E---05	 14.53337	Mdga1	 MAM	domain	containing	glycosylphosphatidylinositol	anchor	1	1396295_at	 1.35E---04	 9.61E---05	 18.684168		 	1396450_at	 1.61E---06	 3.32E---07	 13.833416	 Enah	 enabled	homolog	(Drosophila)	1396451_at	 1.61E---04	 1.18E---04	 19.985548		 	1396472_at	 1.14E---05	 4.33E---06	 10.173385		 	1396473_at	 1.47E---04	 1.06E---04	 16.081354		 	1396533_at	 2.09E---04	 1.61E---04	 10.343154		 	1396877_at	 3.66E---04	 3.12E---04	 17.113886		 	1396894_at	 0.001998209	 0.00194427	 11.504197		 	1397045_at	 2.02E---04	 1.55E---04	 10.265491		 	1397165_at	 8.99E---07	 1.27E---07	 9.351287		 	1397166_at	 2.89E---04	 2.38E---04	 13.546398		 	1397217_at	 0.00283257	 0.002794339	 12.0261545		 	1397247_at	 1.84E---05	 8.08E---06	 22.898329	 Cdcp1	 CUB	domain	containing	protein	1	1397301_at	 1.36E---06	 2.39E---07	 67.580696		 	1397340_at	 4.83E---05	 2.70E---05	 22.609924		 	1397343_at	 2.53E---05	 1.19E---05	 13.363558		 	1397397_at	 5.52E---05	 3.16E---05	 17.601234	 Pof1b	 premature	ovarian	failure	1B	1397429_at	 1.86E---07	 1.64E---08	 53.784847	 Creb5	 cAMP	responsive	element	binding	protein	5	1397437_at	 5.73E---04	 5.17E---04	 15.621894	 Arid5a	 AT	rich	interactive	domain	5A	(Mrf1	like)	1397449_at	 7.83E---04	 7.23E---04	 11.14315		 	1397496_at	 6.34E---05	 3.78E---05	 21.460426		 	1397505_at	 2.32E---05	 1.06E---05	 13.507577	 Kif1a	 kinesin	family	member	1A	1397581_at	 1.52E---06	 2.95E---07	 15.820169	 Rhov	 ras	homolog	family	member	V	1397622_at	 4.14E---06	 1.17E---06	 9.560967		 	1397729_x_at	 8.99E---07	 1.28E---07	 14.286232	 LOC363060	 similar	to	RIKEN	cDNA	1600029D21	1397769_at	 0.001196739	 0.001142408	 10.821973		 	1397853_s_at	 2.77E---04	 2.26E---04	 9.898485	 Arhgef9///LOC10	0912165	 Cdc42	guanine	nucleotide	exchange	factor	(GEF)	9///rho	guanine	nucleotide	exchange	factor	9---like	1397929_at	 2.43E---06	 5.96E---07	 20.89912		 	1398071_at	 6.31E---05	 3.74E---05	 21.912308		 	1398116_at	 3.30E---05	 1.69E---05	 21.120111		 	1398149_at	 1.27E---04	 8.90E---05	 14.068488	 Sema5a	 sema	domain,	seven	thrombospondin	repeats	(type	1	and	type	1---like),	transmembrane	domain	(TM)	and	short	cytoplasmic	domain,	(semaphorin)	5A	1398491_at	 8.12E---05	 5.16E---05	 10.2140465	 Ildr1	 immunoglobulin---like	domain	containing	receptor	1	1398624_x_at	 1.79E---04	 1.35E---04	 16.012417	 Tubb4a	 tubulin,	beta	4A	class	IVa	1398645_at	 2.40E---05	 1.11E---05	 21.713133	Wnt7a	 wingless---type	MMTV	integration	site	family,	member	7A	1398660_at	 3.39E---04	 2.86E---04	 11.173163	 Slc35f2	 solute	carrier	family	35,	member	F2	1398661_at	 3.09E---04	 2.57E---04	 11.808041	 Egflam	 EGF---like,	fibronectin	type	III	and	laminin	G	domains	1398716_at	 1.48E---05	 6.19E---06	 21.686409		 		
Rat	liver	zone	I	signature		 Probe	Set	ID	 Corrected	p---value	 p---value	 FCAbsolute	 Gene	Symbol	 Gene	Title	1367648_at	 1.66173E---05	 6.63638E---06	 3.6937318	Igfbp2	 insulin---like	growth	factor	binding	protein	2	1367794_at	 7.74949E---06	 2.83698E---06	 4.4454145	A2m///LOC10091	1545	 alpha---2---macroglobulin///alpha---2---macroglobulin---like	1367838_at	 8.74562E---12	 3.74218E---13	 2.0272317	Cth	 cystathionase	(cystathionine	gamma---lyase)	1367847_at	 0.0012359	 0.001152303	 2.2924562	Nupr1	 nuclear	protein,	transcriptional	regulator,	1	1367937_at	 0.000820913	 0.000694719	 2.981706	Miox	 myo---inositol	oxygenase	
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	 1368102_at	 0.000150731	 8.98176E---05	 4.1293287	Hsd11b2	 hydroxysteroid	11---beta	dehydrogenase	2	1368266_at	 4.59332E---12	 1.67427E---13	 2.094581	Arg1	 arginase,	liver	1368416_at	 0.000597629	 0.00047261	 3.279828	Ibsp	 integrin---binding	sialoprotein	1368426_at	 2.17058E---05	 9.11574E---06	 2.4443064	Crot	 carnitine	O---octanoyltransferase	1368453_at	 5.78058E---07	 1.43827E---07	 2.3285973	Fads2	 fatty	acid	desaturase	2	1368520_at	 7.22804E---06	 2.58881E---06	 2.0486774	Apoa4	 apolipoprotein	A---IV	1368720_at	 7.21106E---11	 4.57119E---12	 2.387428	Tdo2	 tryptophan	2,3---dioxygenase	1368729_a_at	 0.000574704	 0.000450838	 2.8171394	Adcyap1r1	 adenylate	cyclase	activating	polypeptide	1	receptor	1	1368778_at	 7.91622E---09	 9.66005E---10	 5.8277526	Slc6a6	 solute	carrier	family	6	(neurotransmitter	transporter,	taurine),	member	6	1369074_at	 2.50963E---12	 6.36356E---14	 3.1168466	Slc38a4	 solute	carrier	family	38,	member	4	1369126_at	 0.000226138	 0.000148011	 3.2452126	Ptgfr	 prostaglandin	F	receptor	1369195_at	 0.00073948	 0.000619944	 2.036656	Fabp2	 fatty	acid	binding	protein	2,	intestinal	1369455_at	 0.001096129	 0.000990165	 3.844251	Abcg5	 ATP---binding	cassette,	subfamily	G	(WHITE),	member	5	1369460_at	 1.72483E---07	 3.6902E---08	 2.955335	Slc7a2	 solute	carrier	family	7	(cationic	amino	acid	transporter,	y+	system),	member	2	1369864_a_at	 1.10558E---07	 2.26022E---08	 8.347958	Sds	 serine	dehydratase	1370053_at	 0.001354706	 0.001286005	 2.873849	Dlgap1	 discs,	large	(Drosophila)	homolog---associated	protein	1	1370080_at	 0.000710423	 0.000585071	 2.1743906	Hmox1	 heme	oxygenase	(decycling)	1	1370089_at	 0.001393068	 0.001333625	 2.4282	Ppargc1a	 peroxisome	proliferator---activated	receptor	gamma,	coactivator	1	alpha	1370241_at	 0.000397491	 0.000291661	 2.0246	Cyp2c7///LOC100	911552	 cytochrome	P450,	family	2,	subfamily	c,	polypeptide	7///cytochrome	P450	2C7---	like	1370374_at	 2.05418E---07	 4.59163E---08	 3.4965487	Steap3	 STEAP	family	member	3,	metalloreductase	1370375_at	 2.12564E---12	 5.05302E---14	 6.3545413	Gls2	 glutaminase	2	(liver,	mitochondrial)	1370964_at	 6.03146E---10	 4.6837E---11	 2.3260958	Ass1	 argininosuccinate	synthase	1	1371904_at	 6.086E---09	 7.04085E---10	 3.5865204	Smyd2	 SET	and	MYND	domain	containing	2	1371922_at	 9.10919E---05	 5.03821E---05	 5.8845096		 	1372715_at	 1.89667E---12	 3.90756E---14	 2.991027	Sfxn1	 sideroflexin	1	1372966_at	 0.000154644	 9.23944E---05	 2.5092628	Mfsd2a	 major	facilitator	superfamily	domain	containing	2A	1373146_at	 0.001057496	 0.000950238	 2.4072814	Ssx2ip	 synovial	sarcoma,	X	breakpoint	2	interacting	protein	1373386_at	 1.09026E---06	 2.92003E---07	 7.3849897	Gjb2	 gap	junction	protein,	beta	2	1373710_at	 1.92218E---12	 4.26474E---14	 3.2702208		 	1374140_at	 0.001511965	 0.001480815	 2.10401		 	1374176_at	 9.82265E---05	 5.49508E---05	 2.2728093	Lurap1l	 leucine	rich	adaptor	protein	1---like	1374204_at	 3.70403E---08	 6.1636E---09	 2.499544	Wsb1	 WD	repeat	and	SOCS	box---containing	1	1374249_at	 0.001119731	 0.001015033	 3.0191834	LOC100911963///	Syne4	 nesprin---4---like///spectrin	repeat	containing,	nuclear	envelope	family	member	4	1374307_at	 0.000139287	 8.1453E---05	 2.5931883		 	1374531_at	 4.90556E---07	 1.20501E---07	 3.9573247		 	1374635_at	 1.95688E---07	 4.34173E---08	 2.1834464		 	1374863_at	 0.000179461	 0.000111488	 4.4275994	Rbp7	 retinol	binding	protein	7,	cellular	1374883_at	 7.25906E---06	 2.63199E---06	 2.6764364	Mtmr7	 myotubularin	related	protein	7	1375615_at	 0.000329045	 0.000229967	 3.2495608	Ntrk1	 neurotrophic	tyrosine	kinase,	receptor,	type	1	1375781_at	 5.52611E---05	 2.6711E---05	 2.761816		 	1375845_at	 0.000168782	 0.000102981	 2.237519	Aig1	 androgen---induced	1	1375854_at	 9.96514E---09	 1.31079E---09	 2.5078256	Ctnnbip1	 catenin,	beta---interacting	protein	1	1376051_at	 9.81411E---08	 1.8975E---08	 7.632752	Cryl1	 crystallin,	lambda	1	1376082_at	 0.00089463	 0.000769864	 2.1529212	Mecom	 MDS1	and	EVI1	complex	locus	1376279_at	 0.000506009	 0.000387325	 3.6832664	Pop1	 processing	of	precursor	1,	ribonuclease	P/MRP	subunit	(S.	cerevisiae)	1376295_at	 0.001404824	 0.001352624	 3.0598922		 	1376427_a_at	 1.86094E---07	 4.09937E---08	 10.539987	Gldc	 glycine	dehydrogenase	(decarboxylating)	1376977_at	 1.73489E---08	 2.47909E---09	 4.811215	Ptger3	 prostaglandin	E	receptor	3	(subtype	EP3)	1377733_at	 2.55576E---08	 3.96933E---09	 2.4493504	Ctnnbip1	 catenin,	beta---interacting	protein	1	1377758_at	 9.23918E---13	 1.75705E---14	 6.0091925	Hsd17b13	 hydroxysteroid	(17---beta)	dehydrogenase	13	1383165_at	 1.50574E---09	 1.52721E---10	 9.436019	RGD1310209	 similar	to	KIAA1324	protein	1387052_at	 1.40303E---07	 2.91278E---08	 4.690243	Gpt	 glutamic---pyruvate	transaminase	(alanine	aminotransferase)	1387111_at	 0.000271484	 0.000183869	 3.143453	Ddah1	 dimethylarginine	dimethylaminohydrolase	1	1387196_at	 0.001161264	 0.001063725	 2.1306484	Khdrbs3	 KH	domain	containing,	RNA	binding,	signal	transduction	associated	3	1387215_at	 7.59049E---08	 1.41946E---08	 2.2417426	Agxt	 alanine---glyoxylate	aminotransferase	1387302_at	 0.000315352	 0.000217898	 2.636403	Adcyap1r1	 adenylate	cyclase	activating	polypeptide	1	receptor	1	1387307_at	 3.64818E---12	 1.15632E---13	 5.841219	Hal	 histidine	ammonia	lyase	1387396_at	 7.25906E---06	 2.63443E---06	 2.3939595	Hamp	 hepcidin	antimicrobial	peptide	1387470_at	 0.000111131	 6.30506E---05	 3.4535	Cldn1	 claudin	1	1387877_at	 1.45177E---09	 1.44947E---10	 2.0452023	Ftcd	 formiminotransferase	cyclodeaminase	1387901_at	 2.73387E---07	 6.36892E---08	 2.1149042	Ptprs	 protein	tyrosine	phosphatase,	receptor	type,	S	1387933_s_at	 0.001587569	 0.001587569	 2.1596723	Podxl	 podocalyxin---like	1387959_at	 1.1598E---09	 1.08444E---10	 5.032056	Aspg	 asparaginase	homolog	(S.	cerevisiae)	1388271_at	 0.001017392	 0.000910977	 2.1525948	Mt2A	 metallothionein	2A	1388753_at	 0.000316567	 0.000219239	 2.5514033	Sulf2	 sulfatase	2	1389066_at	 1.74545E---05	 6.99839E---06	 3.9805324	Rcan2	 regulator	of	calcineurin	2	1389486_at	 1.64391E---06	 4.63998E---07	 2.548056		 	1389876_at	 5.84277E---05	 2.85194E---05	 2.3595757	Camk2n1	 calcium/calmodulin---dependent	protein	kinase	II	inhibitor	1	1390507_at	 0.000667778	 0.000540784	 2.817059	Isg20	 interferon	stimulated	exonuclease	gene	20	1391981_at	 0.000227411	 0.000149335	 2.237152		 	1398348_at	 3.6198E---05	 1.62257E---05	 3.1626263		 	1398433_at	 0.000441785	 0.000330463	 4.2805495		 	1377968_at	 1.63146E---07	 3.43873E---08	 3.2775307		 	1378798_at	 0.000193149	 0.00012239	 3.2295156	Stox2	 storkhead	box	2	1378927_at	 9.88365E---12	 4.6516E---13	 2.6971712		 	1379076_at	 8.79281E---10	 7.6641E---11	 12.220338		 	1379334_at	 9.88365E---12	 4.72771E---13	 6.828374	Gldc	 glycine	dehydrogenase	(decarboxylating)	1379493_at	 0.0006172	 0.000492	 3.0510228		 	1379716_at	 2.01278E---05	 8.2531E---06	 2.3512921		 	1379812_at	 6.83998E---07	 1.75606E---07	 2.305712	Nnmt	 nicotinamide	N---methyltransferase	1379888_at	 8.7967E---11	 5.85518E---12	 8.185714	LOC100912602	 uncharacterized	LOC100912602	1380306_at	 0.000716983	 0.000594266	 4.746584		 	1380389_at	 4.03586E---08	 6.84369E---09	 7.093584		 	1380738_at	 0.000179461	 0.000111252	 2.0285673		 	1381238_at	 0.001120099	 0.001018917	 2.4229047		 	1381474_at	 0.001017392	 0.000909685	 3.6478584	Mbnl3	 muscleblind---like	splicing	regulator	3	1382410_at	 0.001172507	 0.001080163	 2.7802474	Cd209b	 CD209b	antigen	1382631_at	 0.001393166	 0.001337969	 4.38149		 	1383353_at	 2.46554E---06	 7.42398E---07	 2.9383965		 	1383472_at	 8.07149E---07	 2.09782E---07	 15.884483	Aldh1b1	 aldehyde	dehydrogenase	1	family,	member	B1	1383600_at	 0.000144762	 8.55727E---05	 4.7522774	Slc13a5	 solute	carrier	family	13	(sodium---dependent	citrate	transporter),	member	5	1383605_at	 8.74562E---12	 3.70956E---13	 2.1274457	LOC360919	 similar	to	alpha---fetoprotein	1383946_at	 7.16742E---09	 8.63271E---10	 3.5352538	Cldn1	 claudin	1	1384035_at	 0.000179194	 0.000110754	 8.594747		 	1384036_s_at	 0.000896455	 0.000772855	 3.8624878		 	1384086_at	 6.06165E---05	 2.9972E---05	 3.9952228		 	1384225_at	 0.000167329	 0.000101829	 3.2368116		 	1384226_at	 0.000719902	 0.000599832	 3.207952		 	1384510_at	 2.39828E---11	 1.36827E---12	 2.9424775		 	1385670_at	 1.22925E---05	 4.64022E---06	 4.530677	Sdsl	 serine	dehydratase---like	1385798_at	 0.000967704	 0.000851236	 2.9534197		 	1386379_at	 0.001151437	 0.001052899	 3.0645876		 	1386656_at	 1.24585E---08	 1.67824E---09	 5.2525334		 	1390765_at	 5.16104E---08	 9.01986E---09	 4.3436403	Wfdc2	 WAP	four---disulfide	core	domain	2	1391206_at	 9.61923E---05	 5.35079E---05	 4.8279605	RGD1311892	 similar	to	hypothetical	protein	FLJ10901	1391345_at	 0.001576065	 0.001566167	 3.1383886	Bmper	 BMP---binding	endothelial	regulator	1393241_at	 0.000644899	 0.000518168	 4.0441394	Prss32	 protease,	serine,	32	1393266_at	 0.001331721	 0.001257854	 3.1408734		 	1393831_at	 0.001578267	 0.001573264	 5.0113277		 	1393875_at	 6.83417E---07	 1.74374E---07	 2.6981573		 	1393917_at	 1.24257E---06	 3.36734E---07	 2.1066668	Cd163	 CD163	molecule	1394503_at	 0.000179539	 0.000111821	 5.45474		 	1395287_at	 0.000504905	 0.00038568	 3.4769726		 	
	 131	
	 1395518_at	 0.001404824	 0.001355845	 3.4780712		 	1395519_at	 0.00067553	 0.000548132	 2.1330464	MGC95152	 similar	to	B230212L03Rik	protein	1395536_at	 1.04164E---07	 2.06347E---08	 4.959911		 	1396028_at	 0.000121595	 6.99509E---05	 3.0576525		 	1396051_at	 0.00069082	 0.000564918	 2.0172832		 	1396136_at	 0.00025567	 0.000170581	 3.3224285		 	1396150_at	 1.29657E---06	 3.55477E---07	 3.0579352	Cldn1	 claudin	1	1396155_at	 0.000822243	 0.000697148	 3.6707249		 	1396467_at	 0.000338254	 0.000239083	 2.7516313		 	1396729_at	 0.001225822	 0.001140345	 2.658079	Fer1l5	 fer---1---like	5	(C.	elegans)	1397225_at	 2.29058E---05	 9.65602E---06	 3.5713804		 	1397740_at	 1.30614E---09	 1.26267E---10	 5.936366	Sfxn1	 sideroflexin	1		
Rat	liver	zone	III	signature		
Probe	Set	ID	 Corrected	p---value	 p---value	 FCAbsolute	 Gene	Symbol	 Gene	Title	
1367568_a_at	 9.23918E---13	 1.46884E---14	 30.590137	Mgp	 matrix	Gla	protein	
1367570_at	 2.33361E---05	 9.94835E---06	 5.567781	 Tagln	 transgelin	
1367574_at	 1.94916E---06	 5.65286E---07	 2.3459675	 Vim	 vimentin	
1367584_at	 6.59193E---05	 3.39521E---05	 2.8423278	 Anxa2	 annexin	A2	
1367614_at	 1.70066E---06	 4.85134E---07	 3.0449252	 Anxa1	 annexin	A1	
1367628_at	 0.000362706	 0.000260964	 2.4219353	 Lgals1	 lectin,	galactoside---binding,	soluble,	1	
1367631_at	 5.07698E---08	 8.77006E---09	 9.380143	 Ctgf	 connective	tissue	growth	factor	
1367632_at	 3.28169E---21	 1.56024E---23	 7.031913	 Glul	 glutamate---ammonia	ligase	
1367633_at	 6.79745E---24	 1.07725E---26	 14.239751	 Glul	 glutamate---ammonia	ligase	




















1367661_at	 0.000126516	 7.33831E---05	 3.4628007	 S100a6	 S100	calcium	binding	protein	A6	




1367679_at	 1.11585E---14	 1.06103E---16	 3.2851596	 Cd74	 Cd74	molecule,	major	histocompatibility	complex,	class	II	invariant	chain	
1367722_at	 6.68056E---05	 3.46203E---05	 2.0210023	 Dpp7	 dipeptidylpeptidase	7	
1367729_at	 5.20956E---09	 5.77922E---10	 3.5751574	 Oat	 ornithine	aminotransferase	
1367733_at	 1.80867E---08	 2.66571E---09	 7.8691754	 Ca2	 carbonic	anhydrase	2	
1367749_at	 1.76667E---05	 7.11149E---06	 8.093615	 Lum	 lumican	
1367765_at	 8.52364E---10	 7.15932E---11	 2.97117	 Tcn2	 transcobalamin	2	
1367806_at	 0.000196241	 0.000125022	 2.373126	 Gls	 glutaminase	
1367823_at	 6.08546E---07	 1.52378E---07	 4.3489704	 Timp2	 TIMP	metallopeptidase	inhibitor	2	
1367846_at	 0.000909124	 0.000790981	 3.7208025	 S100a4	 S100	calcium---binding	protein	A4	
1367866_at	 0.000932478	 0.000815733	 2.1600084	 Fbln5	 fibulin	5	
1367880_at	 2.01278E---05	 8.20105E---06	 2.3676596	 Lamb2	 laminin,	beta	2	
1367912_at	 2.01512E---10	 1.43709E---11	 2.7338285	 Ltbp1	 latent	transforming	growth	factor	beta	binding	protein	1	
1367940_at	 7.25906E---06	 2.62705E---06	 2.5055134	 Cxcr7	 chemokine	(C---X---C	motif)	receptor	7	
1367964_at	 2.38324E---05	 1.02355E---05	 2.187739	 Tnni2	 troponin	I	type	2	(skeletal,	fast)	
1367998_at	 1.30508E---07	 2.68875E---08	 7.9457197	 Slpi	 secretory	leukocyte	peptidase	inhibitor	





1368047_at	 9.04539E---11	 6.16405E---12	 9.068183	 Slc13a3	 solute	carrier	family	13	(sodium---dependent	dicarboxylate	transporter),	member	3	
1368105_at	 0.001493471	 0.001457968	 2.9996443	 Tspan2	 tetraspanin	2	
1368128_at	 0.001552682	 0.001532997	 2.276957	 Pla2g2a	 phospholipase	A2,	group	IIA	(platelets,	synovial	fluid)	
1368144_at	 0.000227411	 0.000149565	 3.8337867	 Rgs2	 regulator	of	G---protein	signaling	2	
1368167_at	 7.49475E---08	 1.38968E---08	 10.275245	 Ctse	 cathepsin	E	
1368171_at	 5.2349E---05	 2.52204E---05	 13.622135	 Lox	 lysyl	oxidase	
1368172_a_at	 0.000355849	 0.000254339	 8.14488	 Lox	 lysyl	oxidase	
1368191_a_at	 2.24155E---07	 5.07991E---08	 2.382594	 Slc22a1	 solute	carrier	family	22	(organic	cation	transporter),	member	1	
1368192_at	 0.000568558	 0.000445115	 2.2764735	 Cxcr3	 chemokine	(C---X---C	motif)	receptor	3	
1368207_at	 5.0228E---06	 1.69549E---06	 2.5181236	 Fxyd5	 FXYD	domain---containing	ion	transport	regulator	5	
1368281_at	 4.22341E---05	 1.96111E---05	 3.963022	 Dpep1	 dipeptidase	1	(renal)	
1368282_at	 4.04462E---05	 1.83963E---05	 3.5054543	 Dpep1	 dipeptidase	1	(renal)	
1368284_at	 2.3939E---05	 1.03192E---05	 3.3803117	 Plvap	 plasmalemma	vesicle	associated	protein	
1368290_at	 2.01278E---05	 8.26167E---06	 3.2573795	 Cyr61	 cysteine---rich,	angiogenic	inducer,	61	
1368293_at	 3.65151E---07	 8.79602E---08	 5.657552	 Cpz	 carboxypeptidase	Z	
1368320_at	 6.32103E---05	 3.17554E---05	 3.915199	 Ncam1	 neural	cell	adhesion	molecule	1	
1368358_a_at	 5.13918E---07	 1.27054E---07	 5.36159	 Ptprr	 protein	tyrosine	phosphatase,	receptor	type,	R	
1368369_at	 5.44668E---08	 9.66764E---09	 7.118615	 Pnoc	 prepronociceptin	
1368370_at	 4.40509E---05	 2.06546E---05	 2.9944942	 Adcy4	 adenylate	cyclase	4	
1368448_at	 5.69409E---09	 6.49722E---10	 13.023233	 Ltbp2	 latent	transforming	growth	factor	beta	binding	protein	2	
1368458_at	 2.45139E---07	 5.67199E---08	 9.099698	 Cyp7a1	 cytochrome	P450,	family	7,	subfamily	a,	polypeptide	1	




1368482_at	 4.40509E---05	 2.06641E---05	 3.561673	 Bcl2a1	 BCL2---related	protein	A1	
1368490_at	 7.91148E---05	 4.25038E---05	 2.0579531	 Cd14	 CD14	molecule	
1368533_at	 1.76596E---07	 3.86215E---08	 4.4054756	 Heph	 hephaestin	
1368604_at	 0.000193612	 0.00012304	 4.0279293	Mefv	 Mediterranean	fever	
1368637_at	 7.34765E---05	 3.88925E---05	 2.4678326	 Card9	 caspase	recruitment	domain	family,	member	9	
1368671_at	 0.000440803	 0.00032903	 2.4177887	 Srpx	 sushi---repeat---containing	protein,	X---linked	
1368754_at	 1.44134E---06	 3.99736E---07	 6.5009184	 P2ry6	 pyrimidinergic	receptor	P2Y,	G---protein	coupled,	6	
1368797_at	 9.08315E---05	 5.00153E---05	 5.207363	 Nr1i3	 nuclear	receptor	subfamily	1,	group	I,	member	3	
1368829_at	 1.81603E---06	 5.21143E---07	 2.1618636	 Fbn1	 fibrillin	1	
1368884_at	 0.0006954	 0.000569765	 3.62847	 Entpd1	 ectonucleoside	triphosphate	diphosphohydrolase	1	
1368885_at	 4.16707E---05	 1.90771E---05	 4.7927313		 	1368901_at	 2.38324E---05	 1.02168E---05	 3.1886022	 Thbd	 thrombomodulin	
1368921_a_at	 0.000374101	 0.000271534	 2.3644216	 Cd44	 Cd44	molecule	
1368926_at	 6.11053E---06	 2.11371E---06	 3.282264	 Sema4f	
sema	domain,	immunoglobulin	domain	(Ig),	transmembrane	domain	(TM)	and	short		
cytoplasmic	domain,	(semaphorin)	4F	
1368991_at	 4.99317E---06	 1.66967E---06	 2.1962628	 Smpd3	 sphingomyelin	phosphodiesterase	3,	neutral	membrane	
1369105_a_at	 8.92814E---05	 4.87623E---05	 5.16415	 Pkib	 protein	kinase	(cAMP---dependent,	catalytic)	inhibitor	beta	
1369146_a_at	 2.05418E---07	 4.62272E---08	 2.7706332	 Ahr	 aryl	hydrocarbon	receptor	
1369214_a_at	 0.000279071	 0.000189733	 3.4900792	 Ciita	 class	II,	major	histocompatibility	complex,	transactivator	
1369264_at	 0.000420854	 0.000310805	 3.405944	 Cyp21a1	 cytochrome	P450,	family	21,	subfamily	a,	polypeptide	1	
1369518_at	 0.001199546	 0.00111286	 2.9583325	 Pik3r3	 phosphoinositide---3---kinase,	regulatory	subunit	3	(gamma)	
1369527_at	 0.000107282	 6.05266E---05	 4.3797193	 Cx3cr1	 chemokine	(C---X3---C	motif)	receptor	1	
1369547_at	 0.000582596	 0.000458875	 3.2385366	 Serpinb7	 serpin	peptidase	inhibitor,	clade	B	(ovalbumin),	member	7	
1369625_at	 3.63063E---06	 1.13925E---06	 3.5069585	 Aqp1	 aquaporin	1	
1369693_a_at	 1.08375E---15	 8.58754E---18	 72.1144	 Slc1a2	 solute	carrier	family	1	(glial	high	affinity	glutamate	transporter),	member	2	
1369694_at	 3.9195E---12	 1.30443E---13	 14.504282	 Slc1a2	 solute	carrier	family	1	(glial	high	affinity	glutamate	transporter),	member	2	
1369732_a_at	 0.000156451	 9.37217E---05	 2.6942098	 St3gal2	 ST3	beta---galactoside	alpha---2,3---sialyltransferase	2	
1369736_at	 7.65559E---05	 4.08864E---05	 3.722521	 Emp1	 epithelial	membrane	protein	1	
1369837_at	 4.59332E---12	 1.60623E---13	 2.9848118	 Gulo	 gulonolactone	(L---)	oxidase	
1369921_at	 8.81628E---05	 4.7784E---05	 4.600448	 Gstm3	 glutathione	S---transferase	mu	3	
1369926_at	 7.04586E---10	 5.58309E---11	 2.9906623	 Gpx3	 glutathione	peroxidase	3	




1369964_at	 0.000176268	 0.000108387	 3.0173218	 Coro1a	 coronin,	actin	binding	protein	1A	
1369968_at	 2.23679E---08	 3.40944E---09	 3.0142543	 Ptn	 pleiotrophin	
1370018_at	 0.0012359	 0.001153637	 2.380999	 Hspb2	 heat	shock	protein	beta	2	















1370154_at	 5.56683E---10	 4.23467E---11	 2.6449745	 Lyz2	 lysozyme	2	




1370156_at	 2.10561E---06	 6.24009E---07	 3.1348898	 Prnp	 prion	protein	
1370236_at	 3.11932E---08	 5.09176E---09	 2.0483217	 Ppt1	 palmitoyl---protein	thioesterase	1	
1370247_a_at	 6.34757E---05	 3.20899E---05	 2.4112895	 Pmp22	 peripheral	myelin	protein	22	
1370269_at	 0.000190061	 0.00011988	 6.705091	 Cyp1a1	 cytochrome	P450,	family	1,	subfamily	a,	polypeptide	1	
1370282_at	 3.95984E---06	 1.2802E---06	 3.1376367	 Csrp2	 cysteine	and	glycine---rich	protein	2	
1370291_at	 0.000710536	 0.000586671	 2.0945866	 Pdlim3	 PDZ	and	LIM	domain	3	
1370301_at	 0.000689134	 0.000560263	 2.7007055	Mmp2	 matrix	metallopeptidase	2	
1370312_at	 1.50188E---05	 5.879E---06	 3.2338943	 Spon1	 spondin	1,	extracellular	matrix	protein	
1370328_at	 1.06603E---07	 2.12868E---08	 3.4779558	 Dkk3	 dickkopf	WNT	signaling	pathway	inhibitor	3	
1370382_at	 2.06701E---06	 6.06016E---07	 6.919508	 RT1---Db1	 RT1	class	II,	locus	Db1	
1370383_s_at	 3.22697E---12	 8.69389E---14	 6.4288993	 RT1---Db1	 RT1	class	II,	locus	Db1	
1370389_at	 8.81628E---05	 4.77459E---05	 4.1359377	 Gpm6b	 glycoprotein	m6b	
1370423_at	 0.001136775	 0.00103769	 2.9050167	 Gna15	 guanine	nucleotide	binding	protein,	alpha	15	
1370433_at	 0.000126089	 7.29361E---05	 2.1174026	 Hsd3b7	 hydroxy---delta---5---steroid	dehydrogenase,	3	beta---	and	steroid	delta---isomerase	7	
1370436_at	 0.001393068	 0.001332405	 3.7552779	 Acsm2a	 acyl---CoA	synthetase	medium---chain	family	member	2A	
1370454_at	 6.61226E---05	 3.41616E---05	 2.411264	 Homer1	 homer	homolog	1	(Drosophila)	
1370476_at	 0.001350926	 0.001280276	 2.149745	 Stambp	 Stam	binding	protein	
1370538_at	 6.22077E---06	 2.17875E---06	 4.3305287	 Lama3	 laminin,	alpha	3	
1370603_a_at	 0.000105991	 5.96303E---05	 2.0525808	 Ptprc	 protein	tyrosine	phosphatase,	receptor	type,	C	
1370740_at	 6.09329E---05	 3.0225E---05	 4.257574	 Klra5	 killer	cell	lectin---like	receptor,	subfamily	A,	member	5	
1370822_at	 0.000467894	 0.000353701	 3.918141	 RT1---Ba	 RT1	class	II,	locus	Ba	
1370834_at	 0.000184392	 0.00011572	 5.4341273	 Hs3st1	 heparan	sulfate	(glucosamine)	3---O---sulfotransferase	1	
1370855_at	 1.43486E---09	 1.40985E---10	 2.8090081	 Cst3	 cystatin	C	
1370857_at	 2.01849E---05	 8.31706E---06	 3.7574267	 Acta2	 smooth	muscle	alpha---actin	
1370864_at	 9.23918E---13	 1.62935E---14	 47.731823	 Col1a1	 collagen,	type	I,	alpha	1	
1370883_at	 9.23918E---13	 1.67924E---14	 5.1444645	 RT1---Da	 RT1	class	II,	locus	Da	
1370887_at	 1.15486E---05	 4.33757E---06	 3.1824303	 Tgfb1i1	 transforming	growth	factor	beta	1	induced	transcript	1	
1370895_at	 0.000955865	 0.000837707	 2.1287818	 Col5a2	 collagen,	type	V,	alpha	2	
1370896_a_at	 1.27236E---05	 4.87971E---06	 3.7565975	Myh11	 myosin,	heavy	chain	11,	smooth	muscle	




1370956_at	 0.000117163	 6.66584E---05	 4.812715	 Dcn	 decorin	
1370959_at	 9.94529E---12	 5.08309E---13	 2.467053	 Col3a1	 collagen,	type	III,	alpha	1	
1370962_at	 0.000409884	 0.000301405	 2.7735686	 Parm1	 prostate	androgen---regulated	mucin---like	protein	1	





1371247_at	 4.87213E---06	 1.61375E---06	 4.9732723	 Tnnt3	 troponin	T	type	3	(skeletal,	fast)	
1371349_at	 8.4315E---09	 1.04225E---09	 2.9132755	 Col6a1	 collagen,	type	VI,	alpha	1	
1371360_at	 7.60714E---05	 4.05071E---05	 3.0052998	 Ndrg1	 N---myc	downstream	regulated	1	
1371369_at	 4.70516E---05	 2.237E---05	 4.2548704	 Col6a2	 collagen,	type	VI,	alpha	2	
1371382_at	 0.000718012	 0.000596257	 2.242717	 Flna	 filamin	A,	alpha	
1371406_at	 4.01046E---05	 1.81774E---05	 2.5902507		 	1371414_at	 2.53188E---11	 1.48462E---12	 4.883963	 Gsn	 gelsolin	
1371441_at	 3.40418E---06	 1.06279E---06	 2.0579555	 Pea15	 phosphoprotein	enriched	in	astrocytes	15	
1371447_at	 2.85291E---05	 1.25239E---05	 2.1467342	 Plac8	 placenta---specific	8	
1371527_at	 6.12918E---06	 2.13696E---06	 3.286014	 Emp1	 epithelial	membrane	protein	1	
1371575_at	 5.06475E---05	 2.4274E---05	 2.0098178	Msn	 moesin	




1371703_at	 8.79281E---10	 7.54291E---11	 4.1900077	 Ahnak	 AHNAK	nucleoprotein	
1371937_at	 6.70572E---05	 3.49633E---05	 2.5508134	 RGD1562618	 similar	to	RIKEN	cDNA	6030419C18	gene	
1371951_at	 5.92163E---05	 2.9092E---05	 3.922168	 Fhl2	 four	and	a	half	LIM	domains	2	
1372006_at	 9.72034E---05	 5.42244E---05	 2.249812		 	1372015_at	 0.000320817	 0.000223199	 2.4218733	 Tacc1	 transforming,	acidic	coiled---coil	containing	protein	1	
1372016_at	 0.001298241	 0.001218001	 3.3958225	 Gadd45b	 growth	arrest	and	DNA---damage---inducible,	beta	
1372055_at	 2.07047E---05	 8.59689E---06	 2.3032584		 	1372064_at	 5.39285E---09	 6.06803E---10	 3.41978	 Cxcl16	 chemokine	(C---X---C	motif)	ligand	16	
1372097_at	 2.94548E---07	 7.00194E---08	 4.3218775		 	1372107_at	 3.3612E---05	 1.4915E---05	 3.3110003	 Fhl1	 four	and	a	half	LIM	domains	1	
1372110_at	 0.000842045	 0.000719275	 3.380638		 	1372111_at	 6.34757E---05	 3.2035E---05	 5.7374754	 Cav1	 caveolin	1,	caveolae	protein	
1372168_s_at	 4.16707E---05	 1.90853E---05	 3.0117838	 Igfbp6	 insulin---like	growth	factor	binding	protein	6	
1372219_at	 1.1153E---11	 6.00956E---13	 14.144561	 Tpm2	 tropomyosin	2,	beta	
1372256_at	 0.000108093	 6.11556E---05	 2.5870664	 Crip1	 cysteine---rich	protein	1	(intestinal)	





1372301_at	 6.86902E---08	 1.25188E---08	 7.721273	 Aebp1	 AE	binding	protein	1	
1372440_at	 2.33773E---07	 5.3349E---08	 2.2202873	 Serpine2	
serpin	peptidase	inhibitor,	clade	E	(nexin,	plasminogen	activator	inhibitor	type	1),	
member	2	
1372449_at	 0.000214917	 0.000139645	 2.9540925	 Slc8a1	 solute	carrier	family	8	(sodium/calcium	exchanger),	member	1	
1372481_at	 1.86301E---11	 1.03337E---12	 15.638624		 	1372516_at	 0.00074393	 0.000624854	 2.4959576	 Kif22	 kinesin	family	member	22	
1372518_at	 0.001366399	 0.00129927	 2.5174825	 Fbln1	 fibulin	1	
1372521_at	 7.19362E---06	 2.56508E---06	 2.1323028	 Rnd2	 Rho	family	GTPase	2	
1372539_at	 2.23679E---08	 3.43848E---09	 10.870731		 	1372615_at	 1.22542E---09	 1.16521E---10	 17.58193	 Aoc3	 amine	oxidase,	copper	containing	3	
1372729_at	 7.68429E---08	 1.46135E---08	 6.118515	 Procr	 protein	C	receptor,	endothelial	
1372750_at	 1.98688E---05	 8.03733E---06	 5.862038		 	1372897_at	 0.000200236	 0.000127884	 3.0137339	 Plod2	 procollagen	lysine,	2---oxoglutarate	5---dioxygenase	2	
1372926_at	 0.000566504	 0.000442609	 3.2090514		 	1372935_at	 0.000367721	 0.000265738	 3.3936296	 Tmem119	 transmembrane	protein	119	
1372980_at	 2.83883E---06	 8.77294E---07	 2.748683	 Tspan33	 tetraspanin	33	
1373000_at	 2.7749E---07	 6.50848E---08	 11.171035	 Srpx2	 sushi---repeat---containing	protein,	X---linked	2	
1373267_at	 0.000538036	 0.000416957	 2.1065607	 Sh3yl1	 SH3	domain	containing,	Ysc84---like	1	(S.	cerevisiae)	
1373286_at	 0.00146993	 0.001430328	 2.9702616	 Fblim1	 filamin	binding	LIM	protein	1	
1373401_at	 7.87593E---06	 2.89575E---06	 7.614543	 Tnc	 tenascin	C	
1373463_at	 5.0228E---06	 1.69013E---06	 2.9158478	 Col5a2	 collagen,	type	V,	alpha	2	
1373504_at	 0.000559733	 0.000435545	 2.1544402	 Glipr1	 GLI	pathogenesis---related	1	
1373544_at	 0.00069082	 0.000564047	 2.4786491	 Cxcl9	 chemokine	(C---X---C	motif)	ligand	9	
1373615_at	 2.41091E---05	 1.04307E---05	 3.156928	 Frzb	 frizzled---related	protein	
1373651_at	 7.84099E---05	 4.20008E---05	 5.9315524		 	1373734_at	 0.000187997	 0.00011828	 3.361332		 	1373839_at	 8.76099E---06	 3.23504E---06	 7.8314867		 	1373882_at	 1.9092E---08	 2.84414E---09	 10.278648		 	1373908_at	 6.42547E---07	 1.62928E---07	 11.04327		 	1373928_at	 0.000283179	 0.000192975	 5.3121576	 Il17re	 interleukin	17	receptor	E	
1373935_at	 0.000493867	 0.000375684	 2.1039338	 Pold2	 polymerase	(DNA	directed),	delta	2,	accessory	subunit	
1374142_at	 1.2901E---08	 1.75829E---09	 15.159431	 Prr15	 proline	rich	15	
1374172_at	 0.001172507	 0.001081457	 3.6418538	 Col8a2	 collagen,	type	VIII,	alpha	2	
1374237_at	 9.74577E---07	 2.57931E---07	 6.182794	 Lmod1	 leiomodin	1	(smooth	muscle)	
1374265_at	 9.65631E---09	 1.25486E---09	 4.750055		 	1374298_at	 8.92814E---05	 4.88147E---05	 5.813765		 	1374774_at	 0.000450689	 0.000338553	 3.4809675		 	1374818_at	 0.001576065	 0.001567231	 2.3610883	 Nxph3	 neurexophilin	3	
1374830_at	 0.000532796	 0.000412051	 2.6066055	 Ccdc3	 coiled---coil	domain	containing	3	
1374969_at	 3.88938E---06	 1.2451E---06	 2.8820775		 	1375014_at	 0.000362655	 0.000260353	 3.7106023	 Arl4c	 ADP---ribosylation	factor---like	4C	
1375026_at	 2.31259E---05	 9.8221E---06	 3.1402228	 Calml4	 calmodulin---like	4	
1375043_at	 0.000844281	 0.000722523	 3.9040523		 	1375138_at	 0.000465836	 0.000350669	 2.5476942	 Timp3	 TIMP	metallopeptidase	inhibitor	3	
	 133	
	
1375144_at	 6.11053E---06	 2.12077E---06	 2.6039722		 	1375170_at	 3.41823E---12	 1.02926E---13	 7.8860073	 S100a11	 S100	calcium	binding	protein	A11	
1375267_at	 9.08315E---05	 5.00941E---05	 4.8477945	 Ppic	 peptidylprolyl	isomerase	C	
1375633_at	 0.001413522	 0.00136648	 2.00457	 Clic1	 chloride	intracellular	channel	1	
1375726_at	 0.000971262	 0.000861975	 2.1619089	 Lmo7	 LIM	domain	7	
1375739_at	 0.000300149	 0.000206441	 2.0188825	 Ehd4	 EH---domain	containing	4	
1375857_at	 0.000931598	 0.000813487	 2.7843993	Myof	 myoferlin	
1375862_at	 0.000210971	 0.000136078	 2.587309	 Pxdn	 peroxidasin	homolog	(Drosophila)	
1375945_at	 0.001120099	 0.001018496	 2.8157635	 Plxdc2	 plexin	domain	containing	2	
1375959_at	 1.55435E---05	 6.10903E---06	 3.2381563	 Nkd1	 naked	cuticle	homolog	1	(Drosophila)	
1375961_at	 5.16104E---08	 9.07886E---09	 4.1456947	 Frzb	 frizzled---related	protein	
1376110_at	 2.71987E---06	 8.3622E---07	 3.7979505	 Rpp25	 ribonuclease	P/MRP	25	subunit	
1376218_a_at	 0.001393068	 0.001335667	 2.1709888	 LOC685152	 ATPase,	class	I,	type	8B,	member	2	
1376287_at	 0.000166161	 0.000100065	 5.235001	 Capn13	 calpain	13	
1376394_at	 1.29284E---10	 9.01504E---12	 15.328652	 Clec9a	 C---type	lectin	domain	family	9,	member	A	
1376398_at	 0.000531034	 0.000409847	 3.4356234	 Synpo2	 synaptopodin	2	
1376457_at	 0.000484099	 0.000367486	 3.2282748	 Crispld2	 cysteine---rich	secretory	protein	LCCL	domain	containing	2	
1376481_at	 0.000969097	 0.00085645	 2.8673854	 Adamts9	 ADAM	metallopeptidase	with	thrombospondin	type	1	motif,	9	
1376617_at	 2.22959E---09	 2.43806E---10	 5.2372785		 	1376632_at	 5.94498E---05	 2.93009E---05	 2.1659467	 Lmcd1	 LIM	and	cysteine---rich	domains	1	




1376750_at	 0.000340752	 0.000241388	 2.7029169		 	1376816_at	 9.5179E---05	 5.27934E---05	 5.1691785		 	1376818_at	 0.000231435	 0.000152578	 2.9976008	Wtip	 Wilms	tumor	1	interacting	protein	
1376895_at	 0.000285696	 0.000195548	 3.1649199	 Il16	 interleukin	16	
1376897_at	 4.3964E---06	 1.44224E---06	 6.6599474	 Kif26b	 kinesin	family	member	26B	
1376905_at	 2.77161E---05	 1.2123E---05	 4.555384		 	1376937_at	 0.000258157	 0.00017265	 2.1764693	 Filip1l	 filamin	A	interacting	protein	1---like	
1376943_at	 0.000362404	 0.000259598	 2.778507	 LOC100910940	 protein	EVI2B---like	
1377001_at	 0.000967704	 0.000852684	 3.980909	 Nrcam	 neuronal	cell	adhesion	molecule	
1377034_at	 9.92795E---07	 2.64326E---07	 6.885087	 Serpinb1a	 serine	(or	cysteine)	proteinase	inhibitor,	clade	B,	member	1a	
1377091_at	 0.000239224	 0.000158995	 2.9769216	 Prrt1	 proline---rich	transmembrane	protein	1	
1377161_at	 5.90297E---05	 2.89068E---05	 6.0779376		 	1377177_at	 0.000285696	 0.000195595	 3.3277717	 Irx1	 iroquois	homeobox	1	
1377182_at	 0.00082633	 0.000701922	 2.948495	 Itgb3bp	 integrin	beta	3	binding	protein	(beta3---endonexin)	
1377267_at	 0.001170068	 0.001073644	 2.0916424	Magee1	 melanoma	antigen,	family	E,	1	
1377334_at	 0.000214673	 0.000139146	 4.922169	 RT1---Ba	 RT1	class	II,	locus	Ba	
1377369_at	 0.000193149	 0.00012244	 2.1617262	 Cybrd1	 cytochrome	b	reductase	1	
1377423_at	 0.000971262	 0.000860987	 2.13079		 	1379492_at	 5.06475E---05	 2.43204E---05	 3.2367957		 	1379936_at	 3.6198E---05	 1.62346E---05	 4.833004		 	1381464_at	 0.000909124	 0.000789159	 4.101349	 Tbx3	 T---box	3	
1381504_at	 1.48505E---05	 5.78956E---06	 5.3469934	 Aspn	 asporin	
1383017_at	 7.27076E---05	 3.81398E---05	 2.012063	 Ptprm	 protein	tyrosine	phosphatase,	receptor	type,	M	
1383058_at	 0.000235283	 0.000155861	 3.7698		 	1383263_at	 1.22925E---05	 4.65596E---06	 2.9274406	 LOC100910855///O	
gn	
mimecan---like///osteoglycin	
1383322_at	 0.001322317	 0.00124478	 2.8262334	 Rasl11b	 RAS---like	family	11	member	B	

















1385354_at	 0.000184344	 0.000115398	 2.6651628	 Itga8	 integrin,	alpha	8	




1386865_at	 3.03758E---07	 7.26901E---08	 4.9240646	 Sparcl1	 SPARC---like	1	(hevin)	
1386870_at	 7.14238E---23	 2.26383E---25	 9.579763	 Glul	 glutamate---ammonia	ligase	
1386881_at	 9.88365E---12	 4.85568E---13	 2.2923703	 Igfbp3	 insulin---like	growth	factor	binding	protein	3	
1386911_at	 0.001537545	 0.001513178	 2.9552596	 Atp1a2	 ATPase,	Na+/K+	transporting,	alpha	2	polypeptide	
1386921_at	 8.07226E---10	 6.65225E---11	 21.6365	 Cpe	 carboxypeptidase	E	
1386922_at	 2.42886E---07	 5.58137E---08	 5.4277296	 Ca2	 carbonic	anhydrase	2	
1386940_at	 0.000610862	 0.000485011	 2.0748522	 Timp2	 TIMP	metallopeptidase	inhibitor	2	
1386965_at	 6.1217E---07	 1.54255E---07	 5.4441376	 Lpl	 lipoprotein	lipase	
1387053_at	 8.05679E---10	 6.51183E---11	 6.8947177	 Fmo1	 flavin	containing	monooxygenase	1	
1387074_at	 7.33096E---05	 3.8688E---05	 2.4041564	 Rgs2	 regulator	of	G---protein	signaling	2	
1387135_at	 0.000132987	 7.7558E---05	 2.6292737	 Adam15	 ADAM	metallopeptidase	domain	15	
1387146_a_at	 1.04796E---08	 1.39507E---09	 3.2032824	 Ednrb	 endothelin	receptor	type	B	
1387184_at	 6.44803E---09	 7.56187E---10	 4.711103	 Axin2	 axin	2	
1387232_at	 2.7647E---08	 4.33764E---09	 8.973679	 Bmp4	 bone	morphogenetic	protein	4	
1387348_at	 0.001346999	 0.001274419	 2.9215627	 Igfbp5	 insulin---like	growth	factor	binding	protein	5	
1387351_at	 4.21532E---05	 1.944E---05	 2.52121	 Fbn1	 fibrillin	1	
1387581_at	 3.94419E---08	 6.62574E---09	 9.810616	 Rassf9	 Ras	association	(RalGDS/AF---6)	domain	family	(N---terminal)	member	9	
1387616_at	 0.000704222	 0.00057811	 3.4130201	 Pdgfc	 platelet	derived	growth	factor	C	
1387651_at	 0.000371942	 0.000269378	 2.4839175	 Aqp1	 aquaporin	1	
1387725_at	 9.88365E---12	 4.57845E---13	 2.7208862	 Gulo	 gulonolactone	(L---)	oxidase	
1387819_at	 2.78724E---07	 6.5816E---08	 7.7816772	 Cela1	 chymotrypsin---like	elastase	family,	member	1	




1387922_at	 0.000440803	 0.000328475	 3.643623	 Crispld2	 cysteine---rich	secretory	protein	LCCL	domain	containing	2	
1387925_at	 0.000506366	 0.000388401	 3.5533633	 Asns	 asparagine	synthetase	(glutamine---hydrolyzing)	
1387952_a_at	 6.70572E---05	 3.49393E---05	 2.554428	 Cd44	 Cd44	molecule	
1388014_at	 1.03848E---07	 2.04074E---08	 16.181425	 Obp1f	 odorant	binding	protein	I	f	
1388111_at	 5.08557E---14	 6.44763E---16	 23.46591	 Eln	 elastin	
1388112_at	 0.000783254	 0.000660366	 2.2467024	 Slc25a4	
solute	carrier	family	25	(mitochondrial	carrier;	adenine	nucleotide	translocator),	
member	4	
1388116_at	 1.83823E---14	 2.03924E---16	 13.399812	 Col1a1	 collagen,	type	I,	alpha	1	
1388131_at	 3.07579E---08	 4.97196E---09	 13.104549	 Tubb2b	 tubulin,	beta	2B	class	IIb	
1388142_at	 0.000925674	 0.000806848	 4.29704	 Vcan	 versican	
1388145_at	 6.85645E---05	 3.58578E---05	 2.9667175	 Tnxb	 tenascin	XB	
1388146_at	 1.08375E---15	 7.99359E---18	 45.85238	 LOC100912222	 uncharacterized	LOC100912222	
1388312_at	 0.001393068	 0.001330802	 2.1300669		 	1388427_at	 0.000167329	 0.000101703	 3.6383202	Mxra8	 matrix---remodelling	associated	8	
1388557_at	 9.26937E---10	 8.22639E---11	 27.796534	 C7///Tubb4b	 complement	component	7///tubulin,	beta	4B	class	IVb	
1388673_at	 7.68429E---08	 1.46031E---08	 4.866844	 Lsp1	 lymphocyte---specific	protein	1	
1388763_at	 2.11693E---05	 8.82333E---06	 2.0544763		 	1388786_at	 0.000728351	 0.000608493	 2.2497241		 	1388879_at	 9.25868E---09	 1.17384E---09	 2.8467658	 Abi3bp	 ABI	family,	member	3	(NESH)	binding	protein	
1388936_at	 0.000969097	 0.000856983	 3.0707588	 Cdh11	 cadherin	11	
1388955_at	 2.50849E---06	 7.60606E---07	 3.2211163		 	1389020_at	 0.001571732	 0.001554296	 2.1612043	 LOC686539	 similar	to	immunoglobulin	superfamily	containing	leucine---rich	repeat	
1389092_at	 0.001172507	 0.001078411	 2.293468	 Il2rg	 interleukin	2	receptor,	gamma	
1389112_at	 7.174E---08	 1.31883E---08	 2.886483	 Nkd1	 naked	cuticle	homolog	1	(Drosophila)	
1389185_at	 9.08315E---05	 5.00399E---05	 3.0755537	 Ak1	 adenylate	kinase	1	
1389210_at	 1.73631E---07	 3.74228E---08	 3.79275	 Lcp1	 lymphocyte	cytosolic	protein	1	
1389234_at	 8.20406E---11	 5.33069E---12	 51.40059	 Vwf	 von	Willebrand	factor	
1389250_at	 0.000467894	 0.000353251	 2.5476272		 	1389253_at	 7.5239E---05	 3.99446E---05	 7.4233227	 Vnn1	 vanin	1	
1389413_at	 0.000345252	 0.00024567	 4.6462426	 Evi2a	 ecotropic	viral	integration	site	2A	
1389512_at	 2.03509E---05	 8.41773E---06	 3.008208		 	1389533_at	 6.70754E---09	 7.97252E---10	 9.41373	 Fbln2	 fibulin	2	
1389568_at	 1.56903E---05	 6.21644E---06	 3.341711	 Calhm2	 calcium	homeostasis	modulator	2	
1389586_at	 2.07244E---06	 6.10893E---07	 2.422569		 	
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1389611_at	 8.92768E---05	 4.85292E---05	 5.3722205	 Vldlr	 very	low	density	lipoprotein	receptor	
1389698_at	 0.000908751	 0.000786336	 2.712509		 	1389836_a_at	 0.000144288	 8.50639E---05	 2.394913	 Timp3	 TIMP	metallopeptidase	inhibitor	3	
1389873_at	 4.96222E---06	 1.65145E---06	 2.1449242	 Pycard	 PYD	and	CARD	domain	containing	
1389966_at	 0.001067442	 0.000960867	 4.1509485	 Col6a3	 collagen,	type	VI,	alpha	3	
1390227_at	 1.39587E---05	 5.37552E---06	 13.328595	 Pcp4l1	 Purkinje	cell	protein	4---like	1	
1390250_x_at	 0.000167329	 0.000101518	 2.5900576	 LOC685152	 ATPase,	class	I,	type	8B,	member	2	
1390306_at	 0.00011858	 6.76528E---05	 2.4352193	 LOC100912470	 uncharacterized	LOC100912470	





1390429_at	 3.79316E---06	 1.20828E---06	 2.5057359		 	1390450_a_at	 0.000865805	 0.000742315	 2.942699	 LOC100910855///O	
gn	
mimecan---like///osteoglycin	
1390472_at	 0.000301373	 0.000207761	 4.1313148	 Naaa	 N---acylethanolamine	acid	amidase	
1390506_at	 0.00069082	 0.000563582	 2.0670316	Med1	 mediator	complex	subunit	1	
1390532_at	 4.71264E---07	 1.15015E---07	 3.104424	 Slc13a4	 solute	carrier	family	13	(sodium/sulfate	symporters),	member	4	
1390533_at	 4.21532E---05	 1.95067E---05	 2.6234598	 LOC691920	 similar	to	kinesin---like	motor	protein	C20orf23	
1390547_at	 0.00144634	 0.00140279	 4.531088		 	1390632_at	 2.93854E---08	 4.65696E---09	 2.8503778		 	1390687_at	 0.000376569	 0.000274519	 2.0481522	 Plek	 pleckstrin	
1390707_at	 1.09196E---07	 2.21507E---08	 3.7147343	 Rgs10	 regulator	of	G---protein	signaling	10	
1392407_at	 0.000353912	 0.000252394	 4.275584	 Arhgap30	 Rho	GTPase	activating	protein	30	













1398286_at	 1.84241E---09	 1.95628E---10	 5.0844216	 Csad	 cysteine	sulfinic	acid	decarboxylase	
1398347_at	 0.000719902	 0.000600108	 2.1893353	 Axl	 Axl	receptor	tyrosine	kinase	
1398350_at	 2.50849E---06	 7.63281E---07	 3.2989917	 Basp1	 brain	abundant,	membrane	attached	signal	protein	1	
1398373_at	 1.48373E---05	 5.73741E---06	 5.828922	 B3galnt1	 beta---1,3---N---acetylgalactosaminyltransferase	1	(globoside	blood	group)	
1398390_at	 1.58501E---09	 1.63274E---10	 26.053364	 Cxcl13	 chemokine	(C---X---C	motif)	ligand	13	
1377546_at	 0.000262835	 0.000176612	 5.388679		 	1377761_at	 0.000164379	 9.87316E---05	 2.8196638	 Gfpt2	 glutamine---fructose---6---phosphate	transaminase	2	
1377795_at	 0.001576065	 0.001568572	 3.8781815		 	1377882_at	 2.14273E---05	 8.96485E---06	 4.0582356	 Flt3	 fms---related	tyrosine	kinase	3	
1377994_at	 0.000132943	 7.7322E---05	 3.7058427		 	1378213_at	 1.19816E---06	 3.22801E---07	 4.415251		 	1378258_at	 6.21111E---05	 3.09079E---05	 3.926266		 	1378396_at	 0.001034686	 0.000928102	 2.0818934		 	1378418_at	 5.6177E---05	 2.72427E---05	 2.3754206	 Tifab	 TRAF---interacting	protein	with	forkhead---associated	domain,	family	member	B	
1378443_at	 0.000166675	 0.000100639	 3.6071358	 Slamf9	 SLAM	family	member	9	
1378645_at	 0.000450251	 0.00033751	 5.1012154		 	1378699_at	 9.94529E---12	 5.20118E---13	 11.548689	 Pkhd1l1	 polycystic	kidney	and	hepatic	disease	1---like	1	
1378780_at	 0.001583329	 0.00158082	 2.451916		 	1378916_at	 5.85478E---06	 2.00417E---06	 2.1797583		 	1379008_at	 0.001526866	 0.001500248	 2.8380694		 	1379022_at	 0.001176903	 0.001087376	 3.4669268	 Adamts8	 ADAM	metallopeptidase	with	thrombospondin	type	1	motif,	8	
1379381_at	 1.64391E---06	 4.66339E---07	 4.5342946	 Ciita	 class	II,	major	histocompatibility	complex,	transactivator	
1379541_at	 0.000269256	 0.000181353	 2.9466634		 	1379625_at	 0.000665379	 0.000537786	 2.5378683	 Zc2hc1a	 zinc	finger,	C2HC---type	containing	1A	
1379633_a_at	 7.46411E---07	 1.92813E---07	 2.0026662	 Uba7	 ubiquitin---like	modifier	activating	enzyme	7	
1379639_at	 0.000728351	 0.00060946	 2.6838512		 	1379656_a_at	 0.001199546	 0.001114	 2.9362245	 Coro2a	 coronin,	actin	binding	protein	2A	
1379742_at	 6.8391E---06	 2.41699E---06	 2.1034894	 Sp100	 SP100	nuclear	antigen	
1379785_at	 0.000119324	 6.84555E---05	 2.7587144	 Slc1a4	 solute	carrier	family	1	(glutamate/neutral	amino	acid	transporter),	member	4	
1380017_at	 0.001007488	 0.000898916	 2.034759		 	1380063_at	 0.000836384	 0.000713113	 3.401918	 Ch25h	 cholesterol	25---hydroxylase	
1380077_at	 8.68975E---07	 2.27228E---07	 7.460445		 	1380079_at	 2.87358E---05	 1.26601E---05	 2.8126707	 Samd9l	 sterile	alpha	motif	domain	containing	9---like	
1380244_at	 1.64391E---06	 4.66055E---07	 3.4277337	 Jam2	 junctional	adhesion	molecule	2	
1380351_at	 3.38872E---12	 9.6667E---14	 4.150351		 	1380363_at	 0.000654483	 0.000526906	 3.1657624	 Klf7	 Kruppel---like	factor	7	(ubiquitous)	
1380410_at	 6.27258E---05	 3.14126E---05	 3.8753777		 	1380455_at	 6.45963E---05	 3.28612E---05	 3.4581037	 Col6a5	 collagen,	type	VI,	alpha	5	
1380545_at	 0.000211192	 0.000136555	 2.2745008	 Asap1	 ArfGAP	with	SH3	domain,	ankyrin	repeat	and	PH	domain	1	
1380682_at	 0.000582596	 0.000458687	 2.696835	Mex3b	 mex3	homolog	B	(C.	elegans)	
1380726_at	 1.09196E---07	 2.20494E---08	 5.78175		 	1380784_at	 0.000144122	 8.46515E---05	 2.0823224	 Klhl5	 kelch---like	family	member	5	
1380930_at	 2.30413E---05	 9.74963E---06	 2.5968668	 RGD1564142	 similar	to	chromosome	10	open	reading	frame	64	
1380967_at	 0.00023282	 0.000153861	 4.22098	 Nts	 neurotensin	
1381088_at	 0.000385274	 0.000282086	 2.683475		 	1381221_at	 0.000590165	 0.000465772	 5.534136	 RGD1311300	 similar	to	T	cell	receptor	V	delta	6	
1381357_at	 0.000900534	 0.000777799	 3.9428735	 Ptpn22	 protein	tyrosine	phosphatase,	non---receptor	type	22	(lymphoid)	
1381387_at	 0.000378213	 0.000276317	 2.8366952		 	1381450_at	 0.000644899	 0.000517313	 2.9568226		 	1381487_at	 0.0013296	 0.001253743	 2.4990027	 Angpt1	 angiopoietin	1	
1381591_at	 0.00042843	 0.000317279	 3.7640345		 	1381715_at	 0.000125489	 7.239E---05	 3.0313687		 	1381986_at	 0.000605733	 0.000479979	 3.0387967		 	1382031_at	 0.000715826	 0.000592173	 3.782801		 	1382072_at	 1.2877E---06	 3.51004E---07	 8.211142	 Olfml2a	 olfactomedin---like	2A	
1382083_at	 3.20753E---05	 1.41823E---05	 2.5138676	 Coch	 cochlin	
1382351_at	 0.000514082	 0.000395134	 4.500563	 Gem	 GTP	binding	protein	overexpressed	in	skeletal	muscle	
1382372_at	 1.08443E---09	 9.96783E---11	 3.4179208		 	1382442_at	 1.11247E---05	 4.16076E---06	 5.375487	 37499	septin	6	
1382454_at	 0.000271484	 0.000184144	 2.9294903	 Cxcl9	 chemokine	(C---X---C	motif)	ligand	9	




1382692_at	 1.98688E---05	 8.06089E---06	 3.6539237	 Clec7a	 C---type	lectin	domain	family	7,	member	A	
1382700_at	 0.000208377	 0.000133745	 3.9614873		 	1382726_at	 0.000662769	 0.000534627	 3.856265	 Nkd1	 naked	cuticle	homolog	1	(Drosophila)	
1382873_at	 0.000420553	 0.000309916	 2.079076	 Cttnbp2nl	 CTTNBP2	N---terminal	like	
1382905_at	 5.5704E---06	 1.898E---06	 3.9724796		 	1382926_s_at	 0.000215111	 0.000140199	 3.7336886		 	1382953_at	 1.80867E---08	 2.63883E---09	 4.276895		 	1383197_at	 2.84722E---06	 8.84399E---07	 6.1478	 Jam2	 junctional	adhesion	molecule	2	
1383284_at	 5.65158E---05	 2.74966E---05	 4.7206135		 	1383291_at	 8.60079E---08	 1.64928E---08	 8.324201	 C7///Tubb4b	 complement	component	7///tubulin,	beta	4B	class	IVb	
1383330_at	 6.58621E---05	 3.38182E---05	 2.4705935		 	1383398_at	 0.001404824	 0.001354421	 2.709008	 Itga8	 integrin,	alpha	8	
1383404_at	 6.58089E---05	 3.36867E---05	 4.564208		 	1383453_at	 0.000119324	 6.83448E---05	 2.2679532	 Olfml1	 olfactomedin---like	1	
1383469_at	 1.51626E---08	 2.11459E---09	 6.253115	 Aldh1a3	 aldehyde	dehydrogenase	1	family,	member	A3	
1383546_at	 3.55034E---08	 5.8516E---09	 8.411332	 Gdpd2	 glycerophosphodiester	phosphodiesterase	domain	containing	2	
1383708_at	 5.23444E---12	 2.07387E---13	 6.1856084	 Itgbl1	 integrin,	beta---like	1	
1383914_at	 1.75417E---07	 3.80859E---08	 2.9510264	Mrvi1	 murine	retrovirus	integration	site	1	homolog	
1384161_at	 0.00036602	 0.000263929	 3.0665708	 Csnk1e	 casein	kinase	1,	epsilon	
1384187_at	 4.16888E---06	 1.361E---06	 3.4986734	 Ap1s2	 adaptor---related	protein	complex	1,	sigma	2	subunit	
1384312_at	 3.67184E---06	 1.16326E---06	 5.9537754	 Irx1	 iroquois	homeobox	1	
1384406_at	 1.60179E---07	 3.3508E---08	 2.380763	 Ccrl1	 chemokine	(C---C	motif)	receptor---like	1	
1384460_at	 0.000998222	 0.000887484	 3.3615768		 	1384509_s_at	 2.75364E---05	 1.20008E---05	 6.14418	 Pcdh17	 protocadherin	17	
1384558_at	 6.72654E---08	 1.21525E---08	 5.481333	 Plac9	 placenta---specific	9	
1384707_at	 7.27853E---05	 3.82959E---05	 5.0429606	 Scara5	 scavenger	receptor	class	A,	member	5	(putative)	
1384812_at	 0.00157467	 0.001559696	 5.185218		 	
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1385143_at	 0.000335729	 0.000236234	 2.3905818	 RGD1561963	 similar	to	Dedicator	of	cytokinesis	protein	10	(Protein	zizimin	3)	
1385608_at	 0.000271484	 0.000183592	 3.8665802	 Rab7b	 Rab7b,	member	RAS	oncogene	family	
1385637_at	 1.30017E---06	 3.58525E---07	 8.294608		 	1385659_at	 8.65358E---09	 1.08341E---09	 13.83722	 Apcdd1	 adenomatosis	polyposis	coli	down---regulated	1	
1385701_at	 4.01046E---05	 1.81674E---05	 5.37573		 	1385702_at	 4.69716E---05	 2.22575E---05	 3.3473763	 Ifi204	 interferon	activated	gene	204	
1385707_at	 1.81603E---06	 5.238E---07	 2.0418074	 Lect2	 leukocyte	cell---derived	chemotaxin	2	
1385925_at	 2.54358E---05	 0.000011045	 6.9560733		 	1386043_at	 0.000831481	 0.000707615	 2.3222082		 	1386061_at	 0.00042843	 0.000317758	 2.660119		 	1386125_at	 5.88574E---06	 2.0241E---06	 2.6817493	 Hoxb4	 homeo	box	B4	
1386242_at	 0.000215111	 0.000140453	 4.763677		 	1386795_at	 0.000376569	 0.000274365	 3.1833355	 Hepacam2	 HEPACAM	family	member	2	
1390843_at	 0.000559733	 0.000434979	 2.6082654	 Ccdc102a	 coiled---coil	domain	containing	102A	
1390901_at	 0.001136775	 0.001036315	 2.620268	 Igsf10	 immunoglobulin	superfamily,	member	10	
1390912_at	 1.70167E---07	 3.61369E---08	 15.125416	 Pcp4l1	 Purkinje	cell	protein	4---like	1	
1390931_at	 0.00050098	 0.000381888	 3.759329	 Adamts15	 ADAM	metallopeptidase	with	thrombospondin	type	1	motif,	15	
1390946_at	 4.06133E---06	 1.31945E---06	 3.9268203	 Runx3	 runt---related	transcription	factor	3	
1391039_at	 6.27258E---05	 3.13456E---05	 5.919039		 	1391083_at	 1.00367E---07	 1.95643E---08	 7.6426916	 Arhgap22	 Rho	GTPase	activating	protein	22	
1391450_at	 4.75823E---05	 2.26977E---05	 5.37836	 Loxl2	 lysyl	oxidase---like	2	
1391468_at	 1.64852E---05	 6.55751E---06	 4.700059	Myct1	 myc	target	1	
1391557_at	 0.000632235	 0.000504987	 3.3011181	 Sox15	 SRY	(sex	determining	region	Y)---box	15	
1391562_at	 0.001485415	 0.00144775	 3.2878757		 	1391721_at	 5.58733E---08	 1.00058E---08	 11.781904		 	1391925_at	 0.000878525	 0.000754613	 2.2548354	 Ccl19	 chemokine	(C---C	motif)	ligand	19	
1392274_at	 0.000182573	 0.000114	 3.074976		 	1392296_at	 1.73489E---08	 2.50198E---09	 5.365514		 	1392309_at	 4.13386E---07	 1.00235E---07	 4.268289	 Jam2	 junctional	adhesion	molecule	2	























1392521_at	 0.000172188	 0.000105605	 4.020242		 	1392578_at	 8.8977E---07	 2.34076E---07	 8.093776		 	1392645_at	 2.15193E---06	 6.41146E---07	 3.2168238		 	1392754_at	 0.001305113	 0.001226517	 2.8363743	 Adam8	 ADAM	metallopeptidase	domain	8	
1392886_a_at	 5.20914E---06	 1.76665E---06	 4.722019	 Fcrla	 Fc	receptor---like	A	














1393060_at	 1.32816E---08	 1.83121E---09	 4.8255806	 Adamtsl2	 ADAMTS---like	2	
1393067_at	 4.49195E---06	 1.48071E---06	 2.3442204	 Tek	 TEK	tyrosine	kinase,	endothelial	
1393109_at	 9.21423E---06	 3.41701E---06	 3.1697443		 	1393160_at	 2.03634E---09	 2.19448E---10	 3.7208838		 	1393174_at	 3.95984E---06	 1.27766E---06	 3.340138	 Fam171b	 family	with	sequence	similarity	171,	member	B	
1393210_at	 2.56353E---06	 7.8409E---07	 6.3344035	 LOC100361383	 extracellular	matrix	protein	2---like	
1393225_at	 6.4629E---05	 3.29803E---05	 2.0690155	 Adamts10	 ADAM	metallopeptidase	with	thrombospondin	type	1	motif,	10	
1393227_at	 4.66631E---05	 2.20374E---05	 5.5482545		 	1393240_at	 0.001468247	 0.001426364	 2.982464	 Efemp2	 EGF---containing	fibulin---like	extracellular	matrix	protein	2	
1393250_at	 1.24912E---05	 4.75103E---06	 4.0126305		 	1393252_at	 4.73286E---11	 2.92523E---12	 18.770403		 	1393281_at	 3.67184E---06	 1.16382E---06	 9.119468	 Cav1	 caveolin	1,	caveolae	protein	
1393324_at	 1.62007E---06	 4.51874E---07	 3.8163154	 Jam2	 junctional	adhesion	molecule	2	
1393330_at	 0.000104851	 5.88229E---05	 3.9773836	 LOC100909539	 uncharacterized	LOC100909539	
1393401_at	 0.000643674	 0.000515143	 6.1602025		 	1393449_at	 2.15597E---10	 1.57171E---11	 3.908153	 Jam2	 junctional	adhesion	molecule	2	
1393454_at	 0.000259889	 0.00017422	 4.6113076	 Pcdh17	 protocadherin	17	
1393559_at	 0.000437204	 0.000324958	 7.9346104		 	1393571_at	 4.20448E---05	 1.93233E---05	 4.130112	 Sox4	 SRY	(sex	determining	region	Y)---box	4	
1393708_at	 0.000332246	 0.00023273	 4.680258	 Bhlhe22	 basic	helix---loop---helix	family,	member	e22	
1393927_at	 2.01614E---08	 3.0354E---09	 12.253391		 	1394200_at	 0.001085454	 0.000978801	 3.2939148	 Hspa2	 heat	shock	protein	2	
1394415_at	 4.42498E---05	 2.08275E---05	 3.9674797	 LOC687813	 similar	to	Tnf	receptor---associated	factor	1	
1394451_at	 0.000909124	 0.000790797	 3.529826	 Anxa1	 annexin	A1	
1394475_at	 0.000758611	 0.000638387	 2.704211		 	1394517_at	 3.94825E---05	 1.77702E---05	 4.759022		 	1394678_at	 8.46645E---05	 4.56196E---05	 2.0297542	 Fgd2	 FYVE,	RhoGEF	and	PH	domain	containing	2	
1394681_at	 0.000144122	 8.47372E---05	 2.1111798	 Akr1cl	 aldo---keto	reductase	family	1,	member	C---like	
1395166_at	 0.000616155	 0.00049019	 2.3888547	 Ehd2	 EH---domain	containing	2	
1395184_at	 6.86854E---06	 2.43828E---06	 4.8504725	 Clec12a	 C---type	lectin	domain	family	12,	member	A	





1395472_at	 0.000148794	 8.81915E---05	 2.9568658	 Lrrc17	 leucine	rich	repeat	containing	17	
1395501_at	 0.000320817	 0.000223044	 3.7562106		 	1395644_at	 0.000474109	 0.000359151	 2.1377718	 Abca8	 ATP---binding	cassette,	subfamily	A	(ABC1),	member	8	
1395753_at	 1.48483E---05	 5.7652E---06	 7.404484	 Eln	 elastin	
1395983_at	 0.001519816	 0.001490913	 2.2411356	 Rmdn2	 regulator	of	microtubule	dynamics	2	
1396055_at	 0.000328845	 0.000229306	 2.151869	 Col6a3	 collagen,	type	VI,	alpha	3	
1396132_at	 0.000171489	 0.000104905	 2.4429908	 Fcrla	 Fc	receptor---like	A	
1396613_at	 0.001540156	 0.001518189	 2.7671452		 	1396694_at	 0.001414344	 0.001369515	 2.4392087		 	1396974_at	 0.001199546	 0.001110874	 2.4224997		 	1397022_at	 0.001511965	 0.001479757	 2.770665		 	1397050_at	 0.001002586	 0.000892953	 2.4066973	 Cpne8	 copine	VIII	
1397249_at	 0.000295577	 0.000202828	 4.254638		 	1397427_at	 0.000149125	 8.86241E---05	 4.3747163	 Ces1c	 carboxylesterase	1C	
1397429_at	 0.000210283	 0.000135301	 5.8441133	 Creb5	 cAMP	responsive	element	binding	protein	5	
1397668_at	 0.000800096	 0.000675833	 3.808793		 	1398231_at	 0.000176472	 0.000108792	 3.8051686		 	1398616_at	 3.47456E---05	 1.54731E---05	 2.4632313	 Ap1s2	 adaptor---related	protein	complex	1,	sigma	2	subunit	
1398703_at	 3.02858E---10	 2.25583E---11	 7.2161446		 		
Male	rat	liver	zone	I	signature		
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1374307_at	 1.66E---04	 1.53E---05	 2.6543653		 	1376082_at	 0.009171167	 0.001693139	 2.5005655	Mecom	 MDS1	and	EVI1	complex	locus	
1387111_at	 2.57E---07	 5.94E---09	 3.5038505	 Ddah1	 dimethylarginine	dimethylaminohydrolase	1	
1389876_at	 0.007545118	 0.001160787	 2.113492	 Camk2n1	 calcium/calmodulin---dependent	protein	kinase	II	inhibitor	1	
1398348_at	 4.17E---06	 1.93E---07	 2.6440198		 	1378798_at	 0.037235864	 0.010624247	 2.204123	 Stox2	 storkhead	box	2	
1379076_at	 0.018219834	 0.004064424	 2.6486177		 	1380389_at	 0.030691367	 0.007790885	 2.0545697		 	1382631_at	 3.88E---04	 4.48E---05	 4.664542		 	1384035_at	 5.24E---06	 2.82E---07	 13.242892		 	1384036_s_at	 1.52E---06	 5.83E---08	 7.124467		 	
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1385670_at	 0.021947639	 0.00506484	 2.0117233	 Sdsl	 serine	dehydratase---like	
1390765_at	 4.74E---07	 1.46E---08	 3.075217	Wfdc2	 WAP	four---disulfide	core	domain	2		
Female	rat	liver	zone	I	signature		
Probe	Set	ID	 Corrected	p---value	 p---value	 FCAbsolute	 Gene	Symbol	 Gene	Title	
1367847_at	 3.38E---04	 3.38E---05	 2.274325	 Nupr1	 nuclear	protein,	transcriptional	regulator,	1	
1369126_at	 0.027340967	 0.006730084	 2.0997062	 Ptgfr	 prostaglandin	F	receptor	
1369195_at	 1.39E---04	 1.18E---05	 2.0734417	 Fabp2	 fatty	acid	binding	protein	2,	intestinal	
1370080_at	 6.74E---05	 4.67E---06	 2.3850334	 Hmox1	 heme	oxygenase	(decycling)	1	




1371922_at	 0.003324047	 4.60E---04	 3.4437294		 	1373386_at	 0.001667833	 2.18E---04	 3.287276	 Gjb2	 gap	junction	protein,	beta	2	
1376279_at	 0.010885246	 0.002093317	 2.5299816	 Pop1	 processing	of	precursor	1,	ribonuclease	P/MRP	subunit	(S.	cerevisiae)	
1383472_at	 0.004852043	 7.09E---04	 3.9102445	 Aldh1b1	 aldehyde	dehydrogenase	1	family,	member	B1	
1384225_at	 3.88E---04	 4.24E---05	 3.515745		 	1384226_at	 0.013258733	 0.002753737	 2.174665		 	1393241_at	 1.61E---07	 2.48E---09	 4.933111	 Prss32	 protease,	serine,	32	
1396155_at	 1.01E---09	 7.80E---12	 6.4710135		 		
Male	rat	liver	zone	III	signature		
Probe	Set	ID	 Corrected	p---value	 p---value	 FCAbsolute	 Gene	Symbol	 Gene	Title	
1367568_a_at	 1.97E---02	 7.20E---03	 3.4364784	Mgp	 matrix	Gla	protein	
1367570_at	 0.002994248	 0.000363	 5.066586	 Tagln	 transgelin	
1367574_at	 0.003296671	 0.000447	 2.3799796	 Vim	 vimentin	
1367584_at	 1.99E---02	 7.34E---03	 2.2204938	 Anxa2	 annexin	A2	
1367614_at	 0.019996617	 0.007543634	 2.2698913	 Anxa1	 annexin	A1	




















1367661_at	 6.55E---04	 4.45E---05	 4.9478893	 S100a6	 S100	calcium	binding	protein	A6	
1367749_at	 0.00049	 0.0000274	 5.5054755	 Lum	 lumican	
1367823_at	 3.75E---02	 1.81E---02	 2.332806	 Timp2	 TIMP	metallopeptidase	inhibitor	2	
1367846_at	 1.40E---02	 4.14E---03	 3.3632684	 S100a4	 S100	calcium---binding	protein	A4	
1367866_at	 0.003555084	 0.000504	 2.2241719	 Fbln5	 fibulin	5	
1367880_at	 0.00225122	 0.000225	 2.9701128	 Lamb2	 laminin,	beta	2	
1367940_at	 0.006249851	 0.001372223	 2.31592	 Cxcr7	 chemokine	(C---X---C	motif)	receptor	7	
1367998_at	 1.08E---02	 2.88E---03	 2.4994452	 Slpi	 secretory	leukocyte	peptidase	inhibitor	





1368128_at	 0.006004391	 0.001186496	 2.6273537	 Pla2g2a	 phospholipase	A2,	group	IIA	(platelets,	synovial	fluid)	
1368167_at	 0.019541342	 0.007059846	 2.705863	 Ctse	 cathepsin	E	
1368171_at	 2.81E---13	 1.68E---15	 22.392555	 Lox	 lysyl	oxidase	
1368172_a_at	 1.21E---13	 4.84E---16	 15.957376	 Lox	 lysyl	oxidase	
1368207_at	 5.12E---03	 9.40E---04	 2.230316	 Fxyd5	 FXYD	domain---containing	ion	transport	regulator	5	
1368281_at	 0.003233416	 4.20E---04	 4.841948	 Dpep1	 dipeptidase	1	(renal)	
1368282_at	 3.62E---03	 5.20E---04	 3.6044595	 Dpep1	 dipeptidase	1	(renal)	
1368284_at	 2.65E---02	 1.14E---02	 2.0511272	 Plvap	 plasmalemma	vesicle	associated	protein	
1368320_at	 0.015223616	 0.004732144	 2.5161479	 Ncam1	 neural	cell	adhesion	molecule	1	
1368448_at	 1.32E---02	 3.77E---03	 3.3078399	 Ltbp2	 latent	transforming	growth	factor	beta	binding	protein	2	
1368797_at	 0.004900231	 0.000861	 3.0210655	 Nr1i3	 nuclear	receptor	subfamily	1,	group	I,	member	3	
1368829_at	 0.001606949	 0.000144	 2.1843097	 Fbn1	 fibrillin	1	
1368921_a_at	 7.20E---03	 1.74E---03	 2.9003222	 Cd44	 Cd44	molecule	
1368926_at	 0.006249851	 0.001357982	 2.2086632	 Sema4f	
sema	domain,	immunoglobulin	domain	(Ig),	transmembrane	domain	(TM)	and	short	
cytoplasmic	domain,	(semaphorin)	4F	
1369527_at	 0.015542509	 0.00491718	 2.653278	 Cx3cr1	 chemokine	(C---X3---C	motif)	receptor	1	
1369921_at	 5.03E---03	 9.14E---04	 2.5903316	 Gstm3	 glutathione	S---transferase	mu	3	
1369926_at	 2.00E---04	 5.99E---06	 3.031266	 Gpx3	 glutathione	peroxidase	3	




1369964_at	 6.15E---03	 1.28E---03	 2.273728	 Coro1a	 coronin,	actin	binding	protein	1A	
1369968_at	 2.83E---04	 1.12E---05	 2.1539533	 Ptn	 pleiotrophin	
1370018_at	 0.003620693	 0.000528	 2.6014082	 Hspb2	 heat	shock	protein	beta	2	
1370026_at	 0.025581494	 0.010875965	 2.3872576	 Cryab	 crystallin,	alpha	B	




1370156_at	 2.41E---03	 2.60E---04	 2.537972	 Prnp	 prion	protein	
1370247_a_at	 0.00382353	 5.88E---04	 2.4264011	 Pmp22	 peripheral	myelin	protein	22	
1370291_at	 0.002746988	 0.000316	 2.8277662	 Pdlim3	 PDZ	and	LIM	domain	3	
1370301_at	 0.000263	 0.0000084	 3.214848	Mmp2	 matrix	metallopeptidase	2	
1370312_at	 0.006145863	 1.31E---03	 2.6855993	 Spon1	 spondin	1,	extracellular	matrix	protein	
1370328_at	 3.66E---03	 5.41E---04	 2.2414434	 Dkk3	 dickkopf	WNT	signaling	pathway	inhibitor	3	
1370423_at	 5.22E---03	 9.95E---04	 2.4440804	 Gna15	 guanine	nucleotide	binding	protein,	alpha	15	
1370538_at	 0.007523394	 1.83E---03	 2.106403	 Lama3	 laminin,	alpha	3	
1370857_at	 6.15E---03	 1.29E---03	 3.6731007	 Acta2	 smooth	muscle	alpha---actin	
1370864_at	 3.56E---02	 1.68E---02	 3.4342391	 Col1a1	 collagen,	type	I,	alpha	1	
1370887_at	 0.003194604	 0.000408	 2.6827934	 Tgfb1i1	 transforming	growth	factor	beta	1	induced	transcript	1	
1370895_at	 2.41E---03	 2.57E---04	 2.0990355	 Col5a2	 collagen,	type	V,	alpha	2	
1370896_a_at	 0.01739069	 0.005803644	 3.2328322	Myh11	 myosin,	heavy	chain	11,	smooth	muscle	
1370956_at	 0.006145863	 0.001307725	 3.499347	 Dcn	 decorin	
1370962_at	 2.42E---02	 9.99E---03	 2.0388489	 Parm1	 prostate	androgen---regulated	mucin---like	protein	1	
1371247_at	 0.03293959	 0.015187716	 2.1964839	 Tnnt3	 troponin	T	type	3	(skeletal,	fast)	
1371349_at	 0.00116446	 0.000093	 2.2794113	 Col6a1	 collagen,	type	VI,	alpha	1	
1371360_at	 6.08E---03	 1.24E---03	 2.9441957	 Ndrg1	 N---myc	downstream	regulated	1	
1371369_at	 2.76E---04	 9.60E---06	 4.4959407	 Col6a2	 collagen,	type	VI,	alpha	2	
1371382_at	 0.000429	 0.0000216	 3.7944925	 Flna	 filamin	A,	alpha	
1371406_at	 4.88E---03	 8.47E---04	 2.584559		 	1371414_at	 3.48E---03	 4.86E---04	 2.909865	 Gsn	 gelsolin	
1371447_at	 0.010109841	 0.002643491	 2.0089037	 Plac8	 placenta---specific	8	
1371527_at	 0.005215114	 0.000981	 3.0236259	 Emp1	 epithelial	membrane	protein	1	




1371951_at	 9.86E---03	 2.56E---03	 2.407298	 Fhl2	 four	and	a	half	LIM	domains	2	
1372107_at	 0.02197756	 8.79E---03	 2.360852	 Fhl1	 four	and	a	half	LIM	domains	1	
1372111_at	 0.017063163	 0.005585547	 3.4560928	 Cav1	 caveolin	1,	caveolae	protein	
1372168_s_at	 0.000901	 0.0000647	 3.411398	 Igfbp6	 insulin---like	growth	factor	binding	protein	6	
1372256_at	 0.00306171	 3.85E---04	 2.8317332	 Crip1	 cysteine---rich	protein	1	(intestinal)	





1372301_at	 6.02E---03	 1.20E---03	 3.3762465	 Aebp1	 AE	binding	protein	1	
1372481_at	 0.008606446	 2.15E---03	 3.9705498		 	1372518_at	 3.35E---03	 4.62E---04	 3.1681821	 Fbln1	 fibulin	1	
1372539_at	 4.50E---02	 2.27E---02	 2.5117233		 	1372615_at	 0.003945599	 0.000614	 5.5381174	 Aoc3	 amine	oxidase,	copper	containing	3	
1372897_at	 2.75E---03	 3.18E---04	 2.839459	 Plod2	 procollagen	lysine,	2---oxoglutarate	5---dioxygenase	2	
1372935_at	 8.35E---08	 8.33E---10	 5.645368	 Tmem119	 transmembrane	protein	119	
1373000_at	 0.009662118	 0.002487851	 3.8154464	 Srpx2	 sushi---repeat---containing	protein,	X---linked	2	
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1373401_at	 1.52E---02	 4.69E---03	 2.970261	 Tnc	 tenascin	C	
1373463_at	 0.00092	 0.0000716	 2.9104047	 Col5a2	 collagen,	type	V,	alpha	2	
1373651_at	 0.000613	 0.0000355	 6.495147		 	1373839_at	 5.22E---03	 9.74E---04	 4.155223		 	1373882_at	 3.98E---02	 1.97E---02	 2.473075		 	1373908_at	 0.006081592	 0.001235174	 4.2663445		 	1373928_at	 4.78E---03	 8.20E---04	 4.6853886	 Il17re	 interleukin	17	receptor	E	
1374172_at	 4.05E---03	 6.38E---04	 3.5346124	 Col8a2	 collagen,	type	VIII,	alpha	2	
1374237_at	 0.0216732	 0.008565457	 2.9913423	 Lmod1	 leiomodin	1	(smooth	muscle)	
1375043_at	 0.04799066	 0.024809543	 2.2700224		 	1375144_at	 0.006888195	 0.001608664	 2.374481		 	1375170_at	 4.24E---03	 6.85E---04	 3.698078	 S100a11	 S100	calcium	binding	protein	A11	
1375267_at	 0.038247757	 1.88E---02	 2.4829235	 Ppic	 peptidylprolyl	isomerase	C	
1375739_at	 0.00092	 0.000069	 2.4270043	 Ehd4	 EH---domain	containing	4	
1375857_at	 0.03293959	 0.0151767	 2.095752	Myof	 myoferlin	
1376457_at	 0.042823758	 2.14E---02	 2.8666012	 Crispld2	 cysteine---rich	secretory	protein	LCCL	domain	containing	2	
1376632_at	 1.35E---02	 3.96E---03	 2.168106	 Lmcd1	 LIM	and	cysteine---rich	domains	1	
1376750_at	 1.32E---02	 3.78E---03	 2.0378191		 	1376818_at	 0.024395643	 1.01E---02	 2.1585822	Wtip	 Wilms	tumor	1	interacting	protein	
1376905_at	 2.68E---02	 1.16E---02	 2.1944203		 	1376937_at	 1.45E---04	 3.46E---06	 3.8603601	 Filip1l	 filamin	A	interacting	protein	1---like	
1379936_at	 0.004138464	 0.000661	 4.7772703		 	1381504_at	 2.45E---02	 1.02E---02	 2.603942	 Aspn	 asporin	
1383058_at	 0.004782096	 0.000821	 3.9789212		 	1383322_at	 0.006145863	 0.001308714	 3.5566857	 Rasl11b	 RAS---like	family	11	member	B	
1385354_at	 1.77E---02	 6.07E---03	 2.2685876	 Itga8	 integrin,	alpha	8	
1386911_at	 0.0405929	 0.020174915	 2.378294	 Atp1a2	 ATPase,	Na+/K+	transporting,	alpha	2	polypeptide	
1386921_at	 0.01312728	 0.003694504	 6.138241	 Cpe	 carboxypeptidase	E	
1386940_at	 3.27E---03	 4.31E---04	 2.3397868	 Timp2	 TIMP	metallopeptidase	inhibitor	2	
1386965_at	 2.01E---02	 7.63E---03	 2.4958344	 Lpl	 lipoprotein	lipase	
1387232_at	 0.00145111	 0.000125	 4.398603	 Bmp4	 bone	morphogenetic	protein	4	
1387348_at	 7.07E---03	 1.68E---03	 3.4784317	 Igfbp5	 insulin---like	growth	factor	binding	protein	5	
1387351_at	 6.33E---04	 4.14E---05	 3.1855562	 Fbn1	 fibrillin	1	
1387581_at	 0.011933667	 0.003287118	 3.4999845	 Rassf9	 Ras	association	(RalGDS/AF---6)	domain	family	(N---terminal)	member	9	
1387616_at	 0.011782614	 0.00322196	 2.4712117	 Pdgfc	 platelet	derived	growth	factor	C	




1387922_at	 2.20E---02	 8.80E---03	 3.1326766	 Crispld2	 cysteine---rich	secretory	protein	LCCL	domain	containing	2	
1387925_at	 0.02888819	 1.29E---02	 2.0813034	 Asns	 asparagine	synthetase	(glutamine---hydrolyzing)	
1387952_a_at	 0.020473994	 0.007887187	 2.2983193	 Cd44	 Cd44	molecule	
1388014_at	 0.002994248	 0.000358	 4.152831	 Obp1f	 odorant	binding	protein	I	f	
1388116_at	 0.014139078	 4.21E---03	 3.0266993	 Col1a1	 collagen,	type	I,	alpha	1	
1388142_at	 4.91E---03	 8.82E---04	 3.2232754	 Vcan	 versican	
1388312_at	 1.55E---02	 4.93E---03	 2.023181		 	1388427_at	 0.002043257	 1.88E---04	 3.2201211	Mxra8	 matrix---remodelling	associated	8	
1388557_at	 2.00E---02	 7.50E---03	 4.9911227	 C7///Tubb4b	 complement	component	7///tubulin,	beta	4B	class	IVb	
1388673_at	 1.59E---02	 5.16E---03	 2.0289483	 Lsp1	 lymphocyte---specific	protein	1	
1388955_at	 0.006249851	 0.001363676	 2.7368715		 	1389092_at	 2.21E---02	 8.91E---03	 2.0110495	 Il2rg	 interleukin	2	receptor,	gamma	
1389185_at	 0.009171339	 0.00232487	 2.1861207	 Ak1	 adenylate	kinase	1	
1389234_at	 0.031225063	 0.014272533	 3.757972	 Vwf	 von	Willebrand	factor	
1389253_at	 7.16E---03	 1.72E---03	 3.091454	 Vnn1	 vanin	1	
1389533_at	 0.028530663	 0.012555627	 2.5693622	 Fbln2	 fibulin	2	
1389611_at	 0.028530663	 0.01264233	 2.773913	 Vldlr	 very	low	density	lipoprotein	receptor	
1389698_at	 5.22E---03	 1.01E---03	 2.4832437		 	1389966_at	 2.83E---04	 1.18E---05	 4.744158	 Col6a3	 collagen,	type	VI,	alpha	3	
1390227_at	 0.000181	 0.00000506	 6.7924924	 Pcp4l1	 Purkinje	cell	protein	4---like	1	
1390250_x_at	 1.08E---02	 2.86E---03	 2.2128115	 LOC685152	 ATPase,	class	I,	type	8B,	member	2	
1390306_at	 6.61E---03	 1.50E---03	 2.0875475	 LOC100912470	 uncharacterized	LOC100912470	




1390472_at	 0.02007464	 0.007653206	 2.431504	 Naaa	 N---acylethanolamine	acid	amidase	
1390547_at	 0.025651934	 0.010957114	 3.3583617		 	1393528_at	 3.60E---02	 1.71E---02	 2.7502158	 Synpo2	 synaptopodin	2	
1377761_at	 0.003296671	 4.44E---04	 2.1618855	 Gfpt2	 glutamine---fructose---6---phosphate	transaminase	2	
1378258_at	 0.015436175	 0.004837284	 2.2217898		 	1378645_at	 0.000633	 0.0000417	 6.4879146		 	1378699_at	 0.038017657	 1.85E---02	 2.4988987	 Pkhd1l1	 polycystic	kidney	and	hepatic	disease	1---like	1	
1379022_at	 1.52E---02	 4.74E---03	 2.7357194	 Adamts8	 ADAM	metallopeptidase	with	thrombospondin	type	1	motif,	8	
1380017_at	 6.61E---03	 1.50E---03	 2.0447373		 	1380063_at	 0.039815117	 1.96E---02	 2.2410743	 Ch25h	 cholesterol	25---hydroxylase	
1380077_at	 3.82E---02	 1.88E---02	 2.2269967		 	1380410_at	 4.70E---02	 2.40E---02	 2.0704854		 	1380682_at	 0.00306171	 0.000384	 2.084744	Mex3b	 mex3	homolog	B	(C.	elegans)	
1380726_at	 1.32E---02	 3.80E---03	 2.7375722		 	1380930_at	 0.001606949	 0.000144	 2.021375	 RGD1564142	 similar	to	chromosome	10	open	reading	frame	64	
1381088_at	 0.019882035	 0.007381354	 2.0599062		 	1381357_at	 4.86E---02	 2.53E---02	 2.2652588	 Ptpn22	 protein	tyrosine	phosphatase,	non---receptor	type	22	(lymphoid)	
1381450_at	 0.020456001	 0.007839426	 2.3194776		 	1382072_at	 0.021586416	 0.008444985	 3.3730297	 Olfml2a	 olfactomedin---like	2A	
1382905_at	 1.35E---02	 3.96E---03	 2.459424		 	1383284_at	 1.57E---02	 5.02E---03	 2.43935		 	1383291_at	 0.019217895	 0.006843543	 3.8926442	 C7///Tubb4b	 complement	component	7///tubulin,	beta	4B	class	IVb	
1383398_at	 6.59E---03	 1.46E---03	 2.8107495	 Itga8	 integrin,	alpha	8	
1383469_at	 1.18E---02	 3.17E---03	 2.4359684	 Aldh1a3	 aldehyde	dehydrogenase	1	family,	member	A3	
1383708_at	 0.004782096	 0.000812	 2.9687467	 Itgbl1	 integrin,	beta---like	1	
1384707_at	 0.019217895	 0.006866886	 2.9341333	 Scara5	 scavenger	receptor	class	A,	member	5	(putative)	
1384812_at	 0.012606613	 0.003520929	 3.7688484		 	1385608_at	 2.31E---02	 9.46E---03	 2.189908	 Rab7b	 Rab7b,	member	RAS	oncogene	family	
1385637_at	 0.026473254	 1.14E---02	 2.7373888		 	1385701_at	 0.002746988	 0.000309	 4.1846795		 	1386242_at	 0.018725293	 0.006503395	 2.463274		 	1390843_at	 0.000122	 2.44E---06	 3.1479461	 Ccdc102a	 coiled---coil	domain	containing	102A	
1390912_at	 1.87E---05	 2.62E---07	 6.5733566	 Pcp4l1	 Purkinje	cell	protein	4---like	1	
1391039_at	 1.27E---03	 1.06E---04	 3.8312535		 	1391562_at	 0.018939046	 6.69E---03	 2.4742591		 	1391925_at	 1.26E---02	 3.52E---03	 2.2955365	 Ccl19	 chemokine	(C---C	motif)	ligand	19	
1392274_at	 2.84E---04	 1.25E---05	 3.1828156		 	1392521_at	 0.015912475	 0.00511359	 2.4317882		 	1392645_at	 2.06E---03	 1.98E---04	 2.5804687		 	1392754_at	 0.015020075	 0.004586969	 2.653747	 Adam8	 ADAM	metallopeptidase	domain	8	
1392886_a_at	 0.006736134	 0.001549219	 2.5240977	 Fcrla	 Fc	receptor---like	A	
1393109_at	 1.44E---02	 4.34E---03	 2.466343		 	1393210_at	 0.036970377	 0.017784154	 2.5019417	 LOC100361383	 extracellular	matrix	protein	2---like	
1393225_at	 0.000296	 0.0000136	 2.3276951	 Adamts10	 ADAM	metallopeptidase	with	thrombospondin	type	1	motif,	10	
1393240_at	 2.26E---02	 9.17E---03	 2.4385018	 Efemp2	 EGF---containing	fibulin---like	extracellular	matrix	protein	2	
1393250_at	 2.26E---02	 9.20E---03	 2.0880785		 	1393281_at	 0.018798737	 0.006603947	 3.5936713	 Cav1	 caveolin	1,	caveolae	protein	
1393330_at	 2.37E---03	 2.46E---04	 3.36193	 LOC100909539	 uncharacterized	LOC100909539	
1393401_at	 1.76E---02	 6.00E---03	 3.6327126		 	1393559_at	 0.00092	 0.0000717	 6.3740506		 	1393708_at	 0.03561064	 0.016845752	 2.3613	 Bhlhe22	 basic	helix---loop---helix	family,	member	e22	
1394200_at	 0.023150388	 0.009518922	 3.0160742	 Hspa2	 heat	shock	protein	2	
1394451_at	 3.12E---02	 1.41E---02	 2.5684376	 Anxa1	 annexin	A1	
1395166_at	 0.004590933	 7.61E---04	 2.6662836	 Ehd2	 EH---domain	containing	2	
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1395184_at	 0.014385296	 0.004317068	 2.300228	 Clec12a	 C---type	lectin	domain	family	12,	member	A	
1395753_at	 0.02160576	 0.008495678	 3.3889565	 Eln	 elastin	
1396055_at	 0.000633	 3.84E---05	 2.5738285	 Col6a3	 collagen,	type	VI,	alpha	3		
Female	rat	liver	zone	III	signature		
Probe	Set	ID	 Corrected	p---value	 p---value	 FCAbsolute	 Gene	Symbol	 Gene	Title	
1367729_at	 7.40E---07	 8.87E---09	 3.3560843	 Oat	 ornithine	aminotransferase	
1367733_at	 0.009332594	 0.002384375	 2.2751527	 Ca2	 carbonic	anhydrase	2	
1368047_at	 0.008036036	 0.001988959	 3.41109	 Slc13a3	 solute	carrier	family	13	(sodium---dependent	dicarboxylate	transporter),	member	3	
1368458_at	 8.50E---04	 5.94E---05	 5.9561276	 Cyp7a1	 cytochrome	P450,	family	7,	subfamily	a,	polypeptide	1	
1369693_a_at	 0.031172356	 0.014183976	 3.360717	 Slc1a2	 solute	carrier	family	1	(glial	high	affinity	glutamate	transporter),	member	2	
1369694_at	 0.04495169	 0.022670021	 2.1028576	 Slc1a2	 solute	carrier	family	1	(glial	high	affinity	glutamate	transporter),	member	2	
1370282_at	 8.47E---05	 1.35E---06	 2.6022782	 Csrp2	 cysteine	and	glycine---rich	protein	2	
1370436_at	 6.78E---14	 1.35E---16	 10.747984	 Acsm2a	 acyl---CoA	synthetase	medium---chain	family	member	2A	
1376897_at	 0.011782614	 0.003221992	 2.517401	 Kif26b	 kinesin	family	member	26B	
1377161_at	 4.29E---04	 2.23E---05	 3.9994276		 	1377177_at	 4.12E---04	 1.97E---05	 4.073607	 Irx1	 iroquois	homeobox	1	
1377423_at	 0.005939242	 0.001161768	 2.251542		 	1381464_at	 0.019707581	 0.007159241	 2.4482985	 Tbx3	 T---box	3	
1388146_at	 0.017932095	 0.006192121	 3.8361456	 LOC100912222	 uncharacterized	LOC100912222	
1379541_at	 4.42E---12	 3.53E---14	 4.181176		 	1379656_a_at	 0.002539977	 2.79E---04	 2.589711	 Coro2a	 coronin,	actin	binding	protein	2A	
1380351_at	 0.045627158	 0.023223404	 2.1178446		 	1381221_at	 0.019988563	 0.007491838	 2.570647	 RGD1311300	 similar	to	T	cell	receptor	V	delta	6	
1382953_at	 0.004914751	 8.83E---04	 2.3394399		 	1384312_at	 9.25E---05	 1.66E---06	 6.597049	 Irx1	 iroquois	homeobox	1	
1385707_at	 1.39E---04	 3.05E---06	 2.9118605	 Lect2	 leukocyte	cell---derived	chemotaxin	2	
1393160_at	 0.003672809	 5.57E---04	 2.3327503		 	1394681_at	 2.83E---04	 1.19E---05	 2.2198792	 Akr1cl	 aldo---keto	reductase	family	1,	member	C---like	
1395983_at	 2.76E---04	 9.92E---06	 3.5884063	 Rmdn2	 regulator	of	microtubule	dynamics	2		
Dog	bile	duct	signature		
Probe	Set	ID	 Corrected	p---value	 p---value	 FCAbsolute	 Gene	Symbol	 Gene	Title	
AFFX---PheX---5_at	 0.003869136	 0.003559725	 10.043593		 	AFFX---r2---Bs---thr---M_s_at	 0.003742879	 0.003421874	 9.843218		 	AFFX---Cfa---r2---Bs---thr---
M_s_at	
0.004291911	 0.00399201	 11.424598		 	Cfa.3796.1.A1_s_at	 2.37638E---06	 1.54981E---07	 15.539841	 ANXA13	 annexin	A13	
Cfa.5.1.S1_s_at	 0.007331138	 0.007240068	 12.706672	 GNB3	 guanine	nucleotide	binding	protein	(G	protein),	beta	polypeptide	3	
Cfa.305.1.A2_at	 0.000972938	 0.000667007	 26.147636	 HSPB8	 heat	shock	22kDa	protein	8	
CfaAffx.14256.1.S1_s_at	 0.001234545	 0.000901947	 14.36072	 PFKM	 phosphofructokinase,	muscle	
Cfa.3524.1.S1_s_at	 1.39486E---05	 2.3392E---06	 19.016079	 EGF	 epidermal	growth	factor	
Cfa.3524.1.S2_at	 4.17443E---05	 9.82027E---06	 16.59218	 EGF	 epidermal	growth	factor	
Cfa.3514.1.S1_s_at	 7.64362E---05	 2.25511E---05	 8.998031	 CLDN2	 claudin	2	
Cfa.3850.1.S2_at	 3.83694E---05	 8.81084E---06	 12.501918	 CAV1	 caveolin	1,	caveolae	protein,	22kDa	
CfaAffx.21188.1.S1_s_at	 0.005655398	 0.005435856	 8.941732	 DUOX1	 dual	oxidase	1	
Cfa.16181.1.S1_s_at	 0.000471733	 0.000256023	 24.304327	 CFTR	
cystic	fibrosis	transmembrane	conductance	regulator	(ATP---binding	cassette	sub---
family	
C,	member	7)	CfaAffx.7493.1.S1_s_at	 0.000975191	 0.000669308	 16.594934	 SOX9	 SRY	(sex	determining	region	Y)---box	9	
Cfa.3484.1.S1_at	 3.64074E---06	 3.42026E---07	 11.330937	 PGR	 progesterone	receptor	
CfaAffx.20792.1.S1_s_at	 2.15434E---05	 3.93067E---06	 93.27175	 SLC5A1	 solute	carrier	family	5	(sodium/glucose	cotransporter),	member	1	
Cfa.16330.1.S1_s_at	 8.44046E---05	 2.52296E---05	 52.612694	 SLCO2A1	 solute	carrier	organic	anion	transporter	family,	member	2A1	
Cfa.15829.1.S1_at	 5.07165E---06	 5.59142E---07	 14.0841465	 CAV2	 caveolin	2	
Cfa.15812.1.S1_at	 0.000187115	 7.56887E---05	 9.176506	 CCL20	 chemokine	(C---C	motif)	ligand	20	
Cfa.15798.1.S1_s_at	 5.25678E---07	 1.26522E---08	 16.751566	 FUT8	 fucosyltransferase	8	(alpha	(1,6)	fucosyltransferase)	
Cfa.3473.1.S1_at	 9.75793E---06	 1.44702E---06	 11.389474	 CAV2	 caveolin	2	
CfaAffx.10800.1.S1_s_at	 0.000593791	 0.000351218	 22.233406	 EOGT	 glycosyltransferase	AER61	
Cfa.3780.1.S1_at	 5.24963E---07	 1.19898E---08	 98.86601	WFDC2	 WAP	four---disulfide	core	domain	2	
Cfa.138.1.A1_at	 3.14967E---07	 6.1135E---09	 8.20898	 ANXA2	 annexin	A2	
Cfa.6416.1.A1_at	 5.81695E---06	 6.95505E---07	 40.79555	 SGCG	 sarcoglycan,	gamma	(35kDa	dystrophin---associated	glycoprotein)	
Cfa.200.1.A1_at	 2.43162E---06	 1.74963E---07	 53.49894	 TFF3	 trefoil	factor	3	(intestinal)	
Cfa.3872.1.S1_at	 0.000645192	 0.000395089	 11.260409	 GP2	 glycoprotein	2	(zymogen	granule	membrane)	
Cfa.16246.1.S1_at	 0.002043447	 0.001661094	 17.606924	 GIF	 gastric	intrinsic	factor	(vitamin	B	synthesis)	
Cfa.81.1.S1_at	 2.22494E---06	 1.37478E---07	 8.526816	 ANXA4	 annexin	A4	
Cfa.135.1.S1_at	 0.00017338	 6.78139E---05	 45.842575	 LAMC2	 laminin,	gamma	2	
Cfa.15807.1.S1_at	 0.000906825	 0.000611121	 21.823992	 CCL28	 chemokine	(C---C	motif)	ligand	28	




Cfa.7074.1.A1_at	 2.55595E---06	 1.94474E---07	 220.8137	MUC1	 mucin	1,	cell	surface	associated	
Cfa.797.1.S1_at	 3.40139E---05	 7.44715E---06	 29.41107	 LGALS3	 lectin,	galactoside---binding,	soluble,	3	
CfaAffx.22164.1.S1_s_at	 0.000104302	 3.37517E---05	 13.130114	 LGALS3	 lectin,	galactoside---binding,	soluble,	3	
CfaAffx.9899.1.S1_s_at	 2.43162E---06	 1.71508E---07	 8.841413	 SPINT2	 serine	peptidase	inhibitor,	Kunitz	type,	2	
Cfa.3586.1.S1_at	 5.59529E---05	 1.45964E---05	 171.23973	 DUOX2	 dual	oxidase	2	
Cfa.3854.1.S1_at	 1.76859E---06	 9.6119E---08	 23.907526	 CD9	 CD9	molecule	
Cfa.20172.1.S1_s_at	 0.001840153	 0.001457372	 14.153175	 SLIT2	 slit	homolog	2	(Drosophila)	
Cfa.3915.1.S1_s_at	 1.29669E---05	 2.09694E---06	 89.85594	 LAMB3	 laminin,	beta	3	




Cfa.299.1.A1_at	 0.000426081	 0.000227265	 18.573118	 FABP3	 fatty	acid	binding	protein	3,	muscle	and	heart	(mammary---derived	growth	inhibitor)	
Cfa.299.1.A1_s_at	 0.002594559	 0.002203764	 22.271511	 FABP3	 fatty	acid	binding	protein	3,	muscle	and	heart	(mammary---derived	growth	inhibitor)	
Cfa.1238.3.A1_at	 3.83706E---06	 3.75364E---07	 8.268237	 GSN	 gelsolin	
Cfa.5295.1.A1_at	 0.000112549	 3.79415E---05	 8.750082	 PLP2	 proteolipid	protein	2	(colonic	epithelium---enriched)	
Cfa.410.1.A1_at	 2.81129E---05	 5.544E---06	 28.783533	 PLLP	 plasmolipin	
Cfa.12226.1.A1_at	 0.001562756	 0.00119148	 17.580036	 LOC478056	 double---headed	protease	inhibitor,	submandibular	gland---like	
Cfa.7131.1.A1_at	 4.54676E---05	 1.08315E---05	 12.81181		 	Cfa.12202.1.A1_at	 1.73037E---06	 8.96368E---08	 103.865326	 GPX2	 glutathione	peroxidase	2	(gastrointestinal)	
Cfa.11754.1.A1_at	 3.08055E---06	 2.72657E---07	 13.1838	 ZNF532	 zinc	finger	protein	532	
CfaAffx.1121.1.S1_s_at	 2.42024E---05	 4.58492E---06	 16.640472	 ZNF532	 zinc	finger	protein	532	
Cfa.2400.1.A1_at	 8.72809E---07	 2.87519E---08	 13.771323	 FRZB	 frizzled---related	protein	
Cfa.6341.1.A1_at	 1.4277E---06	 6.87248E---08	 9.095833	 PDZK1IP1	 PDZK1	interacting	protein	1	
Cfa.12206.1.A1_at	 1.25855E---07	 2.9314E---10	 17.045073	 LOC100685470	 placenta---specific	gene	8	protein---like	
Cfa.12411.1.A1_at	 4.31498E---08	 4.99734E---11	 18.171152	 GALNT12	
UDP---N---acetyl---alpha---D---galactosamine:polypeptide	N---
acetylgalactosaminyltransferase	
12	(GalNAc---T12)	Cfa.6355.1.A1_at	 4.56855E---07	 9.57693E---09	 42.157864	 SLC13A2	 solute	carrier	family	13	(sodium---dependent	dicarboxylate	transporter),	member	2	
Cfa.11867.1.A1_at	 0.000529917	 0.000301233	 9.485682	 FAM129A	 family	with	sequence	similarity	129,	member	A	
Cfa.12228.1.A1_at	 1.53355E---05	 2.60752E---06	 26.757048	 SCGB1A1	 secretoglobin,	family	1A,	member	1	(uteroglobin)	
Cfa.12228.1.A1_s_at	 3.66864E---05	 8.23164E---06	 14.342029	 SCGB1A1	 secretoglobin,	family	1A,	member	1	(uteroglobin)	
Cfa.9465.1.A1_at	 1.36184E---05	 2.26269E---06	 9.303791	 SYT13	 synaptotagmin	XIII	
Cfa.15610.1.A1_at	 8.47325E---05	 2.55908E---05	 11.443425	 GPR116	 G	protein---coupled	receptor	116	
Cfa.11992.1.A1_at	 8.93141E---05	 2.75293E---05	 18.947681	 TCEA2	 transcription	elongation	factor	A	(SII),	2	
Cfa.12149.1.S1_at	 2.43162E---06	 1.70948E---07	 8.549634	 ANXA5	 annexin	A5	
Cfa.15654.1.A1_at	 1.49387E---06	 7.53896E---08	 190.44144		 	Cfa.10919.1.A1_at	 0.000240513	 0.000105131	 31.484049	 LOC100684429	 protein	BEX2---like	
Cfa.2364.1.A1_at	 0.000383856	 0.000198186	 13.561629		 	Cfa.4902.1.A1_at	 4.61022E---06	 4.86794E---07	 21.765694	 PDGFD	 platelet	derived	growth	factor	D	
Cfa.12054.1.A1_s_at	 2.43162E---06	 1.82007E---07	 17.810598	 AHCYL2	 adenosylhomocysteinase---like	2	
Cfa.7473.1.A1_at	 1.83149E---07	 1.76373E---09	 19.267792	 LOC100856512	 epithelial	discoidin	domain---containing	receptor	1---like	
Cfa.13560.1.A1_at	 0.00013376	 4.73561E---05	 22.416117	 ARHGEF28	 Rho	guanine	nucleotide	exchange	factor	(GEF)	28	
Cfa.11815.1.A1_at	 2.35816E---06	 1.50131E---07	 40.20934	 C30H15orf48	 chromosome	30	open	reading	frame,	human	C15orf48	
Cfa.15678.1.A1_at	 0.000125588	 4.41443E---05	 9.237352		 	Cfa.11829.1.A1_s_at	 0.000329412	 0.000159776	 16.668087	 LOC100685413	 uncharacterized	LOC100685413	
Cfa.6730.1.A1_at	 0.001785864	 0.001401793	 12.475679	 YPEL1	 yippee---like	1	(Drosophila)	
Cfa.13779.1.A1_at	 2.43162E---06	 1.81907E---07	 18.245874	 HNF1B	 HNF1	homeobox	B	
Cfa.9812.1.A1_at	 0.000122212	 4.20174E---05	 10.201421		 	
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Cfa.4784.1.A1_at	 0.000473699	 0.000257813	 8.93	LOC100856418	 RIMS---binding	protein	2---like	
Cfa.12558.1.A1_s_at	 6.34435E---05	 1.71439E---05	 10.627808	 PRKD1	 protein	kinase	D1	
Cfa.9356.1.A1_at	 2.38014E---06	 1.62618E---07	 18.04852	 GOLM1	 golgi	membrane	protein	1	
Cfa.12344.1.A1_at	 0.000529917	 0.000301576	 8.48218		 	Cfa.6869.1.A1_at	 0.000220324	 9.32153E---05	 16.324532	 C10H22orf23	 chromosome	10	open	reading	frame,	human	C22orf23	
Cfa.8427.1.A1_s_at	 0.002564652	 0.002159241	 8.807109	 AGBL5	 ATP/GTP	binding	protein---like	5	
Cfa.15675.1.A1_at	 0.000182503	 7.32562E---05	 29.112425		 	Cfa.15783.1.A1_at	 0.000232359	 0.000100845	 39.556606	 FBP2	 fructose---1,6---bisphosphatase	2	
Cfa.6345.1.A1_at	 0.00025583	 0.000115203	 40.068394		 	Cfa.11499.1.A1_at	 0.006333116	 0.006151601	 9.5127125	 FAM188B	 family	with	sequence	similarity	188,	member	B	
Cfa.11200.1.A1_at	 2.43162E---06	 1.76221E---07	 32.61186	MAP2	 microtubule---associated	protein	2	
Cfa.11405.1.A1_at	 0.002667964	 0.002286827	 8.56738	 ALDH1L2	 aldehyde	dehydrogenase	1	family,	member	L2	
Cfa.9852.1.A1_at	 0.000916762	 0.000620665	 14.606047		 	Cfa.7017.1.A1_s_at	 6.34435E---05	 1.71908E---05	 16.092505	 PDGFD	 platelet	derived	growth	factor	D	
Cfa.9405.1.A1_at	 2.38014E---06	 1.60145E---07	 15.862546		 	Cfa.12168.1.A1_s_at	 6.35497E---05	 1.72689E---05	 64.0456	 FAM3B	 family	with	sequence	similarity	3,	member	B	
Cfa.4763.1.A1_at	 0.00500597	 0.004745566	 10.747296	 FAM83F	 family	with	sequence	similarity	83,	member	F	
Cfa.15635.1.A1_s_at	 0.001557834	 0.001184099	 9.019208	 NBEA	 neurobeachin	
Cfa.11944.1.A1_at	 0.000928926	 0.000631943	 12.515857	 LOC607638	 uncharacterized	LOC607638	
Cfa.6733.1.A1_s_at	 0.00023617	 0.000102682	 16.534458	 ASB9	 ankyrin	repeat	and	SOCS	box	containing	9	
Cfa.9931.1.A1_at	 8.48933E---06	 1.15344E---06	 15.2504425		 	Cfa.2644.1.A1_at	 9.01468E---06	 1.2667E---06	 10.687785	 CA2	 carbonic	anhydrase	II	
Cfa.11162.1.A1_s_at	 2.63116E---06	 2.05639E---07	 9.6108465	 PPP2R2B	 protein	phosphatase	2,	regulatory	subunit	B,	beta	
Cfa.9134.1.A1_at	 9.56813E---05	 3.02749E---05	 19.740377		 	Cfa.5536.1.A1_at	 0.003228046	 0.002877171	 31.240194		 	Cfa.9626.1.A1_at	 0.005136023	 0.004880817	 15.981504	 CCDC181	 coiled---coil	domain	containing	181	
Cfa.11192.1.A1_at	 2.89827E---06	 2.47523E---07	 8.850655	 ZNF532	 zinc	finger	protein	532	
Cfa.10957.1.A1_at	 1.07512E---05	 1.6611E---06	 27.859629	 PLCB4	 phospholipase	C,	beta	4	
Cfa.11304.1.A1_at	 0.000506688	 0.000283241	 24.45029	 TPBG	 trophoblast	glycoprotein	
Cfa.9613.1.A1_at	 0.001198288	 0.000869876	 20.311426		 	Cfa.8914.1.A1_at	 0.002564652	 0.002157676	 15.412039	 KCNIP1	 Kv	channel	interacting	protein	1	
Cfa.13606.1.A1_at	 0.000248735	 0.000111236	 8.864612		 	Cfa.6303.1.A1_at	 1.18299E---06	 5.1746E---08	 17.025253	 LENG1	 leukocyte	receptor	cluster	(LRC)	member	1	
Cfa.6303.1.A1_s_at	 1.83149E---07	 1.71641E---09	 11.837524	 TMC4	 transmembrane	channel---like	4	
Cfa.10075.1.A1_at	 3.29525E---05	 7.01008E---06	 11.215967	 TTC39A	 tetratricopeptide	repeat	domain	39A	
Cfa.6250.2.A1_a_at	 2.82493E---05	 5.59284E---06	 45.2246	 LOC100685189	 uncharacterized	LOC100685189	
Cfa.13946.1.S1_a_at	 2.02653E---06	 1.16431E---07	 72.41698	 FXYD2	 FXYD	domain	containing	ion	transport	regulator	2	
Cfa.13946.1.S1_s_at	 1.79199E---07	 8.27163E---10	 43.401356	 FXYD2	 FXYD	domain	containing	ion	transport	regulator	2	
Cfa.4050.1.A1_a_at	 6.90787E---05	 1.97904E---05	 49.175045	 TAC1	 tachykinin,	precursor	1	
Cfa.6237.1.S1_at	 5.78307E---07	 1.57149E---08	 40.79857	 TSPAN8	 tetraspanin	8	
Cfa.9763.1.A1_at	 0.00136314	 0.001009756	 10.531444		 	Cfa.13845.1.A1_at	 6.29106E---07	 1.75837E---08	 9.718362	 CLDN2	 claudin	2	
Cfa.12050.1.A1_a_at	 0.000166264	 6.33816E---05	 34.11384	 TSPAN5	 tetraspanin	5	
Cfa.13673.1.A1_at	 9.21042E---06	 1.32293E---06	 100.64316	 EHF	 ets	homologous	factor	
Cfa.8942.1.A1_at	 0.002781115	 0.002405405	 13.618081		 	Cfa.12462.1.A1_at	 0.001647695	 0.001279266	 9.463901		 	Cfa.12089.1.A1_at	 0.003815219	 0.003498272	 42.163746	 GRIP1	 glutamate	receptor	interacting	protein	1	
Cfa.15294.1.A1_at	 9.04904E---07	 3.21367E---08	 35.625492		 	Cfa.9040.1.A1_at	 0.000632845	 0.000383245	 21.525782		 	Cfa.3167.1.A1_at	 0.000105613	 3.47337E---05	 52.66287	 IGSF11	 immunoglobulin	superfamily,	member	11	
Cfa.9199.1.A1_at	 3.726E---06	 3.54161E---07	 33.00564	 FA2H	 fatty	acid	2---hydroxylase	
Cfa.9240.1.S1_at	 2.63116E---06	 2.07774E---07	 26.734303	 SPP1	 secreted	phosphoprotein	1	
Cfa.568.1.A1_at	 0.002512046	 0.002106374	 9.927288		 	Cfa.2576.1.S1_at	 4.98594E---05	 1.22713E---05	 9.844979		 	Cfa.7626.1.S1_s_at	 0.001309742	 0.00096502	 18.615887	 SPATA6	 spermatogenesis	associated	6	
Cfa.448.1.S1_at	 0.000434688	 0.000232194	 20.422358	 TTC8	 tetratricopeptide	repeat	domain	8	
Cfa.9013.1.A1_at	 0.002653102	 0.002265848	 8.560938		 	Cfa.6848.1.A1_a_at	 0.002593707	 0.002201026	 9.365253		 	Cfa.6219.1.A1_at	 6.99376E---05	 2.01984E---05	 79.31575	 TMEM54	 transmembrane	protein	54	
Cfa.6219.1.A1_s_at	 0.000144151	 5.15943E---05	 8.951576	 TMEM54	 transmembrane	protein	54	
Cfa.9487.1.A1_at	 2.86766E---05	 5.83328E---06	 10.271737	MATN2	 matrilin	2	
Cfa.1629.1.A1_at	 4.00496E---06	 4.01118E---07	 17.071047	 DMXL2	 Dmx---like	2	
Cfa.10505.1.A1_at	 2.27978E---07	 3.54003E---09	 47.12045	 GPD1L	 glycerol---3---phosphate	dehydrogenase	1---like	
Cfa.12666.1.A1_at	 8.4289E---05	 2.51296E---05	 11.700338	 FRAS1	 Fraser	syndrome	1	
Cfa.15394.1.A1_at	 2.18785E---05	 4.02578E---06	 18.510633	 PDGFD	 platelet	derived	growth	factor	D	
Cfa.8787.1.A1_at	 0.000149046	 5.35779E---05	 17.388319		 	Cfa.10048.1.A1_at	 0.000672633	 0.00041674	 8.342149		 	Cfa.18202.2.S1_a_at	 0.000237232	 0.000103513	 25.82871	 FEZ1	 fasciculation	and	elongation	protein	zeta	1	(zygin	I)	
Cfa.16308.1.S1_a_at	 0.000295128	 0.000137369	 8.456769	 PMP22	 peripheral	myelin	protein	22	
Cfa.16308.1.S1_s_at	 0.005042257	 0.004787796	 9.202114	 PMP22	 peripheral	myelin	protein	22	
Cfa.1637.1.S1_s_at	 6.36162E---06	 7.85325E---07	 25.229582	 SSBP2	 single---stranded	DNA	binding	protein	2	
Cfa.1851.1.S1_at	 1.3856E---05	 2.31292E---06	 23.51836	 B3GALNT1	 beta---1,3---N---acetylgalactosaminyltransferase	1	(globoside	blood	group)	
Cfa.9951.1.A1_at	 5.76855E---07	 1.47797E---08	 11.192989		 	Cfa.19449.1.S1_at	 0.001498262	 0.00112835	 9.14352	 GULP1	 GULP,	engulfment	adaptor	PTB	domain	containing	1	
Cfa.16392.1.A1_at	 3.89732E---06	 3.84286E---07	 16.956415		 	Cfa.20396.1.S1_at	 1.42943E---06	 7.0875E---08	 15.376722	 BACE2	 beta---site	APP---cleaving	enzyme	2	
Cfa.2557.1.S1_at	 0.004474087	 0.004175351	 11.685853	 PLA2G4A	 phospholipase	A2,	group	IVA	(cytosolic,	calcium---dependent)	
Cfa.2112.1.A1_at	 1.14955E---06	 4.46255E---08	 14.489094		 	Cfa.6261.1.S1_at	 6.41178E---06	 7.96495E---07	 14.153604	 KRTCAP3	 keratinocyte	associated	protein	3	
CfaAffx.13535.1.S1_s_at	 0.000179098	 7.14723E---05	 11.550639	MEIS2	 Meis	homeobox	2	
Cfa.2730.1.S1_at	 5.30574E---06	 5.89068E---07	 27.163088	 RASEF	 RAS	and	EF---hand	domain	containing	
Cfa.19564.1.S1_at	 0.000369317	 0.000188966	 25.519695	WNT5A	 wingless---type	MMTV	integration	site	family,	member	5A	
Cfa.19670.1.S1_s_at	 0.000171176	 6.56529E---05	 15.045179	 SORBS1	 sorbin	and	SH3	domain	containing	1	
Cfa.16945.1.S1_at	 0.001845267	 0.001464179	 15.017514	 CCDC164	 coiled---coil	domain	containing	164	
CfaAffx.7441.1.S1_at	 0.00514452	 0.00489688	 15.478372	 CCDC164	 coiled---coil	domain	containing	164	
CfaAffx.7441.1.S1_s_at	 0.000405237	 0.000212057	 16.535223	 CCDC164	 coiled---coil	domain	containing	164	
Cfa.19675.1.S1_at	 4.44219E---06	 4.62153E---07	 16.051968		 	Cfa.6795.1.S1_at	 0.000191069	 7.75848E---05	 39.011192	 LOC100683874	 putative	uncharacterized	protein	C17orf110---like	
Cfa.14311.1.A1_at	 1.45728E---05	 2.4552E---06	 126.81184	 LOC100856604	 riboflavin	transporter	2---like	
Cfa.9712.1.A1_at	 7.71168E---05	 2.28117E---05	 10.10267		 	Cfa.2624.1.A1_at	 0.000370242	 0.000190295	 8.976321	 ADAMTS6	 ADAM	metallopeptidase	with	thrombospondin	type	1	motif,	6	
Cfa.5528.1.S1_at	 0.003491935	 0.003153044	 9.217439	 PPP2R2B	 protein	phosphatase	2,	regulatory	subunit	B,	beta	
Cfa.8772.1.A1_a_at	 0.000092672	 2.8996E---05	 60.3723	 ADTRP	 androgen---dependent	TFPI---regulating	protein	
Cfa.8772.1.A1_s_at	 0.000324345	 0.000156129	 15.761602	 ADTRP	 androgen---dependent	TFPI---regulating	protein	
Cfa.7424.1.S1_s_at	 0.001954213	 0.001576418	 9.576307	 AMPD3	 adenosine	monophosphate	deaminase	3	
Cfa.13580.1.S1_at	 0.000172218	 6.68463E---05	 11.094712	 LOC100856418	 RIMS---binding	protein	2---like	
Cfa.11894.1.A1_a_at	 2.84543E---05	 5.72936E---06	 44.619247		 	Cfa.10538.1.A1_at	 8.06558E---06	 1.06456E---06	 9.818013	 PION	 pigeon	homolog	(Drosophila)	
Cfa.18211.1.A1_s_at	 0.000999753	 0.000691599	 18.922766	 EFCAB11	 EF---hand	calcium	binding	domain	11	
Cfa.7090.1.S1_s_at	 9.44042E---05	 2.96846E---05	 8.721469	 ABI2	 abl---interactor	2	
Cfa.14245.1.A1_s_at	 1.1018E---05	 1.71942E---06	 35.557804	 GPR110	 G	protein---coupled	receptor	110	
Cfa.14251.1.A1_at	 0.000175667	 6.94165E---05	 50.415653	 TTC12	 tetratricopeptide	repeat	domain	12	
Cfa.14251.1.A1_s_at	 0.000582842	 0.00033984	 10.492943	 TTC12	 tetratricopeptide	repeat	domain	12	
Cfa.1387.1.A1_at	 5.97131E---06	 7.27869E---07	 12.418851	 AGRN	 agrin	
Cfa.2927.1.S1_at	 1.79199E---07	 1.27915E---09	 40.349648	 LOC100683693	 signal	transducer	CD24---like	
Cfa.17958.1.S1_s_at	 1.79199E---07	 9.03941E---10	 16.685595	MARCKSL1	 MARCKS---like	1	
Cfa.10891.1.A1_at	 0.00179293	 0.00140895	 15.239695	 TMEM218	 transmembrane	protein	218	
Cfa.1193.1.S1_at	 8.96837E---06	 1.24638E---06	 12.186453		 	Cfa.15083.1.S1_at	 0.000638686	 0.000389757	 11.237442	 EFEMP1	 EGF	containing	fibulin---like	extracellular	matrix	protein	1	
CfaAffx.5306.1.S1_s_at	 0.001051459	 0.000741246	 16.361128	 EFEMP1	 EGF	containing	fibulin---like	extracellular	matrix	protein	1	
Cfa.11001.1.A1_at	 0.000545716	 0.000312261	 23.016708		 	Cfa.4306.1.S1_a_at	 5.78307E---07	 1.54603E---08	 16.107666	 S100A6	 S100	calcium	binding	protein	A6	
Cfa.4306.1.S1_s_at	 2.27978E---07	 3.441E---09	 10.680236	 S100A6	 S100	calcium	binding	protein	A6	
Cfa.1851.2.S1_s_at	 0.000574439	 0.000333603	 51.33899	 B3GALNT1	 beta---1,3---N---acetylgalactosaminyltransferase	1	(globoside	blood	group)	
Cfa.4322.1.A1_at	 2.83092E---06	 2.3298E---07	 17.23415		 	
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Cfa.233.1.A1_at	 0.000312638	 0.000147823	 35.695683	 KIAA1324	 KIAA1324	ortholog	
Cfa.13795.1.A1_at	 9.14188E---06	 1.29179E---06	 11.809833	 CYBRD1	 cytochrome	b	reductase	1	
Cfa.17853.1.S1_at	 4.54676E---05	 1.08374E---05	 8.419062	 LOC100856291	 neuronal	protein	3.1---like	
Cfa.19443.1.S1_at	 0.000206488	 8.59296E---05	 14.231235	 CCDC160	 coiled---coil	domain---containing	protein	160---like	
Cfa.15316.1.A1_at	 0.000376621	 0.000193866	 15.592182	 ECSCR	 endothelial	cell	surface	expressed	chemotaxis	and	apoptosis	regulator	
Cfa.432.1.A1_at	 1.79199E---07	 1.20008E---09	 12.247755	 PRSS23	 protease,	serine,	23	
Cfa.10902.1.S1_at	 8.46977E---05	 2.54488E---05	 49.476177	 UGT8	 UDP	glycosyltransferase	8	
Cfa.16364.1.A1_at	 7.03631E---06	 8.90464E---07	 10.878502		 	Cfa.9769.1.A1_at	 0.00252043	 0.002115361	 9.432722		 	Cfa.12664.2.A1_s_at	 7.47728E---06	 9.62025E---07	 8.367712	 ANK3	 ankyrin	3,	node	of	Ranvier	(ankyrin	G)	
Cfa.8772.2.A1_at	 6.86343E---06	 8.61819E---07	 264.53848	 ADTRP	 androgen---dependent	TFPI---regulating	protein	
Cfa.13994.1.S1_at	 0.000437261	 0.000233907	 71.30538	 TFPI2	 tissue	factor	pathway	inhibitor	2	
Cfa.4115.1.A1_at	 0.006868676	 0.006740688	 13.140668	 DSCAML1	 Down	syndrome	cell	adhesion	molecule	like	1	
Cfa.10484.1.S1_at	 1.06179E---05	 1.59927E---06	 8.721476	 SLC38A1	 solute	carrier	family	38,	member	1	
Cfa.10484.1.S1_s_at	 0.002756828	 0.002380119	 9.269938	 SLC38A1	 solute	carrier	family	38,	member	1	
Cfa.1339.1.A1_at	 6.71065E---05	 1.90691E---05	 8.186108	 CHGA	 chromogranin	A	(parathyroid	secretory	protein	1)	
Cfa.15992.1.S1_at	 1.79199E---07	 1.04071E---09	 16.636522	 ROGDI	 rogdi	homolog	(Drosophila)	
Cfa.16704.1.S1_at	 4.63676E---06	 4.93196E---07	 54.43405	 ST6GALNAC2	
ST6	(alpha---N---acetyl---neuraminyl---2,3---beta---galactosyl---1,3)---N---
acetylgalactosaminide	alpha---2,6---sialyltransferase	2	
Cfa.4077.1.S1_at	 2.27978E---07	 3.47749E---09	 107.21464	 CA4	 carbonic	anhydrase	IV	
Cfa.4077.1.S1_s_at	 7.24987E---06	 9.2312E---07	 99.15406	 CA4	 carbonic	anhydrase	IV	
Cfa.16994.1.S1_at	 1.55125E---05	 2.66169E---06	 8.877538	 ITGA3	 integrin,	alpha	3	(antigen	CD49C,	alpha	3	subunit	of	VLA---3	receptor)	
Cfa.4359.1.S1_at	 0.000366501	 0.000187234	 17.194208	 LOC484210	 serine/threonine---protein	kinase	WNK2---like	
Cfa.16786.1.S1_at	 1.79199E---07	 1.39129E---09	 13.79786	 RRAGD	 Ras---related	GTP	binding	D	
Cfa.18710.1.S1_at	 0.007119413	 0.00701439	 12.993197	 GATM	 glycine	amidinotransferase	(L---arginine:glycine	amidinotransferase)	
Cfa.4306.2.S1_a_at	 8.10883E---07	 2.39236E---08	 16.26344	 S100A6	 S100	calcium	binding	protein	A6	
Cfa.21327.1.S1_at	 0.000242746	 0.000106673	 14.941704	 LCN	 allergen	Fel	d	4---like	
Cfa.21053.1.S1_s_at	 0.000687201	 0.000430034	 8.488392	 OXCT1	 3---oxoacid	CoA	transferase	1	
Cfa.20636.1.S1_at	 7.10232E---05	 2.05681E---05	 10.106704	 PPP1R1B	 protein	phosphatase	1,	regulatory	(inhibitor)	subunit	1B	
CfaAffx.7185.1.S1_s_at	 0.001874397	 0.001496025	 13.840655	 SPAG6	 sperm	associated	antigen	6	
Cfa.18546.1.S1_at	 3.93658E---05	 9.13799E---06	 48.862484	 SPAM1	 sperm	adhesion	molecule	1	(PH---20	hyaluronidase,	zona	pellucida	binding)	
Cfa.16067.1.S1_at	 0.002464639	 0.002055142	 10.80802	 DNAJA4	 DnaJ	(Hsp40)	homolog,	subfamily	A,	member	4	
Cfa.18258.1.S1_a_at	 0.000276742	 0.000126553	 11.285985	 LOC100856746	 protein	FAM107A---like	
Cfa.20479.1.S1_at	 0.007937967	 0.007870174	 9.452199	 KIF5C	 kinesin	family	member	5C	
Cfa.20847.1.S1_s_at	 3.64699E---05	 8.09812E---06	 66.21445	 TCN1	 transcobalamin	I	(vitamin	B12	binding	protein,	R	binder	family)	
Cfa.20309.1.S1_s_at	 0.003609962	 0.003273219	 10.050318	 PDE1C	 phosphodiesterase	1C,	calmodulin---dependent	70kDa	
CfaAffx.22343.1.S1_at	 0.003866478	 0.003554278	 9.335956	 SAV1	 salvador	homolog	1	(Drosophila)	
Cfa.20005.1.S1_s_at	 6.38256E---05	 1.73935E---05	 12.749285	 ATL1	 atlastin	GTPase	1	
Cfa.21572.1.S1_at	 2.74062E---06	 2.21292E---07	 11.265955	 AGRN	 agrin	
Cfa.19066.1.S1_at	 0.00393876	 0.00362684	 10.475471	 NXN	 nucleoredoxin	
Cfa.19027.1.S1_s_at	 6.52426E---07	 1.87421E---08	 10.889626	ME2	 malic	enzyme	2,	NAD(+)---dependent,	mitochondrial	
Cfa.19237.1.S1_at	 0.001421088	 0.001055886	 8.466962	 GMDS	 GDP---mannose	4,6---dehydratase	
Cfa.17122.1.S1_at	 2.27978E---07	 3.01574E---09	 52.886612	 RIPPLY1	 ripply1	homolog	(zebrafish)	
Cfa.16962.1.S1_s_at	 0.000324345	 0.000156015	 13.148721	 LTBP2	 latent	transforming	growth	factor	beta	binding	protein	2	
Cfa.5528.2.S1_s_at	 0.000418388	 0.000221862	 15.769544	 PPP2R2B	 protein	phosphatase	2,	regulatory	subunit	B,	beta	
Cfa.18961.1.S1_s_at	 5.73496E---06	 6.76837E---07	 11.699898	 SLC25A24	 solute	carrier	family	25	(mitochondrial	carrier;	phosphate	carrier),	member	24	
Cfa.20994.1.S1_s_at	 0.005325746	 0.005085922	 8.650565	 SBSPON	 somatomedin	B	and	thrombospondin,	type	1	domain	containing	
Cfa.17930.1.S1_s_at	 0.000849041	 0.000564929	 14.38387	 KCNK1	 potassium	channel,	subfamily	K,	member	1	
Cfa.17644.1.S1_s_at	 0.000113158	 3.8393E---05	 11.530364	 RRAGD	 Ras---related	GTP	binding	D	
CfaAffx.4331.1.S1_at	 0.00293813	 0.002577707	 25.150396	 LRRC1	 leucine	rich	repeat	containing	1	
CfaAffx.7184.1.S1_s_at	 0.000617721	 0.000370729	 9.024984	 SPAG6	 sperm	associated	antigen	6	
Cfa.20373.1.S1_at	 6.30708E---05	 1.69919E---05	 8.69777	 ABR	 active	BCR---related	
Cfa.17440.1.S1_s_at	 0.001648207	 0.001280943	 16.945232	 GPD1L	 glycerol---3---phosphate	dehydrogenase	1---like	
Cfa.18519.1.S1_s_at	 0.00041756	 0.0002211	 9.162884	 CCDC30	 coiled---coil	domain	containing	30	














CfaAffx.23343.1.S1_s_at	 0.000860261	 0.000574462	 12.771817	 CD9	 CD9	molecule	
Cfa.1186.1.A1_a_at	 5.24963E---07	 1.14669E---08	 13.117786	 CCDC30	 coiled---coil	domain	containing	30	
Cfa.1186.1.A1_s_at	 0.000105613	 3.47668E---05	 21.997078	 CCDC30	 coiled---coil	domain	containing	30	
Cfa.17318.1.S1_s_at	 1.15825E---06	 4.65623E---08	 25.228182	 KRT7///KRT86	 keratin	7///keratin	86	
CfaAffx.7229.1.S1_s_at	 0.000172218	 6.68548E---05	 11.69753	 ARMC3	 armadillo	repeat	containing	3	





Cfa.20087.1.S1_s_at	 8.69476E---06	 1.19485E---06	 18.12254	 GALNT3	
UDP---N---acetyl---alpha---D---galactosamine:polypeptide	N---
acetylgalactosaminyltransferase	
3	(GalNAc---T3)	Cfa.20111.1.S1_s_at	 1.69929E---05	 2.99486E---06	 17.963196	 NSUN7	 NOP2/Sun	domain	family,	member	7	
Cfa.14170.1.S1_a_at	 3.0806E---05	 6.40995E---06	 36.635574	 USH1C	 Usher	syndrome	1C	(autosomal	recessive,	severe)	
Cfa.17229.1.S1_s_at	 8.48091E---05	 2.56798E---05	 13.963705	 CHD3	 chromodomain	helicase	DNA	binding	protein	3	
Cfa.19166.1.S1_at	 8.10614E---06	 1.0762E---06	 11.440071	 KDM4B	 lysine	(K)---specific	demethylase	4B	
CfaAffx.14914.1.S1_s_at	 0.000567662	 0.000328703	 8.328977	 INPP1	 inositol	polyphosphate---1---phosphatase	
Cfa.17207.1.S1_at	 2.37638E---06	 1.53907E---07	 17.904182	 LOC490390	 uncharacterized	LOC490390	
Cfa.20055.1.A1_at	 0.000474754	 0.000259124	 16.038736		 	Cfa.21549.1.S1_at	 3.37741E---05	 7.35622E---06	 23.89694	 AQP3	 aquaporin	3	(Gill	blood	group)	
Cfa.9685.2.S1_a_at	 8.48933E---06	 1.13423E---06	 8.386961	 TSC22D1	 TSC22	domain	family,	member	1	
Cfa.15592.1.A1_at	 0.000351687	 0.000177482	 12.443376		 	Cfa.7054.1.A1_at	 0.001444866	 0.001078041	 8.938738		 	Cfa.7273.2.A1_a_at	 0.001035165	 0.000724133	 11.468615		 	Cfa.13829.1.A1_at	 1.18299E---06	 5.40078E---08	 76.33072	MUC20	 mucin	20,	cell	surface	associated	
Cfa.13946.2.A1_at	 2.31118E---05	 4.30256E---06	 176.84499	 FXYD2	 FXYD	domain	containing	ion	transport	regulator	2	
Cfa.9383.1.A1_at	 0.000835725	 0.000554101	 8.759654		 	Cfa.5013.1.A1_at	 0.000736	 0.000468	 22.861055		 	Cfa.8021.1.A1_at	 0.002359462	 0.001954616	 8.305117		 	Cfa.15774.1.A1_at	 0.002377298	 0.00197493	 8.487178		 	Cfa.11662.1.A1_s_at	 0.001091216	 0.000775204	 11.581353	 LRRC48	 leucine	rich	repeat	containing	48	
Cfa.11503.1.A1_at	 0.000111873	 3.73488E---05	 38.67133	MUC5B	 mucin	5B,	oligomeric	mucus/gel---forming	
Cfa.13470.2.A1_a_at	 0.000242746	 0.000106612	 19.365654	 DPEP1	 dipeptidase	1	(renal)	
Cfa.14260.1.A1_at	 0.000227212	 9.75529E---05	 12.337224		 	Cfa.2595.1.A1_at	 0.005016063	 0.004759029	 17.13894	 BAMBI	 BMP	and	activin	membrane---bound	inhibitor	homolog	(Xenopus	laevis)	
Cfa.12531.1.A1_at	 1.29721E---05	 2.11502E---06	 29.914022		 	Cfa.6572.1.A1_a_at	 0.001105755	 0.000790683	 16.627436		 	Cfa.5104.1.A1_at	 0.000563297	 0.00032534	 25.635275		 	Cfa.12309.1.A1_s_at	 5.36362E---05	 1.35756E---05	 28.35283	 NSUN7	 NOP2/Sun	domain	family,	member	7	
Cfa.10032.1.A1_at	 0.000294983	 0.000136764	 21.372498		 	Cfa.12467.2.A1_a_at	 3.33042E---05	 7.16247E---06	 14.517796		 	Cfa.9064.1.A1_at	 0.00655419	 0.006406619	 10.495075	 PLXNA2	 plexin	A2	
Cfa.10739.1.A1_s_at	 4.10135E---06	 4.1714E---07	 10.933695	 CADM1	 cell	adhesion	molecule	1	
Cfa.4720.1.A1_at	 8.04512E---06	 1.05561E---06	 406.2316	 DMBT1	 deleted	in	malignant	brain	tumors	1	
Cfa.15612.1.A1_at	 0.000823612	 0.000542893	 36.006004		 	Cfa.6228.1.A1_at	 6.02377E---05	 1.60883E---05	 24.088121	 SLC28A3	 solute	carrier	family	28	(sodium---coupled	nucleoside	transporter),	member	3	
Cfa.432.2.A1_at	 0.000124015	 4.32319E---05	 9.523299	 PRSS23	 protease,	serine,	23	
Cfa.12399.1.A1_at	 0.005306216	 0.005059032	 8.325382		 	Cfa.7057.1.A1_at	 0.001473659	 0.001104279	 8.589191		 	Cfa.7842.1.A1_s_at	 1.22564E---05	 1.96977E---06	 8.735041	 ENPP3	 ectonucleotide	pyrophosphatase/phosphodiesterase	3	
Cfa.5672.1.A1_s_at	 0.00491648	 0.004637829	 9.145544	 LOC481027	 kita---kyushu	lung	cancer	antigen	1	homolog	
Cfa.7163.1.A1_at	 9.01468E---06	 1.26681E---06	 15.067506	 TMEM51	 transmembrane	protein	51	
Cfa.14357.1.A1_at	 1.1823E---05	 1.87258E---06	 38.062428	 DMBT1	 deleted	in	malignant	brain	tumors	1	
Cfa.14085.1.A1_at	 2.18517E---05	 4.00389E---06	 29.697372		 	Cfa.3164.1.A1_at	 0.002769334	 0.002393066	 8.927593		 	Cfa.8233.1.A1_s_at	 0.000575018	 0.000334385	 12.923119	 FHAD1	 forkhead---associated	(FHA)	phosphopeptide	binding	domain	1	
Cfa.7798.1.A1_at	 0.000354401	 0.000179127	 46.60583	 IGSF11	 immunoglobulin	superfamily,	member	11	
Cfa.9800.1.A1_at	 0.000244302	 0.000108305	 58.60764	 CTNND2	 catenin	(cadherin---associated	protein),	delta	2	
Cfa.15600.1.A1_at	 0.0018717	 0.001492419	 36.040375		 	Cfa.11643.1.A1_at	 0.001967299	 0.001590029	 13.703433		 	
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Cfa.443.1.A1_at	 2.06888E---06	 1.22201E---07	 18.593288		 	Cfa.1553.1.A1_at	 3.2053E---06	 2.96142E---07	 11.715248		 	Cfa.2633.1.A1_at	 0.001116881	 0.000802474	 29.366852	 AVIL	 advillin	
Cfa.2428.1.A1_at	 0.000563297	 0.000325383	 13.068334		 	Cfa.2871.1.A1_at	 0.003743216	 0.003426437	 14.25448	 CLHC1	 clathrin	heavy	chain	linker	domain	containing	1	
Cfa.13542.1.A1_at	 5.82823E---06	 7.01379E---07	 42.930687	 PKHD1	 polycystic	kidney	and	hepatic	disease	1	(autosomal	recessive)	
Cfa.5582.1.A1_at	 0.001234545	 0.00090101	 14.923911		 	Cfa.2608.1.A1_at	 0.000193509	 7.90261E---05	 50.38765	 CDC42BPG	 CDC42	binding	protein	kinase	gamma	(DMPK---like)	
Cfa.9561.1.A1_at	 0.004009479	 0.003707523	 9.048995		 	Cfa.9165.1.A1_s_at	 0.003473769	 0.003133944	 13.204778	 EVA1C	 eva---1	homolog	C	(C.	elegans)	
Cfa.6275.1.A1_at	 0.007452053	 0.007365266	 9.88584		 	Cfa.14200.1.A1_s_at	 1.20991E---06	 5.63624E---08	 39.93073	 ATP2C2	 ATPase,	Ca++	transporting,	type	2C,	member	2	
Cfa.13645.1.A1_at	 5.6036E---06	 6.43892E---07	 85.479256		 	Cfa.14035.1.A1_at	 8.03534E---06	 1.04809E---06	 17.227924		 	Cfa.13720.1.A1_at	 0.000747474	 0.000478198	 20.80519		 	Cfa.7663.1.A1_at	 0.003673806	 0.003341876	 8.311094		 	Cfa.9166.1.A1_at	 0.001847657	 0.001468945	 8.341711		 	Cfa.13653.1.A1_at	 3.83256E---05	 8.71848E---06	 21.15787	WFDC2	 WAP	four---disulfide	core	domain	2	
Cfa.6288.1.A1_at	 2.68868E---06	 2.15011E---07	 52.92139		 	Cfa.13819.1.A1_at	 0.000687201	 0.00042842	 18.518661	 AHCYL2	 adenosylhomocysteinase---like	2	
Cfa.7146.1.A1_at	 3.32894E---05	 7.13345E---06	 37.10383	 LOC100685154	 uncharacterized	LOC100685154	
Cfa.5138.1.A1_at	 0.000969151	 0.000663658	 27.316141		 	Cfa.6650.1.A1_at	 0.003418094	 0.0030731	 9.507441		 	Cfa.4896.1.A1_at	 0.004583865	 0.004281359	 10.630574		 	Cfa.6163.1.A1_at	 0.001225255	 0.000892305	 16.857897		 	Cfa.14884.1.A1_at	 0.000681433	 0.000423779	 8.424942		 	Cfa.13523.1.A1_at	 0.000206543	 8.62736E---05	 24.255383		 	Cfa.9770.1.A1_at	 0.000370242	 0.000190266	 17.392803		 	Cfa.1636.1.A1_s_at	 4.50119E---06	 4.71787E---07	 9.899923	 SSBP2	 single---stranded	DNA	binding	protein	2	
Cfa.8974.1.A1_s_at	 0.000764569	 0.000496851	 25.178776	 PCSK1	 proprotein	convertase	subtilisin/kexin	type	1	
Cfa.7863.1.A1_at	 1.08817E---05	 1.6897E---06	 126.40788		 	Cfa.14663.1.A1_at	 0.001054697	 0.000744347	 32.580128		 	Cfa.13135.1.A1_s_at	 6.49341E---05	 1.80485E---05	 9.490747	 CHD3	 chromodomain	helicase	DNA	binding	protein	3	
Cfa.9117.1.A1_at	 5.74851E---05	 1.50407E---05	 13.558179	 ELOVL7	 ELOVL	fatty	acid	elongase	7	
CfaAffx.12643.1.S1_s_at	 0.000459694	 0.000248406	 24.29481	 O3FAR1	 omega---3	fatty	acid	receptor	1	
Cfa.5354.1.A1_s_at	 3.92832E---06	 3.90392E---07	 8.186849	 PIGR	 polymeric	immunoglobulin	receptor	
Cfa.9413.1.A1_at	 0.001050327	 0.000739057	 20.306393	 SYT13	 synaptotagmin	XIII	
Cfa.6405.1.A1_at	 0.005388094	 0.005153829	 9.564256		 	Cfa.5182.1.A1_at	 0.002108516	 0.001720536	 12.487829		 	Cfa.10063.1.A1_at	 0.001515429	 0.001143631	 9.324904	 PTK2B	 PTK2B	protein	tyrosine	kinase	2	beta	
Cfa.13369.1.A1_at	 0.000152023	 5.58077E---05	 13.295719	 PTX3	 pentraxin	3,	long	
Cfa.7866.1.A1_at	 6.99376E---05	 2.01994E---05	 17.879051		 	Cfa.5150.1.A1_at	 0.000657863	 0.000405546	 9.132712		 	Cfa.4847.1.A1_at	 2.8545E---06	 2.41569E---07	 19.487076		 	Cfa.4686.1.A1_at	 0.002158544	 0.00176471	 10.819988	MCAM	 melanoma	cell	adhesion	molecule	
Cfa.4621.1.A1_at	 0.00483238	 0.004550992	 8.743851		 	Cfa.12645.1.A1_at	 0.000105613	 3.46454E---05	 9.152567	 C17H1orf56	 chromosome	17	open	reading	frame,	human	C1orf56	
Cfa.5913.1.A1_at	 0.000293629	 0.000135872	 12.45811	 GULP1	 GULP,	engulfment	adaptor	PTB	domain	containing	1	
Cfa.5913.1.A1_s_at	 3.06789E---06	 2.69155E---07	 15.204512	 GULP1	 GULP,	engulfment	adaptor	PTB	domain	containing	1	
Cfa.19508.1.A1_at	 0.000125588	 4.41704E---05	 17.740232		 	Cfa.9053.1.A1_at	 0.001256946	 0.000919288	 14.37992		 	Cfa.14003.1.A1_at	 0.001961296	 0.001583655	 9.455918		 	Cfa.13744.1.A1_at	 3.82933E---06	 3.71635E---07	 119.84223		 	Cfa.12837.1.A1_at	 0.002832006	 0.002456506	 12.036987	 LRRC14B	 leucine	rich	repeat	containing	14B	
Cfa.5475.1.A1_at	 0.00136314	 0.001011772	 21.14226		 	Cfa.3073.1.A1_at	 1.16814E---06	 4.80681E---08	 11.233287		 	Cfa.6574.1.A1_at	 0.004086056	 0.003786244	 8.337941	 DZIP1L	 DAZ	interacting	protein	1---like	
Cfa.8323.1.A1_at	 0.000149963	 5.43731E---05	 17.878927		 	Cfa.14061.1.A1_at	 0.004439037	 0.004139195	 8.369896		 	Cfa.6646.1.A1_at	 8.70874E---05	 2.66401E---05	 10.048485	 CEP104	 centrosomal	protein	104kDa	
Cfa.2704.1.A1_at	 9.18071E---06	 1.3044E---06	 15.417641		 	Cfa.12976.1.A1_at	 0.001455456	 0.001088432	 13.988864		 	Cfa.6436.1.A1_at	 2.3688E---05	 4.4323E---06	 39.493702	 BAIAP2L2	 BAI1---associated	protein	2---like	2	
Cfa.5711.1.A1_at	 0.005655398	 0.005432665	 13.802143		 	Cfa.3409.1.A1_at	 5.73496E---06	 6.76367E---07	 27.067104	 EHF	 ets	homologous	factor	
Cfa.16572.1.A1_at	 1.05349E---05	 1.57859E---06	 15.730888		 	Cfa.16636.1.S1_at	 4.56855E---07	 9.34294E---09	 46.151787		 	Cfa.3401.1.A1_at	 0.002590383	 0.002192172	 8.556105		 	CfaAffx.13709.1.S1_s_at	 0.006333116	 0.006156103	 8.21997	 CA13	 carbonic	anhydrase	XIII	
CfaAffx.230.1.S1_at	 0.000333561	 0.000163414	 25.099607	 LOC608794	 uncharacterized	LOC608794	
CfaAffx.268.1.S1_at	 0.001100522	 0.000786087	 18.499342	 LOC481027	 kita---kyushu	lung	cancer	antigen	1	homolog	
CfaAffx.297.1.S1_at	 0.000758929	 0.000488472	 20.099873		 	CfaAffx.324.1.S1_at	 0.002239322	 0.00184292	 16.18011	 LOC100856280	 uncharacterized	LOC100856280	
CfaAffx.426.1.S1_at	 0.000859025	 0.000572239	 14.487288	 cOR2AV2	 cOR2AV2	olfactory	receptor	family	2	subfamily	AV---like	
CfaAffx.491.1.S1_at	 0.000622841	 0.000375591	 10.201038		 	CfaAffx.808.1.S1_s_at	 3.35579E---05	 7.25061E---06	 33.33017	 CCL28	 chemokine	(C---C	motif)	ligand	28	
CfaAffx.851.1.S1_s_at	 5.33885E---05	 1.343E---05	 27.723545	 C30H15orf48	 chromosome	30	open	reading	frame,	human	C15orf48	
CfaAffx.1041.1.S1_at	 0.000232232	 0.00010061	 14.499216	 SERPINB8	 serpin	peptidase	inhibitor,	clade	B	(ovalbumin),	member	8	
CfaAffx.1224.1.S1_s_at	 2.23679E---05	 4.1332E---06	 10.316443	ME2	 malic	enzyme	2,	NAD(+)---dependent,	mitochondrial	
CfaAffx.1271.1.S1_at	 0.000575323	 0.000335009	 10.90161	 STAC3	 SH3	and	cysteine	rich	domain	3	
CfaAffx.1400.1.S1_at	 0.000724003	 0.000459247	 31.027843	 AVIL	 advillin	
CfaAffx.1435.1.S1_at	 0.001005349	 0.000696563	 9.146038	 ZNF354C	 zinc	finger	protein	354C	
CfaAffx.1463.1.S1_s_at	 0.000301525	 0.00014093	 19.872036	 LOC100856646	 calpain---7---like	protein---like	
CfaAffx.1465.1.S1_s_at	 0.000404793	 0.000211126	 22.973515	 LOC100856646	 calpain---7---like	protein---like	
CfaAffx.1466.1.S1_at	 1.07512E---05	 1.64328E---06	 55.601704	 LOC100856646	 calpain---7---like	protein---like	
CfaAffx.1646.1.S1_s_at	 8.40561E---07	 2.5938E---08	 25.467722	 TSPAN8	 tetraspanin	8	
CfaAffx.1679.1.S1_at	 0.001311066	 0.000967013	 9.302989	 NIPAL2	 NIPA---like	domain	containing	2	
CfaAffx.1750.1.S1_s_at	 3.7253E---05	 8.42317E---06	 13.651545	 SPAG1	 sperm	associated	antigen	1	
CfaAffx.1885.1.S1_s_at	 1.14258E---06	 4.34677E---08	 13.382188	 SLC12A2	 solute	carrier	family	12	(sodium/potassium/chloride	transporters),	member	2	
CfaAffx.1888.1.S1_at	 5.73496E---06	 6.81249E---07	 20.577137	 SLC12A2	 solute	carrier	family	12	(sodium/potassium/chloride	transporters),	member	2	
CfaAffx.1888.1.S1_s_at	 3.1349E---06	 2.85623E---07	 19.66593	 SLC12A2	 solute	carrier	family	12	(sodium/potassium/chloride	transporters),	member	2	
CfaAffx.1922.1.S1_s_at	 8.40561E---07	 2.6757E---08	 51.051975	 SLC44A4	 solute	carrier	family	44,	member	4	
CfaAffx.2078.1.S1_s_at	 0.00162223	 0.001251198	 8.699302	 PACRG	 PARK2	co---regulated	
CfaAffx.2119.1.S1_s_at	 0.007120309	 0.007020801	 8.568912	 LOC481728	 butyrophilin---like	protein	1---like	
CfaAffx.2121.1.S1_at	 2.42899E---05	 4.62036E---06	 30.862347	 LOC100856021	 butyrophilin	subfamily	1	member	A1---like	
CfaAffx.2174.1.S1_at	 3.726E---06	 3.55822E---07	 35.4295	 SAMD12	 sterile	alpha	motif	domain	containing	12	
CfaAffx.2292.1.S1_at	 6.59819E---05	 1.85998E---05	 11.755526	 ROS1	 c---ros	oncogene	1	,	receptor	tyrosine	kinase	
CfaAffx.2294.1.S1_at	 5.35824E---05	 1.35204E---05	 14.945389	 ROS1	 c---ros	oncogene	1	,	receptor	tyrosine	kinase	
CfaAffx.2591.1.S1_s_at	 0.002048797	 0.001667034	 9.697935	 NDRG1	 N---myc	downstream	regulated	1	
CfaAffx.2916.1.S1_at	 2.90576E---07	 5.41446E---09	 20.030636	 GOLM1	 golgi	membrane	protein	1	
CfaAffx.2951.1.S1_at	 0.000780736	 0.000509782	 14.960096	MAPK13	 mitogen---activated	protein	kinase	13	
CfaAffx.2963.1.S1_at	 6.73307E---05	 1.91851E---05	 58.973026	 SLC28A3	 solute	carrier	family	28	(sodium---coupled	nucleoside	transporter),	member	3	
CfaAffx.3038.1.S1_at	 0.007059157	 0.006938581	 8.333131	 BAIAP2L2	 BAI1---associated	protein	2---like	2	
CfaAffx.3050.1.S1_at	 0.000122212	 4.20341E---05	 11.514186	 C10H22orf23	 chromosome	10	open	reading	frame,	human	C22orf23	
CfaAffx.3084.1.S1_at	 0.000179469	 7.17598E---05	 23.122366	 RASEF	 RAS	and	EF---hand	domain	containing	
CfaAffx.3139.1.S1_at	 0.000253241	 0.000113841	 15.183069	 CDC42EP1	 CDC42	effector	protein	(Rho	GTPase	binding)	1	
CfaAffx.3228.1.S1_s_at	 1.17469E---06	 4.92493E---08	 28.60948	 KCNK16	 potassium	channel,	subfamily	K,	member	16	
CfaAffx.3229.1.S1_at	 0.002471367	 0.002062671	 8.895413	 KCNK17	 potassium	channel,	subfamily	K,	member	17	
CfaAffx.3263.1.S1_at	 0.005858573	 0.005644789	 22.412739	 UNC5CL	 unc---5	homolog	C	(C.	elegans)---like	
CfaAffx.3294.1.S1_at	 4.05096E---05	 9.46692E---06	 38.19013	 NCR2	 natural	cytotoxicity	triggering	receptor	2	
CfaAffx.3408.1.S1_at	 0.000176888	 7.01784E---05	 40.895737	 IFNE	 interferon,	epsilon	
CfaAffx.3545.1.S1_at	 1.07059E---06	 3.98977E---08	 179.16513	 SPAM1	 sperm	adhesion	molecule	1	(PH---20	hyaluronidase,	zona	pellucida	binding)	
CfaAffx.3574.1.S1_at	 0.000315591	 0.000150578	 8.350628	 ASB15	 ankyrin	repeat	and	SOCS	box	containing	15	
CfaAffx.3737.1.S1_s_at	 0.003684927	 0.003355916	 15.022637	 C14H7orf63	 chromosome	14	open	reading	frame,	human	C7orf63	
CfaAffx.3948.1.S1_at	 9.37478E---06	 1.35381E---06	 9.805205	 ENPP5	 ectonucleotide	pyrophosphatase/phosphodiesterase	5	(putative)	
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CfaAffx.3983.1.S1_at	 0.000337491	 0.000165863	 28.241486	 TFPI2	 tissue	factor	pathway	inhibitor	2	
CfaAffx.4020.1.S1_s_at	 2.22494E---06	 1.37724E---07	 19.893684	 GLIS3	 GLIS	family	zinc	finger	3	
CfaAffx.4028.1.S1_s_at	 0.000175667	 6.93406E---05	 12.0417185	 GPR110	 G	protein---coupled	receptor	110	
CfaAffx.4066.1.S1_at	 5.43032E---05	 1.39552E---05	 22.542818	 NCK2	 NCK	adaptor	protein	2	
CfaAffx.4072.1.S1_at	 3.05974E---05	 6.29526E---06	 15.5929785	 PPP1R9A	 protein	phosphatase	1,	regulatory	subunit	9A	
CfaAffx.4106.1.S1_s_at	 3.1349E---06	 2.82467E---07	 8.316679	 ANXA2	 annexin	A2	
CfaAffx.4150.1.S1_s_at	 3.11645E---05	 6.53294E---06	 21.15254	 PKHD1	 polycystic	kidney	and	hepatic	disease	1	(autosomal	recessive)	
CfaAffx.4200.1.S1_at	 0.008022028	 0.007959745	 9.97598	 EFHC1	 EF---hand	domain	(C---terminal)	containing	1	
CfaAffx.4293.1.S1_at	 2.06888E---06	 1.23683E---07	 22.554296	 THSD7A	 thrombospondin,	type	I,	domain	containing	7A	
CfaAffx.4318.1.S1_at	 0.000590211	 0.000346378	 12.481081	 LOC100856559	 clathrin	light	chain	A---like	
CfaAffx.4351.1.S1_at	 8.60092E---05	 2.61767E---05	 49.85847	 FAM83B	 family	with	sequence	similarity	83,	member	B	
CfaAffx.4532.1.S1_at	 4.76435E---05	 1.1504E---05	 280.35873	 AGR2	 anterior	gradient	2	homolog	(Xenopus	laevis)	
CfaAffx.4532.1.S1_s_at	 5.8699E---05	 1.54344E---05	 127.03371	 AGR2	 anterior	gradient	2	homolog	(Xenopus	laevis)	
CfaAffx.4549.1.S1_at	 2.52459E---05	 4.82181E---06	 16.906698	 BEND6	 BEN	domain---containing	protein	6---like	
CfaAffx.4615.1.S1_at	 0.000109659	 3.62694E---05	 16.49695	 GALNT12	
UDP---N---acetyl---alpha---D---galactosamine:polypeptide	N---
acetylgalactosaminyltransferase	
12	(GalNAc---T12)	CfaAffx.4623.1.S1_s_at	 0.000860261	 0.000576402	 8.853461	 DYNC2LI1	 dynein,	cytoplasmic	2,	light	intermediate	chain	1	
CfaAffx.4646.1.S1_at	 6.46002E---05	 1.7755E---05	 9.623337	MACC1	 metastasis	associated	in	colon	cancer	1	
CfaAffx.4655.1.S1_at	 0.000154336	 5.70373E---05	 16.588612	 ITGB8	 integrin,	beta	8	
CfaAffx.4986.1.S1_s_at	 0.001892844	 0.001516626	 16.454208	 DNAH11	 dynein,	axonemal,	heavy	chain	11	
CfaAffx.4988.1.S1_s_at	 0.000822924	 0.000541801	 30.106031	 DNAH11	 dynein,	axonemal,	heavy	chain	11	
CfaAffx.5064.1.S1_s_at	 0.004105404	 0.003808974	 14.966041	 EML6	 echinoderm	microtubule	associated	protein	like	6	
CfaAffx.5079.1.S1_at	 0.000223004	 9.53832E---05	 19.215984	 ZNF462	 zinc	finger	protein	462	
CfaAffx.5084.1.S1_at	 6.59819E---05	 1.86471E---05	 12.785454	 ZNF462	 zinc	finger	protein	462	
CfaAffx.5146.1.S1_at	 0.000835725	 0.000552236	 15.337511	 LOC611704	 uncharacterized	LOC611704	
CfaAffx.5550.1.S1_s_at	 0.004993203	 0.004729587	 10.307933	 LCN	 allergen	Fel	d	4---like	
CfaAffx.5565.1.S1_at	 2.84543E---05	 5.74388E---06	 13.530967	 SPACA1	 sperm	acrosome	associated	1	
CfaAffx.5584.1.S1_at	 0.001115984	 0.000800597	 12.273976	 LOC100856633	 peptidase	M20	domain---containing	protein	2---like	
CfaAffx.5585.1.S1_s_at	 0.000404592	 0.000210463	 9.566137	 GABRR1///GABRR2	
gamma---aminobutyric	acid	(GABA)	A	receptor,	rho	1///gamma---aminobutyric	acid	
(GABA)	A	receptor,	rho	2	
CfaAffx.5597.1.S1_s_at	 0.000359197	 0.000182108	 18.123672	 ANKRD6	 ankyrin	repeat	domain	6	
CfaAffx.5712.1.S1_s_at	 0.000805193	 0.000526376	 10.998292	 NPSR1	 neuropeptide	S	receptor	1	
CfaAffx.5761.1.S1_at	 0.002590383	 0.002190581	 16.262945	 LOC482707	 solute	carrier	family	23	member	2---like	
CfaAffx.5787.1.S1_s_at	 0.000174527	 6.84286E---05	 18.807266	 BSPRY	 B---box	and	SPRY	domain	containing	
CfaAffx.5886.1.S1_s_at	 2.43931E---07	 4.16653E---09	 10.975632	 ANXA4	 annexin	A4	
CfaAffx.6001.1.S1_at	 0.002614392	 0.002224669	 8.695706	 OSCP1	 organic	solute	carrier	partner	1	
CfaAffx.6032.1.S1_s_at	 0.000763916	 0.00049524	 10.664287	 GRHL1	 grainyhead---like	1	(Drosophila)	
CfaAffx.6036.1.S1_s_at	 1.20611E---05	 1.91967E---06	 23.64786	 CAV2	 caveolin	2	
CfaAffx.6117.1.S1_s_at	 0.000591446	 0.000348071	 11.806558	 KLHL32	 kelch---like	32	(Drosophila)	
CfaAffx.6223.1.S1_s_at	 1.99576E---05	 3.56386E---06	 15.133091	 LOC482730	 protein	FAM115A---like	
CfaAffx.6291.1.S1_at	 0.000479983	 0.000263096	 17.041191	 POU6F2	 POU	class	6	homeobox	2	
CfaAffx.6292.1.S1_at	 0.000344227	 0.000170777	 61.92335	 POU6F2	 POU	class	6	homeobox	2	
CfaAffx.6296.1.S1_at	 0.000155112	 5.75055E---05	 63.453423	 SLC13A1	 solute	carrier	family	13	(sodium/sulfate	symporters),	member	1	
CfaAffx.6296.1.S1_s_at	 0.000744586	 0.000475194	 51.401405	 SLC13A1	 solute	carrier	family	13	(sodium/sulfate	symporters),	member	1	
CfaAffx.6489.1.S1_at	 0.000209917	 8.78457E---05	 154.2489	 SCOC	 short	coiled---coil	protein	
CfaAffx.6555.1.S1_at	 5.43345E---05	 1.40055E---05	 21.140106	 SCML4	 sex	comb	on	midleg---like	4	(Drosophila)	
CfaAffx.6581.1.S1_s_at	 0.003243874	 0.002893797	 8.315182	 TRPM4	 transient	receptor	potential	cation	channel,	subfamily	M,	member	4	
CfaAffx.6687.1.S1_at	 0.000518171	 0.000291672	 9.338868	 AKD1	 adenylate	kinase	domain	containing	1	
CfaAffx.6688.1.S1_at	 5.28326E---05	 1.31261E---05	 17.425278	 AKD1	 adenylate	kinase	domain	containing	1	
CfaAffx.6699.1.S1_at	 0.001840153	 0.001458693	 15.043034	 AKD1	 adenylate	kinase	domain	containing	1	
CfaAffx.6747.1.S1_s_at	 5.89748E---06	 7.14291E---07	 107.91786	 SLC26A3	 solute	carrier	family	26,	member	3	
CfaAffx.6743.1.S1_at	 5.544E---05	 1.44196E---05	 46.823425	 SLC26A3	 solute	carrier	family	26,	member	3	
CfaAffx.6771.1.S1_s_at	 9.95878E---05	 3.1933E---05	 27.7467	 TTC39A	 tetratricopeptide	repeat	domain	39A	
CfaAffx.6866.1.S1_at	 8.62054E---05	 2.63034E---05	 14.327895	 RAB19	 RAB19,	member	RAS	oncogene	family	
CfaAffx.6875.1.S1_at	 0.004816898	 0.004532671	 9.888635	 TP53I3	 tumor	protein	p53	inducible	protein	3	
CfaAffx.6885.1.S1_s_at	 0.000212997	 8.96308E---05	 28.937567	 PGR	 progesterone	receptor	
CfaAffx.6975.1.S1_at	 6.47396E---05	 1.78939E---05	 11.80613	 C19orf68	 chromosome	19	open	reading	frame	68	
CfaAffx.7045.1.S1_s_at	 0.001523158	 0.001151829	 19.802452	 LOC100856352	 tetratricopeptide	repeat	protein	26---like	
CfaAffx.7149.1.S1_at	 0.003534831	 0.003197266	 12.284031	 ANXA5	 annexin	A5	
CfaAffx.7149.1.S1_x_at	 0.000975692	 0.000671167	 11.332041	 ANXA5	 annexin	A5	
CfaAffx.7221.1.S1_s_at	 4.95882E---05	 1.20891E---05	 25.914322	 SLC1A5	 solute	carrier	family	1	(neutral	amino	acid	transporter),	member	5	
CfaAffx.7346.1.S1_s_at	 0.000610733	 0.00036558	 24.199978	 ATP6V0A4	 ATPase,	H+	transporting,	lysosomal	V0	subunit	a4	
CfaAffx.7310.1.S1_s_at	 0.00805424	 0.00801672	 8.802979	 PRKD2	 protein	kinase	D2	
CfaAffx.7338.1.S1_s_at	 0.001348446	 0.00099563	 39.187878	 ATP6V0A4	 ATPase,	H+	transporting,	lysosomal	V0	subunit	a4	
CfaAffx.7375.1.S1_at	 2.57291E---05	 4.94144E---06	 8.608115	 PION	 pigeon	homolog	(Drosophila)	
CfaAffx.7390.1.S1_s_at	 4.76435E---05	 1.15031E---05	 18.240587	 PION	 pigeon	homolog	(Drosophila)	
CfaAffx.7608.1.S1_s_at	 7.86483E---05	 2.33258E---05	 34.028984	MYO7B	 myosin	VIIB	
CfaAffx.7845.1.S1_s_at	 2.90576E---07	 5.39491E---09	 8.734603	 TSC22D1	 TSC22	domain	family,	member	1	
CfaAffx.7972.1.S1_s_at	 0.000191618	 7.79562E---05	 27.01191	 HID1	 HID1	domain	containing	
CfaAffx.8025.1.S1_s_at	 0.000860261	 0.000576303	 10.258968	 FRMD4A	 FERM	domain	containing	4A	
CfaAffx.8210.1.S1_at	 2.38014E---06	 1.62359E---07	 86.568344	 OLFM4	 olfactomedin	4	
CfaAffx.8262.1.S1_at	 2.83666E---06	 2.3689E---07	 40.819233	 PCDP1	 primary	ciliary	dyskinesia	protein	1	
CfaAffx.8272.1.S1_at	 2.38014E---06	 1.58977E---07	 23.90965	 SCTR	 secretin	receptor	
CfaAffx.8275.1.S1_at	 0.003119594	 0.002761131	 9.155202	 TMEM37	 transmembrane	protein	37	
CfaAffx.8298.1.S1_s_at	 0.000509964	 0.000285469	 10.386502	 ITGB4	 integrin,	beta	4	
CfaAffx.8384.1.S1_at	 0.000104302	 3.37687E---05	 10.955408	 DACH1	 dachshund	homolog	1	(Drosophila)	
CfaAffx.8473.1.S1_s_at	 2.40353E---07	 3.91881E---09	 36.17533	 KLF5	 Kruppel---like	factor	5	(intestinal)	
CfaAffx.8612.1.S1_s_at	 3.41368E---05	 7.50055E---06	 48.608734	 ST6GALNAC2	
ST6	(alpha---N---acetyl---neuraminyl---2,3---beta---galactosyl---1,3)---N---
acetylgalactosaminide	alpha---2,6---sialyltransferase	2	
CfaAffx.9032.1.S1_at	 0.000590267	 0.000346919	 32.814957	 GPD1L	 glycerol---3---phosphate	dehydrogenase	1---like	
CfaAffx.9033.1.S1_s_at	 1.40546E---06	 6.65632E---08	 184.49016	 FCGBP	 Fc	fragment	of	IgG	binding	protein	
CfaAffx.9034.1.S1_s_at	 4.36958E---06	 4.51207E---07	 360.41922	 FCGBP	 Fc	fragment	of	IgG	binding	protein	
CfaAffx.9035.1.S1_at	 3.06789E---06	 2.67819E---07	 105.744	 FCGBP	 Fc	fragment	of	IgG	binding	protein	
CfaAffx.9199.1.S1_at	 0.002507798	 0.002100865	 9.147075	 DNAH17	 dynein,	axonemal,	heavy	chain	17	
CfaAffx.9443.1.S1_at	 0.000247567	 0.000110137	 33.347427	 NEK10	 NIMA	(never	in	mitosis	gene	a)---	related	kinase	10	
CfaAffx.9443.1.S1_s_at	 0.001132642	 0.000816944	 11.057043	 NEK10	 NIMA	(never	in	mitosis	gene	a)---	related	kinase	10	
CfaAffx.9447.1.S1_s_at	 0.000916762	 0.000620618	 8.649264	 NEK10	 NIMA	(never	in	mitosis	gene	a)---	related	kinase	10	
CfaAffx.9457.1.S1_s_at	 0.000105613	 3.44734E---05	 8.847667	 LGALS4	 lectin,	galactoside---binding,	soluble,	4	
CfaAffx.9559.1.S1_at	 0.001984501	 0.001605474	 25.555239	 ZMAT4	 zinc	finger,	matrin---type	4	
CfaAffx.9677.1.S1_s_at	 4.67098E---06	 5.04088E---07	 29.371775	 PLCB4	 phospholipase	C,	beta	4	
CfaAffx.9700.1.S1_at	 2.13519E---05	 3.87914E---06	 21.480347	 PLCB4	 phospholipase	C,	beta	4	
CfaAffx.9723.1.S1_at	 0.000471714	 0.000255525	 16.612885	 PLCB4	 phospholipase	C,	beta	4	
CfaAffx.9727.1.S1_at	 0.008050141	 0.007994059	 10.242696	 ADAM32	 ADAM	metallopeptidase	domain	32	
CfaAffx.9873.1.S1_at	 0.006817245	 0.006684923	 12.779023	 LOC607806	 carbonyl	reductase	[NADPH]	2---like	
CfaAffx.9928.1.S1_s_at	 0.002564652	 0.002156576	 12.908589	 LRRIQ1	 leucine---rich	repeats	and	IQ	motif	containing	1	
CfaAffx.9930.1.S1_at	 0.001577641	 0.001207728	 28.44302	 LRRIQ1	 leucine---rich	repeats	and	IQ	motif	containing	1	
CfaAffx.9992.1.S1_at	 7.4676E---05	 2.17998E---05	 8.96077	 FREM2	 FRAS1	related	extracellular	matrix	protein	2	
CfaAffx.10165.1.S1_at	 0.000140328	 5.00081E---05	 23.99654		 	CfaAffx.10285.1.S1_at	 0.003493907	 0.003157537	 8.734836	 ATP11A	 ATPase,	class	VI,	type	11A	
CfaAffx.10947.1.S1_s_at	 0.001591508	 0.001222051	 12.734059	 LOC478056	 double---headed	protease	inhibitor,	submandibular	gland---like	
CfaAffx.11002.1.S1_at	 4.97776E---05	 1.21739E---05	 13.823738	 LOC100856418	 RIMS---binding	protein	2---like	
CfaAffx.11032.1.S1_s_at	 0.00129207	 0.000950995	 9.699824	 LOC475605	 low---density	lipoprotein	receptor---related	protein	2---like	




CfaAffx.11273.1.S1_at	 9.18852E---06	 1.31265E---06	 57.24826	 EHF	 ets	homologous	factor	
CfaAffx.11273.1.S1_s_at	 8.40561E---07	 2.6538E---08	 33.874596	 EHF	 ets	homologous	factor	
CfaAffx.11304.1.S1_at	 8.70319E---06	 1.20277E---06	 85.689995	 SLC5A8	 solute	carrier	family	5	(iodide	transporter),	member	8	
CfaAffx.11553.1.S1_at	 0.002348833	 0.001943988	 14.275229	 FXYD3	 FXYD	domain	containing	ion	transport	regulator	3	
CfaAffx.11587.1.S1_at	 7.5327E---06	 9.76678E---07	 11.448601	 ELOVL7	 ELOVL	fatty	acid	elongase	7	
CfaAffx.11609.1.S1_s_at	 0.003332214	 0.002977778	 8.72305	 SGCG	 sarcoglycan,	gamma	(35kDa	dystrophin---associated	glycoprotein)	
CfaAffx.11702.1.S1_at	 0.000758929	 0.000488389	 25.114868	 LOC100856692	 protein	FAM3D---like	




CfaAffx.11840.1.S1_at	 2.22494E---06	 1.38195E---07	 36.10939	 KRT7///KRT86	 keratin	7///keratin	86	
CfaAffx.11969.1.S1_s_at	 0.000755149	 0.00048428	 9.102153	 TMEM232	 transmembrane	protein	232	
CfaAffx.11972.1.S1_at	 9.56163E---06	 1.40307E---06	 36.99334	 TMEM232	 transmembrane	protein	232	
	 143	
	
CfaAffx.12064.1.S1_s_at	 0.000250027	 0.000112008	 10.651009	 GLT8D2	 glycosyltransferase	8	domain	containing	2	
CfaAffx.12107.1.S1_s_at	 0.000487164	 0.000269215	 19.524998	 DZIP1L	 DAZ	interacting	protein	1---like	




CfaAffx.12187.1.S1_at	 9.52585E---06	 1.38838E---06	 10.077421		 	CfaAffx.12232.1.S1_s_at	 3.82933E---06	 3.71506E---07	 16.010983	MAST4	 microtubule	associated	serine/threonine	kinase	family	member	4	
CfaAffx.12239.1.S1_s_at	 0.003271056	 0.002920586	 16.88818	MAST4	 microtubule	associated	serine/threonine	kinase	family	member	4	




CfaAffx.12378.1.S1_at	 0.000425228	 0.00022648	 21.960958	 ABCB9///VPS37B	
ATP---binding	cassette,	sub---family	B	(MDR/TAP),	member	9///vacuolar	protein	sorting	
37	homolog	B	(S.	cerevisiae)	
CfaAffx.12438.1.S1_at	 0.000153146	 5.64784E---05	 16.822815	 SLC4A8	 solute	carrier	family	4,	sodium	bicarbonate	cotransporter,	member	8	
CfaAffx.12475.1.S1_s_at	 0.002593707	 0.002197335	 12.150907	 GALNT6	
UDP---N---acetyl---alpha---D---galactosamine:polypeptide	N---
acetylgalactosaminyltransferase	
6	(GalNAc---T6)	CfaAffx.12515.1.S1_at	 0.008050141	 0.008000915	 9.95546	 HIP1R	 huntingtin	interacting	protein	1	related	
CfaAffx.12524.1.S1_s_at	 0.000652544	 0.000401254	 13.02908	 HIP1R	 huntingtin	interacting	protein	1	related	
CfaAffx.12642.1.S1_at	 0.006116667	 0.005926709	 10.601462	 PCSK1	 proprotein	convertase	subtilisin/kexin	type	1	
CfaAffx.12726.1.S1_s_at	 0.000719325	 0.000455721	 10.501227	 ASB14	 ankyrin	repeat	and	SOCS	box	containing	14	
CfaAffx.12806.1.S1_at	 0.005340368	 0.005104031	 10.077652	 SBSPON	 somatomedin	B	and	thrombospondin,	type	1	domain	containing	
CfaAffx.13041.1.S1_s_at	 3.1349E---06	 2.87203E---07	 29.469414	 FMN1	 formin	1	
CfaAffx.13140.1.S1_s_at	 0.000172218	 6.67317E---05	 12.174981	 ARHGEF28	 Rho	guanine	nucleotide	exchange	factor	(GEF)	28	
CfaAffx.13169.1.S1_at	 0.000601362	 0.000357364	 9.451588	 SORBS1	 sorbin	and	SH3	domain	containing	1	
CfaAffx.13191.1.S1_s_at	 0.001684757	 0.001314582	 9.401873	 SORBS1	 sorbin	and	SH3	domain	containing	1	
CfaAffx.13633.1.S1_at	 0.000476237	 0.000260615	 13.60731	 E2F5	 E2F	transcription	factor	5,	p130---binding	
CfaAffx.13680.1.S1_s_at	 2.34933E---06	 1.47745E---07	 13.569626	 SHROOM3	 shroom	family	member	3	
CfaAffx.13723.1.S1_s_at	 4.24713E---06	 4.35265E---07	 12.6563015	 CA2	 carbonic	anhydrase	II	
CfaAffx.13758.1.S1_s_at	 0.003673806	 0.003342935	 9.189729	 PRKCD	 protein	kinase	C,	delta	
CfaAffx.13847.1.S1_s_at	 0.000838813	 0.000556821	 16.712887	 PLCH1	 phospholipase	C,	eta	1	
CfaAffx.13856.1.S1_at	 0.000498974	 0.000277418	 9.769147	 CX3CL1	 chemokine	(C---X3---C	motif)	ligand	1	
CfaAffx.13886.1.S1_s_at	 0.000987074	 0.000680724	 20.43905	 FRAS1	 Fraser	syndrome	1	


















CfaAffx.14036.1.S1_at	 0.000471733	 0.000256377	 11.10872	 KIAA1755	 KIAA1755	ortholog	
CfaAffx.14042.1.S1_at	 6.17584E---05	 1.65424E---05	 20.344181	 VEPH1	 ventricular	zone	expressed	PH	domain	homolog	1	(zebrafish)	
CfaAffx.14202.1.S1_at	 9.04904E---07	 3.14582E---08	 34.716095	 DOCK5	 dedicator	of	cytokinesis	5	
CfaAffx.14222.1.S1_s_at	 3.83694E---05	 8.81781E---06	 12.792562	 DOCK5	 dedicator	of	cytokinesis	5	
CfaAffx.14227.1.S1_s_at	 0.000264576	 0.000120579	 12.894	 USH1C	 Usher	syndrome	1C	(autosomal	recessive,	severe)	
CfaAffx.14328.1.S1_s_at	 1.18299E---06	 5.40624E---08	 38.942463	 ADAM28	 ADAM	metallopeptidase	domain	28	
CfaAffx.14362.1.S1_at	 1.00274E---05	 1.49477E---06	 9.281099	 ADAM28	 ADAM	metallopeptidase	domain	28	
CfaAffx.14440.1.S1_at	 9.48651E---05	 2.99031E---05	 21.798832	 CDH17	 cadherin	17,	LI	cadherin	(liver---intestine)	
CfaAffx.14527.1.S1_s_at	 2.84517E---05	 5.6616E---06	 10.602098	 GMDS	 GDP---mannose	4,6---dehydratase	
CfaAffx.14583.1.S1_at	 0.000123828	 4.30706E---05	 80.58489	 SFRP5	 secreted	frizzled---related	protein	5	
CfaAffx.14587.1.S1_at	 0.000305705	 0.000143596	 37.05416	 BCL2L15	 BCL2---like	15	
CfaAffx.14615.1.S1_at	 0.000303975	 0.000142311	 9.479598	 F2RL1	 coagulation	factor	II	(thrombin)	receptor---like	1	
CfaAffx.14676.1.S1_at	 0.003158068	 0.002800088	 12.075594	 ESRP1	 epithelial	splicing	regulatory	protein	1	
CfaAffx.14683.1.S1_s_at	 0.000247567	 0.000110019	 43.04233	 ESRP1	 epithelial	splicing	regulatory	protein	1	
CfaAffx.14702.1.S1_s_at	 0.000114605	 3.90389E---05	 41.273003	 CCDC148	 coiled---coil	domain	containing	148	
CfaAffx.14756.1.S1_at	 0.005912953	 0.005701776	 9.128182	 LOC100855577	 protein	phosphatase	1	regulatory	subunit	14D---like	
CfaAffx.14775.1.S1_at	 0.001126315	 0.000810632	 16.810213	 SPINT1	 serine	peptidase	inhibitor,	Kunitz	type	1	
CfaAffx.15042.1.S1_s_at	 5.24963E---07	 1.22274E---08	 25.425577	 SPP1	 secreted	phosphoprotein	1	
CfaAffx.15043.1.S1_at	 1.06745E---05	 1.6161E---06	 35.5832	 CLIC6	 chloride	intracellular	channel	6	
CfaAffx.15085.1.S1_s_at	 6.49101E---05	 1.79914E---05	 15.453947	 RUNX1	 runt---related	transcription	factor	1	
CfaAffx.15143.1.S1_at	 9.52585E---06	 1.39042E---06	 8.219752	 CBR3	 carbonyl	reductase	3	
CfaAffx.15227.1.S1_s_at	 1.55125E---05	 2.65968E---06	 45.651367	WFDC2	 WAP	four---disulfide	core	domain	2	
CfaAffx.15538.1.S1_at	 5.9161E---05	 1.57054E---05	 119.44347	 ITGB6	 integrin,	beta	6	
CfaAffx.15557.1.S1_at	 0.000230413	 9.91061E---05	 69.44786	 ITGB6	 integrin,	beta	6	
CfaAffx.15557.1.S1_s_at	 8.48718E---05	 2.57647E---05	 39.46737	 ITGB6	 integrin,	beta	6	
CfaAffx.15563.1.S1_s_at	 0.000260978	 0.000118129	 80.769684		 	CfaAffx.15565.1.S1_s_at	 0.001176596	 0.000851387	 18.882612		 	CfaAffx.15591.1.S1_s_at	 0.000187467	 7.59763E---05	 17.282396	MUC5B	 mucin	5B,	oligomeric	mucus/gel---forming	
CfaAffx.15602.1.S1_s_at	 4.89115E---05	 1.18481E---05	 163.58846	MUC5B	 mucin	5B,	oligomeric	mucus/gel---forming	
CfaAffx.15659.1.S1_at	 0.003011295	 0.002657768	 9.276832	 CTNND2	 catenin	(cadherin---associated	protein),	delta	2	
CfaAffx.15668.1.S1_s_at	 0.002890804	 0.002520476	 11.821953	 CTNND2	 catenin	(cadherin---associated	protein),	delta	2	
CfaAffx.15892.1.S1_at	 0.002920206	 0.002557448	 27.857567	 DSCAM	 Down	syndrome	cell	adhesion	molecule	
CfaAffx.15899.1.S1_s_at	 2.97655E---05	 6.0779E---06	 9.753296	 BACE2	 beta---site	APP---cleaving	enzyme	2	
CfaAffx.15940.1.S1_s_at	 0.000529877	 0.000300318	 11.08372	 TMPRSS2	 transmembrane	protease,	serine	2	
CfaAffx.15971.1.S1_at	 5.37562E---06	 6.11536E---07	 23.40372	MBOAT1	 membrane	bound	O---acyltransferase	domain	containing	1	
CfaAffx.15999.1.S1_at	 0.001086294	 0.00077002	 14.146239	 KCNQ1	 potassium	voltage---gated	channel,	KQT---like	subfamily,	member	1	
CfaAffx.16002.1.S1_at	 0.000351562	 0.000177146	 28.037931	 KCNQ1	 potassium	voltage---gated	channel,	KQT---like	subfamily,	member	1	
CfaAffx.16042.1.S1_at	 2.4011E---05	 4.51814E---06	 16.160902	 DCDC2	 doublecortin	domain	containing	2	
CfaAffx.16101.1.S1_s_at	 0.000177705	 7.06404E---05	 9.903347	 TSPAN5	 tetraspanin	5	
CfaAffx.16182.1.S1_at	 5.73496E---06	 6.79448E---07	 38.51755	 TCN1	 transcobalamin	I	(vitamin	B12	binding	protein,	R	binder	family)	
CfaAffx.16190.1.S1_s_at	 2.43162E---06	 1.83127E---07	 124.19287	 TFF3	 trefoil	factor	3	(intestinal)	
CfaAffx.16335.1.S1_at	 0.000232232	 0.000100531	 15.388324	 TM4SF20	 transmembrane	4	L	six	family	member	20	
CfaAffx.16375.1.S1_s_at	 0.001883547	 0.00150479	 10.620576	 SLC37A1	 solute	carrier	family	37	(glycerol---3---phosphate	transporter),	member	1	
CfaAffx.16571.1.S1_at	 0.000323478	 0.000155209	 12.106237	 BOC	 Boc	homolog	(mouse)	
CfaAffx.16576.1.S1_at	 0.000997357	 0.000689168	 20.83024	 LRRK1	 leucine---rich	repeat	kinase	1	
CfaAffx.16581.1.S1_at	 0.000420584	 0.000223354	 23.015741	 ELF3	 E74---like	factor	3	(ets	domain	transcription	factor,	epithelial---specific	)	
CfaAffx.16691.1.S1_s_at	 0.000476237	 0.000260673	 13.443485	 SIDT1	 SID1	transmembrane	family,	member	1	
CfaAffx.16714.1.S1_at	 0.00293813	 0.002575573	 8.490257	 CERS3	 ceramide	synthase	3	

















CfaAffx.16982.1.S1_s_at	 0.000291298	 0.000134115	 10.651318	 IGSF11	 immunoglobulin	superfamily,	member	11	
CfaAffx.16998.1.S1_at	 1.56461E---05	 2.69854E---06	 11.405106	 ARHGEF38	 Rho	guanine	nucleotide	exchange	factor	(GEF)	38	
CfaAffx.17007.1.S1_s_at	 0.000187115	 7.56104E---05	 31.928825	 ARHGEF38	 Rho	guanine	nucleotide	exchange	factor	(GEF)	38	
CfaAffx.17027.1.S1_at	 0.000618009	 0.000371381	 14.903154	 SLC9A3	 solute	carrier	family	9	(sodium/hydrogen	exchanger),	member	3	
CfaAffx.17211.1.S1_at	 0.001903122	 0.001527817	 12.446191	 GIMD1	 GIMAP	family	P---loop	NTPase	domain	containing	1	
CfaAffx.17260.1.S1_at	 0.000716013	 0.000452511	 10.4512005	 PLEKHG4B	 pleckstrin	homology	domain	containing,	family	G	(with	RhoGef	domain)	member	4B	
CfaAffx.17264.1.S1_at	 0.000151621	 5.54453E---05	 8.246776	 ROBO4	 roundabout,	axon	guidance	receptor,	homolog	4	(Drosophila)	
CfaAffx.17273.1.S1_at	 0.005323429	 0.005079576	 10.253711	 PLEKHG4B	 pleckstrin	homology	domain	containing,	family	G	(with	RhoGef	domain)	member	4B	
CfaAffx.17421.1.S1_s_at	 0.003992272	 0.003682313	 14.695663	 PLEKHS1	 pleckstrin	homology	domain	containing,	family	S	member	1	
CfaAffx.17424.1.S1_at	 0.000206488	 8.56439E---05	 23.552618	 PLEKHS1	 pleckstrin	homology	domain	containing,	family	S	member	1	
CfaAffx.17517.1.S1_at	 0.002854371	 0.002482061	 14.9277	 SLCO3A1	 solute	carrier	organic	anion	transporter	family,	member	3A1	
CfaAffx.17792.1.S1_s_at	 0.000634457	 0.000385699	 17.808702	 CASC1	 cancer	susceptibility	candidate	1	
CfaAffx.17875.1.S1_at	 0.00048241	 0.000265176	 15.498193	 BCAT1	 branched	chain	amino---acid	transaminase	1,	cytosolic	
CfaAffx.17962.1.S1_at	 8.48933E---06	 1.15115E---06	 19.872154	 KCNK1	 potassium	channel,	subfamily	K,	member	1	
CfaAffx.18050.1.S1_s_at	 3.65552E---05	 8.14545E---06	 9.441288	 GRAMD1B	 GRAM	domain	containing	1B	
CfaAffx.18086.1.S1_s_at	 0.001713722	 0.001339843	 10.412281	 ZFHX2	 zinc	finger	homeobox	2	
CfaAffx.18401.1.S1_at	 0.00198887	 0.001612097	 12.10773	 PLXNA2	 plexin	A2	
CfaAffx.18415.1.S1_at	 0.000860261	 0.000574199	 20.14643	 ST8SIA1	 ST8	alpha---N---acetyl---neuraminide	alpha---2,8---sialyltransferase	1	
CfaAffx.18424.1.S1_at	 0.000341267	 0.000168514	 12.144808		 	CfaAffx.18577.1.S1_at	 9.61467E---06	 1.41831E---06	 11.704167	 TRPM8	 transient	receptor	potential	cation	channel,	subfamily	M,	member	8	
CfaAffx.18590.1.S1_at	 0.001785864	 0.001401324	 9.237141	 TRPM8	 transient	receptor	potential	cation	channel,	subfamily	M,	member	8	
CfaAffx.18590.1.S1_s_at	 5.89206E---05	 1.55536E---05	 114.512985	 TRPM8	 transient	receptor	potential	cation	channel,	subfamily	M,	member	8	
CfaAffx.18867.1.S1_at	 5.37212E---05	 1.36388E---05	 19.512232	 AGAP1	 ArfGAP	with	GTPase	domain,	ankyrin	repeat	and	PH	domain	1	
CfaAffx.18890.1.S1_at	 0.000304537	 0.000142811	 33.91604	 ARSJ	 arylsulfatase	family,	member	J	
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CfaAffx.18933.1.S1_at	 3.12321E---05	 6.59394E---06	 58.92371	 UGT8	 UDP	glycosyltransferase	8	
CfaAffx.18944.1.S1_s_at	 2.69004E---05	 5.22135E---06	 66.03307	 UGT8	 UDP	glycosyltransferase	8	


















CfaAffx.19425.1.S1_s_at	 1.76859E---06	 9.55591E---08	 58.310722	MUC13	 mucin	13,	cell	surface	associated	
CfaAffx.19474.1.S1_s_at	 9.84206E---05	 3.14361E---05	 139.55843	 DMBT1	 deleted	in	malignant	brain	tumors	1	
CfaAffx.19521.1.S1_s_at	 2.57698E---06	 1.98075E---07	 88.76967	 DMBT1	 deleted	in	malignant	brain	tumors	1	
CfaAffx.19516.1.S1_s_at	 1.76929E---05	 3.13197E---06	 91.078156	 DMBT1	 deleted	in	malignant	brain	tumors	1	
CfaAffx.19517.1.S1_at	 0.002911371	 0.002546378	 10.235342	 BBS1	 Bardet---Biedl	syndrome	1	
CfaAffx.19822.1.S1_at	 1.87562E---06	 1.06304E---07	 382.56808	MUC20	 mucin	20,	cell	surface	associated	
CfaAffx.19822.1.S1_s_at	 2.31118E---05	 4.30654E---06	 31.736591	MUC20	 mucin	20,	cell	surface	associated	
CfaAffx.20104.1.S1_at	 6.46002E---05	 1.76618E---05	 9.578731	 GPR64	 G	protein---coupled	receptor	64	
CfaAffx.20266.1.S1_at	 0.000711135	 0.000448877	 8.683356	 CXHXorf23	 chromosome	X	open	reading	frame,	human	CXorf23	
CfaAffx.20331.1.S1_at	 6.54654E---05	 1.83994E---05	 14.949099	 CLRN3	 clarin	3	
CfaAffx.20501.1.S1_s_at	 0.000159368	 5.97632E---05	 8.892198	 LOC100856156	 lipase	member	H---like	
CfaAffx.20618.1.S1_s_at	 0.000122212	 4.19978E---05	 10.3375	 IGF2BP2	 insulin---like	growth	factor	2	mRNA	binding	protein	2	
CfaAffx.20839.1.S1_at	 1.73037E---06	 9.00117E---08	 13.587931	 CADM1	 cell	adhesion	molecule	1	
CfaAffx.20842.1.S1_at	 0.000902031	 0.00060719	 16.921839	 CADM1	 cell	adhesion	molecule	1	
CfaAffx.20845.1.S1_s_at	 5.8699E---05	 1.54495E---05	 8.360872	 CADM1	 cell	adhesion	molecule	1	
CfaAffx.21149.1.S1_s_at	 0.00015734	 5.88802E---05	 34.530605	 DUOX2	 dual	oxidase	2	
CfaAffx.21225.1.S1_s_at	 2.27978E---07	 3.01064E---09	 19.77938	MAP2	 microtubule---associated	protein	2	
CfaAffx.21232.1.S1_s_at	 2.43162E---06	 1.73238E---07	 24.723236	MAP2	 microtubule---associated	protein	2	
CfaAffx.21245.1.S1_at	 0.000835725	 0.000554122	 8.460225	 CUX1	 cut---like	homeobox	1	





















CfaAffx.21539.1.S1_at	 0.000369317	 0.000189246	 9.599781	 TSPAN15	 tetraspanin	15	
CfaAffx.21545.1.S1_at	 2.4011E---05	 4.53002E---06	 8.818848	 VPS51	 vacuolar	protein	sorting	51	homolog	(S.	cerevisiae)	
CfaAffx.21632.1.S1_s_at	 7.42385E---05	 2.15568E---05	 32.588024	 ATP2A3	 ATPase,	Ca++	transporting,	ubiquitous	
CfaAffx.21611.1.S1_s_at	 0.005587248	 0.005353	 10.151468	 PIH1D2	 PIH1	domain	containing	2	
CfaAffx.21683.1.S1_at	 0.000291473	 0.000134422	 9.675335	 CDCP1	 CUB	domain	containing	protein	1	
CfaAffx.21803.1.S1_at	 0.000248299	 0.000110848	 44.45582	 C18H7orf57	 chromosome	18	open	reading	frame,	human	C7orf57	
CfaAffx.21925.1.S1_at	 8.4579E---05	 2.53474E---05	 24.000021	 C11orf53	 chromosome	11	open	reading	frame	53	
CfaAffx.21934.1.S1_s_at	 0.001812814	 0.001428576	 15.197305	 DNAJA4	 DnaJ	(Hsp40)	homolog,	subfamily	A,	member	4	
CfaAffx.22128.1.S1_at	 0.000182007	 7.2916E---05	 17.440243	 S100P	 S100	calcium	binding	protein	P	
CfaAffx.22283.1.S1_s_at	 0.000740356	 0.000471345	 12.858521	 SI	 sucrase---isomaltase	(alpha---glucosidase)	
CfaAffx.22699.1.S1_at	 0.002658393	 0.002276558	 13.933722	 VIL1	 villin	1	
CfaAffx.22795.1.S1_at	 1.18299E---06	 5.41899E---08	 16.278305	 GULP1	 GULP,	engulfment	adaptor	PTB	domain	containing	1	
CfaAffx.23201.1.S1_at	 7.58907E---05	 2.22134E---05	 259.17712	MMP7	 matrix	metallopeptidase	7	(matrilysin,	uterine)	
CfaAffx.23286.1.S1_at	 0.000149118	 5.38353E---05	 27.431824	 KIAA1377	 KIAA1377	ortholog	
CfaAffx.23448.1.S1_at	 2.63116E---06	 2.08368E---07	 33.831665	 C8H14orf105	 chromosome	8	open	reading	frame,	human	C14orf105	
CfaAffx.23488.1.S1_s_at	 4.98594E---05	 1.22576E---05	 104.61509	 PROM1	 prominin	1	
CfaAffx.23594.1.S1_s_at	 9.84206E---05	 3.13719E---05	 9.618271	 TNXB	 tenascin	XB	
CfaAffx.24036.1.S1_at	 0.001010513	 0.00070375	 10.115947	MYO5C	 myosin	VC	
CfaAffx.24148.1.S1_s_at	 1.18115E---06	 5.04371E---08	 18.28551	 SFTPD	 surfactant	protein	D	
CfaAffx.24247.1.S1_at	 0.005602432	 0.005371897	 9.89372	 PADI2	 peptidyl	arginine	deiminase,	type	II	
CfaAffx.24360.1.S1_s_at	 0.000891142	 0.000599169	 8.752004	 FKBP10	 FK506	binding	protein	10,	65	kDa	
CfaAffx.24358.1.S1_at	 0.002182016	 0.001787288	 13.489994	 NSUN7	 NOP2/Sun	domain	family,	member	7	
CfaAffx.24358.1.S1_s_at	 0.000195166	 8.0006E---05	 12.289798	 NSUN7	 NOP2/Sun	domain	family,	member	7	
CfaAffx.24412.1.S1_at	 0.00156663	 0.00119565	 8.713826	 DYX1C1	 dyslexia	susceptibility	1	candidate	1	
CfaAffx.24542.1.S1_at	 0.000655126	 0.00040335	 35.671562	 KRT23	 keratin	23	(histone	deacetylase	inducible)	
CfaAffx.24612.1.S1_at	 0.000338008	 0.000166381	 11.469828	 TEX9	 testis	expressed	9	
CfaAffx.24647.1.S1_s_at	 0.001115984	 0.000800084	 8.424809	 C18H11orf9	 chromosome	18	open	reading	frame,	human	C11orf9	
CfaAffx.24730.1.S1_at	 6.86343E---06	 8.63258E---07	 11.998539	 CLDN7	 claudin	7	
CfaAffx.24822.1.S1_s_at	 0.001831483	 0.001448977	 22.759684	 ANXA8L1	 annexin	A8---like	1	
CfaAffx.24807.1.S1_at	 7.47728E---06	 9.63686E---07	 436.4179	 GPX2	 glutathione	peroxidase	2	(gastrointestinal)	
CfaAffx.24807.1.S1_s_at	 9.8491E---07	 3.594E---08	 128.37411	 GPX2	 glutathione	peroxidase	2	(gastrointestinal)	
CfaAffx.24813.1.S1_at	 1.61938E---05	 2.84145E---06	 38.193752	 RAB15	 RAB15,	member	RAS	onocogene	family	
CfaAffx.24826.1.S1_s_at	 5.37562E---06	 6.10367E---07	 25.382092	 ANXA8L1	 annexin	A8---like	1	
CfaAffx.24850.1.S1_s_at	 4.92436E---06	 5.3908E---07	 10.488416	 LOC490390	 uncharacterized	LOC490390	
CfaAffx.25019.1.S1_at	 7.96108E---05	 2.36731E---05	 32.63243	 FHAD1	 forkhead---associated	(FHA)	phosphopeptide	binding	domain	1	
CfaAffx.25025.1.S1_s_at	 0.000406977	 0.000213915	 11.36839	 FHAD1	 forkhead---associated	(FHA)	phosphopeptide	binding	domain	1	
CfaAffx.25104.1.S1_at	 0.006237274	 0.006053255	 10.038526	 LOC100686830	 cytochrome	c	oxidase	subunit	6A1,	mitochondrial---like	
CfaAffx.25134.1.S1_at	 0.000705719	 0.00044491	 8.48998	 SEL1L3	 sel---1	suppressor	of	lin---12---like	3	(C.	elegans)	
CfaAffx.25298.1.S1_s_at	 0.000587461	 0.00034299	 33.510532	 ALDH1A2	 aldehyde	dehydrogenase	1	family,	member	A2	
CfaAffx.25306.1.S1_x_at	 9.04904E---07	 3.2318E---08	 59.830795	 C30H15orf48	 chromosome	30	open	reading	frame,	human	C15orf48	
CfaAffx.25463.1.S1_at	 0.000747474	 0.00047781	 30.790516	 HEPH	 hephaestin	
CfaAffx.25479.1.S1_at	 0.000232144	 0.000100211	 11.171734	 FAM81A	 family	with	sequence	similarity	81,	member	A	
CfaAffx.25482.1.S1_at	 0.000123533	 4.28719E---05	 81.10276	 GCNT3	 glucosaminyl	(N---acetyl)	transferase	3,	mucin	type	
CfaAffx.25604.1.S1_at	 9.79958E---05	 3.11182E---05	 48.464787	 DNAH2	 dynein,	axonemal,	heavy	chain	2	
CfaAffx.25667.1.S1_s_at	 0.001591499	 0.001220808	 12.131167	 DNAH2	 dynein,	axonemal,	heavy	chain	2	
CfaAffx.25710.1.S1_at	 0.001050327	 0.000739633	 13.516623	 PRR15L	 proline	rich	15---like	
CfaAffx.25784.1.S1_at	 0.000315591	 0.000150935	 19.976757	 RAB25	 RAB25,	member	RAS	oncogene	family	
CfaAffx.25799.1.S1_s_at	 3.9008E---05	 8.99487E---06	 27.6081	 TTLL6	 tubulin	tyrosine	ligase---like	family,	member	6	
CfaAffx.25874.1.S1_at	 0.000626105	 0.000378191	 16.696285	 GON4L	 gon---4---like	(C.	elegans)	
CfaAffx.25914.1.S1_s_at	 0.000485293	 0.000267137	 35.454086	 KCNIP1	 Kv	channel	interacting	protein	1	
CfaAffx.26061.1.S1_at	 8.72809E---07	 2.91388E---08	 29.727827	MUC1	 mucin	1,	cell	surface	associated	
CfaAffx.26165.1.S1_s_at	 0.00179293	 0.001410123	 10.473141	 LOC100855729	 glycerophosphodiester	phosphodiesterase	domain---containing	protein	3---like	
CfaAffx.26409.1.S1_at	 0.002874053	 0.00250364	 10.804853	 ATP10B	 ATPase,	class	V,	type	10B	
CfaAffx.26410.1.S1_s_at	 3.10629E---05	 6.48751E---06	 48.73429	 ATP10B	 ATPase,	class	V,	type	10B	
CfaAffx.26620.1.S1_at	 0.000164675	 6.25608E---05	 97.89524	 POF1B	 premature	ovarian	failure,	1B	
CfaAffx.26635.1.S1_at	 5.34857E---06	 5.97977E---07	 8.418213	 RGL3	 ral	guanine	nucleotide	dissociation	stimulator---like	3	
CfaAffx.26924.1.S1_at	 0.000291039	 0.000133769	 14.013778	 GDPD1	 glycerophosphodiester	phosphodiesterase	domain	containing	1	
CfaAffx.26924.1.S1_s_at	 6.47396E---05	 1.78657E---05	 9.126445	 GDPD1	 glycerophosphodiester	phosphodiesterase	domain	containing	1	
CfaAffx.26999.1.S1_at	 4.73309E---05	 1.13183E---05	 8.764973	 GALNT10	
UDP---N---acetyl---alpha---D---galactosamine:polypeptide	N---
acetylgalactosaminyltransferase	
10	(GalNAc---T10)	CfaAffx.27004.1.S1_s_at	 0.000294983	 0.000136956	 49.775665	 ERN2	 endoplasmic	reticulum	to	nucleus	signaling	2	
CfaAffx.27034.1.S1_at	 0.002590253	 0.002186029	 15.623755	 SLC14A1	 solute	carrier	family	14	(urea	transporter),	member	1	(Kidd	blood	group)	
CfaAffx.27080.1.S1_at	 0.000247789	 0.000110428	 10.328145	 SCNN1B	 sodium	channel,	non---voltage---gated	1,	beta	subunit	
CfaAffx.27504.1.S1_at	 0.000211095	 8.85024E---05	 31.173523		 	CfaAffx.27538.1.S1_at	 0.003224326	 0.002868849	 13.801069		 	CfaAffx.27600.1.S1_at	 3.1349E---06	 2.80667E---07	 13.899856	 CENPV	 centromere	protein	V	
CfaAffx.27609.1.S1_s_at	 0.000633656	 0.000384228	 27.92573	 GP2	 glycoprotein	2	(zymogen	granule	membrane)	
CfaAffx.27726.1.S1_s_at	 0.00041756	 0.000221019	 11.4205885	 TMC5	 transmembrane	channel---like	5	
CfaAffx.27789.1.S1_at	 4.31498E---08	 6.70027E---11	 19.620419	 HNF1B	 HNF1	homeobox	B	
CfaAffx.27870.1.S1_s_at	 0.004661599	 0.004361201	 10.1471405	MFAP4	 microfibrillar---associated	protein	4	
CfaAffx.27890.1.S1_s_at	 0.000622841	 0.000375736	 22.567442	 ABCC1	 ATP---binding	cassette,	sub---family	C	(CFTR/MRP),	member	1	
CfaAffx.27900.1.S1_s_at	 0.002964111	 0.002605104	 10.488089	 AMOT	 angiomotin	
CfaAffx.27957.1.S1_at	 2.69833E---05	 5.28057E---06	 35.391438	 SLC6A14	 solute	carrier	family	6	(amino	acid	transporter),	member	14	
CfaAffx.28023.1.S1_at	 0.00704333	 0.006917556	 10.896791	 LLGL1	 lethal	giant	larvae	homolog	1	(Drosophila)	
CfaAffx.28173.1.S1_s_at	 0.001560005	 0.00118696	 10.74902	 LRRC48	 leucine	rich	repeat	containing	48	
CfaAffx.28187.1.S1_at	 0.000203927	 8.42306E---05	 73.5849	 ITGA2	 integrin,	alpha	2	(CD49B,	alpha	2	subunit	of	VLA---2	receptor)	
CfaAffx.28191.1.S1_s_at	 3.0747E---05	 6.3738E---06	 18.339886	 ITGA2	 integrin,	alpha	2	(CD49B,	alpha	2	subunit	of	VLA---2	receptor)	
CfaAffx.28378.1.S1_s_at	 0.000329412	 0.000159512	 10.478395	 GRIA3	 glutamate	receptor,	ionotropic,	AMPA	3	
CfaAffx.28412.1.S1_at	 4.67098E---06	 5.02704E---07	 15.669679	 OXCT1	 3---oxoacid	CoA	transferase	1	
CfaAffx.28412.1.S1_s_at	 0.000498974	 0.000277768	 12.7633505	 OXCT1	 3---oxoacid	CoA	transferase	1	
CfaAffx.28417.1.S1_at	 0.003981067	 0.003668887	 11.673332	 ARHGAP28	 Rho	GTPase	activating	protein	28	
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CfaAffx.28540.1.S1_at	 6.51682E---05	 1.81814E---05	 17.551582	 CCDC165	 coiled---coil	domain	containing	165	
CfaAffx.28574.1.S1_s_at	 1.07512E---05	 1.65907E---06	 25.523348	 SLC13A2	 solute	carrier	family	13	(sodium---dependent	dicarboxylate	transporter),	member	2	
CfaAffx.28935.1.S1_at	 0.002731117	 0.002347318	 8.49313	 UHRF1	 ubiquitin---like	with	PHD	and	ring	finger	domains	1	
CfaAffx.29013.1.S1_at	 0.002234845	 0.001837501	 10.28491	 TTC22	 tetratricopeptide	repeat	domain	22	
CfaAffx.29105.1.S1_s_at	 0.000242753	 0.000107037	 26.965755	 ABR	 active	BCR---related	
CfaAffx.29124.1.S1_s_at	 0.000182847	 7.36784E---05	 17.566816	 NXN	 nucleoredoxin	
CfaAffx.29150.1.S1_at	 8.81404E---05	 2.70306E---05	 21.125515	 STAP2	 signal	transducing	adaptor	family	member	2	
CfaAffx.29235.1.S1_s_at	 5.958E---05	 1.58664E---05	 42.145603	 LRP8	 low	density	lipoprotein	receptor---related	protein	8,	apolipoprotein	e	receptor	
CfaAffx.29230.1.S1_at	 0.003718613	 0.003392369	 8.225798	 LRP8	 low	density	lipoprotein	receptor---related	protein	8,	apolipoprotein	e	receptor	
CfaAffx.29237.1.S1_at	 0.000100078	 3.2168E---05	 65.13065	 GABRE	 gamma---aminobutyric	acid	(GABA)	A	receptor,	epsilon	
CfaAffx.29519.1.S1_at	 2.10812E---05	 3.81361E---06	 27.56459	 TTLL10	 tubulin	tyrosine	ligase---like	family,	member	10	
CfaAffx.29521.1.S1_s_at	 2.84517E---05	 5.68207E---06	 12.819419	 TTLL10	 tubulin	tyrosine	ligase---like	family,	member	10	
CfaAffx.29842.1.S1_at	 2.06099E---05	 3.71235E---06	 16.21091	 NPDC1	 neural	proliferation,	differentiation	and	control,	1	
CfaAffx.29979.1.S1_at	 2.15099E---07	 2.33803E---09	 22.785696	 GNG13	 guanine	nucleotide	binding	protein	(G	protein),	gamma	13	
CfaAffx.30305.1.S1_at	 0.000510872	 0.000286374	 18.823105	 EPS8L3	 EPS8---like	3	
CfaAffx.30305.1.S1_s_at	 0.0001614	 6.07003E---05	 9.637291	 EPS8L3	 EPS8---like	3	
CfaAffx.30313.1.S1_s_at	 0.004155927	 0.003862302	 8.265865	 VAV2	 vav	2	guanine	nucleotide	exchange	factor	
CfaAffx.30380.1.S1_s_at	 0.000492874	 0.000272935	 10.000504	 KIAA1324	 KIAA1324	ortholog	
CfaAffx.30511.1.S1_s_at	 0.000105613	 3.47671E---05	 9.02191	 SLC25A24	 solute	carrier	family	25	(mitochondrial	carrier;	phosphate	carrier),	member	24	
CfaAffx.30515.1.S1_at	 0.000123533	 4.28673E---05	 28.872879	 LOC611915	 calcium---binding	mitochondrial	carrier	protein	SCaMC---1---like	
CfaAffx.30543.1.S1_at	 1.79199E---07	 1.04298E---09	 18.397976	 ATP2C2	 ATPase,	Ca++	transporting,	type	2C,	member	2	
CfaAffx.30543.1.S1_s_at	 5.61687E---07	 1.3955E---08	 38.978043	 ATP2C2	 ATPase,	Ca++	transporting,	type	2C,	member	2	
CfaAffx.30723.1.S1_s_at	 0.000347397	 0.000173429	 15.193184	 GOLGA2	 golgin	A2	
CfaAffx.30776.1.S1_s_at	 0.006212803	 0.006024682	 13.926233	 FA2H	 fatty	acid	2---hydroxylase	
CfaAffx.31009.1.S1_s_at	 2.27978E---07	 2.75308E---09	 71.22375	 CLCA4	 chloride	channel	accessory	4	
CfaAffx.31067.1.S1_s_at	 0.001529618	 0.001157902	 8.310162	 DAB2IP	 DAB2	interacting	protein	




CfaAffx.31178.1.S1_at	 0.000333351	 0.000162702	 17.105856	 ZDHHC1	 zinc	finger,	DHHC---type	containing	1	
CfaAffx.31251.1.S1_at	 0.003220776	 0.00286319	 13.553174	 LRRIQ3	 leucine---rich	repeats	and	IQ	motif	containing	3	
CfaAffx.31261.1.S1_at	 3.0747E---05	 6.37216E---06	 10.797248	 CMTM4	 CKLF---like	MARVEL	transmembrane	domain	containing	4		
Dog	liver	zone	I	signature		
Probe	Set	ID	 Corrected	p---value	 p---value	 FCAbsolute	 Gene	Symbol	 Gene	Title	
CfaAffx.51.1.S1_at	 4.47E---04	 2.36E---04	 2.3622184		 	CfaAffx.51.1.S1_s_at	 4.69E---04	 2.63E---04	 2.7912495		 	RPTR---Cfa---AJ002682---
2_s_at	
0.001023478	 9.43E---04	 2.2066429		 	RPTR---Cfa---U89963---1_s_at	 7.20E---04	 5.30E---04	 5.35554		 	RPTR---Cfa---XXU09476---1_at	 4.88E---04	 2.81E---04	 2.5119522		 	Cfa.115.1.S1_at	 2.19E---05	 3.84E---06	 9.281441	 DNASE1	 deoxyribonuclease	I	
Cfa.19.1.S1_s_at	 7.45E---06	 9.15E---07	 2.0813742	 ABCB1	 ATP---binding	cassette,	sub---family	B	(MDR/TAP),	member	1	
Cfa.16248.1.S1_at	 4.43E---04	 2.33E---04	 6.082133	 CCND1	 cyclin	D1	
Cfa.88.1.S1_s_at	 4.52E---04	 2.47E---04	 3.9615724	 GCG	 glucagon	
Cfa.3822.1.S1_s_at	 0.001137103	 0.001130162	 2.2908456	 CXCR7	 chemokine	(C---X---C	motif)	receptor	7	
Cfa.3039.1.A1_at	 2.14E---05	 3.53E---06	 3.3773682	 ATP1A1	 ATPase,	Na+/K+	transporting,	alpha	1	polypeptide	
Cfa.200.1.A1_at	 5.62E---05	 1.33E---05	 7.2378883	 TFF3	 trefoil	factor	3	(intestinal)	
Cfa.14486.1.S1_at	 1.70E---06	 1.39E---07	 6.290087	 HAMP	 hepcidin	antimicrobial	peptide	
Cfa.14486.1.S1_s_at	 4.79E---07	 2.90E---08	 4.991958	 HAMP	 hepcidin	antimicrobial	peptide	
Cfa.10248.1.S1_at	 3.05E---08	 9.89E---10	 2.6874793	 HSD11B1	 hydroxysteroid	(11---beta)	dehydrogenase	1	
Cfa.13172.1.S1_at	 2.68E---06	 2.49E---07	 4.8278613	 HSD3B2	 hydroxy---delta---5---steroid	dehydrogenase,	3	beta---	and	steroid	delta---isomerase	2	
Cfa.3900.1.S1_s_at	 4.71E---04	 2.66E---04	 5.9206276	 IFNG	 interferon	gamma	
Cfa.77.1.S1_s_at	 0.001109468	 0.001070823	 3.5266132	 PCK1	 phosphoenolpyruvate	carboxykinase	1	(soluble)	
Cfa.3460.1.S1_s_at	 6.89E---04	 4.85E---04	 4.7177715	 KCNIP2	 Kv	channel	interacting	protein	2	
Cfa.3579.1.S1_s_at	 1.19E---04	 3.87E---05	 4.103144	 SRD5A2	
steroid---5---alpha---reductase,	alpha	polypeptide	2	(3---oxo---5	alpha---steroid	delta	4-
--	
dehydrogenase	alpha	2)	Cfa.4540.1.S1_at	 2.55E---04	 1.04E---04	 2.0706987	 TARP	 TCR	gamma	alternate	reading	frame	protein	
















Cfa.11243.1.A1_at	 1.70E---08	 3.83E---10	 3.1972885	 GOT1	 glutamic---oxaloacetic	transaminase	1,	soluble	(aspartate	aminotransferase	1)	
Cfa.4791.1.A1_at	 2.73E---04	 1.15E---04	 2.1429024	 GSTT1	 glutathione	S---transferase	theta	1	
Cfa.12186.1.A1_at	 1.38E---04	 4.71E---05	 2.3316627	 PCK1	 phosphoenolpyruvate	carboxykinase	1	(soluble)	
Cfa.6341.1.A1_at	 1.76E---04	 6.26E---05	 2.7850494	 PDZK1IP1	 PDZK1	interacting	protein	1	
Cfa.12127.1.A1_at	 2.19E---05	 3.75E---06	 2.7573106	 INMT	 indolethylamine	N---methyltransferase	
Cfa.10250.1.A1_at	 1.49E---05	 2.21E---06	 2.1126008	 CISD1	 CDGSH	iron	sulfur	domain	1	
Cfa.12031.1.A1_at	 0.001137103	 0.001132292	 2.2310576	 FAM46B	 family	with	sequence	similarity	46,	member	B	
Cfa.11563.1.A1_at	 1.55E---05	 2.36E---06	 13.797901	 CDKN1A	 cyclin---dependent	kinase	inhibitor	1A	(p21,	Cip1)	
Cfa.12228.1.A1_s_at	 1.18E---04	 3.81E---05	 3.729864	 SCGB1A1	 secretoglobin,	family	1A,	member	1	(uteroglobin)	
Cfa.13329.1.A1_at	 1.20E---05	 1.68E---06	 2.2961	 A1CF	 APOBEC1	complementation	factor	
Cfa.12533.1.A1_at	 6.72E---07	 4.46E---08	 3.3139002	 INSIG1	 insulin	induced	gene	1	
Cfa.2065.1.A1_at	 1.49E---05	 2.19E---06	 2.5247438	 CTH	 cystathionase	(cystathionine	gamma---lyase)	
Cfa.9465.1.A1_at	 8.95E---05	 2.58E---05	 9.477575	 SYT13	 synaptotagmin	XIII	
Cfa.7475.1.A1_at	 1.17E---04	 3.75E---05	 3.6872158	 SAP30BP	 SAP30	binding	protein	
Cfa.7437.1.A1_at	 1.98E---09	 2.79E---11	 8.119272	 GLS2	 glutaminase	2	(liver,	mitochondrial)	
Cfa.261.1.A1_a_at	 4.91E---06	 5.33E---07	 5.1000943	 CRYM	 crystallin,	mu	
Cfa.10794.1.A1_at	 5.32E---05	 1.22E---05	 18.466257	 SCG5	 secretogranin	V	(7B2	protein)	
Cfa.11335.1.A1_at	 1.12E---07	 4.87E---09	 4.1235185	 AMDHD1	 amidohydrolase	domain	containing	1	
CfaAffx.10568.1.S1_at	 3.30E---04	 1.50E---04	 2.9100509	 AMDHD1	 amidohydrolase	domain	containing	1	
CfaAffx.10568.1.S1_s_at	 8.86E---06	 1.15E---06	 3.2318864	 AMDHD1	 amidohydrolase	domain	containing	1	
Cfa.11358.1.A1_at	 4.15E---04	 2.15E---04	 2.1719885		 	Cfa.6369.1.A1_at	 3.11E---05	 6.19E---06	 2.0269942	 FBP1	 fructose---1,6---bisphosphatase	1	
Cfa.6224.1.A1_at	 1.49E---05	 2.23E---06	 6.3605933		 	Cfa.2657.1.A1_at	 2.36E---06	 2.09E---07	 2.490895		 	Cfa.5193.1.A1_at	 8.89E---04	 7.46E---04	 2.0879204		 	Cfa.6763.1.A1_at	 1.49E---05	 2.24E---06	 3.675365	 CRHR2	 corticotropin	releasing	hormone	receptor	2	
Cfa.10873.1.A1_at	 1.54E---06	 1.21E---07	 2.6299667	 PTPN3	 protein	tyrosine	phosphatase,	non---receptor	type	3	
Cfa.15708.1.A1_at	 2.94E---06	 2.82E---07	 2.6508162	 CPB2	 carboxypeptidase	B2	(plasma)	
Cfa.9216.1.A1_at	 6.40E---04	 4.33E---04	 2.15436	 IER2	 immediate	early	response	2	
Cfa.5100.1.A1_at	 6.20E---04	 4.09E---04	 2.1360412		 	Cfa.5095.1.A1_s_at	 1.17E---04	 3.77E---05	 3.4504335	 KCNN2	 potassium	intermediate/small	conductance	calcium---activated	channel,	subfamily	N,	
member	2	
Cfa.12353.1.A1_a_at	 7.93E---05	 2.14E---05	 2.140886	 SIK3	 SIK	family	kinase	3	
Cfa.11714.1.A1_x_at	 5.90E---04	 3.83E---04	 3.709542	 LOC476453	 cytochrome	P450	2F2---like	
Cfa.604.1.A1_at	 1.05E---09	 8.91E---12	 5.867393	 LOC100856598	 nicotinamide	phosphoribosyltransferase---like	
Cfa.13946.1.S1_s_at	 8.91E---04	 7.51E---04	 6.1073008	 FXYD2	 FXYD	domain	containing	ion	transport	regulator	2	
Cfa.11607.1.S1_at	 1.83E---04	 6.62E---05	 6.1609282	 AQP8	 aquaporin	8	
Cfa.13211.1.A1_at	 2.71E---06	 2.56E---07	 2.2727952	 TDO2	 tryptophan	2,3---dioxygenase	
CfaAffx.13588.1.S1_at	 3.06E---04	 1.35E---04	 2.415012	 TDO2	 tryptophan	2,3---dioxygenase	
CfaAffx.13588.1.S1_s_at	 2.72E---05	 5.18E---06	 2.1222477	 TDO2	 tryptophan	2,3---dioxygenase	
CfaAffx.7926.1.S1_s_at	 4.64E---04	 2.57E---04	 4.958221	 ABP1	 amiloride	binding	protein	1	(amine	oxidase	(copper---containing))	
Cfa.11241.1.A1_at	 3.99E---04	 2.01E---04	 3.24493		 	Cfa.14517.1.A1_at	 2.75E---05	 5.32E---06	 2.26174	 FGA	 fibrinogen	alpha	chain	
Cfa.12500.1.A1_at	 7.73E---05	 2.04E---05	 2.0471642		 	Cfa.6020.1.A1_at	 1.66E---04	 5.88E---05	 4.6586995		 	Cfa.15431.1.A1_at	 8.16E---04	 6.45E---04	 2.9712937		 	Cfa.12266.1.A1_at	 6.17E---04	 4.05E---04	 6.6837234		 	Cfa.10820.1.S1_at	 4.91E---06	 5.26E---07	 3.0222366	 TPR	 translocated	promoter	region,	nuclear	basket	protein	
Cfa.13146.1.A1_at	 8.61E---04	 7.03E---04	 3.768973	 FBXO2	 F---box	protein	2	
Cfa.14986.1.A1_at	 6.18E---05	 1.51E---05	 3.40883		 	Cfa.16469.1.S1_x_at	 8.86E---06	 1.14E---06	 2.095468	 SERPINA1	 serpin	peptidase	inhibitor,	clade	A	(alpha---1	antiproteinase,	antitrypsin),	member	1	
Cfa.506.1.S1_at	 5.36E---04	 3.24E---04	 2.794601	 LOC100686903	 uncharacterized	LOC100686903	
Cfa.2326.1.S1_at	 1.04E---05	 1.40E---06	 2.3006694	 LOC100856436	 gamma---glutamyl	hydrolase---like	
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Cfa.1760.1.A1_at	 8.95E---05	 2.56E---05	 2.0890467	MAN2A1	 mannosidase,	alpha,	class	2A,	member	1	
Cfa.2170.1.S1_at	 8.86E---06	 1.15E---06	 4.7451415	 ALDH1B1	 aldehyde	dehydrogenase	1	family,	member	B1	
Cfa.6037.1.S1_at	 2.28E---08	 6.76E---10	 4.986616	 A2M	 alpha---2---macroglobulin	
Cfa.6037.1.S1_s_at	 1.09E---04	 3.39E---05	 4.3954763	 A2M	 alpha---2---macroglobulin	
Cfa.2730.1.S1_at	 0.001007302	 9.08E---04	 6.9273295	 RASEF	 RAS	and	EF---hand	domain	containing	
Cfa.15049.1.S1_a_at	 7.41E---05	 1.93E---05	 2.0167336	 NMI	 N---myc	(and	STAT)	interactor	
Cfa.14027.1.A1_at	 2.12E---04	 8.04E---05	 12.260447	 AGXT2L1	 alanine---glyoxylate	aminotransferase	2---like	1	
Cfa.14925.1.A1_s_at	 2.78E---07	 1.53E---08	 3.5611627	 AMDHD1	 amidohydrolase	domain	containing	1	
Cfa.15025.1.S1_at	 1.20E---04	 3.96E---05	 4.8702397	 IVNS1ABP	 influenza	virus	NS1A	binding	protein	
Cfa.1818.1.S1_at	 9.93E---05	 2.95E---05	 20.003351		 	CfaAffx.11365.1.S1_at	 3.06E---04	 1.36E---04	 2.6706333	 PLK2	 polo---like	kinase	2	
Cfa.716.1.S1_at	 1.15E---07	 5.17E---09	 2.3502603	 GNMT	 glycine	N---methyltransferase	
CfaAffx.3512.1.S1_s_at	 6.61E---05	 1.68E---05	 2.0003722	 GNMT	 glycine	N---methyltransferase	
Cfa.9537.1.S1_at	 5.45E---06	 6.15E---07	 2.0389786		 	Cfa.18689.1.S1_at	 1.23E---04	 4.15E---05	 4.5825443	 A2M	 alpha---2---macroglobulin	
Cfa.18689.1.S1_s_at	 9.65E---04	 8.51E---04	 7.4107733	 A2M	 alpha---2---macroglobulin	
Cfa.21446.1.S1_at	 9.11E---05	 2.63E---05	 2.4368663	 SDC4	 syndecan	4	
Cfa.19344.1.S1_at	 9.79E---04	 8.72E---04	 2.478196	 TMEM184C	 transmembrane	protein	184C	
Cfa.19549.1.S1_at	 7.05E---04	 5.09E---04	 18.537493	 AGXT2L1	 alanine---glyoxylate	aminotransferase	2---like	1	
Cfa.19549.1.S1_s_at	 1.83E---04	 6.60E---05	 10.5841875	 AGXT2L1	 alanine---glyoxylate	aminotransferase	2---like	1	
Cfa.4354.1.S1_a_at	 3.05E---06	 2.97E---07	 9.582985	 CRYL1	 crystallin,	lambda	1	
Cfa.21147.1.S1_at	 1.20E---04	 3.95E---05	 2.4453192	 PRG4	 proteoglycan	4	
Cfa.20197.1.S1_s_at	 6.17E---04	 4.05E---04	 5.3378077	 KLHL10	 kelch---like	10	(Drosophila)	
Cfa.17338.1.S1_at	 8.67E---04	 7.14E---04	 2.06938	 PRKAB1	 protein	kinase,	AMP---activated,	beta	1	non---catalytic	subunit	
Cfa.17754.1.S1_s_at	 9.23E---04	 7.93E---04	 3.7816126	MYPN	 myopalladin	
Cfa.18110.1.S1_s_at	 3.31E---04	 1.53E---04	 4.5418205	 GAS6	 growth	arrest---specific	6	
Cfa.17292.1.S1_at	 8.95E---05	 2.57E---05	 2.3273602	 CLK1	 CDC---like	kinase	1	
Cfa.19914.1.S1_at	 8.17E---04	 6.48E---04	 4.515733	 C2H16orf78	 chromosome	2	open	reading	frame,	human	C16orf78	
Cfa.18345.1.S1_at	 1.04E---06	 7.50E---08	 7.479455	 LOC100856598	 nicotinamide	phosphoribosyltransferase---like	
Cfa.18345.1.S1_s_at	 6.37E---04	 4.27E---04	 5.9291267	 LOC100856598	 nicotinamide	phosphoribosyltransferase---like	





Cfa.16871.1.S1_at	 1.56E---05	 2.42E---06	 2.677464	 SLC27A6	 solute	carrier	family	27	(fatty	acid	transporter),	member	6	
Cfa.10462.3.S1_a_at	 2.55E---04	 1.05E---04	 2.1855497	 TOB1	 transducer	of	ERBB2,	1	
Cfa.18520.1.S1_s_at	 4.01E---04	 2.03E---04	 4.342034	 ZPBP	 zona	pellucida	binding	protein	
Cfa.20245.1.S1_s_at	 9.23E---04	 7.93E---04	 2.124119	 NNAT	 neuronatin	
Cfa.18172.1.S1_at	 0.00101319	 9.29E---04	 2.880345	 TMEM130	 transmembrane	protein	130	
Cfa.6583.1.A1_at	 3.80E---04	 1.87E---04	 3.0895784	 RSPH6A	 radial	spoke	head	6	homolog	A	(Chlamydomonas)	




Cfa.14390.1.A1_at	 3.50E---04	 1.66E---04	 2.5185163	 HSD17B13	 hydroxysteroid	(17---beta)	dehydrogenase	13	
Cfa.5149.1.A1_at	 9.54E---04	 8.33E---04	 11.50878	 CLDN18	 claudin	18	
Cfa.14347.1.A1_a_at	 8.43E---04	 6.76E---04	 6.2065945	 PABPC1	 poly(A)	binding	protein,	cytoplasmic	1	
Cfa.6787.1.A1_at	 8.03E---04	 6.26E---04	 5.3045893	 FAM211B	 family	with	sequence	similarity	211,	member	B	
Cfa.13841.1.A1_at	 5.37E---04	 3.27E---04	 2.3758984		 	Cfa.13333.1.A1_at	 5.10E---06	 5.61E---07	 2.867027		 	Cfa.6572.1.A1_at	 6.69E---04	 4.62E---04	 4.857863		 	Cfa.6500.1.A1_at	 3.31E---04	 1.53E---04	 4.550751		 	Cfa.5975.1.A1_at	 0.001109468	 0.001072649	 3.5205276		 	Cfa.2817.1.A1_at	 4.47E---04	 2.40E---04	 5.615039		 	Cfa.7610.1.A1_at	 5.36E---04	 3.24E---04	 3.790045		 	Cfa.14409.1.A1_at	 1.07E---04	 3.31E---05	 2.8406126	 LOC100687790	 uncharacterized	LOC100687790	
Cfa.14519.1.A1_at	 6.32E---05	 1.57E---05	 3.4406133	 CDA	 cytidine	deaminase	
Cfa.14357.1.A1_at	 2.19E---05	 3.76E---06	 10.819984	 DMBT1	 deleted	in	malignant	brain	tumors	1	
Cfa.1331.1.A1_s_at	 0.001137103	 0.001131316	 2.242029	 DNPEP	 aspartyl	aminopeptidase	
Cfa.4794.1.A1_x_at	 2.55E---04	 1.05E---04	 2.8934968	 RGS10	 regulator	of	G---protein	signaling	10	
Cfa.2593.1.S1_at	 6.92E---04	 4.96E---04	 2.9763377	 PLAUR	 plasminogen	activator,	urokinase	receptor	
Cfa.2391.1.S1_at	 5.52E---05	 1.29E---05	 2.2369497	 AASS	 aminoadipate---semialdehyde	synthase	
Cfa.422.1.A1_at	 5.55E---04	 3.44E---04	 16.590569		 	Cfa.3095.1.A1_at	 7.40E---04	 5.51E---04	 6.4090285		 	Cfa.8795.1.A1_at	 8.03E---04	 6.26E---04	 2.4415514	 PKNOX2	 PBX/knotted	1	homeobox	2	
Cfa.9729.1.A1_at	 2.12E---04	 8.02E---05	 4.8876214		 	Cfa.7030.1.A1_at	 4.47E---04	 2.38E---04	 2.3493683		 	Cfa.7551.1.A1_at	 6.92E---04	 4.97E---04	 3.4050791	 LOC100687680	 uncharacterized	LOC100687680	
Cfa.5383.1.A1_s_at	 2.88E---04	 1.22E---04	 6.457627	 SLC22A3	 solute	carrier	family	22	(extraneuronal	monoamine	transporter),	member	3	
Cfa.8011.2.S1_at	 5.61E---04	 3.53E---04	 4.9271407	 CTU2	 cytosolic	thiouridylase	subunit	2	homolog	(S.	pombe)	
Cfa.14836.1.A1_at	 1.67E---07	 8.26E---09	 4.7328577		 	Cfa.9388.1.A1_at	 3.73E---04	 1.79E---04	 2.4713075	 STPG1	 sperm---tail	PG---rich	repeat	containing	1	
Cfa.14510.1.A1_at	 2.47E---05	 4.59E---06	 2.6009297	 C8B	 complement	component	8,	beta	polypeptide	
Cfa.5354.1.A1_at	 5.35E---04	 3.21E---04	 3.1786656	 PIGR	 polymeric	immunoglobulin	receptor	
Cfa.9819.1.A1_at	 9.98E---05	 2.98E---05	 2.2327995	 BHMT	 betaine------homocysteine	S---methyltransferase	
Cfa.13273.1.A1_x_at	 2.46E---04	 9.78E---05	 2.3439674	 FGG	 fibrinogen	gamma	chain	
Cfa.13351.1.A1_at	 8.43E---04	 6.83E---04	 8.0946665	 LOC609690	 phosphatidylcholine	transfer	protein---like	
Cfa.13959.1.A1_at	 9.03E---04	 7.67E---04	 2.1979938	 PCK1	 phosphoenolpyruvate	carboxykinase	1	(soluble)	
Cfa.4874.1.A1_at	 6.92E---04	 4.96E---04	 2.674564		 	Cfa.14509.1.A1_at	 6.77E---04	 4.68E---04	 3.6801898	 ACE2	 angiotensin	I	converting	enzyme	(peptidyl---dipeptidase	A)	2	
Cfa.14509.1.A1_s_at	 8.69E---08	 3.07E---09	 9.317055	 ACE2	 angiotensin	I	converting	enzyme	(peptidyl---dipeptidase	A)	2	
Cfa.14559.1.A1_at	 4.88E---04	 2.80E---04	 5.2467756		 	Cfa.12799.1.A1_at	 4.69E---04	 2.63E---04	 2.4946578		 	Cfa.14451.1.A1_at	 1.56E---04	 5.38E---05	 3.1871827	 UROC1	 urocanate	hydratase	1	
Cfa.12626.1.A1_at	 9.22E---04	 7.88E---04	 3.084733		 	Cfa.6319.1.A1_at	 3.05E---04	 1.33E---04	 3.6481128		 	Cfa.14468.1.A1_s_at	 9.65E---04	 8.54E---04	 5.200644	 NNMT	 nicotinamide	N---methyltransferase	
Cfa.12914.1.A1_at	 5.40E---04	 3.30E---04	 2.0093505		 	Cfa.13427.1.A1_at	 4.34E---04	 2.28E---04	 2.9480019		 	Cfa.4873.1.A1_at	 3.38E---04	 1.59E---04	 2.0670514		 	Cfa.12871.1.A1_x_at	 3.31E---04	 1.52E---04	 2.8619752	 CARKD	 carbohydrate	kinase	domain	containing	
Cfa.5993.1.A1_at	 4.05E---04	 2.06E---04	 2.264425	 FGB	 fibrinogen	beta	chain	
Cfa.8857.2.A1_at	 8.35E---04	 6.66E---04	 3.2224762	WFDC3	 WAP	four---disulfide	core	domain	3	
Cfa.5991.1.A1_x_at	 6.74E---06	 7.90E---07	 2.2316887	 ALB	 albumin	
Cfa.331.1.S1_at	 5.89E---04	 3.81E---04	 4.5389204		 	Cfa.15859.1.A1_x_at	 8.64E---04	 7.08E---04	 3.7841198	 ACTA1	 actin,	alpha	1,	skeletal	muscle	
























CfaAffx.1087.1.S1_s_at	 7.41E---05	 1.92E---05	 2.0482466	 ORMDL2	 ORM1---like	2	(S.	cerevisiae)	
CfaAffx.1173.1.S1_s_at	 9.84E---06	 1.30E---06	 7.154202	 GLS2	 glutaminase	2	(liver,	mitochondrial)	
CfaAffx.1174.1.S1_s_at	 7.50E---04	 5.60E---04	 3.7941115	 RBMS2	 RNA	binding	motif,	single	stranded	interacting	protein	2	
CfaAffx.1454.1.S1_at	 1.11E---04	 3.46E---05	 10.854353	 AVPR1A	 arginine	vasopressin	receptor	1A	
CfaAffx.1463.1.S1_s_at	 6.67E---04	 4.58E---04	 4.8920646	 LOC100856646	 calpain---7---like	protein---like	
CfaAffx.1600.1.S1_at	 1.95E---09	 2.30E---11	 9.849651	 CCDC170	 coiled---coil	domain	containing	170	
CfaAffx.2031.1.S1_at	 1.93E---04	 7.11E---05	 6.0346947		 	CfaAffx.2034.1.S1_s_at	 4.74E---05	 1.07E---05	 9.819643	 SLC22A3	 solute	carrier	family	22	(extraneuronal	monoamine	transporter),	member	3	
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CfaAffx.2039.1.S1_s_at	 3.06E---04	 1.37E---04	 7.1145825	 SLC22A1	 solute	carrier	family	22	(organic	cation	transporter),	member	1	
CfaAffx.2043.1.S1_at	 3.64E---05	 7.55E---06	 27.338125	 SLC22A3	 solute	carrier	family	22	(extraneuronal	monoamine	transporter),	member	3	













CfaAffx.3022.1.S1_s_at	 6.74E---06	 7.86E---07	 3.291371	 GLDC	 glycine	dehydrogenase	(decarboxylating)	
CfaAffx.3129.1.S1_at	 0.001142826	 0.001142826	 2.232532	 SSMEM1	 serine---rich	single---pass	membrane	protein	1	
CfaAffx.3747.1.S1_at	 8.29E---04	 6.59E---04	 4.013817	 COX7B2	 cytochrome	c	oxidase	subunit	VIIb2	
CfaAffx.4178.1.S1_at	 6.83E---04	 4.76E---04	 2.9879646	 RNF149	 ring	finger	protein	149	
CfaAffx.4463.1.S1_at	 3.92E---05	 8.45E---06	 7.7291245	 ALDH1B1	 aldehyde	dehydrogenase	1	family,	member	B1	
CfaAffx.4562.1.S1_at	 6.40E---04	 4.34E---04	 4.2133856	 FOXE1	 forkhead	box	E1	(thyroid	transcription	factor	2)	
CfaAffx.4714.1.S1_s_at	 0.00100411	 9.02E---04	 2.0869815	 COL19A1	 collagen,	type	XIX,	alpha	1	
CfaAffx.4809.1.S1_at	 7.17E---04	 5.25E---04	 4.5047193	 GP6	 glycoprotein	VI	(platelet)	
CfaAffx.5174.1.S1_at	 6.40E---04	 4.33E---04	 2.0150173	 VSIG10L	 V---set	and	immunoglobulin	domain	containing	10	like	
CfaAffx.5960.1.S1_s_at	 0.001109468	 0.00107349	 3.5105672	 C11H9orf91	 chromosome	11	open	reading	frame,	human	C9orf91	
CfaAffx.6209.1.S1_at	 7.92E---04	 6.10E---04	 6.2101383	 PTPRZ1	 protein	tyrosine	phosphatase,	receptor---type,	Z	polypeptide	1	
CfaAffx.6438.1.S1_at	 0.001083552	 0.001026711	 2.0580971	 HMGB4	 high	mobility	group	box	4	
CfaAffx.6722.1.S1_s_at	 4.63E---05	 1.04E---05	 7.8102875	 CCDC7	 coiled---coil	domain	containing	7	
CfaAffx.6906.1.S1_at	 2.17E---08	 5.82E---10	 5.451332	 LOC100856598	 nicotinamide	phosphoribosyltransferase---like	
CfaAffx.6985.1.S1_at	 9.01E---04	 7.64E---04	 2.600856	 RFPL4B	 ret	finger	protein---like	4B	
CfaAffx.7050.1.S1_at	 2.26E---04	 8.80E---05	 2.735839	 GLTSCR1	 glioma	tumor	suppressor	candidate	region	gene	1	
CfaAffx.7578.1.S1_at	 4.61E---04	 2.54E---04	 2.3411555	 CDADC1	 cytidine	and	dCMP	deaminase	domain	containing	1	
CfaAffx.7713.1.S1_s_at	 2.47E---06	 2.26E---07	 2.2303488	 CPB2	 carboxypeptidase	B2	(plasma)	
CfaAffx.7883.1.S1_at	 8.56E---04	 6.98E---04	 2.4556303	 PVRL2	 poliovirus	receptor---related	2	(herpesvirus	entry	mediator	B)	
CfaAffx.8272.1.S1_at	 8.95E---05	 2.56E---05	 6.0447187	 SCTR	 secretin	receptor	
CfaAffx.8833.1.S1_at	 5.19E---04	 3.08E---04	 2.9791503	 LOC100856134	 urocortin---3---like	
CfaAffx.9544.1.S1_s_at	 0.001136777	 0.001126907	 2.1030495	 SLC38A10	 solute	carrier	family	38,	member	10	
CfaAffx.9641.1.S1_at	 0.001008789	 9.21E---04	 2.3556573	 ART5	 ADP---ribosyltransferase	5	
CfaAffx.9846.1.S1_at	 6.80E---04	 4.71E---04	 2.8093987	 SPRED3	 sprouty---related,	EVH1	domain	containing	3	
CfaAffx.10100.1.S1_at	 3.38E---04	 1.58E---04	 4.943786	 SULT6B1	 sulfotransferase	family,	cytosolic,	6B,	member	1	
CfaAffx.10256.1.S1_at	 1.64E---04	 5.75E---05	 2.062443	 HDAC3	 histone	deacetylase	3	
CfaAffx.10607.1.S1_at	 9.17E---05	 2.68E---05	 16.09443	 HAL	 histidine	ammonia---lyase	
CfaAffx.10791.1.S1_at	 8.43E---04	 6.78E---04	 2.1881874	 DEAF1	 deformed	epidermal	autoregulatory	factor	1	(Drosophila)	





CfaAffx.10948.1.S1_at	 4.87E---04	 2.78E---04	 2.9258432	 TMC2	 transmembrane	channel---like	2	
CfaAffx.11313.1.S1_at	 2.41E---05	 4.39E---06	 3.582794	 SLC7A2	 solute	carrier	family	7	(cationic	amino	acid	transporter,	y+	system),	member	2	
CfaAffx.11451.1.S1_at	 8.39E---04	 6.71E---04	 3.6733086	MOS	 v---mos	Moloney	murine	sarcoma	viral	oncogene	homolog	
CfaAffx.11552.1.S1_s_at	 8.81E---04	 7.28E---04	 4.5987954	 C20H3orf14	 chromosome	20	open	reading	frame,	human	C3orf14	
CfaAffx.11741.1.S1_s_at	 3.30E---04	 1.50E---04	 4.125406	 IL1B	 interleukin	1,	beta	
CfaAffx.11760.1.S1_at	 4.91E---04	 2.84E---04	 3.008066	 IL1F8	 interleukin	1	family,	member	8	(eta)	
CfaAffx.11798.1.S1_s_at	 3.92E---05	 8.47E---06	 7.36029	 CRYL1	 crystallin,	lambda	1	
CfaAffx.11895.1.S1_at	 7.50E---04	 5.64E---04	 3.379391	 KCTD15	 potassium	channel	tetramerisation	domain	containing	15	
CfaAffx.12001.1.S1_s_at	 6.31E---04	 4.20E---04	 2.2082994	MAN2A1	 mannosidase,	alpha,	class	2A,	member	1	
CfaAffx.12092.1.S1_s_at	 5.72E---05	 1.38E---05	 11.159875	 CLDN18	 claudin	18	
CfaAffx.12380.1.S1_at	 3.72E---07	 2.20E---08	 2.8957467	 AADAT	 aminoadipate	aminotransferase	
CfaAffx.12658.1.S1_s_at	 4.47E---04	 2.40E---04	 2.0004745	 ELL2	 elongation	factor,	RNA	polymerase	II,	2	
CfaAffx.12764.1.S1_s_at	 7.36E---04	 5.47E---04	 5.4150953	 EMC4	 ER	membrane	protein	complex	subunit	4	
CfaAffx.12970.1.S1_at	 3.06E---04	 1.36E---04	 5.390561	 LOC100687650	 olfactory	receptor	4P4---like	
CfaAffx.13043.1.S1_at	 7.97E---04	 6.16E---04	 2.8684509		 	CfaAffx.13264.1.S1_s_at	 8.03E---04	 6.24E---04	 3.2924228	 TMPRSS15	 transmembrane	protease,	serine	15	
CfaAffx.13328.1.S1_at	 6.55E---04	 4.48E---04	 4.670266	 C1QTNF4	 C1q	and	tumor	necrosis	factor	related	protein	4	
CfaAffx.14193.1.S1_s_at	 0.001052243	 9.84E---04	 2.6901436	 LOC100856038	 serine/threonine---protein	kinase	PAK	6---like	
CfaAffx.14346.1.S1_s_at	 3.71E---05	 7.80E---06	 9.408821	 SDS	 serine	dehydratase	
CfaAffx.14452.1.S1_at	 7.24E---04	 5.34E---04	 5.381346	 LOC100856070	 olfactory	receptor	5K1---like	
CfaAffx.14574.1.S1_at	 1.30E---05	 1.87E---06	 6.022402	 SLC38A4	 solute	carrier	family	38,	member	4	
CfaAffx.14612.1.S1_at	 9.58E---04	 8.42E---04	 5.0486627	 CRHBP	 corticotropin	releasing	hormone	binding	protein	
CfaAffx.14901.1.S1_s_at	 1.04E---05	 1.40E---06	 2.4154148	 GOT1	 glutamic---oxaloacetic	transaminase	1,	soluble	(aspartate	aminotransferase	1)	

































CfaAffx.15479.1.S1_at	 5.71E---04	 3.64E---04	 2.0457256	 SLC6A5	 solute	carrier	family	6	(neurotransmitter	transporter,	glycine),	member	5	
CfaAffx.16591.1.S1_at	 0.001126333	 0.001105681	 5.059919	 CCDC147	 coiled---coil	domain	containing	147	
CfaAffx.16731.1.S1_s_at	 3.99E---04	 2.00E---04	 2.8347592	 SLC6A3	 solute	carrier	family	6	(neurotransmitter	transporter,	dopamine),	member	3	
CfaAffx.16895.1.S1_at	 4.15E---04	 2.13E---04	 2.4084287	 PDCD4	 programmed	cell	death	4	(neoplastic	transformation	inhibitor)	
CfaAffx.17140.1.S1_at	 4.89E---04	 2.82E---04	 4.576503	 LOC610995	 uncharacterized	LOC610995	
CfaAffx.17155.1.S1_s_at	 0.001093915	 0.001039914	 2.6258764		 	CfaAffx.17541.1.S1_s_at	 0.001118269	 0.001091456	 3.783531	 ALDH3B2	 aldehyde	dehydrogenase	3	family,	member	B2	
CfaAffx.17644.1.S1_at	 1.93E---04	 7.04E---05	 19.054476	 AGXT2L1	 alanine---glyoxylate	aminotransferase	2---like	1	
CfaAffx.17740.1.S1_at	 6.27E---04	 4.15E---04	 3.1915338	WSCD2	 WSC	domain	containing	2	
CfaAffx.17752.1.S1_at	 5.59E---04	 3.49E---04	 4.4084883	 LOC489338	 putative	olfactory	receptor	10D3---like	
CfaAffx.17833.1.S1_at	 0.001000575	 8.95E---04	 3.1105645		 	CfaAffx.17869.1.S1_at	 7.78E---04	 5.92E---04	 3.3322694	 LOC488312	 olfactory	receptor	2G6---like	
CfaAffx.17884.1.S1_s_at	 3.31E---04	 1.52E---04	 2.9325092	 PIGR	 polymeric	immunoglobulin	receptor	
CfaAffx.17915.1.S1_at	 2.99E---04	 1.29E---04	 4.160895	 C7H1orf116	 chromosome	7	open	reading	frame,	human	C1orf116	
CfaAffx.18662.1.S1_at	 3.32E---04	 1.54E---04	 2.6680589	 BMP7	 bone	morphogenetic	protein	7	
CfaAffx.18846.1.S1_at	 1.22E---04	 4.05E---05	 6.4208555	 ACE2	 angiotensin	I	converting	enzyme	(peptidyl---dipeptidase	A)	2	
CfaAffx.19048.1.S1_s_at	 8.06E---04	 6.33E---04	 5.546906		 	CfaAffx.19098.1.S1_s_at	 5.63E---05	 1.35E---05	 7.0807405	 cOR52A10	 cOR52A10	olfactory	receptor	family	52	subfamily	A---like	
CfaAffx.19377.1.S1_at	 6.85E---04	 4.79E---04	 2.8293104	 cOR52S3	 cOR52S3	olfactory	receptor	family	52	subfamily	S---like	
CfaAffx.19397.1.S1_at	 1.48E---08	 2.71E---10	 2.9584477	 ICA1L	 islet	cell	autoantigen	1,69kDa---like	
CfaAffx.19509.1.S1_s_at	 2.47E---04	 9.88E---05	 4.4929786	 PIK3C2G	 phosphatidylinositol---4---phosphate	3---kinase,	catalytic	subunit	type	2	gamma	
CfaAffx.19565.1.S1_at	 6.30E---04	 4.18E---04	 2.0244954	 LOC477425	 olfactory	receptor	family	9	subfamily	S	
CfaAffx.19565.1.S1_x_at	 8.82E---04	 7.31E---04	 2.8546588	 LOC477425	 olfactory	receptor	family	9	subfamily	S	





CfaAffx.20253.1.S1_at	 4.91E---04	 2.85E---04	 3.380909	 NOS1AP	 nitric	oxide	synthase	1	(neuronal)	adaptor	protein	
CfaAffx.20901.1.S1_at	 6.92E---04	 4.90E---04	 6.2004437	 NNMT	 nicotinamide	N---methyltransferase	
CfaAffx.20905.1.S1_at	 8.29E---04	 6.59E---04	 3.2357028	 INMT	 indolethylamine	N---methyltransferase	
CfaAffx.20987.1.S1_s_at	 1.97E---06	 1.70E---07	 4.8975644	 IVNS1ABP	 influenza	virus	NS1A	binding	protein	
CfaAffx.21142.1.S1_s_at	 1.97E---06	 1.68E---07	 9.750079	 PRG4	 proteoglycan	4	
CfaAffx.21253.1.S1_s_at	 2.99E---07	 1.69E---08	 2.012042	 LOC611458	 alpha---2---macroglobulin---like	
CfaAffx.21435.1.S1_at	 0.001098713	 0.001050673	 5.3653603	 RIMKLB	 ribosomal	modification	protein	rimK---like	family	member	B	
CfaAffx.21460.1.S1_at	 4.34E---05	 9.61E---06	 17.05622	 GGT1	 gamma---glutamyltransferase	1	
CfaAffx.21462.1.S1_s_at	 0.001130208	 0.001111079	 3.9970117	 GGT1	 gamma---glutamyltransferase	1	
CfaAffx.21670.1.S1_s_at	 0.001031781	 9.55E---04	 2.6099608		 	CfaAffx.21967.1.S1_s_at	 7.17E---05	 1.84E---05	 5.237938	 YJEFN3	 YjeF	N---terminal	domain	containing	3	
CfaAffx.22767.1.S1_at	 3.41E---04	 1.61E---04	 2.4412951	 LOC100856319	 low---density	lipoprotein	receptor	class	A	domain---containing	protein	2---like	
CfaAffx.22787.1.S1_at	 3.99E---04	 2.01E---04	 2.6936347	 SHC4	 SHC	(Src	homology	2	domain	containing)	family,	member	4	
CfaAffx.23060.1.S1_at	 0.001009791	 9.24E---04	 4.6272225	 C7H1orf129	 chromosome	7	open	reading	frame,	human	C1orf129	
CfaAffx.23448.1.S1_at	 9.23E---04	 7.91E---04	 5.2805195	 C8H14orf105	 chromosome	8	open	reading	frame,	human	C14orf105	
CfaAffx.23785.1.S1_x_at	 3.81E---04	 1.88E---04	 2.8482275	 LOC607715	 	CfaAffx.24373.1.S1_at	 7.66E---04	 5.80E---04	 5.3245897	 CACNA1F	 calcium	channel,	voltage---dependent,	L	type,	alpha	1F	subunit	
CfaAffx.24432.1.S1_at	 7.09E---04	 5.14E---04	 3.5549517	 KRT14	 keratin	14	
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CfaAffx.24621.1.S1_s_at	 0.001095686	 0.001043143	 3.4331741	 LDB3	 LIM	domain	binding	3	
CfaAffx.25033.1.S1_at	 7.50E---04	 5.63E---04	 2.0124445	 GNA12	 guanine	nucleotide	binding	protein	(G	protein)	alpha	12	
CfaAffx.25117.1.S1_at	 0.001121901	 0.001096817	 3.439408	 TMEM229B	 transmembrane	protein	229B	
CfaAffx.25347.1.S1_at	 4.61E---04	 2.54E---04	 2.1658816		 	CfaAffx.25568.1.S1_s_at	 8.89E---04	 7.47E---04	 2.6252992	 STARD8	 StAR---related	lipid	transfer	(START)	domain	containing	8	
CfaAffx.25710.1.S1_at	 0.00100411	 9.03E---04	 3.384554	 PRR15L	 proline	rich	15---like	
CfaAffx.25716.1.S1_at	 5.01E---04	 2.95E---04	 2.1446939	 LSMD1	 LSM	domain	containing	1	
CfaAffx.25748.1.S1_at	 0.001008789	 9.19E---04	 2.331887	 HOXB2	 homeobox	B2	
CfaAffx.25763.1.S1_at	 0.00103103	 9.51E---04	 2.351187	 PRSS36	 protease,	serine,	36	
CfaAffx.26532.1.S1_at	 7.88E---04	 6.06E---04	 2.3910594	 ZNF653	 zinc	finger	protein	653	
CfaAffx.26577.1.S1_at	 4.47E---04	 2.41E---04	 5.729099	 RPS6KA6	 ribosomal	protein	S6	kinase,	90kDa,	polypeptide	6	
CfaAffx.26814.1.S1_at	 5.70E---04	 3.61E---04	 3.0324247	 SPC24	 SPC24,	NDC80	kinetochore	complex	component,	homolog	(S.	cerevisiae)	
CfaAffx.27276.1.S1_at	 6.20E---04	 4.10E---04	 3.6256466	 TBC1D21	 TBC1	domain	family,	member	21	
CfaAffx.27291.1.S1_at	 1.00E---04	 3.03E---05	 3.6334188	 CCDC33	 coiled---coil	domain	containing	33	
CfaAffx.27489.1.S1_s_at	 0.001008789	 9.20E---04	 4.0318727	 LMAN1L	 lectin,	mannose---binding,	1	like	
CfaAffx.27554.1.S1_at	 9.75E---04	 8.67E---04	 4.8467274	 C30H15orf39	 chromosome	30	open	reading	frame,	human	C15orf39	
CfaAffx.27957.1.S1_at	 2.67E---05	 5.05E---06	 19.74556	 SLC6A14	 solute	carrier	family	6	(amino	acid	transporter),	member	14	
CfaAffx.28037.1.S1_at	 1.17E---04	 3.75E---05	 5.838383	 ASPG	 asparaginase	homolog	(S.	cerevisiae)	
CfaAffx.28043.1.S1_at	 7.50E---04	 5.61E---04	 2.1878998		 	CfaAffx.28148.1.S1_s_at	 9.43E---04	 8.19E---04	 3.4768114	 AHNAK2	 AHNAK	nucleoprotein	2	
CfaAffx.28389.1.S1_s_at	 3.86E---04	 1.93E---04	 4.4312162	 LOC100856415	 SH3---containing	GRB2---like	protein	3---interacting	protein	1---like	
CfaAffx.28583.1.S1_at	 5.43E---04	 3.35E---04	 3.18739	 FOXN1	 forkhead	box	N1	
CfaAffx.28608.1.S1_at	 5.36E---04	 3.25E---04	 3.439379	 TXNDC2	 thioredoxin	domain	containing	2	(spermatozoa)	
CfaAffx.29305.1.S1_at	 6.92E---04	 4.96E---04	 2.1967502	 PIP5K1C	 phosphatidylinositol---4---phosphate	5---kinase,	type	I,	gamma	
CfaAffx.30380.1.S1_s_at	 0.001007584	 9.15E---04	 2.4656074	 KIAA1324	 KIAA1324	ortholog	
CfaAffx.30553.1.S1_at	 2.90E---04	 1.23E---04	 2.2216477	 KCNG4	 potassium	voltage---gated	channel,	subfamily	G,	member	4	
CfaAffx.32029.1.S1_at	 7.88E---04	 6.05E---04	 2.4735296		 		
Dog	liver	zone	III	signature		 Probe	Set	ID	 Corrected	p---value	 p---value	 FCAbsolute	 Gene	Symbol	 Gene	Title	AFFX---Cf_P450---2E1_5_s_at	 3.74622E---05	 7.92571E---06	 3.3132603		 	AFFX---Cf_P450---2E1_M_s_at	 5.88112E---07	 3.73273E---08	 2.9717898		 	Cfa.3895.1.A1_s_at	 0.000646713	 0.000440568	 2.163789	 SEC61B	 Sec61	beta	subunit	Cfa.111.1.A1_s_at	 0.000226226	 8.78325E---05	 3.6086776	 VWF	 von	Willebrand	factor	Cfa.35.1.A1_s_at	 8.9545E---08	 3.41003E---09	 21.71001	 RHBG	 Rh	family,	B	glycoprotein	CfaAffx.20286.1.S1_s_at	 1.05304E---09	 5.83423E---12	 15.537946	 GLUL	 glutamate---ammonia	ligase	Cfa.1407.1.S2_at	 1.33523E---07	 6.40308E---09	 13.302963	 GLUL///LOC1006	82914	 glutamate---ammonia	ligase///glutamine	synthetase---like	Cfa.10529.1.S2_at	 0.001135682	 0.001119046	 2.110271	MTPN	 myotrophin	Cfa.3709.1.S1_s_at	 6.73788E---06	 7.98282E---07	 4.771196	 PLA2G7	 phospholipase	A2,	group	VII	(platelet---activating	factor	acetylhydrolase,	plasma)	Cfa.184.1.S1_at	 1.63119E---08	 3.22096E---10	 10.397098	 KIT	 v---kit	Hardy---Zuckerman	4	feline	sarcoma	viral	oncogene	homolog	Cfa.3590.1.S1_s_at	 0.000255424	 0.000104623	 3.7217104	 EDNRB	 endothelin	receptor	type	B	Cfa.3662.1.S1_at	 0.000862893	 0.000705892	 3.6257021	MS4A2	 membrane---spanning	4---domains,	subfamily	A,	member	2	Cfa.3770.1.S1_at	 0.000932148	 0.000803304	 3.6484907	 ADRB2	 adrenoceptor	beta	2,	surface	Cfa.16336.1.S1_at	 7.72542E---05	 2.04849E---05	 8.208239	 CMA1	 chymase	1,	mast	cell	Cfa.11341.1.A1_at	 4.96557E---05	 1.12758E---05	 3.2248018	 COMT	 catechol---O---methyltransferase	Cfa.2682.1.S1_s_at	 0.001008789	 0.000921996	 2.5253048	MITF	 microphthalmia---associated	transcription	factor	Cfa.3648.1.S1_s_at	 1.31653E---06	 1.00272E---07	 3.7671416	 DHDH	 dihydrodiol	dehydrogenase	(dimeric)	CfaAffx.11223.1.S1_s_at	 2.31584E---07	 1.24121E---08	 18.29748	 SLC1A2	 solute	carrier	family	1	(glial	high	affinity	glutamate	transporter),	member	2	Cfa.3565.1.S1_s_at	 0.000559414	 0.000349535	 4.395624	 UACA	 uveal	autoantigen	with	coiled---coil	domains	and	ankyrin	repeats	CfaAffx.10131.1.S1_s_at	 0.000215514	 8.23756E---05	 12.932066	 KITLG	 KIT	ligand	Cfa.3663.1.A1_s_at	 2.80974E---05	 5.50851E---06	 10.472548	 FCER1A	 Fc	fragment	of	IgE,	high	affinity	I,	receptor	for;	alpha	polypeptide	Cfa.12195.1.S1_at	 2.98268E---05	 5.88964E---06	 18.221287		 	Cfa.3478.1.S1_at	 4.28852E---06	 4.41554E---07	 22.281797		 	Cfa.3741.1.A2_s_at	 1.59152E---06	 1.2795E---07	 2.2347062	 CYP2C18	 cytochrome	P450	2C21	Cfa.3731.1.S1_s_at	 0.000749794	 0.00056211	 2.9175982	 RAB12	 RAB12,	member	RAS	oncogene	family	Cfa.3502.1.S1_at	 0.000249916	 0.00010046	 4.0674777	 SULT1D1	 sulfotransferase	family,	cytosolic,	1D,	member	1	CfaAffx.5229.1.S1_s_at	 0.000138032	 4.71138E---05	 7.6424556	 SULT1D1	 sulfotransferase	family,	cytosolic,	1D,	member	1	Cfa.3705.1.S1_at	 2.18422E---05	 3.63814E---06	 5.155496	 COL4A3	 collagen,	type	IV,	alpha	3	(Goodpasture	antigen)	Cfa.99.1.S1_s_at	 0.000255032	 0.000103789	 4.808408	 COL6A3	 collagen,	type	VI,	alpha	3	Cfa.3515.1.S1_s_at	 8.25804E---05	 2.24796E---05	 7.1844215	 SCNN1A	 sodium	channel,	non---voltage---gated	1	alpha	subunit	Cfa.16.1.S1_s_at	 8.8661E---08	 3.25132E---09	 3.018781	 SLCO1B3	 solute	carrier	organic	anion	transporter	family,	member	1B3	Cfa.878.1.A1_at	 6.32485E---05	 1.58068E---05	 2.2646947	 GSTM3	 glutathione	S---transferase	mu	3	(brain)	Cfa.878.1.A1_s_at	 2.28328E---08	 6.70762E---10	 6.9192905	 GSTM3	 glutathione	S---transferase	mu	3	(brain)	CfaAffx.24225.1.S1_s_at	 0.00108212	 0.001019543	 2.2179728	 ENO3	 enolase	3	(beta,	muscle)	CfaAffx.5916.1.S1_at	 0.000708904	 0.000514309	 2.3670437	 LOC100685620	 alpha---1---acid	glycoprotein---like	CfaAffx.22816.1.S1_s_at	 0.000580389	 0.000373282	 2.2917888	 COPS6	 COP9	constitutive	photomorphogenic	homolog	subunit	6	(Arabidopsis)	Cfa.1145.1.A2_at	 2.3385E---05	 4.15586E---06	 4.747193	 DSTN	 destrin	(actin	depolymerizing	factor)	Cfa.5408.1.A1_s_at	 0.000447449	 0.000243318	 2.2873194	 RARRES2	 retinoic	acid	receptor	responder	(tazarotene	induced)	2	Cfa.1320.1.A1_at	 0.001048153	 0.000974235	 3.9071565	 FXYD6	 FXYD	domain	containing	ion	transport	regulator	6	Cfa.4454.1.S1_at	 4.02757E---05	 8.86179E---06	 16.339565	 DKK3	 dickkopf	3	homolog	(Xenopus	laevis)	Cfa.15484.1.A1_at	 0.000798016	 0.000617928	 3.5560951	MYO5B	 myosin	VB	CfaAffx.29003.1.S1_s_at	 1.96308E---06	 1.63359E---07	 9.979354	MYO5B	 myosin	VB	CfaAffx.20685.1.S1_s_at	 0.000245336	 9.72345E---05	 3.7215776	 APOD	 apolipoprotein	D	Cfa.1715.1.S1_at	 1.11941E---07	 4.89444E---09	 2.4505908	 ALDH1A1	 aldehyde	dehydrogenase	1	family,	member	A1	Cfa.4426.1.S1_at	 0.000464414	 0.000258744	 2.8490698	 YWHAH	 tyrosine	3---monooxygenase/tryptophan	5---monooxygenase	activation	protein,	eta	polypeptide	Cfa.4465.2.S1_at	 0.000376595	 0.000184314	 8.410434	 LOC100683822///	LOC608238	 immunoglobulin	lambda---like	polypeptide	5---like///immunoglobulin	lambda---like	polypeptide	5---like			Cfa.4465.2.S1_s_at	 		 0.000158265			 5.46895E---05			 17.275257	 LOC100683822///	LOC100687054///	LOC100856278///	LOC486474///LO	C607364///LOC60	7582///LOC60823	8///LOC608248	 	immunoglobulin	lambda---like	polypeptide	5---like///immunoglobulin	lambda---like	polypeptide	5---like///uncharacterized	LOC100856278///immunoglobulin	lambda	like	polypeptide	5---like///immunoglobulin	lambda---like	polypeptide	5---	like///immunoglobulin	lambda---like	polypeptide	5---like///immunoglobulin	lambda---like	polypeptide	5---like///immunoglobulin	lambda---like	polypeptide	5---like	Cfa.4578.1.A1_s_at	 0.000630896	 0.000420894	 2.1680102	 VAMP8	 vesicle---associated	membrane	protein	8	Cfa.4710.1.A1_at	 0.001007584	 0.000910508	 4.2544	 GYG1	 glycogenin	1	Cfa.11417.1.A1_at	 0.00010727	 3.30609E---05	 3.7455792	 AARS	 alanyl---tRNA	synthetase	Cfa.12076.1.A1_at	 2.31584E---07	 1.22532E---08	 13.682153	 SLC13A3	 solute	carrier	family	13	(sodium---dependent	dicarboxylate	transporter),	member	3	Cfa.12192.1.A1_s_at	 7.67562E---05	 2.01363E---05	 2.9230626	 PTGR1	 prostaglandin	reductase	1	Cfa.12195.8.A1_at	 3.67438E---05	 7.67008E---06	 47.341812		 	Cfa.1704.1.A1_at	 0.000372714	 0.000178272	 2.5019126	 LOC100683892	 uncharacterized	LOC100683892	Cfa.303.1.A1_at	 0.000388689	 0.000194618	 5.7572703	 XG	 Xg	blood	group	Cfa.12290.1.A1_at	 0.000705405	 0.000508718	 3.7441661	 SFRP1	 secreted	frizzled---related	protein	1	Cfa.12457.1.A1_at	 0.000117222	 3.73863E---05	 2.3623722		 	Cfa.5260.1.A1_at	 0.000964912	 0.000854675	 2.04495	 C8H14orf1	 chromosome	8	open	reading	frame,	human	C14orf1	Cfa.6245.1.A1_at	 0.000958026	 0.000840182	 4.664761	 RBP2	 retinol	binding	protein	2,	cellular	CfaAffx.23994.1.S1_s_at	 3.91866E---05	 8.51161E---06	 2.7927663	 SLC2A9	 solute	carrier	family	2	(facilitated	glucose	transporter),	member	9	Cfa.307.9.A1_s_at	 9.16789E---05	 2.66872E---05	 2.3184936	MRPL14	 mitochondrial	ribosomal	protein	L14	Cfa.12045.1.A1_at	 0.000808263	 0.000637192	 2.442836		 	Cfa.12118.1.A1_at	 5.6345E---05	 1.35101E---05	 4.9605503	 SGPL1	 sphingosine---1---phosphate	lyase	1	Cfa.5544.1.A1_at	 7.79804E---05	 2.07874E---05	 2.4624555		 	Cfa.10986.1.A1_s_at	 0.000842522	 0.00067938	 2.1503632	 ZNF207	 zinc	finger	protein	207	Cfa.400.1.A1_at	 0.000415374	 0.000213974	 3.336148	 TACC1	 transforming,	acidic	coiled---coil	containing	protein	1	Cfa.12307.1.A1_at	 0.000613164	 0.000399551	 6.305845	 CHST15	 carbohydrate	(N---acetylgalactosamine	4---sulfate	6---O)	sulfotransferase	15	Cfa.4127.1.A1_at	 0.000162829	 5.68245E---05	 5.2848372	 SYBU	 syntabulin	(syntaxin---interacting)	Cfa.6387.1.A1_at	 0.000203002	 7.59475E---05	 3.9649045	 DPP4	 dipeptidyl---peptidase	4	Cfa.12136.1.A1_at	 0.000523698	 0.000312446	 3.9189298	 ADA	 adenosine	deaminase	Cfa.10817.1.A1_at	 0.000771661	 0.000585548	 3.241774		 	Cfa.4784.1.A1_at	 0.000866656	 0.000712638	 2.5297263	 LOC100856418	 RIMS---binding	protein	2---like	Cfa.12195.14.S1_s_at	 0.000343698	 0.000162881	 8.812621	 IGKC	 	Cfa.2571.1.A1_at	 0.000550193	 0.000340669	 3.5736191	 OBFC1	 oligonucleotide/oligosaccharide---binding	fold	containing	1	Cfa.11599.1.A1_at	 0.000333152	 0.000155064	 2.2552266	 SORT1	 sortilin	1	
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	 Cfa.4712.1.A1_at	 0.001071813	 0.001006809	 4.8869042	 ZBTB38	 zinc	finger	and	BTB	domain	containing	38	Cfa.12371.1.A1_s_at	 0.000100575	 3.04988E---05	 8.058077	 FMO2	 flavin	containing	monooxygenase	2	(non---functional)	Cfa.537.1.S1_at	 7.45187E---06	 9.24915E---07	 2.1957808	 GSTA4	 glutathione	S---transferase	alpha	4	Cfa.1364.1.A1_s_at	 0.000459822	 0.000252286	 2.4105124	 RPN2	 ribophorin	II	Cfa.5627.1.A1_at	 0.000684929	 0.000479051	 6.082355	 SFRP4	 secreted	frizzled---related	protein	4	Cfa.1133.1.A1_s_at	 6.32485E---05	 1.56406E---05	 5.9039884	 SLC25A33	 solute	carrier	family	25	(pyrimidine	nucleotide	carrier),	member	33	Cfa.15210.1.A1_at	 3.67809E---07	 2.12696E---08	 9.81365		 	Cfa.11787.1.A1_at	 0.000491787	 0.000285777	 6.3062377	 CYFIP2	 cytoplasmic	FMR1	interacting	protein	2	Cfa.6898.1.A1_at	 0.000885302	 0.000736392	 7.212905		 	Cfa.11206.1.A1_at	 8.95124E---05	 2.52804E---05	 4.0430956	 GABRB3	 gamma---aminobutyric	acid	(GABA)	A	receptor,	beta	3	Cfa.5258.1.A1_s_at	 0.000265028	 0.000109957	 2.92875	 SDC2	 syndecan	2	Cfa.1176.1.S1_at	 0.000447109	 0.000239611	 2.499946	 GRSF1	 G---rich	RNA	sequence	binding	factor	1	Cfa.10395.1.A1_at	 0.000330652	 0.000151294	 2.8875067	 IRGQ	 immunity---related	GTPase	family,	Q	Cfa.349.1.A1_s_at	 7.69533E---07	 5.31835E---08	 2.5315976	 DST	 dystonin	Cfa.12553.1.A1_s_at	 0.000372714	 0.000178051	 4.260033	 GFPT2	 glutamine---fructose---6---phosphate	transaminase	2	Cfa.11159.1.S1_at	 0.000964788	 0.000849122	 2.627128	 ATP6V0D1	 ATPase,	H+	transporting,	lysosomal	38kDa,	V0	subunit	d1	Cfa.15225.1.S1_a_at	 0.000736475	 0.000547422	 2.0888155	 CPT2	 carnitine	palmitoyltransferase	2	Cfa.6941.1.S1_s_at	 0.00083129	 0.000662452	 7.0080214	 ZNF474	 zinc	finger	protein	474---like	Cfa.13710.1.S1_at	 0.000561696	 0.00035413	 2.646721	 TGFBR3	 transforming	growth	factor,	beta	receptor	III	Cfa.6237.1.S1_at	 0.0002354	 9.29648E---05	 11.46203	 TSPAN8	 tetraspanin	8	Cfa.10879.1.S1_at	 0.000972321	 0.000863981	 2.110705	 FSD1L	 fibronectin	type	III	and	SPRY	domain	containing	1---like	Cfa.15549.1.A1_s_at	 0.00069238	 0.000497068	 3.5878794	MSN	 moesin	Cfa.4948.1.A1_s_at	 0.001097984	 0.001048428	 2.0224166	 ECM2	 extracellular	matrix	protein	2,	female	organ	and	adipocyte	specific	CfaAffx.19812.1.S1_s_at	 0.001109468	 0.001076607	 2.9654722	 ANK3	 ankyrin	3,	node	of	Ranvier	(ankyrin	G)	Cfa.1004.1.A1_at	 0.000843029	 0.000681774	 7.594965	 ADCY10	 adenylate	cyclase	10	(soluble)	Cfa.14230.1.A1_at	 0.000907407	 0.000774303	 3.621418	 PMEPA1	 prostate	transmembrane	protein,	androgen	induced	1	Cfa.13057.1.A1_s_at	 0.000718476	 0.00052695	 3.2985606	 PDE6D	 phosphodiesterase	6D,	cGMP---specific,	rod,	delta	Cfa.7574.1.A1_s_at	 0.001052243	 0.000983446	 2.820961		 	Cfa.2048.1.S1_at	 1.98035E---05	 3.17561E---06	 2.0343955	 HIBADH	 3---hydroxyisobutyrate	dehydrogenase	Cfa.1645.1.S1_at	 0.000372714	 0.00017926	 15.523831	MYH11	 myosin,	heavy	chain	11,	smooth	muscle	Cfa.2294.1.S1_at	 0.000615427	 0.000401894	 2.0155952		 	Cfa.1243.1.A1_at	 0.000464414	 0.000258251	 3.9472747	 TUSC3	 tumor	suppressor	candidate	3	Cfa.1970.1.S1_at	 0.000842522	 0.000679722	 2.0129232		 	Cfa.2111.1.S1_at	 0.000535067	 0.000321493	 5.3657737	 SLA	 Src---like---adaptor	Cfa.9797.1.A1_at	 0.000719982	 0.00052907	 2.3941298	 P2RX4	 purinergic	receptor	P2X,	ligand---gated	ion	channel,	4	Cfa.15691.1.A1_at	 1.17904E---06	 8.81368E---08	 6.274625		 	Cfa.14174.1.A1_at	 0.000447109	 0.000241527	 2.3447382		 	Cfa.15412.1.A1_s_at	 0.000178355	 6.38957E---05	 2.357841	 ABCD4	 ATP---binding	cassette,	sub---family	D	(ALD),	member	4	Cfa.5543.1.A1_at	 0.000949939	 0.000828004	 4.283221		 	Cfa.8129.1.A1_s_at	 0.000727566	 0.000537722	 2.4103203	 R3HCC1	 R3H	domain	and	coiled---coil	containing	1	Cfa.9500.1.S1_at	 0.000617584	 0.000405915	 4.7807	 TCEAL1	 transcription	elongation	factor	A	(SII)---like	1	Cfa.21641.1.S1_at	 0.000415374	 0.00021501	 2.046423	 RCN2	 reticulocalbin	2,	EF---hand	calcium	binding	domain	Cfa.10210.1.S1_at	 0.000635775	 0.000425045	 5.966225	 ALOX5AP	 arachidonate	5---lipoxygenase---activating	protein	Cfa.10687.1.S1_at	 0.000129211	 4.37385E---05	 12.138619	 STK39	 serine	threonine	kinase	39	Cfa.17716.1.S1_s_at	 0.000842522	 0.000676815	 2.2854202	 TMED5	 transmembrane	emp24	protein	transport	domain	containing	5	Cfa.16351.1.S1_at	 2.74704E---05	 5.34684E---06	 14.262284	 FRY	 furry	homolog	(Drosophila)	Cfa.19737.1.S1_at	 0.000666841	 0.000457364	 2.280433	 AHR	 aryl	hydrocarbon	receptor	Cfa.19610.1.S1_s_at	 0.000447109	 0.00023973	 2.4912512	 SLC30A6	 solute	carrier	family	30	(zinc	transporter),	member	6	Cfa.6381.1.A1_at	 0.000375619	 0.000182776	 3.0846417	 LPHN2	 latrophilin	2	Cfa.19866.1.S1_at	 0.000302104	 0.000130812	 2.6602774	 SLC1A4	 solute	carrier	family	1	(glutamate/neutral	amino	acid	transporter),	member	4	Cfa.9955.1.A1_at	 0.000203413	 7.66028E---05	 2.511433	 LOC100685792	 interferon---activable	protein	203---like	Cfa.15309.1.A1_at	 0.000470841	 0.000266235	 2.8773222	 ADPRM	 ADP---ribose/CDP---alcohol	diphosphatase,	manganese---dependent	Cfa.8856.1.A1_s_at	 0.000667705	 0.000459577	 2.7355921	 TTLL7	 tubulin	tyrosine	ligase---like	family,	member	7	Cfa.1340.1.S1_at	 0.000888601	 0.000746353	 5.576259	 CLTCL1	 clathrin,	heavy	chain---like	1	Cfa.1230.1.S1_at	 8.30692E---05	 2.27298E---05	 4.046356	 GPM6A	 glycoprotein	M6A	Cfa.247.1.S1_at	 1.95479E---09	 2.38186E---11	 2.9497216	 GLUD1///LOC100	856077	 glutamate	dehydrogenase	1///interferon	gamma	receptor	1---like	Cfa.9940.2.S1_at	 0.000464414	 0.000258025	 2.5428064		 	Cfa.9007.1.A1_at	 0.001007584	 0.000911316	 6.2394586	 ANKRD37	 ankyrin	repeat	domain	37	CfaAffx.16848.1.S1_s_at	 0.001019401	 0.000937446	 3.3601415	 LOC100855477	 CDGSH	iron---sulfur	domain---containing	protein	2---like	Cfa.18191.1.S1_s_at	 0.001136777	 0.001127157	 3.1705344	 CAP2	 CAP,	adenylate	cyclase---associated	protein,	2	(yeast)	Cfa.11172.1.A1_at	 0.000407252	 0.000207934	 2.0523455		 	Cfa.1373.1.S1_at	 2.38444E---06	 2.15239E---07	 15.373627		 	Cfa.2356.1.S1_at	 0.000636647	 0.000426897	 2.2827692	 CGGBP1	 CGG	triplet	repeat	binding	protein	1	Cfa.4399.1.S1_at	 0.000464414	 0.000259391	 2.4086745		 	Cfa.10416.1.S1_at	 4.25619E---06	 4.32223E---07	 6.694993	 FAM177A1	 family	with	sequence	similarity	177,	member	A1	Cfa.10960.2.A1_a_at	 0.000200245	 7.42797E---05	 2.1633456	 CDK2AP1	 cyclin---dependent	kinase	2	associated	protein	1	Cfa.1007.1.S1_at	 2.18422E---05	 3.69554E---06	 2.2912052	 PDK1	 pyruvate	dehydrogenase	kinase,	isozyme	1	Cfa.9369.1.S1_at	 1.56269E---05	 2.40316E---06	 20.815073		 	Cfa.1650.1.S1_at	 0.00105121	 0.000980042	 2.5132136	 PPP2R3C	 protein	phosphatase	2,	regulatory	subunit	B'',	gamma	Cfa.6009.2.A1_at	 0.000802554	 0.000626101	 2.0153184	 FBLN1	 fibulin	1	Cfa.13388.1.S1_at	 1.21483E---05	 1.73057E---06	 2.9907348	 SLC44A1	 solute	carrier	family	44,	member	1	Cfa.1655.2.A1_a_at	 2.1186E---08	 5.37868E---10	 30.454763	 KCNJ5	 potassium	inwardly---rectifying	channel,	subfamily	J,	member	5	Cfa.18215.1.S1_at	 0.00101319	 0.000930306	 6.4261928		 	Cfa.10541.1.S1_at	 6.76839E---07	 4.58226E---08	 23.238184	NADKD1///RANB	P3L	 NAD	kinase	domain	containing	1///RAN	binding	protein	3---like	Cfa.19510.1.S1_at	 0.000728266	 0.000539266	 4.191199	 NEO1	 neogenin	1	Cfa.14613.1.A1_s_at	 2.07069E---05	 3.38787E---06	 8.389631	 RSPO3	 R---spondin	3	Cfa.19444.1.S1_at	 0.000425615	 0.000222112	 5.6322074		 	CfaAffx.13734.1.S1_s_at	 0.000447449	 0.000242406	 5.2590218	 CCNG2	 cyclin	G2	Cfa.9415.1.S1_s_at	 0.000690542	 0.000487957	 2.0805297	 HERC1	 HECT	and	RLD	domain	containing	E3	ubiquitin	protein	ligase	family	member	1	Cfa.20099.1.S1_s_at	 0.000203002	 7.61615E---05	 7.294184	 LOC100856496	 E3	ubiquitin---protein	ligase	SIAH1---like	Cfa.18229.1.S1_s_at	 0.000104711	 3.19008E---05	 5.7194967	 TACC1	 transforming,	acidic	coiled---coil	containing	protein	1	Cfa.4155.1.A1_at	 1.95479E---09	 2.4814E---11	 22.72636		 	Cfa.10658.1.A1_at	 1.09643E---07	 4.33006E---09	 4.3983965	 LRAT	 lecithin	retinol	acyltransferase	(phosphatidylcholine------retinol	O---acyltransferase)	Cfa.17154.1.S1_at	 1.15223E---05	 1.5764E---06	 2.4392455	 SORD	 sorbitol	dehydrogenase	Cfa.16886.1.A1_at	 0.00064036	 0.000432504	 5.552202	 LOC100686908	 zinc	finger	protein	652---like	Cfa.4077.1.S1_at	 0.00069238	 0.000492743	 2.7095726	 CA4	 carbonic	anhydrase	IV	Cfa.16407.1.A1_at	 1.88349E---08	 4.51613E---10	 13.849963	 DCK	 deoxycytidine	kinase	Cfa.966.1.S1_s_at	 7.82572E---05	 2.09716E---05	 2.0592682	 BZW1	 basic	leucine	zipper	and	W2	domains	1	Cfa.4315.1.S1_at	 0.000100349	 3.02792E---05	 2.2582934	 PHB	 prohibitin	Cfa.17867.1.S1_s_at	 3.16223E---05	 6.33338E---06	 3.6392202	 NUCB1	 nucleobindin	1	Cfa.21306.1.S1_at	 5.48944E---05	 1.26977E---05	 6.3926473	 TSPAN13	 tetraspanin	13	Cfa.4482.1.S1_at	 2.40555E---05	 4.30895E---06	 8.92449	 PEG3	 paternally	expressed	3	Cfa.13282.2.A1_a_at	 4.02123E---05	 8.79112E---06	 2.060062	 BRP44	 brain	protein	44	Cfa.13282.1.S1_s_at	 6.72416E---07	 4.39369E---08	 2.9895825	 BRP44	 brain	protein	44	Cfa.3177.1.S1_at	 7.28557E---06	 8.83722E---07	 6.9751554	 GNAI1	 guanine	nucleotide	binding	protein	(G	protein),	alpha	inhibiting	activity	polypeptide	1	Cfa.21159.1.S1_at	 0.000587177	 0.000379305	 4.412333	 RGS5	 regulator	of	G---protein	signaling	5	Cfa.17583.1.S1_at	 0.000541885	 0.000333233	 4.619514	 RRAD	 Ras---related	associated	with	diabetes	Cfa.16552.1.S1_at	 0.000384341	 0.000190992	 2.6200385	 TM2D1	 TM2	domain	containing	1	Cfa.17831.1.S1_s_at	 9.55249E---05	 2.8159E---05	 5.469524	 FMOD	 fibromodulin	Cfa.17308.1.S1_s_at	 0.000809233	 0.000639168	 3.6815317	 AARS	 alanyl---tRNA	synthetase	Cfa.17338.1.S1_s_at	 0.000785079	 0.000601186	 3.097648	 PRKAB1	 protein	kinase,	AMP---activated,	beta	1	non---catalytic	subunit	Cfa.4276.1.S1_at	 0.001083552	 0.001025718	 2.6564686	 C3H4orf48	 chromosome	3	open	reading	frame,	human	C4orf48	Cfa.21591.1.S1_at	 0.000765337	 0.00057859	 3.3628395	 38595	septin	9	Cfa.21171.1.S1_s_at	 0.001109468	 0.001076533	 2.1432447	 PRKAR2A	 protein	kinase,	cAMP---dependent,	regulatory,	type	II,	alpha	Cfa.18925.1.S1_s_at	 0.000711146	 0.000518565	 7.0233626	MSN	 moesin	CfaAffx.2475.1.S1_s_at	 0.00089413	 0.000755904	 7.3695903	 TRMT11	 tRNA	methyltransferase	11	homolog	(S.	cerevisiae)	Cfa.20009.1.S1_s_at	 0.00025257	 0.000102239	 3.5902214	 PSME4	 proteasome	(prosome,	macropain)	activator	subunit	4	Cfa.4202.1.S1_at	 2.18422E---05	 3.69684E---06	 2.693591		 	Cfa.21480.1.S1_s_at	 0.000942658	 0.000819009	 6.1842012	 SIAE	 sialic	acid	acetylesterase	Cfa.18701.1.S1_s_at	 0.000964912	 0.000852068	 2.0781698	 TMEM27	 transmembrane	protein	27	Cfa.21318.2.S1_at	 0.00064036	 0.000434433	 4.766016	 AGPAT9	 1---acylglycerol---3---phosphate	O---acyltransferase	9	Cfa.18326.1.S1_s_at	 3.62662E---05	 7.46808E---06	 14.165292	 SORD	 sorbitol	dehydrogenase	Cfa.16748.2.S1_s_at	 0.000808263	 0.000637262	 2.834584	 CRIPT	 cysteine---rich	PDZ---binding	protein	
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	 Cfa.20931.1.S1_s_at	 0.00012228	 4.07025E---05	 2.9557915	 PDXK	 pyridoxal	(pyridoxine,	vitamin	B6)	kinase	Cfa.19950.1.S1_s_at	 0.000570153	 0.000361874	 2.6671698	 SESTD1	 SEC14	and	spectrin	domains	1	CfaAffx.1251.1.S1_s_at	 0.000936071	 0.000810646	 2.3345058	 LRP1	 low	density	lipoprotein	receptor---related	protein	1	Cfa.17869.1.S1_s_at	 1.21483E---05	 1.71617E---06	 4.234617	 TTC7B	 tetratricopeptide	repeat	domain	7B	Cfa.17312.1.S1_s_at	 0.001034634	 0.000958751	 3.0220814	 SSFA2	 sperm	specific	antigen	2	CfaAffx.3839.1.S1_s_at	 0.000802554	 0.000627102	 4.3794575	 TXNRD1	 thioredoxin	reductase	1	Cfa.14623.1.S1_at	 0.000291781	 0.000124285	 3.2112064	 TGM2	 transglutaminase	2	(C	polypeptide,	protein---glutamine---gamma---	glutamyltransferase)	Cfa.1584.2.S1_s_at	 2.07069E---05	 3.36605E---06	 23.459467	 HPGDS	 hematopoietic	prostaglandin	D	synthase	Cfa.19943.1.S1_s_at	 0.000933946	 0.000807488	 6.369647	 ATP1B3	 ATPase,	Na+/K+	transporting,	beta	3	polypeptide	Cfa.19882.1.S1_s_at	 0.000541885	 0.000331747	 5.2500777	 GRINA	 glutamate	receptor,	ionotropic,	N---methyl	D---aspartate---associated	protein	1	(glutamate	binding)	Cfa.18719.1.S1_s_at	 0.000652019	 0.000445102	 2.7240605	 LOC100856736	 heat	shock	factor---binding	protein	1---like	Cfa.17300.1.S1_at	 3.72653E---09	 5.78164E---11	 12.6078825	 NADKD1	 NAD	kinase	domain	containing	1	Cfa.17300.1.S1_s_at	 1.05304E---09	 7.00867E---12	 21.954231	NADKD1///RANB	P3L	 NAD	kinase	domain	containing	1///RAN	binding	protein	3---like	Cfa.19934.1.S1_at	 0.000536515	 0.000326147	 5.123675	 NMT2	 N---myristoyltransferase	2	Cfa.17299.1.S1_at	 8.70168E---10	 1.50772E---12	 19.232334	NADKD1///RANB	P3L	 NAD	kinase	domain	containing	1///RAN	binding	protein	3---like	Cfa.20149.1.S1_at	 0.001121901	 0.001098166	 6.965492	 CHD1L	 chromodomain	helicase	DNA	binding	protein	1---like	Cfa.19578.1.S1_s_at	 0.000423563	 0.000220444	 4.015751	 CRYZL1///LOC10	0856647	 crystallin,	zeta	(quinone	reductase)---like	1///quinone	oxidoreductase---like	protein	1---like	Cfa.15967.1.S1_at	 9.13862E---06	 1.19872E---06	 2.2081788	 FADS6	 fatty	acid	desaturase	domain	family,	member	6	Cfa.4285.1.A1_at	 0.000309434	 0.000139706	 4.5514116		 	Cfa.11597.1.A1_at	 0.000493269	 0.00028803	 5.446816	 SAMD11	 sterile	alpha	motif	domain	containing	11	Cfa.15530.1.A1_at	 0.000907051	 0.000772721	 5.8292747		 	Cfa.7780.1.A1_s_at	 0.000805603	 0.000631756	 4.0453043	 RANGRF	 RAN	guanine	nucleotide	release	factor	Cfa.2441.1.A1_at	 0.000381539	 0.000188886	 5.692052		 	Cfa.13124.1.A1_at	 8.95124E---05	 2.54608E---05	 2.59982	 AKR1D1	 3---oxo---5---beta---steroid	4---dehydrogenase---like	Cfa.8532.1.A1_s_at	 0.000296038	 0.000126933	 5.4359665	 SEMA3D	 sema	domain,	immunoglobulin	domain	(Ig),	short	basic	domain,	secreted,	(semaphorin)	3D	Cfa.13318.1.A1_at	 0.00100411	 0.000903557	 2.6066477		 	Cfa.13245.1.A1_at	 5.07964E---05	 1.16065E---05	 2.5273943		 	Cfa.5339.1.A1_at	 4.39635E---06	 4.58857E---07	 25.095253		 	Cfa.11974.1.A1_at	 0.00089413	 0.000756668	 6.4765005		 	Cfa.2388.1.A1_at	 0.00012163	 4.0143E---05	 3.09967	 BCO2	 beta---carotene	oxygenase	2	Cfa.9289.1.A1_at	 2.65316E---05	 4.97701E---06	 17.101181	 DAB1	 disabled	homolog	1	(Drosophila)	Cfa.1817.1.A1_at	 0.000579986	 0.000372206	 3.3853612	 PCDH18	 protocadherin	18	Cfa.3003.1.A1_s_at	 0.000500934	 0.000293965	 2.0361366	 ZAK	 sterile	alpha	motif	and	leucine	zipper	containing	kinase	AZK	Cfa.9744.1.A1_at	 2.62432E---08	 8.14316E---10	 70.02661		 	Cfa.10541.2.A1_at	 8.70168E---10	 2.45464E---12	 39.60929		 	Cfa.13971.1.A1_at	 0.000493269	 0.000287547	 4.816408		 	Cfa.13336.1.A1_at	 0.000215481	 8.20591E---05	 2.840348	 AHR	 aryl	hydrocarbon	receptor	Cfa.13181.1.A1_at	 0.000272981	 0.000114989	 3.8197572	 SLC6A11	 solute	carrier	family	6	(neurotransmitter	transporter,	GABA),	member	11	Cfa.13297.1.A1_at	 0.001007584	 0.000912826	 4.374981		 	Cfa.15285.3.S1_at	 0.000888601	 0.000741952	 6.0946283	 CSRP1	 cysteine	and	glycine---rich	protein	1	Cfa.13327.1.A1_s_at	 0.000118868	 3.86369E---05	 3.6391299	 GALNT13	 UDP---N---acetyl---alpha---D---galactosamine:polypeptide	N---	acetylgalactosaminyltransferase	13	(GalNAc---T13)	Cfa.10687.2.S1_a_at	 0.000571476	 0.000364102	 11.637523	 STK39	 serine	threonine	kinase	39	Cfa.13607.1.A1_at	 0.000510449	 0.000300942	 2.7555273		 	Cfa.9467.1.A1_at	 0.000226226	 8.80654E---05	 2.7485807	 RELN	 reelin	Cfa.9789.1.A1_at	 5.85442E---05	 1.42025E---05	 5.017309		 	Cfa.14588.1.A1_at	 0.001116423	 0.001088079	 6.016479		 	Cfa.4752.1.A1_at	 1.44458E---05	 2.09861E---06	 4.5659337		 	Cfa.4619.1.A1_at	 0.001100508	 0.001053942	 5.625718		 	Cfa.5711.1.A1_at	 0.000404964	 0.000206195	 9.75789		 	Cfa.11642.3.A1_s_at	 0.000377688	 0.000185381	 7.824859	 ACTG2	 actin,	gamma	2,	smooth	muscle,	enteric	Cfa.1953.1.A1_at	 8.72797E---06	 1.09561E---06	 3.801019	 TMEM168	 transmembrane	protein	168	Cfa.1645.2.S1_s_at	 0.000189774	 6.90574E---05	 17.11082	MYH11	 myosin,	heavy	chain	11,	smooth	muscle	CfaAffx.227.1.S1_s_at	 0.001136777	 0.001125108	 2.1219134	 BRP44L	 brain	protein	44---like	CfaAffx.471.1.S1_s_at	 0.000541885	 0.000333096	 6.3948736	 LOC478825///TU	BB4B	 tubulin	beta---3	chain---like///tubulin,	beta	4B	class	IVb	CfaAffx.741.1.S1_at	 0.000470841	 0.000265897	 2.991092	 FYB	 FYN	binding	protein	CfaAffx.747.1.S1_s_at	 2.40826E---05	 4.34791E---06	 2.184471	 DBI///LOC608150	 diazepam	binding	inhibitor	(GABA	receptor	modulator,	acyl---CoA	binding	protein)///acyl---CoA---binding	protein---like	CfaAffx.1080.1.S1_at	 0.000688951	 0.000484202	 2.3575935	 KDSR	 3---ketodihydrosphingosine	reductase	CfaAffx.1171.1.S1_at	 0.000449158	 0.000245168	 4.204787	 SPRYD4	 SPRY	domain	containing	4	CfaAffx.1280.1.S1_at	 0.000519386	 0.000308409	 2.0482295	 FEM1C	 fem---1	homolog	c	(C.	elegans)	CfaAffx.1647.1.S1_at	 1.44146E---06	 1.1182E---07	 10.425791	 LGR5	 leucine---rich	repeat	containing	G	protein---coupled	receptor	5	CfaAffx.1657.1.S1_at	 0.000958026	 0.0008409	 2.9815702	 TBC1D15	 TBC1	domain	family,	member	15	CfaAffx.1679.1.S1_at	 0.000447109	 0.00024106	 6.4707417	 NIPAL2	 NIPA---like	domain	containing	2	CfaAffx.1720.1.S1_s_at	 2.19496E---05	 3.81129E---06	 15.367436	 LOC100687624///	ZNF474	 zinc	finger	protein	474---like///zinc	finger	protein	474---like	CfaAffx.1974.1.S1_at	 0.000161974	 5.61996E---05	 3.952404	 RSPO2	 R---spondin	2	CfaAffx.2129.1.S1_s_at	 2.40826E---05	 4.41571E---06	 5.2711277	 FBLN1	 fibulin	1	CfaAffx.2197.1.S1_s_at	 0.000309434	 0.000140096	 3.3562727	 DLA---DMA	 major	histocompatibility	complex,	class	II,	DM	alpha	CfaAffx.2338.1.S1_s_at	 0.000179281	 6.44803E---05	 3.4948668	 CYB5R3	 cytochrome	b5	reductase	3		CfaAffx.2447.1.S1_s_at	 	 0.000888601		 0.00074823	 	 4.528036	 LOC100683164///	LOC609886///NH	P2L1	 NHP2---like	protein	1---like///NHP2---like	protein	1---like///NHP2	non---histone	chromosome	protein	2---like	1	(S.	cerevisiae)	CfaAffx.2997.1.S1_x_at	 0.00029873	 0.000128509	 4.1627393		 	CfaAffx.3286.1.S1_at	 0.00105737	 0.000991751	 2.933598	 GNA14	 guanine	nucleotide	binding	protein	(G	protein),	alpha	14	CfaAffx.3464.1.S1_at	 0.001140238	 0.00113863	 3.8542662	 TEK	 TEK	tyrosine	kinase,	endothelial	CfaAffx.3596.1.S1_s_at	 1.69727E---08	 3.62372E---10	 3.0253918	 ALDH1A1	 aldehyde	dehydrogenase	1	family,	member	A1	CfaAffx.3791.1.S1_s_at	 0.000904094	 0.000768926	 2.5792792	 NUDT2	 nudix	(nucleoside	diphosphate	linked	moiety	X)---type	motif	2	CfaAffx.4021.1.S1_s_at	 6.44776E---06	 7.36627E---07	 10.234394	 KIT	 v---kit	Hardy---Zuckerman	4	feline	sarcoma	viral	oncogene	homolog	CfaAffx.4145.1.S1_at	 0.000888601	 0.000742951	 2.9290287	 SYK	 spleen	tyrosine	kinase	CfaAffx.4252.1.S1_s_at	 1.98035E---05	 3.18421E---06	 2.7453666	 GSTA4	 glutathione	S---transferase	alpha	4	CfaAffx.4258.1.S1_s_at	 0.000949939	 0.000828014	 4.0430226	 ICK	 intestinal	cell	(MAK---like)	kinase	CfaAffx.4323.1.S1_s_at	 7.17259E---05	 1.84006E---05	 2.9262464	 ECM2	 extracellular	matrix	protein	2,	female	organ	and	adipocyte	specific	CfaAffx.4524.1.S1_s_at	 0.000981938	 0.00087668	 4.872234	 TSPAN13	 tetraspanin	13	CfaAffx.4552.1.S1_at	 5.61993E---05	 1.3256E---05	 3.4679244	 AHR	 aryl	hydrocarbon	receptor	CfaAffx.4964.1.S1_s_at	 0.001031596	 0.000953026	 2.5226119	 ARF1	 ADP---ribosylation	factor	1	CfaAffx.5317.1.S1_at	 0.000334623	 0.000156221	 5.295739	 DCK	 deoxycytidine	kinase	CfaAffx.5338.1.S1_at	 0.000226627	 8.85411E---05	 2.1865406	 SLC4A4	 solute	carrier	family	4,	sodium	bicarbonate	cotransporter,	member	4	CfaAffx.5344.1.S1_at	 0.000690088	 0.000486663	 3.3837628	 SLC4A4	 solute	carrier	family	4,	sodium	bicarbonate	cotransporter,	member	4	CfaAffx.5402.1.S1_s_at	 0.000115309	 3.64306E---05	 3.4740286	 HIBADH	 3---hydroxyisobutyrate	dehydrogenase	CfaAffx.5887.1.S1_s_at	 0.000296038	 0.000126607	 3.1467137	 DOCK4	 dedicator	of	cytokinesis	4	CfaAffx.6119.1.S1_s_at	 0.000193352	 7.11776E---05	 14.682623	 TNC	 tenascin	C	CfaAffx.6597.1.S1_s_at	 6.32485E---05	 1.57189E---05	 2.6400685	 FTL	 ferritin,	light	polypeptide	CfaAffx.6815.1.S1_at	 9.05611E---07	 6.38653E---08	 4.677633	 SLC16A10	 solute	carrier	family	16,	member	10	(aromatic	amino	acid	transporter)	CfaAffx.7216.1.S1_s_at	 0.000473418	 0.000268426	 3.3396316	 PIP4K2A	 phosphatidylinositol---5---phosphate	4---kinase,	type	II,	alpha	CfaAffx.7249.1.S1_s_at	 4.92793E---07	 3.05824E---08	 2.6368322	 GLUD1	 glutamate	dehydrogenase	1	CfaAffx.8128.1.S1_s_at	 0.000272981	 0.000115122	 6.4206185	 GAB2///NARS2	 GRB2---associated	binding	protein	2///asparaginyl---tRNA	synthetase	2,	mitochondrial	(putative)	CfaAffx.8488.1.S1_at	 2.40939E---05	 4.45177E---06	 2.3166409	 SLC6A11	 solute	carrier	family	6	(neurotransmitter	transporter,	GABA),	member	11	CfaAffx.9050.1.S1_s_at	 0.00023311	 9.17315E---05	 2.590134	 APEX1	 APEX	nuclease	(multifunctional	DNA	repair	enzyme)	1	CfaAffx.9091.1.S1_s_at	 0.001096351	 0.001045322	 2.0753102	 SLCO2B1	 solute	carrier	organic	anion	transporter	family,	member	2B1	CfaAffx.9168.1.S1_at	 2.31975E---05	 4.08982E---06	 6.944003	 DSTN	 destrin	(actin	depolymerizing	factor)	CfaAffx.9237.1.S1_at	 0.000880968	 0.000728134	 6.3423076	MBNL2	 muscleblind---like	splicing	regulator	2	CfaAffx.9556.1.S1_at	 0.001093337	 0.001037822	 2.6318173	 SFRP1	 secreted	frizzled---related	protein	1	CfaAffx.10216.1.S1_at	 0.001083552	 0.001027006	 5.6280727	 TUBGCP3	 tubulin,	gamma	complex	associated	protein	3	CfaAffx.10453.1.S1_s_at	 0.00024734	 9.90755E---05	 3.8527875	 PDK1	 pyruvate	dehydrogenase	kinase,	isozyme	1	CfaAffx.10624.1.S1_at	 0.000596747	 0.000388012	 5.0495954	 EIF4E3	 eukaryotic	translation	initiation	factor	4E	family	member	3	CfaAffx.10969.1.S1_at	 0.000196849	 7.27424E---05	 9.64748	 FLT1	 fms---related	tyrosine	kinase	1	(vascular	endothelial	growth	factor/vascular	permeability	factor	receptor)	CfaAffx.11014.1.S1_at	 0.000304654	 0.000133059	 5.015389	 SYT9	 synaptotagmin	IX	CfaAffx.11275.1.S1_s_at	 0.000226226	 8.76752E---05	 2.009499	 LOC100688649	 uncharacterized	LOC100688649	
	 151	
	 CfaAffx.11491.1.S1_at	 3.31907E---05	 6.69431E---06	 11.075902	 CSAD	 cysteine	sulfinic	acid	decarboxylase	CfaAffx.11514.1.S1_s_at	 1.57479E---05	 2.46547E---06	 22.331785	 CYP7A1	 cytochrome	P450,	family	7,	subfamily	A,	polypeptide	1	CfaAffx.11845.1.S1_at	 0.000269147	 0.000112366	 3.752204	 PRRG4	 proline	rich	Gla	(G---carboxyglutamic	acid)	4	(transmembrane)	CfaAffx.11970.1.S1_s_at	 0.000536041	 0.000324346	 6.592709	 ABHD6	 abhydrolase	domain	containing	6	CfaAffx.12206.1.S1_at	 0.000754313	 0.000568129	 6.080185	 LOC100855424	 hedgehog---interacting	protein---like	CfaAffx.12247.1.S1_s_at	 0.000958026	 0.000838239	 2.4949484	 PAM	 peptidylglycine	alpha---amidating	monooxygenase	CfaAffx.12273.1.S1_s_at	 0.001103782	 0.001058634	 2.6890967	 NMNAT3	 nicotinamide	nucleotide	adenylyltransferase	3	CfaAffx.12439.1.S1_at	 0.000795043	 0.000613383	 5.5372734	 ATP1B3	 ATPase,	Na+/K+	transporting,	beta	3	polypeptide	CfaAffx.12697.1.S1_s_at	 7.20569E---05	 1.85986E---05	 6.069988	 ROBO1	 roundabout,	axon	guidance	receptor,	homolog	1	(Drosophila)	CfaAffx.12712.1.S1_s_at	 3.91866E---05	 8.41243E---06	 3.4833987	 ROBO1	 roundabout,	axon	guidance	receptor,	homolog	1	(Drosophila)	CfaAffx.12761.1.S1_s_at	 0.000932331	 0.000804777	 3.1924503	 EMC4	 ER	membrane	protein	complex	subunit	4	CfaAffx.12853.1.S1_at	 0.000535067	 0.000320662	 2.6022103	 LOC611428	 UPF0672	protein	C3orf58---like	CfaAffx.13018.1.S1_at	 0.000444394	 0.000234419	 3.5755334	 FCHO2	 FCH	domain	only	2	CfaAffx.13076.1.S1_at	 1.19152E---05	 1.64695E---06	 17.273584	 CPA3	 carboxypeptidase	A3	(mast	cell)	CfaAffx.13342.1.S1_at	 0.000557411	 0.000346711	 2.2158117	 VEGFC	 vascular	endothelial	growth	factor	C	CfaAffx.13352.1.S1_at	 1.24761E---07	 5.80692E---09	 29.15885	 LOC486100	 L---gulonolactone	oxidase---like	CfaAffx.13409.1.S1_at	 2.1005E---06	 1.83683E---07	 8.286384	 LRAT	 lecithin	retinol	acyltransferase	(phosphatidylcholine------retinol	O---acyltransferase)	CfaAffx.13623.1.S1_at	 0.000304868	 0.000133729	 3.8605843	 STBD1	 starch	binding	domain	1	CfaAffx.13822.1.S1_s_at	 0.00054245	 0.000334345	 2.6787975	 THBS1	 thrombospondin	1	CfaAffx.14130.1.S1_at	 0.000110638	 3.46172E---05	 5.0477967	 SFXN5	 sideroflexin	5	CfaAffx.14369.1.S1_at	 0.00048708	 0.00027892	 7.484151	 HPSE	 heparanase	CfaAffx.14657.1.S1_at	 0.000682784	 0.000473808	 4.048732	 FAM82A2	 family	with	sequence	similarity	82,	member	A2	CfaAffx.14671.1.S1_s_at	 8.23276E---05	 2.22946E---05	 2.4972491	 FAM82A2	 family	with	sequence	similarity	82,	member	A2	CfaAffx.14892.1.S1_at	 4.62343E---06	 4.8908E---07	 8.701089	 FMOD	 fibromodulin	CfaAffx.15184.1.S1_s_at	 0.000376265	 0.000183621	 3.1303012	 SCD	 stearoyl---CoA	desaturase	(delta---9---desaturase)	CfaAffx.15421.1.S1_s_at	 0.000178103	 6.35543E---05	 8.135605	 TBC1D7	 TBC1	domain	family,	member	7	CfaAffx.15444.1.S1_s_at	 3.13959E---06	 3.09973E---07	 13.439858	 NKD1	 naked	cuticle	homolog	1	(Drosophila)	CfaAffx.15752.1.S1_at	 9.93408E---05	 2.9564E---05	 16.204338	 GABRB3	 gamma---aminobutyric	acid	(GABA)	A	receptor,	beta	3	CfaAffx.15830.1.S1_s_at	 4.63365E---05	 1.03813E---05	 2.0973158	 SEMA5A	 sema	domain,	seven	thrombospondin	repeats	(type	1	and	type	1---like),	transmembrane	domain	(TM)	and	short	cytoplasmic	domain,	(semaphorin)	5A	CfaAffx.16017.1.S1_s_at	 0.001007584	 0.000914103	 3.725349	 ARHGAP32	 Rho	GTPase	activating	protein	32	CfaAffx.16168.1.S1_at	 0.00068284	 0.000475773	 4.8904185	 DPPA2	 developmental	pluripotency	associated	2	CfaAffx.16227.1.S1_at	 7.10612E---06	 8.51932E---07	 8.877456	 PHLDB2///PLCXD	2	 pleckstrin	homology---like	domain,	family	B,	member	2///phosphatidylinositol---	specific	phospholipase	C,	X	domain	containing	2	CfaAffx.16313.1.S1_s_at	 8.85038E---05	 2.47162E---05	 5.657892	 CPNE8	 copine	VIII	CfaAffx.16356.1.S1_s_at	 0.000375542	 0.00018115	 2.732608	 HSPD1	 heat	shock	60kDa	protein	1	(chaperonin)	CfaAffx.16371.1.S1_at	 0.000855977	 0.000696613	 5.6205015	 SYT10	 synaptotagmin	X	CfaAffx.16401.1.S1_at	 0.000885302	 0.000736711	 3.7324662	 SPPL3	 signal	peptide	peptidase	like	3	CfaAffx.16457.1.S1_s_at	 0.000265028	 0.000110273	 4.3876867	 SLC13A3	 solute	carrier	family	13	(sodium---dependent	dicarboxylate	transporter),	member	3	CfaAffx.16529.1.S1_s_at	 0.00069238	 0.000493174	 2.4281223	 VIMP	 VCP---interacting	membrane	protein	CfaAffx.16558.1.S1_at	 0.000559542	 0.000350405	 5.316946	 RGS2	 regulator	of	G---protein	signaling	2,	24kDa	CfaAffx.16663.1.S1_at	 0.000375547	 0.000182212	 4.985196	 SLC16A14	 solute	carrier	family	16,	member	14	(monocarboxylic	acid	transporter	14)	CfaAffx.17171.1.S1_s_at	 6.32485E---05	 1.5879E---05	 2.6268845	 CHD1L	 chromodomain	helicase	DNA	binding	protein	1---like	CfaAffx.17218.1.S1_at	 0.000122402	 4.09159E---05	 7.56362	 LGMN	 legumain	CfaAffx.17446.1.S1_at	 0.00105121	 0.000979517	 5.424298	 SIAE	 sialic	acid	acetylesterase	CfaAffx.17502.1.S1_at	 2.31584E---07	 1.22192E---08	 29.840849	 AXIN2	 axin	2	CfaAffx.17636.1.S1_at	 0.000764269	 0.000576705	 2.2316697	 GET4	 golgi	to	ER	traffic	protein	4	homolog	(S.	cerevisiae)	CfaAffx.18273.1.S1_at	 0.000423563	 0.00022028	 5.9526463	 FCER1A	 Fc	fragment	of	IgE,	high	affinity	I,	receptor	for;	alpha	polypeptide	CfaAffx.18371.1.S1_s_at	 0.000688951	 0.000483827	 2.7532446	 CERS6	 ceramide	synthase	6	CfaAffx.18457.1.S1_at	 0.001135682	 0.001121265	 2.4227931	 LOC100688543///	LOC100688763	 UDP---glucuronosyltransferase	1---8---like///UDP---glucuronosyltransferase	1---10---like	CfaAffx.18602.1.S1_s_at	 0.000630896	 0.000420281	 2.6839082	 ZNRF3	 zinc	and	ring	finger	3	CfaAffx.18906.1.S1_at	 0.00056074	 0.000352667	 2.208585	 LOC100856343	 translation	initiation	factor	eIF---2B	subunit	epsilon---like	CfaAffx.18955.1.S1_x_at	 0.000576703	 0.000368472	 3.0803466	 ACTA1	 actin,	alpha	1,	skeletal	muscle	CfaAffx.19086.1.S1_at	 0.000805603	 0.000631271	 3.384487	 LOC100855619	 insulin---like	growth	factor---binding	protein	3---like	CfaAffx.19194.1.S1_at	 1.11941E---07	 4.80148E---09	 2.4686623	 SLCO1B3	 solute	carrier	organic	anion	transporter	family,	member	1B3	CfaAffx.19341.1.S1_at	 0.000384341	 0.000191357	 3.690166	 STXBP6	 syntaxin	binding	protein	6	(amisyn)	CfaAffx.19874.1.S1_at	 0.000882335	 0.000731753	 2.4669995		 	CfaAffx.19898.1.S1_at	 0.000696832	 0.000501247	 3.8895724	 RERG	 RAS---like,	estrogen---regulated,	growth	inhibitor	CfaAffx.19964.1.S1_s_at	 0.001116423	 0.001086259	 3.985013	 ARHGDIB	 Rho	GDP	dissociation	inhibitor	(GDI)	beta	CfaAffx.20291.1.S1_at	 3.3986E---06	 3.40339E---07	 14.2934675	 RGSL1	 regulator	of	G---protein	signaling	like	1	CfaAffx.20294.1.S1_s_at	 0.000785079	 0.000601267	 3.8037186	 RAPGEF4	 Rap	guanine	nucleotide	exchange	factor	(GEF)	4	CfaAffx.20306.1.S1_at	 0.000495709	 0.000290154	 5.8168435	 RGSL1	 regulator	of	G---protein	signaling	like	1	CfaAffx.20465.1.S1_s_at	 0.000447449	 0.000243604	 2.7826455	 CIR1	 corepressor	interacting	with	RBPJ,	1	CfaAffx.20572.1.S1_s_at	 0.000162829	 5.69559E---05	 3.1579492	 SMS	 spermine	synthase	CfaAffx.20589.1.S1_at	 5.54699E---08	 1.87768E---09	 21.235073	 DNAJC12	 DnaJ	(Hsp40)	homolog,	subfamily	C,	member	12	CfaAffx.20631.1.S1_s_at	 0.000229598	 9.00256E---05	 6.3417835	 FAM177A1	 family	with	sequence	similarity	177,	member	A1			CfaAffx.21065.1.S1_s_at	 		 0.000113053			 3.55582E---05			 24.547401	 LOC100683822///	LOC100687054///	LOC100856278///	LOC486474///LO	C607364///LOC60	7582///LOC60823	8///LOC608248	 	immunoglobulin	lambda---like	polypeptide	5---like///immunoglobulin	lambda---like	polypeptide	5---like///uncharacterized	LOC100856278///immunoglobulin	lambda	like	polypeptide	5---like///immunoglobulin	lambda---like	polypeptide	5---	like///immunoglobulin	lambda---like	polypeptide	5---like///immunoglobulin	lambda---like	polypeptide	5---like///immunoglobulin	lambda---like	polypeptide	5---like			CfaAffx.21066.1.S1_s_at	 		 0.00016564			 5.84063E---05			 40.161816	 LOC100683822///	LOC100687054///	LOC100856278///	LOC486474///LO	C607364///LOC60	7582///LOC60823	8///LOC608248	 	immunoglobulin	lambda---like	polypeptide	5---like///immunoglobulin	lambda---like	polypeptide	5---like///uncharacterized	LOC100856278///immunoglobulin	lambda	like	polypeptide	5---like///immunoglobulin	lambda---like	polypeptide	5---	like///immunoglobulin	lambda---like	polypeptide	5---like///immunoglobulin	lambda---like	polypeptide	5---like///immunoglobulin	lambda---like	polypeptide	5---like	CfaAffx.21119.1.S1_at	 2.74704E---05	 5.28058E---06	 3.7447164	 SORD	 sorbitol	dehydrogenase	CfaAffx.21187.1.S1_at	 0.000305893	 0.000135453	 3.4055922	 RTP3	 receptor	(chemosensory)	transporter	protein	3	CfaAffx.21778.1.S1_at	 0.00015034	 5.15269E---05	 8.126965	 SESTD1	 SEC14	and	spectrin	domains	1	CfaAffx.22010.1.S1_s_at	 0.000203002	 7.59648E---05	 5.095695	 COMT	 catechol---O---methyltransferase	CfaAffx.22444.1.S1_s_at	 1.17904E---06	 8.74617E---08	 4.9481807	 PLCB3///PRDX5	 phospholipase	C,	beta	3	(phosphatidylinositol---specific)///peroxiredoxin	5	CfaAffx.22488.1.S1_at	 0.000218698	 8.3901E---05	 2.1492941	 PYGL	 phosphorylase,	glycogen,	liver	CfaAffx.22781.1.S1_at	 0.000785079	 0.000599567	 5.4645	 PHC3	 polyhomeotic	homolog	3	(Drosophila)	CfaAffx.22814.1.S1_s_at	 1.05304E---09	 8.14896E---12	 5.7984076	 RGN	 regucalcin	(senescence	marker	protein---30)	CfaAffx.22992.1.S1_at	 0.000410031	 0.000209931	 2.2796757	 CYP27A1	 cytochrome	P450,	family	27,	subfamily	A,	polypeptide	1	CfaAffx.23200.1.S1_at	 0.000259643	 0.0001073	 6.6540155	 HDC	 histidine	decarboxylase	CfaAffx.23264.1.S1_s_at	 0.000863661	 0.000708957	 2.4138463	 LOC100682666///	REST	 RE1---silencing	transcription	factor---like///RE1---silencing	transcription	factor	CfaAffx.23615.1.S1_at	 0.001126333	 0.001105184	 2.1587198	 CPEB2	 cytoplasmic	polyadenylation	element	binding	protein	2	CfaAffx.23632.1.S1_s_at	 0.001109468	 0.00107641	 3.6813333	 STAT5A	 signal	transducer	and	activator	of	transcription	5A	CfaAffx.23806.1.S1_s_at	 3.43896E---05	 7.00711E---06	 3.3765085	 SLC3A2	 solute	carrier	family	3	(activators	of	dibasic	and	neutral	amino	acid	transport),	member	2	CfaAffx.23960.1.S1_s_at	 0.000055239	 1.29196E---05	 3.6218507	 SGMS1	 sphingomyelin	synthase	1	CfaAffx.23965.1.S1_s_at	 0.000712265	 0.000520385	 2.2152998	 TMEM179B	 transmembrane	protein	179B	CfaAffx.24310.1.S1_at	 0.000643182	 0.000437255	 3.5016887	 KIAA1370	 KIAA1370	ortholog	CfaAffx.25013.1.S1_s_at	 0.00104125	 0.000966351	 2.6670475	 HUWE1	 HECT,	UBA	and	WWE	domain	containing	1,	E3	ubiquitin	protein	ligase	CfaAffx.25070.1.S1_s_at	 0.001083552	 0.001023739	 4.0470896	 NVL	 nuclear	VCP---like	CfaAffx.25078.1.S1_at	 0.000846528	 0.000686535	 3.6596284	 PNMT	 phenylethanolamine	N---methyltransferase	CfaAffx.25131.1.S1_at	 0.00070982	 0.000516597	 11.087355	MAGI2	 membrane	associated	guanylate	kinase,	WW	and	PDZ	domain	containing	2	CfaAffx.25135.1.S1_s_at	 6.3398E---05	 1.6006E---05	 12.534671	 GNAI1	 guanine	nucleotide	binding	protein	(G	protein),	alpha	inhibiting	activity	polypeptide	1	CfaAffx.25859.1.S1_at	 0.001137734	 0.001134524	 2.2164733	 ZNF652	 zinc	finger	protein	652	CfaAffx.25945.1.S1_at	 8.41225E---05	 2.31366E---05	 2.8218381	 AREL1	 apoptosis	resistant	E3	ubiquitin	protein	ligase	1	CfaAffx.26081.1.S1_s_at	 5.45299E---06	 6.13393E---07	 5.6314144	 FLVCR2	 feline	leukemia	virus	subgroup	C	cellular	receptor	family,	member	2	CfaAffx.26084.1.S1_at	 3.43896E---05	 7.03313E---06	 3.4451003	 C8H14orf1	 chromosome	8	open	reading	frame,	human	C14orf1	CfaAffx.26270.1.S1_s_at	 0.000375547	 0.000182085	 7.26013	 ODZ2	 odz,	odd	Oz/ten---m	homolog	2	(Drosophila)	CfaAffx.26434.1.S1_s_at	 0.001116423	 0.001087729	 3.3299744	 DIS3L	 DIS3	mitotic	control	homolog	(S.	cerevisiae)---like	CfaAffx.26916.1.S1_at	 0.000855453	 0.00069498	 3.9066484	 LOC100686328	 transmembrane	protein	220---like	CfaAffx.27017.1.S1_s_at	 0.000567833	 0.0003588	 2.416146	 SERPINA11	 serpin	peptidase	inhibitor,	clade	A	(alpha---1	antiproteinase,	antitrypsin),	member	11	CfaAffx.27698.1.S1_s_at	 0.000309434	 0.000139787	 2.9490607	 RCN2	 reticulocalbin	2,	EF---hand	calcium	binding	domain	
	152	
	 CfaAffx.27863.1.S1_at	 0.000523698	 0.000312041	 3.5758338	 NOMO2	 NODAL	modulator	2	CfaAffx.28227.1.S1_at	 0.001105833	 0.001063721	 3.6831172		 	CfaAffx.28431.1.S1_s_at	 0.000708904	 0.000514931	 4.165196	MYH11	 myosin,	heavy	chain	11,	smooth	muscle	CfaAffx.28586.1.S1_s_at	 1.20245E---08	 2.03518E---10	 117.25511	NADKD1///RANB	P3L	 NAD	kinase	domain	containing	1///RAN	binding	protein	3---like	CfaAffx.28593.1.S1_at	 1.92738E---05	 3.04466E---06	 33.489536	NADKD1///RANB	P3L	 NAD	kinase	domain	containing	1///RAN	binding	protein	3---like	CfaAffx.28635.1.S1_at	 0.000432906	 0.000226528	 4.765197	MPV17L	 MPV17	mitochondrial	membrane	protein---like	CfaAffx.28987.1.S1_at	 0.000932148	 0.00080205	 8.517217	 ZIC3	 Zic	family	member	3	CfaAffx.29054.1.S1_s_at	 8.45095E---05	 2.33623E---05	 2.874679	 ATP11C	 ATPase,	class	VI,	type	11C	CfaAffx.29256.1.S1_s_at	 0.00048708	 0.000278682	 4.0642586	 NSDHL	 NAD(P)	dependent	steroid	dehydrogenase---like	CfaAffx.30489.1.S1_s_at	 0.001105833	 0.001062688	 4.018253	 COX4NB	 COX4	neighbor	CfaAffx.30572.1.S1_at	 0.000776733	 0.000590493	 3.0469193	MLYCD	 malonyl---CoA	decarboxylase	CfaAffx.30622.1.S1_s_at	 0.00010594	 3.24245E---05	 5.2440095	 VCAM1	 vascular	cell	adhesion	molecule	1	CfaAffx.30821.1.S1_s_at	 9.26314E---05	 2.71753E---05	 11.883978	 AARS	 alanyl---tRNA	synthetase	CfaAffx.30923.1.S1_s_at	 0.00100411	 0.000901114	 2.849306	 PHLPP2	 PH	domain	and	leucine	rich	repeat	protein	phosphatase	2	CfaAffx.31165.1.S1_s_at	 8.78111E---05	 2.43989E---05	 9.046315	 LOC100856678	 nexilin---like		
Monkey	bile	duct	signature		 Probe	Set	ID	 Corrected	p---value	 p---value	 FCAbsolute	 Gene	Symbol	 Gene	Title	AFFX---LysX---5_at	 0.007590598	 0.007532947	 9.754974		 	200632_s_at	 8.20E---05	 1.89E---05	 10.573509	 NDRG1	 N---myc	downstream	regulated	1	201136_at	 4.25E---04	 2.04E---04	 13.670461	 PLP2	 proteolipid	protein	2	(colonic	epithelium---enriched)	201301_s_at	 3.06E---07	 5.16E---10	 12.829881	 ANXA4	 annexin	A4	201302_at	 4.55E---06	 1.42E---07	 22.364914	 ANXA4	 annexin	A4	201613_s_at	 1.42E---05	 1.20E---06	 29.707111	 AP1G2	 adaptor---related	protein	complex	1,	gamma	2	subunit	201650_at	 4.04E---05	 6.99E---06	 130.87476	 KRT19	 keratin	19	201839_s_at	 1.84E---05	 1.77E---06	 30.869284	 EPCAM	 epithelial	cell	adhesion	molecule	201860_s_at	 0.003179834	 0.002817575	 13.198988	 PLAT	 plasminogen	activator,	tissue	202018_s_at	 9.14E---04	 5.89E---04	 29.405645	 LTF	 lactotransferrin	202267_at	 1.45E---04	 4.33E---05	 17.813307	 LAMC2	 laminin,	gamma	2	202286_s_at	 7.71E---04	 4.73E---04	 34.630943	 TACSTD2	 tumor---associated	calcium	signal	transducer	2	202421_at	 8.40E---04	 5.26E---04	 9.310548	 IGSF3	 immunoglobulin	superfamily,	member	3	202488_s_at	 0.00336244	 0.003002077	 10.625242	 FXYD3	 FXYD	domain	containing	ion	transport	regulator	3	202790_at	 3.88E---05	 6.40E---06	 13.869911	 CLDN7	 claudin	7	202826_at	 5.44E---04	 2.89E---04	 16.824333	 SPINT1	 serine	peptidase	inhibitor,	Kunitz	type	1	202831_at	 7.86E---05	 1.80E---05	 191.78606	 GPX2	 glutathione	peroxidase	2	(gastrointestinal)	202921_s_at	 1.96E---04	 6.76E---05	 10.095616	 ANK2	 ankyrin	2,	neuronal	202935_s_at	 1.30E---06	 6.17E---09	 47.543934	 SOX9	 SRY	(sex	determining	region	Y)---box	9	202936_s_at	 1.77E---06	 2.15E---08	 14.076472	 SOX9	 SRY	(sex	determining	region	Y)---box	9	203065_s_at	 1.36E---05	 1.05E---06	 10.533267	 CAV1	 caveolin	1,	caveolae	protein,	22kDa	203146_s_at	 9.92E---04	 6.54E---04	 28.41594	 GABBR1	 gamma---aminobutyric	acid	(GABA)	B	receptor,	1	203601_s_at	 2.26E---04	 8.31E---05	 10.912976	 ZBTB17	 zinc	finger	and	BTB	domain	containing	17	203631_s_at	 2.08E---05	 2.42E---06	 22.363693	 GPRC5B	 G	protein---coupled	receptor,	family	C,	group	5,	member	B	203726_s_at	 4.43E---04	 2.18E---04	 17.974949	 LAMA3	 laminin,	alpha	3	203783_x_at	 9.15E---05	 2.23E---05	 13.838298	 POLRMT	 polymerase	(RNA)	mitochondrial	(DNA	directed)	203889_at	 1.54E---04	 4.73E---05	 10.748801	 SCG5	 secretogranin	V	(7B2	protein)	203961_at	 6.97E---06	 3.41E---07	 21.029171	 NEBL	 nebulette	204213_at	 1.40E---05	 1.17E---06	 10.779538	 PIGR	 polymeric	immunoglobulin	receptor	204259_at	 2.40E---05	 3.17E---06	 21.396217	MMP7	 matrix	metallopeptidase	7	(matrilysin,	uterine)	204272_at	 2.40E---05	 3.16E---06	 32.379562	 LGALS4	 lectin,	galactoside---binding,	soluble,	4	204304_s_at	 7.65E---04	 4.64E---04	 32.711346	 PROM1	 prominin	1	204358_s_at	 7.75E---04	 4.77E---04	 9.38694	 FLRT2///LOC1005	fibronectin	leucine	rich	transmembrane	protein	2///uncharacterized	LOC100506718	204519_s_at	 1.05E---04	 2.79E---05	 13.585548	 PLLP	 plasmolipin	204540_at	 1.25E---04	 3.53E---05	 9.305641	 EEF1A2	 eukaryotic	translation	elongation	factor	1	alpha	2	204542_at	 3.88E---05	 6.37E---06	 11.425742	 ST6GALNAC2	 ST6	(alpha---N---acetyl---neuraminyl---2,3---beta---galactosyl---1,3)---N---acetylgalactosaminide	alpha---2,6---sialyltransferase	2	204777_s_at	 6.01E---05	 1.26E---05	 25.151676	MAL	 mal,	T---cell	differentiation	protein	204875_s_at	 0.00147572	 0.001077213	 23.08333	 GMDS	 GDP---mannose	4,6---dehydratase	205009_at	 2.71E---04	 1.10E---04	 17.68557	 TFF1	 trefoil	factor	1	205016_at	 0.002840828	 0.00247164	 22.84447	 TGFA	 transforming	growth	factor,	alpha	205043_at	 1.07E---04	 2.88E---05	 14.782101	 CFTR	 cystic	fibrosis	transmembrane	conductance	regulator	(ATP---binding	cassette	sub---	family	C,	member	7)	205044_at	 0.00577056	 0.005561164	 12.389158	 GABRP	 ga ma---aminobutyric	acid	(GABA)	A	receptor,	pi	205047_s_at	 1.07E---04	 2.85E---05	 32.973373	 ASNS	 asparagine	synthetase	(glutamine---hydrolyzing)	205313_at	 1.79E---06	 2.72E---08	 16.084911	 HNF1B	 HNF1	homeobox	B	205316_at	 1.40E---05	 1.17E---06	 22.952332	 SLC15A2	 solute	carrier	family	15	(H+/peptide	transporter),	member	2	205317_s_at	 3.28E---05	 4.95E---06	 21.514566	 SLC15A2	 solute	carrier	family	15	(H+/peptide	transporter),	member	2	205328_at	 1.30E---06	 6.60E---09	 19.294895	 CLDN10	 claudin	10	205342_s_at	 4.51E---04	 2.24E---04	 9.643227	 SULT1C2	 sulfotransferase	family,	cytosolic,	1C,	member	2	205360_at	 0.002864503	 0.002499491	 9.2035055	 PFDN4	 prefoldin	subunit	4	205376_at	 4.47E---04	 2.21E---04	 9.142418	 INPP4B	 inositol	polyphosphate---4---phosphatase,	type	II,	105kDa	205379_at	 3.32E---05	 5.06E---06	 18.467173	 CBR3	 carbonyl	reductase	3	205470_s_at	 2.39E---04	 9.21E---05	 18.128016	 KLK11	 kallikrein---related	peptidase	11	205532_s_at	 5.83E---04	 3.15E---04	 12.5754595	 CDH6	 cadherin	6,	type	2,	K---cadherin	(fetal	kidney)	205533_s_at	 0.006122714	 0.005957651	 9.890403	 CDH6	 cadherin	6,	type	2,	K---cadherin	(fetal	kidney)	205625_s_at	 2.01E---05	 2.11E---06	 15.471472	 CALB1	 calbindin	1,	28kDa	205626_s_at	 1.79E---06	 2.60E---08	 35.616817	 CALB1	 calbindin	1,	28kDa	205767_at	 0.0011303	 7.72E---04	 14.258832	 EREG	 epiregulin	205814_at	 4.06E---04	 1.94E---04	 16.304878	 GRM3	 glutamate	receptor,	metabotropic	3	205893_at	 2.08E---04	 7.42E---05	 16.31367	 NLGN1	 neuroligin	1	205922_at	 2.36E---04	 9.10E---05	 10.284211	 VNN2	 vanin	2	205997_at	 1.48E---04	 4.50E---05	 46.06536	 ADAM28	 ADAM	metallopeptidase	domain	28	206002_at	 1.97E---04	 6.81E---05	 22.749891	 GPR64	 G	protein---coupled	receptor	64	206059_at	 6.28E---04	 3.50E---04	 16.868776	 ZNF91	 zinc	finger	protein	91	206123_at	 6.41E---04	 3.60E---04	 9.43653	 LLGL1	 lethal	giant	larvae	homolog	1	(Drosophila)	206197_at	 4.55E---05	 8.41E---06	 32.659492	 NME5	 NME/NM23	family	member	5	206208_at	 7.45E---05	 1.68E---05	 19.509794	 CA4	 carbonic	anhydrase	IV	206209_s_at	 3.37E---04	 1.45E---04	 9.912885	 CA4	 carbonic	anhydrase	IV	206364_at	 0.007025329	 0.00694233	 10.989167	 KIF14	 kinesin	family	member	14	206385_s_at	 5.24E---05	 1.03E---05	 20.8784	 ANK3	 ankyrin	3,	node	of	Ranvier	(ankyrin	G)	206391_at	 0.004282489	 0.003975306	 10.353978	 RARRES1	 retinoic	acid	receptor	responder	(tazarotene	induced)	1	206399_x_at	 1.47E---05	 1.30E---06	 9.806497	 CACNA1A	 calcium	channel,	voltage---dependent,	P/Q	type,	alpha	1A	subunit	206429_at	 0.001162013	 8.02E---04	 13.585832	 F2RL1	 coagulation	factor	II	(thrombin)	receptor---like	1	206520_x_at	 6.73E---04	 3.85E---04	 11.292526	 SIGLEC6	 sialic	acid	binding	Ig---like	lectin	6	206524_at	 0.002701921	 0.002317009	 11.334983	 T	 T,	brachyury	homolog	(mouse)	206595_at	 6.18E---04	 3.41E---04	 13.568236	 CST6	 cystatin	E/M	206628_at	 3.99E---04	 1.88E---04	 22.983038	 SLC5A1	 solute	carrier	family	5	(sodium/glucose	cotransporter),	member	1	206661_at	 0.007976072	 0.007928956	 9.451004	 DBF4B	 DBF4	homolog	B	(S.	cerevisiae)	206884_s_at	 9.77E---04	 6.41E---04	 59.929455	 SCEL	 sciellin	206940_s_at	 3.96E---04	 1.84E---04	 15.418744	 POU4F1	 POU	class	4	homeobox	1	206946_at	 4.28E---04	 2.07E---04	 10.0242195	 HCN4	 hyperpolarization	activated	cyclic	nucleotide---gated	potassium	channel	4	207017_at	 3.43E---05	 5.30E---06	 12.502662	 RAB27B	 RAB27B,	member	RAS	oncogene	family	207169_x_at	 4.43E---04	 2.17E---04	 9.3316145	 DDR1///MIR4640	 discoidin	domain	receptor	tyrosine	kinase	1///microRNA	4640	207225_at	 9.79E---04	 6.43E---04	 9.695378	 AANAT	 aralkylamine	N---acetyltransferase	207249_s_at	 0.001959193	 0.001557435	 13.312831	 SLC28A2	 solute	carrier	family	28	(sodium---coupled	nucleoside	transporter),	member	2	207279_s_at	 1.04E---05	 6.49E---07	 16.267622	 NEBL	 nebulette	207434_s_at	 0.003152431	 0.002790633	 10.421672	 FXYD2///FXYD6---F	 FXYD	domain	containing	ion	transport	regulator	2///FXYD6---FXYD2	readthrough	207468_s_at	 2.21E---04	 8.08E---05	 9.385944	 SFRP5	 secreted	frizzled---related	protein	5	207615_s_at	 0.001911563	 0.001514732	 11.531261	 C16orf3	 chromosome	16	open	reading	frame	3	207847_s_at	 0.001157947	 7.97E---04	 45.562386	MUC1	 mucin	1,	cell	surface	associated	207880_at	 6.54E---05	 1.43E---05	 13.157702	 ADAM11	 ADAM	metallopeptidase	domain	11	207950_s_at	 1.77E---06	 2.37E---08	 36.158894	 ANK3	 ankyrin	3,	node	of	Ranvier	(ankyrin	G)	207989_at	 0.006783033	 0.006657103	 9.329288	 OPRM1	 opioid	receptor,	mu	1	
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	 208084_at	 0.002072633	 0.001670969	 17.626076	 ITGB6	 integrin,	beta	6	208135_at	 2.16E---05	 2.64E---06	 29.316442	 HNF1B	 HNF1	homeobox	B	208136_s_at	 6.23E---04	 3.46E---04	 13.7232895	 ZNF205---AS1	 ZNF205	antisense	RNA	1	208140_s_at	 0.002303465	 0.001903031	 14.9177265	 LRRC48	 leucine	rich	repeat	containing	48	208143_s_at	 6.48E---04	 3.66E---04	 10.457069	 EDDM3A	 epididymal	protein	3A	208250_s_at	 3.32E---05	 5.07E---06	 29.432346	 DMBT1	 deleted	in	malignant	brain	tumors	1	208323_s_at	 2.68E---04	 1.08E---04	 41.94592	 ANXA13	 annexin	A13	208358_s_at	 0.005798084	 0.005592582	 18.00785	 UGT8	 UDP	glycosyltransferase	8	208394_x_at	 0.002026785	 0.001624849	 19.778212	 ESM1	 endothelial	cell---specific	molecule	1	208430_s_at	 0.006567651	 0.006418009	 9.143717	 DTNA	 dystrobrevin,	alpha	208431_s_at	 0.001394233	 0.001002699	 12.966413	 TUB	 tubby	homolog	(mouse)	208450_at	 7.04E---04	 4.12E---04	 11.336568	 LGALS2	 lectin,	galactoside---binding,	soluble,	2	208650_s_at	 1.43E---05	 1.22E---06	 40.748802	 CD24	 CD24	molecule	209097_s_at	 2.53E---04	 9.91E---05	 11.742224	 JAG1	 jagged	1	209098_s_at	 1.21E---05	 8.88E---07	 13.330439	 JAG1	 jagged	1	209173_at	 9.34E---05	 2.29E---05	 206.51149	 AGR2	 anterior	gradient	2	homolog	(Xenopus	laevis)	209211_at	 3.88E---05	 6.53E---06	 23.698734	 KLF5	 Kruppel---like	factor	5	(intestinal)	209212_s_at	 1.63E---06	 1.38E---08	 24.949917	 KLF5	 Kruppel---like	factor	5	(intestinal)	209369_at	 2.71E---04	 1.09E---04	 15.882639	 ANXA3	 annexin	A3	209442_x_at	 1.36E---05	 1.05E---06	 17.407969	 ANK3	 ankyrin	3,	node	of	Ranvier	(ankyrin	G)	209488_s_at	 8.35E---06	 4.37E---07	 9.4250145	 RBPMS	 RNA	binding	protein	with	multiple	splicing	209529_at	 2.49E---04	 9.72E---05	 11.067101	 PPAP2C	 phosphatidic	acid	phosphatase	type	2C	209530_at	 0.001003689	 6.63E---04	 10.679267	 CACNB3	 calcium	channel,	voltage---dependent,	beta	3	subunit	209615_s_at	 5.24E---05	 1.04E---05	 20.63451	 PAK1	 p21	protein	(Cdc42/Rac)---activated	kinase	1	209617_s_at	 3.83E---05	 6.18E---06	 14.187726	 CTNND2	 catenin	(cadherin---associated	protein),	delta	2	209618_at	 2.29E---04	 8.49E---05	 15.728557	 CTNND2	 catenin	(cadherin---associated	protein),	delta	2	209728_at	 0.007136361	 0.007064094	 11.252374	 HLA---DRB4	 major	histocompatibility	complex,	class	II,	DR	beta	4	209772_s_at	 3.14E---05	 4.59E---06	 38.24131	 CD24	 CD24	molecule	209791_at	 0.001146043	 7.86E---04	 9.781555	 PADI2	 peptidyl	arginine	deiminase,	type	II	209792_s_at	 3.88E---05	 6.37E---06	 51.081463	 KLK10	 kallikrein---related	peptidase	10	209875_s_at	 3.75E---06	 1.11E---07	 59.396572	 SPP1	 secreted	phosphoprotein	1	209908_s_at	 5.09E---04	 2.63E---04	 9.184215	 TGFB2	 transforming	growth	factor,	beta	2	210119_at	 4.32E---05	 7.65E---06	 107.66456	 KCNJ15	 potassium	inwardly---rectifying	channel,	subfamily	J,	member	15	210121_at	 3.76E---05	 5.93E---06	 9.162879	 B3GALT2	 UDP---Gal:betaGlcNAc	beta	1,3---galactosyltransferase,	polypeptide	2	210505_at	 0.006710854	 0.006569275	 10.83258	 ADH7	 alcohol	dehydrogenase	7	(class	IV),	mu	or	sigma	polypeptide	210534_s_at	 1.45E---05	 1.24E---06	 30.337643	 B9D1	 B9	protein	domain	1	210641_at	 7.32E---04	 4.32E---04	 12.581538	 CAPN9	 calpain	9	210736_x_at	 0.003527739	 0.00317943	 21.337812	 DTNA	 dystrobrevin,	alpha	210781_x_at	 4.52E---04	 2.25E---04	 11.905989	 GRIN1	 glutamate	receptor,	ionotropic,	N---methyl	D---aspartate	1	210827_s_at	 3.16E---04	 1.34E---04	 12.3604555	 ELF3	 E74---like	factor	3	(ets	domain	transcription	factor,	epithelial---specific	)	210829_s_at	 5.16E---05	 9.97E---06	 10.235393	 SSBP2	 single---stranded	DNA	binding	protein	2	210869_s_at	 1.16E---05	 8.04E---07	 11.144834	MCAM	 melanoma	cell	adhesion	molecule	211002_s_at	 9.19E---04	 5.95E---04	 11.1645975	 TRIM29	 tripartite	motif	containing	29	211057_at	 3.98E---04	 1.86E---04	 11.673606	 ROR1	 receptor	tyrosine	kinase---like	orphan	receptor	1	211164_at	 0.001051172	 7.05E---04	 17.599524	 EPHA3	 EPH	receptor	A3	211181_x_at	 1.97E---04	 6.84E---05	 12.140086	 LOC100506403///	 uncharacterized	LOC100506403///runt---related	transcription	factor	1	211258_s_at	 3.17E---04	 1.34E---04	 15.489263	 TGFA	 transforming	growth	factor,	alpha	211379_x_at	 0.002518768	 0.002117041	 12.293867	 B3GALNT1	 beta---1,3---N---acetylgalactosaminyltransferase	1	(globoside	blood	group)	211398_at	 4.05E---04	 1.93E---04	 14.105396	 FGFR2	 fibroblast	growth	factor	receptor	2	211465_x_at	 0.001814013	 0.001397632	 9.28565	 FUT6	 fucosyltransferase	6	(alpha	(1,3)	fucosyltransferase)	211493_x_at	 1.99E---04	 6.95E---05	 15.111289	 DTNA	 dystrobrevin,	alpha	211592_s_at	 0.001132926	 7.76E---04	 11.962104	 CACNA1C	 calcium	channel,	voltage---dependent,	L	type,	alpha	1C	subunit	211620_x_at	 6.97E---06	 3.39E---07	 10.776594	 LOC100506403///	 uncharacterized	LOC100506403///runt---related	transcription	factor	1	211695_x_at	 1.36E---04	 3.95E---05	 13.136052	MUC1	 mucin	1,	cell	surface	associated	211806_s_at	 8.01E---05	 1.84E---05	 20.910797	 KCNJ15	 potassium	inwardly---rectifying	channel,	subfamily	J,	member	15	211812_s_at	 6.15E---05	 1.31E---05	 29.857916	 B3GALNT1	 beta---1,3---N---acetylgalactosaminyltransferase	1	(globoside	blood	group)	211873_s_at	 2.30E---04	 8.60E---05	 10.5178175	 PCDHGA9	 protocadherin	gamma	subfamily	A,	9	211900_x_at	 1.25E---04	 3.50E---05	 14.129642	 CD6	 CD6	molecule	212091_s_at	 3.92E---04	 1.82E---04	 11.106757	 COL6A1	 collagen,	type	VI,	alpha	1	212336_at	 1.36E---05	 1.06E---06	 28.096264	 EPB41L1	 erythrocyte	membrane	protein	band	4.1---like	1	212339_at	 3.60E---05	 5.65E---06	 40.527557	 EPB41L1	 erythrocyte	membrane	protein	band	4.1---like	1	212533_at	 3.58E---04	 1.60E---04	 9.747216	WEE1	 WEE1	homolog	(S.	pombe)	212611_at	 0.001734353	 0.001320158	 11.672231	 DTX4	 deltex	homolog	4	(Drosophila)	212670_at	 6.51E---04	 3.70E---04	 15.201399	 ELN	 elastin	212775_at	 2.22E---04	 8.14E---05	 10.265405	 OBSL1	 obscurin---like	1	212776_s_at	 3.21E---04	 1.37E---04	 24.5508	 OBSL1	 obscurin---like	1	212906_at	 1.37E---05	 1.09E---06	 56.529102	 GRAMD1B	 GRAM	domain	containing	1B	212942_s_at	 7.71E---04	 4.72E---04	 14.312297	 KIAA1199	 KIAA1199	213280_at	 1.20E---04	 3.33E---05	 47.156425	 RAP1GAP2	 RAP1	GTPase	activating	protein	2	213426_s_at	 7.88E---04	 4.86E---04	 10.132942	 CAV2	 caveolin	2	213429_at	 0.002409789	 0.002017309	 11.708273	 BICC1	 bicaudal	C	homolog	1	(Drosophila)	213436_at	 0.001683194	 0.001274114	 11.930345	 CNR1	 cannabinoid	receptor	1	(brain)	213506_at	 3.67E---04	 1.66E---04	 14.172241	 F2RL1	 coagulation	factor	II	(thrombin)	receptor---like	1	213516_at	 2.30E---04	 8.60E---05	 10.135801	 AKAP13	 A	kinase	(PRKA)	anchor	protein	13	213731_s_at	 0.001806397	 0.001384441	 11.781514	 TCF3	 transcription	factor	3	213809_x_at	 4.77E---04	 2.43E---04	 9.722728	 TCF3	 transcription	factor	3	213953_at	 0.001351396	 9.66E---04	 23.160204	 KRT20	 keratin	20	213989_x_at	 2.33E---04	 8.86E---05	 11.109252	 SETD4	 SET	domain	containing	4	213997_at	 0.001171411	 8.14E---04	 9.336968	 FAM189A1	 family	with	sequence	similarity	189,	member	A1	214031_s_at	 3.84E---04	 1.77E---04	 36.460464	 KRT7	 keratin	7	214262_at	 2.07E---05	 2.37E---06	 13.402645	 TRIP6	 thyroid	hormone	receptor	interactor	6	214341_at	 2.68E---06	 6.63E---08	 25.078867	 AP1G2	 adaptor---related	protein	complex	1,	gamma	2	subunit	214373_at	 3.72E---04	 1.69E---04	 14.956957		 	214774_x_at	 0.001524796	 0.001123683	 25.211277	 TOX3	 TOX	high	mobility	group	box	family	member	3	214803_at	 9.63E---04	 6.29E---04	 9.280332	 CDH6	 cadherin	6,	type	2,	K---cadherin	(fetal	kidney)	214806_at	 0.001713679	 0.001302694	 9.544204	 BICD1	 bicaudal	D	homolog	1	(Drosophila)	214966_at	 6.35E---05	 1.38E---05	 16.58	 GRIK5	 glutamate	receptor,	ionotropic,	kainate	5	215108_x_at	 2.31E---04	 8.71E---05	 26.501263	 TOX3	 TOX	high	mobility	group	box	family	member	3	215382_x_at	 1.49E---05	 1.33E---06	 16.422377	 TPSAB1	 tryptase	alpha/beta	1	215657_at	 3.88E---05	 6.55E---06	 18.532475	 SLC26A3	 solute	carrier	family	26,	member	3	215672_s_at	 1.25E---05	 9.31E---07	 9.7296505	 AHCYL2	 adenosylhomocysteinase---like	2	215702_s_at	 1.24E---06	 3.13E---09	 203.72252	 CFTR	 cystic	fibrosis	transmembrane	conductance	regulator	(ATP---binding	cassette	sub---	family	C,	member	7)	215703_at	 1.40E---05	 1.16E---06	 73.2913	 CFTR	 cystic	fibrosis	transmembrane	conductance	regulator	(ATP---binding	cassette	sub---	family	C,	member	7)	215711_s_at	 4.86E---04	 2.48E---04	 9.275378	WEE1	 WEE1	ho olog	(S.	pombe)	215784_at	 0.00471781	 0.004403289	 12.372058	 CD1E	 CD1e	molecule	215955_x_at	 0.001021539	 6.78E---04	 10.603116	 ARHGAP26	 Rho	GTPase	activating	protein	26	215971_at	 2.87E---04	 1.18E---04	 9.155803		 	216135_at	 1.06E---04	 2.82E---05	 18.836273	 IQCK	 IQ	motif	containing	K	216142_at	 9.15E---05	 2.22E---05	 10.332584		 	216161_at	 7.67E---04	 4.65E---04	 10.667711	 SBNO1	 strawberry	notch	homolog	1	(Drosophila)	216379_x_at	 1.60E---04	 5.03E---05	 24.011486	 CD24	 CD24	molecule	216446_at	 1.70E---04	 5.43E---05	 11.72488		 	216477_at	 7.75E---04	 4.77E---04	 13.567382	 RPL23AP22///RPL	ribosomal	protein	L23a	pseudogene	22///NULL	216623_x_at	 3.55E---04	 1.58E---04	 37.243332	 TOX3	 TOX	high	mobility	group	box	family	member	3	216782_at	 4.90E---06	 1.82E---07	 71.45796		 	216867_s_at	 2.07E---05	 2.34E---06	 15.229227	 PDGFA	 platelet---derived	growth	factor	alpha	polypeptide	216882_s_at	 6.55E---05	 1.44E---05	 16.330215	 NEBL	 nebulette	216966_at	 0.00107372	 7.24E---04	 18.499031	 ITGA2B	 integrin,	alpha	2b	(platelet	glycoprotein	IIb	of	IIb/IIIa	complex,	antigen	CD41)	217026_at	 9.40E---04	 6.11E---04	 14.285501	 CFTR	 cystic	fibrosis	transmembrane	conductance	regulator	(ATP---binding	cassette	sub---	family	C,	member	7)	217054_at	 1.87E---04	 6.33E---05	 26.531956	 OTTHUMG0000015	NULL///NULL	217182_at	 8.75E---04	 5.53E---04	 18.518875		 	217187_at	 0.001830152	 0.001422815	 44.77701	MUC5AC	 mucin	5AC,	oligomeric	mucus/gel---forming	217237_at	 1.23E---04	 3.44E---05	 12.013807	 ADAM3B///ADAM	 NULL///ADAM	metallopeptidase	domain	3B	(pseudogene)	
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	 217264_s_at	 1.48E---04	 4.47E---05	 13.601606	 SCNN1A	 sodium	channel,	non---voltage---gated	1	alpha	subunit	217463_s_at	 2.06E---04	 7.33E---05	 27.757303	MYRF	 myelin	regulatory	factor	217634_at	 8.94E---05	 2.13E---05	 16.171844	 SVIL	 supervillin	217711_at	 0.008267904	 0.008246972	 12.533059	 TEK	 TEK	tyrosine	kinase,	endothelial	218186_at	 1.24E---06	 4.17E---09	 47.26175	 RAB25	 RAB25,	member	RAS	oncogene	family	218261_at	 4.62E---04	 2.33E---04	 15.115448	 AP1M2	 adaptor---related	protein	complex	1,	mu	2	subunit	218368_s_at	 1.26E---04	 3.58E---05	 10.663235	 TNFRSF12A	 tumor	necrosis	factor	receptor	superfamily,	member	12A	218376_s_at	 7.71E---04	 4.71E---04	 12.361067	MICAL1	 microtubule	associated	monooxygenase,	calponin	and	LIM	domain	containing	1	218445_at	 5.77E---05	 1.18E---05	 10.151193	 H2AFY2	 H2A	histone	family,	member	Y2	218644_at	 7.71E---04	 4.72E---04	 15.878833	 PLEK2	 pleckstrin	2	218677_at	 1.50E---04	 4.58E---05	 10.461276	 S100A14	 S100	calcium	binding	protein	A14	218885_s_at	 1.39E---04	 4.08E---05	 42.876446	 GALNT12	 UDP---N---acetyl---alpha---D---galactosamine:polypeptide	N---	acetylgalactosaminyltransferase	12	(GalNAc---T12)	218921_at	 1.41E---04	 4.18E---05	 9.47954	 SIGIRR	 single	immunoglobulin	and	toll---interleukin	1	receptor	(TIR)	domain	218963_s_at	 2.24E---04	 8.24E---05	 24.063215	 KRT23	 keratin	23	(histone	deacetylase	inducible)	219077_s_at	 0.002755151	 0.002383147	 10.308208	WWOX	 WW	domain	containing	oxidoreductase	219121_s_at	 5.09E---05	 9.78E---06	 123.54625	 ESRP1	 epithelial	splicing	regulatory	protein	1	219257_s_at	 3.33E---05	 5.11E---06	 26.381027	 SPHK1	 sphingosine	kinase	1	219304_s_at	 2.68E---06	 6.95E---08	 30.03212	 PDGFD	 platelet	derived	growth	factor	D	219388_at	 5.50E---04	 2.94E---04	 26.84399	 GRHL2	 grainyhead---like	2	(Drosophila)	219468_s_at	 5.25E---04	 2.74E---04	 9.486332	 CUEDC1	 CUE	domain	containing	1	219476_at	 0.002409247	 0.002014822	 11.878861	 C1orf116	 chromosome	1	open	reading	frame	116	219498_s_at	 3.55E---04	 1.56E---04	 31.25175	 BCL11A	 B---cell	CLL/lymphoma	11A	(zinc	finger	protein)	219564_at	 0.002237393	 0.001840893	 10.688598	 KCNJ16	 potassium	inwardly---rectifying	channel,	subfamily	J,	member	16	219686_at	 2.51E---04	 9.81E---05	 16.209522	 STK32B	 serine/threonine	kinase	32B	219697_at	 0.00187421	 0.001478807	 9.164882	 HS3ST2	 heparan	sulfate	(glucosamine)	3---O---sulfotransferase	2	219703_at	 9.84E---05	 2.51E---05	 10.332835	MNS1	 meiosis---specific	nuclear	structural	1	219752_at	 0.001048873	 7.02E---04	 9.142463	 RASAL1	 RAS	protein	activator	like	1	(GAP1	like)	219833_s_at	 0.001526267	 0.001128278	 24.882479	 EFHC1	 EF---hand	domain	(C---terminal)	containing	1	219850_s_at	 2.67E---06	 6.25E---08	 36.943134	 EHF	 ets	homologous	factor	220120_s_at	 8.18E---06	 4.21E---07	 21.260798	 EPB41L4A	 erythrocyte	membrane	protein	band	4.1	like	4A	220218_at	 0.005908871	 0.005709415	 9.823468	 SPATA6L	 spermatogenesis	associated	6---like	220220_at	 2.95E---04	 1.22E---04	 12.3678665	 LRRC37A4P	 leucine	rich	repeat	containing	37,	member	A4,	pseudogene	220272_at	 0.001310307	 9.31E---04	 9.506173	 BNC2	 basonuclin	2	220298_s_at	 1.31E---04	 3.75E---05	 11.074696	 SPATA6	 spermatogenesis	associated	6	220299_at	 6.85E---04	 3.97E---04	 12.385091	 SPATA6	 spermatogenesis	associated	6	220303_at	 1.86E---05	 1.80E---06	 28.486647	 PDZD3	 PDZ	domain	containing	3	220377_at	 3.07E---04	 1.29E---04	 14.039273	 KIAA0125	 KIAA0125	220406_at	 2.16E---05	 2.66E---06	 13.680102	 TGFB2	 transforming	growth	factor,	beta	2	220446_s_at	 5.24E---05	 1.03E---05	 40.805798	 CHST4	 carbohydrate	(N---acetylglucosamine	6---O)	sulfotransferase	4	220461_at	 5.61E---04	 3.01E---04	 13.221404	 PCNXL2	 pecanex---like	2	(Drosophila)	220468_at	 0.001082261	 7.32E---04	 9.871957	 ARL14	 ADP---ribosylation	factor---like	14	220475_at	 6.14E---05	 1.31E---05	 43.445732	 SLC28A3	 solute	carrier	family	28	(sodium---coupled	nucleoside	transporter),	member	3	220484_at	 1.70E---04	 5.42E---05	 20.476727	MCOLN3	 mucolipin	3	220710_at	 0.002059793	 0.001653049	 9.249805	 ANP32A---IT1	 ANP32A	intronic	transcript	1	(non---protein	coding)	220806_x_at	 0.003341766	 0.002977979	 13.853031	 GNG13	 guanine	nucleotide	binding	protein	(G	protein),	gamma	13	220919_s_at	 5.87E---04	 3.18E---04	 17.356274	WDR96	 WD	repeat	domain	96	221173_at	 2.07E---05	 2.28E---06	 41.417828	 USH1C	 Usher	syndrome	1C	(autosomal	recessive,	severe)	221199_at	 9.30E---04	 6.04E---04	 13.358225	 GFRA4	 GDNF	family	receptor	alpha	4	221283_at	 0.001427327	 0.001035866	 9.800603	 RUNX2	 runt---related	transcription	factor	2	221294_at	 0.004372665	 0.004062704	 11.389156	 GPR21	 G	protein---coupled	receptor	21	221365_at	 1.82E---04	 6.02E---05	 10.946323	MLNR	 motilin	receptor	221655_x_at	 8.79E---04	 5.57E---04	 12.503999	 EPS8L1	 EPS8---like	1	221665_s_at	 8.90E---04	 5.69E---04	 12.4659815	 EPS8L1	 EPS8---like	1	221696_s_at	 2.91E---05	 4.03E---06	 12.197986	 STYK1	 serine/threonine/tyrosine	kinase	1	221859_at	 7.51E---04	 4.50E---04	 17.671015	 SYT13	 synaptotagmin	XIII	221976_s_at	 2.69E---04	 1.08E---04	 12.176625	 HDGFRP3	 hepatoma---derived	growth	factor,	related	protein	3	222022_at	 7.46E---04	 4.45E---04	 10.561483	 DTX3	 deltex	homolog	3	(Drosophila)	222066_at	 9.94E---05	 2.55E---05	 20.530214	 EPB41L1	 erythrocyte	membrane	protein	band	4.1---like	1	222075_s_at	 0.005195146	 0.004949637	 10.242946	 OAZ3	 ornithine	decarboxylase	antizyme	3	222234_s_at	 1.92E---04	 6.63E---05	 13.257382	 DBNDD1	 dysbindin	(dystrobrevin	binding	protein	1)	domain	containing	1	222249_at	 0.006122714	 0.005962542	 12.14773		 	222298_at	 0.00490055	 0.004640014	 24.68264		 	222325_at	 7.32E---04	 4.32E---04	 11.767524		 	266_s_at	 3.80E---05	 6.06E---06	 11.278719	 CD24	 CD24	molecule	40093_at	 3.13E---05	 4.46E---06	 9.4559765	 BCAM	 basal	cell	adhesion	molecule	(Lutheran	blood	group)	49049_at	 0.00186332	 0.001462353	 10.161979	 DTX3	 deltex	homolog	3	(Drosophila)	91826_at	 1.16E---05	 8.22E---07	 19.94288	 EPS8L1	 EPS8---like	1	222449_at	 4.55E---06	 1.39E---07	 10.032866	 PMEPA1	 prostate	transmembrane	protein,	androgen	induced	1	222519_s_at	 5.98E---04	 3.24E---04	 10.826259	 IFT57	 intraflagellar	transport	57	homolog	(Chlamydomonas)	222694_at	 9.88E---04	 6.50E---04	 11.163988	MGC2752	 CENPB	DNA---binding	domains	containing	1	pseudogene	222829_s_at	 9.15E---05	 2.22E---05	 13.872188	 IL20RA	 interleukin	20	receptor,	alpha	222853_at	 3.99E---04	 1.88E---04	 10.075132	 FLRT3	 fibronectin	leucine	rich	transmembrane	protein	3	222860_s_at	 1.77E---06	 2.21E---08	 30.570236	 PDGFD	 platelet	derived	growth	factor	D	222901_s_at	 0.001329649	 9.47E---04	 10.114138	 KCNJ16	 potassium	inwardly---rectifying	channel,	subfamily	J,	member	16	222932_at	 1.01E---05	 6.11E---07	 31.07456	 EHF	 ets	homologous	factor	222933_at	 0.002229078	 0.001826528	 12.554409	MORN1	 MORN	repeat	containing	1	223698_at	 0.006762901	 0.006631638	 14.540373	 SLC25A36	 solute	carrier	family	25	(pyrimidine	nucleotide	carrier	),	member	36	223748_at	 0.001171411	 8.16E---04	 14.575098	 SLC4A11	 solute	carrier	family	4,	sodium	borate	transporter,	member	11	223768_at	 0.001101669	 7.49E---04	 9.42515	 SSR4P1	 signal	sequence	receptor,	delta	pseudogene	1	223915_at	 5.10E---04	 2.64E---04	 9.634829	 BCOR	 BCL6	corepressor	223923_at	 1.49E---04	 4.52E---05	 11.219766	 C21orf62	 chromosome	21	open	reading	frame	62	223974_at	 0.00592491	 0.005734913	 10.329405	 DLGAP1---AS2	 DLGAP1	antisense	RNA	2	224157_at	 5.79E---05	 1.20E---05	 11.708758	 KAAG1	 kidney	associated	antigen	1	224168_at	 0.001738483	 0.001324768	 9.604853	 TXNDC2	 thioredoxin	domain	containing	2	(spermatozoa)	224189_x_at	 2.12E---05	 2.51E---06	 51.28004	 EHF	 ets	homologous	factor	224240_s_at	 7.39E---04	 4.39E---04	 17.067583	 CCL28	 chemokine	(C---C	motif)	ligand	28	224251_at	 3.74E---04	 1.71E---04	 11.077557	WDR96	 WD	repeat	domain	96	224277_at	 0.002592308	 0.002191977	 9.423566	MOP---1	 MOP---1	224355_s_at	 1.48E---04	 4.49E---05	 53.31728	MS4A8	 membrane---spanning	4---domains,	subfamily	A,	member	8	225150_s_at	 5.25E---04	 2.75E---04	 10.966467	 RTKN	 rhotekin	225237_s_at	 4.21E---05	 7.35E---06	 9.704395	MSI2	 musashi	RNA---binding	protein	2	225238_at	 2.06E---06	 3.99E---08	 9.259546	MSI2	 musashi	RNA---binding	protein	2	225457_s_at	 0.001569093	 0.00116391	 25.035736	 LINC00263///PP7	 long	intergenic	non---protein	coding	RNA	263///uncharacterized	LOC25845	225500_x_at	 0.001032017	 6.87E---04	 9.948278	 SCAF1	 SR---related	CTD---associated	factor	1	225617_at	 7.88E---04	 4.85E---04	 12.052499	 ODF2	 outer	dense	fiber	of	sperm	tails	2	225645_at	 1.16E---05	 8.28E---07	 33.56338	 EHF	 ets	homologous	factor	225822_at	 3.58E---04	 1.60E---04	 12.123997	 TMEM125	 transmembrane	protein	125	225846_at	 0.002394932	 0.001998808	 32.988415	 ESRP1	 epithelial	splicing	regulatory	protein	1	225911_at	 6.49E---04	 3.68E---04	 12.859749	 NPNT	 nephronectin	225996_at	 0.002069784	 0.001662814	 20.385994	 LONRF2	 LON	peptidase	N---terminal	domain	and	ring	finger	2	226055_at	 7.36E---05	 1.65E---05	 23.727343	 ARRDC2	 arrestin	domain	containing	2	226086_at	 3.95E---04	 1.83E---04	 24.051788	 SYT13	 synaptotagmin	XIII	226145_s_at	 2.09E---04	 7.49E---05	 10.332328	 FRAS1	 Fraser	syndrome	1	226248_s_at	 0.001863247	 0.001459151	 30.692993	 KIAA1324	 KIAA1324	226535_at	 9.14E---04	 5.90E---04	 14.864879	 ITGB6	 integrin,	beta	6	226560_at	 5.79E---04	 3.12E---04	 16.011183		 	226623_at	 9.50E---04	 6.19E---04	 20.037853	 PHYHIPL	 phytanoyl---CoA	2---hydroxylase	interacting	protein---like	226869_at	 0.003256794	 0.002891263	 10.027069	MEGF6	 multiple	EGF---like---domains	6	226961_at	 0.002720583	 0.002339472	 11.100825	 PRR15	 proline	rich	15	226980_at	 0.004727106	 0.004415955	 9.902899	 DEPDC1B	 DEP	domain	containing	1B	227048_at	 9.31E---04	 6.05E---04	 11.882622	 LAMA1	 laminin,	alpha	1	227084_at	 3.88E---05	 6.54E---06	 17.246822	 DTNA	 dystrobrevin,	alpha	227177_at	 1.07E---04	 2.84E---05	 17.584064	 CORO2A	 coronin,	actin	binding	protein,	2A	227194_at	 2.67E---05	 3.61E---06	 73.305176	 FAM3B	 family	with	sequence	similarity	3,	member	B	
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	 227399_at	 0.006707925	 0.006560747	 10.608356	 VGLL3	 vestigial	like	3	(Drosophila)	227720_at	 5.52E---05	 1.11E---05	 9.543253	 ANKRD13B	 ankyrin	repeat	domain	13B	227747_at	 4.48E---04	 2.22E---04	 19.23433	MPZL3	 myelin	protein	zero---like	3	227812_at	 2.91E---05	 4.06E---06	 14.7879305	 TNFRSF19	 tumor	necrosis	factor	receptor	superfamily,	member	19	227992_s_at	 0.007111583	 0.007033566	 10.940874	 LINC00085	 long	intergenic	non---protein	coding	RNA	85	228067_at	 0.006000844	 0.005823604	 18.528948	 KIAA1211L	 KIAA1211---like	228241_at	 4.31E---05	 7.59E---06	 101.49069	 AGR3	 anterior	gradient	3	homolog	(Xenopus	laevis)	228491_at	 8.10E---04	 5.01E---04	 15.700081	 KRT19	 keratin	19	228776_at	 0.001584864	 0.00117962	 17.14341	 GJC1	 gap	junction	protein,	gamma	1,	45kDa	228850_s_at	 0.001164374	 8.05E---04	 13.435195	 SLIT2	 slit	homolog	2	(Drosophila)	228860_at	 2.16E---05	 2.63E---06	 11.596407	 UBE3B	 ubiquitin	protein	ligase	E3B	228865_at	 4.55E---05	 8.38E---06	 48.366005	 C1orf116	 chromosome	1	open	reading	frame	116	228956_at	 9.15E---04	 5.92E---04	 36.14803	 UGT8	 UDP	glycosyltransferase	8	229046_s_at	 5.24E---05	 1.02E---05	 13.449312	 PLEKHB1	 pleckstrin	homology	domain	containing,	family	B	(evectins)	member	1	229047_at	 1.54E---04	 4.76E---05	 19.712955	 PLEKHB1	 pleckstrin	homology	domain	containing,	family	B	(evectins)	member	1	229147_at	 0.001427327	 0.001035619	 9.850531	 RASSF6	 Ras	association	(RalGDS/AF---6)	domain	family	member	6	229190_at	 0.001870152	 0.001472449	 10.758549	 LOC100507376	 uncharacterized	LOC100507376	229242_at	 2.28E---04	 8.44E---05	 17.85943	 TNFSF15	 tumor	necrosis	factor	(ligand)	superfamily,	member	15	229263_at	 0.001696633	 0.001285719	 11.0779295	 IL17RD	 interleukin	17	receptor	D	229276_at	 7.55E---04	 4.53E---04	 11.292273	 IGSF9	 immunoglobulin	superfamily,	member	9	229324_x_at	 1.55E---04	 4.81E---05	 10.436306	 ISYNA1	 inositol---3---phosphate	synthase	1	229627_at	 8.79E---04	 5.58E---04	 17.603468	 CCDC180///LOC10	coiled---coil	domain	containing	180///LOC100499484---C9orf174	readthrough	229741_at	 0.001623493	 0.001219333	 9.693807	MAVS	 mitochondrial	antiviral	signaling	protein	229759_s_at	 7.29E---05	 1.62E---05	 108.406204	 VEPH1	 ventricular	zone	expressed	PH	domain---containing	1	229760_at	 7.28E---04	 4.29E---04	 12.618239	 VEPH1	 ventricular	zone	expressed	PH	domain---containing	1	229782_at	 0.004044001	 0.003716386	 9.917708	 RMST	 rhabdomyosarcoma	2	associated	transcript	(non---protein	coding)	229890_at	 3.99E---04	 1.89E---04	 9.671778	 LOC100507547///	 uncharacterized	LOC100507547///proline---rich	transmembrane	protein	1	229990_at	 2.40E---05	 3.14E---06	 17.448982	 TSC22D1---AS1	 TSC22D1	antisense	RNA	1	230012_at	 1.48E---04	 4.45E---05	 10.242456	 LINC00324	 long	intergenic	non---protein	coding	RNA	324	230054_at	 0.002624435	 0.002225787	 9.260708	 LOC100507547///	 uncharacterized	LOC100507547///proline---rich	transmembrane	protein	1	230100_x_at	 0.002132909	 0.001736926	 11.014069	 PAK1	 p21	protein	(Cdc42/Rac)---activated	kinase	1	230252_at	 6.12E---04	 3.35E---04	 9.53768	 LPAR5	 lysophosphatidic	acid	receptor	5	230280_at	 6.72E---04	 3.85E---04	 32.819424	 TRIM9	 tripartite	motif	containing	9	230349_at	 2.54E---04	 1.00E---04	 11.811716	 XKRX	 XK,	Kell	blood	group	complex	subunit---related,	X---linked	230378_at	 0.001830152	 0.001420263	 11.9238	 SCGB3A1	 secretoglobin,	family	3A,	member	1	230432_at	 2.68E---06	 7.12E---08	 77.80164	 LOC100422737	 uncharacterized	LOC100422737	230435_at	 0.002344293	 0.001942697	 11.04161	 FAM228B	 family	with	sequence	similarity	228,	member	B	230495_at	 0.001587587	 0.001182987	 10.673325	 LOC150568	 uncharacterized	LOC150568	230585_at	 2.74E---04	 1.12E---04	 22.075768		 	230682_x_at	 8.22E---05	 1.90E---05	 20.310078	 ABCC3	 ATP---binding	cassette,	sub---family	C	(CFTR/MRP),	member	3	230746_s_at	 1.40E---04	 4.15E---05	 9.145222		 	230815_at	 0.001967976	 0.001567738	 15.373846	 LOC389765	 kinesin	family	member	27	pseudogene	230876_at	 8.89E---04	 5.67E---04	 20.749125	 ZNF883	 zinc	finger	protein	883	230894_s_at	 1.04E---05	 6.51E---07	 10.114002		 	230980_x_at	 0.005171787	 0.004918653	 9.307927	MIR142	 microRNA	142	231076_at	 5.33E---04	 2.81E---04	 9.314831	 C16orf82	 chromosome	16	open	reading	frame	82	231084_at	 9.03E---04	 5.78E---04	 14.054569	WDR96	 WD	repeat	domain	96	231094_s_at	 2.18E---05	 2.73E---06	 21.61475	 LOC100996643///	monofunctional	C1---tetrahydrofolate	synthase,	mitochondrial---	like///methylenetetrahydrofolate	dehydrogenase	(NADP+	dependent)	1---like	231211_s_at	 8.58E---06	 4.65E---07	 12.79827	 YIF1B	 Yip1	interacting	factor	homolog	B	(S.	cerevisiae)	231270_at	 6.21E---04	 3.44E---04	 15.24883	 CA13///LOC10050	carbonic	anhydrase	XIII///uncharacterized	LOC100507258	231339_at	 0.002177355	 0.001778633	 11.464766	 TSPYL6	 TSPY---like	6	231361_at	 0.005914654	 0.005719995	 12.056276	 NLGN1	 neuroligin	1	231888_at	 4.33E---04	 2.11E---04	 11.880709		 	231925_at	 5.26E---06	 2.02E---07	 11.271834	 OTTHUMG0000015	NULL///NULL	231966_at	 3.07E---05	 4.30E---06	 11.354624	 PPP1R9A	 protein	phosphatase	1,	regulatory	subunit	9A	231978_at	 0.001031091	 6.86E---04	 9.192797	 TPCN2	 two	pore	segment	channel	2	232058_at	 0.005104645	 0.004846182	 9.557048		 	232279_at	 1.84E---04	 6.13E---05	 10.4553175	 PHF15	 PHD	finger	protein	15	232354_at	 9.56E---04	 6.24E---04	 15.900315	 OTTHUMG0000016	NULL///NULL	232360_at	 9.15E---05	 2.22E---05	 17.802946	 EHF	 ets	homologous	factor	232361_s_at	 1.02E---04	 2.67E---05	 71.544876	 EHF	 ets	homologous	factor	232406_at	 2.05E---04	 7.28E---05	 17.65848		 	232584_at	 4.45E---05	 8.04E---06	 20.444557		 	232656_at	 0.00181753	 0.001404943	 10.094017		 	232677_at	 9.68E---04	 6.33E---04	 16.360933	 SYT11	 synaptotagmin	XI	232684_at	 1.25E---04	 3.54E---05	 9.979774	 ZNF503---AS1	 ZNF503	antisense	RNA	1	232769_at	 0.003346748	 0.002985243	 10.937857		 	232816_s_at	 0.001249628	 8.81E---04	 9.467244	 DDX11	 DEAD/H	(Asp---Glu---Ala---Asp/His)	box	helicase	11	232944_at	 0.002140281	 0.00174595	 19.498919		 	232968_at	 0.00479763	 0.004498031	 11.400988	 FANK1	 fibronectin	type	III	and	ankyrin	repeat	domains	1	232995_at	 1.04E---04	 2.76E---05	 25.747149		 	233318_at	 0.00384227	 0.003501816	 9.587525		 	233416_at	 0.002537158	 0.00213892	 10.532397	 CTB---12A17.2///OT	NULL///NULL	233428_at	 1.34E---06	 7.92E---09	 48.985233		 	233449_at	 2.46E---05	 3.28E---06	 12.611312		 	233603_at	 0.001085394	 7.36E---04	 12.739119		 	233607_at	 8.75E---04	 5.52E---04	 22.44843		 	233682_at	 0.004834679	 0.004561326	 13.275307		 	233690_at	 6.98E---04	 4.08E---04	 11.344979		 	233731_at	 3.21E---04	 1.37E---04	 17.43134		 	233794_at	 1.72E---04	 5.51E---05	 9.14928		 	233891_at	 0.002374042	 0.001975363	 13.613127	MUC3	 intestinal	mucin---like	233999_s_at	 7.64E---04	 4.61E---04	 10.949024	 TTC26	 tetratricopeptide	repeat	domain	26	234222_at	 0.002016266	 0.001613013	 11.153973		 	234260_at	 0.002234734	 0.00183682	 17.705086		 	234465_at	 7.42E---04	 4.42E---04	 17.413914	 EME1	 essential	meiotic	endonuclease	1	homolog	1	(S.	pombe)	234484_s_at	 0.001394233	 0.001003613	 9.374227	 ACSS1	 acyl---CoA	synthetase	short---chain	family	member	1	234547_at	 1.70E---04	 5.42E---05	 11.485429		 	234612_at	 4.52E---04	 2.26E---04	 14.251362		 	234613_at	 9.39E---06	 5.39E---07	 45.064644		 	234673_at	 4.63E---06	 1.63E---07	 33.47462	 HHLA2	 HERV---H	LTR---associating	2	234702_x_at	 6.71E---04	 3.83E---04	 18.422346	 CFTR	 cystic	fibrosis	transmembrane	conductance	regulator	(ATP---binding	cassette	sub---	family	C,	member	7)	234706_x_at	 1.87E---04	 6.34E---05	 27.979406	 AC000111.3///OTT	NULL///NULL	234783_at	 1.58E---04	 4.93E---05	 16.910969		 	234794_at	 0.002121273	 0.00172566	 11.047991		 	234932_s_at	 9.54E---05	 2.38E---05	 13.7294235	 CDCP1	 CUB	domain	containing	protein	1	234940_s_at	 1.63E---06	 1.14E---08	 86.07231	 OTTHUMG0000015	NULL///NULL	234971_x_at	 6.37E---04	 3.55E---04	 10.438281	 PLCD3	 phospholipase	C,	delta	3	235094_at	 0.003847102	 0.003522452	 12.47159		 	235213_at	 0.003692318	 0.003355803	 9.387317	 ITPKB	 inositol---trisphosphate	3---kinase	B	235247_at	 3.14E---05	 4.55E---06	 21.734371		 	235315_at	 1.00E---04	 2.58E---05	 18.20525	 TSC22D1	 TSC22	domain	family,	member	1	235324_at	 7.65E---04	 4.63E---04	 9.841036	 SRSF3	 serine/arginine---rich	splicing	factor	3	235329_at	 0.004208155	 0.00389565	 9.186983	 NOXO1	 NADPH	oxidase	organizer	1	235515_at	 0.00580131	 0.00560059	 18.300842	 SYNE4	 spectrin	repeat	containing,	nuclear	envelope	family	member	4	235525_at	 0.003847102	 0.003520892	 12.7906		 	235527_at	 0.005976538	 0.005790419	 14.766477	 DLGAP1	 discs,	large	(Drosophila)	homolog---associated	protein	1	235546_at	 0.003652867	 0.003316865	 11.080208	 SPINT1	 serine	peptidase	inhibitor,	Kunitz	type	1	235663_at	 3.77E---04	 1.73E---04	 13.434085		 	235736_at	 0.003617597	 0.003278733	 13.466194	 SMKR1	 small	lysine---rich	protein	1	235774_at	 4.62E---06	 1.48E---07	 27.906317	 LOC100422737	 uncharacterized	LOC100422737	235775_at	 0.003141942	 0.002778697	 14.969998	 TMTC2	 transmembrane	and	tetratricopeptide	repeat	containing	2	235911_at	 1.86E---04	 6.24E---05	 30.698381	MFI2	 antigen	p97	(melanoma	associated)	identified	by	monoclonal	antibodies	133.2	and	96.5	
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	 235988_at	 8.23E---04	 5.12E---04	 13.107081	 GPR110	 G	protein---coupled	receptor	110	235995_at	 6.98E---04	 4.07E---04	 10.392147	 PUM2	 pumilio	homolog	2	(Drosophila)	236075_s_at	 0.00186792	 0.001467539	 12.555516	 AC012146.7///OTT	NULL///NULL	236083_at	 6.07E---04	 3.30E---04	 23.068436	 BCL2L15	 BCL2---like	15	236085_at	 1.81E---04	 5.95E---05	 36.803455	 CAPSL	 calcyphosine---like	236414_at	 0.00187421	 0.001478021	 13.7446785		 	236489_at	 0.003090063	 0.002721716	 15.787826	 GPR110	 G	protein---coupled	receptor	110	236513_at	 4.26E---04	 2.05E---04	 40.926456		 	236551_at	 1.00E---04	 2.59E---05	 9.219437	 ZNF311	 zinc	finger	protein	311	236636_at	 8.96E---05	 2.14E---05	 11.364258		 	236637_at	 2.12E---04	 7.69E---05	 10.598813	 TAS2R14	 taste	receptor,	type	2,	member	14	236666_s_at	 0.004834679	 0.004559414	 12.453005	 LRRC10B	 leucine	rich	repeat	containing	10B	236909_at	 5.26E---06	 2.15E---07	 50.203876	 CCDC173	 coiled---coil	domain	containing	173	236938_at	 0.002517324	 0.002113702	 15.7298975		 	236952_at	 9.44E---06	 5.50E---07	 11.899035		 	236960_at	 9.31E---05	 2.28E---05	 9.659253		 	237087_at	 1.99E---04	 6.95E---05	 11.291783		 	237137_at	 0.001182302	 8.26E---04	 11.996122	 SCARNA2	 small	Cajal	body---specific	RNA	2	237216_at	 0.008027392	 0.007993521	 13.522857		 	237238_at	 0.001107518	 7.54E---04	 10.366672	WWC1	 WW	and	C2	domain	containing	1	237272_at	 6.31E---05	 1.36E---05	 16.432991	 LOC100506907	 uncharacterized	LOC100506907	237328_at	 0.001524796	 0.001124618	 20.05386	 C14orf105	 chromosome	14	open	reading	frame	105	237369_at	 6.76E---04	 3.89E---04	 20.56959		 	237420_at	 0.005182798	 0.004933498	 11.317534	 ODF2L	 outer	dense	fiber	of	sperm	tails	2---like	237639_at	 4.76E---04	 2.42E---04	 12.045369	 TMEM207	 transmembrane	protein	207	237656_at	 6.45E---04	 3.62E---04	 10.6296015	WWC2	 WW	and	C2	domain	containing	2	237697_at	 5.48E---04	 2.93E---04	 10.465488	 LOC100506403///	 uncharacterized	LOC100506403///runt---related	transcription	factor	1	237795_s_at	 3.17E---04	 1.35E---04	 11.799117	 SP2	 Sp2	transcription	factor	237804_at	 4.08E---05	 7.09E---06	 51.122284	 DNAH11	 dynein,	axonemal,	heavy	chain	11	237812_at	 0.002317098	 0.00191625	 9.328435	 AC004009.1///OTT	NULL///NULL	237851_at	 8.58E---04	 5.38E---04	 9.969121		 	237860_at	 0.002096211	 0.001696428	 16.415071	 RBMS3	 RNA	binding	motif,	single	stranded	interacting	protein	3	237888_at	 7.56E---04	 4.54E---04	 47.585297	 LOC100422737	 uncharacterized	LOC100422737	237889_s_at	 2.39E---06	 5.03E---08	 70.900276	 LOC100422737	 uncharacterized	LOC100422737	238157_at	 6.60E---04	 3.76E---04	 30.747192		 	238276_at	 0.001849044	 0.001443347	 12.281342		 	238344_at	 3.99E---04	 1.89E---04	 13.018753		 	238458_at	 0.005432257	 0.005184711	 11.384384	MICU3	 mitochondrial	calcium	uptake	family,	member	3	238470_at	 9.08E---04	 5.83E---04	 12.180815	 SYS1	 SYS1	Golgi---localized	integral	membrane	protein	homolog	(S.	cerevisiae)	238567_at	 0.004443804	 0.00414005	 19.26131	 SGPP2	 sphingosine---1---phosphate	phosphatase	2	238584_at	 0.004820192	 0.004535455	 11.090679	 IQCA1	 IQ	motif	containing	with	AAA	domain	1	238626_at	 0.00310773	 0.002740572	 10.041104	 ANKS6	 ankyrin	repeat	and	sterile	alpha	motif	domain	containing	6	238689_at	 0.001591397	 0.001187169	 10.182427	 GPR110	 G	protein---coupled	receptor	110	238718_at	 0.005753064	 0.005539448	 10.997554		 	238750_at	 2.07E---05	 2.34E---06	 22.700378	 CCL28	 chemokine	(C---C	motif)	ligand	28	238771_at	 7.28E---04	 4.28E---04	 11.415668		 	238786_at	 8.31E---04	 5.19E---04	 20.096943	 ANK3	 ankyrin	3,	node	of	Ranvier	(ankyrin	G)	238843_at	 0.003485563	 0.003135536	 11.395241	 NPHP1	 nephronophthisis	1	(juvenile)	238844_s_at	 0.002072633	 0.001672098	 21.439987	 NPHP1	 nephronophthisis	1	(juvenile)	238861_at	 0.003612693	 0.003268191	 14.344231	 SSBP2	 single---stranded	DNA	binding	protein	2	238986_at	 0.00830324	 0.008296233	 12.274752	 FLJ43663	 uncharacterized	LOC378805	239171_at	 3.67E---04	 1.66E---04	 16.798512		 	239192_at	 0.005063573	 0.004802917	 10.344479	 PARD3B	 par---3	partitioning	defective	3	homolog	B	(C.	elegans)	239421_at	 0.005029314	 0.004766177	 10.256429	 DLGAP1---AS1	 DLGAP1	antisense	RNA	1	239464_at	 1.86E---05	 1.85E---06	 35.63852		 	239657_x_at	 2.40E---05	 3.13E---06	 62.475414	 FOXO6///FOXO6	 forkhead	box	O6///NULL	239704_at	 0.001435297	 0.001042861	 12.91507	 RNF144B	 ring	finger	protein	144B	239713_at	 4.99E---04	 2.57E---04	 9.852018	 CASC2	 cancer	susceptibility	candidate	2	(non---protein	coding)	239726_at	 5.62E---06	 2.42E---07	 11.624519	 ANK3	 ankyrin	3,	node	of	Ranvier	(ankyrin	G)	239746_at	 0.008275781	 0.008261813	 11.113466	MESDC2	 mesoderm	development	candidate	2	239837_at	 2.04E---04	 7.22E---05	 11.898371	 ADAM11	 ADAM	metallopeptidase	domain	11	239924_at	 1.99E---04	 6.92E---05	 10.768611	 GUSBP11	 glucuronidase,	beta	pseudogene	11	239928_at	 0.004805443	 0.004509412	 11.189949	 TCTN2	 tectonic	family	member	2	239936_at	 0.007574581	 0.00751066	 9.161222	 DLEU2	 deleted	in	lymphocytic	leukemia	2	(non---protein	coding)	239994_at	 2.78E---05	 3.80E---06	 12.033568		 	240072_at	 0.003043942	 0.002668908	 11.132172	 ASXL2	 additional	sex	combs	like	2	(Drosophila)	240112_at	 2.30E---04	 8.67E---05	 11.6778555		 	240245_at	 0.001675668	 0.001267003	 10.643582		 	240270_x_at	 3.88E---04	 1.79E---04	 13.495025		 	240356_s_at	 0.001171411	 8.15E---04	 13.559552		 	240365_at	 0.005703221	 0.00548183	 10.683062	 LINC00669	 long	intergenic	non---protein	coding	RNA	669	240414_at	 0.001987287	 0.001584798	 11.738828		 	240471_at	 9.23E---04	 5.98E---04	 9.18334		 	240584_at	 0.002728534	 0.002350914	 9.3332815	 SHANK2---AS2///SH	SHANK2	antisense	RNA	2///NULL	240656_at	 0.002806285	 0.00243685	 14.790627		 	240828_at	 0.003239705	 0.002873359	 10.234536	 JARID2---AS1	 JARID2	antisense	RNA	1	240927_at	 3.55E---04	 1.58E---04	 13.061043		 	240935_at	 2.04E---04	 7.22E---05	 31.853796		 	241397_at	 9.04E---04	 5.80E---04	 10.049128		 	241481_at	 0.00479763	 0.004496902	 9.346114	 FAM81A	 family	with	sequence	similarity	81,	member	A	241628_at	 0.003090063	 0.002722385	 9.4058275		 	241631_at	 0.001346301	 9.60E---04	 15.965557	 ARHGEF40	 Rho	guanine	nucleotide	exchange	factor	(GEF)	40	241713_s_at	 0.001185424	 8.30E---04	 56.11458	 DYX1C1///DYX1C1	dyslexia	susceptibility	1	candidate	1///DYX1C1---CCPG1	readthrough	(NMD	candidate)	241747_s_at	 8.79E---04	 5.59E---04	 11.338421	 CUL7	 cullin	7	242013_at	 0.001297293	 9.20E---04	 14.989882	 BCL2L15	 BCL2---like	15	242038_at	 0.002228468	 0.001824147	 12.781484	 LRRC8B	 leucine	rich	repeat	containing	8	family,	member	B	242045_at	 0.006567651	 0.006417054	 12.8510685		 	242057_at	 0.001507134	 0.001109047	 9.150752		 	242080_at	 3.99E---04	 1.88E---04	 9.678622		 	242098_at	 8.38E---04	 5.23E---04	 9.346645	 KIAA1244	 KIAA1244	242228_at	 0.00422257	 0.003912558	 10.050408		 	242319_at	 2.30E---04	 8.63E---05	 11.932533	 DGKG	 diacylglycerol	kinase,	gamma	90kDa	242322_at	 1.52E---04	 4.64E---05	 15.300788		 	242372_s_at	 0.00162743	 0.001223663	 17.594627	MFSD4	 major	facilitator	superfamily	domain	containing	4	242405_at	 6.53E---06	 3.00E---07	 17.74782		 	242544_x_at	 0.00100579	 6.65E---04	 17.851545		 	242572_at	 0.00148059	 0.001083267	 11.694415		 	242773_at	 4.45E---05	 8.04E---06	 31.29685	 SLC5A1	 solute	carrier	family	5	(sodium/glucose	cotransporter),	member	1	242774_at	 2.05E---05	 2.21E---06	 17.87066	 SYNE2	 spectrin	repeat	containing,	nuclear	envelope	2	242798_at	 0.003784469	 0.003445942	 10.293033	 AL773604.8///OTT	NULL///NULL	242801_at	 6.77E---04	 3.92E---04	 17.021389		 	242820_at	 0.007983767	 0.007943342	 9.325976		 	242827_x_at	 9.35E---06	 5.29E---07	 19.403103		 	242874_at	 5.61E---04	 3.01E---04	 11.065356	 OTTHUMG0000017	NULL///NULL	242916_at	 8.31E---04	 5.18E---04	 14.582943	 CNTRL	 centriolin	243010_at	 4.26E---04	 2.05E---04	 9.827557	MSI2	 musashi	RNA---binding	protein	2	243037_at	 0.006839373	 0.006729712	 9.9949045		 	243082_at	 0.002882273	 0.002517428	 10.346411		 	243198_at	 0.003591908	 0.003246358	 12.311801	 TEX9	 testis	expressed	9	243349_at	 4.86E---04	 2.49E---04	 18.975801	 KIAA1324	 KIAA1324	243386_at	 9.54E---05	 2.35E---05	 19.112347	 CASZ1	 castor	zinc	finger	1	243429_at	 0.001525754	 0.001126612	 9.2018175		 	243563_at	 0.007286889	 0.007219247	 15.374826		 	243579_at	 4.53E---05	 8.26E---06	 12.4680805	 MSI2	 musashi	RNA---binding	protein	2	
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	 243693_at	 3.59E---04	 1.61E---04	 10.243996		 	243896_at	 6.38E---04	 3.56E---04	 16.640202	WDR96	 WD	repeat	domain	96	244050_at	 0.002749993	 0.002374044	 11.038347	 PTPLAD2	 protein	tyrosine	phosphatase---like	A	domain	containing	2	244240_at	 0.004436554	 0.004129552	 12.601256		 	244278_at	 0.002599844	 0.002202737	 9.254769	 OTTHUMG0000017	NULL///NULL	244333_at	 5.77E---04	 3.10E---04	 15.108922		 	244363_at	 0.001713679	 0.001302975	 9.870069	 ROS1	 c---ros	oncogene	1	,	receptor	tyrosine	kinase	244469_at	 0.001802416	 0.00137805	 10.895751		 	244478_at	 1.44E---04	 4.30E---05	 13.774608	 LRRC37A3	 leucine	rich	repeat	containing	37,	member	A3	244527_at	 0.002108302	 0.001709771	 11.138928	 TRIO	 trio	Rho	guanine	nucleotide	exchange	factor	244568_at	 0.002650978	 0.002255009	 14.348578		 	244575_at	 4.48E---04	 2.22E---04	 14.829588	 POLA2	 polymerase	(DNA	directed),	alpha	2,	accessory	subunit	244593_at	 2.76E---05	 3.75E---06	 17.163343	 HID1	 HID1	domain	containing	244626_at	 0.00211897	 0.001721999	 32.04564		 	244646_at	 0.003049827	 0.002676641	 15.314977		 	244780_at	 0.00573544	 0.005517639	 14.648462	 SGPP2	 sphingosine---1---phosphate	phosphatase	2	244838_at	 4.83E---05	 9.09E---06	 12.449867		 	1552325_at	 5.26E---06	 2.09E---07	 18.551413	 CCDC11	 coiled---coil	domain	containing	11	1552389_at	 4.44E---05	 7.95E---06	 13.073278	 C8orf47	 chromosome	8	open	reading	frame	47	1552596_at	 0.002643442	 0.002244137	 9.412173	 GAS2L2	 growth	arrest---specific	2	like	2	1552769_at	 0.001087635	 7.39E---04	 10.381464	 ZNF625	 zinc	finger	protein	625	1552848_a_at	 1.11E---05	 7.17E---07	 9.857122	 PTCHD1	 patched	domain	containing	1	1552858_at	 0.00693829	 0.006838754	 12.086302	MAGEB6	 melanoma	antigen	family	B,	6	1564757_a_at	 7.39E---04	 4.40E---04	 11.056455	 CCDC148	 coiled---coil	domain	containing	148	1553081_at	 0.004766739	 0.004461024	 11.104801	WFDC12	 WAP	four---disulfide	core	domain	12	1553163_at	 5.48E---04	 2.92E---04	 9.467901	 ADPRHL1	 ADP---ribosylhydrolase	like	1	1553194_at	 1.92E---04	 6.62E---05	 21.974987	 NEGR1	 neuronal	growth	regulator	1	1553574_at	 2.43E---04	 9.44E---05	 11.379251	 IFNE	 interferon,	epsilon	1553625_at	 0.004173239	 0.003856284	 9.936452	 FAM98B	 family	with	sequence	similarity	98,	member	B	1553710_at	 0.001870152	 0.001472342	 15.143964	 FAM218A	 family	with	sequence	similarity	218,	member	A	1553809_a_at	 9.13E---04	 5.88E---04	 9.474896	 TMEM252	 transmembrane	protein	252	1553812_at	 1.63E---06	 1.25E---08	 30.923784	 TLE6	 transducin---like	enhancer	of	split	6	(E(sp1)	homolog,	Drosophila)	1554113_a_at	 6.46E---04	 3.64E---04	 13.40821	 SLC4A8	 solute	carrier	family	4,	sodium	bicarbonate	cotransporter,	member	8	1554188_at	 0.001497732	 0.001099088	 9.381889	 C11orf53	 chromosome	11	open	reading	frame	53	1554256_a_at	 4.63E---06	 1.62E---07	 52.06049	 PCNXL2	 pecanex---like	2	(Drosophila)	1554261_at	 5.16E---04	 2.69E---04	 10.428659	 KLHL29	 kelch---like	family	member	29	1554271_a_at	 0.001180905	 8.24E---04	 21.225235	 CENPL	 centromere	protein	L	1554506_x_at	 1.76E---04	 5.75E---05	 18.92844	 NAALAD2	 N---acetylated	alpha---linked	acidic	dipeptidase	2	1554513_s_at	 2.07E---05	 2.37E---06	 10.45751	 CEP89	 centrosomal	protein	89kDa	1554522_at	 0.002651433	 0.00226153	 10.004256	 CNNM2	 cyclin	M2	1554547_at	 7.72E---04	 4.74E---04	 9.325613	 FAM13C	 family	with	sequence	similarity	13,	member	C	1554677_s_at	 0.001227222	 8.64E---04	 10.969522	 CMTM4	 CKLF---like	MARVEL	transmembrane	domain	containing	4	1554694_at	 0.00338032	 0.003020894	 11.21627	 CCNY	 cyclin	Y	1554813_at	 0.003847102	 0.003513295	 10.63067		 	1554912_at	 0.006235969	 0.006078097	 13.057538	 ESYT3	 extended	synaptotagmin---like	protein	3	1555002_at	 0.001827313	 0.00141449	 14.612737	MGC39545	 uncharacterized	LOC403312	1555038_at	 0.002810376	 0.002442774	 18.860676	 EPB41L4A	 erythrocyte	membrane	protein	band	4.1	like	4A	1555039_a_at	 9.57E---05	 2.41E---05	 15.433027	 ABCC4	 ATP---binding	cassette,	sub---family	C	(CFTR/MRP),	member	4	1555052_a_at	 0.001439486	 0.00104712	 22.454824	 SYT9	 synaptotagmin	IX	1555053_at	 0.005642525	 0.005409206	 9.518323	 SYT9	 synaptotagmin	IX	1555203_s_at	 9.75E---04	 6.38E---04	 11.1498575	 SLC44A4	 solute	carrier	family	44,	member	4	1555277_a_at	 5.60E---05	 1.13E---05	 10.192579	 SLC4A5	 solute	carrier	family	4,	sodium	bicarbonate	cotransporter,	member	5	1555383_a_at	 4.31E---05	 7.61E---06	 115.66774	 POF1B	 premature	ovarian	failure,	1B	1555392_at	 7.16E---04	 4.21E---04	 15.874092		 	1555397_at	 0.001185424	 8.30E---04	 10.365807	MYO1D	 myosin	ID	1555400_at	 0.006012787	 0.005840269	 9.693525	 LOC645261	 PP565	1555407_s_at	 2.07E---05	 2.38E---06	 9.684505	 FGD3	 FYVE,	RhoGEF	and	PH	domain	containing	3	1555650_at	 1.50E---05	 1.35E---06	 17.823742	 KLHL17	 kelch---like	family	member	17	1555724_s_at	 1.32E---04	 3.82E---05	 10.624196	 TAGLN	 transgelin	1555731_a_at	 3.14E---05	 4.52E---06	 21.483456	 AP1S3	 adaptor---related	protein	complex	1,	sigma	3	subunit	1555733_s_at	 9.84E---05	 2.51E---05	 33.109776	 AP1S3	 adaptor---related	protein	complex	1,	sigma	3	subunit	1555734_x_at	 1.54E---04	 4.75E---05	 11.401026	 AP1S3	 adaptor---related	protein	complex	1,	sigma	3	subunit	1556014_at	 2.94E---04	 1.22E---04	 9.637482	MESP2	 mesoderm	posterior	2	homolog	(mouse)	1556017_at	 0.001936153	 0.001537485	 10.015839	 NBEAL2	 neurobeachin---like	2	1556425_a_at	 0.001465374	 0.001068425	 14.691621	 LOC284219	 uncharacterized	LOC284219	1556653_at	 0.001830152	 0.00142135	 12.376773	 ANKAR	 ankyrin	and	armadillo	repeat	containing	1556889_s_at	 1.04E---04	 2.76E---05	 23.787687		 	1556894_at	 1.11E---05	 7.23E---07	 17.713064	 NT5DC2	 5'---nucleotidase	domain	containing	2	1556937_at	 0.002802702	 0.002431374	 10.05778		 	1557176_a_at	 2.49E---04	 9.72E---05	 42.679096	 C14orf37	 chromosome	14	open	reading	frame	37	1557350_at	 0.003017606	 0.00264327	 9.604865	 G3BP1	 GTPase	activating	protein	(SH3	domain)	binding	protein	1	1557680_at	 3.46E---04	 1.51E---04	 42.46066	 SAMD15	 sterile	alpha	motif	domain	containing	15	1557700_at	 2.11E---04	 7.65E---05	 15.843484	 POLH	 polymerase	(DNA	directed),	eta	1557803_at	 0.002070559	 0.001666931	 11.420504		 	1558195_at	 0.002799675	 0.002426385	 14.641076	 LINC00592	 long	intergenic	non---protein	coding	RNA	592	1558392_at	 5.03E---05	 9.60E---06	 46.307884	 SYNE2	 spectrin	repeat	containing,	nuclear	envelope	2	1558393_at	 7.67E---04	 4.67E---04	 13.960542	 KRT7	 keratin	7	1558525_at	 0.001911118	 0.001512284	 10.396356		 	1558839_at	 0.008065201	 0.008037977	 13.377173	MAPKBP1	 mitogen---activated	protein	kinase	binding	protein	1	1558953_s_at	 5.03E---05	 9.60E---06	 9.487525	 CEP164	 centrosomal	protein	164kDa	1559109_a_at	 3.71E---04	 1.68E---04	 15.283865	 LOC100996816///	 uncharacterized	LOC100996816///vacuolar	protein	sorting	53	homolog	(S.	cerevisiae)	1559296_at	 6.14E---04	 3.38E---04	 12.062514	 ADAMTS9---AS2	 ADAMTS9	antisense	RNA	2	1559347_at	 0.005547425	 0.005313357	 9.41536		 	1559360_at	 0.002660707	 0.002276191	 10.067954		 	1559400_s_at	 2.03E---04	 7.15E---05	 29.773304	 PAPPA	 pregnancy---associated	plasma	protein	A,	pappalysin	1	1559405_a_at	 0.001038575	 6.93E---04	 10.002368	 TRPV6	 transient	receptor	potential	cation	channel,	subfamily	V,	member	6	1559882_at	 0.002230318	 0.001829425	 12.721977	 SAMHD1	 SAM	domain	and	HD	domain	1	1559990_at	 0.002085611	 0.001684329	 12.545151		 	1560019_at	 2.19E---04	 7.99E---05	 12.08872	 DLGAP1---AS2	 DLGAP1	antisense	RNA	2	1560063_a_at	 0.003528022	 0.003185641	 13.579546	 CTD---2540F13.2///	NULL///NULL	1560101_at	 0.004051597	 0.003730204	 12.082341	 SYDE2	 synapse	defective	1,	Rho	GTPase,	homolog	2	(C.	elegans)	1560149_at	 0.002326381	 0.00192589	 9.593785	 SLC29A2	 solute	carrier	family	29	(nucleoside	transporters),	member	2	1560156_at	 3.34E---04	 1.44E---04	 15.79455	 OTTHUMG0000016	NULL///NULL	1560340_s_at	 0.004117552	 0.003801352	 32.39228	 RP9P	 retinitis	pigmentosa	9	pseudogene	1560419_at	 4.02E---04	 1.92E---04	 10.623244	 LOC100127974	 uncharacterized	LOC100127974	1560430_at	 6.48E---04	 3.66E---04	 15.414474	 NKPD1	 NTPase,	KAP	family	P---loop	domain	containing	1	1560458_s_at	 1.04E---04	 2.72E---05	 13.319516	 CAPS2	 calcyphosine	2	1560696_x_at	 0.002655935	 0.002268191	 9.845674	 QTRTD1	 queuine	tRNA---ribosyltransferase	domain	containing	1	1560834_a_at	 5.44E---04	 2.88E---04	 13.623179	 RMST	 rhabdomyosarcoma	2	associated	transcript	(non---protein	coding)	1560899_at	 2.37E---05	 3.06E---06	 15.292304		 	1560998_x_at	 0.005703221	 0.005477401	 9.988319		 	1561149_at	 0.001505482	 0.001106561	 17.155903		 	1561316_at	 0.003917941	 0.003593925	 10.442309	 GABRB3	 gamma---aminobutyric	acid	(GABA)	A	receptor,	beta	3	1561467_at	 6.12E---04	 3.36E---04	 12.1520195		 	1561504_s_at	 0.003341766	 0.002976238	 12.441745	MYLK4	 myosin	light	chain	kinase	family,	member	4	1561633_at	 6.77E---04	 3.91E---04	 9.989858	 HMGA2	 high	mobility	group	AT---hook	2	1561713_at	 0.006750693	 0.00661397	 10.26809	 CTD---2076M15.1///	NULL///NULL	1561867_at	 5.10E---04	 2.64E---04	 11.134578		 	1562019_at	 0.007774426	 0.007721941	 9.414624	 NT5DC4	 5'---nucleotidase	domain	containing	4	1562022_s_at	 0.006990561	 0.006896174	 11.523403	 LOC100130987///	 uncharacterized	LOC100130987///RAD9	homolog	A	(S.	pombe)	1562049_at	 1.37E---04	 4.00E---05	 21.877703	 AC013275.2///OTT	NULL///NULL	1562074_a_at	 4.62E---04	 2.32E---04	 47.16255	 UNC13C	 unc---13	homolog	C	(C.	elegans)	1562222_at	 4.99E---04	 2.56E---04	 9.723425	 OTTHUMG0000017	NULL///NULL	1562332_at	 0.001997729	 0.001596498	 12.006876		 	
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	 1562378_s_at	 6.04E---05	 1.28E---05	 33.20028	 PROM2	 prominin	2	1566152_a_at	 0.001911118	 0.001512767	 9.629547	 AP000662.4///OTT	NULL///NULL	1562632_at	 3.88E---05	 6.28E---06	 10.105089	 LOC285191	 uncharacterized	LOC285191	1562637_at	 0.001382088	 9.93E---04	 16.084953	 SAMD12	 sterile	alpha	motif	domain	containing	12	1562788_at	 0.001192286	 8.36E---04	 10.069833	 LOC254099	 uncharacterized	LOC254099	1562970_at	 0.003644211	 0.00330593	 10.097459		 	1563092_at	 0.001408882	 0.001017724	 16.658587	 OTTHUMG0000017	NULL///NULL	1563597_at	 9.54E---05	 2.37E---05	 15.6376295		 	1563776_at	 3.43E---04	 1.48E---04	 10.463311	 LOC100507283	 uncharacterized	LOC100507283	1563946_at	 1.10E---04	 2.97E---05	 14.0125475		 	1564000_at	 6.49E---04	 3.68E---04	 12.908135	 ANKRD31	 ankyrin	repeat	domain	31	1564077_at	 3.75E---04	 1.71E---04	 13.26066		 	1564192_at	 6.41E---04	 3.59E---04	 10.7572365		 	1564276_at	 4.63E---06	 1.64E---07	 17.425608	 C5orf56	 chromosome	5	open	reading	frame	56	1564295_at	 3.48E---04	 1.52E---04	 11.847257	 FLJ25917	 uncharacterized	LOC401585	1564466_at	 0.001578177	 0.001173312	 10.788683	 FLJ37644	 uncharacterized	LOC400618	1564819_at	 4.34E---04	 2.12E---04	 11.385895	 OTTHUMG0000016	NULL///NULL	1565662_at	 1.48E---04	 4.42E---05	 9.451534		 	1565666_s_at	 2.14E---05	 2.55E---06	 10.190565	MUC6	 mucin	6,	oligomeric	mucus/gel---forming	1565685_at	 4.32E---04	 2.10E---04	 17.00032	 LOC400940	 uncharacterized	LOC400940	1565716_at	 0.001171411	 8.12E---04	 9.432322	 FUS	 fused	in	sarcoma	1565737_at	 0.002884027	 0.002521394	 9.52948	 SCTR	 secretin	receptor	1565846_at	 0.004814343	 0.004525889	 9.318266		 	1565929_s_at	 0.002650978	 0.002254014	 9.304388		 	1566439_at	 1.32E---04	 3.82E---05	 32.919643		 	1566868_at	 0.001830152	 0.001425078	 12.47608		 	1566950_at	 1.07E---04	 2.86E---05	 13.324545		 	1567237_at	 0.001132926	 7.76E---04	 12.237158	 OR2L2	 olfactory	receptor,	family	2,	subfamily	L,	member	2	1567361_at	 0.004113578	 0.00379074	 13.852781	 BDNF---AS	 BDNF	antisense	RNA	1568574_x_at	 2.06E---06	 3.91E---08	 47.452972	 SPP1	 secreted	phosphoprotein	1	1568713_a_at	 0.004884684	 0.004616747	 13.271148	 TBC1D1	 TBC1	(tre---2/USP6,	BUB2,	cdc16)	domain	family,	member	1	1568720_at	 1.36E---05	 1.06E---06	 26.150497	 ZNF506	 zinc	finger	protein	506	1568736_s_at	 0.002440755	 0.00204735	 16.856682		 	1569098_s_at	 2.83E---05	 3.89E---06	 9.370172	 TP53BP1	 tumor	protein	p53	binding	protein	1	1569128_at	 4.43E---04	 2.19E---04	 23.810427	 C3orf38	 chromosome	3	open	reading	frame	38	1569230_at	 0.001176654	 8.20E---04	 9.475482		 	1569310_at	 3.58E---04	 1.60E---04	 16.074282	 IRGQ	 immunity---related	GTPase	family,	Q	1569512_at	 8.69E---04	 5.48E---04	 21.998262		 	1569596_at	 7.56E---04	 4.55E---04	 25.480385		 	1569652_at	 0.002660707	 0.002276757	 12.115336	MLLT3	 myeloid/lymphoid	or	mixed---lineage	leukemia	(trithorax	homolog,	Drosophila);	translocated	to,	3	1569794_at	 7.39E---04	 4.38E---04	 13.14039	 OTTHUMG0000003	NULL///NULL	1569818_at	 2.09E---04	 7.53E---05	 14.949877		 	1569916_at	 0.002384406	 0.001985999	 13.731745		 	1569980_x_at	 0.001812842	 0.001394	 11.6297	 HKR1///LOC10050	HKR1,	GLI---Kruppel	zinc	finger	family	member///uncharacterized	LOC100507342	1570050_at	 0.002530895	 0.002131505	 12.0527		 	1570057_x_at	 4.99E---04	 2.56E---04	 23.865248		 	1570181_a_at	 2.06E---06	 3.52E---08	 56.839527		 	1570284_x_at	 0.001261955	 8.91E---04	 10.066106		 	1570393_at	 0.001214765	 8.54E---04	 32.806366	 EML5	 echinoderm	microtubule	associated	protein	like	5		
Monkey	liver	zone	I	signature		 Probe	Set	ID	 Corrected	p---value	 p---value	 FCAbsolute	 Gene	Symbol	 Gene	Title	201929_s_at	 1.60E---04	 1.16E---04	 2.0226698	PKP4	 plakophilin	4	202668_at	 2.76E---06	 5.53E---07	 4.160641	EFNB2	 ephrin---B2	203017_s_at	 0.000132694	 9.05E---05	 3.1553092	SSX2IP	 synovial	sarcoma,	X	breakpoint	2	interacting	protein	203238_s_at	 0.00026628	 2.39E---04	 5.9945574	NOTCH3	 notch	3	203355_s_at	 1.09482E---06	 1.62179E---07	 2.4077823	PSD3	 pleckstrin	and	Sec7	domain	containing	3	203373_at	 3.72E---05	 1.65E---05	 2.1142237	SOCS2	 suppressor	of	cytokine	signaling	2	204608_at	 1.55E---05	 5.03E---06	 2.2172706	ASL	 argininosuccinate	lyase	204836_at	 4.74947E---06	 1.22E---06	 2.3754406	GLDC	 glycine	dehydrogenase	(decarboxylating)	204948_s_at	 0.000125069	 8.42E---05	 2.8610394	FST	 follistatin	205502_at	 6.94709E---08	 4.93801E---09	 2.5972629	CYP17A1	 cytochrome	P450,	family	17,	subfamily	A,	polypeptide	1	205531_s_at	 4.24E---08	 2.45E---09	 11.614553	GLS2	 glutaminase	2	(liver,	mitochondrial)	205695_at	 3.09E---05	 1.25E---05	 3.816197	SDS	 serine	dehydratase	206643_at	 0.000224802	 1.84E---04	 7.8267226	HAL	 histidine	ammonia---lyase	206867_at	 8.50204E---05	 5.20E---05	 2.1786163	GCKR	 glucokinase	(hexokinase	4)	regulator	207076_s_at	 6.09225E---08	 3.77619E---09	 2.3339326	ASS1	 argininosuccinate	synthase	1	207192_at	 1.81E---04	 1.36E---04	 3.3498814	DNASE1L2	 deoxyribonuclease	I---like	2	207626_s_at	 1.73E---05	 5.92E---06	 2.7783868	SLC7A2	 solute	carrier	family	7	(cationic	amino	acid	transporter,	y+	system),	member	2	207732_s_at	 4.76252E---05	 2.50E---05	 3.903643	DLG3	 discs,	large	homolog	3	(Drosophila)	208078_s_at	 0.000114633	 7.58E---05	 2.3262808	SIK1	 salt---inducible	kinase	1	208234_x_at	 5.40444E---05	 3.01487E---05	 5.290659	FGFR2	 fibroblast	growth	factor	receptor	2	208813_at	 9.02E---06	 2.68E---06	 3.1203167	GOT1	 glutamic---oxaloacetic	transaminase	1,	soluble	209641_s_at	 1.78E---05	 6.18E---06	 4.128098	ABCC3	 ATP---binding	cassette,	sub---family	C	(CFTR/MRP),	member	3	209993_at	 5.58686E---05	 3.16E---05	 4.7021565	ABCB1	 ATP---binding	cassette,	sub---family	B	(MDR/TAP),	member	1	210082_at	 4.0781E---05	 1.89E---05	 3.1807747	ABCA4	 ATP---binding	cassette,	sub---family	A	(ABC1),	member	4	211357_s_at	 2.75764E---05	 1.09394E---05	 2.129223	ALDOB	 aldolase	B,	fructose---bisphosphate	211401_s_at	 6.61E---05	 3.82E---05	 2.1148927	FGFR2	 fibroblast	growth	factor	receptor	2	211652_s_at	 4.61E---05	 2.38E---05	 2.853481	LBP	 lipopolysaccharide	binding	protein	212729_at	 9.62799E---05	 5.93E---05	 2.804292	DLG3	 discs,	large	homolog	3	(Drosophila)	213363_at	 0.000193519	 1.52E---04	 2.248653	CA5BP1	 carbonic	anhydrase	VB	pseudogene	1		213380_x_at	 	 3.23938E---07		 3.61419E---08		 2.0742316	LOC101060347///	MST1///MST1L//	/MST1P2	 hepatocyte	growth	factor---like	protein---like///macrophage	stimulating	1	(hepatocyte	growth	factor---like)///macrophage	stimulating	1---like///macrophage	stimulating	1	(hepatocyte	growth	factor---like)	pseudogene	2	214423_x_at	 6.09E---09	 1.75E---10	 2.4237053	ALDOB	 aldolase	B,	fructose---bisphosphate	214424_s_at	 6.95E---08	 5.17E---09	 2.5824673	ALDOB	 aldolase	B,	fructose---bisphosphate	214535_s_at	 0.000107263	 6.91E---05	 4.3361683	ADAMTS2	 ADAM	metallopeptidase	with	thrombospondin	type	1	motif,	2	215387_x_at	 5.17509E---06	 1.35E---06	 2.092774		 	216320_x_at	 2.45169E---07	 2.63405E---08	 2.0353086	MST1	 macrophage	stimulating	1	(hepatocyte	growth	factor---like)	216600_x_at	 1.70E---08	 7.03E---10	 2.276072	ALDOB	 aldolase	B,	fructose---bisphosphate	217521_at	 2.99E---04	 2.94E---04	 4.6426773	HAL	 histidine	ammonia---lyase	218330_s_at	 0.000185705	 1.44E---04	 2.7302983	NAV2	 neuron	navigator	2	218510_x_at	 2.63715E---05	 1.00E---05	 2.7069287	FAM134B	 family	with	sequence	similarity	134,	member	B	220491_at	 1.68396E---06	 2.71382E---07	 6.357575	HAMP	 hepcidin	antimicrobial	peptide	221008_s_at	 4.01E---05	 1.83E---05	 3.2736363	ETNPPL	 ethanolamine---phosphate	phospho---lyase	221409_at	 2.39E---04	 2.02E---04	 4.589332	OR2S2	 olfactory	receptor,	family	2,	subfamily	S,	member	2	37201_at	 0.000175613	 1.31E---04	 2.928964	ITIH4	 inter---alpha---trypsin	inhibitor	heavy	chain	family,	member	4	223784_at	 3.15504E---05	 1.29E---05	 2.4458632	TMEM27	 transmembrane	protein	27	223946_at	 3.38329E---05	 1.42602E---05	 2.386193	MED23	 mediator	complex	subunit	23	225949_at	 1.41E---04	 9.71E---05	 2.4913821	NRBP2	 nuclear	receptor	binding	protein	2	226847_at	 4.12E---05	 1.93E---05	 2.500492	FST	 follistatin	227217_at	 6.76147E---05	 3.97E---05	 12.520038	WNK2	 WNK	lysine	deficient	protein	kinase	2	227311_at	 0.000207654	 1.66E---04	 3.1206114	SNX25	 sorting	nexin	25	227411_at	 0.00026628	 0.000239835	 2.3511484	WTIP	 Wilms	tumor	1	interacting	protein	229148_at	 2.62E---04	 2.30E---04	 3.9022493		 	229596_at	 1.70E---04	 1.25E---04	 2.458349	AMDHD1	 amidohydrolase	domain	containing	1	229901_at	 0.000141813	 9.84E---05	 3.8694465	ZNF488	 zinc	finger	protein	488	230107_at	 0.000147187	 1.05E---04	 2.6501658		 	230602_at	 0.000131435	 8.90716E---05	 3.3236809	ACMSD	 aminocarboxymuconate	semialdehyde	decarboxylase	230603_at	 2.65E---04	 2.36E---04	 2.9553885	COL27A1	 collagen,	type	XXVII,	alpha	1	230657_at	 1.00E---04	 6.39E---05	 6.214824		 	230658_at	 9.80892E---05	 6.08E---05	 3.9699845	SLC7A2	 solute	carrier	family	7	(cationic	amino	acid	transporter,	y+	system),	member	2	231306_at	 0.000272559	 2.51E---04	 4.062453	LYZL4	 lysozyme---like	4	
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	 231662_at	 2.86436E---06	 5.95014E---07	 3.561257	ARG1	 arginase,	liver	231663_s_at	 3.19E---06	 7.14E---07	 3.8506296	ARG1	 arginase,	liver	231665_at	 3.77E---06	 8.88E---07	 5.0547843	ARG1	 arginase,	liver	231691_at	 4.00928E---05	 1.84E---05	 2.154672	C3P1	 complement	component	3	precursor	pseudogene	232376_at	 0.000254989	 2.23E---04	 5.6355305	PCCA	 propionyl	CoA	carboxylase,	alpha	polypeptide	232573_at	 0.000254989	 0.000222918	 4.594921		 	233514_x_at	 1.85E---04	 1.43E---04	 6.807696	TEX11	 testis	expressed	11	234296_s_at	 6.30E---06	 1.74E---06	 17.898396	TEX11	 testis	expressed	11	234472_at	 2.76246E---06	 5.59E---07	 8.569138	GALNT13	 UDP---N---acetyl---alpha---D---galactosamine:polypeptide	N---	acetylgalactosaminyltransferase	13	(GalNAc---T13)	235453_at	 0.000144341	 1.03E---04	 2.0961618	TOR1AIP2	 torsin	A	interacting	protein	2	235557_at	 0.000272559	 0.00025401	 5.755047	GPAT2	 glycerol---3---phosphate	acyltransferase	2,	mitochondrial	236708_at	 2.90E---04	 2.80E---04	 4.3267956		 	238259_at	 2.74E---04	 2.60E---04	 3.0915186	ADSSL1	 adenylosuccinate	synthase	like	1	238532_at	 0.000184829	 1.42E---04	 2.1110234	DPF3	 D4,	zinc	and	double	PHD	fingers,	family	3	238961_s_at	 0.000218235	 1.78E---04	 2.047418	FNDC3A	 fibronectin	type	III	domain	containing	3A	238984_at	 0.000271766	 0.00024706	 4.584979	REG4	 regenerating	islet---derived	family,	member	4	239278_at	 2.75E---04	 2.62E---04	 5.3486648		 	239733_at	 8.43E---05	 5.12E---05	 4.9863415	DYDC2	 DPY30	domain	containing	2	242168_at	 0.000142078	 9.92E---05	 2.4522848	NDUFS7	 NADH	dehydrogenase	(ubiquinone)	Fe---S	protein	7,	20kDa	(NADH---coenzyme	Q	reductase)	242315_at	 0.000234257	 1.97E---04	 6.2356443		 	242668_x_at	 0.000272559	 0.000257917	 2.5640159	SUN5	 Sad1	and	UNC84	domain	containing	5	242972_at	 3.72E---05	 1.66E---05	 2.2804952	HCG18	 HLA	complex	group	18	(non---protein	coding)	243691_at	 2.65E---04	 2.35E---04	 3.895336		 	1552390_a_at	 0.000231353	 1.91E---04	 10.946081	C8orf47	 chromosome	8	open	reading	frame	47	1555345_at	 3.78679E---05	 1.71E---05	 2.068106	SLC38A4	 solute	carrier	family	38,	member	4	1555898_at	 0.000229671	 0.000188862	 7.213749	ANKRD36C	 ankyrin	repeat	domain	36C		1558449_at	 	 2.55E---04		 2.22E---04		 3.7342243	OTTHUMG000001	77541///RP11---	421E14.2	 	NULL///NULL	1559957_a_at	 3.16E---05	 1.32E---05	 4.435049	LOC642852	 uncharacterized	LOC642852	1564706_s_at	 8.53527E---06	 2.47E---06	 10.846187	GLS2	 glutaminase	2	(liver,	mitochondrial)	1564707_x_at	 3.88026E---06	 9.62E---07	 5.3590403	GLS2	 glutaminase	2	(liver,	mitochondrial)	1564933_at	 4.64099E---05	 2.41638E---05	 6.253354		 		1566108_at	 	 2.88E---04		 2.76E---04		 3.1932533	OTTHUMG000001	84028///RP11---	362K14.5	 	NULL///NULL		
Monkey	liver	zone	III	signature		
Probe	Set	ID	 Corrected	p---value	 p---value	 FCAbsolute	 Gene	Symbol	 Gene	Title	
1431_at	 5.68E---06	 1.52E---06	 2.035073	 CYP2E1	 cytochrome	P450,	family	2,	subfamily	E,	polypeptide	1	
200648_s_at	 4.63E---11	 3.82E---13	 14.877427	 GLUL	 glutamate---ammonia	ligase	
200762_at	 4.33E---05	 2.16E---05	 2.0935678	 DPYSL2	 dihydropyrimidinase---like	2	
200831_s_at	 1.78E---05	 6.34E---06	 3.167257	 SCD	 stearoyl---CoA	desaturase	(delta---9---desaturase)	
200832_s_at	 2.67E---05	 1.04E---05	 3.0721378	 SCD	 stearoyl---CoA	desaturase	(delta---9---desaturase)	
200974_at	 2.73E---04	 2.58E---04	 3.3604124	 ACTA2	 actin,	alpha	2,	smooth	muscle,	aorta	
201116_s_at	 1.58E---07	 1.37E---08	 28.467802	 CPE	 carboxypeptidase	E	
201117_s_at	 1.15E---04	 7.70E---05	 11.10634	 CPE	 carboxypeptidase	E	
201341_at	 6.09E---09	 1.76E---10	 6.427483	 ENC1	 ectodermal---neural	cortex	1	(with	BTB	domain)	
201505_at	 1.49E---05	 4.74E---06	 3.7487588	 LAMB1	 laminin,	beta	1	
201792_at	 5.58E---07	 7.38E---08	 4.9137363	 AEBP1	 AE	binding	protein	1	
201842_s_at	 1.69E---04	 1.24E---04	 9.803346	 EFEMP1	 EGF	containing	fibulin---like	extracellular	matrix	protein	1	
201852_x_at	 1.43E---04	 1.00E---04	 2.0042007	 COL3A1	 collagen,	type	III,	alpha	1	
201893_x_at	 4.24E---08	 2.38E---09	 2.4181	 DCN	 decorin	
202112_at	 4.85E---05	 2.61E---05	 5.5790243	 VWF	 von	Willebrand	factor	
202291_s_at	 2.73E---04	 2.52E---04	 2.7271845	MGP	 matrix	Gla	protein	
202310_s_at	 2.11E---04	 1.69E---04	 3.6278934	 COL1A1	 collagen,	type	I,	alpha	1	
202403_s_at	 7.02E---05	 4.15E---05	 2.4008274	 COL1A2	 collagen,	type	I,	alpha	2	
202478_at	 5.02E---05	 2.74E---05	 2.0922978	 TRIB2	 tribbles	homolog	2	(Drosophila)	
202728_s_at	 6.65E---08	 4.40E---09	 4.3974094	 LTBP1	 latent	transforming	growth	factor	beta	binding	protein	1	
202729_s_at	 9.97E---05	 6.29E---05	 2.980554	 LTBP1	 latent	transforming	growth	factor	beta	binding	protein	1	
202992_at	 2.27E---05	 8.36E---06	 2.8978126	 C7	 complement	component	7	
203088_at	 1.02E---05	 3.10E---06	 5.634558	 FBLN5	 fibulin	5	
203300_x_at	 3.11E---04	 3.11E---04	 2.1585739	 AP1S2	 adaptor---related	protein	complex	1,	sigma	2	subunit	
203424_s_at	 5.42E---05	 3.04E---05	 4.8441024	 IGFBP5	 insulin---like	growth	factor	binding	protein	5	
203476_at	 7.35E---06	 2.10E---06	 8.718351	 TPBG	 trophoblast	glycoprotein	
203666_at	 3.46E---05	 1.47E---05	 2.1706047	 CXCL12	 chemokine	(C---X---C	motif)	ligand	12	
203887_s_at	 1.59E---07	 1.44E---08	 20.653921	 THBD	 thrombomodulin	
203888_at	 2.66E---05	 1.02E---05	 8.692131	 THBD	 thrombomodulin	
204271_s_at	 2.71E---05	 1.07E---05	 2.0230274	 EDNRB	 endothelin	receptor	type	B	
204284_at	 2.54E---04	 2.19E---04	 2.3123982	 PPP1R3C	 protein	phosphatase	1,	regulatory	subunit	3C	
204684_at	 1.40E---09	 1.74E---11	 24.883291	 NPTX1	 neuronal	pentraxin	I	
204971_at	 1.80E---06	 3.20E---07	 5.0787926	 CSTA	 cystatin	A	(stefin	A)	
205243_at	 1.55E---05	 5.07E---06	 11.223402	 SLC13A3	 solute	carrier	family	13	(sodium---dependent	dicarboxylate	transporter),	member	3	
205244_s_at	 1.66E---06	 2.61E---07	 17.454174	 SLC13A3	 solute	carrier	family	13	(sodium---dependent	dicarboxylate	transporter),	member	3	
205430_at	 4.78E---05	 2.53E---05	 2.2563703	 BMP5	 bone	morphogenetic	protein	5	
205549_at	 8.27E---09	 2.73E---10	 126.31053	 PCP4	 Purkinje	cell	protein	4	
205648_at	 1.80E---04	 1.35E---04	 6.2938004	WNT2	 wingless---type	MMTV	integration	site	family	member	2	
205723_at	 2.34E---04	 1.96E---04	 3.4714375	 CNTFR	 ciliary	neurotrophic	factor	receptor	
205923_at	 1.60E---07	 1.65E---08	 2.535016	 RELN	 reelin	
205935_at	 2.76E---06	 5.52E---07	 5.5806346	 FOXF1	 forkhead	box	F1	
205939_at	 2.20E---08	 1.04E---09	 2.479733	 CYP3A7	 cytochrome	P450,	family	3,	subfamily	A,	polypeptide	7	
206049_at	 4.28E---05	 2.08E---05	 5.6925597	 SELP	 selectin	P	(granule	membrane	protein	140kDa,	antigen	CD62)	




206140_at	 4.28E---05	 2.05E---05	 2.967638	 LHX2	 LIM	homeobox	2	
206170_at	 6.50E---05	 3.73E---05	 2.471291	 ADRB2	 adrenoceptor	beta	2,	surface	
206214_at	 2.73E---04	 2.56E---04	 5.6300383	 PLA2G7	 phospholipase	A2,	group	VII	(platelet---activating	factor	acetylhydrolase,	plasma)	
206354_at	 1.03E---06	 1.45E---07	 4.642869	 SLCO1B3	 solute	carrier	organic	anion	transporter	family,	member	1B3	
206440_at	 3.19E---06	 7.04E---07	 2.840402	 LIN7A	 lin---7	homolog	A	(C.	elegans)	
206535_at	 5.02E---05	 2.73E---05	 2.279424	 SLC2A2	 solute	carrier	family	2	(facilitated	glucose	transporter),	member	2	
207420_at	 1.25E---05	 3.93E---06	 3.7526972	 COLEC10	 collectin	sub---family	member	10	(C---type	lectin)	
207486_x_at	 2.73E---04	 2.49E---04	 2.1267917	 CHN2	 chimerin	2	
207608_x_at	 3.88E---06	 9.78E---07	 5.225593	 CYP1A2	 cytochrome	P450,	family	1,	subfamily	A,	polypeptide	2	
208131_s_at	 4.82E---05	 2.57E---05	 5.4147186	 PTGIS	 prostaglandin	I2	(prostacyclin)	synthase	
208335_s_at	 2.90E---04	 2.82E---04	 4.168195	 DARC	 Duffy	blood	group,	chemokine	receptor	
208963_x_at	 8.12E---05	 4.87E---05	 2.7604668	 FADS1///MIR1908	 fatty	acid	desaturase	1///microRNA	1908	
208964_s_at	 2.16E---04	 1.74E---04	 2.63432	 FADS1///MIR1908	 fatty	acid	desaturase	1///microRNA	1908	
208983_s_at	 2.32E---04	 1.93E---04	 2.0008516	 PECAM1	 platelet/endothelial	cell	adhesion	molecule	1	
209014_at	 5.35E---05	 2.96E---05	 2.4107947	MAGED1	 melanoma	antigen	family	D,	1	
209047_at	 2.39E---04	 2.03E---04	 3.70033	 AQP1	 aquaporin	1	(Colton	blood	group)	
209070_s_at	 9.02E---06	 2.68E---06	 3.274502	 RGS5	 regulator	of	G---protein	signaling	5	
209071_s_at	 3.16E---05	 1.31E---05	 2.3304284	 RGS5	 regulator	of	G---protein	signaling	5	
209286_at	 1.68E---05	 5.69E---06	 5.3740406	 CDC42EP3	 CDC42	effector	protein	(Rho	GTPase	binding)	3	
209470_s_at	 1.49E---04	 1.07E---04	 10.591253	 GPM6A	 glycoprotein	M6A	
209505_at	 4.33E---05	 2.15E---05	 2.9830382	 NR2F1	 nuclear	receptor	subfamily	2,	group	F,	member	1	
209687_at	 1.60E---07	 1.63E---08	 4.0524507	 CXCL12	 chemokine	(C---X---C	motif)	ligand	12	
209763_at	 6.67E---05	 3.88E---05	 7.5667996	 CHRDL1	 chordin---like	1	
209909_s_at	 2.73E---04	 2.55E---04	 3.4340563	 TGFB2	 transforming	growth	factor,	beta	2	
209976_s_at	 1.69E---06	 2.79E---07	 2.4294944	 CYP2E1	 cytochrome	P450,	family	2,	subfamily	E,	polypeptide	1	
210139_s_at	 1.41E---04	 9.67E---05	 6.636576	 PMP22	 peripheral	myelin	protein	22	
210353_s_at	 5.68E---06	 1.52E---06	 14.1236	 SLC6A2	 solute	carrier	family	6	(neurotransmitter	transporter,	noradrenalin),	member	2	
211162_x_at	 3.23E---06	 7.48E---07	 3.4691007	 SCD	 stearoyl---CoA	desaturase	(delta---9---desaturase)	
211231_x_at	 2.86E---06	 6.04E---07	 3.1054645	 CYP4A11	 cytochrome	P450,	family	4,	subfamily	A,	polypeptide	11	
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211446_at	 5.19E---05	 2.85E---05	 7.937799	 RGSL1	 regulator	of	G---protein	signaling	like	1	
211651_s_at	 6.85E---06	 1.92E---06	 2.5509596	 LAMB1	 laminin,	beta	1	
211696_x_at	 1.64E---05	 5.50E---06	 2.8153446	 HBB	 hemoglobin,	beta	
211708_s_at	 3.00E---06	 6.45E---07	 3.6494808	 SCD	 stearoyl---CoA	desaturase	(delta---9---desaturase)	
211813_x_at	 1.73E---06	 2.93E---07	 2.3402781	 DCN	 decorin	
211820_x_at	 5.67E---05	 3.23E---05	 3.717114	 GYPA	 glycophorin	A	(MNS	blood	group)	
211896_s_at	 2.36E---04	 1.99E---04	 2.3829098	 DCN	 decorin	
212713_at	 3.46E---05	 1.49E---05	 6.003065	MFAP4	 microfibrillar---associated	protein	4	
213174_at	 1.78E---05	 6.34E---06	 5.2318587	 TTC9	 tetratricopeptide	repeat	domain	9	




213880_at	 3.80E---06	 9.27E---07	 15.47983	 LGR5	 leucine---rich	repeat	containing	G	protein---coupled	receptor	5	
214460_at	 1.98E---06	 3.61E---07	 14.667987	 LSAMP	 limbic	system---associated	membrane	protein	
214622_at	 2.10E---05	 7.54E---06	 2.820437	 CYP21A2	 cytochrome	P450,	family	21,	subfamily	A,	polypeptide	2	
215001_s_at	 6.62E---14	 2.73E---16	 5.6179895	 GLUL	 glutamate---ammonia	ligase	
215241_at	 1.56E---04	 1.12E---04	 4.7711515	 ANO3	 anoctamin	3	




216611_s_at	 2.38E---06	 4.52E---07	 8.573141	 SLC6A2	 solute	carrier	family	6	(neurotransmitter	transporter,	noradrenalin),	member	2	
217202_s_at	 2.41E---09	 4.02E---11	 18.476679	 GLUL	 glutamate---ammonia	ligase	
217213_at	 4.40E---05	 2.24E---05	 9.983754	 SLC6A2	 solute	carrier	family	6	(neurotransmitter	transporter,	noradrenalin),	member	2	
217214_s_at	 1.09E---06	 1.63E---07	 16.480368	 SLC6A2	 solute	carrier	family	6	(neurotransmitter	transporter,	noradrenalin),	member	2	
217232_x_at	 3.19E---06	 7.25E---07	 2.806825	 HBB	 hemoglobin,	beta	
217621_at	 8.12E---05	 4.90E---05	 6.3332825	 SLC6A2	 solute	carrier	family	6	(neurotransmitter	transporter,	noradrenalin),	member	2	
218084_x_at	 9.81E---05	 6.12E---05	 2.1107783	 FXYD5	 FXYD	domain	containing	ion	transport	regulator	5	
218162_at	 2.21E---05	 8.02E---06	 2.429233	 OLFML3	 olfactomedin---like	3	
218332_at	 3.25E---07	 3.90E---08	 2.5156305	 BEX1	 brain	expressed,	X---linked	1	
218353_at	 2.90E---04	 2.80E---04	 2.6854308	 RGS5	 regulator	of	G---protein	signaling	5	
219087_at	 1.14E---04	 7.51E---05	 2.0482557	 ASPN	 asporin	
219367_s_at	 1.86E---04	 1.46E---04	 2.4363072	 NRP2	 neuropilin	2	
219682_s_at	 3.33E---07	 4.13E---08	 3.5890403	 TBX3	 T---box	3	
219884_at	 6.30E---06	 1.74E---06	 11.746349	 LHX6	 LIM	homeobox	6	
220510_at	 1.17E---06	 1.78E---07	 6.8438015	 RHBG	 Rh	family,	B	glycoprotein	(gene/pseudogene)	
222100_at	 3.25E---07	 3.78E---08	 3.2986734	 CYP2E1	 cytochrome	P450,	family	2,	subfamily	E,	polypeptide	1	
32625_at	 3.67E---05	 1.61E---05	 3.5482817	 NPR1	
natriuretic	peptide	receptor	A/guanylate	cyclase	A	(atrionatriuretic	peptide	receptor	
A)	
222696_at	 9.97E---05	 6.30E---05	 6.3932266	 AXIN2	 axin	2	
223235_s_at	 1.08E---04	 7.04E---05	 4.1362023	 SMOC2	 SPARC	related	modular	calcium	binding	2	
223509_at	 3.46E---05	 1.50E---05	 3.099317	 CLDN2	 claudin	2	
223839_s_at	 4.59E---07	 5.88E---08	 2.5346212		 	224099_at	 1.63E---04	 1.19E---04	 5.6362486	 KCNH7	 potassium	voltage---gated	channel,	subfamily	H	(eag---related),	member	7	
224560_at	 4.28E---05	 2.07E---05	 2.0329819	 TIMP2	 TIMP	metallopeptidase	inhibitor	2	
224694_at	 1.16E---05	 3.60E---06	 3.0481799	 ANTXR1	 anthrax	toxin	receptor	1	
224847_at	 3.78E---06	 9.06E---07	 11.888823	 CDK6	 cyclin---dependent	kinase	6	
225016_at	 1.95E---04	 1.54E---04	 4.524202	 APCDD1	 adenomatosis	polyposis	coli	down---regulated	1	
225241_at	 2.52E---05	 9.49E---06	 9.486634	 CCDC80	 coiled---coil	domain	containing	80	
225242_s_at	 1.60E---07	 1.62E---08	 8.755893	 CCDC80	 coiled---coil	domain	containing	80	
225367_at	 1.81E---04	 1.37E---04	 2.3691063	 PGM2	 phosphoglucomutase	2	
226016_at	 2.18E---04	 1.76E---04	 2.443767	 CD47	 CD47	molecule	
226237_at	 2.94E---04	 2.87E---04	 7.0640454	 COL8A1	 collagen,	type	VIII,	alpha	1	
226303_at	 1.81E---04	 1.37E---04	 3.7970037	 PGM5	 phosphoglucomutase	5	
226425_at	 2.03E---04	 1.61E---04	 3.0454032	 CLIP4	 CAP---GLY	domain	containing	linker	protein	family,	member	4	
226769_at	 2.42E---04	 2.07E---04	 2.894106	 FIBIN	 fin	bud	initiation	factor	homolog	(zebrafish)	
226939_at	 9.08E---07	 1.24E---07	 2.506574	 CPEB2	 cytoplasmic	polyadenylation	element	binding	protein	2	
226946_at	 4.28E---05	 2.09E---05	 2.2867131	 NADK2	 NAD	kinase	2,	mitochondrial	
227140_at	 2.95E---04	 2.89E---04	 3.002679	 INHBA	 inhibin,	beta	A	
227195_at	 2.40E---05	 8.92E---06	 5.014571	 ZNF503	 zinc	finger	protein	503	
227235_at	 2.73E---04	 2.55E---04	 2.8981478	 GUCY1A3	 guanylate	cyclase	1,	soluble,	alpha	3	
228186_s_at	 7.62E---08	 6.30E---09	 9.02042	 RSPO3	 R---spondin	3	
228335_at	 9.10E---06	 2.75E---06	 11.475331	 CLDN11	 claudin	11	
228608_at	 1.82E---04	 1.39E---04	 3.4475253	 NALCN	 sodium	leak	channel,	non---selective	
229477_at	 4.25E---05	 2.00E---05	 4.5065765	 THRSP	 thyroid	hormone	responsive	
230135_at	 2.20E---08	 1.09E---09	 3.745248	 HHIP	 hedgehog	interacting	protein	
231024_at	 4.33E---05	 2.18E---05	 7.9859414	 PGM5---AS1	 PGM5	antisense	RNA	1	
231579_s_at	 2.95E---05	 1.18E---05	 2.4674778	 TIMP2	 TIMP	metallopeptidase	inhibitor	2	
231675_s_at	 1.33E---08	 4.95E---10	 2.8346462	 ADH4	 alcohol	dehydrogenase	4	(class	II),	pi	polypeptide	
231678_s_at	 2.41E---09	 4.98E---11	 2.7749605	 ADH4	 alcohol	dehydrogenase	4	(class	II),	pi	polypeptide	
231747_at	 4.61E---05	 2.36E---05	 4.7382207	 CYSLTR1	 cysteinyl	leukotriene	receptor	1	
233606_at	 3.03E---04	 3.01E---04	 6.362521		 	233882_s_at	 1.64E---05	 5.42E---06	 2.7763536	 SEMA6D	 sema	domain,	transmembrane	domain	(TM),	and	cytoplasmic	domain,	(semaphorin)	
6D	
235111_at	 7.97E---05	 4.74E---05	 8.813405	 LSAMP	 limbic	system---associated	membrane	protein	
235349_at	 2.71E---04	 2.45E---04	 4.2362795	 RMDN2	 regulator	of	microtubule	dynamics	2	
237466_s_at	 7.24E---08	 5.68E---09	 4.8819046	 HHIP	 hedgehog	interacting	protein	
241789_at	 2.66E---04	 2.40E---04	 2.6873555	 RBMS3	 RNA	binding	motif,	single	stranded	interacting	protein	3	
242281_at	 1.15E---04	 7.73E---05	 9.330574	 GLUL	 glutamate---ammonia	ligase	
1555316_a_at	 4.33E---05	 2.17E---05	 10.405118	 KCNH7	 potassium	voltage---gated	channel,	subfamily	H	(eag---related),	member	7	
1556167_at	 1.43E---04	 1.01E---04	 7.835601	MROH2A	 maestro	heat---like	repeat	family	member	2A	
1556499_s_at	 3.03E---04	 3.01E---04	 4.0777473	 COL1A1	 collagen,	type	I,	alpha	1	
1558254_s_at	 1.02E---04	 6.54E---05	 3.0067284	 SRPK2	 SRSF	protein	kinase	2	
1559921_at	 2.48E---04	 2.13E---04	 3.5523612	 PECAM1	 platelet/endothelial	cell	adhesion	molecule	1	
1560291_at	 3.06E---04	 3.05E---04	 4.2468786	 RIPPLY1	 ripply1	homolog	(zebrafish)			 	
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Methapyrilene	induced	genes	
Bile	duct	 genes	 induced	 in	treated	 animals	 vs.	untreated	animals	 at	day	3		 Probe	 Set	 ID	 Gene	 Symbol	 Gene	 Title	1367581_a_at	 Spp1	 secreted		phosphoprotein	1	1367584_at	 Anxa2	 annexin		A2	1367592_at	 Tnnt2	 troponin		T	type	 2	(cardiac)				1367655_at	 LOC100359493//	/LOC100359496/	//LOC100361392	///LOC10036159	6///LOC1003616	20///LOC100364	435///LOC10090	9821///LOC1009	11590///Tmsb10	
		thymosin,	beta	 10---like///thymosin,	beta	10---like///thymosin,	beta	 10---like///hypothetical	protein	LOC100361596///thymosin,	beta	10---like///thymosin,	beta		10---like///thymosin	beta---10---like///thymosin	beta---10---	like///thymosin,	beta	 10	
1368007_at	 Dmbt1///LOC100	913031	 deleted	in	malignant	brain	tumors	1///deleted	in	malignant		brain	 tumors		1	protein---like	1368008_at	 Prom1	 prominin	1	1368013_at	 Ddit4l///LOC1003	63484	 DNA---damage---inducible	transcript	4---like///DNA---damage---	inducible	transcript	4---like		protein---like	1368052_at	 Tspan8	 tetraspanin	8	1368097_a_at	 Rtn1	 reticulon	1	1368278_at	 Lgals2	 lectin,	 galactoside---binding,	soluble,		2	1368374_a_at	 Ggt1	 gamma---glutamyltransferase	1	1368391_at	 Slc7a1	 solute	carrier	family	7	(cationic	amino	acid	transporter,	y+		system),		member		1	1368392_at	 Slc7a1	 solute	carrier	family	7	(cationic	amino	acid	transporter,	y+		system),		member		1	1368413_at	 Abp1	 amiloride	binding		protein		1	(amine		oxidase,		copper---	containing)	1368515_at	 Epb41l3	 erythrocyte	membrane	protein		band	 4.1---like	3	1368555_at	 Cd37	 CD37	 molecule	1368921_a_at	 Cd44	 Cd44	molecule	1369105_a_at	 Pkib	 protein		kinase	 (cAMP---dependent,	catalytic)	inhibitor		beta	1369513_at	 Ccl28	 chemokine	(C---C	 motif)	 ligand	 28	1369698_at	 Abcc3	 ATP---binding	cassette,		subfamily	C	(CFTR/MRP),	member		3	1369953_a_at	 Cd24	 CD24	 molecule	1369963_at	 Pafah1b3	 platelet---activating	factor	 acetylhydrolase	1b,	 catalytic	subunit		3	1370026_at	 Cryab	 crystallin,	alpha	 B	1370269_at	 Cyp1a1	 cytochrome	P450,	 family	 1,	subfamily	a,	polypeptide	1	1370379_at	 Prss8	 protease,	serine,	 8	1370594_at	 Igsf1	 immunoglobulin	superfamily,	member		1	1370894_at	 Cldn7	 claudin		7	1370902_at	 Akr1b8	 aldo---keto	reductase	family	 1,	member		B8	1371256_at	 Ptpn18	 protein		tyrosine		phosphatase,	non---receptor	type	 18	1371360_at	 Ndrg1	 N---myc	downstream	regulated	1	1371472_at	 	 	1371883_at	 Mmd	 monocyte	to	macrophage	differentiation---associated	1372064_at	 Cxcl16	 chemokine	(C---X---C	motif)	 ligand	 16	1372179_at	 Hpcal1	 hippocalcin---like	1	1372256_at	 Crip1	 cysteine---rich	protein		1	(intestinal)	1372725_at	 Plscr2	 phospholipid	scramblase	2	1373035_at	 	 	1373458_at	 Bex4	 brain	 expressed,	X---linked	4	1373631_at	 Rap1gap	 Rap1	 GTPase---activating	protein	1373908_at	 	 	1374070_at	 Gpx2	 glutathione	peroxidase	2	1374573_at	 Dync2li1	 dynein		cytoplasmic	2	light	 intermediate	chain	 1	1374976_a_at	 Soat1	 sterol	 O---acyltransferase	1	1375170_at	 S100a11	 S100	 calcium		binding		protein		A11	1375267_at	 Ppic	 peptidylprolyl	isomerase	C	1375958_at	 Tsc22d4	 TSC22	 domain		family,	 member		4	1376292_at	 	 	1376770_at	 Efhd1	 EF---hand	domain		family,	 member		D1	1376877_at	 Cdcp1	 CUB	 domain		containing	protein		1	1377008_at	 RGD1566401	 similar		to	GTL2,	 imprinted	maternally	expressed	untranslated	1377018_at	 	 	1377034_at	 Serpinb1a	 serine	 (or	 cysteine)	proteinase	inhibitor,	clade	 B,	member		1a	1379031_at	 Gca	 grancalcin	1382849_at	 	 	1383935_at	 	 	1386466_at	 	 	1386862_at	 Anxa5	 annexin		A5	1387195_at	 St14	 suppression	of	tumorigenicity	14	(colon	 carcinoma)	1387454_at	 Fam129a	 family	 with	 sequence	similarity	129,	member		A	1387459_at	 Pkib	 protein		kinase	 (cAMP---dependent,	catalytic)	inhibitor		beta	1387671_at	 Sctr	 secretin		receptor	1387952_a_at	 Cd44	 Cd44	molecule	1388074_at	 Krt20	 keratin		20	1388152_at	 Map2	 microtubule---associated	protein		2	1388199_at	 Epcam	 epithelial	cell	 adhesion	molecule	1388335_at	 Tagln2	 transgelin	2	1388547_at	 Cldn4	 claudin		4	1388557_at	 C7///Tubb4b	 complement	component	7///tubulin,	beta	 4B	class	 IVb	1388802_at	 Bex1///LOC1009	12195	 brain	 expressed,	X---linked	1///protein	BEX1---like	1388932_at	 Lama5	 laminin,		alpha	 5	1389360_at	 Fxyd3	 FXYD	 domain---containing	ion	 transport	regulator	3	1389409_at	 Tes	 testis	 derived		transcript	
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	 1390070_at	 LOC100911253	 uncharacterized	LOC100911253	1390557_at	 Gca	 grancalcin	1390659_at	 	 	1393018_at	 LOC100912649	 uncharacterized	LOC100912649	1398373_at	 B3galnt1	 beta---1,3---N---acetylgalactosaminyltransferase	1	(globoside	blood	 group)	1377940_at	 Fam101b	 family	 with	 sequence	similarity	101,	member		B	1378015_at	 Ccl21	 chemokine	(C---C	 motif)	 ligand	 21	1378168_at	 Fam101b	 family	 with	 sequence	similarity	101,	member		B	1379008_at	 	 	1379440_at	 Fstl3	 follistatin---like	3	(secreted	glycoprotein)	1380086_at	 	 	1380574_at	 	 	1380909_at	 Slc25a24	 solute	 carrier	 family	 25	(mitochondrial	carrier,		phosphate	carrier),		member		24	1381434_s_at	 LOC100912349//	/LOC302022	 nidogen---2---like///similar	to	nidogen		2	protein	1382217_at	 	 	1382291_at	 	 	1382776_at	 Mboat1	 membrane	bound	 O---acyltransferase	domain		containing	1	1382835_at	 	 	1382882_x_at	 	 	1383291_at	 C7///Tubb4b	 complement	component	7///tubulin,	beta	 4B	class	 IVb	1383311_at	 Mtmr11	 myotubularin	related		protein		11	1383401_at	 Tes	 testis	 derived		transcript	1383668_at	 Mmp15	 matrix	 metallopeptidase	15	1383766_at	 Sgcb	 sarcoglycan,	beta	 (dystrophin---associated	glycoprotein)	1384000_at	 Sox4	 SRY	 (sex	 determining	region	 Y)---box	4	1384468_at	 	 	1384960_at	 Cftr	 cystic	 fibrosis		transmembrane	conductance	regulator	1385472_at	 Zbtb8a	 zinc	 finger	 and	BTB	 domain		containing	8a	1385534_at	 Ngfrap1	 nerve	 growth		factor	 receptor		(TNFRSF16)	associated	protein	1	1385706_at	 	 	1385716_at	 	 	1385830_at	 RGD1561507	 similar		to	hypothetical	protein		FLJ31606	1385978_at	 	 	1391063_at	 Kif23	 kinesin		family	 member		23	1391162_at	 Dcdc2	 doublecortin	domain		containing	2	1391187_at	 Ppl	 periplakin	1392557_at	 	 	1392813_at	 	 	1393167_at	 	 	1393234_at	 LOC687105	 hypothetical	protein		LOC687105	1393252_at	 	 	1393337_at	 Tfcp2l1	 transcription	factor	 CP2---like	1	1393584_at	 Tnfrsf21	 tumor	 necrosis		factor	 receptor		superfamily,	member		21	1393641_at	 Blnk	 B---cell		linker	1395390_at	 	 	1395966_at	 Kctd14	 potassium	channel		tetramerisation	domain		containing	14	1398716_at	 	 		
Bile	duct	 genes	 induced	 in	treated	 animals	 vs.	untreated	animals	 at	day	7		 Probe	 Set	 ID	 Gene	 Symbol	 Gene	 Title	1367581_a_at	 Spp1	 secreted		phosphoprotein	1	1367584_at	 Anxa2	 annexin		A2	1367592_at	 Tnnt2	 troponin		T	type	 2	(cardiac)				1367655_at	 LOC100359493//	/LOC100359496/	//LOC100361392	///LOC10036159	6///LOC1003616	20///LOC100364	435///LOC10090	9821///LOC1009	11590///Tmsb10	
		thymosin,	beta	 10---like///thymosin,	beta	10---like///thymosin,	beta	 10---like///hypothetical	protein	LOC100361596///thymosin,	beta	 10---like///thymosin,	beta	10---like///thymosin	beta---10---like///thymosin	beta---10---	like///thymosin,	beta	 10	
1368007_at	 Dmbt1///LOC100	913031	 deleted		in	malignant	brain	 tumors		1///deleted	in	malignant	brain	 tumors		1	protein---like	1368008_at	 Prom1	 prominin	1	1368013_at	 Ddit4l///LOC1003	63484	 DNA---damage---inducible	transcript	4---like///DNA---damage---	inducible	transcript	4---like		protein---like	1368052_at	 Tspan8	 tetraspanin	8	1368097_a_at	 Rtn1	 reticulon	1	1368278_at	 Lgals2	 lectin,	 galactoside---binding,	soluble,		2	1368374_a_at	 Ggt1	 gamma---glutamyltransferase	1	1368391_at	 Slc7a1	 solute	 carrier	 family	 7	(cationic		amino	 acid	 transporter,	y+	system),		member		1	1368392_at	 Slc7a1	 solute	 carrier	 family	 7	(cationic		amino	 acid	 transporter,	y+	system),		member		1	1368413_at	 Abp1	 amiloride	binding		protein		1	(amine		oxidase,		copper---	containing)	1368469_at	 Aqp5	 aquaporin	5	1368515_at	 Epb41l3	 erythrocyte	membrane	protein		band	 4.1---like	3	1368527_at	 Ptgs2	 prostaglandin---endoperoxide	synthase	2	1368555_at	 Cd37	 CD37	 molecule	1368921_a_at	 Cd44	 Cd44	molecule	1369105_a_at	 Pkib	 protein		kinase	 (cAMP---dependent,	catalytic)	inhibitor		beta	1369513_at	 Ccl28	 chemokine	(C---C	 motif)	 ligand	 28	1369698_at	 Abcc3	 ATP---binding	cassette,		subfamily	C	(CFTR/MRP),	member		3	1369953_a_at	 Cd24	 CD24	 molecule	
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	 1369963_at	 Pafah1b3	 platelet---activating	factor	 acetylhydrolase	1b,	catalytic	subunit	3	1370026_at	 Cryab	 crystallin,	alpha	 B	1370218_at	 Ldhb	 lactate	 dehydrogenase	B	1370269_at	 Cyp1a1	 cytochrome	P450,	 family	 1,	subfamily	a,	polypeptide	1	1370379_at	 Prss8	 protease,	serine,		8	1370594_at	 Igsf1	 immunoglobulin	superfamily,	member		1	1370894_at	 Cldn7	 claudin		7	1370902_at	 Akr1b8	 aldo---keto	reductase	family	 1,	member		B8	1371256_at	 Ptpn18	 protein		tyrosine		phosphatase,	non---receptor	type	 18	1371260_at	 Mcpt2	 mast	 cell	 protease		2	1371360_at	 Ndrg1	 N---myc	downstream	regulated	1	1371472_at	 	 	1371499_at	 Cd9	 CD9	molecule	1371883_at	 Mmd	 monocyte	to	macrophage	differentiation---associated	1372064_at	 Cxcl16	 chemokine	(C---X---C	motif)	 ligand	 16	1372179_at	 Hpcal1	 hippocalcin---like	1	1372256_at	 Crip1	 cysteine---rich	protein		1	(intestinal)	1372725_at	 Plscr2	 phospholipid	scramblase	2	1373035_at	 	 	1373458_at	 Bex4	 brain	 expressed,	X---linked	4	1373631_at	 Rap1gap	 Rap1	 GTPase---activating	protein	1373908_at	 	 	1374070_at	 Gpx2	 glutathione	peroxidase	2	1374573_at	 Dync2li1	 dynein	 cytoplasmic	2	light	 intermediate	chain	 1	1374976_a_at	 Soat1	 sterol	 O---acyltransferase	1	1375170_at	 S100a11	 S100	 calcium		binding		protein		A11	1375267_at	 Ppic	 peptidylprolyl	isomerase	C	1375958_at	 Tsc22d4	 TSC22	 domain		family,	 member		4	1376292_at	 	 	1376770_at	 Efhd1	 EF---hand	domain		family,	 member		D1	1376877_at	 Cdcp1	 CUB	 domain		containing	protein		1	1376937_at	 Filip1l	 filamin		A	interacting	protein		1---like	1377008_at	 RGD1566401	 similar		to	GTL2,	 imprinted	maternally	expressed	untranslated	1377018_at	 	 	1377034_at	 Serpinb1a	 serine	 (or	cysteine)	proteinase	inhibitor,	clade	 B,	member		1a	1379031_at	 Gca	 grancalcin	1382849_at	 	 	1383935_at	 	 	1386466_at	 	 	1386862_at	 Anxa5	 annexin		A5	1387195_at	 St14	 suppression	of	tumorigenicity	14	(colon	 carcinoma)	1387454_at	 Fam129a	 family	 with	 sequence	similarity	129,	member		A	1387459_at	 Pkib	 protein		kinase	 (cAMP---dependent,	catalytic)	inhibitor		beta	1387671_at	 Sctr	 secretin		receptor	1387952_a_at	 Cd44	 Cd44	molecule	1388074_at	 Krt20	 keratin		20	1388152_at	 Map2	 microtubule---associated	protein		2	1388199_at	 Epcam	 epithelial	cell	 adhesion	molecule	1388335_at	 Tagln2	 transgelin	2	1388433_at	 Krt19	 keratin		19	1388547_at	 Cldn4	 claudin		4	1388557_at	 C7///Tubb4b	 complement	component	7///tubulin,	beta	 4B	class	 IVb	1388802_at	 Bex1///LOC1009	12195	 brain	 expressed,	X---linked	1///protein	BEX1---like	1388902_at	 Loxl1	 lysyl	 oxidase---like	1	1388932_at	 Lama5	 laminin,		alpha	 5	1389360_at	 Fxyd3	 FXYD	 domain---containing	ion	 transport	regulator	3	1389409_at	 Tes	 testis	 derived		transcript	1390070_at	 LOC100911253	 uncharacterized	LOC100911253	1390557_at	 Gca	 grancalcin	1390659_at	 	 	1393018_at	 LOC100912649	 uncharacterized	LOC100912649	1398373_at	 B3galnt1	 beta---1,3---N---acetylgalactosaminyltransferase	1	(globoside	blood	 group)	1377940_at	 Fam101b	 family	 with	 sequence	similarity	101,	member		B	1378015_at	 Ccl21	 chemokine	(C---C	 motif)	 ligand	 21	1378168_at	 Fam101b	 family	 with	 sequence	similarity	101,	member		B	1379008_at	 	 	1379440_at	 Fstl3	 follistatin---like	3	(secreted	glycoprotein)	1380086_at	 	 	1380574_at	 	 	1380909_at	 Slc25a24	 solute	 carrier	 family	 25	(mitochondrial	carrier,		phosphate	carrier),		member		24	1381434_s_at	 LOC100912349//	/LOC302022	 nidogen---2---like///similar	to	nidogen		2	protein	1382217_at	 	 	1382291_at	 	 	1382776_at	 Mboat1	 membrane	bound	 O---acyltransferase	domain		containing	1	1382835_at	 	 	1382882_x_at	 	 	1383137_at	 Sox4	 SRY	 (sex	 determining	region	 Y)---box	4	1383291_at	 C7///Tubb4b	 complement	component	7///tubulin,	beta	 4B	class	 IVb	1383311_at	 Mtmr11	 myotubularin	related		protein		11	1383401_at	 Tes	 testis	 derived		transcript	1383668_at	 Mmp15	 matrix	 metallopeptidase	15	1383766_at	 Sgcb	 sarcoglycan,	beta	 (dystrophin---associated	glycoprotein)	1383879_at	 LOC688163	 hypothetical	protein		LOC688163	
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	 1384000_at	 Sox4	 SRY	 (sex	 determining	region	 Y)---box	4	1384468_at	 	 	1384960_at	 Cftr	 cystic	 fibrosis		transmembrane	conductance	regulator	1385472_at	 Zbtb8a	 zinc	 finger	 and	BTB	 domain		containing	8a	1385534_at	 Ngfrap1	 nerve	 growth		factor	 receptor		(TNFRSF16)	associated	protein	1	1385706_at	 	 	1385716_at	 	 	1385830_at	 RGD1561507	 similar		to	hypothetical	protein		FLJ31606	1385978_at	 	 	1391022_at	 Lamb3	 laminin,		beta	 3	1391063_at	 Kif23	 kinesin		family	 member		23	1391162_at	 Dcdc2	 doublecortin	domain		containing	2	1391187_at	 Ppl	 periplakin	1391331_at	 	 	1392557_at	 	 	1392813_at	 	 	1393167_at	 	 	1393234_at	 LOC687105	 hypothetical	protein		LOC687105	1393252_at	 	 	1393337_at	 Tfcp2l1	 transcription	factor	 CP2---like	1	1393584_at	 Tnfrsf21	 tumor	 necrosis		factor	 receptor		superfamily,	member		21	1393641_at	 Blnk	 B---cell		linker	1395390_at	 	 	1395966_at	 Kctd14	 potassium	channel		tetramerisation	domain		containing	14	1398716_at	 	 		
Bile	duct	genes	 induced	 in	treated	 animals	 vs.	untreated	animals	 at	day	14		 Probe	 Set	 ID	 Gene	 Symbol	 Gene	 Title	1367581_a_at	 Spp1	 secreted		phosphoprotein	1	1367584_at	 Anxa2	 annexin		A2	1367592_at	 Tnnt2	 troponin		T	type	 2	(cardiac)				1367655_at	 LOC100359493//	/LOC100359496/	//LOC100361392	///LOC10036159	6///LOC1003616	20///LOC100364	435///LOC10090	9821///LOC1009	11590///Tmsb10	
	thymosin,	beta	 10---like///thymosin,	beta	10---like///thymosin,	beta	 10---like///hypothetical	protein	LOC100361596///thymosin,	beta	 10---like///thymosin,	beta	10---like///thymosin	beta---10---like///thymosin	beta---10---	like///thymosin,	beta	 10	
	1368007_at	 Dmbt1///LOC100	913031	 deleted		in	malignant	brain	 tumors		1///deleted	in	malignant	brain	 tumors		1	protein---like	1368008_at	 Prom1	 prominin	1		1368013_at	 Ddit4l///LOC1003	63484	 DNA---damage---inducible	transcript	4---like///DNA---damage---	inducible	transcript	4---like		protein---like	1368052_at	 Tspan8	 tetraspanin	8	1368097_a_at	 Rtn1	 reticulon	1	1368278_at	 Lgals2	 lectin,	 galactoside---binding,	soluble,		2	1368374_a_at	 Ggt1	 gamma---glutamyltransferase	1		1368391_at	 	Slc7a1	 solute	 carrier	 family	 7	(cationic		amino	 acid	 transporter,	y+	system),		member		1		1368392_at	 	Slc7a1	 solute	 carrier	 family	 7	(cationic		amino	 acid	 transporter,	y+	system),		member		1		1368413_at	 	Abp1	 amiloride	binding		protein		1	(amine		oxidase,		copper---	containing)	1368469_at	 Aqp5	 aquaporin	5	1368515_at	 Epb41l3	 erythrocyte	membrane	protein		band	 4.1---like	3	1368527_at	 Ptgs2	 prostaglandin---endoperoxide	synthase	2	1368555_at	 Cd37	 CD37	 molecule	1368921_a_at	 Cd44	 Cd44	molecule	1369105_a_at	 Pkib	 protein		kinase	 (cAMP---dependent,	catalytic)	inhibitor		beta	1369513_at	 Ccl28	 chemokine	(C---C	 motif)	 ligand	 28	1369698_at	 Abcc3	 ATP---binding	cassette,		subfamily	C	(CFTR/MRP),	member		3	1369953_a_at	 Cd24	 CD24	 molecule		1369963_at	 	Pafah1b3	 platelet---activating	factor	 acetylhydrolase	1b,	catalytic	subunit	3	1370026_at	 Cryab	 crystallin,	alpha	 B	1370218_at	 Ldhb	 lactate	 dehydrogenase	B	1370269_at	 Cyp1a1	 cytochrome	P450,	 family	 1,	subfamily	a,	polypeptide	1	1370379_at	 Prss8	 protease,	serine,		8	1370594_at	 Igsf1	 immunoglobulin	superfamily,	member		1	1370894_at	 Cldn7	 claudin		7	1370902_at	 Akr1b8	 aldo---keto	reductase	family	 1,	member		B8		1371164_at	 Mcpt10///RGD15	65970	 	mast	 cell	 protease		10///similar	to	mast	 cell	 protease		8	1371256_at	 Ptpn18	 protein		tyrosine		phosphatase,	non---receptor	type	 18	1371260_at	 Mcpt2	 mast	 cell	 protease		2	1371360_at	 Ndrg1	 N---myc	downstream	regulated	1	1371472_at	 	 	1371499_at	 Cd9	 CD9	molecule	1371883_at	 Mmd	 monocyte	to	macrophage	differentiation---associated	1372064_at	 Cxcl16	 chemokine	(C---X---C	motif)	 ligand	 16	1372179_at	 Hpcal1	 hippocalcin---like	1	1372256_at	 Crip1	 cysteine---rich	protein		1	(intestinal)	1372725_at	 Plscr2	 phospholipid	scramblase	2	1373035_at	 	 	1373458_at	 Bex4	 brain	 expressed,	X---linked	4	1373631_at	 Rap1gap	 Rap1	 GTPase---activating	protein	
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	 1373908_at	 	 	1374070_at	 Gpx2	 glutathione	peroxidase	2	1374573_at	 Dync2li1	 dynein	 cytoplasmic	2	light	 intermediate	chain	 1	1374976_a_at	 Soat1	 sterol	 O---acyltransferase	1	1375170_at	 S100a11	 S100	 calcium		binding		protein		A11	1375267_at	 Ppic	 peptidylprolyl	isomerase	C	1375958_at	 Tsc22d4	 TSC22	 domain		family,	 member		4	1376292_at	 	 	1376770_at	 Efhd1	 EF---hand	domain		family,	 member		D1	1376877_at	 Cdcp1	 CUB	 domain		containing	protein		1	1376937_at	 Filip1l	 filamin		A	interacting	protein		1---like		1377008_at	 	RGD1566401	 	similar		to	GTL2,	 imprinted	maternally	expressed	untranslated	1377018_at	 	 	1377034_at	 Serpinb1a	 serine	 (or	cysteine)	proteinase	inhibitor,	clade	 B,	member		1a	1379031_at	 Gca	 grancalcin	1382849_at	 	 	1383935_at	 	 	1386466_at	 	 	1386862_at	 Anxa5	 annexin		A5	1387195_at	 St14	 suppression	of	tumorigenicity	14	(colon	 carcinoma)	1387454_at	 Fam129a	 family	 with	 sequence	similarity	129,	member		A	1387459_at	 Pkib	 protein		kinase	 (cAMP---dependent,	catalytic)	inhibitor		beta	1387671_at	 Sctr	 secretin		receptor	1387952_a_at	 Cd44	 Cd44	molecule	1388074_at	 Krt20	 keratin		20	1388152_at	 Map2	 microtubule---associated	protein		2	1388199_at	 Epcam	 epithelial	cell	 adhesion	molecule	1388335_at	 Tagln2	 transgelin	2	1388433_at	 Krt19	 keratin		19	1388547_at	 Cldn4	 claudin		4	1388557_at	 C7///Tubb4b	 complement	component	7///tubulin,	beta	 4B	class	 IVb		1388802_at	 Bex1///LOC1009	12195	 	brain	 expressed,	X---linked	1///protein	BEX1---like	1388902_at	 Loxl1	 lysyl	 oxidase---like	1	1388932_at	 Lama5	 laminin,		alpha	 5	1389360_at	 Fxyd3	 FXYD	 domain---containing	ion	 transport	regulator	3	1389409_at	 Tes	 testis	 derived		transcript	1390070_at	 LOC100911253	 uncharacterized	LOC100911253	1390557_at	 Gca	 grancalcin	1390659_at	 	 	1393018_at	 LOC100912649	 uncharacterized	LOC100912649		1398373_at	 	B3galnt1	 beta---1,3---N---acetylgalactosaminyltransferase	1	(globoside	blood	 group)	1377940_at	 Fam101b	 family	 with	 sequence	similarity	101,	member		B	1378015_at	 Ccl21	 chemokine	(C---C	 motif)	 ligand	 21	1378168_at	 Fam101b	 family	 with	 sequence	similarity	101,	member		B	1379008_at	 	 	1379440_at	 Fstl3	 follistatin---like	3	(secreted	glycoprotein)	1380086_at	 	 	1380574_at	 	 		1380909_at	 	Slc25a24	 solute	 carrier	 family	 25	(mitochondrial	carrier,		phosphate	carrier),		member		24		1381434_s_at	 LOC100912349//	/LOC302022	 	nidogen---2---like///similar	to	nidogen		2	protein	1382217_at	 	 	1382291_at	 	 	1382776_at	 Mboat1	 membrane	bound	 O---acyltransferase	domain		containing	1	1382835_at	 	 	1382882_x_at	 	 	1383137_at	 Sox4	 SRY	 (sex	 determining	region	 Y)---box	4	1383291_at	 C7///Tubb4b	 complement	component	7///tubulin,	beta	 4B	class	 IVb	1383311_at	 Mtmr11	 myotubularin	related		protein		11	1383401_at	 Tes	 testis	 derived		transcript	1383668_at	 Mmp15	 matrix	 metallopeptidase	15	1383766_at	 Sgcb	 sarcoglycan,	beta	 (dystrophin---associated	glycoprotein)	1383879_at	 LOC688163	 hypothetical	protein		LOC688163	1384000_at	 Sox4	 SRY	 (sex	 determining	region	 Y)---box	4	1384468_at	 	 	1384960_at	 Cftr	 cystic	 fibrosis		transmembrane	conductance	regulator	1385472_at	 Zbtb8a	 zinc	 finger	 and	BTB	 domain		containing	8a		1385534_at	 	Ngfrap1	 nerve	 growth		factor	 receptor		(TNFRSF16)	associated	protein	1	1385706_at	 	 	1385716_at	 	 	1385830_at	 RGD1561507	 similar		to	hypothetical	protein		FLJ31606	1385978_at	 	 	1391022_at	 Lamb3	 laminin,		beta	 3	1391063_at	 Kif23	 kinesin		family	 member		23	1391162_at	 Dcdc2	 doublecortin	domain		containing	2	1391187_at	 Ppl	 periplakin	1391331_at	 	 	1392557_at	 	 	1392813_at	 	 	1393167_at	 	 	1393234_at	 LOC687105	 hypothetical	protein		LOC687105	1393252_at	 	 	1393337_at	 Tfcp2l1	 transcription	factor	 CP2---like	1	1393584_at	 Tnfrsf21	 tumor	 necrosis		factor	 receptor		superfamily,	member		21	
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Working	Experiences:	
January	2018	-	now	
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Responsible	for	the	Department	of	Biomedicine	Histology	Core	Facility.	Department	 of	 Biomedicine,	 Zentrum	 für	 Lehre	 und	 Forschung,	 University	Hospital	Basel.	As	 responsible	 for	 the	 Histology	 Core	 Facility	 my	 duty	 is	 to	 support	 the	development	of	new	histological	assays	 in	a	multidisciplinary	environment	and	in	 synergy	 with	 the	 Microscopy	 Core	 Facility.	 In	 addition	 I	 am	 personally	involved	in	the	training	of	new	users,	providing	them	with	principle	for	the	good	laboratory	 practices	 (GLP),	 identify	 and	 propose	 new	 equipment	 and	technologies	to	extend	the	experimental	capabilities	in	the	histology	field	and	to	supervise	 the	 laboratories,	 ensuring	 the	 proper	 functioning	 of	 the	 available	equipment.	
April	2012	–	now	
Senior	Post-doc	&	Project	leader	University	Hospital	Basel,	Department	of	Biomedicine,	Hepatology	Laboratory.	Project	 aimed	 at	 establishing	 an	 innovative	 in-vitro	 system	 for	 HBV-host	interaction	and	(innate)	immune	response	study,	taking	advantage	from	the	use	of	ex-vivo	liver	tissue	culture	and	hepatocyte-like	induced	pluripotent	stem	cell	(HL-iPSC)	derived	cells.	
October	2013	
Scientific	 fellowship	 at	 Scottish	 Centre	 for	 Regenerative	 Medicine	
(SCRM).	
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Scientific	 felloship	 for	 learning	 the	 reprogramming	 and	 differenziation	 of	iPSCs	into	hepatocyte-like	cells.	Guest	of	Pluripotent	Stem	Cell	Hepatocyte	
Development,	group	lead	by	Dr.	David	Hay.	
January	2009	–	April	2012:	
Ph.D.	"Pharmaceutical	Sciences	-	Molecular	and	System	Toxicology".	Experimental	 work	 on	 liver	 molecular	 map	 profiling,	 across	 different	 species	(Rat,	 Dog	 and	 Monkey),	 performed	 using	 laser	 capture	 microdissection	 to	characterize	the	gene	expression	profile	of	morpho-functional	liver	parenchymal	regions	 and	 the	 “portal	 triad”	 components.	 Gene	 signatures	 generated	 by	 this	study	have	been	validated	by	a	preclinical	study	and	are	currently	used	for	liver	drug-induced	injury	detection,	and	drug	safety	assessment.	
October 2008 – December 2008: 
Instructor for the “Human Anatomy Laboratory” course. Inter-University School 
of Specialization for Secondary School Teaching (S.I.C.S.I.), Naples University 
“Federico II” (IT). 
May	2008	–	October	2008:	
Scientific	 fellowship	 at	 Pathology	 Institute	 of	 University	 Hospital	 Basel	(CH):	"Analysis	of	apoptotic	markers	in	cardiac	ischemia	by	tissue	microarray”.	
November	2005	–	October	2008:	
! Teaching fellow and exam committee member for the Human Anatomy 
course at Pharmacy and Biotechnology faculties. University of Naples “Federico 
II” (IT). 
! Tutor and master thesis supervisor for students of Biotechnology, Pharmacy and 
Biology faculties. University of Naples “Federico II” (IT). 
November	2005	–	October	2008:	
Ph.D.	 in	 “Clinical	 and	 Pathological	 Morphology	 –	 Normal	 Human	
Morphology”	Experimental	 work	 on	 cardiovascular	 diseases	 (aorta	 aneurysm	 and	 post-ischemic	cardiac	diseases).	
May	2004	–	July	2005:	




Ph.D.	 in	 "Pharmaceutical	 Sciences	 -	 Molecular	 and	 Systems	 Toxicology".	University	 of	 Basel	 and	 Novartis	 Institute	 for	 Biomedical	 Research	(NIBR/TS/PCS/iTox/	Mol.Pathology	&	Immunology),	Basel	(CH).	
September	2005	–	October	2008:	
Ph.D.	 in	 “Clinical	 and	 Pathological	 Morphology	 –	 Normal	 Human	
Morphology”.	 Anatomy	 Department	 of	 Medicine	 and	 Surgery	 School,	 Naples	University	“Federico	II”	(IT).		Thesis	 entitled	 “Apoptosis	 markers	 analysis	 in	 cardiac	 ischemia	 by	 tissue	
microarray”.	
July 2005: 
Master degree in Biological Sciences, Naples University “Federico II” (IT). 
Thesis entitled “p27BBP/eIF6 expression during embryogenesis of Xenopus laevis”. 
Grants	&	Awards:	Winner	of	“Research	Fund	 Junior	Researchers”,	the	University	of	Basel	grant	for	 promoting	 the	 academic	 careers	 of	 outstanding	 junior	 researchers,	September	2015.	The	 long-term	goals	 of	 the	 experiments	 proposed	 in	 this	 application	was	 to	build	on	the	current	state	of	the	iPSC/HLC	field	and	establish	a	physiologically	relevant	 patient-specific	 in	 vitro	 liver	model	 system.	 Specifically,	 I	 aimed	 at	establishing	 iPSC-hepatocyte	 like	 cell	 (iPSC-HLC)	 cultures,	 paired	with	 iPSC-sinusoidal	 endotelial	 cells	 (iPSC-SEC),	 mirroring	 the	 liver	 cell	 composition,	intercellular	 interactions	 and	 paracrine	 signaling	 in	 a	 dynamic	microenvironment	 resembling	 the	 liver	 lobules	 in	 terms	 of	 extracellular	matrix	and	sinusoidal	microcirculation.	
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